<SEC-DOCUMENT>0001548233-13-000020.txt : 20131224
<SEC-HEADER>0001548233-13-000020.hdr.sgml : 20131224

<ACCEPTANCE-DATETIME>20131105151557

<PRIVATE-TO-PUBLIC>

ACCESSION NUMBER:		0001548233-13-000020

CONFORMED SUBMISSION TYPE:	S-1/A

PUBLIC DOCUMENT COUNT:		4

FILED AS OF DATE:		20131105

DATE AS OF CHANGE:		20131108


FILER:


	COMPANY DATA:	

		COMPANY CONFORMED NAME:			NANOANTIBIOTICS, INC.

		CENTRAL INDEX KEY:			0001580149

		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]

		IRS NUMBER:				462510769

		STATE OF INCORPORATION:			NV

		FISCAL YEAR END:			0630



	FILING VALUES:

		FORM TYPE:		S-1/A

		SEC ACT:		1933 Act

		SEC FILE NUMBER:	333-190635

		FILM NUMBER:		131192372



	BUSINESS ADDRESS:	

		STREET 1:		9511 COLLINS AVENUE

		STREET 2:		SUITE 807

		CITY:			SURFSIDE

		STATE:			FL

		ZIP:			33154

		BUSINESS PHONE:		3055154118



	MAIL ADDRESS:	

		STREET 1:		9511 COLLINS AVENUE

		STREET 2:		SUITE 807

		CITY:			SURFSIDE

		STATE:			FL

		ZIP:			33154



</SEC-HEADER>

<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>nano1105S-1.htm
<DESCRIPTION>NANOANTIBIOTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE>Nanoantibiotics S-1 Amendment 3 (EDGARizerExpress.com)</TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 74%; font: 10pt/normal Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>As Filed with the Securities and Exchange Commission on November 5, 2013</b></font></td>
    <td style="width: 26%; font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Registration No. 333-190635</b></font></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDMENT NO. 3 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>UNDER</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NANOANTIBIOTICS, INC.</B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 33%; font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nevada</b></font></td>
    <td style="vertical-align: bottom; width: 1%; font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; width: 33%; font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>8731</b></font></td>
    <td style="vertical-align: bottom; width: 1%; font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; width: 32%; font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>46-2510769</b></font></td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(State or other jurisdiction of</b></P>
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>incorporation or organization)</b></P></td>
    <td style="vertical-align: bottom; font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Primary Standard Industrial</b></P>
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Classification Code Number)</b></P></td>
    <td style="vertical-align: bottom; font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(I.R.S. Employer</b></P>
        <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Identification Number)</b></P></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>9511 Collins Ave., Suite 807</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Surfside, Florida 33154</B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Elliot Ehrlich</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NanoAntibiotics, Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>9511 Collins Ave., Suite 807</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Surfside, Florida 33154</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Telephone: (305) 515-4118</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Name, address, including zip code,
and telephone number, including area code, of agent for service)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 100%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>Copies to:</i></b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Clayton E. Parker, Esq.</b></P></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>K&amp;L Gates LLP</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>200 South Biscayne Boulevard, Suite 3900</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Miami, Florida 33131-2399</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt/normal Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Telephone: (305) 539-3306</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 10pt/normal Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Facsimile: (305) 358-7095</b></font></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Approximate date of commencement of proposed sale to the
public: <B>As soon as practicable after this Registration Statement becomes effective.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If any of the securities being registered on this Form are
to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
[x]</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act of 1933, please check the following box and list the Securities Act
registration Statement number of the earlier effective registration statement for the same offering. [ ]</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If this Form is a post-effective amendment filed pursuant
to Rule 462(c) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering. [ ]</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If this Form is a post-effective amendment filed pursuant
to Rule 462(d) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering. [ ]</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-family: Calibri, Helvetica, Sans-Serif">
<tr>
    <td style="width: 24%; line-height: normal; font-size: 11pt">&nbsp;</td>
    <td style="width: 1%; line-height: normal; font-size: 1pt">&nbsp;</td>
    <td style="width: 17%; line-height: normal; font-size: 1pt">&nbsp;</td>
    <td style="width: 1%; line-height: normal; font-size: 1pt">&nbsp;</td>
    <td style="width: 24%; line-height: normal; font-size: 1pt">&nbsp;</td>
    <td style="width: 1%; line-height: normal; font-size: 1pt">&nbsp;</td>
    <td style="width: 32%; line-height: normal; font-size: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer [ ]</font></td>
    <td style="line-height: normal; font-size: 10pt">&nbsp;</td>
    <td style="line-height: normal; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Accelerated filer [ ]</font></td>
    <td style="line-height: normal; font-size: 10pt">&nbsp;</td>
    <td>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Non-accelerated filer [ ]</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>(Do not check if a smaller reporting company)</i></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><i>&nbsp;</i></P></td>
    <td style="line-height: normal; font-size: 10pt">&nbsp;</td>
    <td style="line-height: normal; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company [X]</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED</b></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>AMOUNT TO BE REGISTERED (1)</b></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>PROPOSED MAXIMUM OFFERING PRICE PER SHARE (2)</b></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>PROPOSED MAXIMUM AGGREGATE OFFERING PRICE</b></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>AMOUNT OF REGISTRATION FEE</b></font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td></tr>
<tr style="background-color: #CCFFCC">
    <td style="vertical-align: bottom; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Common Stock</font></td>
    <td style="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">&nbsp;&nbsp;5,000,000</font></td>
    <td style="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">$</font></td>
    <td style="vertical-align: bottom; width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0.10 per share</font></td>
    <td style="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">$</font></td>
    <td style="vertical-align: bottom; width: 13%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">&nbsp;&nbsp;500,000 </font></td>
    <td style="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">$</font></td>
    <td style="vertical-align: bottom; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">69</font></td></tr>
<tr style="background-color: #CCFFCC">
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Common Stock underlying Warrants </font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">&nbsp;&nbsp;5,000,000 </font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">$</font></td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0.10 per share </font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">$</font></td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">&nbsp;&nbsp;500,000</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">$</font></td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">69</font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>TOTAL</b></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>10,000,000</b></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>$</b></font></td>
    <td style="vertical-align: bottom; border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>1,000,000</b></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>$</b></font></td>
    <td style="vertical-align: bottom; border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>138.00 (3)</b></font></td></tr>
</table>
<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">(1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">This Registration Statement covers the resale by selling securityholders
of the Registrant named herein of up to 10,000,000 shares of our common stock, par value $0.0001 per share, including: (i) up to
5,000,000 shares of our common stock previously issued to such selling securityholders in a private placement that closed on June
30, 2013 (the &ldquo;Private Placement&rdquo;) and (ii) up to 5,000,000 shares of our common stock issuable upon exercise of outstanding
warrants that were issued to the selling securityholders in connection with the Private Placement, exercisable by the selling securityholders
at a price of $0.50 per share (the &ldquo;Warrants&rdquo;) which may be adjusted from time to time in accordance with the terms
of the Warrant. Pursuant to Rule 416 under the Securities Act of 1933, the shares being registered hereunder include such indeterminate
number of shares of common stock as may be issuable with respect to the shares being registered hereunder as a result of stock
splits, stock dividends or similar transactions.</FONT></TD></TR></TABLE>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The offering price has been estimated solely for the purpose of computing
the amount of the registration fee in accordance with Rule 457(o). Our common stock is not traded on any national exchange and
is not quoted on any over-the-counter bulletin board and in accordance with Rule 457 the offering price was determined by the price
of the shares that were sold to our selling securityholders pursuant to the Private Placement memorandum. We expect that our common
stock will be quoted on the OTC Bulletin Board and/or the OTC Markets, at which time the shares may be sold at prevailing market
prices or privately negotiated prices. However, we can make no assurance that a market maker will file the necessary documents
with the Financial Industry Regulatory Authority (FINRA), which operates the OTC Bulletin Board, or any comparable marketplace
nor can there be any assurance that such an application for quotation will be approved. </FONT></TD></TR></TABLE>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">(3)</FONT></TD><TD><FONT STYLE="font: 9pt Times New Roman, Times, Serif">Previously paid.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>The Registrant amends this registration statement on such
date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically
states that this registration statement shall hereafter become effective in accordance with Section 8(a) of the Securities Act
of 1933, or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section
8(a), may determine.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: red"><B>The information in this prospectus is not
complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange
Commission becomes effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy
these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: #DC2300"><B><I>Subject to completion,
dated November 5, 2013</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NANOANTIBIOTICS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>10,000,000 Shares of Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The selling securityholders named in this prospectus are
offering up to 10,000,000 shares of our common stock, par value $0.0001 per share, which constitutes all of the shares of common
stock being offered in this prospectus. Of the 10,000,000 shares being offered hereunder, <FONT STYLE="color: black">(i) up to
5,000,000 shares were previously issued to the selling securityholders in a private placement that closed on June 30, 2013 (the
&ldquo;Private Placement&rdquo;) and (ii) up to 5,000,000 shares of our common stock issuable upon exercise of outstanding warrants
that were issued to the selling securityholders in connection with the Private Placement, exercisable at a price of $0.50 per share
(the &ldquo;Warrants&rdquo;) which may be adjusted from time to time in accordance with the terms of the Warrant. See &ldquo;Description
of Securities &ndash; Warrants&rdquo;.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We will not receive any proceeds from the sale of the common
stock covered by this prospectus, however we will receive proceeds upon the exercise of the Warrants by the selling securityholders.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our common stock is presently not traded or quoted on any
market or securities exchange. The selling securityholders have not engaged any underwriter in connection with the sale of their
shares of common stock.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The&nbsp;common stock being registered in this prospectus
is being offered by the selling securityholders initially at a fixed price of $0.10 per share until our common stock is quoted
on the OTC Bulletin Board (&ldquo;OTCBB&rdquo;) and/or other comparable marketplaces including, without limitation, the OTC Markets,
and thereafter, the selling securityholders may sell our common stock at varying prices which may reflect prevailing market prices
or privately negotiated prices or in transactions that are not in the public market.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>Securities being sold by Selling Stockholders</b></font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td colspan="2" style="line-height: normal; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Per Share</b></font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td>
    <td colspan="2" style="line-height: normal; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td>
    <td style="line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="width: 78%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">Initial offering price of common stock</font></td>
    <td style="width: 1%; line-height: normal; text-align: right">&nbsp;</td>
    <td style="width: 1%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.10</font></td>
    <td style="width: 1%; line-height: normal">&nbsp;</td>
    <td style="width: 1%; line-height: normal; text-align: right">&nbsp;</td>
    <td style="width: 1%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 8%; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="width: 1%; line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">Initial offering price of common stock underlying Warrants</font></td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.10</font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">500,000</font></td>
    <td style="line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">Proceeds to the Company</font></td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">Net proceeds to the Selling Stockholders</font></td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.20</font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td>
    <td style="background-color: #CCFFCC; line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal; text-align: right">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Although our common stock is not listed or quoted on any
market or securities exchange, we intend to apply for quotation on the OTCBB after the effectiveness of our registration statement
to which this prospectus is made a part. In order to be quoted on the OTCBB, a market maker must file an application on our behalf
in order to make a market for our common stock. There can be no assurance that a market maker will file the necessary documents
with FINRA, which operates the OTCBB, and there can be no assurance that such an application for quotation will be approved.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The selling securityholders may sell the shares of common
stock described in this prospectus in a number of different ways. See &ldquo;Plan of Distribution&rdquo; for more information about
how the selling securityholders may sell the shares of common stock being registered pursuant to this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We will pay the expenses incurred in registering the shares,
including legal and accounting fees.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are an &ldquo;emerging growth company&rdquo; as that term
is used in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;) and, as such, may elect to comply with
certain reduced public company reporting requirements for future filings.&nbsp;Please refer to discussions under &ldquo;Prospectus
Summary&rdquo; on page 3 and &ldquo;Risk Factors&rdquo; on page 6 of how and when we may lose emerging growth company status and
the various exemptions that are available to us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Investing in our common stock involves a high degree of
risk. See &ldquo;Risk Factors&rdquo; beginning on page 6 to read about factors you should consider before buying shares of our
common stock.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY
STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is , 2013.</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 92%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">PROSPECTUS SUMMARY</font></td>
    <td style="width: 8%; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">3</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">THE OFFERING</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">5</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">RISK FACTORS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">6</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">RISKS RELATING TO OUR COMMON STOCK</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">14</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">FORWARD-LOOKING STATEMENTS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">18</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">USE OF PROCEEDS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">19</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">DETERMINATION OF OFFERING PRICE</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">20</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">MARKET FOR COMMON EQUITY AND RELATED SHAREHOLDER MATTERS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">21</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">DILUTION</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">23</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">24</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">DESCRIPTION OF OUR BUSINESS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">28</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">MANAGEMENT</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">38</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">EXECUTIVE COMPENSATION</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">40</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">41</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">42</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">SELLING SECURITYHOLDERS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">43</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">DESCRIPTION OF SECURITIES</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">47</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">PLAN OF DISTRIBUTION</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">50</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">LEGAL MATTERS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">52</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">EXPERTS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">52</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">52</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION&nbsp;&nbsp;FOR SECURITIES ACT LIABILITY</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">53</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">AUDITED FINANCIAL STATEMENTS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">F-I</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">PART II: INFORMATION NOT REQUIRED IN THE PROSPECTUS</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">II-1</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">SIGNATURES</font></td>
    <td style="line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">II-5</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">You should rely only on the information contained in this
prospectus. We have not, and the selling securityholders have not, authorized any person to provide you with different information.
If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus is not an offer to
sell, nor are the selling securityholders seeking an offer to buy, securities in any state where the offer or solicitation is not
permitted. The information contained in this prospectus is complete and accurate as of the date on the front cover of this prospectus,
but information may have changed since that date. We are responsible for updating this prospectus to ensure that all material information
is included and will update this prospectus to the extent required by law.</P>


<!-- Field: Page; Sequence: 4; Section: Main; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">PROSPECTUS SUMMARY</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>This summary highlights selected information contained
elsewhere in this prospectus.&nbsp;This summary does not contain all the information that you should consider before investing
in our common stock.&nbsp;You should carefully read the entire prospectus, including &ldquo;Risk Factors&rdquo;, &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the financial statements and related notes
beginning on page F-1 before making an investment decision.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Overview</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">NanoAntibiotics, Inc. was incorporated
on April 10, 2013 in the State of Nevada. As of the date of this prospectus, we had 300,000,000 shares of common stock, par value
$0.0001 per share (our &ldquo;Common Stock&rdquo;), authorized for issuance and 87,060,000 shares of Common Stock issued and outstanding.
Of these shares, 34,000,000 shares are currently held by our officers and directors, which such shares constitute 39.05% of the
total issued and outstanding shares of Common Stock as of the date hereof. Certain immediate family members of our officers and
directors own an aggregate 43,870,000 shares, which currently constitutes 50.39% of our common stock, however our officers and
directors specifically disclaim any beneficial ownership in such shares (see &ldquo;Certain Relationships and Related Party Transactions&rdquo;).
</FONT>Our officers, directors and their immediate family members currently own 89.44% of the outstanding shares of our common
stock.<FONT STYLE="color: black"> We also have authorized for issuance 10,000,000 shares of blank check preferred stock, par value
$0.001 per share, none of which are issued and outstanding. The Company does not currently have any subsidiaries, affiliated companies
or joint venture partners. All references to the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; or &ldquo;us&rdquo;
and other similar terms means NanoAntibiotics, Inc., a Nevada corporation.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are an early developmental stage biotechnology company
engaged in the discovery, development and commercialization of new classes of broad spectrum antibiotics for gram-negative and
gram-positive bacterial infections, including some of the most difficult-to-treat Multi Drug Resistant Bacteria, also called &ldquo;Superbugs.&rdquo;
The Company plans on developing the following eight (8) pharmaceutical compounds:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Multi Drug Resistant Bacteria (&rdquo;Superbugs&rdquo;)</b></font></td>
    <td style="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Nano Efflux Pump Blocker</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>(&ldquo;NEB&rdquo;)</b></P></td>
    <td style="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 22%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Nano Antibiotic</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>(&ldquo;NA&rdquo;)</b></P></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><i>Methicillin-resistant Staphylococcus aureus (MRSA)</i></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-MRSA</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-MRSA</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Drug-resistant tuberculosis (<i>MDR-TB and XDR-TB</i>)</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-TB</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-TB</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Drug-resistant<i> Enterococcus</i></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-EC</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-EC</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Drug-resistant<i> Streptococcus pneumonia</i></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-SC</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-SC</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our drug discovery platform currently provides a multi-pronged
level understanding of interactions between drug candidates and their bacterial targets and enables us to engineer antibiotics
with enhanced characteristics to attack a Drug Resistant Bacteria with a multi-targeted approach. The Company plans on developing
eight pharmaceutical compounds. Our drug candidates are in the development stage. Our pharmaceutical compounds originated at Kard
Scientific, Inc. (&ldquo;Kard&rdquo;), a preclinical contract research organization founded by our President Rajah Menon in 2002
and of which Mr. Menon is its principal shareholder. These compounds were composed and formulated by researchers at Kard who then
conducted in-vitro studies. On October 3, 2013, Kard and Mr. Menon assigned all of their rights, formulations, and all studies
and data related to efflux pump antibiotics to the Company. The candidates have only been studied in cell-based assays (in-vitro),
but have not been studied in small animals (in-vivo) or animals with drug resistant bacteria for efficacy, efficiency and toxicity.
We currently own all development and marketing rights to our products. We plan on contracting research and development of our technologies
to third parties. The Company intends to file patent applications for each of these candidates as studies advance and funds become
available. The Company has assigned a priority to the development of NEB-MRSA and NA-MRSA and has designated these as our leading
drug candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The business plan we have developed for the next twelve months
is to engage outside vendors capable of providing the research and development needed for a future filing of an Investigational
New Drug (&ldquo;IND&rdquo;) application for NEB-MRSA, NA-MRSA, NEB-TB and NA-TB with the US Food and Drug Administration. We need
to undertake studies in animal models to obtain necessary data regarding efficacy, pharmaco-kinetic, and pharmaco-dynamic profiles
of our drug candidates. An approved IND application allows for testing in human patients (clinical trials). Regulatory approval
is not guaranteed, and the approval process is expensive and may take several years.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company presently has approximately $500,000 of cash
on hand and will be unable to proceed with its planned drug development, meet its administrative expense requirements, capital
costs, or staffing costs without obtaining additional net financing of approximately $275,000 to meet its budget for the next twelve
months.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our independent auditors have issued a going concern opinion
that raises substantial doubt about our ability to continue as a going concern. As reflected in the financial statements in this
prospectus, we are a development stage company with limited operations. We had a net loss of $17,510 since inception (April 10,
2013) through June 30, 2013. We incurred professional fees totaling $17,500 and general and administrative expenses of $15for the
period of inception through June 30, 2013. Cash on hand as of June 30, 2013 was $505,696.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Private Placement</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On June 30, 2013, we closed on a Private Placement which
raised gross proceeds of $500,000 through the sale of 5,000,000 units (the &ldquo;Units&rdquo;), each Unit consisting of one (1)
share of Common Stock and a Warrant to purchase one (1) share of our Common Stock (the &ldquo;Warrants&rdquo;), solely to certain
accredited investors. The investors entered into a subscription agreement (the &ldquo;Subscription Agreement&rdquo;) for the sale
of our Common Stock in the form of Exhibit 10.1 provided herewith. Pursuant to the terms of the Subscription Agreement, we offered
the Units for sale at a purchase price of $0.10 per Unit. Each investor also received one (1) five (5) year Warrant (see Exhibit
10.2 provided herewith), to purchase one (1) share of Common Stock for every one (1) share of Common Stock which the investor purchased
in this offering at an exercise price of $0.50 per share, which may be adjusted from time to time in accordance with the terms
of the Warrant.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Emerging Growth Company</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are an &ldquo;emerging growth company&rdquo; under the
federal securities laws and will be subject to reduced public company reporting requirements. In addition, Section 107 of the JOBS
Act also provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in
Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) for complying with new or revised
accounting standards. In other words, an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies. We are choosing to take advantage of the extended transition
period for complying with new or revised accounting standards.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NanoAntibiotics, Inc. was incorporated on April 10, 2013
in the State of Nevada. Our principal executive offices are located at 9511 Collins Ave., Suite 807, Surfside, Florida 33154 and
our telephone number is (305) 515-4118. Our website address is http://www.nanoantibiotics.com/, although the information contained
in, or that can be accessed through, our website is not part of this prospectus.</P>


<!-- Field: Page; Sequence: 6; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">THE OFFERING</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: #CCFFCC">
    <td style="width: 19%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Securities offered by the selling securityholders</b></font></td>
    <td style="width: 2%; line-height: normal">&nbsp;</td>
    <td style="width: 79%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">10,000,000 shares of our Common Stock, which includes: (i)
        up to 5,000,000 shares of our Common Stock previously issued to the selling securityholders in the Private Placement; and (ii)
        to up to 5,000,000 shares of our Common Stock issuable upon exercise of the outstanding Warrants, exercisable at a price of $0.50
        per share subject to certain adjustments as set forth in the Warrants, that were issued to the selling securityholders in connection
        with the Private Placement. See &ldquo;Description of Securities &ndash; Warrants&rdquo;.</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The 5,000,000 shares of Common Stock previously issued to
        the selling securityholders in the Private Placement represents 5.75% of our current outstanding Common Stock.</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have the option to &quot;call&quot; all of the Warrants
        presently outstanding and included in the Units (the &quot;<u>Warrant Call</u>&quot;). We may exercise the Warrant Call by giving
        to each Warrant holder a written notice of call (the &quot;<u>Call Notice</u>&quot;) during the period in which the Warrant may
        be exercised. The Warrant holders shall exercise their Warrant rights, purchase the shares underlying the Warrants and pay for
        the shares of Common Stock underlying the Warrants (which such shares are being registered hereunder) within fourteen (14) business
        days of the date of the Call Notice. Thereafter, the Warrants will no longer be exercisable.</P></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: top; background-color: #CCFFCC">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Common stock outstanding before the offering</b></font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">87,060,000 shares of Common Stock</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: top; background-color: #CCFFCC">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Common Stock outstanding after the offering</b></font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">92,060,000 shares of Common Stock, assuming the exercise of all outstanding Warrants.</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: top; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Market for our Common Stock</b></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Our Common Stock is not quoted on any market or listed on any securities exchange. Although we intend to have our Common Stock quoted on a market in the near future, we cannot provide any assurance that an active market in our Common Stock will ever develop. We expect that our Common Stock will be quoted on the OTC Bulletin Board and/or the OTC Markets, however, we can make no assurance that a market maker will file the necessary documents with FINRA, which operates the OTC Bulletin Board, or any comparable marketplace nor can there be any assurance that such an application for quotation will be approved.</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: top; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Use of proceeds</b></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">We will not receive any proceeds from the sale of the shares of Common Stock by selling securityholders. The selling securityholders may sell up to 10,000,000 shares of our Common Stock covered by this prospectus which includes 5,000,000 shares issuable to the selling securityholders upon exercise of Warrants. To the extent that the selling securityholders exercise in cash all of the Warrants at the exercise price of $0.50 per share, we would receive $2,500,000 in the aggregate from such exercise.&nbsp;The proceeds from the cash exercise of such Warrants, if any, will be used by us for working capital and other general corporate purposes.</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td></tr>
<tr style="vertical-align: top; background-color: #CCFFCC">
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Risk Factors</b></font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">The Common Stock offered hereby involves a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investment. See &ldquo;Risk Factors&rdquo; beginning on page 6.</font></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">RISK FACTORS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>THE SECURITIES BEING OFFERED INVOLVE A HIGH DEGREE OF
RISK AND, THEREFORE, SHOULD BE CONSIDERED EXTREMELY SPECULATIVE. THEY SHOULD NOT BE PURCHASED BY PERSONS WHO CANNOT AFFORD THE
POSSIBILITY OF THE LOSS OF THE ENTIRE INVESTMENT. PROSPECTIVE INVESTORS SHOULD READ THE ENTIRE PROSPECTUS, INCLUDING ALL EXHIBITS,
AND CAREFULLY CONSIDER, AMONG OTHER FACTORS THE FOLLOWING RISK FACTORS.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Risks Relating to Our Business and Industry</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We are a development stage company with a limited operating
history, making it difficult for you to evaluate our business and your investment.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">NanoAntibiotics, Inc. was incorporated on April 10, 2013.
We are a development stage biopharmaceutical company with conceptual compounds which need to be developed into drug candidates,
and our operations subject to all of the risks inherent in the establishment of a new business enterprise, including but not limited
to the absence of an operating history, the lack of commercialized products, insufficient capital, expected substantial and continual
losses for the foreseeable future, limited experience in dealing with regulatory issues, the lack of manufacturing experience and
limited marketing experience, possible reliance on third parties for the development and commercialization of our proposed products,
a competitive environment characterized by numerous, well-established and well capitalized competitors and reliance on key personnel.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Since inception, we have not established any revenues or
operations that shall provide financial stability in the long term, and there can be no assurance that the Company will realize
its plans on its projected timetable in order to reach sustainable or profitable operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Investors are subject to all the risks incident to the creation
and development of a new business and each Investor should be prepared to withstand a complete loss of his, her or its investment.
Furthermore, the accompanying financial statements have been prepared assuming that the Company will continue as a going concern.
The Company has not emerged from the development stage, and may be unable to raise further equity. These factors raise substantial
doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Because we are subject to these risks, you may have a difficult
time evaluating our business and your investment in our Company. Our ability to become profitable depends primarily on our ability
to develop drugs, to obtain approval for such drugs, and if approved, to successfully commercialize our drugs, our R&amp;D efforts,
including the timing and cost of clinical trials; and our ability to enter into favorable alliances with third-parties who can
provide substantial capabilities in clinical development, regulatory affairs, sales, marketing and distribution.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Even if we successfully develop and market our drug candidates,
we may not generate sufficient or sustainable revenue to achieve or sustain profitability, which could cause us to cease operations
and you will lose all of your investment</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have no products approved for commercial sale, have
never generated any revenues and may never achieve revenues or profitability, which could cause us to cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have no products approved for commercial sale and, to
date, we have not generated any revenues. Our ability to generate revenue depends heavily on (a) successful development and demonstration
in human clinical trials that our nanoantibiotics and nano efflux pump blocker drug candidates are safe and effective; (b) our
ability to seek and obtain regulatory approvals, including, without limitation, with respect to the indications we are seeking;
(c) successful commercialization of our product candidates; and (d) market acceptance of our products. There are no assurances
that we will achieve any of the forgoing objectives. Furthermore, our drug candidates are in the development stage. The candidates
have only been studied in cell-based assays (in vitro), but have not been studied in small animals (in-vivo) or animals with drug
resistant bacteria for efficacy, efficiency and toxicity. If we do not successfully develop and commercialize these products, we
will not achieve revenues or profitability in the foreseeable future, if at all. If we are unable to generate revenues or achieve
profitability, we may be unable to continue our operations.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 8; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We will need to raise substantial additional capital
in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could
have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Developing biopharmaceutical products, including conducting
pre-clinical studies and clinical trials and establishing manufacturing capabilities, requires substantial funding. As of June
30, 2013, we had cash and cash equivalents totaling $505,696. Other than our cash on hand, we currently have no commitments or
arrangements for any additional financing to fund the research and development of our product candidates. We have not generated
any product revenues, and do not expect to generate any revenues until, and only if, we develop, and receive approval to sell our
drug candidates from the FDA and other regulatory authorities for our product candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We currently do not have the resources to complete the development
and commercialization of any of our proposed products. We expect to incur costs of a minimum of $775,000 in the upcoming twelve
months to operate our business in accordance with our business plans. We will require additional financing to further the clinical
development of our drug candidates. In the event that we cannot obtain the required financing, we will be unable to complete the
preclinical development necessary to file an investigational new drug application with the FDA for our leading nano efflux pump
blocker and nanoantibiotics drug candidates. This will delay research and development programs, preclinical studies and clinical
trials, material characterization studies, regulatory processes, the establishment of our own laboratory or a search for third
party marketing partners to market our products for us, which could have a materially adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The amount of capital we may need will depend on many factors,
including the progress, timing and scope of our research and development programs, the progress, timing and scope of our preclinical
studies and clinical trials, the time and cost necessary to obtain regulatory approvals, the time and cost necessary to establish
our own marketing capabilities or to seek marketing partners, the time and cost necessary to respond to technological and market
developments, changes made or new developments in our existing collaborative, licensing and other commercial relationships, and
new collaborative, licensing and other commercial relationships that we may establish.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Until we can generate a sufficient amount of product revenue,
if ever, we expect to finance future cash needs, through public or private equity offerings, debt financings, or corporate collaboration
and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all.
If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research
or development programs or our commercialization efforts. In addition, we could be forced to discontinue product development and
reduce or forego attractive business opportunities. To the extent that we raise additional funds by issuing equity securities,
our stockholders may experience additional significant dilution, and debt financing, if available, may involve restrictive covenants.
To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish
some rights to our technologies or our product candidates, or grant licenses on terms that may not be favorable to us. We may seek
to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for
additional capital at that time.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our fixed expenses, such as rent and other contractual commitments,
will likely increase in the future, as we may enter into leases for new facilities and capital equipment; enter into additional
licenses and collaborative agreements. Therefore, if we fail to raise substantial additional capital to fund these expenses, we
could be forced to cease operations, which could cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have limited experience in drug development and
may not be able to successfully develop any drugs, which would cause us to cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have limited experience in drug development and may not
be able to successfully develop any drugs. Our ability to achieve revenues and profitability in our business will depend on, among
other things, our ability to develop products internally or to obtain rights to them from others on favorable terms; complete laboratory
testing and human studies; obtain and maintain necessary intellectual property rights to our products;&nbsp;successfully complete
regulatory review to obtain requisite governmental agency approvals;&nbsp;enter into arrangements with third parties to manufacture
our products on our behalf; and&nbsp;enter into arrangements with third parties to provide sales and marketing functions. If we
are unable to achieve these objectives we will be forced to cease operations and you will lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 9; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Development of pharmaceutical products is a time-consuming
process, subject to a number of factors, many of which are outside of our control. Consequently, if we are unsuccessful or fail
to timely develop new drugs, we could be forced to discontinue our operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our drug candidates are in early developmental stage. Further
development and extensive testing will be required to determine their technical feasibility and commercial viability. Our success
will depend on our ability to achieve scientific and technological advances and to translate such advances into reliable, commercially
competitive drugs on a timely basis. Drugs that we may develop are not likely to be commercially available for a few years, if
ever. The proposed development schedules for our drug candidates may be affected by a variety of factors, including technological
difficulties, proprietary technology of others, and changes in government regulation, many of which will not be within our control.
Any delay in the development, introduction or marketing of our drug candidates could result either in such drugs being marketed
at a time when their cost and performance characteristics would not be competitive in the marketplace or in the shortening of their
commercial lives. In light of the long-term nature of our projects, the unproven technology involved and the other factors described
elsewhere in this prospectus, we may not be able to complete successfully the development or marketing of any drugs which could
cause us to cease operations.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We may fail to successfully develop and commercialize our
drug candidates if they are found to be unsafe or ineffective in clinical trials; do not receive necessary approval from the FDA
or foreign regulatory agencies; fail to conform to a changing standard of care for the diseases they seek to treat; or are less
effective or more expensive than current or alternative treatment methods.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Drug development failure can occur at any stage of clinical
trials and as a result of many factors and there can be no assurance that we or our collaborators will reach our anticipated clinical
targets. Even if we or our collaborators complete our clinical trials, we do not know what the long-term effects of exposure to
our drug candidates will be. Furthermore, our drug candidates may be used in combination with other treatments and there can be
no assurance that such use will not lead to unique safety issues. Failure to complete clinical trials or to prove that our drug
candidates are safe and effective would have a material adverse effect on our ability to generate revenue and could require us
to reduce the scope of or discontinue our operations, which could cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have no manufacturing experience, and the failure
to comply with all applicable manufacturing regulations and requirements could have a materially adverse effect on our business.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have never manufactured products in the highly regulated
environment of pharmaceutical manufacturing. There are numerous regulations and requirements that must be maintained to obtain
licensure and permitting required prior to the commencement of manufacturing, as well as additional requirements to continue manufacturing
pharmaceutical products. We do not own or lease facilities currently that could be used to manufacture any products that might
be developed by the Company, nor do we have the resources at this time to acquire or lease suitable facilities. If we fail to comply
with regulations, to obtain the necessary licenses and knowhow or to obtain the requisite financing in order to comply with all
applicable regulations and to own or lease the required facilities in order to manufacture our products, we could be forced to
cease operations, which would cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We do not have the sales and marketing personnel necessary
to sell products, and the failure to hire and retain such staff could have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are an early stage development Company with limited resources.
Even if we had products available for sale, which we currently do not, we have not secured sales and marketing staff at this early
stage of operations to sell products. We cannot generate sales without sales or marketing staff and must rely on officers to provide
any sales or marketing services until such personnel are secured, if ever. If we fail to hire and retain the requisite expertise
in order to market and sell our products or fail to raise sufficient capital in order to afford to pay such sales or marketing
staff, then we could be forced to cease operations and you could lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 10; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Even if we were to successfully develop approvable
drugs, we will not be able to sell these drugs if we or our third party manufacturers fail to comply with manufacturing regulations,
which could have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If we were to successfully develop approvable drugs, before
we can begin selling these drugs, we must obtain regulatory approval of our manufacturing facility and process or the manufacturing
facility and process of the third party or parties with whom we may outsource our manufacturing activities. In addition, the manufacture
of our products must comply with the FDA's current Good Manufacturing Practices regulations, commonly known as GMP regulations.
The GMP regulations govern quality control and documentation policies and procedures. Our manufacturing facilities, if any in the
future, and the manufacturing facilities of our third party manufacturers will be continually subject to inspection by the FDA
and other state, local and foreign regulatory authorities, before and after product approval. We cannot guarantee that we, or any
potential third party manufacturer of our products, will be able to comply with the GMP regulations or other applicable manufacturing
regulations. The failure to comply with all necessary regulations would have a materially adverse effect on our business and could
force us to cease operations and you could lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We must comply with significant and complex government
regulations, compliance with which may delay or prevent the commercialization of our drug candidates, which could have a materially
adverse effect on our business.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The R&amp;D, manufacture and marketing of drug candidates
are subject to regulation, primarily by the FDA in the United States and by comparable authorities in other countries. These national
agencies and other federal, state, local and foreign entities regulate, among other things, R&amp;D activities (including testing
in animals and in humans) and the testing, manufacturing, handling, labeling, storage, record keeping, approval, advertising and
promotion of the products that we are developing. Noncompliance with applicable requirements can result in various adverse consequences,
including approval delays or refusals to approve drug licenses or other applications, suspension or termination of clinical investigations,
revocation of approvals previously granted, fines, criminal prosecution, recalls or seizures of products, injunctions against shipping
drugs and total or partial suspension of production and/or refusal to allow a company to enter into governmental supply contracts.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The process of obtaining FDA approval has historically been
costly and time consuming. Current FDA requirements for a new human drug or biological product to be marketed in the United States
include: (a) the successful conclusion of pre-clinical laboratory and animal tests, if appropriate, to gain preliminary information
on the product's safety; (b) filing with the FDA of an IND application to conduct human clinical trials for drugs or biologics;
(c) the successful completion of adequate and well-controlled human clinical investigations to establish the safety and efficacy
of the product for its recommended use; and (d) filing by a company and acceptance and approval by the FDA of a New Drug Application
(NDA) for a drug product or a biological license application (BLA) for a biological product to allow commercial distribution of
the drug or biologic. A delay in one or more of the procedural steps outlined above could be harmful to us in terms of getting
our drug candidates through clinical testing and to market, which could have a materially adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The FDA reviews the results of the clinical trials and may
order the temporary or permanent discontinuation of clinical trials at any time if it believes the drug candidate exposes clinical
subjects to an unacceptable health risk. Investigational drugs used in clinical studies must be produced in compliance with current
good manufacturing practice (GMP) rules pursuant to FDA regulations.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Sales outside the United States of products that we develop
will also be subject to regulatory requirements governing human clinical trials and marketing for drugs and biological products
and devices. The requirements vary widely from country to country, but typically the registration and approval process takes several
years and requires significant resources.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If we experience delays or discontinuations of our clinical
trials by the FDA or comparable authorities in other countries, or if we fail to obtain registration or other approvals of our
products or devices then we could be forced to cease our operations and you will lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 11; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have no experience in conducting or supervising
clinical trials and must outsource all clinical trials which will severely limit our ability to control the compliance by subcontractors
of all regulations necessary to validate our drugs in a timely manner, if at all, which could have a materially adverse effect
on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Even if we are successful in developing our nano efflux pump
blocker or our nanoantibiotics, we have no experience in conducting or supervising clinical trials that must be performed to obtain
data to submit in concert with applications for approval by the FDA. The regulatory process to obtain approval for drugs for commercial
sale involves numerous steps. Drugs are subjected to clinical trials that allow development of case studies to examine safety,
efficacy, and other issues to ensure that sale of drugs meets the requirements set forth by various governmental agencies, including
the FDA. In the event that our protocols do not meet standards set forth by the FDA, or that our data is not sufficient to allow
such trials to validate our drugs in the face of such examination, we might not be able to meet the requirements that allow our
drugs to be approved for sale which could have a materially adverse affect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Because we have no experience in conducting or supervising
clinical trials, we will need to outsource our clinical trials to third parties. We have limited control over their compliance
with procedures and protocols used to complete clinical trials in accordance with standards required by the agencies that approve
drugs for sale. If these subcontractors fail to meet these standards, the validation of our drugs would be adversely effected,
causing a delay in or indefinitely prohibiting our ability to meet revenue-generating operations and we could be forced to cease
operations and you could lose all of your investment</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We can provide no assurance that our drug candidates
will obtain regulatory approval or that the results of clinical studies will be favorable.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The business plan we have developed for the next twelve months
is to engage an outside vendor capable of providing the research needed for a future filing of an Investigational New Drug (IND)
application for our portfolio of nanoantibiotic drugs. We need to undertake studies in animal models to obtain necessary data regarding
efficacy, pharmaco-kinetic, and pharmaco-dynamic profiles of our drug candidates. The data will then be used to file an IND application,
towards the goal of obtaining FDA approval for testing the drugs in human patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The testing, marketing and manufacturing of any product for
use in the United States will require approval from the FDA. We cannot predict with any certainty the amount of time necessary
to obtain such FDA approval and whether any such approval will ultimately be granted. Preclinical and clinical trials may reveal
that one or more products are ineffective or unsafe, in which event further development of such products could be seriously delayed
or terminated. Moreover, obtaining approval for certain products may require testing on human subjects of substances whose effects
on humans are not fully understood or documented. Delays in obtaining FDA or any other necessary regulatory approvals of any proposed
drug and failure to receive such approvals would have an adverse effect on the drug's potential commercial success and on our business,
prospects, financial condition and results of operations. In addition, it is possible that a proposed drug may be found to be ineffective
or unsafe due to conditions or facts that arise after development has been completed and regulatory approvals have been obtained.
In this event, we may be required to withdraw such proposed drug from the market. To the extent that our success will depend on
any regulatory approvals from government authorities outside of the United States that perform roles similar to that of the FDA,
uncertainties similar to those stated above will also exist and should it result in our drug candidates failing to receive regulatory
approval you could lose all of your investment.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>The Company does not currently have product liability
insurance and is therefore exposed to product liability, preclinical and clinical liability risks which could place a substantial
financial burden upon the Company and which could cause you to lose all of your investment.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company does not currently have product liability insurance
or other liability insurance relating to clinical trials or to the marketing of any products or compounds. The Company cannot assure
you that it will be able to obtain or maintain adequate product liability insurance on acceptable terms, if at all, or that such
insurance will provide adequate coverage against the Company's potential liabilities. Claims or losses as a result of such may
have a material adverse effect on our business, financial condition and results of&nbsp;operations and you could lose all of your
investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 12; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Confidentiality agreements with employees and others
may not adequately prevent disclosure of trade secrets and other proprietary information and disclosure of our trade secrets or
proprietary information could compromise any competitive advantage that we have, which could have a materially adverse effect on
our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We depend heavily upon confidentiality agreements with our
officers, employees, consultants and subcontractors to maintain the proprietary nature of our technology. These measures may not
afford us complete or even sufficient protection, and may not afford an adequate remedy in the event of an unauthorized disclosure
of confidential information. In addition, others may independently develop technology similar to ours, otherwise avoiding the confidentiality
agreements, or produce patents that would materially and adversely affect our business, prospects, financial condition and results
of operations in which event and you could lose all of your investment.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may be unable to obtain or protect intellectual
property rights relating to our products, and we may be liable for infringing upon the intellectual property rights of others,
which could have a materially adverse effect on our business.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our ability to compete effectively will depend on our ability
to maintain the proprietary nature of our technologies. Although we expect to file a number of patent applications in the coming
years,&nbsp;we have not filed any patent applications on our intellectual property to date. Even if we do file patent applications,
there can be no assurance that the applications will ultimately result in the issuance of a patent with respect to the technology
owned by us or licensed to us. The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain
and involves complex legal and factual considerations. The standards that the United States Patent and Trademark Office use to
grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding
the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. Accordingly, we do not
know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued
to us or to others. Further, we rely on a combination of trade secrets, know-how, technology and nondisclosure, and other contractual
agreements and technical measures to protect our rights in the technology. If any trade secret, know-how or other technology not
protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition
could be materially adversely affected.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not believe that any of the drug candidates we are
currently developing infringe upon the rights of any third parties nor are they infringed upon by third parties. However, there
can be no assurance that our technology will not be found in the future to infringe upon the rights of others or be infringed upon
by others. In such a case, others may assert infringement claims against us, and should we be found to infringe upon their patents,
or otherwise impermissibly utilize their intellectual property, we might be forced to pay damages, potentially including treble
damages, if we are found to have willfully infringed on such parties' patent rights. In addition to any damages we might have to
pay, we may be required to obtain licenses from the holders of this intellectual property, enter into royalty agreements, or redesign
our drug candidates so as not to utilize this intellectual property, each of which may prove to be uneconomical or otherwise impossible.
Conversely, we may not always be able to successfully pursue our claims against others that infringe upon our technology. Thus,
the proprietary nature of our technology or technology licensed by us may not provide adequate protection against competitors.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Moreover, the cost to us of any litigation or other proceeding
relating to our patents and other intellectual property rights, even if resolved in our favor, could be substantial, and the litigation
would divert our management's efforts. Uncertainties resulting from the initiation and continuation of any litigation could limit
our ability to continue our operations and you could lose all of your investment.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We depend upon our management and their loss or unavailability
could put us at a competitive disadvantage which could have a material adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We currently depend upon the efforts and abilities of our
management team of Rajah Menon, our President and a Director, and Elliot Ehrlich, our Chief Executive Officer, Chief Financial
Officer, Treasurer, Corporate Secretary and Chairman of the Board. Mr. Menon serves the Company part-time. The loss or unavailability
of the services of either of these individuals for any significant period of time could have a material adverse effect on our business,
prospects, financial condition and results of operations which may cause you to lose all of your investment. We have not obtained,
do not own, nor are we the beneficiary of key-person life insurance.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may not be able to attract and retain highly skilled
personnel, which could have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our ability to attract and retain highly skilled personnel
is critical to our operations and expansion. We face competition for these types of personnel from other pharmaceutical companies
and more established organizations, many of which have significantly larger operations and greater financial, technical, human
and other resources than us. We may not be successful in attracting and retaining qualified personnel on a timely basis, on competitive
terms, or at all. If we are not successful in attracting and retaining these personnel, our business, prospects, financial condition
and results of operations will be materially and adversely affected.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 13; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>The biotechnology and biopharmaceutical industries
are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with enterprises
equipped with more substantial resources than us, which could cause us to curtail or cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The biotechnology and biopharmaceutical industries are characterized
by rapid technological developments and a high degree of competition based primarily on scientific and technological factors. These
factors include the availability of patent and other protection for technology and products, the ability to commercialize technological
developments and the ability to obtain government approval for testing, manufacturing and marketing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We compete with biopharmaceutical firms in the United States,
Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.
Many biopharmaceutical companies have focused their development efforts in the human therapeutics area, including antibiotics.
Many major pharmaceutical companies have developed or acquired internal biotechnology capabilities or made commercial arrangements
with other biopharmaceutical companies. These companies, as well as academic institutions, government agencies and private research
organizations, also compete with us in recruiting and retaining highly qualified scientific personnel and consultants. Our ability
to compete successfully with other companies in the pharmaceutical field will also depend to a considerable degree on the continuing
availability of capital to us.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are aware of numerous products under development or manufactured
by competitors that are used for the treatment of bacterial diseases we have targeted for drug development. The field of antibiotics
is one of the most competitive segments of the pharmaceutical business. Numerous companies including Cubist Pharmaceuticals, Nabriva
Therapeutics, Forest Laboratories, Theravance, Trius Therapeutics, Basilea Pharmaceutical, Teva Pharmaceuticals, Eli Lilly and
Company, Pfizer, Roche, Salix Pharmaceuticals and Viropharma Pharmaceuticals are developing biopharmaceutical products that potentially
directly compete with our drug candidates even though their approach to such treatment is different.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">With respect to our nanoantibiotics, the three major branded
antibiotics used for the treatment of serious infections, that we are aware of are Zyvox (linezolid), Cubicin (daptomycin) and
Tygacil (tigecycline). In addition, there were over four million courses of vancomycin, a generic drug used to treat serious infections
caused by resistant gram-positive bacteria like MRSA, dosed in 2009.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our competition will be determined in part by the potential
indications for which drugs are developed and ultimately approved by regulatory authorities. Additionally, the timing of the market
introduction of some of our potential drugs or of competitors' products may be an important competitive factor. Accordingly, the
relative speed with which we can develop drugs, complete pre-clinical testing, clinical trials, approval processes and supply commercial
quantities to market are important competitive factors. We expect that competition among drugs approved for sale will be based
on various factors, including product efficacy, safety, reliability, availability, price and patent protection.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The successful development of biopharmaceuticals is highly
uncertain. A variety of factors including, pre-clinical study results or regulatory approvals, could cause us to abandon the development
of our drug candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 14; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Successful development of biopharmaceuticals is highly
uncertain and is dependent on numerous factors, many of which are beyond our control. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Products that appear promising in the early phases of development
may fail to reach the market for several reasons. Pre-clinical study results that may show the product to be less effective than
desired (e.g., the study failed to meet its primary objectives) or to have harmful or problematic side effects. Products may fail
to receive the necessary regulatory approvals or may be delayed in receiving such approvals. Among other things, such delays may
be caused by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements for data
analysis or a IND and later NDA, preparation, discussions with the FDA, an FDA request for additional pre-clinical or clinical
data or unexpected safety or manufacturing issues;&nbsp;manufacturing costs, pricing or reimbursement issues, or other factors
that make the product not economical. Proprietary rights of others and their competing products and technologies may also prevent
the product from being commercialized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Success in pre-clinical and early clinical studies does not
ensure that large-scale clinical studies will be successful. Clinical results are frequently susceptible to varying interpretations
that may delay, limit or prevent regulatory approvals. The length of time necessary to complete clinical studies and to submit
an application for marketing approval for a final decision by a regulatory authority varies significantly from one product to the
next, and may be difficult to predict. There can be no assurance that any of our products will develop successfully, and the failure
to develop our products will have a materially adverse effect on our business and will cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have no employment or compensation agreements with
our two officers and directors, and as such they may have little incentive to devote time and energy to the operation of the Company.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our officers are not subject to any employment or compensation
agreement with the Company. Therefore, it is possible that our officers may decide to focus their respective efforts on other projects
or companies which have a higher economic benefit. Currently, they are not obligated to spend a minimum amount of time on Company
business and could opt to leave the Company for other opportunities or focus on other business which could negatively impact the
Company&rsquo;s ability to succeed. We do not have any expectation that our officers and directors will enter into an employment
or compensation agreement with the Company in the foreseeable future and their loss would be highly detrimental to our ability
to conduct ongoing operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>There are conflicts of interest among our officers,
directors and stockholders. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Certain of our executive officers and directors and their
affiliates are engaged in other activities and have interests in other entities on their own behalf or on behalf of other persons.
Neither we nor any of our shareholders will have any rights in these ventures or their income or profits. In particular, our executive
officers or directors or their affiliates may have an economic interest in or other business relationship with partner companies
that invest in us or are engaged in competing drug development.&nbsp;Presently, Kard Scientific, a contract research organization
for the biotech industry is a company controlled by Rajah Menon, our President and Director. We have not yet engaged or contracted
with Kard to conduct any studies, however in the future we may decide to do so. Our executive officers or directors may have conflicting
fiduciary duties to us and third parties. The terms of transactions with third parties may not be subject to arm's length negotiations
and therefore may be on terms less favorable to us than those that could be procured through arm's length negotiations. Although
the Company is not aware of any conflict that has arisen to date, we do not have any policy in place to deal with such should such
a conflict arise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may enter into employment agreements with our executive
officers and compensation payable thereunder may not be based on arms-length negotiations. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company&rsquo;s current executive officers also serve
as directors of the Company, and the Company does not have an independent compensation committee to determine compensation and
to approve employment agreements. Therefore, compensation which may be paid by the Company to its management may not be determined
based on arms-length negotiations. The Company may grant stock options and other equity incentives to its executive officers and
directors that are consistent with the nature of the pharmaceutical industry. There can be no assurance made that the consideration
which may be payable to management will reflect the true market value of services provided to the Company.</P>


<!-- Field: Page; Sequence: 15; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">RISKS RELATING TO OUR COMMON
STOCK</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>There is a risk of dilution of your percentage ownership
of Common Stock in the Company. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">The Company has the right to raise
additional capital or incur borrowings from third parties to finance its business. The Company may also implement public or private
mergers, business combinations, business acquisitions and similar transactions pursuant to which it would issue substantial additional
capital stock to outside parties, causing substantial dilution in the ownership of the Company by its existing stockholders. Our
Board of Directors has the authority, without the consent of any of the stockholders, to cause the Company to issue more shares
of Common Stock and/or preferred stock at such price and on such terms and conditions as are determined by the Board in its sole
discretion. The issuance of additional shares of capital stock by the Company will dilute your ownership percentage in the Company
</FONT>and could impair our ability to raise capital in the future through the sale of equity securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Certain stockholders who are also officers and directors
of the Company may have significant control over our management.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">The directors and executive officers
of the Company own more than 39.05% of the Common Stock of the Company. Certain immediate family members of our officers and directors
own an aggregate 43,870,000 shares, which currently constitutes 50.39% of our common stock, however our officers and directors
specifically disclaim any beneficial ownership in such shares (see &ldquo;Certain Relationships and Related Party Transactions&rdquo;).
</FONT>Our officers, directors and their immediate family members currently own 89.44% of the outstanding shares of our common
stock.<FONT STYLE="color: black"> As a result, such entities may have a significant influence on the affairs and management of
the Company, as well as on all matters requiring member approval, including electing and removing members of the Company&rsquo;s
Board of Directors, causing the Company to engage in transactions with affiliated entities, causing or restricting the sale or
merger of the Company, and certain other matters. Such concentration of ownership and control could have the effect of delaying,
deferring or preventing a change in control of the Company even when such a change of control would be in the best interests of
the Company&rsquo;s stockholders. </FONT></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>There is no liquidity and no established public market
for our Common Stock and we may not be successful at obtaining a quotation on a recognized quotation service. In such event it
may be difficult for you to sell your shares.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There is presently no public market in our shares. There
can be no assurance that we will be successful at developing a public market or in having our Common Stock quoted on a quotation
facility such as the OTC Bulletin Board. There are risks associated with obtaining a quotation, including that broker dealers will
not be willing to make a market in our shares, or to request that our shares be quoted on a quotation service. In addition, even
if a quotation is obtained, the OTC Bulletin Board and similar quotation services are often characterized by low trading volumes,
and price volatility, which may make it difficult for an investor to sell our Common Stock on acceptable terms. If trades in our
Common Stock are not quoted on a quotation facility, it may be very difficult for an investor to find a buyer for their shares
in our Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our Common Stock is subject to the &ldquo;penny stock&rdquo;
rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may
reduce the value of an investment in our stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Under U.S. federal securities legislation, our Common Stock
will constitute &ldquo;penny stock&rdquo;. Penny stock is any equity security that has a market price of less than $5.00 per share,
subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require that a broker or dealer
approve a potential investor&rsquo;s account for transactions in penny stocks, and the broker or dealer receive from the investor
a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. In order to
approve an investor&rsquo;s account for transactions in penny stocks, the broker or dealer must obtain financial information and
investment experience objectives of the person, and make a reasonable determination that the transactions in penny stocks are suitable
for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks
of transactions in penny stocks. The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure
schedule prepared by the Securities and Exchange Commission relating to the penny stock market, which, in highlight form sets forth
the basis on which the broker or dealer made the</P>


<!-- Field: Page; Sequence: 16; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">suitability determination. Brokers may be less willing to
execute transactions in securities subject to the &ldquo;penny stock&rdquo; rules. This may make it more difficult for investors
to dispose of our common stock and cause a decline in the market value of our stock. Disclosure also has to be made about the risks
of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer
and the registered representative, current quotations for the securities and the rights and remedies available to an investor in
cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for
the penny stock held in the account and information on the limited market in penny stocks.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may, in the future, issue additional common stock,
which would reduce investors&rsquo; percent of ownership and may dilute our share value.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our Articles of Incorporation authorize the issuance of 300,000,000
shares of Common Stock. As of the date of this prospectus, the Company had 87,060,000 shares of Common Stock outstanding. Accordingly,
we may issue up to an additional 212,940,000 shares of Common Stock. The future issuance of Common Stock may result in substantial
dilution in the percentage of our Common Stock held by our then existing shareholders. We may value any Common Stock in the future
on an arbitrary basis. The issuance of Common Stock for future services or acquisitions or other corporate actions may have the
effect of diluting the value of the shares held by our investors, might have an adverse effect on any trading market for our Common
Stock and could impair our ability to raise capital in the future through the sale of equity securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have a large number of restricted shares outstanding,
a portion of which may be sold under Rule 144 which may reduce the market price of our shares.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Of the 87,060,000 shares of Common Stock currently issued
and outstanding, and assuming no Warrants are exercised, <FONT STYLE="color: black">29,190,000 </FONT>shares are held by non-affiliates
and 52,870,000 are owned by affiliates of the Company, consisting of our officers and directors and a large shareholder. All of
these securities are deemed &ldquo;restricted securities&rdquo; within the meaning of Rule 144 as promulgated under the Securities
Act. Other than the 5,000,000 shares previously issued to the selling securityholders in the Private Placement and other than the
5,000,000 shares underlying the Warrants purchased in the Private Placement, none of the above described shares are being offered
for sale in this prospectus. Consequently, the sale of such shares is subject to Rule 144.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">It is anticipated that all of the &ldquo;restricted securities&rdquo;
will be eligible for resale under Rule 144. In general, under Rule 144, subject to the satisfaction of certain other conditions,
a person, who is not an affiliate (and who has not been an affiliate for a period of at least three months immediately preceding
the sale) and who has beneficially owned restricted shares of our common stock for at least six months is permitted to sell such
shares without restriction, provided that there is sufficient public information about us as contemplated by Rule 144. An affiliate
who has beneficially owned restricted shares of our common stock for a period of at least one year may sell a number of shares
equal to one percent of our issued and outstanding common stock approximately every three months.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The respective holding periods for the shares issued to affiliates
and non-affiliates holding restricted securities commenced and were issued between May 17, 2013 and June 30, 2013. The possibility
that substantial amounts of our Common Stock may be sold under Rule 144 into the public market may adversely affect prevailing
market prices for the Common&nbsp;Stock and could impair our ability to raise capital in the future through the sale of equity
securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>The lack of public company experience of our management
team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially
adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our officers lack public company experience, which could
impair our ability to comply with legal and regulatory requirements such as those imposed by Sarbanes-Oxley Act of 2002. Our two
officers and directors have never been responsible for managing a publicly traded company. Such responsibilities include complying
with federal securities laws and making required disclosures on a timely basis. Any such deficiencies, weaknesses or lack of compliance
could have a materially adverse effect on our ability to comply with the reporting requirements of the Securities Exchange Act
of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which is necessary to maintain our public company status. If we were to fail
to fulfill those obligations, our ability to continue as a U.S. public company would be in jeopardy in which event you could lose
your entire investment in our Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>The Company is considered a smaller reporting company
and is exempt from certain disclosure requirements, which could make our stock less attractive to potential investors.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Rule 12b-2 of the Exchange Act defines a &ldquo;smaller reporting
company&rdquo; as an issuer that is not an investment company, an asset-backed issuer), or a majority-owned subsidiary of a parent
that is not a smaller reporting company and that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%; line-height: normal; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="width: 93%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">Had a public float of less than $75 million as of the last business day of its most recently completed second fiscal quarter, computed by multiplying the aggregate worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market for the common equity; or</font></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%; line-height: normal; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="width: 93%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">In the case of an initial registration statement under the Securities Act or Exchange Act for shares of its common equity, had a public float of less than $75 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated public offering price of the shares; or</font></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%; line-height: normal; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="width: 93%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">In the case of an issuer whose public float as calculated under paragraph (1) or (2) of this definition was zero, had annual revenues of less than $50 million during the most recently completed fiscal year for which audited financial statements are available.</font></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">As a &ldquo;smaller reporting company&rdquo; (in addition
to and without regard to our status as an &ldquo;emerging growth company&rdquo;) we are not required and may not include a Compensation
Discussion and Analysis (&quot;CD&amp;A&quot;) section in our proxy statements; we provide only 3 years of business development
information; provide fewer years of selected financial data; and have other &ldquo;scaled&rdquo; disclosure requirements that are
less comprehensive than issuers that are not &ldquo;smaller reporting companies&rdquo; which could make our stock less attractive
to potential investors, which could make it more difficult for you to sell your shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>The Company is considered an &ldquo;emerging growth
company&rdquo; and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make
our Common Stock less attractive to investors.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are an &ldquo;emerging growth company,&rdquo; as defined
in the Jumpstart our Business Startups Act of 2012, and we may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies, including, but not limited to, not being required to comply with the auditor attestation
requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic
reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation
and shareholder approval of any golden parachute payments not previously approved.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We will remain an emerging growth company until the earlier
of (i) the last day of the fiscal year (A) following the fifth anniversary of our first sale of common equity securities pursuant
to an effective registration statement, (B) in which we have total annual gross revenue of at least $1.0 billion, or (C) the date
that we become a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the Exchange Act, which would occur if the
market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently
completed second fiscal quarter, and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during
the prior three-year period.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We cannot predict if investors will find our Common Stock
less attractive because we will rely on these exemptions. If some investors find our Common Stock less attractive as a result,
there may be a less active trading market for our Common Stock and our stock price may be more volatile when trading occurs.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We intend to become subject to the periodic reporting
requirements of the Exchange Act, which will require us to incur audit fees and legal fees in connection with the preparation of
such reports. These additional costs will negatively affect our ability to earn a profit.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Following the effective date of the registration statement
in which this prospectus is included, we will be required to file periodic reports with the Securities and Exchange Commission
pursuant to the Exchange Act and the rules and regulations thereunder. In order to comply with such requirements, our independent
registered auditors will have to review our financial statements on a quarterly basis and audit our financial statements on&nbsp;an
annual basis. Moreover, our legal counsel will have to review and assist in the preparation of such reports. Factors such as the
number and type of transactions that we engage in and the complexity of our reports cannot accurately be determined at this time
and may have a major negative effect on the cost and amount of time to be spent by our auditors and attorneys. However, the incurrence
of such costs will be an expense to our operations and thus have a negative effect on our ability to meet our overhead requirements
and earn a profit.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">However, for as long as we remain an &ldquo;emerging growth
company&rdquo; we intend to take advantage of certain exemptions from various reporting requirements until we are no longer an
&ldquo;emerging growth company.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We also qualify as a smaller reporting company, and so long
as we remain a smaller reporting company, we benefit from the same exemptions and exclusions as an emerging growth company. In
the event that we cease to be an emerging growth company as a result of a lapse of the five year period, but continue to be a smaller
reporting company, we would continue to be subject to the exemptions available to emerging growth companies until such time as
we were no longer a smaller reporting company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">After, and if ever, we are no longer an &ldquo;emerging growth
company,&rdquo; we expect to incur significant additional expenses and devote substantial management effort toward ensuring compliance
with those requirements applicable to companies that are not &ldquo;emerging growth companies,&rdquo; including Section 404 of
the Sarbanes-Oxley Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>The JOBS Act allows us to delay the adoption of new
or revised accounting standards that have different effective dates for public and private companies, which means that our financial
statements may not be comparable to companies that comply with public company effective dates, which could make our Common Stock
less attractive to investors.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Since, we have elected to use the extended transition period
for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act, this election allows us to delay
the adoption of new or revised accounting standards that have different effective dates for public and private companies until
those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies
that comply with public company effective dates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Because we do not intend to pay any cash dividends
on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We intend to retain any future earnings to finance the development
and expansion of our business. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Unless
we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. There is no assurance
that stockholders will be able to sell shares when desired.</P>


<!-- Field: Page; Sequence: 19; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">This prospectus contains forward-looking statements which
relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology
such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue&rdquo; or the negative of these terms
or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other
factors, including the risks in the section entitled &ldquo;Risk Factors&rdquo; that may cause our or our industry&rsquo;s actual
results, levels of activity, performance or achievements to be materially different from any future results, levels of activity,
performance or achievements expressed or implied by these forward-looking statements. In addition, you are directed to factors
discussed in the Business section&nbsp;the Management&rsquo;s Discussion and Analysis or Plan of Operation section&nbsp;and those
discussed elsewhere in this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">While these forward-looking statements, and any assumptions
upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual
results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future
performance suggested herein. Except as required by applicable law, including by the securities laws of the United States, we do
not intend to update any of the forward-looking statements to conform these statements to actual results.</P>


<!-- Field: Page; Sequence: 20; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">USE OF PROCEEDS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We will not receive any proceeds from the sale of the Common
Stock offered through this prospectus by the selling securityholders. To the extent that the selling securityholders exercise in
cash all of the Warrants at an exercise price of $0.50 per share which may be adjusted from time to time in accordance with the
terms of the Warrant, we would receive $2,500,000 in the aggregate from such exercise.&nbsp;The proceeds from the cash exercise
of such Warrants, if any, will be used by us for working capital and other general corporate purposes.</P>


<!-- Field: Page; Sequence: 21; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">DETERMINATION OF OFFERING
PRICE</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Since our Common Stock is not listed or quoted on any exchange
or quotation system, the offering price of the shares of Common Stock was determined by the price of the Common Stock that was
sold to the selling securityholders pursuant to an exemption under Section 4(2) of the Securities Act and Rule 506 of Regulation
D promulgated under the Securities Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The offering price of the shares of our Common Stock does
not necessarily bear any relationship to our book value, assets, past operating results, financial condition or any other established
criteria of value. The facts considered in determining the offering price were our financial condition and prospects, our limited
operating history and the general condition of the securities market.</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Although our Common Stock is not listed on a public exchange,
we intend to apply for our Common Stock to be quoted on the OTCBB concurrently with the filing of this prospectus. In order to
be quoted on the OTCBB, a market maker must file an application on our behalf in order to make a market for our Common Stock. We
can make no assurance that a market maker will file the necessary documents with FINRA, which operates the OTCBB, nor can there
be any assurance that such an application for quotation will be approved even if a market maker does file the necessary documents.</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In addition, can be no assurance that our Common Stock will
trade or be quoted at market prices in excess of the initial offering price as prices for the Common Stock in any public market
which may develop will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity
of our Common Stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">MARKET FOR COMMON EQUITY
AND RELATED SHAREHOLDER MATTERS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There is presently no public market for our shares of Common
Stock. We intend to apply for our Common Stock to be quoted on the OTCBB. However, we can provide no assurance that our shares
of Common Stock will be quoted on the OTCBB or, if quoted, that any public market will materialize.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Holders</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">As of June 30, 2013,&nbsp;we had approximately 56 record
holders of our Common Stock, and a total of 87,060,000 shares of Common Stock issued and outstanding. We do not have any shares
of preferred stock issued or outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Since inception we have not paid any dividends on our Common
Stock. We currently do not anticipate paying any cash dividends in the foreseeable future on our Common Stock,&nbsp;although we
intend to retain our earnings, if any, to finance the exploration and growth of our business, our Board of Directors will have
the discretion to declare and pay dividends in the future. Payment of dividends in the future will depend upon our earnings, capital
requirements, and other factors, which our Board of Directors may deem relevant.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Founder Shares </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On April 10, 2013, we issued an aggregate of 82,060,000 shares
of Common Stock to our founders, of which 52,870,000 shares were issued to affiliates and 29,190,000 shares issued to non-affiliates
at par value ($0.0001 per share), for aggregate proceeds to the Company of $8,206.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Private Placement</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On June 30, 2013, we raised gross proceeds of $500,000 through
the private placement of 5,000,000 Units at $0.10 per Unit, with each Unit consisting of one (1) share of our Common Stock, and
a five (5) year Warrant to purchase one (1) share of our Common Stock exercisable at a price of $0.50 per share which may be adjusted
from time to time in accordance with the terms of the Warrant, to certain accredited investors pursuant to Rule 506 under Regulation
D. The following sets forth the identity of persons to whom we sold shares of Common Stock and corresponding Warrants and the amount
of shares of Common Stock beneficially owned by each stockholder as of the date of this prospectus (half of each holder&rsquo;s
equity set forth below constitute shares of common stock underlying Warrants):</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 40%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Name <sup>(1)</sup></b></font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="width: 58%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Shares of Common Stock Beneficially Owned <sup>(2)</sup></b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Boro Park Physical Therapy PLLC </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,000,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Cook Street Plaza LLC </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">100,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Corr, Keith P. </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Frankel, Marsha </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">400,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Ginsburg, Faiga Zipporah </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">500,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Gorelik, Roman </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Jones, Byron D.</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Kirschbaum, Scott </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Landesman, Joseph </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">400,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Lawrence Partners LLC </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,666,668</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Logan, Benjamin and Malgorzata </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">600,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Monsey Equities LLC </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,666,666</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Pace Jr., John </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Patarkatsi, Merabi </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,000,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Pelcovitz, Baruch </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Road Holdings LLC </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,666,666</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Schechter, Barry</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">50,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Sugar, Shmuel </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Zimmerman, Michael and Risa </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">50,000</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Zwick. Jeffrey </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Total</b></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>10,220,000</b></font></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">__________________________________________________________________________</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">(1) Shareholdings of spouses are listed together.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">(2) Beneficial ownership is determined in accordance with
the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership
of that person, securities that are currently convertible or exercisable into shares of our Common Stock, or convertible or exercisable
into shares of our Common Stock within 60 days of the date of this prospectus are deemed outstanding. Such shares, however, are
not deemed outstanding for the purposes of computing the percentage ownership of any other person.</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">No underwriters were utilized and no commissions or fees
were paid with respect to any of the above transactions. These persons were the only offerees in connection with these transactions.
We relied on Section 4(2) and Rule 506 of Regulation D of the Securities Act for both of the transactions set forth above since
neither of the two transactions involved any public offering.</P>


<!-- Field: Page; Sequence: 24; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">DILUTION</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Common Stock to be sold by the selling securityholders
is provided in the &ldquo;Selling Securityholders&rdquo; section in this prospectus below and represents Common Stock that is currently
issued. Accordingly, there will be no dilution to our existing stockholders.</P>


<!-- Field: Page; Sequence: 25; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">MANAGEMENT&rsquo;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">This section of the prospectus includes a number of forward-looking
statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are
often identified by words like &ldquo;believe&rdquo;, &ldquo;expect&rdquo;, &ldquo;estimate&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;intend&rdquo;,
&ldquo;project&rdquo; and similar expressions, or words which, by their nature, refer to future events. You should not place undue
certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties
that could cause actual results to differ materially from our predictions.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Management&rsquo;s Plan of Operation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We were incorporated under the laws of the State of Nevada
on <FONT STYLE="color: black">April 10, 2013</FONT>. <FONT STYLE="color: black">We are an early developmental stage biotechnology
company engaged in the discovery, development and commercialization of new classes of broad spectrum antibiotics for gram-negative
and gram-positive bacterial infections, including some of the most difficult-to-treat Multi Drug Resistant Bacteria, also called
&ldquo;Superbugs&rdquo;.&nbsp;We have no products for sale and will not generate or realize any revenues until we develop our antibiotics
and receive approval from the FDA or equivalent foreign regulatory bodies to begin selling our pharmaceutical candidates. Developing
pharmaceutical products, however, is a lengthy and very expensive process with no assurance of regulatory or commercial success.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">The Company will initially spend
most of its efforts and resources on NEB-MRSA and NA-MRSA for the treatment of <I>Methicillin-resistant Staphylococcus aureus (MRSA)</I>.
This compound&rsquo;s efflux pump blocker is furthest along in its development. Further work is needed in sourcing materials and
synthesizing the compound before beginning in-vivo studies against <I>Methicillin-resistant Staphylococcus aureus (MRSA)</I>. We
plan on making multiple variations of this compound and pairing them with suitable antibiotics and test it in cell-based assays.
Thereafter, we will engage a contract research organization for in-vivo testing. The results of this testing will determine if
the Company will pursue and complete US Food and Drug Administration &ldquo;IND&rdquo; (investigational new drug) enabling studies.
We anticipate development costs of NEB-MRSA and NA-MRSA during the next 12 months to be approximately $250,000. We also plan on
developing a second efflux pump blocker, NEB-TB and NA-TB, for the treatment of Drug-resistant tuberculosis (<I>MDR-TB and XDR-TB</I>).
The development pathway is similar to NEB-MRSA and NA-</FONT>MRSA and we expect these costs during the next 12 months to also be
approximately $250,000. Accordingly, we must raise cash to fund the development of these compounds. As of June 30, 2013, the Company&rsquo;s
available funds are not sufficient to fund our activities for the next 12 months.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We recorded $17,515 as selling, general and administrative
expenses at June 30, 2013, of which $17,500 was attributable to professional (legal and accounting) fees. Prior to the Company&rsquo;s
inception our compounds were composed and formulated by researchers at Kard, a preclinical contract research organization founded
by our President Rajah Menon in 2002 and of which Mr. Menon is its principal shareholder, who then conducted in-vitro studies.
On October 3, 2013 Kard and Mr. Menon assigned all of their rights, formulations, and all studies and data related to efflux pump
antibiotics to the Company. <FONT STYLE="background-color: white">According to ASC 845-10-S99, transfers of non-monetary assets
to a company by its promoters or shareholders in exchange for stock prior to or at the time of the entity&rsquo;s initial public
offering should be recorded at the transferors' historical cost basis determined under GAAP. &nbsp;</FONT>As such the<FONT STYLE="background-color: white">
cost basis carried on Kard&rsquo;s books and records was zero. &nbsp;Therefore, the accounting principles in ASC 845-10-S99 were
followed and the Company recorded the rights at its historical cost basis, which was </FONT>at the historical cost basis of zero.
Although the transfer was at $1, this amount was determined by the Company to be de-minimus and immaterial.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are now engaged in organizational activities and sourcing
compounds and materials. In July 2013, we engaged a third party vendor, S&amp;T Global, Inc. (&quot;S&amp;T&quot;) of Woburn, MA,
for formulation and pre-clinical testing. &nbsp;We have not yet entered into a material definitive written agreement with S&amp;T
as we first want to see how their work progresses.&nbsp; Either party may terminate the relationship at any time.&nbsp;S&amp;T
is paid on an hourly basis for their work. &nbsp; As of the date of this prospectus, we incurred and have paid, in cash, $9,600
in costs by S&amp;T&nbsp;for the months of July through September 30, 2013. We anticipate incurring other costs associated with
equipment purchases and general and administrative expenses, including employee salaries and benefits, legal expenses, and other
costs associated with an early stage, publicly-traded company. We anticipate adding at least one employe<FONT STYLE="color: black">e
in the area of research, and possibly another employee to perform general and administrative functions. We expect to incur significant
legal and related expenses to protect our intellectual property.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The amounts that we actually spend for any specific purpose
may vary significantly, and will depend on a number of factors including, but not limited to, the pace of progress of our research
and development, market conditions, and our ability to qualify vendors. In addition, we may use a portion of any net proceeds to
acquire complementary compounds; however, we do not have plans for any acquisitions at this time. We will have significant discretion
in the use of any net proceeds. Investors will be relying on the judgment of our management regarding the application of the proceeds
of any sale of our Common Stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Requirement for Additional Capital</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company has engaged in limited research and development
activities. We currently do not have sufficient funds to meet our planned drug development for the next twelve (12) months and
we may not be able to obtain the necessary financing on terms and conditions acceptable to the Company. Assuming that we are successful
in raising additional financing, we plan to incur the following expenses over the next twelve (12) months:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and Development of $500,000, which includes planned costs
for NEB-MRSA, NA-MRSA, and NEB-TB, NA-TB;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Corporate overhead of $100,000, which includes budgeted legal, accounting
and other costs expected to be incurred;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital costs of $75,000, which is the estimated cost for equipment
to be deployed at vendor sites to be selected; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Staffing costs of $100,000.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company presently has approximately $500,000 cash on
hand and will be unable to proceed with its planned drug development, meet its administrative expense requirements, capital costs,
or staffing costs without obtaining additional net financing of approximately $275,000 to meet its budget.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company has limited experience with pharmaceutical drug
development. As such these budget estimates may not be accurate. In addition, the actual work to be performed is not known at this
time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional work may become
necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget. Such changes
may also have an adverse impact on our projected timeline of drug development.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Management intends to use capital and debt financing, as
required, to fund the Company's operations. There can be no assurance that the Company will be able to obtain the additional capital
resources necessary to fund its anticipated obligations for the next twelve (12) months.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Capital Resources and Liquidity</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">As of June 30, 2013, we had $505,696 of cash on hand in our
corporate bank account. <FONT STYLE="color: black">The Company is considered to be a development stage company and will continue
in the development stage until generating revenues from the sales of its products or services. As a result, the report of the independent
registered public accounting firm on our financial statem</FONT>ents as of June 30, 2013, contains an explanatory paragraph regarding
a substantial doubt about our ability to continue as a going concern.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not have sufficient funds for the next (12) twelve
months and must raise cash to implement our strategy and stay in business. If we are unable to raise additional funds&nbsp;to develop
our compounds, we may be required to scale back our development plans by reducing expenditures for employees, consultants, business
development, and other envisioned expenditures. This could reduce our ability to develop our planned antibiotics and implement
our business plan. In that event, investors should anticipate that their entire investment may be lost and there may be no ability
to profit from this investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We cannot assure you that our compounds will be developed,
work, or receive regulatory approval; that we will ever earn revenues sufficient to support our operations or that we will ever
be profitable. Furthermore, since we have no committed source of financing, we cannot assure you that we will be able to raise
money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required
to severely curtail, or even to cease, our operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We plan to allocate approximately $250,000 to be utilized
for lab studies for the quarter ending December 31, 2013, including, without limitation, the de-minimus payment for the Kard assignment
described above and payments to S&amp;T for formulation and pre-clinical testing described above. We plan to target the studies
for our NEB-MRSA, NA-MRSA, and NEB-TB, NA-TB compounds which involve two or more testing protocols. Depending on the results of
our lab studies, if we are successful in at least one of the studies, we plan to allocate an additional $100,000 for repeats and
verification. If we are successful in more than one study we will increase our allocation for further studies by allocating an
additional $100,000. We believe that by March 31, 2014, we may require additional funds to continue our research and development.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If we are unable to raise additional
funds, we will need to do one or more of the following:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delay, scale-back or eliminate some or
all of our research and product development programs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">provide licenses to third parties to develop
and commercialize products or technologies that we would otherwise seek to develop and commercialize ourselves;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">seek strategic alliances or business combinations;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">attempt to sell our company;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">cease operations; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: black">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">declare bankruptcy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We believe that our existing cash, cash equivalents will
be sufficient to meet our operating and capital requirements until March 31, 2014. Any debt financing secured by us in the future
could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which
may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions.
We may not be able to secure additional debt or equity financing in a timely manner, or at all, which could require us to scale
back our business plan and operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The above conditions raise substantial doubt about our ability
to continue as a going concern.&nbsp;&nbsp;The financial statements included elsewhere herein were prepared under the assumption
that we would continue our operations as a going concern.&nbsp;&nbsp;Our financial statements do not include any adjustments that
may result from the outcome of this uncertainty.&nbsp;&nbsp;Without additional funds from debt or equity financing, sales of our
intellectual property or technologies, or from a business combination or a similar transaction, we will soon exhaust our resources
and will be unable to continue operations.&nbsp;&nbsp;If we cannot continue as a viable entity, our stockholders may lose some
or all of their investment in us.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our management intends to attempt to secure additional required
funding primarily through additional equity or debt financings.&nbsp;&nbsp;We may also seek to secure required funding through
sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties
to co-develop and fund research and development efforts, or similar transactions.&nbsp;&nbsp;However, there can be no assurance
that we will be able to obtain required funding.&nbsp;&nbsp;If we are unsuccessful in securing funding from any of these sources,
we will defer, reduce or eliminate certain planned expenditures in our research protocols. &nbsp;&nbsp;If we do not have sufficient
funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our
stockholders losing some or all of their investment in us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Emerging Growth<FONT STYLE="color: black"> Company</FONT></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are an &ldquo;emerging growth company&rdquo; under the
federal securities laws and will be subject to reduced public company reporting requirements. In addition, Section 107 of the JOBS
Act also provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in
Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an &ldquo;emerging
growth company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise apply to private
companies. We are choosing to take advantage of the extended transition period for complying with new or revised accounting standards.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company has no off-balance sheet arrangements that have
or are reasonably likely to have a current or future effect or change on the Company&rsquo;s financial condition, revenues or expenses,
results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term &ldquo;off-balance
sheet arrangement&rdquo; generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated
with the Company is a party, under which the Company has (i) any obligation arising under a guarantee contract, derivative instrument
or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that
serves as credit, liquidity or market risk support for such assets.&nbsp;</P>


<!-- Field: Page; Sequence: 29; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">DESCRIPTION OF OUR BUSINESS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Introduction</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are an early developmental stage biotechnology company
engaged in the discovery, development and commercialization of new classes of broad spectrum antibiotics for gram-negative and
gram-positive bacterial infections, including some of the most difficult-to-treat Multi Drug Resistant Bacteria, also called &ldquo;Superbugs&rdquo;
The Company plans on developing the following eight (8) pharmaceutical compounds:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Multi Drug Resistant Bacteria (&rdquo;Superbugs&rdquo;)</b></font></td>
    <td style="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Nano Efflux Pump Blocker (NEB)</b></font></td>
    <td style="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Nano Antibiotic (NA)</b></font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><i>Methicillin-resistant Staphylococcus aureus (MRSA)</i></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-MRSA</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-MRSA</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Drug-resistant tuberculosis (<i>MDR-TB and XDR-TB</i>)</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-TB</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-TB</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Drug-resistant<i> Enterococcus</i></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-EC</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-EC</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Drug-resistant<i> Streptococcus pneumonia</i></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-SC</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-SC</font></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our drug discovery platform currently provides a multi-pronged
level understanding of interactions between drug candidates and their bacterial targets and enables us to engineer antibiotics
with enhanced characteristics to attack a Drug Resistant Bacteria with a multi-targeted approach. The Company plans on developing
eight (8) pharmaceutical compounds. Our drug candidates are in the development stage. Our pharmaceutical compounds originated at
Kard, a preclinical contract research organization founded by our President Rajah Menon in 2002 and of which Mr. Menon is its principal
shareholder. These compounds were composed and formulated by researchers at Kard who then conducted in-vitro studies. On October
3, <SUP> </SUP>2013, Kard and Mr. Menon assigned all of their rights, formulations, and all studies and data related to efflux
pump antibiotics to the Company. The exhibit is attached herewith as Exhibit 10.3.The candidates have only been studied in cell-based
assays (in-vitro), but have not been studied in small animals (in-vivo) or animals with drug resistant bacteria for efficacy, efficiency
and toxicity. We currently own all development and marketing rights to our products. We plan on contracting research and development
of our technologies to third parties. The Company intends to file patent applications for each of these candidates as studies advance
and funds become available. The Company has assigned a priority to the development of NEB-MRSA and NA-MRSA and has designated these
as our leading drug candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>The Need for New Broad Range Antibiotics</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">According to an October 2010 market research report by Global
Industry Analysts, Inc., or GIA, entitled &ldquo;Antiobiotics: A Global Strategic Business Report&rdquo;, or the GIA Report, the
global market for antibiotics is forecast to reach US $40.3 billion by the year 2015, propelled by intensive research in new areas
of treatment, a favorable regulatory environment and the emergence of new drug classes. In addition, according to the GIA Report,
huge investments in R&amp;D aid in new breakthroughs and technological developments.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There has been a steady growing demand for anti-bacterials
across the world. A continuing increase in the elderly population has also contributed substantially to the rising severity and
incidence of bacterial infections. Of the total affected population, nearly one-fifth of the patients suffer from hospital-acquired
infections. In the US alone, approximately 90,000 people die each year due to such infections. The growing resistance of pathogens,
leading to virulent forms of infection that are difficult to treat, further complicates the situation (source: GIA Report).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>About Bacteria</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt">The Gram stain test, developed in the 1800s by Hans
Christian Gram, is a method for classifying different types of bacteria using a chemical stain and viewing through a microscope
the results on the bacteria&rsquo;s protective cell wall. Most bacteria are classified into two groups: Gram-positive or Gram-negative,
depending on whether they retain a specific stain color.&nbsp; Gram-positive bacteria retain a purple-colored stain in their thick
cell walls, while Gram-negative bacteria appear pinkish or red.</P>


<!-- Field: Page; Sequence: 30; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Gram-positive bacteria normally found on the skin, such as
<I>Staphylococcus epidermidis</I> or<I> Staphylococcus aureus</I>, are the most common bacterial contaminants of blood products.
This type of contamination is thought to occur when the bacteria on the skin is passed into the collected blood through the collection
needle. <FONT STYLE="color: black">Gram-negative</FONT> bacteria can cause infections including pneumonia, bloodstream infections,
wound or surgical site infections, and meningitis. Examples include <I>Acineobacter, Klebsiella</I>, and <I>Escherichia coli (E.coli</I>).
Gram-negative bacteria are resistant to multiple drugs and are increasingly resistant to most available antibiotics. Bacteria,
such as <I>E. coli, </I>may contaminate the donation when blood is collected from donors who have bacterial infection without symptoms
(source: Center for Disease Control and Prevention article entitled &ldquo;Blood Safety&rdquo;, 2013).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>Antibiotics and Drug Resistance</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">An antibiotic is given for the treatment of an infection
caused by bacteria. The discovery of penicillin in 1928 was followed by the discovery and commercial production of many other antibiotics.
We now take for granted that any infectious disease is curable by antibiotic therapy. Antibiotics are manufactured at an estimated
scale of about 100,000 tons annually worldwide, and their use had a profound impact on the life of bacteria on earth. More strains
of pathogens have become antibiotic resistant, and some have become resistant to many antibiotics and chemotherapeutic agents,
the phenomenon of multidrug resistance (source: Nikaido, H., &ldquo;Multidrug Resistance in Bacteria&rdquo; in Annual Review of
Biochemistry, 2009, or Nikaido 2009).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt"><B>Mechanisms of Drug Resistance</B><FONT STYLE="color: #C00000">
</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in"><B><I>Mutation of Target Protein</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt">Bacteria can become resistant through mutations that
make the target protein less susceptible to the agent. High-level production of drug-resistant target enzymes from plasmids can
make the bacteria resistant, and the resistant genes spread on plasmids. <FONT STYLE="color: #333333; background-color: white">A
plasmid is a small, circular, double-stranded DNA molecule that is distinct from a cell's chromosomal DNA and naturally exist in
bacterial cells</FONT> (source: Nikaido 2009).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt">Most drug resistance genes are effective when expressed
from plasmids. Often, many genes are present on a single plasmid, so that multidrug resistance can be transferred to a bacterium
in a single conjugation event. <FONT STYLE="color: black">Resistance plasmids are not only stably maintained, but also transferred
between bacterial cells at a very high efficiency, in many cases approaching 100% (source: Nikaido 2009).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in"><B><I>Bypassing the Target</I></B></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Vancomycin,
<FONT STYLE="color: black; background-color: white">a</FONT>n antibiotic</FONT><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; color: black; background-color: white">&nbsp;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black; background-color: white">used
in the treatment of infections caused by Gram-positive bacteria</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">,
has an unusual mode of action. Instead of inhibiting an enzyme, it binds to a substrate, a precursor of the cell wall.. Because
of this mechanism, it was assumed that it would be impossible to generate resistance against vancomycin. However, vancomycin resistance
is now prevalent among certain bacteria normally present in the intestinal tract (source: Nikaido 2009).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in"><B><I>Bacterial Efflux Pumps</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt">In Gram-negative bacteria, access can be generally
reduced by decreasing the influx across the outer membrane barrier. Drug access to the target can be reduced by active efflux processes.
Drug-specific efflux pumps produce drug resistance by active efflux of a specific drug. Multi-drug efflux pumps produce resistance
to multiple bacteria-cides and were causing hospital-acquired bacterial (<I>S. aureus) </I>infections (source: Nikaido 2009).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Major Targets of our Candidates</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following paragraphs summarize the major targets of our
candidates:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in"><B><I>Methicillin-Resistant Staphylococcus
Aureus (MRSA)</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt">Methicillin-resistant Staphylococcus aureus (MRSA)
is resistant not only to methicillin (which was developed to fight against penicillinase-producing <I>S. aureus</I>) but also to
many antibiotics (such as aminoglycosides, macrolides, tetracycline, chloramphenicol, and lincosamides). Such strains are also
resistant to disinfectants. MRSA can be a major source of hospital-acquired infections. An old antibiotic, vancomycin, was resurrected
for treatment of MRSA infections. However, transferable resistance to vancomycin is now quite common in <I>Enterococcus</I> and
found its way to MRSA in 2002, although such strains are still rare. An even more serious threat may be the emergence of Gram-negative
pathogens that are resistant to essentially all of the available agents. Research had time to react against the threat by MRSA.
Thus, there are newly developed antibiotic agents that are active against vancomycin-resistant MRSA, such as linezolid and quinupristin/dalfopristin
(source: Nikaido 2009).</P>


<!-- Field: Page; Sequence: 31; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in"><B><I>Drug-Resistant Tuberculosis
(MDR-TB and XDR-TB)</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt"><FONT STYLE="color: #231F20">With 1.4 million deaths
in 2011 resulting from tuberculosis (TB), a</FONT> chronic disease resulting from infection with a slow-growing pathogen, <I>Mycobacterium
tuberculosis,</I> <FONT STYLE="color: #231F20">the disease competes with the human immunodeficiency virus (HIV) as the top cause
of death from an infectious agent. Following neglect of the disease during the 1980s the recognition of its substantial burden
has kept TB control high on the international public health agenda since the early 1990s. The dramatic effect of the HIV epidemic
on numbers of TB cases and deaths in Africa, evidence that short-course chemotherapy is among the most cost-effective of all healthcare
interventions, and most recently the global concerns about the emergence of multidrug-resistant TB (MDR-TB) and extensively drug
resistant TB (XDR-TB) have emphasized the need to address TB more effectively on a global scale (source: Glaziou, P., Floyd, K,
Raviglione, M., &ldquo;Global Burden and Epidemiology of Tuberculosis&rdquo; in Clinics in Chest Medicine, 2009).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in"><B><I>Drug-resistant Enterococcus</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt"><I>Enterococcus </I>are normal inhabitants of the gastrointestinal
tract of humans and animals. Two species cause the most enterococcal infections: <I>Enterococcus faecalis</I> and <I>E. faecium.
</I>The relative importance of <I>E. faecium</I> as a pathogen has increased with the occurrence of high-level resistance to multiple
antimicrobial drugs, such as ampicillin and vancomycin. The rapid increase of vancomycin resistance compromises physicians' ability
to treat infections caused by many of these strains because often no other antimicrobial drugs are available. The emergence of
Vancomycin-Resistant <I>Enterococci</I> (VRE) was first identified in 1987 in Europe and within 10 years VRE represented &gt;25%
of <I>Enterococci</I> associated with bloodstream infections in hospitalized patients in the United States (source: Center for
Disease Control and Prevention, Emerging Infectious Disease article entitled &ldquo;Global Spread of Vancomycin-resistant <I>Enterococcus
faecium</I> from Distinct Nosocomial Genetic Complex, 2005).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in"><B><I>Drug-Resistant Streptococcus
Pneumoniae</I></B><I> </I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt">Gram-positive <I>Streptococcus pneumonia</I> is one
of the most virulent human pathogens and causes a wide range of infections, including invasive and non-invasive diseases. There
are about one million new pneumococcal infections every year, majority of which occur among children &lt;5 years, and the organism
is responsible for 10&ndash;20% of all deaths in this age group. A distinct population of <I>S. pneumonia</I> showed significantly
higher levels of resistance against various antibiotics (penicillin, erythromycin, tetracycline, chloramphenicol, and cefotaxime)
compared to other pneumococcal sub-populations that did not show evidence of recombination (source: Donkor, ES, &ldquo;Understanding
the Pneumococcus: Transmission and Evolution&rdquo; in Frontiers in Cellular and Infection Microbiology, 2013).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our Novel Broad Range Antibiotics for Multi-Drug Resistant
Bacteria</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We plan on developing eight (8) new pharmaceutical candidates
that are designed for treatment of gram-negative and gram-positive bacterial infections and other diseases. The Company will initially
spend most of its efforts and resources on its NEB-MRSA candidate, an efflux pump blocker that combines with NA-MRSA, its nanoantibiotic,
to &ldquo;seek and destroy&rdquo; the most difficult-to-treat &ldquo;Superbugs&rdquo;, including methicillin-resistant Staphylococcus
aureus (MRSA). Bacteria resistant testing has been limited to cell-based assay studies (in-vitro). We have not yet tested these
candidates in small animals with resistant bacteria.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our current portfolio of product candidates in Preclinical
Development includes:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; width: 46%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Multi Drug Resistant Bacteria(&rdquo;Superbugs&rdquo;)</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></P></td>
    <td style="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 30%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Nano Efflux Pump Blocker (NEB)</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></P></td>
    <td style="vertical-align: top; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 19%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Nano Antibiotic (NA)</b></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><i>Methicillin-resistant Staphylococcus aureus (MRSA)</i></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-MRSA</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-MRSA</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Drug-resistant tuberculosis (<i>MDR-TB and XDR-TB</i>)</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-TB</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-TB</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Drug-resistant<i> Enterococcus</i></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-EC</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-EC</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">Drug-resistant<i> Streptococcus pneumoniae</i></font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NEB-SC</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black">NA-SC</font></td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><IMG SRC="neb-na.jpg" ALT="" STYLE="height: 355px; width: 434px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Our Drug Candidates are Designed to Block Efflux Pumps
and Destroy Drug Resistant Bacteria</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are designing drug candidates to block efflux pumps by
mechanisms such as (1) interference with the regulatory steps needed for the expression of the efflux pump, (2) chemical changes
in the antibiotic structure hence hindering its attachment as the specific substrate, (3) disruption of the assembly of the efflux
pump-components, (4) inhibition of the substrate (antibiotic) binding by either competitive or non-competitive binding using other
compounds, (5) blocking the outer most pores responsible for the efflux of antibiotic compound and (6) interference with the energy
required for the pump activity.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 6pt">A bactericidal antibiotic, such as Penicillin kills
the bacteria. A bactericidal usually either interferes with the formation of the bacterium's cell wall or its cell contents. A
bacteriostatic, such as tetracyclines, stops bacteria from multiplying. Our drug candidates are designed to inhibit infection acting
as both bactericidal and bacteriostatic agents. By using nano technology to deliver an efflux pump blocker and antibiotic into
the bacteria, it enables the antibiotics to maintain a high concentration at their target inside the bacteria greatly improving
the efficacy of the antibiotics.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Research and Development</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">From the Company&rsquo;s inception to June 30, 2013, the
Company spent $0 on research and development activities, however prior to the Company&rsquo;s incorporation, research on efflux
pump blockers and in-vitro studies were performed at Kard, a preclinical contract research organization founded by our President
Mr. Menon in 2002 and of which Mr. Menon is its principal shareholder.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Outsourcing</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We plan to out-source the manufacture of our research materials,
regulatory studies, and clinical trials to outside vendors. As of June 30, 2013, we have been in discussions with chemists for
the purpose of developing our antibiotics. In July 2013, management identified a potential chemical compound and engaged a third
party vendor, S&amp;T Global, Inc. (&quot;S&amp;T&quot;) of Woburn, MA, for formulation and pre-clinical testing. &nbsp;We have
not yet entered into a material definitive written agreement with S&amp;T as we first want to see how their work progresses.&nbsp;
Either party may terminate the relationship at any time.&nbsp;S&amp;T is paid on an hourly basis for their work. &nbsp; As of the
date of this prospectus, we incurred $9,600 in costs by S&amp;T&nbsp;for the months of July through September 30, 2013.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 33; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Our Employees</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not have any employees at this time. Our business is
managed by our officers. To advance our business development efforts, our Chief Executive Officer, Chief Financial Officer, Treasurer
and Corporate Secretary, Elliot Ehrlich devotes his full time to the Company&rsquo;s activities and our President and Director
Rajah Menon devotes part time to the Company&rsquo;s activities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Description of Our Properties</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not own any properties. Elliot Ehrlich has agreed to
provide his home office for administrative use by the Company free of charge. That address, which we deem as our administrative
office, is 9511 Collins Ave. #807, Surfside, Florida 33154. The office is equipped with standard office equipment including computers,
scanners, copiers, and fax machine, and telephone system.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Government Regulation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Government authorities in the United States, at the federal,
state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture,
quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring
and reporting, marketing and export and import of products such as those we are developing. Any pharmaceutical candidate that we
develop must be approved by the FDA before it may be legally marketed in the United States and by the appropriate foreign regulatory
agency before it may be legally marketed in foreign countries.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>United States Drug Development Process</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In the United States, the FDA regulates drugs under the Federal
Food, Drug and Cosmetic Act, or FDCA, and implementing regulations. Drugs are also subject to other federal, state and local statutes
and regulations. Biologics are subject to regulation by the FDA under the FDCA, the Public Health Service Act, or the PHSA, and
related regulations, and other federal, state and local statutes and regulations. Biological products include, among other things,
viruses, therapeutic serums, vaccines and most protein products. The process of obtaining regulatory approvals and the subsequent
compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time
and financial resources. Failure to comply with the applicable United States requirements at any time during the product development
process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could
include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls,
product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse
effect on us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The process required by the FDA before a drug or biological
product may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull; </I>Completion of preclinical laboratory tests,
animal studies and formulation studies according to Good Laboratory Practices or other applicable regulations;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull; </I>Submission to the FDA of an Investigational
New Drug Application, or an IND, which must become effective before human clinical trials may begin;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull; </I>Performance of adequate and well-controlled
human clinical trials according to the FDA's current good clinical practices, or GCPs, to establish the safety and efficacy of
the proposed drug or biologic for its intended use;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull;</I>Submission to the FDA of a New Drug Application,
or an NDA, for a new drug product, or a Biologics License Application, or a BLA, for a new biological product;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull;</I>Satisfactory completion of an FDA inspection
of the manufacturing facility or facilities where the drug or biologic is to be produced to assess compliance with the FDA's current
good manufacturing practice standards, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the
drug's or biologic's identity, strength, quality and purity;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull; </I>Potential FDA audit of the nonclinical and
clinical trial sites that generated the data in support of the NDA or BLA; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull; </I>FDA review and approval of the NDA or BLA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The lengthy process of seeking required approvals and the
continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources. There
can be no certainty that approvals will be granted.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Before testing any compounds with potential therapeutic value
in humans, the drug or biological candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug
or biological candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including good
laboratory practices. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical
data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. The IND automatically
becomes effective 30&nbsp;days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that
30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial
can begin. The FDA may also impose clinical holds on a drug or biological candidate at any time before or during clinical trials
due to safety concerns or non-compliance. Accordingly, we cannot assure that submission of an IND will result in the FDA allowing
clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trial.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Clinical trials involve the administration of the drug or
biological candidate to healthy volunteers or patients having the disease being studied under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor's control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the
parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND. Clinical trials
must be conducted in accordance with the FDA's good clinical practices requirements. Further, each clinical trial must be reviewed
and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial
will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether
the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits.
The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative
and must monitor the clinical trial until it is completed.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Human clinical trials prior to approval are typically conducted
in three sequential Phases that may overlap or be combined:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull; Phase&nbsp;1.</I>&nbsp;&nbsp;The drug or biologic
is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution
and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently
toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients having the specific
disease.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull; Phase&nbsp;2.</I>&nbsp;&nbsp;The drug or biologic
is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the
efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for
patients having the specific disease.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&bull; Phase&nbsp;3.</I>&nbsp;&nbsp;Clinical trials are
undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed
clinical trial sites. These clinical trials, which usually involve more subjects than earlier trials, are intended to establish
the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, at least two adequate
and well-controlled Phase&nbsp;3 clinical trials are required by the FDA for approval of an NDA or BLA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Post-approval studies, or Phase&nbsp;4 clinical trials, may
be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients
in the intended therapeutic indication and may be required by the FDA as part of the approval process.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Progress reports detailing the results of the clinical trials
must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA by the investigators
for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for
human subjects. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not be completed successfully within any specified
period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various
grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly,
an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in
accordance with the IRB's requirements or if the drug or biologic has been associated with unexpected serious harm to patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Concurrent with clinical trials, companies usually complete
additional animal studies and develop additional information about the chemistry and physical characteristics of the drug or biologic
as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The
manufacturing process must be capable of consistently producing quality batches of the drug or biological candidate and, among
other things, must include methods for testing the identity, strength, quality and purity of the final drug or biologic. Additionally,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug or biological
candidate does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>U.S. Review and Approval Processes</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The results of product development, preclinical studies and
clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug
or biologic, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval
to market the product. The submission of an NDA or BLA is subject to the payment of substantial user fees; a waiver of such fees
may be obtained under certain limited circumstances.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The FDA reviews all NDAs and BLAs submitted before it accepts
them for filing and may request additional information rather than accepting an NDA or BLA for filing. Once the submission is accepted
for filing, the FDA begins an in-depth review of the NDA or BLA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">After the NDA or BLA submission is accepted for filing, the
FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use,
and whether the product is being manufactured in accordance with cGMP to assure and preserve the product's identity, strength,
quality and purity. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent and the
facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product's continued safety,
purity and potency. In addition to its own review, the FDA may refer applications for novel drug or biological products or drug
or biological products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that
includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved
and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions. During the approval process, the FDA also will determine whether a risk evaluation and mitigation
strategy, or REMS, is necessary to assure the safe use of the drug or biologic. If the FDA concludes that a REMS is needed, the
sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Before approving an NDA or BLA, the FDA will inspect the
facilities at which the product is to be manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within
required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites
to assure compliance with cGMP. If the FDA determines the application, manufacturing process or manufacturing facilities are not
acceptable it will outline the deficiencies in the submission and often will request additional testing or information.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The NDA or BLA review and approval process is lengthy and
difficult and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require
additional clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately
decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive
and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA will issue
a &quot;complete response&quot; letter if the agency decides not to approve the NDA or BLA. The complete response letter usually
describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The deficiencies identified may be minor, for
example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response
letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a
complete response letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified
in the letter, or withdraw the application.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If a product receives regulatory approval, the approval may
be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial
value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product
labeling. In addition, the FDA may require Phase&nbsp;4 testing which involves clinical trials designed to further assess a product's
safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have
been commercialized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Orphan Drug Designation</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Under the Orphan Drug Act, the FDA may grant orphan designation
to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects
fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there
is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States
for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested
before submitting an NDA or BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its
potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten
the duration of the regulatory review and approval process.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If a product that has orphan designation subsequently receives
the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product
exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for
the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product
with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan
product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has
exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains
approval of the same drug or biological product as defined by the FDA or if our drug or biological candidate is determined to be
contained within the competitor's product for the same indication or disease. If a drug or biological product designated as an
orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan
product exclusivity. Orphan drug status in the European Union has similar but not identical benefits in the European Union.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Expedited Development and Review Programs</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The FDA has a Fast Track program that is intended to expedite
or facilitate the process for reviewing new drug and biological products that meet certain criteria. Specifically, new drug and
biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition
and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination
of the product and the specific indication for which it is being studied. Unique to a Fast Track product, the FDA may consider
for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides
a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or
BLA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Any product submitted to the FDA for marketing approval,
including those submitted to a Fast Track program, may also be eligible for other types of FDA programs intended to expedite development
and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential
to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment,
diagnosis or prevention of a disease compared with marketed products. The FDA will attempt to direct additional resources to the
evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the
review. Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety
and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing
treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled
clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical
benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval,
the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled
post-marketing clinical studies to establish safety and efficacy for the approved indication. Failure to conduct such studies,
or conducting such studies that do not establish the required safety and efficacy may result in revocation of the original approval.
In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could
adversely impact the timing of the commercial launch or subsequent marketing of the product. Fast Track designation, priority review
and accelerated approval do not change the standards for approval but may expedite the development or approval process.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Post-Approval Requirements</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Any drug or biological products for which we receive FDA
approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting
of adverse experiences with the product, providing the FDA with updated safety and efficacy information on an annual basis or as
required more frequently for specific events, product sampling and distribution requirements, complying with certain electronic
records and signature requirements and complying with FDA promotion and advertising requirements, which include, among others,
standards for direct-to-consumer advertising, prohibitions against promoting drugs and biologics for uses or in patient populations
that are not described in the drug's or biologic's approved labeling (known as &quot;off-label use&quot;), rules for conducting
industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply
with FDA requirements can have negative consequences, including the immediate discontinuation of noncomplying materials, adverse
publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal
penalties. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market
or promote such off-label uses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We will need to rely, on third parties for the production
of our product candidates. Manufacturers of our product candidates are required to comply with applicable FDA manufacturing requirements
contained in the FDA's cGMP regulations. cGMP regulations require among other things, quality control and quality assurance as
well as the corresponding maintenance of comprehensive records and documentation. Drug and biologic manufacturers and other entities
involved in the manufacture and distribution of approved drugs and biologics are also required to register their establishments
and list any products made there with the FDA and comply with related requirements in certain states, and are subject to periodic
unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers
must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Discovery
of problems with a product after approval may result in serious and extensive restrictions on a product, manufacturer, or holder
of an approved NDA or BLA, including suspension of a product until the FDA is assured that quality standards can be met, continuing
oversight of manufacturing by the FDA under a &quot;consent decree,&quot; which frequently includes the imposition of costs and
continuing inspections over a period of many years, and possible withdrawal of the product from the market. In addition, changes
to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved
product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The FDA also may require post-marketing testing, known as
Phase&nbsp;4 testing, risk minimization action plans and surveillance to monitor the effects of an approved product or place conditions
on an approval that could otherwise restrict the distribution or use of the product.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 38; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">To our knowledge, neither the Company nor any of our officers
or directors is a party to any material legal proceeding or litigation and such persons know of no material legal proceeding or
contemplated or threatened litigation. There are no judgments against us or our officers or directors. None of our officers or
directors has been convicted of a felony or misdemeanor relating to securities or performance in corporate office.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">NanoAntibiotics, Inc. was incorporated
on April 10, 2013 in the State of Nevada. As of the date of this prospectus, we had 300,000,000 shares of Common Stock, par value
$0.0001 per share, authorized for issuance and 87,060,000 shares of Common Stock issued and outstanding. Of these shares, 34,000,000
shares, or 39.05%, are currently held by our officers and directors. Certain immediate family members of our officers and directors
own an aggregate 43,870,000 shares, which currently constitutes 50.39% of our common stock, however our officers and directors
specifically disclaim any beneficial ownership in such shares (see &ldquo;Certain Relationships and Related Party Transactions&rdquo;).
</FONT>Our officers, directors and their immediate family members currently own 89.44% of the outstanding shares of our common
stock.<FONT STYLE="color: black"> We also have authorized for issuance 10,000,000 shares of blank check preferred stock, par value
$0.001 per share, none of which are issued and outstanding. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">The Company does not currently
have any subsidiaries, affiliated companies or joint venture partners. Our executive offices are located presently at 9511 Collins
Ave. #807, Surfside, Florida 33154, Telephone (305) 515-4118. You may contact Elliot Ehrlich, the Company&rsquo;s Chief Executive
Officer, Chief Financial Officer, Treasurer, Corporate Secretary and Chairman of the Board, via email at </FONT>elliot@nanoantibiotics.com<FONT STYLE="color: black">.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 39; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">MANAGEMENT</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following table sets forth the name and age of officers
and directors as of the date of this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; width: 20%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>Name</b></font></td>
    <td style="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>Age</b></font></td>
    <td style="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 67%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>Position</b></font></td></tr>
<tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">Elliot Ehrlich</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">27</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, Chief Financial Officer, Treasurer, Corporate Secretary and Director</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">Rajah Menon </font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">34</font></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">President and Director </font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td></tr>
</table>
<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">According to our Bylaws, the number of directors shall be
two (2). The directors shall be elected at the annual meeting of the stockholders and each director shall be elected to serve until
his successor shall be elected and shall qualify. A director need not be a stockholder. Directors shall not receive any stated
salary for their services as directors or as members of committees, but by resolution of the Board a fixed fee and expenses of
attendance may be allowed for attendance at each meeting. The Bylaws shall not be construed to preclude any director from serving
the Company in any other capacity as an officer, agent or otherwise, and receiving compensation therefor.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There are no familial relationships among any of our Directors
or officers. None of our Directors or officers is or has been a Director or has held any form of directorship in any other U.S.
reporting companies except as mentioned above. None of our Directors or officers has been affiliated with any company that has
filed for bankruptcy within the last five years. The Company is not aware of any proceedings to which any of the Company&rsquo;s
Officers or Directors, or any associate of any such officer or Director, is a party that are adverse to the Company. We are also
not aware of any material interest of any of our officers or directors that is adverse to our own interests.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 12pt">Elliot Ehrlich has served as the Company&rsquo;s Chief
Executive Officer, Chief Financial Officer, Treasurer, Corporate Secretary and Chairman of the Board since the Company&rsquo;s
inception on April 10, 2013. He attended as a graduate school student Touro College&rsquo;s Physical Therapy Program from 2006
-2009 and received his degree in 2009 and is a Doctor of Physical Therapy. After graduation, he worked as a physical therapist
for private practices as well as for Metropolitan Jewish Health Services from 2009 to 2012. He was responsible for leadership roles
as directing patient care, coordinating and communicating with other disciplines, and providing physical treatment to patients.
Presently, he is a physical therapist in the State of Florida and is an investor in life science companies. Dr. Elliot Ehrlich,
does not possess a Doctor of Medicine degree only that of a Doctor of Physical Therapy.</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Rajah
Menon has served as the Company&rsquo;s President and as a Director since the Company&rsquo;s inception on April 10, 2013. Mr.
Menon attended Amherst College from 1996 -2000 where he received his Bachelor of Arts&rsquo; degrees in Economics and Law Jurisprudence
and Social Thought. After graduation in 2002, and to 2004, Mr. Menon worked as an analyst for Loan Pricing Corporation, a subsidiary
of Reuters. <FONT STYLE="color: #222222">In 2002, Mr. Menon founded Kard Scientific, a preclinical contract research organization
providing life science services to companies based near Boston, MA, and today he remains its principal shareholder. </FONT></FONT><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; color: #222222">In
the years</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #222222"> 2004-2008, Mr. Menon was employed at Blackrock
Financial Management&nbsp;</FONT><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; color: black">as a Vice President within
the Portfolio&nbsp;</FONT><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; color: #222222">Analytics</FONT><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; color: black">&nbsp;Group.
From </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #222222">2008,</FONT><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; color: #222222">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #222222">Mr.
Menon has been employed at Markit <FONT STYLE="font-size: 10pt">as a Product Manager within its Structured Finance group, and Mr.
Menon currently works at Markit on a part-time basis.</FONT></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Qualifications</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Dr. Ehrlich&rsquo;s qualifications to serve on our Board
of Directors are primarily based on his nearly four (4) years of experience as a health practitioner and investor in life sciences
companies. His entrepreneurial desire led him to be a founder of the Company. Dr. Ehrlich will assist the Company in the prioritization
of tasks to accomplish maximum results in drug development and address organizational issues to help further the growth of Nanoantibiotics.
Due to Dr. Ehrlich&rsquo;s experience and background the shareholders felt Dr. Ehrlich should serve as CEO and Chairman of the
Board of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Mr. Menon&rsquo;s qualifications to serve on our Board of
Directors are primarily based on his over thirteen (13) years of experience of running a preclinical contract laboratory and his
years of expertise within the financial services industry. His entrepreneurial desire led him to be a founder of the Company. Mr.
Menon will assist the Company in the prioritization of tasks to accomplish maximum results in drug development and address organizational
issues to help further the growth of Nanoantibiotics. Due to Mr. Menon&rsquo;s experience and background in life sciences, the
shareholders felt Mr. Menon should serve as President of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Audit Committee and Financial Expert</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not have an audit committee or an audit committee financial
expert. Our corporate financial affairs are simple at this stage of development and each financial transaction can be viewed by
any officer or Director at will.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not currently have a Code of Ethics applicable to our
principal executive, financial and accounting officers; however, the Company plans to implement such a code in the third quarter
of 2013.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Conflicts of Interest</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Since we do not have an audit or compensation committee comprised
of independent Directors, the functions that would be performed by such committees are performed by our Board of Directors. Thus,
there is a potential conflict of interest in that our Directors have the authority to determine issues concerning management compensation,
in essence their own, and audit issues that may affect management decisions. For example, w<FONT STYLE="color: black">e may subcontract
certain laboratory research and development work to Kard Scientific, which Mr. Menon, our President and a Director, is an officer
and shareholder of. We have not yet engaged or contracted with Kard to conduct any studies, however in the future we may decide
to do so. Should work be contracted with Kard, this would require the prior approval of the executive officers of the Company.</FONT>
We are not aware of any other potential or actual conflicts of interest with any of our officers or Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Director Independence and Committees</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have no independent directors and we have not formed any
nominating, audit or compensation committees.</P>


<!-- Field: Page; Sequence: 41; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">EXECUTIVE COMPENSATION</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">We have not paid, nor do we owe, any compensation to any
of our executive officers. We have not paid any compensation to our executive officers since our inception.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: black 1pt solid; line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Annual Compensation</font></td>
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="10" style="line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Long&nbsp;Term&nbsp;Compensation</font></td>
    <td colspan="8" style="line-height: normal; font-size: 8pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Name&nbsp;and&nbsp;Principal Position</font></td>
    <TD STYLE="border-bottom: black 1pt solid; line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Year (1)</font></td>
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Salary</font></td>
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Bonus</font></td>
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Stock Awards</font></td>
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Option Awards</font></td>
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Non-Equity <BR>
Incentive Plan <BR>
Compensation</font></td>
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="3" style="line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Nonqualified Deferred Compensation Earnings</font></td>
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="2" style="line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">All Other <BR>
Compensation</font></td>
    <TD STYLE="line-height: normal; font-size: 8pt">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; line-height: normal; font-size: 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Total</font></td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif"><b>Elliot Ehrlich</b></font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="3" style="border-top: black 1pt solid; line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="2" style="border-top: black 1pt solid; line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">Chief Executive Officer and Chief Financial Officer, Treasurer and Corporate Secretary</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">2013</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="2" style="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif"><b>Rajah Menon</b></font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="2" style="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">President</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">2013</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <td colspan="2" style="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt">&nbsp;</td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">$</font></td>
    <TD STYLE="line-height: normal; font-size: 9pt"><font style="font: 9pt Times New Roman, Times, Serif">0.00</font></td></tr>
<tr>
    <TD STYLE="width: 12%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 6%">&nbsp;</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 6%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 6%">&nbsp;</td>
    <TD STYLE="width: 2%">&nbsp;</td>
    <TD STYLE="width: 1%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">_____________________________________</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;(1) We were incorporated on April
10, 2013.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Option/SAR Grants</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not currently have a stock option plan. No individual
grants of stock options, whether or not in tandem with stock appreciation rights known as SARs or freestanding SARs have been made
to any executive officer or any Director since our inception; accordingly, no stock options have been granted or exercised by any
of the officers or Directors since we were founded.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Long-Term Incentive Plans and Awards</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not have any long-term incentive plans that provide
compensation intended to serve as incentive for performance. No individual grants or agreement s regarding future payouts under
non-stock price-based plans have been made to any executive officer or any Director or any employee or consultant since our inception;
accordingly, no future payouts under non-stock price-based plans or agreement s have been granted or entered into or exercised
by our officer or Director or employees or consultants since we were founded.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There are no arrangements pursuant to which our Director
is or will be compensated in the future for any services provided as a Director.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Employment Contracts, Termination of Employment, Change-in-control
Arrangements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There are currently no employment agreements or other contracts
or arrangements with our officers, Directors or employees. There are no compensation plans or arrangements, including payments
to be made by us, with respect to our officers, Directors or consultants that would result from the resignation, retirement or
any other termination of any of our Directors, officers or consultants. There are no arrangements for our Directors, officers,
employees or consultants that would result from a change-in-control.</P>


<!-- Field: Page; Sequence: 42; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">CERTAIN RELATIONSHIPS AND
RELATED PARTY TRANSACTIONS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #222222"><FONT STYLE="background-color: white">On
April 10, 2013, the following shares were subscribed for, paid for, and issued by the Company to the following officers and directors
of the Company:&nbsp;15,000,000 shares of Common Stock to Elliot Ehrlich, our Chief Executive Officer, Chief Financial Officer,
Corporate Secretary, Treasurer and Chairman of the Board for a payment of $1,500; 19,000,000 shares of Common Stock to Rajah Menon
our President and Director for a payment of $1,900.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #222222"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, the following shares were subscribed for, paid for, and issued by the Company to the following immediate family members
of our officers and directors: 18,870,000 shares of Common Stock to Anita Menon, the sister of Rajah Menon for a payment of $1,887;</FONT><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">&nbsp;2,000,000
shares of Common Stock to Krishna Menon, the father of Rajah Menon for a payment of $200; 8,500,000 shares of Common Stock to Leo
Ehrlich and Helene Ehrlich the parents of Elliot Ehrlich for a payment of $850; 8,500,000 shares of Common Stock to Rebecca Guttman,
the sister-in-law of Elliot Ehrlich, for a payment of $850; 3,000,000 shares of Common Stock to Joshua Ehrlich, the brother of
Elliot Ehrlich, for a payment of $300; 3,000,000 shares of Common Stock to Sarah Ehrlich, the sister of Elliot Ehrlich, for a payment
of $300. </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">The aforementioned immediate family members
of our officers and directors own an aggregate 43,870,000 shares, which currently constitutes 50.39% of our common stock, however
our officers and directors specifically disclaim any beneficial ownership in such shares. </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
officers, directors and their immediate family members currently own 89.44% of the outstanding shares of our common stock.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">No underwriters were utilized and no commissions or fees
were paid with respect to the above transaction. We relied on Section 4(2) and Rule 506 of Regulation D of the Securities Act for
the transaction set forth above since it did not involve any public offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Other than the transaction discussed above, we have not entered
into any transaction nor are there any proposed transactions in which our Director, executive officer, stockholders or any member
of the immediate family of the foregoing had or is to have a direct or indirect material interest.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Director Independence</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">According to Item 407 (a)(1)(ii), we are not subject to listing
requirements of any national securities exchange or national securities association and, as a result, we are not at this time required
to have our board comprised of a majority of &ldquo;independent Directors.&rdquo;&nbsp;We do not believe that any of our directors
currently meets the definition of &ldquo;independent&rdquo; as promulgated by the rules and regulations of NASDAQ.</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following table sets forth certain information concerning
the ownership of the Common Stock by (a) each person who, to the best of our knowledge, beneficially owned on that date more than
5% of our outstanding Common Stock, (b) each of our Directors and executive officers and (c) all current Directors and executive
officers as a group. The following table is based upon an aggregate of 87,060,000 shares of our Common Stock outstanding as of
the date of this prospectus.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>Name and Address of Beneficial Owner</b></font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Shares of Common Stock Beneficially Owned or Right to Direct Vote (1)</b></font></td>
    <td style="line-height: normal">&nbsp;</td>
    <td style="line-height: normal">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>Percent of Common Stock Beneficially Owned or Right to Direct Vote (1)</b></font></td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; line-height: normal">&nbsp;</td></tr>
<tr style="background-color: #CCFFCC">
    <td style="vertical-align: bottom; width: 51%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Elliot Ehrlich (2)</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">c/o NanoAntibiotics, Inc.,</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">9511 Collins Ave., Suite 807</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Surfside, Florida 3315<b>4</b></P></td>
    <td style="vertical-align: top; width: 2%; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 2%; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 16%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">15,000,000</font></td>
    <td style="vertical-align: bottom; width: 2%; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 5%; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 5%; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; width: 17%; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">17.23 %</font></td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td></tr>
<tr style="background-color: #CCFFCC">
    <td style="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Rajah Menon (3)</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">22-25 35<sup>th</sup> St., Astoria, NY 11105</P></td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">19,000,000</font></td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">21.82 %</font></td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>All Directors and executive officers as a group (Two persons):</b></font></td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>34,000,000</b></font></td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>39.05 </b>%</font></td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif"><b>Other 5% or Greater Beneficial Owners:</b></font></td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; line-height: normal">&nbsp;</td></tr>
<tr style="background-color: #CCFFCC">
    <td style="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Anita Menon (3)</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">150 W. 51<sup>st</sup> Street, New York, NY 10019</P></td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">18,870,000</font></td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">21.67 %</font></td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td></tr>
<tr style="background-color: #CCFFCC">
    <td style="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Leo and Helene Ehrlich (2)</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">7846 Tennyson Ct. Boca Raton, FL 33433</P></td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">8,500,000</font></td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">9.76 %</font></td></tr>
<tr>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td></tr>
<tr style="background-color: #CCFFCC">
    <td style="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Rebecca Guttman (2)</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">655 Ibsen St., Woodmere, NY 11598</P></td>
    <td style="vertical-align: top; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">8,500,000</font></td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal">&nbsp;</td>
    <td style="vertical-align: bottom; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif">9.76 %</font></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">_________________________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">(1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial ownership is determined in accordance with the rules of
the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. In accordance
with SEC rules, shares of Common Stock issuable upon the exercise of options or warrants which are currently exercisable or which
become exercisable within 60 days following the date of the information in this table are deemed to be beneficially owned by, and
outstanding with respect to, the holder of such option or warrant, however none of the persons listed hereinabove has the right
to acquire beneficial ownership in any other shares of the Company. Subject to community property laws where applicable, to our
knowledge, each person listed is believed to have sole voting and investment power with respect to all shares of Common Stock owned
by such person.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 9pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Certain immediate family members of Mr. Ehrlich, namely his parent
Leo Ehrlich and Helene Ehrlich, his sister-in-law Rebecca Guttman, his brother Joshua Ehrlich and his sister Sarah Ehrlich, beneficially
own 8,500,000, 8,500,000, 3,000,000 and 3,000,000 shares of common stock, respectively, however Mr. Elliot Ehrlich specifically
disclaims any beneficial ownership in such shares. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol; color: black">(3)</FONT></TD><TD><FONT STYLE="font: 9pt Times New Roman, Times, Serif">Certain immediate family members of Mr. Menon, namely his father, Krishna
Menon and his sister Anita Menon, beneficially own 2,000,000 and 18,870,000 shares of common stock, respectively, however Mr. Rajah
Menon specifically disclaims any beneficial ownership in such shares. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">SELLING SECURITYHOLDERS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The 10,000,000 shares of Common Stock being offered for resale
by the selling securityholders consist of 5,000,000<B> </B>shares of our Common Stock and 5,000,000 shares of Common Stock underlying
Warrants, which were issued in the Private Placement that closed on June 30, 2013.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following table sets forth the names of the selling securityholders,
the number of shares of Common Stock beneficially owned by each of the selling securityholders as of the date of this prospectus
and the number of shares of Common Stock being offered by the selling securityholders. The shares being offered hereby are being
registered to permit public secondary trading, and the selling securityholders may offer all or part of the shares for resale from
time to time. However, the selling securityholders are under no obligation to sell all or any portion of such shares nor are the
selling securityholders obligated to sell any shares immediately upon effectiveness of this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">To our knowledge, none of the selling securityholders listed
in this prospectus has had a material relationship with us other than as a securityholder at any time since inception of the Company
and none of the selling securityholders are broker-dealers or affiliated with any broker-dealers. We do not have any predecessors
and are not affiliated with any other entities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">All information with respect to share ownership has been
furnished to us by the selling securityholders.</P>


<!-- Field: Page; Sequence: 45; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 37%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Name of Selling Securityholder</b></font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: center">&nbsp;</td>
    <td style="width: 14%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Shares Beneficially Owned Prior To Offering<sup>(1)</sup></b></font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: center">&nbsp;</td>
    <td style="width: 12%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Shares to be Offered**</b></font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: center">&nbsp;</td>
    <td style="width: 13%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Amount Beneficially Owned After Offering</b></font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: center">&nbsp;</td>
    <td style="width: 16%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Percent Beneficially Owned after Offering<sup>(2)</sup></b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Boro Park Physical Therapy PLLC <sup>(3)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">1367 51 Street, Brooklyn, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,000,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,000,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Cook Street Plaza LLC <sup>(4)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">1370 51 Street apt 2A, Brooklyn, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">100,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">100,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Corr, Keith P. <sup>(5)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">77 Sea Cove Road, Northport, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Frankel, Marsha <sup>(6)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">181 Ave B apt 3, New York, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">400,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">400,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Ginsburg, Faiga Zipporah <sup>(7)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">1663 Burnett Street, Brooklyn, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">500,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">500,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Gorelik, Roman <sup>(8)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">1625 Emmons Ave apt 4k, Brooklyn, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Jones, Byron D.<sup> (9)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">115 West 71st Street apt 4B, New York, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Kirschbaum, Scott <sup>(10)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">16 Medowrue Lane, E. Northport, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Landesman, Joseph <sup>(11)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">729 Chestnut Street, Cedarhurst, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">400,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">*</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Lawrence Partners LLC <sup>(12)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">15 Manor Lane, Lawrence, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,666,668</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,666,668</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Logan, Benjamin and Malgorzata <sup>(13)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">730 Columbus Ave apt 14E, New York, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">600,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">600,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Monsey Equities LLC <sup>(14)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">16 Grosser Lane, Monsey, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,666,666</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,666,666</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Pace Jr., John <sup>(15)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">5 Anjim Lane, Wakefield, MA</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">200,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Patarkatsi, Merabi <sup>(16)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">14 Oriole Road, New City, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,000,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,000,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Pelcovitz, Baruch <sup>(17)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">39 Gateway Drive, Great Neck, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Road Holdings LLC <sup>(18)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">245 Trenor Drive, New Rochelle, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,666,666</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">1,666,666</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Schechter, Barry<sup>(19)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">7814 Tennyson Ct, Boca Raton, FL</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">50,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">10,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">*</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Sugar, Shmuel <sup>(20)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">601 Ocean Pkwy apt 7B, Brooklyn, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Zimmerman, Michael and Risa <sup>(21)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">7568 Chester Terrace, Boca Raton, FL</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">50,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">10,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">*</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Zwick. Jeffrey <sup>(22)</sup></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">1682 East 28th Street, Brooklyn, NY</P></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">40,000</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black">0%</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>Total</b></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>10,220,000</b></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>10,000,000</b></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif; color: black"><b>220,000</b></font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; font-size: 11pt; text-align: right">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: normal; font-size: 11pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; color: black">&nbsp;</font></td></tr>
</table>
<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">* Represents less than 1%</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">** Includes Common Stock underlying Warrants purchased in
the Private Placement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="color: black">(1)</FONT></TD><TD><FONT STYLE="color: black">For each of the stockholders listed in the table hereinabove, half of the shares indicated as beneficially
owned represent shares underlying Warrants held by such stockholder. Beneficial ownership is determined in accordance with the
rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership
of that person, securities that are currently convertible or exercisable into shares of our Common Stock, or convertible or exercisable
into shares of our Common Stock within 60 days of the date </FONT>of the information in this table <FONT STYLE="color: black">are
deemed outstanding including the shares underlying the Warrants. Such shares, however, are not deemed outstanding for the purposes
of computing the percentage ownership of any other person. Except as indicated in the footnotes below, each selling securityholder
named in the table has sole voting and investment power with respect to the shares set forth opposite such stockholder&rsquo;s
name.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(2)</TD><TD>The percentage of beneficial ownership is based on 92,060,000 shares of Common Stock outstanding post-offering, which includes
the 5,000,000 shares of Common Stock underlying the Warrants.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(3)</TD><TD>Maximum number of shares offered consists of 500,000 shares of our Common Stock and 500,000 shares of our Common Stock underlying
the Warrant issued to Boro Park Physical Therapy, PLLC. Yehuda Litvinchouk is the Principal of Boro Park Physical Therapy, PLLC
and has voting and dispositive power over the shares beneficially owned by Boro Park Physical Therapy, PLLC.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(4)</TD><TD>Maximum number of shares offered consists of 50,000 shares of our Common Stock and 50,000 shares of our Common Stock underlying
the Warrants issued to the selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(5)</TD><TD>Maximum number of shares offered consists of 100,000 shares of our Common Stock and 100,000 shares of our Common Stock underlying
the Warrant issued to selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(6)</TD><TD>Maximum number of shares offered consists of 200,000 shares of our Common Stock and 200,000 shares of our Common Stock underlying
the Warrant issued to selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(7)</TD><TD>Maximum number of shares offered consists of 250,000 shares of our Common Stock and 250,000 shares of our Common Stock underlying
the Warrant issued to selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(8)</TD><TD>Maximum number of shares offered consists of 100,000 shares of our Common Stock and 100,000 shares of our Common Stock underlying
the Warrant issued to selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(9)</TD><TD>Maximum number of shares offered consists of 100,000 shares of our Common Stock and 100,000 shares of our Common Stock underlying
the Warrant issued to selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(10)</TD><TD>Maximum number of shares offered consists of 100,000 shares of our Common Stock and 100,000 shares of our Common Stock underlying
the Warrant issued to selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(11)</TD><TD>Maximum number of shares offered consists of 100,000 shares of our Common Stock directly held by the selling securityholder
and 100,000 shares of our Common Stock underlying the Warrant issued to the selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(12)</TD><TD>Maximum number of shares offered consists of 833,334 shares of our Common Stock and 833,334 shares of our Common Stock underlying
the Warrants issued to Lawrence Partners, LLC. Jessica Beren is a Principal of Lawrence Partners, LLC and has voting and dispositive
powers over the shared beneficially owned by Lawrence Partners, LLC.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(13)</TD><TD>Maximum number of shares offered consists of 300,000 shares of our Common Stock and 300,000 shares of our Common Stock underlying
the Warrants issued to the selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(14)</TD><TD>Maximum number of shares offered consists of 833,333 shares of our Common Stock and 833,333 shares of our Common Stock underlying
the Warrants issued to Monsey Equities, LLC. Naomi Bodner is a Principal of Monsey Equities LLC and has voting and dispositive
powers over the shared beneficially owned by Monsey Equities, LLC.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(15)</TD><TD>Maximum number of shares offered consists of 100,000 shares of our Common Stock and 100,000 shares of our Common Stock underlying
the Warrants issued to the selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(16)</TD><TD>Maximum number of shares offered consists of 500,000 shares of our Common Stock and 500,000 shares of our Common Stock underlying
the Warrants issued to the selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(17)</TD><TD>Maximum number of shares offered consists of 20,000 shares of our Common Stock and 20,000 shares of our Common Stock underlying
the Warrants issued to the selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(18)</TD><TD>Maximum number of shares offered consists of 833,333 shares of our Common Stock and 833,333 shares of our Common Stock underlying
the Warrants issued to Road Holdings, LLC. Mark Nordlicht is a Principal of Road Holdings LLC and has voting and dispositive powers
over the shared beneficially owned by Road Holdings, LLC.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(19)</TD><TD>Maximum number of shares offered consists of 20,000 shares of our Common Stock directly held by the selling securityholder
and 20,000 shares of our Common Stock underlying the Warrant issued to selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(20)</TD><TD>Maximum number of shares offered consists of 20,000 shares of our Common Stock and 20,000 shares of our Common Stock underlying
the Warrants issued to the selling securityholder.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 47; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(21)</TD><TD>Maximum number of shares offered consists of 20,000 shares of our Common Stock directly held by the selling securityholder
and 20,000 shares of our Common Stock underlying the Warrant issued to selling securityholder.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.4in">(22)</TD><TD>Maximum number of shares offered consists of 20,000 shares of our Common Stock and 20,000 shares of our Common Stock underlying
the Warrants issued to the selling securityholder.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 48; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">DESCRIPTION OF SECURITIES</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In the discussion that follows, we have summarized selected
provisions of our Articles of Incorporation relating to our capital stock. This summary is not complete. This discussion is subject
to the relevant provisions of Nevada law and is qualified in its entirety by reference to our Articles of Incorporation and our
Bylaws. You should read the provisions of our Articles of Incorporation and our Bylaws as currently in effect for provisions that
may be important to you.</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">As of the date of this prospectus, we had 300,000,000 shares
of Common Stock, par value $0.0001 per share, authorized for issuance and 87,060,000 shares of Common Stock issued and outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">According to our Articles of Incorporation and subject to
the limitations provided by law and subject to any voting rights applicable to shares of preferred stock, holders of Common Stock
shall have the sole right and power to vote on all matters which a vote of stockholders is to be taken. In all matters, with respect
to actions both by vote and consent, each holder of shares of Common Stock shall be entitled to cast one (1) vote in person or
by proxy for each share of Common Stock standing in such holder&rsquo;s name on the transfer books of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">According to our Bylaws, each stockholder entitled to vote
in accordance with the terms of the Articles of Incorporation shall be entitled to one (1) vote, in person or by proxy, for each
share of stock entitled to vote held by such stockholder, but no proxy shall be voted after three (3) years from its date unless
such proxy provides for a longer period. Upon the demand of any stockholder, the vote for directors and the vote upon any question
before the meeting shall be by ballot. All elections for directors shall be decided by plurality vote, and all other questions
shall be decided by majority vote except as otherwise provided by the Articles of Incorporation or the laws of the State of Nevada.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The holders of the Common Stock have no preemptive or other
preferential rights to purchase additional shares of any class of the Company's capital stock in subsequent stock offerings.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A complete list of the stockholders entitled to vote at the
ensuing election, arranged in alphabetical order, with the address of each, and the number of shares held by each, shall be open
to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of
at least ten (10) days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall
be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall
also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder
who is present.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Preferred Stock </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company authorized 10,000,000 preferred shares par value
$0.001 per share. As of the date of this prospectus, no preferred shares have been issued and none are outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Shares of the Company&rsquo;s preferred stock may be issued
from time to time in one or more series. The Board of Directors of the Company is hereby authorized to provide for the issuance
of shares of preferred stock in series, and, by filing a certificate of designations pursuant to the Nevada Revised Statutes, to
establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences
and rights of the shares of each such series and the qualifications, limitations and restrictions thereof. The authority of the
Board of Directors of the Company with respect to each series shall include, but not be limited to, determination of the following:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(i) the designation of the series, which
may be by distinguishing number, letter or title;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(ii) the number of shares of the series,
which number the Board of Directors of the Company may thereafter (except where otherwise provided in a preferred stock designation)
increase or decrease (but not below the number of shares thereof then outstanding);</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(iii) the amount payable on, and the
preferences, if any, of shares of the series in respect of dividends, and whether such dividends, if any, shall be cumulative or
noncumulative;</P>


<!-- Field: Page; Sequence: 49; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(iv) dates on which dividends, if any,
shall be payable;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">`&#9;(v) the redemption rights and price or prices, if any,
for shares of the series;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(vi) the terms and amount of any sinking
fund provided for the purchase or redemption of shares of the series;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(vii) the amounts payable on and the
preferences, if any, of shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding up
of the affairs of the Company;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(viii) whether the shares of the series
shall be convertible into or exchangeable for shares of any other class of series, or any other security, of the Company or any
other corporation, and, if so, the specification of such other class or series of such other security, the conversion or exchange
price or prices or rate or rates, any adjustments thereof, the date or dates at which such shares shall be convertible or exchangeable
and all other terms and conditions upon which such conversion or exchange may be made;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(ix) restrictions on the issuance of
shares of the same series or of any other class or series; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(x) the voting right, if any, of the
holders of shares of the series.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Series A Units</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company offered and sold 5,000,000 Series A Units (also
referred to herein simply as the &ldquo;Units&rdquo;) to accredited investors in the Private Placement transaction which closed
on June 30, 2013. Each Unit consists of one (1) share of Common Stock and one (1) Series A Warrant (also referred to herein simply
as the &ldquo;Warrant&rdquo;) for the purchase of one (1) share of Common Stock at an exercise price of $0.50 per share. The Company
issued an aggregate of 5,000,000 shares of Common Stock and 5,000,000 Warrants exercisable at $0.50.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Warrants</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Each Warrant is exercisable into one (1) share of Common
Stock at $0.50 per share of Common Stock, subject to the adjustments set forth below. If all of the Warrants are exercised, the
Company will have 92,060,000 shares of Common Stock issued and outstanding and we will receive $2,500,000 in proceeds from the
sale of the Warrants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Warrants may be exercised, in whole or in part (but not
as to fractional shares), at any time or times on or after the Initial Issuance Date (as defined in the Warrant) and on or before
the Expiration Date (as defined in the Warrant) by delivery to the Company at its principal executive offices of a duly executed
original, electronic of facsimile of the Notice of Exercise, a form of which is annexed to the Series A Warrant, together with
aggregate purchase price for the shares of Common Stock specified in the Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The exercise price of the Warrant is subject to adjustments
in the event that the Company shall (A) pay a stock dividend or otherwise make a distribution or distributions on shares of its
common stock in shares of common stock, (B) subdivide outstanding shares of common stock into a larger number of shares, or (C)
combine (including by way of reverse stock split) outstanding shares of common stock into a smaller number of shares, whereby the
current exercise price shall be multiplied by a fraction of which the numerator shall be the number of shares of common stock outstanding
before such event and of which the denominator shall be the number of shares of common stock outstanding after such event, in accordance
with the terms of the Warrant.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The exercise price and number of shares of Common Stock or
other securities issuable on exercise of the Warrants are subject to adjustment in certain circumstances, including in the event
of a stock dividend, recapitalization, reorganization, merger or consolidation of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Warrant and all rights thereunder are transferable, in
whole or in part, upon surrender of the Warrant at the principal office of the Company or its designated agent, together with a
written assignment of the Warrant duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer
taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and
deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of the Warrant
not so assigned, and the Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance therewith, may be
exercised by a new holder for the purchase of shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have the option to &quot;call&quot; all the Warrants presently
outstanding and included in the Units (the &quot;<U>Warrant Call</U>&quot;). We may exercise the Warrant Call by giving to each
Warrant holder a written notice of call (the &quot;<U>Call Notice</U>&quot;) during the period in which the Warrant may be exercised.
The Warrant holders shall exercise their Warrant rights and purchase the shares underlying the Warrants and pay for the Warrant
shares within fourteen (14) business days of the date of the Call Notice. Thereafter, the Warrants will no longer be exercisable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Other Securities</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Except as summarized herein above, the Company does not have
any other equity or debt securities issued and outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Nevada Anti-Takeover Law and Charter and Bylaws Provisions</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Nevada Revised Statutes sections 78.378 to 78.3793 provide
state regulation over the acquisition of a controlling interest in certain Nevada corporations unless the articles of incorporation
or bylaws of the corporation provide that the provisions of these sections do not apply. Our articles of incorporation and bylaws
do not state that these provisions do not apply. The statute creates a number of restrictions on the ability of a person or entity
to acquire control of a Nevada company by setting down certain rules of conduct and voting restrictions in any acquisition attempt,
among other things. The statute is limited to corporations that are organized in the state of Nevada and that have 200 or more
shareholders, at least 100 of whom are shareholders of record and residents of the State of Nevada; and does business in the State
of Nevada directly or through an affiliated corporation. Because of these conditions, the statute does not apply to our Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Provisions of our articles of incorporation and our bylaws
may delay or discourage transactions involving an actual or potential change in our control or change in our management. Therefore,
these provisions could adversely affect the price of our common stock. Among other things, our articles of incorporation and our
bylaws permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any designations, powers, preferences
and rights as they may designate, including the right to approve an acquisition or other change in our control.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">Our independent stock transfer
agent is West Coast Stock </FONT>Transfer, Inc. 721 N. Vulcan Ave., Ste. 205, Encinitas, CA 92024</P>


<!-- Field: Page; Sequence: 51; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">PLAN OF DISTRIBUTION</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">This prospectus relates to the resale of up to 10,000,000<B>&nbsp;</B>shares
of our Common Stock by certain selling securityholders named herein, which includes 5,000,000 shares of Common Stock underlying
Warrants sold in the Private Placement that closed on June 30, 2013.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The selling securityholders named herein and any of their
pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their shares of Common Stock covered
hereby on the principal trading market or any other stock exchange, market or trading facility on which the shares are traded or
in private transactions. These sales may be at fixed or negotiated prices. A selling securityholder may use any one or more of
the following methods when selling shares:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">ordinary brokerage transactions and transactions in which the broker-dealer
solicits purchasers;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">block trades in which the broker-dealer will attempt to sell the shares
as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases by a broker-dealer as principal and resale by the broker-dealer
for its account;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">an exchange distribution in accordance with the rules of the applicable
exchange;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">privately negotiated transactions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">settlement of short sales entered into after the effective date of
the registration statement of which this prospectus is a part;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">in transactions through broker-dealers that agree with the selling
securityholders to sell a specified number of such shares at a stipulated price per share;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">through the writing or settlement of options or other hedging transactions,
whether through an options exchange or otherwise;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">a combination of any such methods of sale; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any other method permitted pursuant to applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The selling securityholders may also sell shares under Rule
144 under the Securities Act, if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Broker-dealers engaged by the selling securityholders may
arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling
securityholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated,
but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance
with FINRA IM-2440.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In connection with the sale of the Common Stock or interests
therein, the selling securityholders may enter into hedging transactions with broker-dealers or other financial institutions, which
may in turn engage in short sales of the Common Stock in the course of hedging the positions they assume. The selling securityholders
may also sell shares of the Common Stock short and deliver these securities to close out their short positions, or loan or pledge
the Common Stock to broker-dealers that in turn may sell these securities. The selling securityholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require
the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The selling securityholders and any broker-dealers or agents
that are involved in selling the shares may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act
in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale
of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. No selling
securityholder has informed the Company that it has any written or oral agreement or understanding, directly or indirectly, with
any person to distribute the Common Stock. In no event shall any broker-dealer receive fees, commissions and markups which, in
the aggregate, would exceed eight percent (8%).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company is required to pay certain fees and expenses
incurred by the Company incident to the registration of the shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Because selling securityholders may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act, they will be subject to the prospectus delivery requirements of the Securities Act including
Rule 172 thereunder. No selling securityholder has advised us that there is an underwriter or coordinating broker acting in connection
with the proposed sale of the resale shares by the selling securityholders.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The resale shares will be sold only through registered or
licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale shares
of Common Stock covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or
an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Under applicable rules and regulations under the Exchange
Act, any person engaged in the distribution of the resale shares may not simultaneously engage in market making activities with
respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the
distribution. In addition, the selling securityholders will be subject to applicable provisions of the Exchange Act and the rules
and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of shares of the Common Stock
by the selling securityholders or any other person. We will make copies of this prospectus available to the selling securityholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">LEGAL MATTERS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The validity of the securities being offered by this prospectus
has been passed upon for us by Burton Bartlett &amp; Glogovac, Reno, Nevada.</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">EXPERTS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: #222222">Messineo &amp; Co, CPAs, LLC</FONT><FONT STYLE="color: black">,
our independent registered public accounting firm, has audited </FONT>our balance sheet as of June 30, 2013 and the related statement
of operations, stockholders' equity and cash flows for the period from April 10, 2013 (date of inception) through June 30, 2013.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">No expert or counsel named in this prospectus as having prepared
or certified any part of this prospectus or having given an opinion upon the validity of the securities being registered or upon
other legal matters in connection with the registration or offering of the Common Stock was employed on a contingency basis, or
had, or is to receive, in connection with the offering, a substantial interest, direct or indirect, in the registrant or any of
its parents or subsidiaries. Nor was any such person connected with the registrant or any of its parents or subsidiaries as a promoter,
managing or principal underwriter, voting trustee, director, officer, or employee.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: aqua">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">WHERE YOU CAN FIND ADDITIONAL
INFORMATION</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">We filed with the Securities and
Exchange Commission a registration statement under the Securities Act of 1933 for the shares of common stock in this offering.
This prospectus does not contain all of the information in the registration statement and the exhibits and schedule that were filed
with the registration statement. For further information with respect to us and our common stock, we refer you to the registration
statement and the exhibits and schedule that were filed with the registration statement. Statements contained in this prospectus
about the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily
complete, and we refer you to the full text of the contract or other document filed as an exhibit to the registration statement.
A copy of the registration statement and the exhibits and schedules that were filed with the registration statement may be inspected
without charge at the Public Reference Room maintained by the Securities and Exchange Commission at 100 F Street, N.E. Washington,
DC 20549, and copies of all or any part of the registration statement may be obtained from the Securities and Exchange Commission
upon payment of the prescribed fee. Information regarding the operation of the Public Reference Room may be obtained by calling
the Securities and Exchange Commission at 1-800-SEC-0330. The Securities and Exchange Commission maintains a website that contains
reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC. The
address of the website is </FONT>www.sec.gov<FONT STYLE="color: black">.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We will file periodic reports under the Exchange Act, including
annual, quarterly and special reports, and other information with the Securities and Exchange Commission. These periodic reports
and other information will be available for inspection and copying at the regional offices, public reference facilities and website
of the Securities and Exchange Commission referred to above.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We will also make available free of charge on or through
our internet website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments
to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after
we electronically file such material with, or furnish it to, the Securities and Exchange Commission.</P>


<!-- Field: Page; Sequence: 54; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">DISCLOSURE OF COMMISSION
POSITION ON INDEMNIFICATION<BR>
FOR SECURITIES ACT LIABILITY</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our Articles of Incorporation and Bylaws include provisions
that eliminate the personal liability of our directors&nbsp;for monetary damages to the fullest extent possible under the laws
of the State of Nevada or other applicable law. These provisions eliminate the liability of directors to us and our stockholders
for monetary damages arising out of any violation of a director of his fiduciary duty of due care. Under Nevada law, however, such
provisions do not eliminate the personal liability of a director for (i) breach of the director&rsquo;s duty of loyalty, (ii) acts
or omissions not in good faith or involving intentional misconduct or knowing violation of law, (iii) payment of dividends or repurchases
of stock other than from lawfully available funds, or (iv) any transaction from which the director derived an improper benefit.
These provisions do not affect a director&rsquo;s liabilities under the federal securities laws or the recovery of damages by third
parties.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have been advised that in the opinion of the Securities
and Exchange Commission indemnification for liabilities arising under the Securities Act is against public policy as expressed
in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
is asserted by one of our directors, officers, or controlling persons in connection with the securities being registered, we will,
unless in the opinion of our legal counsel the matter has been settled by controlling precedent, submit the question of whether
such indemnification is against public policy to a court of appropriate jurisdiction. We will then be governed by the court&rsquo;s
decision.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 55; Section: Main; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>





<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NANOANTIBIOTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(A Development Stage Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">AUDITED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 92%">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 12pt">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Page</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(230,239,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial Statements For the Period from April 10, 2013 (Date of Inception) through June 30, 2013 </B></FONT></TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(230,239,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Report of Independent Registered Public Accounting Firm</FONT></TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(230,239,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Balance Sheet</FONT></TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(230,239,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statements of Operation</FONT></TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(230,239,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement of Stockholders&rsquo; Deficit </FONT></TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(230,239,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statement of Cash Flows</FONT></TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(230,239,255)">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes to Financial Statements</FONT></TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-6</FONT></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 1; Section: f-toc; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Report of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Board of Directors and Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">NanoAntibiotics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Surfside, FL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have audited the accompanying balance sheet of&nbsp;NanoAntibiotics,
Inc. (a development stage entity) as of June 30, 2013 and the related statement of operations, stockholders&rsquo; equity and cash
flows for the period from April 10, 2013 (date of inception) through June 30, 2013. These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on these financial statements based on our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted our audit in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal
control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for
the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly,
we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by
management, as well as, evaluating the overall financial statement presentation. We believe that our audit provides a reasonable
basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In our opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of NanoAntibiotics, Inc. (a development stage entity) as of June 30, 2013
and the results of its operations and its cash flows for the period from April 10, 2013 (date of inception) through June 30, 2013
in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred
a loss, has not emerged from the development stage, and may be unable to raise further equity. These factors raise substantial
doubt about its ability to continue as a going concern. Management&rsquo;s plans regarding those matters are also described in
Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/Messineo &amp; Co, CPAs LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Messineo &amp; Co, CPAs LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Clearwater, Florida</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">August 9, 2013, except for Note 1 and 6, as to which is dated October
3, 2013</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Section: f%2Dpages; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NANOANTIBIOTICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(A Development Stage Company)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>BALANCE SHEET</B>&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">June 30, 2013</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-left: 0.2in">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 84%; font-family: Times New Roman, Times, Serif; padding-left: 0.2in">Cash</TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font-family: Times New Roman, Times, Serif; text-align: right">505,696</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.4in">Total Current Assets</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">505,696</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.2in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.2in">TOTAL ASSETS</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">505,696</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-left: 0.2in">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.2in">Accounts payable</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">15,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.4in">Total Current Liabilities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">15,000</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.2in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-left: 0.2in">STOCKHOLDERS' DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.3in">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.3in">Common stock, $0.0001 par value; 300,000,000 shares authorized; shares issued and 87,060,000 shares issued and outstanding</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">8,706</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-indent: -0.1in; padding-left: 0.3in">Capital in excess of par value</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">499,500</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.3in">Deficit accumulated during development stage</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(17,510</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0.4in">Total Stockholders' Deficit</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">490,696</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-left: 0.2in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.2in">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">505,696</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Section: f%2Dpages; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NANOANTIBIOTICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(A Development Stage Company)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STATEMENT OF OPERATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Period April 10, 2013<BR> (Date of Inception) <BR> through <BR>
June 30, 2013</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">REVENUE:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 0.2in">Sales</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="width: 80%; font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 0.2in">Selling, general and administrative expenses</TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-family: Times New Roman, Times, Serif; text-align: right">17,515</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.4in">TOTAL OPERATING EXPENSES</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">17,515</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1pt">LOSS FROM OPERATIONS</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(17,515</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">OTHER EXPENSE (INCOME)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 0.2in">Interest income</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">(5</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.4in">TOTAL OTHER EXPENSE (INCOME)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(17,510</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS PER COMMON SHARE, BASIC AND DILUTED</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold">WEIGHTED AVERAGE NUMBER OF</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.2in">COMMON SHARES OUTSTANDING, BASIC AND DILUTED</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">41,226,379</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Section: f%2Dpages; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NANOANTIBIOTICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(A Development Stage Company)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STATEMENT OF STOCKHOLDERS' DEFICIT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common <BR> Stock <BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common <BR> Stock <BR> Amount</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital in <BR> Excess of <BR> Par Value</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated<BR> Deficit<BR> Development<BR> Stage</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR> Stockholders <BR> Deficit</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-indent: -0.1in; padding-left: 0.1in">Balance, April 10, 2013</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="width: 30%; font-family: Times New Roman, Times, Serif; text-indent: -0.1in; padding-left: 0.1in">Issuance of Founders Shares, $0.0001</TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">82,060,000</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">8,206</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right">8,206</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common stock for cash, $0.10</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">5,000,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">500</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">499,500</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">500,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(17,510</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(17,510</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Balance, June 30, 2013</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">87,060,000</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">8,706</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">499,500</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(17,510</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">490,696</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Section: f%2Dpages; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NANOANTIBIOTICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(A Development Stage Company)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STATEMENT OF CASH FLOWS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Period April 10, 2013<BR> (Date of Inception) <BR> through <BR>
June 30, 2013</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 80%; font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.2in">Net loss</TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 16%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(17,510</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 0.2in">Adjustments to reconcile net loss to net cash to cash used by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">Increase (decrease) in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">15,000</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.2in">Net cash used by operating activities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">(2,510</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.2in">Net cash used by investing activities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.2in">Issuance of common stock</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">508,206</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.2in">Net cash provided by financing activities</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">508,206</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net increase in cash</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">505,696</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">Cash, beginning of period</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 2.5pt">Cash, end of period</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">505,696</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0.2in">Cash paid for interest</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Section: f%2Dpages; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Nanoantibiotics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(A Development Stage Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Period Ended June 30, 2013,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and the Period April 10, 2013 (Date of Inception)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>through June 30, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1.</B></FONT></TD>
    <TD STYLE="width: 97%; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Background Information</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Nanoantibiotics, Inc. (the &ldquo;Company&rdquo;) is a development
stage enterprise that was incorporated in the state of Nevada on April 10, 2013. To date, the Company&rsquo;s activities have been
limited to raising capital, organizational matters, and the structuring of its business plan. The corporate headquarters is located
in Surfside, FL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">We are an early stage biotechnology company
engaged in the discovery, development and commercialization of new classes of broad spectrum antibiotics for gram-negative and
gram-positive bacterial infections, including some of the most difficult-to-treat Multi Drug Resistant Bacteria, also called &ldquo;Superbugs.&rdquo;
Our drug discovery platform currently provides a multi-pronged level understanding of interactions between drug candidates and
their bacterial targets and enables us to engineer antibiotics with enhanced characteristics to attack a Drug Resistant Bacteria
with a multi-targeted approach. The Company plans on developing eight pharmaceutical compounds. Our pharmaceutical compounds originated
at Kard Scientific, Inc. (&ldquo;Kard&rdquo;), a preclinical contract research organization founded by our President Rajah Menon
in 2002 and of which Mr. Menon is its principal shareholder. These compounds were composed and formulated by researchers at Kard
who then conducted in-vitro studies. On October 3, <SUP> </SUP>2013, Kard </FONT>and Mr. Menon assigned all of their rights, formulations,
and all studies and data related to efflux pump antibiotics to the Company.The candidates have only been studied in cell-based
assays (in-vitro), but have not been studied in small animals (in-vivo) or animals with drug resistant bacteria for efficacy, efficiency
and toxicity. We currently own all development and marketing rights to our products. We plan on contracting research and development
of our technologies to third parties. The Company intends to file patent applications for each of these candidates as studies advance
and funds become available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Non-Monetary Transaction</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">According
to ASC 845-10-S99, transfers of non-monetary assets to a company by its promoters or shareholders in exchange for stock prior to
or at the time of the entity&rsquo;s initial public offering should be recorded at the transferors' historical cost basis determined
under GAAP. &nbsp;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As such the<FONT STYLE="background-color: white">
cost basis carried on Kard&rsquo;s books and records was zero. &nbsp;Therefore, the accounting principles in ASC 845-10-S99 were
followed and the Company recorded the rights at its historical cost basis, which was </FONT>at the historical cost basis of zero.
Although the transfer was at $1, this amount was determined by the Company to be de-minimus and immaterial</FONT><FONT STYLE="font: 12pt Cambria,serif">.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2.</B></FONT></TD>
    <TD STYLE="width: 97%; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Going Concern</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern. For the period ended June 30, 2013 and since April 10, 2013 (date of inception)
through June 30, 2013, the Company had a net loss of $17,510. As of June 30, 2013, the Company has not emerged from the development
stage. In view of these matters, the Company&rsquo;s ability to continue as a going concern is dependent upon the Company&rsquo;s
ability to begin operations and to achieve a level of profitability. Since inception, the Company has financed its activities principally
from the sale of public equity securities. The Company intends on financing its future development activities and its working capital
needs largely from the sale of public equity securities with some additional funding from other traditional financing sources,
including term notes and proceeds from sub-licensing agreements until such time that funds provided by operations are sufficient
to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability
and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company
be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 7; Section: f%2Dpages; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>3.</B></FONT></TD>
    <TD STYLE="width: 97%; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Significant Accounting Policies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The significant accounting policies followed are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those
estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Cash is maintained at financial institutions and, at times, balances
may exceed federally insured limits. We have never experienced any losses related to these balances. All of our non-interest bearing
cash balances were fully insured at June 30, 2013, and our non-interest bearing cash balances may exceed federally insured limits.
At June 30, 2013, there were no amounts held in interest bearing accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&rsquo;s financial instruments include cash and accounts
payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these
items.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Research and development costs are charged to operations when incurred
and are included in operating expenses. There were no amounts expended for research and development for the period ended June 30,
2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred income tax assets and liabilities arise from temporary
differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by
the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are
classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred
tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods
in which the temporary differences are expected to reverse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company follows the provisions of FASB ASC 740-10 &ldquo;<I>Uncertainty
in Income Taxes</I>&rdquo; (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation
of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there
are no unrecognized benefits at December 31, 2012 or 2011 and since the date of adoption. The Company has not recognized interest
expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would
recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Basic earnings per share are computed by dividing net income by
the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share are computed
by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during
the year. The Company did not have any common stock equivalents for the period ended June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company recognizes all share-based payments to employees, including
grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense
will be recognized over the period during which an employee is required to provide services in exchange for the award, known as
the requisite service period (usually the vesting period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There were no grants awarded during the period ended June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In September 2006, the Financial Accounting Standards Board (FASB)
introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities.
The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2008 fiscal year and the
impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 &ldquo;<I>Fair Value Measurements and
Disclosures</I>&rdquo; (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer
a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market
participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity&rsquo;s
own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable
inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three
levels of the fair value hierarchy are described below:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Section: f%2Dpages; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Calibri, Helvetica, Sans-Serif">
<TR>
    <TD STYLE="width: 4%; font-size: 11pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 94%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Fair value estimates discussed herein are based upon certain market
assumptions and pertinent information available to management as of June 30, 2013. The respective carrying value of certain on-balance-sheet
financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments
include accounts payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Recent accounting pronouncements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other recent accounting pronouncements issued by the FASB (including
its EITF), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company&rsquo;s financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>4.</B></FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Income Taxes</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred taxes are recorded for all existing temporary differences
in the Company&rsquo;s assets and liabilities for income tax and financial reporting purposes. Due to the valuation allowance for
deferred tax assets, as noted below, there was no net deferred tax benefit or expense for the period ended June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There is no current or deferred income tax expense or benefit allocated
to continuing operations for the period ended June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The provision for income taxes is different from that which would
be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 84%; background-color: #CCFFCC"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tax expense (benefit) at U.S. statutory rate</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCFFCC">&nbsp;</TD>
    <TD STYLE="width: 1%; background-color: #CCFFCC"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 13%; border-top: black 1pt solid; background-color: #CCFFCC; padding-left: 0.95pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6,000)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">State income tax expense (benefit), net of federal benefit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.95pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(900)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: #CCFFCC"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effect of non-deductible expenses</FONT></TD>
    <TD STYLE="background-color: #CCFFCC">&nbsp;</TD>
    <TD STYLE="background-color: #CCFFCC">&nbsp;</TD>
    <TD STYLE="background-color: #CCFFCC; padding-left: 0.95pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.95pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: #CCFFCC; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Change in valuation allowance</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #CCFFCC; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #CCFFCC; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #CCFFCC; padding-bottom: 1pt; padding-left: 0.95pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,900&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 2pt; padding-left: 0.95pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities at June 30, 2013 are as follows:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 11pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 84%; background-color: #CCFFCC"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Deferred tax assets (liability), noncurrent:</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCFFCC">&nbsp;</TD>
    <TD STYLE="width: 1%; border-top: black 1pt solid; background-color: #CCFFCC">&nbsp;</TD>
    <TD STYLE="width: 13%; border-top: black 1pt solid; background-color: #CCFFCC; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net operating loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,900</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: #CCFFCC; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Valuation allowance</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #CCFFCC; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #CCFFCC; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #CCFFCC; padding-bottom: 1pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6,900)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 2pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 9; Section: f%2Dpages; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Change in valuation allowance:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 84%; background-color: #CCFFCC"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Balance, April 10, 2013</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCFFCC">&nbsp;</TD>
    <TD STYLE="width: 1%; background-color: #CCFFCC"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 13%; background-color: #CCFFCC; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash; </FONT></TD>
    <TD STYLE="width: 1%; background-color: azure">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Increase in valuation allowance</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6,900)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: #CCFFCC"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2012</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #CCFFCC">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #CCFFCC">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #CCFFCC; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6,900)</FONT></TD>
    <TD STYLE="background-color: white">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Since management of the Company believes that it is more likely
than not that the net deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation
allowance on the net deferred tax assets as of June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2013, the Company had federal and state net operating
loss carry-forwards totaling approximately $17,500 which begin expiring in 2022.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>5.</B></FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Equity</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has 300,000,000 shares of authorized $.0001 par value
common stock.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 10, 2013 (date of inception) the Company issued 82,060,000
common shares at par value ($.0001), or $8,206 to its founders.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Between June 20, 2013 and June 25, 2013, the Company issued 5,000,000
shares of common stock at $.10 per share, or $500,000, as part of its Series A Unit offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Series A Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company offered and sold 5,000,000 Series A Units (also referred
to herein simply as the &ldquo;Units&rdquo;) to accredited investors in the Private Placement transaction which closed on June
30, 2013. Each Unit consists of one (1) share of Common Stock and one (1) Series A Warrant (also referred to herein simply as the
&ldquo;Warrant&rdquo;) for the purchase of one (1) share of Common Stock at an exercise price of $0.50 per share. The Company issued
an aggregate of 5,000,000 shares of Common Stock and 5,000,000 Warrants exercisable at $0.50. Total proceeds from this issuance
was $500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Each Warrant is exercisable into one (1) share of Common Stock at
$0.50 per share of Common Stock. The Warrants may be exercised, in whole or in part (but not as to fractional shares), at any time
or times on or after the Initial Issuance Date (as defined in the Warrant) and on or before the Expiration Date (as defined in
the Warrant).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The exercise price and number of shares of Common Stock or other
securities issuable on exercise of the Warrants are subject to adjustment in certain circumstances, including in the event of a
stock dividend, recapitalization, reorganization, merger or consolidation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Warrant and all rights thereunder are transferable, in whole
or in part. We have the option to &quot;call&quot; all the Warrants presently outstanding and included in the Units (the &quot;<U>Warrant
Call</U>&quot;). We may exercise the Warrant Call by giving to each Warrant holder a written notice of call (the &quot;<U>Call
Notice</U>&quot;) during the period in which the Warrant may be exercised. The Warrant holders shall exercise their Warrant rights
and purchase the shares underlying the Warrants and pay for the Warrant shares within fourteen (14) business days of the date of
the Call Notice. Thereafter, the Warrants will no longer be exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>Preferred Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company authorized 10,000,000 preferred shares par value $0.001
per share. As of June 30, 2013, no preferred shares have been issued and none are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares of the Company&rsquo;s preferred stock may be issued from
time to time in one or more series. As of June 30, 2013, there has been no designation to any series of preferred stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 10; Section: f%2Dpages; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>6.</B></FONT></TD>
    <TD STYLE="width: 97%; font: 10pt Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Subsequent Events</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&rsquo;s Management has evaluated subsequent events through
August 9, 2013, the date the financial statements were available to be issued. Management is not aware of any significant events
that occurred subsequent to the balance sheet date that would have a material effect on the financial statements thereby requiring
adjustment or disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Non-Monetary Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On October 3, 2013, Kard Scientific, Inc. and Mr. Menon assigned
all of their rights, formulations, and all studies and data related to efflux pump antibiotics to the Company. According to ASC
845-10-S99, transfers of non-monetary assets to a company by its promoters or shareholders in exchange for stock prior to or at
the time of the entity&rsquo;s initial public offering should be recorded at the transferors' historical cost basis determined
under GAAP. &nbsp;As such the cost basis carried on Kard&rsquo;s books and records was zero. &nbsp;Therefore, the accounting principles
in ASC 845-10-S99 were followed and the Company recorded the rights at its historical cost basis, which was at the historical cost
basis of zero. Although the transfer was at $1, this amount was determined by the Company to be de-minimus and immaterial.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Section: f%2Dpages; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN THIS DOCUMENT
OR THAT WE HAVE REFERRED YOU TO. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION THAT IS DIFFERENT. THIS PROSPECTUS
IS NOT AN OFFER TO SELL COMMON STOCK AND IS NOT SOLICITING AN OFFER TO BUY COMMON STOCK IN ANY STATE WHERE THE OFFER OR SALE IS
NOT PERMITTED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NANOANTIBIOTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>10,000,000 SHARES OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Until _____________, all dealers that effect transactions in these
securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s
obligation to deliver a prospectus when acting as underwriter and with respect to their unsold allotments or subscriptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The Date of This Prospectus is ___________,
2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Section: Main -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">PART II: INFORMATION NOT REQUIRED
IN THE PROSPECTUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 13. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All amounts are estimates other than the Securities and Exchange
Commission&rsquo;s registration fee. We are paying all expenses of the offering listed above. No portion of these expenses will
be borne by the selling securityholders. The selling securityholders, however, will pay any other expenses incurred in selling
their Common Stock, including any brokerage commissions or costs of sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 78%; font-size: 1pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 1pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Amount to</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>be Paid</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SEC registration fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">138*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Printing and engraving expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounting fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Transfer agent and registrar fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Miscellaneous expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,862</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">50,000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">__________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">*Previously paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Articles of Incorporation and Bylaws include provisions that
eliminate the personal liability of our directors&nbsp;for monetary damages to the fullest extent possible under the laws of the
State of Nevada or other applicable law. These provisions eliminate the liability of directors to us and our stockholders for monetary
damages arising out of any violation of a director of his fiduciary duty of due care. Under Nevada law, however, such provisions
do not eliminate the personal liability of a director for (i) breach of the director&rsquo;s duty of loyalty, (ii) acts or omissions
not in good faith or involving intentional misconduct or knowing violation of law, (iii) payment of dividends or repurchases of
stock other than from lawfully available funds, or (iv) any transaction from which the director derived an improper benefit. These
provisions do not affect a director&rsquo;s liabilities under the federal securities laws or the recovery of damages by third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have been advised that in the opinion of the Securities and Exchange
Commission indemnification for liabilities arising under the Securities Act is against public policy as expressed in the Securities
Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities is asserted by one
of our directors, officers, or controlling persons in connection with the securities being registered, we will, unless in the opinion
of our legal counsel the matter has been settled by controlling precedent, submit the question of whether such indemnification
is against public policy to a court of appropriate jurisdiction. We will then be governed by the court&rsquo;s decision.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 15. Recent Sales of Unregistered Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Founder Shares </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 10, 2013, we issued an aggregate of 82,060,000 shares of
Common Stock to our founders, of which 52,870,000 shares were issued to affiliated stockholders and 29,190,000 shares issued to
unaffiliated stockholders at par value ($0.0001 per share), for aggregate proceeds to the Company of $8,206.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Private Placement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 30, 2013, we raised gross proceeds of $500,000 through the
private placement of 5,000,000 Units at $0.10 per Unit, with each Unit consisting of one (1) share of our Common Stock, and a five
(5) year Warrant to purchase one (1) share of our Common Stock initially exercisable at a price of $0.50 per share which may be
adjusted from time to time in accordance with the terms of the Warrant, to certain accredited investors pursuant to Rule 506 under
Regulation D. The following sets forth the identity of persons to whom we sold shares of Common Stock and corresponding Warrants
and the amount of shares of Common Stock beneficially owned by each stockholder as of the date of this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Section: Part A; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 39%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>Name <SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 52%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>Shares of Common Stock Beneficially Owned <SUP>(2)</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Boro Park Physical Therapy PLLC </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">1,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Cook Street Plaza LLC </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">100,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Corr, Keith P. </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">200,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Frankel, Marsha </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">400,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Ginsburg, Faiga Zipporah </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">500,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Gorelik, Roman </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">200,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Jones, Byron D.</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">200,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Kirschbaum, Scott </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">200,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Landesman, Joseph </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">400,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Lawrence Partners LLC </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">1,666,668</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Logan, Benjamin and Malgorzata </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">600,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Monsey Equities LLC </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">1,666,666</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Pace Jr., John </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">200,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Patarkatsi, Merabi </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">1,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Pelcovitz, Baruch </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">40,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Road Holdings LLC </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">1,666,666</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Schechter, Barry</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">50,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Sugar, Shmuel </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">40,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Zimmerman, Michael and Risa </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">50,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Zwick. Jeffrey </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">40,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(230,239,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>Total</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>10,220,000</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">__________________________________________________________________________</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">(1) Shareholdings of spouses are listed together.</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">(2) Beneficial ownership is determined in accordance with the rules
and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that
person, securities that are currently convertible or exercisable into shares of our Common Stock, or convertible or exercisable
into shares of our Common Stock within 60 days of the date of this prospectus are deemed outstanding. Such shares, however, are
not deemed outstanding for the purposes of computing the percentage ownership of any other person.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">No underwriters were utilized and no commissions or fees were paid
with respect to any of the above transactions. These persons were the only offerees in connection with these transactions. We relied
on Section 4(2) and Rule 506 of Regulation D of the Securities Act for both of the transactions set forth above since neither of
the two transactions involved any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Section: Part A -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 16. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 11%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>EXHIBIT NUMBER</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 47%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>DESCRIPTION</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 38%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>LOCATION</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(230,239,255)">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">3.1</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Articles of Incorporation </FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Incorporated by reference to the Company&rsquo;s Registration Statement filed with the SEC on August 15, 2013</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(230,239,255)">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">3.2</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Bylaws </FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Incorporated by reference to the Company&rsquo;s Registration Statement filed with the SEC on August 15, 2013</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(230,239,255)">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">5.1</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Opinion of Burton Bartlett &amp; Glogovac</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Incorporated by reference to the Company&rsquo;s Form S-1/A as filed with the SEC on September 26, 2013</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(230,239,255)">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">10.1</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Subscription Agreement </FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Incorporated by reference to the Company&rsquo;s Registration Statement filed with the SEC on August 15, 2013</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(230,239,255)">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">10.2</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Form of Warrant </FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Incorporated by reference to the Company&rsquo;s Registration Statement filed with the SEC on August 15, 2013</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(230,239,255)">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">10.3</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">General Assignment, dated October 3, 2013, by and between Kard Scientific, Inc. and Rajah Menon, on the one hand, and NanoAntibiotics, Inc., on the other hand.</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Provided herewith</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"></P></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(230,239,255)">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">23.1</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Consent of&nbsp;Messineo &amp; Co., CPAs, LLC</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Provided herewith</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(230,239,255)">
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">23.2</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Consent of Burton Bartlett &amp; Glogovac</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Incorporated by reference to Exhibit 5.1 herein</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 17. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(i) To include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(ii) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in
the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo;
table in the effective registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(iii) To include any material information with respect to the plan
of distribution not previously disclosed in the registration statement or any material change to such information in the registration
statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(2) That, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(4) That, for the purpose of determining liability of the registrant
under the Securities Act of 1933 to any purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Section: Part A -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If the registrant is subject to Rule 430C, each prospectus filed
pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying
on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of
contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus
that was part of the registration statement or made in any such document immediately prior to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or
otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is
against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Amendment No. 2 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 5<SUP>th</SUP> day of November, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 16; Section: Part A -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Amendment No. 3 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 5<SUP>th</SUP> day of November, 2013.</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NANOANTIBIOTICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&#9;By: <I><U>/s/ Elliot Ehrlich&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, Chief Financial Officer, Principal Executive<BR>
Officer and Principal Financial and Accounting Officer</FONT></TD></TR>
<TR STYLE="height: 0px">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 24%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Act, this Registration
Statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 1pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 1pt">&nbsp;</TD>
    <TD STYLE="width: 58%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 1pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 1pt">&nbsp;</TD>
    <TD STYLE="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Signature</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Titles</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date</P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><U>/s/</U></I><U> <I>Elliot Ehrlich&nbsp;&nbsp;&nbsp;&nbsp;</I></U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="height: 41.4pt; vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; height: 41.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Elliot Ehrlich</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; height: 41.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; height: 41.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, Chief Financial Officer, Principal Executive Officer and Principal Financial and Accounting Officer, Corporate Secretary, Treasurer and Chairman of the Board </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; height: 41.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; height: 41.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 5, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><U>/s/ Rajah Menon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Rajah Menon</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Director</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 5, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Section: Part A -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>

    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>





<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>2
<FILENAME>nano1105ex23.1.htm
<DESCRIPTION>CONSENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: green 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: right; color: #006600"><B>Messineo &amp; Co, CPAs LLC</B></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: right; color: #006600"><B>2471 N McMullen Booth Rd,
        Ste. 302</B></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: right; color: #006600"><B>Clearwater, FL 33759-1362</B></P>
        <P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: right; color: #006600"><B>T: (727) 421-6268</B></P>
        <P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: right; color: #006600"><B>F: (727) 674-0511</B></P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/14pt Times New Roman, Times, Serif; margin: 1.4pt 0 0.65pt; text-align: center"><B>Consent of Independent
Registered Public Accounting Firm</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 1.4pt 0 0">&nbsp;</P>

<P STYLE="font: 12pt/14pt Times New Roman, Times, Serif; margin: 1.4pt 0 0.65pt">&nbsp;</P>

<P STYLE="font: 12pt/14pt Times New Roman, Times, Serif; margin: 1.4pt 0 0.65pt">We consent to the inclusion in the Prospectus,
of which this Registration Statement on Form S-1, Amendment 2, is a part, of the report dated August 9, 2013, except for Note 1
and 6 as to which is dated October 3, 2013, relative to the financial statements of NanoAntibiotics, Inc. as of June 30, 2013 and
for the period April 10, 2013 (date of inception) through June 30, 2013.</P>

<P STYLE="font: 12pt/14pt Times New Roman, Times, Serif; margin: 1.4pt 0 0.65pt">&nbsp;</P>

<P STYLE="font: 12pt/14pt Times New Roman, Times, Serif; margin: 1.4pt 0 0.65pt">We also consent to the reference to our firm under
the caption &quot;Experts&quot; in such Registration Statement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 1.4pt 0 0.65pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 1.4pt 0 0.65pt"><I>/s/ Messineo &amp; Co, CPAs LLC</I></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 1.4pt 0 0.65pt">Messineo &amp; Co, CPAs LLC</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 1.4pt 0 0.65pt">Clearwater, Florida</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">November 5, 2013</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>neb-na.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 neb-na.jpg
M_]C_X19817AI9@``34T`*@````@`"`$2``,````!``$```$:``4````!````
M;@$;``4````!````=@$H``,````!``(```$Q``(````>````?@$R``(````4
M````G`$[``(````$:FUP`(=I``0````!````L````-P`+<;````G$``MQL``
M`"<0061O8F4@4&AO=&]S:&]P($-3-2XQ(%=I;F1O=W,`,C`Q,SHP.3HR-2`Q
M.#HS,CHU-0```Z`!``,````!__\``*`"``0````!```%7*`#``0````!```$
M8P`````````&`0,``P````$`!@```1H`!0````$```$J`1L`!0````$```$R
M`2@``P````$``@```@$`!`````$```$Z`@(`!`````$``!46`````````$@`
M```!````2`````'_V/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;
M`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01
M#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``
M$0@`@P"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,`
M`0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#
M`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$
M!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,5
M8W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]526
M'U7)NR,M^&QYKHI`]7:8+G.&X-W?N[?]?YOTZ7[,PSJ:6D^)D_Q44LM$@"Z\
M5PB]2JN1CU9]+\>_>UK;`7"M[F$["VUGOJ+';7^S>U8'[+PO]`W\?[U$])Q?
M5W>DSTRW:YD&29]CMV[Z.TO33F)_1'V_^@JX/%ZFNRNU@LJ<'L=JU[2"#\'!
M27+-Z5@@!K<=@`X`!`_*G&&V@A^+./:-6N82!_:^E[41F/6/XJX/%ZA)5.F9
MAS,-EKA%@)98/Y33M<K:E!L`CJM4DDDBI22222E))+'ZQEW&]N#2\U@L]2Y[
M?I;2=K6-/R_U_F[&RD(BRD"W83&8TY[+E_V;B'5U0<?%Q)/Y4OV7A?Z!OX_W
MJ/WC^[^*[@\79-?4LC-P\JG);1BUML;EXI9N+WG:T`6[F[/1>Q_N5]KFN:'-
M(<UPD$:@@]PN2/1<5]ES;*JW8]S0/3`<UP=&RUWJ-?\`G,]/;L0\#`Z(:3C8
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M![(B.(2&W%MKY($9F'N2`C'BX-)PR>KYOT&ZA?:<<9`Q?59]H+#:*9&_8#L]
M39]+9O\`;N4!D7/RKL=M#V-K8US,E\>FYSMWZ-H#O4_1[?>FPZ+F55V9GI69
MVP,NOJ9M!UW;&;BY_I[OY2BOLALI))(J4L'-$]:N_P"(J_ZJU;RPLW_ENW_B
M*O\`JK5'F^4>:Z.Z9E<A2])$J'ME$A1TES>H9(P*&WFFV_=977LI;N</4>VK
M=_9WH]>)34;#56VMUSO5MV@-+G$!GJ/'[VVO:K%EE=3=]K@QI<UFYV@W/<VJ
MIO\`;L>QC55LPJ,;,R.K@7VWFD5NHK>]P(K-CXJQM_I.L=ZGT?S/\'_.6J2(
MB8UJ#KJ-?</IX8?U>%6J]E9X`E2Z&US<C.D$>]G/]0+#Z_UES^D8X;BW,;U:
MAY>>+*`!4[<]GM:YGZ7W[KJ5A4=-Q7YM]`ZGB4#'=6:LEUA:RTN]WZN\/]SJ
M'>Q_[CT_#@C*1XI\$H2X#'AE/7A_>BK+'+"$9<%PG$Y!+CA'T1R>R?1\_P#.
M/__1[4_\JYW_`!C/_/;%HL^B%G'_`)5SO^,9_P">V*^7BNEUA$AC7.CB=HW0
MJPWEYG\U_95]S*&!SM7/<&5M[N<>PT<[VM][_;]!"&9M<P6@187`>F+"YI:/
M4/J5.KW[-O\`A%4?]L?>=P#W7!S,=Y.U@=7^D/IM8?5I]]5ON]7]/^B]7^;1
M/LK0VI]ANIW%X>_>\NGVAESQ8;7,;8QGI6*2E.@""`YID$2".""LSKG3:NHT
M,ILL?5Z;Q8U]>TF0UU>TBP.;MVV*_CN+JA/T02VL[=DL&E;MGMVH>2F\1B1*
M)H@Z%1`(HBP7(^KOU:QQD,ZB<FYS\2ZQK*R&!IAKJ@7[6;_HV?OKK%E_5_\`
MHM__`(8M_*M13C)/((RF>(UNQB$8V(BA:DDE6SLUF%2+GM+F[@UVWD-/T[/Z
MM3`ZQR1-"RNC$RD(Q%DZ`-E)9=77*['T-](AN0]S&NF8V^FS<=-GOLM;]%__
M`*36H@)`[+LF*>.N,5>WT]*EA9O_`"W;_P`15_U5JW5A9O\`RW;_`,15_P!5
M:F9OE'FB.[=J^@$K[F45.ML^BWMW)/M8QO\`+>[VM2IU:%GOMR+K:KGL#Z;"
M*F-)`8U]K>[1^EW>^K]:W?Z2NK9ZJ;$6EEG5X>;4RGJ6-5D4BUD5%KWO:^=U
M;FLLJ'JL]GZ7:WWU>JQ'JZITZS-/3JKF'*94V[T1H=A+J]!^]7L]]?\`@U6=
M2*\;[1F.?1Z;@;\AUKA[0T_IAZS[6M9CW._J>G^D4Z.H],IP7]0=DUC!A@KR
MW%K0YL;PPO\`;ZFRVVS^7ZGJ?X12`$QJI2&T!'Y?<E_C*2=4QV9>%=B6.<QE
M["QSFQ(_E-W>U8?3OJCBYEV0VS+O#:'L'M%8W`CU';OT;UT-[FNK#FD.:X2U
MP,@CQ!"'T+^D9_\`79_U`3<6;)"7#&1B#=A9/'"0N0!(?__2[4_\JYW_`!C/
M_/;%HU_1$B1W"SC_`,JYW_&,_P#/;%HL^B%6&\O,_FO[-*FNH%M#C:YF+<:J
MX<T-:]TMKVO8YF5_,7[/S_\`P--=B/9ZU@KVW.W5TO>[<]SGN#,;:\E]E==/
M\[_7]7_A/4;)QCZ]@-0L<_WTVM(;8`";;\7][W^K_-_S=E/J;_W%*JFX>J'-
M>WT_3=74TM^BZ67OJ96VOT['U,L9M_[;].RQ2*;=+KG-<;@0=QVR`TD0/I-:
MY[?I[FH>2B4!PJ`=N&KM@=.X,W'TM^[W;MG[R'DIDDK_`%?_`*+?_P"&+?RK
M467]7_Z+?_X8M_*M12X_DCY+#N7!^M'5OK!TTXO[%Z?^T/5]3U]''9M]/TOY
MLM^GOL_S%A?\Z_K]_P#._P#]"S_R:[M"RO7^RW?9_P"?]-WI<?3@[/I^SZ7[
MZLPR1`$3CB?ZTE\<D0*,!+Q+PX^L_P!>P[</JZW=,SL?,QMGZ7[JE_SK^O\`
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M[K3ZFYFS;]G8VPV._2WN_2?U*O\`K;XV$'8/[.S,=AQF5UU>BYK=A#1M=6UH
M<]KZF[*]CT.JC(W.:UCJ1Z1LI9+`#:T^QSF-KK]]7J-]S_I_]:5S'!#7P'MK
MW?HFV3O#=K=V[U)L_G-_TT[B(V/6_J.JELGZ*%T+^D9_]=G_`%`1<CZ*%T+^
MD9_]=G_4!1Q_G!]5'9__T^U/_*N=_P`8S_SVQ:51@`K-/_*N=_QC/_/;%HL^
MB%6&\O,_FO[->C#B1:P"&@%S7'<][7.=]HW,VO8_W?\`&?I+?\&K%=3:Y+9)
M=&YSG%Q,?1&Y\^UJDDG64KE5L@$Z`$GR1*[+W77,LI-559:*;2X.]4$;GO\`
M3;_-;'>SWK!^M5GKT'$'J4BJZIS[W`,J=++'"IEK[:/5_-1A#CE&%\/$>&RM
M)Z@7OI\O_2=OH`(Q;Y$?K%O/Q6HO,L+=T_+IS*;Q8<=QL-+;6M]3VN#J_9D6
M^ZS_`(JQ>@8_4_7=C,.+D4NR6/L_25P*PPANW(>"YM=EF[]'7]-6LF#V8Q'$
M)#;B'[WD@1F8>Y*/#'BX/FC+U5Q?HMU)`9FX]F9;A,)-]#&OL&UVT!^[9^DC
MT]WL^AN1U'=H4DDDDI2PLW_ENW_B*O\`JK5NK"S?^6[?^(J_ZJU1YOE'FNCN
MW:OH((Q=USC8QI:387/GW/#RUU3=/>WT-O\`8].OT4:KZ"'GWY&/@WWXM)R<
MBNMSJJ`0-S@):W5-B"2`.NFNB45F!D'J.-E59=E=-+;&W8YBSU-^S9^DM#[*
MVM=7N?M<KI4*GV/J8^RLTV.:"^HD.+3W9O9['H74,LX6#?E^D^_T*W6>E6)<
M[:-T!'U2,8:6/1&N'][][]+^\E?(!(@:E#Z&UPR,^01[V<_U`LCZU=2->#5B
MBFUAZC6XE_#Z0QU)=ZU;3]%WJ;+/TRY_"P-W4+*F=2QJ/LUM)9>;W-;<2[=^
MK.]OJN9M]/\`KI^'#&9),^$Q)CP\,I?H\7S(RQRPA&7MW"<?<$N*`](R>S\O
MS?SC_]3M3_RKG?\`&,_\]L5]CA$+/L.WJF<#R7UN'P-;4<6PJUT3YG\V3H&T
MYYVG9&Z#MW<3'MW1^;N4<=U_H5_:BPY&T>J:@17N_.]/?[]B!ZWFEZWFE:*3
M5Y6-;;=378U]N.6BY@Y87#>QK_ZS51ZW@5]3QFX]ECJ@RQMK7L`)EH<V-K_;
M]&Q6/5`F($ZF!R?-0>^=/%$3,2)`U(&P5&-@@Z@N9]7_`*K4'(KZ@[*M<<2]
MP;7M8UKM@+&[O:7_`)_[RZ]9?U>UP[7=GWV.:?$2M16/<GD$93/$:W8Q",;$
M16JS@2T@$M)$!PB1YZJGA^KBV5=-(R,AM=.]V?<6D.=NV>F]_M<Z_P#/_F_H
M*ZD@1K:5)))(J4L+-_Y;M_XBK_JK5NK!SY;UFPG3=17M^3K)_P"J4>;Y1YKH
M[MRIP#84]P\53;;`4O647$NIE3U/`OR[L*F]EF3C!INJ!!+=T_\`4Q^D_P!&
MHX&(_#]??E6Y7KW.N'K;3LW?X.O8QGLT40]H<YX`#W@!SNY#9V;OZFY2]9/.
M041'2,A&^+U>J/C_`'D4QZICLSL*[#>]U;+F@%S8)$$/:?=[?I-6)TWZHT96
M1:'YENW%MK,!M8W#VVP[VO6T^R0B=!!-V<[\TV-`/FUH#D[#GR1EPQD1$W8^
MBV>.$M9`$A__U?1.I=+=D6#)QGBO(`VN#OHO'\N%0^Q=9'_:>H^?JD?]\*Z!
M),EBB3>H\DB1#S_V+K7_`''J_P"W?_4:7V+K7_<>K_MW_P!1KH$DWV8]RGC+
MS_V+K7_<>K_MW_U&G;TOJMYV6BO'8?I.#B]T?R=&+?21]F/BKB*+&QZ\:AE%
M0AC!`GGQ+C_614/(N%%%E[@7-J8YY`Y(:-VDH>)E/O\`4;94:;*G!KFDAW+6
MV`AS/ZZ?8%!:V$DDD5*225'!ZSTW/R+\7'N!R<9[V74G1X+'>FYVT_3KW?X1
MB!(%`G?9=''.492C$F,/G(%B%_O-Y4>I=-^V!EE;O3R*IV/C0@_F/1AGX3C#
M;V$Z\$'@%SO\UK'*3,O%?MV7,=O^C#AK/[J!X2**N"8_1(^CBG`ZR#'H5.C\
MX6$`_(L*7V+K/_<>K_MT_P#D%L,SL.PD,N82T!QU&@/'Y5+[9B?Z9@U<W5P&
MK3M>W^RF>U#N?M75D&\3]CB_8NL_]QZO^W3_`.02^Q=9_P"X]7_;I_\`(+:^
MUXNYS?59N88<-PD&-T?YJE7D46F*K&O,3[2#I_9_K)>U'N?M0>,;Q/V.(WIW
M6+#M<RJ@=W[R\C^J-OTEKX.'7A8XIKU[N<>7./+E823HXXQU'XK227__UO54
MDDDE*22224I))))2#.J?=A9%58E]E3VM'&KFEK4+`9?OR+;:C3ZKVEK'%I=#
M6,9)])SV?2;^\A?6"JZWH^3717;=8YHVU8]GHV.]S=PKO(=L]JS?JCBYE%F8
M<C%RL5KA5L^U9`R`XCUM_I#:STMNYGJ?Z3V?Z-'VP8F?%K'3AT_]&1Q5(1K?
MJVV_5QK6&L=2ZAMV[6CU_H_2U:=GYN_\_P#[XB-Z$&V-?]OSB&.:\,-Y@N;'
MT_;OL99M_25/?Z7_``:&'_6X/>\U8#V$$5TBRUI:[\U]F1Z3_49_5QJU-UWU
ME+G^GBXC6A[MA?<^2QIALM926M?;]/\`G$$NJL[I.3TNZS-KZ?4:G49#F91-
M3J]UQ#;;'%UC&>J[])_K5Z:M83\M^)4_-K95E.:#;76XO:UW[K7D-W*MT_JV
M+G9>7C8]5C3BOVVVN9M8YX)K<&N^DYS?3_.2N`TD/4?D_P"Z3Q$"KH2W'>F/
MV[H1;8_?3#/YTANK=V^LE_MW-_F[=Z<Y?06.WFS&#M[22"R=^XM8[3\[?O\`
M?_QG\M`=]8.GC>?LF675E[H&):9V`L+P[T]OZ3;Z=>[Z?_$^])O7>FD3]ER6
ML8RQQ)Q+1`8:Z[*VM]/?8Y[\CV-H99ZOZ5/_`%/[LO\`&C_WB>.?[Q^U.[-Z
M"YI#[,<LK!/NVP`W=NC=^[M<CL;T[+W[&U72T!Y#0?:2[VET?OML_MJ@[ZP8
M`L#7X.8-P+B\XEA&A8[W0SU&_3W_`$/\'_45OIN?C9OJ&FBW'<S;O%U+J7$'
M=L^F&[__`$6A+VZTB;\2#_W*N.7[Q^ULG$Q2[<::RX&0=HF0-L\)ZL?'I`%-
M;:P)`#`&C6)T;_51$DV@KBE56?M4DDDDM?_7]527RJDDI^JDE\JI)*?JI)?*
MJ22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G
MZJ27RJDDI__9_^T>*%!H;W1O<VAO<"`S+C``.$))300$``````!4'`%:``,;
M)4<<`@```@``'`)0``-J;7`<`@4`.$UI8W)O<V]F="!7;W)D("T@34DM(S0T
M-#,R-2U.86YO06YT:6)I;W1I8W-?1F]R;5]3+3$N9&]C.$))300E```````0
M<K2RI8R6XFY<$":"_+&NW#A"24T$.@``````F0```!`````!```````+<')I
M;G1/=71P=70````$`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E
M`````$-L<FT````/<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA
M;65415A4````$@!,`&4`>`!M`&$`<@!K`"``3P!P`'0`<@!A`%0`-@`R`#(`
M```X0DE-!#L``````;(````0`````0``````$G!R:6YT3W5T<'5T3W!T:6]N
M<P```!(`````0W!T;F)O;VP``````$-L8G)B;V]L``````!29W--8F]O;```
M````0W)N0V)O;VP``````$-N=$-B;V]L``````!,8FQS8F]O;```````3F=T
M=F)O;VP``````$5M;$1B;V]L``````!);G1R8F]O;```````0F-K9T]B:F,`
M```!````````4D="0P````,`````4F0@(&1O=6)`;^````````````!'<FX@
M9&]U8D!OX````````````$)L("!D;W5B0&_@````````````0G)D5%5N=$8C
M4FQT````````````````0FQD(%5N=$8C4FQT````````````````4G-L=%5N
M=$8C4'AL0'+````````````*=F5C=&]R1&%T86)O;VP!`````%!G4'-E;G5M
M`````%!G4',`````4&=00P````!,969T56YT1B-2;'0```````````````!4
M;W`@56YT1B-2;'0```````````````!38VP@56YT1B-0<F-`60```````#A"
M24T#[0``````$`$L`````0`!`2P````!``$X0DE-!"8```````X`````````
M````/X```#A"24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S
M```````)```````````!`#A"24TG$```````"@`!``````````(X0DE-`_4`
M`````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`,@``
M``$`6@````8```````$`-0````$`+0````8```````$X0DE-`_@``````'``
M`/____________________________\#Z`````#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z```.$))300````````"```X0DE-!`(`````
M``(``#A"24T$,````````0$`.$))300M```````&``$````".$))300(````
M```0`````0```D````)``````#A"24T$'@``````!``````X0DE-!!H`````
M`Y$````&``````````````1C```%7````"X`4`!A`&<`90!S`"``9@!R`&\`
M;0`@`$T`20`M`",`-``T`#0`,P`R`#4`+0!.`&$`;@!O`$$`;@!T`&D`8@!I
M`&\`=`!I`&,`<P!?`$8`;P!R`&T`7P!3`"T`,0````$`````````````````
M`````````0`````````````%7```!&,``````````````````````0``````
M```````````````````0`````0```````&YU;&P````"````!F)O=6YD<T]B
M:F,````!````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L
M;VYG``````````!"=&]M;&]N9P``!&,`````4F=H=&QO;F<```5<````!G-L
M:6-E<U9L3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)
M1&QO;F<`````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````
M#$53;&EC94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````
M"D53;&EC951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C
M=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O
M;6QO;F<```1C`````%)G:'1L;VYG```%7`````-U<FQ415A4`````0``````
M`&YU;&Q415A4`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%
M6%0````!```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%
M6%0````!```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX`
M```'9&5F875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG
M;@````=D969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O
M;&]R5'EP90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/
M=71S971L;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H
M=$]U='-E=&QO;F<``````#A"24T$*```````#`````(_\````````#A"24T$
M%```````!`````(X0DE-!`P`````%3(````!````H````(,```'@``#UH```
M%18`&``!_]C_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P(
M"`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,
M$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`(,`
MH`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&
M!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'
M!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&
M!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54EA]5R;LC
M+?AL>:Z*0/5VF"YSAN#=W[NW_7^;].E^S,,ZFEI/B9/\5%++1(`NO%<(O4JK
MD8]6?2_'OWM:VP%PK>YA.PMM9[ZBQVU_LWM6!^R\+_0-_'^]1/2<7U=WI,],
MMVN9!DF?8[=N^CM+TTYB?T1]O_H*N#Q>IKLKM8+*G![':M>T@@_!P4ERS>E8
M(`:W'8`.``0/RIQAMH(?BSCVC5KF$@?VOI>U$9CUC^*N#Q>H253IF8<S#9:X
M18"66#^4T[7*VI0;`(ZK5)))(J4DDDDI222Q^L9=QO;@TO-8+/4N>WZ6TG:U
MC3\O]?YNQLI"(LI`MV$QF-.>RY?]FXAU=4''Q<23^5+]EX7^@;^/]ZC]X_N_
MBNX/%V37U+(S</*IR6T8M;;&Y>*6;B]YVM`%NYNST7L?[E?:YKFAS2'-<)!&
MH(/<+DCT7%?9<VRJMV/<T#TP'-<'1LM=ZC7_`)S/3V[$/`P.B&DXV'Z5PPXH
MLVOWD.:&_3+7N4DLW%&Q'Y*^4>D0EZO7/]_C]".#Q>R27+#`HK]U(-#QP^LD
M$?\`26UTC-LRJ'MNUOH=Z=A'?3<U_;Z2;#)Q&B*48T__T.U<)ZIG#_A&?^>V
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MAMQ;:^2!&9A[D@(QXN#2<,GJ^;]!NH7VG'&0,7U6?:"PVBF1OV`[/4V?2V;_
M`&[E`9%S\J[';0]C:V-<S)?'IN<[=^C:`[U/T>WWIL.BYE5=F9Z5F=L#+KZF
M;0==VQFXN?Z>[^4HK[(;*222*E+!S1/6KO\`B*O^JM6\L+-_Y;M_XBK_`*JU
M1YOE'FNCNF97(4O21*A[91(4=)<WJ&2,"AMYIMOW65U[*6[G#U'MJW?V=Z/7
MB4U&PU5MK=<[U;=H#2YQ`9ZCQ^]MKVJQ9974W?:X,:7-9N=H-SW-JJ;_`&['
ML8U5;,*C&S,CJX%]MYI%;J*WO<"*S8^*L;?Z3K'>I]'\S_!_SEJDB(F-:@ZZ
MC7W#Z>&']7A5JO96>`)4NAM<W(SI!'O9S_4"P^O]9<_I&.&XMS&]6H>7GBR@
M`5.W/9[6N9^E]^ZZE85'3<5^;?0.IXE`QW5FK)=86LM+O=^KO#_<ZAWL?^X]
M/PX(RD>*?!*$N`QX93UX?WHJRQRPA&7!<)Q.02XX1]$<GLGT?/\`SC__T>U/
M_*N=_P`8S_SVQ:+/HA9Q_P"5<[_C&?\`GMBOEXKI=81(8USHXG:-T*L-Y>9_
M-?V5?<RA@<[5SW!E;>[G'L-'.]K?>_V_00AF;7,%H$6%P'IBPN:6CU#ZE3J]
M^S;_`(15'_;'WG<`]UP<S'>3M8'5_I#Z;6'U:??5;[O5_3_HO5_FT3[*T-J?
M8;J=Q>'OWO+I]H9<\6&US&V,9Z5BDI3H`@@.:9!$@C@@K,ZYTVKJ-#*;+'U>
MF\6-?7M)D-=7M(L#F[=MBOX[BZH3]$$MK.W9+!I6[9[=J'DIO$8D2B:(.A40
M"*(L%R/J[]6L<9#.HG)N<_$NL:RLA@:8:ZH%^UF_Z-G[ZZQ9?U?_`*+?_P"&
M+?RK44XR3R",IGB-;L8A&-B(H6I))5L[-9A4BY[2YNX-=MY#3].S^K4P.L<D
M30LKHQ,I",19.@#92675URNQ]#?2(;D/<QKIF-OILW'39[[+6_1?_P"DUJ("
M0.R[)BGCKC%7M]/2I86;_P`MV_\`$5?]5:MU86;_`,MV_P#$5?\`56IF;Y1Y
MHCNW:OH!*^YE%3K;/HM[=R3[6,;_`"WN]K4J=6A9[[<BZVJY[`^FPBIC20&-
M?:WNT?I=WOJ_6MW^DKJV>JFQ%I99U>'FU,IZEC59%(M9%1:][VOG=6YK+*AZ
MK/9^EVM]]7JL1ZNJ=.LS3TZJYARF5-N]$:'82ZO0?O5[/?7_`(-5G4BO&^T9
MCGT>FX&_(=:X>T-/Z8>L^UK68]SOZGI_I%.CJ/3*<%_4'9-8P88*\MQ:T.;&
M\,+_`&^ILMML_E^IZG^$4@!,:J4AM`1^7W)?XRDG5,=F7A78ECG,9>PL<YL2
M/Y3=WM6'T[ZHXN9=D-LR[PVA[![16-P(]1V[]&]=#>YKJPYI#FN$M<#((\00
MA]"_I&?_`%V?]0$W%FR0EPQD8@W863QPD+D`2'__TNU/_*N=_P`8S_SVQ:-?
MT1(D=PLX_P#*N=_QC/\`SVQ:+/HA5AO+S/YK^S2IKJ!;0XVN9BW&JN'-#6O=
M+:]KV.9E?S%^S\__`,#378CV>M8*]MSMU=+WNW/<Y[@S&VO)?9773_._U_5_
MX3U&R<8^O8#4+'/]]-K2&V``FV_%_>]_J_S?\W93ZF_]Q2JIN'JAS7M]/TW5
MU-+?HNEE[ZF5MK].Q]3+&;?^V_3LL4BFW2ZYS7&X$'<=L@-)$#Z36N>WZ>YJ
M'DHE`<*@';AJ[8'3N#-Q]+?N]V[9^\AY*9)*_P!7_P"BW_\`ABW\JU%E_5_^
MBW_^&+?RK44N/Y(^2P[EP?K1U;ZP=-.+^Q>G_M#U?4]?1QV;?3]+^;+?I[[/
M\Q87_.OZ_?\`SO\`_0L_\FN[0LKU_LMWV?\`G_3=Z7'TX.SZ?L^E^^K,,D0!
M$XXG^M)?')$"C`2\2\./K/\`7L.W#ZNMW3,['S,;9^E^ZI?\Z_K_`/\`SO\`
M_0L_\FNEP;.OG*J&;4T4-]2NUS7,]QG]!E,9[GMJV4_S6_U=^;_W7]5:R?DE
M"!KV\<NOHEQ!=[T?\W%XCIWUG^N>1UW"Q,SI/H47A_K5P6_HP:]^7ZEF[;]D
MW?S?^'];T_YWT5M9O_+=O_$5?]5:MU86;_RW;_Q%7_56JKS,Q(1J(A79:9"4
MA41&AT;M/T`J;F4LLOH=ZAIJL;D.8PMVMWD6U^Z6WMVWL<[92Y7*OH!4\S')
MO)-;;!<-M;Y#7U6D#:YCM'L]5E/Z-['?SOZ)110OD8=8MMLOI#ZF`^ZT^IN9
MLV_9V-L-COTM[OTG]2K_`*V^-A!V#^SLS'8<9E==7HN:W80T;75M:'/:^INR
MO8]#JHR-SFM8ZD>D;*62P`VM/L<YC:Z_?5ZC?<_Z?_6E<QP0U\![:]WZ)MD[
MPW:W=N]2;/YS?]-.XB-CUOZCJI;)^BA="_I&?_79_P!0$7(^BA="_I&?_79_
MU`4<?YP?51V?_]/M3_RKG?\`&,_\]L6E48`*S3_RKG?\8S_SVQ:+/HA5AO+S
M/YK^S7HPXD6L`AH!<UQW/>USG?:-S-KV/]W_`!GZ2W_!JQ74VN2V271N<YQ<
M3'T1N?/M:I))UE*Y5;(!.@!)\D2NR]UUS+*35566BFTN#O5!&Y[_`$V_S6QW
ML]ZP?K59Z]!Q!ZE(JNJ<^]P#*G2RQPJ9:^VCU?S480XY1A?#Q'ALK2>H%[Z?
M+_TG;Z`",6^1'ZQ;S\5J+S+"W=/RZ<RF\6''<;#2VUK?4]K@ZOV9%ONL_P"*
ML7H&/U/UW8S#BY%+LEC[/TE<"L,(;MR'@N;799N_1U_35K)@]F,1Q"0VXA^]
MY($9F'N2CPQXN#YHR]5<7Z+=20&9N/9F6X3"3?0QK[!M=M`?NV?I(]/=[/H;
MD=1W:%))))*4L+-_Y;M_XBK_`*JU;JPLW_ENW_B*O^JM4>;Y1YKH[MVKZ"",
M7=<XV,:6DV%SY]SP\M=4W3WM]#;_`&/3K]%&J^@AY]^1CX-]^+2<G(KK<ZJ@
M$#<X"6MU38@D@#KIKHE%9@9!ZCC95679732VQMV.8L]3?LV?I+0^RMK75[G[
M7*Z5"I]CZF/LK--CF@OJ)#BT]V;V>QZ%U#+.%@WY?I/O]"MUGI5B7.VC=`1]
M4C&&ECT1KA_>_>_2_O)7R`2(&I0^AM<,C/D$>]G/]0+(^M74C7@U8HIM8>HU
MN)?P^D,=27>M6T_1=ZFRS],N?PL#=U"RIG4L:C[-;267F]S6W$NW?JSO;ZKF
M;?3_`*Z?APQF23/A,28\/#*7Z/%\R,L<L(1E[=PG'W!+B@/2,GL_+\W\X__4
M[4_\JYW_`!C/_/;%?8X1"S[#MZIG`\E];A\#6U'%L*M=$^9_-DZ!M.>=IV1N
M@[=W$Q[=T?F[E''=?Z%?VHL.1M'JFH$5[OSO3W^_8@>MYI>MYI6BDU>5C6VW
M4UV-?;CEHN8.6%PWL:_^LU4>MX%?4\9N/98ZH,L;:U[`"9:'-C:_V_1L5CU0
M)B!.I@<GS4'OG3Q1$S$B0-2!L%1C8(.H+F?5_P"JU!R*^H.RK7'$O<&U[6-:
M[8"QN[VE_P"?^\NO67]7M<.UW9]]CFGQ$K45CW)Y!&4SQ&MV,0C&Q$5JLX$M
M(!+21`<(D>>JIX?JXME732,C(;73O=GW%I#G;MGIO?[7.O\`S_YOZ"NI($:V
ME2222*E+"S?^6[?^(J_ZJU;JP<^6]9L)TW45[?DZR?\`JE'F^4>:Z.[<J<`V
M%/</%4VVP%+UE%Q+J94]3P+\N["IO99DXP:;J@02W=/_`%,?I/\`1J.!B/P_
M7WY5N5Z]SKAZVT[-W^#KV,9[-%$/:'.>``]X`<[N0V=F[^IN4O63SD%$1TC(
M1OB]7JCX_P!Y%,>J8[,["NPWO=6RYH!<V"1!#VGW>WZ35B=-^J-&5D6A^9;M
MQ;:S`;6-P]ML.]KUM/LD(G003=G._--C0#YM:`Y.PY\D9<,9$1-V/HMGCA+6
M0!(?_]7T3J72W9%@R<9XKR`-K@[Z+Q_+A4/L761_VGJ/GZI'_?"N@23)8HDW
MJ/)(D0\_]BZU_P!QZO\`MW_U&E]BZU_W'J_[=_\`4:Z!)-]F/<IXR\_]BZU_
MW'J_[=_]1IV]+ZK>=EHKQV'Z3@XO='\G1BWTD?9CXJXBBQL>O&H914(8P0)Y
M\2X_UD5#R+A119>X%S:F.>0.2&C=I*'B93[_`%&V5&FRIP:YI(=RUM@(<S^N
MGV!06MA)))%2DDE1P>L]-S\B_%Q[@<G&>]EU)T>"QWIN=M/TZ]W^$8@2!0)W
MV71QSE&4HQ)C#YR!8A?[S>5'J73?M@996[T\BJ=CXT(/YCT89^$XPV]A.O!!
MX!<[_-:QRDS+Q7[=ES';_HPX:S^Z@>$BBK@F/T2/HXIP.L@QZ%3H_.%A`/R+
M"E]BZS_W'J_[=/\`Y!;#,[#L)#+F$M`<=1H#Q^52^V8G^F8-7-U<!JT[7M_L
MIGM0[G[5U9!O$_8XOV+K/_<>K_MT_P#D$OL76?\`N/5_VZ?_`""VOM>+N<WU
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MUAK'4NH;=NUH]?Z/TM6G9^;O_/\`^^(C>A!MC7_;\XACFO##>8+FQ]/V[[&6
M;?TE3W^E_P`&AA_UN#WO-6`]A!%=(LM:6N_-?9D>D_U&?U<:M3==]92Y_IXN
M(UH>[87W/DL:8;+64EK7V_3_`)Q!+JK.Z3D]+NLS:^GU&IU&0YF434ZO=<0V
MVQQ=8QGJN_2?ZU>FK6$_+?B5/S:V593F@VUUN+VM=^ZUY#=RK=/ZMBYV7EXV
M/58TXK]MMKF;6.>":W!KOI.<WT_SDK@-)#U'Y/\`ND\1`JZ$MQWIC]NZ$6V/
MWTPS^=(;JW=OK)?[=S?YNW>G.7T%CMYLQ@[>TD@LG?N+6.T_.W[_`'_\9_+0
M'?6#IXWG[)EEU9>Z!B6F=@+"\.]/;^DV^G7N^G_Q/O2;UWII$_9<EK&,L<2<
M2T0&&NNRMK?3WV.>_(]C:&6>K^E3_P!3^[+_`!H_]XGCG^\?M3NS>@N:0^S'
M+*P3[ML`-W;HW?N[7([&].R]^QM5TM`>0T'VDN]I='[[;/[:H.^L&`+`U^#F
M#<"XO.)81H6.]T,]1OT]_P!#_!_U%;Z;GXV;ZAIHMQW,V[Q=2ZEQ!W;/IAN_
M_P!%H2]NM(F_$@_]RKCE^\?M;)Q,4NW&FLN!D':)D#;/">K'QZ0!36VL"0`P
M!HUB=&_U41)-H*XI55G[5))))+7_U_54E\JI)*?JI)?*J22GZJ27RJDDI^JD
ME\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI
M)*?_V3A"24T$(0``````60````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T
M`&\`<P!H`&\`<````!4`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``
M(`!#`%,`-0`N`#$````!`#A"24T$!@``````!P`(`0$``0$`_^$13&AT='`Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+ON[\B
M(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X
M;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O
M<F4@-2XP+6,P-C$@-C0N,30P.30Y+"`R,#$P+S$R+S`W+3$P.C4W.C`Q("`@
M("`@("`B/B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(B!X;6QN<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS.G-T4F5F/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X
M;6QN<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS
M.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP
M+R(@>&UP.DUO9&EF>41A=&4](C(P,3,M,#DM,C54,3@Z,S(Z-34M,#0Z,#`B
M('AM<#I#<F5A=&5$871E/2(R,#$S+3`Y+3(U5#$X.C`P.C0X+3`T.C`P(B!X
M;7`Z365T861A=&%$871E/2(R,#$S+3`Y+3(U5#$X.C,R.C4U+3`T.C`P(B!X
M;7`Z0W)E871O<E1O;VP](E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR(B!D
M8SIF;W)M870](FEM86=E+VIP96<B('AM<$U-.D1O8W5M96YT240](GAM<"YD
M:60Z.3-&.#8S-D,S,C(V13,Q,3@Q,D%&-$0P0S<Y,S4U1#DB('AM<$U-.DEN
M<W1A;F-E240](GAM<"YI:60Z.31&.#8S-D,S,C(V13,Q,3@Q,D%&-$0P0S<Y
M,S4U1#DB('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#TB=75I9#HR9C5F,#@Y
M-BTV,V9B+30Y.3`M83,Y82UE-&$Q9#@X.30U8S,B('!D9CI0<F]D=6-E<CTB
M06-R;V)A="!$:7-T:6QL97(@,3`N,"XP("A7:6YD;W=S*2(@<&AO=&]S:&]P
M.D-O;&]R36]D93TB,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](C$M075R:6$B
M/B`\9&,Z=&ET;&4^(#QR9&8Z06QT/B`\<F1F.FQI('AM;#IL86YG/2)X+61E
M9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@34DM(S0T-#,R-2U.86YO06YT:6)I
M;W1I8W-?1F]R;5]3+3$N9&]C/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT
M:71L93X@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F.FQI/FIM<#PO<F1F
M.FQI/B`\+W)D9CI397$^(#PO9&,Z8W)E871O<CX@/'AM<$U-.DAI<W1O<GD^
M(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T.F%C=&EO;CTB8V]N=F5R=&5D(B!S
M=$5V=#IP87)A;65T97)S/2)F<F]M(&%P<&QI8V%T:6]N+W!D9B!T;R!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P(B\^(#QR9&8Z;&D@<W1%=G0Z
M86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HY,T8X
M-C,V0S,R,C9%,S$Q.#$R048T1#!#-SDS-35$.2(@<W1%=G0Z=VAE;CTB,C`Q
M,RTP.2TR-50Q.#HS,CHU-2TP-#HP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB
M061O8F4@4&AO=&]S:&]P($-3-2XQ(%=I;F1O=W,B('-T179T.F-H86YG960]
M(B\B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F-O;G9E<G1E9"(@<W1%=G0Z
M<&%R86UE=&5R<STB9G)O;2!A<'!L:6-A=&EO;B]P9&8@=&\@:6UA9V4O:G!E
M9R(O/B`\<F1F.FQI('-T179T.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z<&%R
M86UE=&5R<STB8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E
M+G!H;W1O<VAO<"!T;R!I;6%G92]J<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z86-T
M:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HY-$8X-C,V
M0S,R,C9%,S$Q.#$R048T1#!#-SDS-35$.2(@<W1%=G0Z=VAE;CTB,C`Q,RTP
M.2TR-50Q.#HS,CHU-2TP-#HP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O
M8F4@4&AO=&]S:&]P($-3-2XQ(%=I;F1O=W,B('-T179T.F-H86YG960](B\B
M+SX@/"]R9&8Z4V5Q/B`\+WAM<$U-.DAI<W1O<GD^(#QX;7!-33I$97)I=F5D
M1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.CDS1C@V,S9#,S(R-D4S
M,3$X,3)!1C1$,$,W.3,U-40Y(B!S=%)E9CID;V-U;65N=$E$/2)X;7`N9&ED
M.CDS1C@V,S9#,S(R-D4S,3$X,3)!1C1$,$,W.3,U-40Y(B!S=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240](G5U:60Z,F8U9C`X.38M-C-F8BTT.3DP+6$S.6$M
M931A,60X.#DT-6,S(B\^(#PO<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^
M(#PO>#IX;7!M971A/B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(#P_>'!A8VME
M="!E;F0](G<B/S[_XF\@24-#7U!23T9)3$4``0$``&\0``````)```!M;G1R
M4D="(%A96B`'W``*``\`%@`)`!5A8W-P35-&5`````!.3TY%````````````
M`````````0``]M8``0````#3+4-V4W``````````````````````````````
M``````````````````````````````````MD97-C```!"````&)C<')T```!
M;````#QW='!T```!J````!1R6%E:```!O````!1G6%E:```!T````!1B6%E:
M```!Y````!1R5%)#```!^`````YG5%)#```""`````YB5%)#```"&`````YV
M8V=T```"*````Q)40U!T```%/```:=1D97-C``````````@Q+4%U<FEA````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````=&5X=`````!#;W!Y
M<FEG:'0@,C`P-B!#;VQO<E9I<VEO;B!);F,N("A3<'ED97(R(#(N,RXS+3$I
M````6%E:(````````/?4``$````!'=5865H@````````>J```#YC```#:5A9
M6B````````!8S@``N"\``!LI6%E:(````````"-G```)<0``M)MC=7)V````
M``````$",P``8W5R=@`````````!`C,``&-U<G8``````````0(S``!V8V=T
M`````````````P$```$```$!`@,#!`4%!@<'"`D*"@L,#0T.#Q`1$1(3%!46
M%A<8&1H;'!T='A\@(2(C)"4F)R@I*BHK+"TN+S`Q,C,T-38W.#DZ.SP]/C]`
M04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM
M;6YO<'%R<W1U=G=X>7I[?'U^?X"!@H.$A8:'B(F*BXN,C8Z/D)&2DY25EI>8
MF9J;G)V>GZ"AHJ.DI::GJ*FIJJNLK:ZOL+&RM+6VM[BYNKN\O;Z_P,'"P\3%
MQLC)RLO,S<[/T=+3U-76V-G:V]S>W^#AX^3EY^CIZ^SM[_#Q\_3V]_GZ_/W_
M`````0$"`@,#!`0%!@8'"`@)"@H+#`P-#@\/$!$2$Q,4%187%Q@9&AL<'1T>
M'R`A(B,D)"4F)R@I*BLL+"TN+S`Q,C,T-34V-S@Y.CL\/3X^/T!!0D-$149&
M1TA)2DM,34U.3U!14E-45%565UA96EM;7%U>7V!A8F)C9&5F9VAI:6IK;&UN
M;W!Q<7)S='5V=WAY>GI[?'U^?X"!@H.$A8:'B(B)BHN,C8Z/D)&2DY25EI>8
MF9J;G)V>GZ"AHJ.DI::HJ:JKK*VNK["QLK.TM;:WN+F[O+V^O\#!PL/$Q<;'
MR,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.#AXN/DY0````$!`@(#`P0$!04&
M!@<("`D)"@L,#`T.#@\0$1$2$Q05%187&!D9&AL<'1X?'R`A(B,D)28F)R@I
M*BLL+2XN+S`Q,C,T-38W.#@Y.CL\/3X_0$%!0D-$149'2$E*2DM,34Y/4%%2
M4E-455976%E:6EM<75Y?8&%A8F-D969G:&AI:FML;6YO<'!Q<G-T=79W=WAY
M>GM\?7Y_@("!@H.$A8:'B(F*BHN,C8Z/D)&2DY25EI>8F9F:FYR=GI^@H:*C
MI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-SL_0
MT=+3U-76U]?8V=K;W-W>W^```%1#4'0``````````@````8```````#;I0"?
M8Y4``````0```#8N,0``````````````````````````````````````````
M`/T(```R,#`W,3`M.3<X,#(P+3@V,38R``````````````````\`````````
M``````$````"`````0````$````````````````````"`````@``````````
M``````````$`````````<W<@-$-,+VAW(#-#3```````````````````````
M```P,#8T,3DS,P```````````````````````````````#$R,3`Q-3(R,#@R
M,A$````1````$0```!$```#+`0$`IOL```IW`0`,0@$`F`X!``16`0#Z_@$`
MWV\!`*Q<`0`"BP,`4C@"`"5F`0#'RP4`*5P#`#ET`0`K9P@`5JX$`!F$`0`K
MQPL`6F0&`$R7`0#1H@\`DU@(`.6P`0`(#!0`>Y0*`*['`0"LO!@`.?0,`+3H
M`0`W"1\`8"40`%`-`@#7HR4`-7X3`!TZ`@#'RRP`]!T7`-=C`@!BD#0`#@T;
M`'63`@#V2#T`(WL?`)S$`@#3;48`6!DD`'W_`@#^M$D`!L$E`&(0`P``````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````#+`0$`IOL```IW`0`"*P$`XX4!`.QQ`0`W
MZ0$`J"8#`"F\`0"T*`,`.]\%`%(X`@#E$`4`F`X*`/[T`@`?A0<`D6T/`+KI
M`P"Z:0H`B<$5`(L,!0#GNPT`8`4=`$Q7!@"B91$`*P<E`-W$!P`20Q4`+[TM
M`#]5"0##51H`+]TX`---"P!2>!\`'1I$`$96#0`*-R4`TZU0`(N,#P"+;"L`
M!D%>``KW$0"VDS(`+]UM`+*]%``AL#D`-5Y]`%AY%P!4XT$`)S&/`&*0&@``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````#+`0$`IOL```IW`0!_"@$`\.<```)+
M`@`*=P$`UP,!`(&5!`##-0(`O#0!`#6>"`#-3`,`K'P!`-V$#@!FA@0`S<P!
M`.,E%0!W'@8`@34"`-W$'0!,]P<`V:X"`$[")P`Q"`H`AS8#`"?Q,@!M1PP`
M?\H#`%@9/P#^-`\`A8L$`&+P3@!26!(`X5H%`$KL7P#?KQ4`4C@&`$@!<@"1
M+1D`%QD'`/ZTA0!:Y!P`I!`(`!_EF0!<[R```"`)`$[BKP"ZB24`1E8*`#WJ
MR```````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````#+`0$`IOL```IW`0#TO0$`U\,!
M``YM`@!FI@,`R^$#`$0+!0#L,0<`PY4'`+B>"0#R<@P`V2X-`(U7$``UOA(`
MI#`4`-$"&`#NG!H`$J,<`);C(0"3F",`Y5`F`$I,+0!WOBT`S0PQ`/8(.@#V
MJ#@`]+T\`$[B1P#E\$8`Z<9+`*#:60!FQE4`LAU;`)8#;0!8^64`:AQL`/I^
M@0`&@7<`"G=^`$C!EP`E!HL`$%B3`(GAK@!U,Y\`HF6H`-?#QP`G,:\`D_B\
M`(OLXP``````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````````````````````````````````@("`@("`@("`@("``````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````,S,"`/WW``````$`[QX!`&09````
M``````#__P``__\``````````````````````0$!`0$!`0$!`0$!`@("`@,#
M`P,#!`0$!`4%!04&!@8&!@<'!P@("0D)"@H+"PL,#`T-#@X.#P\0$!`1$1(2
M$Q04%186%Q<8&1D:&QL<'!T>'A\@("$A(B,D)28G)R@I*BLL+"TN+S`Q,C(S
M-#4V-S@Y.CL\/3X_0$%"0T1%1TA)2DM,34Y/4%%25%566%E:7%U>8&%B8V5F
M9VEJ:VUN;W%R<W5V>'E[?'Z`@8.$AH>)BHR.CY&2E)67F)J<G9^AHZ6FJ*JL
MKJ^QL[6WN;J\OL#"P\7'R<O-S]'3U=?9V]W?XN3FZ.KL[O#R]/;X^OS_````
M``````````````````$!`0$!`0$!`0$!`0("`@(#`P,#`P0$!`0%!04%!@8&
M!@8'!P<("`D)"0H*"PL+#`P-#0X.#@\/$!`0$1$2$A,4%!46%A<7&!D9&AL;
M'!P='AX?("`A(2(C)"4F)R<H*2HK+"PM+B\P,3(R,S0U-C<X.3H[/#T^/T!!
M0D-$14=(24I+3$U.3U!14E155EA96EQ=7F!A8F-E9F=I:FMM;F]Q<G-U=GAY
M>WQ^@(&#A(:'B8J,CH^1DI25EYB:G)V?H:.EIJBJK*ZOL;.UM[FZO+[`PL/%
MQ\G+S<_1T]77V=O=W^+DYNCJ[.[P\O3V^/K\_P`````````````````````!
M`0$!`0$!`0$!`0$"`@("`P,#`P,$!`0$!04%!08&!@8&!P<'"`@)"0D*"@L+
M"PP,#0T.#@X/#Q`0$!$1$A(3%!05%A87%Q@9&1H;&QP<'1X>'R`@(2$B(R0E
M)B<G*"DJ*RPL+2XO,#$R,C,T-38W.#DZ.SP]/C]`04)#1$5'2$E*2TQ-3D]0
M45)4559865I<75Y@86)C969G:6IK;6YO<7)S=79X>7M\?H"!@X2&AXF*C(Z/
MD9*4E9>8FIR=GZ&CI::HJJRNK[&SM;>YNKR^P,+#Q<?)R\W/T=/5U]G;W=_B
MY.;HZNSN\/+T]OCZ_/\!````!P````$`````````````````````````````
M``````````````````4```A00TE<5D5.7S$P1$4F1$567S`V-#`F4U5"4UE3
M7T,Y-3DS.#0R)E)%5E]!,0``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````7%PN7$1)4U!,05DQ````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````$Y6241)02!'949O
M<F-E(#DU,#`@1U0`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````````````````````@``````H``*`%```!`0``````````````
M```````````````````````````````#````34].251/4EQ73U(R-S8P7'LT
M9#,V93DV92UE,S(U+3$Q8V4M8F9C,2TP.#`P,F)E,3`S,3A]7#`P,#(`````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````%Q<+EQ$25-03$%9,5Q-;VYI=&]R,```````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````````!'
M96YE<FEC(%!N4"!-;VYI=&]R````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````````@``
M`````````````````````````````````````````````0``"%!#25Q614Y?
M,3!$129$159?,#8T,"9354)365-?0SDU.3,X-#(F4D567T$Q````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````!<7"Y<1$E34$Q!63(`````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````3E9)1$E!($=E1F]R8V4@.34P,"!'5```````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````"````"P
M!```@`<```(!``````````````````````````````````````````````,`
M``!-3TY)5$]27$A74#(V,35<>S1D,S9E.39E+64S,C4M,3%C92UB9F,Q+3`X
M,#`R8F4Q,#,Q.'U<,#`P,0``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````7%PN7$1)4U!,05DR
M7$UO;FET;W(P````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````$=E;F5R:6,@4&Y0($UO;FET;W(`````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````````````````#````````````````````````````````````
M```````````(````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````````%Q<
M+EQ$25-03$%95C$`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````!21%!$1"!#:&%I;F5D($1$
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````!```````````````````````
M````````````````````````"``@````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````!<7"Y<1$E34$Q!658R````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````4D10($5N
M8V]D97(@36ER<F]R($1R:79E<@``````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````4`````````
M``````````````````````````````````````@`(```````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````7%PN7$1)4U!,05E6,P``````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````%)$4"!2969L96-T;W(@1&ES<&QA>2!$<FEV97(`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```"``````````````````````````````````````````````![-&0S-F4Y
M-F4M93,R-2TQ,6-E+6)F8S$M,#@P,#)B93$P,S$X?5PP,#`Q````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````1$E34$Q!65Q(5U`R-C$U7#4F,C$U
M1C$T1$0F,295240T,3DT-3<V````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````$=E;F5R:6,@4&Y0($UO;FET;W(`````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````____
M____`"+P%28`````*`X!`X`R'WCJS[6C54F9)1!05*5O@```````````````
M``````````````````````````````![-&0S-F4Y-F4M93,R-2TQ,6-E+6)F
M8S$M,#@P,#)B93$P,S$X?5PP,#`R````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````1$E34$Q!65Q73U(R-S8P7#4F,C$U1C$T1$0F,295240T,3DT
M-3<W````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````$=E;F5R
M:6,@4&Y0($UO;FET;W(`````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````________`%WR8"<``````18!
M!*$\(G@Z;[&G54R>)0Q05*7+``````````,!````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````_^X`(4%D;V)E`&1``````0,`$`,"`P8`
M``````````````#_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"
M`0$!`0$!`@("`@("`@("`@("`@(#`P,#`P,#`P,#`P,#`P,!`0$!`0$!`@$!
M`@,"`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`__"`!$(!&,%7`,!$0`"$0$#$0'_Q`%Y``$``0,%`0$`````
M````````!@(("0$$!0<*`PL!`0`!!0$!`0$````````````#`0($!08(!PD*
M$``!`0<"`P(,!@$#`@8!`@<``1$"`P0%!@<Q"!`3"2`20%`S%#05-18V%S<X
M,"%!&!D*,F!P&B(Y(R1&1TDZ)9"@*"8G2"E**A$```4#`0,$"`P.#@0'"@07
M`0(#!`4`!@<1,1(((4%Q$_"!D:&QP12V$"!1X2(R%75WES@),%!AT8(C--2U
MU1:6MWA`0I+2,],DM#65=M87-_&3-AA@<%*BLZ6'8D-S=)0EQHBXR')31,4F
M)T?'F'EC@U5EA;F0H,-4Q&<HJ#F)"A(``0(#!`$*#PL*`@<#"`$5`0(#`!$$
M(3$2!4%187&!D;$B<A,&$"`P0*'!T3*2LC-SLQ0'4/#A0M(CD],T=#528H*B
MPD.4M!5U%@A@</%3PR2$XM2U8X.CQ"4V=K9$5&2%%W>0H*25)H88\D5EIL8W
MAS@)_]H`#`,!`0(1`Q$```#W\```````````````'SHP(^9])U#HHO1WZPW_
M`"LU0````````````````````````````````````````````````````.`S
M;.?PKP````````````````````````````!CD^48'DH\0<OS$]?</^BO8]I[
MJ4````````````````````````````````````````````````````#S5>^^
M+]*O@3M`````````````````````````````!U!HHO-=Y(Y[*?\`:-GEA^V;
M,````````````````````````````````````````````````````#JWHX/S
M%_Z#_B/ZDG\ZWW/EL:X`````````````````````````````````````````
M````````````````````````````````````````47.H.GQNXN6R>$S+?.?[
MKXWRE?I'P>%?UES7HV\(]CZUOS.^@9G/*72`````````````````````````
M`#&IR./DKZ[(````````````````````````````````````````````````
M``````P.^R^5SQ>-.J`HJ_.:_=GXY^C1^$OV,```````````````````````
M````8:>!Q,RW?98`````````````````````````````````````````````
M````````&'7U+SF3'S_N^V>:R`,0/J'GLOWE[H0`````````````````````
M`````!;/J(^F=?9?]T\X````````````````````````````````````````
M`````````````^%],%7L7EL[GC?J@`````````````````````````````,-
M/`X>9;OLP`#IS0Q6S<?C7^?3LX``````````````````````````````````
M````````````````8-O8'+YKO)73<WB7``1C8V6<?4];?=\;VH``````````
M`````%O'/Y=E/&;#I_49'QH````````L$T&OOHZ#+Y.DH'%X6%@/\G?-([BV
MYV/57TSL[?9P```J.S-E#>'UV!==U6#]*@``````````````````````````
M````````(KBWV/\`%;*V7FLS@(+@``````(?M(\?7L#D\FOBOL``+`?7G*65
M>B-#G3_+OZ2````!S<UMRG1XE[W:ZV;9L8```````T,7?S'<X:?CW0=M;:#C
MXZPK#D@.OEVU*@``````#Y*6NP:.Z>?>@1C5ZZT+XS\?W6QWEZ/V7ZIN9*@`
M`?0F6;'.LV*99D?0.ARLIOU#2YC/KV@Y"2@`````````````````````````
M```````'1FDR<#?POINAM%D]K[6&&8<G7NOEX""X``````#'M[]X3(3X"[L"
M"_1]=CM_4_YAB7_2GYWU?W6#F7_,/Z1D3_+'ZAVU\0W0```YR:V<9L78^RB@
M.!+V-L(<\'W/FKBNAQ``````(KBW^:KSAU\^SXN%ANLNX+=7!9\G<&:DTSZ@
M```````%AF+SE^>5T8`^<6+])<H```"DC\3JW$6VZRVYWL]/WSO<6TOE,[TN
M>D.0[GW..```````````````````````````````!C)^:[C#1\>Z"\SL-?83
MP.WW&!FW"[.LXG<G>```````ZU^AZZT;[MH<@?D;KP(YUF+@5_83X[:K]VT'
MJ!_!O[W-OGNP````V%J#X[H?7(3+B9"/HFFM.Y7.RE_3]+ER^L:(````#@8+
MO+7YA[2]WM==BP^4[^\_:9-P^S?:M/K6E56H```````/F6^P:ZWS'U]P^1L;
M@I]@`````!046U^%*]283'QST66+Z_S>.#YWM_4OZ>XOM7:0````````````
M```````````````````8POF>YQ1_+=W-,N.WOB]YD`Z2O/RT^M:5U5``````
M`'%9T>*[W/PGVBKE@\']\!:E]VT-D_I7F<POYZ?1````!I1\SYTKQ,=;&N?2
M7H=/,LV*][M==F/^OZ`````>>;S_`-5,,N/%K\HZ')UT\TRGIN+J?>ZGUK2N
MK50```````4F//7\_BXUG,>D+HOHO)UN`````&BM-'RI7XT;>V[A8JXO^4MR
MG_7N8LIXS8^J3U%Q50`````````````````````````````!;MSV7YQ_/'6=
MB;"+C^=W=X.[INKZ?>M/M6GTN5*```````6F?>-#A^_0+Y[]+:^C#\A_KX`Z
M]ZS$["Y/+````%*M%'QMKMZ5VUE;8M37KC8:GDI;,Z7W#F[R^PUX```MHYO,
MP$?!^GZIT^5>YF[#L3*IN[K=U?;]ZT^USZ*55IJ````````6CXFJNXR]J```
M``-#17YTK\J-O;7;6W;2RL>BNQ;\Q!?I]"TN0GO]7DN^D:<`````````````
M````````````````#RY^8^SN2Z/$LK^:]+D$Z6F\NMW=]-Q=3[UI]:TKK0:@
M``````CNVBLK]&<Y?MY=Z@``````:%%*_*E?C2NVMKM;:[.RZR'GUR'?<[:E
MRV;ZQ/5/$```#SL>>^K^5*V^<+T-]/0TWTEN]OMW5UNXNI]ZT^M55::T````
M``````````#0I5^='QI7;VUVMMVRLKLK+K;-5=NNFT'4>IG]5'J+B@``````
M``````````````````````!T=I,GSO\`GWJK=^9V&4'H\KFI+=[?;O+[=S=3
M[UI]JTKK2H```````````MQ^N:BX[Y'MP``*5:#Y6U^%&VMNVEM=C9=QL=^*
MGE(;NNVU&:_[/SUWG6X```'DG\H]SO*UOGR]E*I[>0OMWLEN\NMW-U-Q=3ZU
MI75J:J``````````````KH44?*E=O2NWLKM+:[&R[867\;'=BEY6'O'H]?Z@
MO3/&S',C`````````````````````````````Q$?)=[8APVSZIY'>7\])3D9
M+=_?;O+[=U=;N+J?>M/I555JH`````````!;;]<U&%K]#/GOHW_)?ZR``-%=
M*/E1\:5V]M=K;=L[:["._C[+K+M!62=-I+H.GPLYWV[FP`!Q,5WE4\N=KTCS
M&SRU]E=R<EG)26;Z^W>7V[NZFXNM^U7TK2H``````````````^-*1;$@E69D
M_&UM[;MK;7:6W;&R[CH[N,COQK\I6<='J<_/WCE[M^LP0```````````````
M`````````````/.OY[ZNWS097?N+M^]=G;R4EG(7V[V^W=W6[FZGWNI]:TK-
M0````````"!=/BXT/7G(X+OTC^;V!>G^8]._XY_8LG/CSL+BOE.U`&A0?.E?
MA;7;6UVEMVRLNV%EW&QW]=8=UIMVIFN;%Z>?2_'``#J[63>6KS#VFPT^RR<=
M=;RTMG)WV[^2S?7V[NZW=74^]SZUMJJU`````````````.FM)KO/]YW^42')
ME]#WI#Z_S,\VVMKM++ME;=L([N.COXJ.^Q[G;NK\K6YY_NO,Y`>]U8``````
M``````````````````````'FF\X=?;QSV7?_`)^RF.19RDMG(R6;^^W=WV[N
MM-Q=3[74K4JJ`````````V>1;8SZ.YW`?^F/S3&QZTY+U?\`XH?:LBOE3JIK
MSV0`-#YTK\;:_"VNUI7967;&R[CX[^+CNX>*3'W@:SEY[/5GZEXD``=2ZJ?R
MU>8>SW.KV63#K;.8ELY26SD;[=_)9O+J;J^W<5I]JJZTUK0````````````"
MP#YWRV$[X;\YN$Z/:^B+TA]<^%*[:VNSLNV-EW'V7\9%=Q$4EE>@OZ4EUV>'
M[ES.0[Z#J@````````````````````````````/--YPZ^TOE,[*5O<[FYK.6
MECY*2WD+[-[?;N[Z;FZGVK3ZUI56@`````````'0?TO6X3?T&^?^B[\KOJ0`
M`II7YTK\*5V]M=I;7967<?'=QL=_%1W\)#)CBT^#*\^#U9^I>)``'4NJG\M7
MF'L]UK-CDRZVWG)H^7ELY.2S?WV[Z^W=WV[FZGVK3ZUI55J````````````#
M;VVV=\7H;MNPWVYODVUM=K;7967;"R[C8[^*BOX6*2R?G9.DYM=GA^Y<SD.^
M@ZH````````````````````````````#S3><.OM+Y3.RF;[.YZ:+F9K.4DLY
M*2W?7V[R^W=76[BZGUK2NJH``````````Z,^B:[O/YWL0`*2FCXTK\+:[6V[
M9VUV,=_'67<7%?P\5_`02XX-/@RO/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MMD
M$\7-31\K)9R,EN_OMWE]NYNIN+J?6M*S6M````````````!I2M)\J/A;7;6W
M;.V[8V7<?'=Q<=_$17\#!)9)STG2<NOSP_<N9R'?0=4`````````````````
M```````````!YIO.'7VE\IG93=]G2&>+G9H^6ELY.6SD+[=[?;NKK=S=3[74
M^A56@````````````%-*_,^-M=O;7:VW;*R[C[+N-CNXB*_A(98[CR8W]/A2
MO/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MMD>1#STT?+RV<G);R$EF]OMW=UNYN
MI]KJ?0J````````````!H?,^-M=O2NTLNV=MW'QW<='=Q,5_"121W'ELDYZ3
MI.77YX?N7,Y#OH.J`````````````````````````````\TWG#K[2^4SLIN^
MSI%/%(<B+F98^5ELY&2W?WV[RZW=74^]U/K6E1J```````#%SZ[Y+*-Y$ZT`
M``:%)\J5^%*[:RNSMNV-EW'1W<7'?PL,G`021O'EQOZ?"E>?!ZL_4O$@`#J7
M53^6KS#V>ZUFQR9];;),B&13Q\U-'RLMG)7V;Z2W>76[JZGWNI]:TJ-0````
M```0W#@QE?+N6N<ZG:WE]INP`-"D^=*_"E=M;7:67;&R[CK+N,BOX:*3@(+X
MWCS62<])TG+K\\/W+F<AWT'5`````````````````````````````>:;SAU]
MI?*9V4W?9TBGBDF1#SL\?,2V<G)9O[[=[?;N[Z;BMOVN5J5```````'0?T;7
M>2+]G?CWM9_!S[D```-#YT?*E=O2[:6UV5EVPCNXR._B(K^"ADCN/)&\>;&_
MI\*5Y\'JS]2\2``.I=5/Y:O,/9[K6;')GUMLDR(9)D1\]-%S,T?)R6\A)9O;
MK=W=3<7T^U:5UIJ:@``````&$CX;Q&*GY/REV?7;;TM>G/I@`&A12OQI7;VU
MVMM=E9=L++N-COXF*_@X9([CR1K'FLDYZ3I.77YX?N7,Y#OH.J``````````
M```````````````````\TWG#K[2^4SLIN^SI%/%)<F&0S1\W-'RDMG)26;Z^
MW>WTW-UOVK3ZUI55J`````"!]#C^=G],/G/FD_4[YC9-]YT7H0_-KZ+Z@OR;
M^IY!/.'0@`:%-'S5^%M=M;=M+*["R[CK+^*BOX:&^.P31S'OC>/-C?T^%*\^
M#U9^I>)``'4NJG\M7F'L]UK-CDSZVV29$,ER(Y#D1<[+'RLL?)26[Z^W>7V[
MFZGWNM^AK4```````,;GS3F\7WRSF,PGV3K[X.ZW@`"CYGQMKMK:[2V[867<
M?'?Q<5_#17QZ":.8]\:QYK).>DZ3EU^>'[ES.0[Z#J@```````````+9>0QL
M!/F329/OL6RRI?:-D``````````````!YIO.'7VE\IG93=]G2*>*2Y,,CGCY
M^>+F)8^3EMY"^W>WV[NZW[W4^U:55```````8]O2/.^1C]EOD/OI_G<^_P#W
MCJ!'ME%(=;*!31\J5V]M=K;=LK+MA97C(Y.'AOX&"2-P31S'OC>/-C?T^%*\
M^#U9^I>)``'4NJG\M7F'L]UK-CDSZVV29$,ER(Y'/%(,B'F9;.4DLW\EN^OM
MW5UNXNI]:T^@J``````````"B@^5*_"VNUMNV5M>/COXZ.[AXI.#ADC>/-',
M>^-8\UDG/2=)RZ_/#]RYG(=]!U0```````````'EI\:<WBC^*:S*;]FV7JE]
MH=*``````````````!YIO.'7VE\IG93=]G2*>*2Y,,CGCD>1%SDT?*RQ\E?;
MOI+-Y=3<W4^U:?6M-:@`````!\KJ>?']&_G_`*$_SB^@@#SM?I-\\]$7YM?0
MZZ-*/FK\;:[:E=G978V7\='=Q45_"0R1W'EC4$T<Q[XWCS8W]/A2O/@]6?J7
MB0`!U+JI_+5YA[/=:S8Y,^MMDF1#)<B.1Y$4CR(>=FCY>6SD;[-_);O+K=S=
M3[74K*J@`````````!I10?&VNVI7:65V-E_'1W<5'?PT,GGO]3_$\+_J_P"%
M:W6TTKLK7P4^>QQMS4+F^3Z/W^>1_1O8>)D@`````````8LOC.MQ]_+\'-YZ
M(W%RO79```````````````'FF\X=?:7RF=E-WV=(IXI+DPR.>.29$4@GBYF6
M/E);.0OMWM]NZOM^]:?6JJK4``````'!YUG.8-X'%Y5OY]?]$_P'V"?C/]=R
M1^9NCIH^=&WI7;67;*V[CX[N,COX>*^/P2X?_N_S'SR>W/-K(AI5XVVE=:?;
M88_RJ':VBVWL?\U?=,LO!=?U+JI_+5YA[/=:S8Y,^MMDF1#)<B.1Y$4DR(9#
M-%S4\?*26<A);O;J;JZVNK50```````````"A7;VUV5EW'V7<9%?Q$5_`0R>
M.7]!_*E7J/X2```+;>6Z'WE^(/5M_'*="``````````````````````````!
MYIO.'7VE\IG93=]G2*>*2Y,,CGCDN1#(LB+G9H^6ELY.2S?7V[R^WZU5*```
M``````8[?2'/^6[]6?F/G>_1WY]?OY^WWI7_`#%^C^CK\U/H<[Y_(^-*[2RN
MQLNXVR[B8I.#ADCN/+YBO:'G>T_VMYJD63C@``=,:+<9!?@OU[W)^8_O/4NJ
MG\M7F'L]UK-CDSZVV29$,ER(Y'D123(AD<\7/SQ<O+9R4EN]OMJ4U7:TJ5``
M````````!32M-%NBNTMKQT=W$12<+#)'8)/')^@_E2KU'\)```%M_+=#[Q?$
M'JV_SE.A````````^=&'CX/J8]B4S6>A-N````````````````!YIO.'7VE\
MIG93=]G2*>*2Y,,CGCDN1#(\B*0Y$7-2Q\K);OY+/O6A76EVJH`````````\
M/'[M?$O8M^,'U_O'A,[132MI3Y4KQ]E_%QW<-!)'H98YCR^8KVAYWM/]K>:I
M%DXX``'36BV]_?P;Z][F_,7WKJ753^6KS#V>ZUFQR9];;),B&2Y$<CR(I)D0
MR.>*1Y$7-S1\I)9]:JJ7%0````````````*:V4'&QW<+%)P./+'()/')^@_E
M2KU'\)```%M_+=#[+?*GZ%Y0/GF-VIH^+```````&,GY!KO*'XHYF:;"_P!O
MGZ)=AV%M)````````````````!YIO.'7VE\IG93=]G2*>*2Y,,CGCDN1#(\B
M*1Y$7/SQ<O)9O;[=5VM+@`````````!BU]6\QE*\I=.`.L.IQ.S>7GVEMW$Q
M7PW$VEIO.??>_P#<>??,5[0\[VG^UO-4BR<<``#IK1;>_OX-]>]S?F+[UU+J
MI_+5YA[/=:S8Y,^MMDF1#)<B.1Y$4DR(9'/%)<F'GYH^2DMJI=JJ-;FM:@``
M```````#2E-+0%-8]C9=T3HH>N=<[:W.TP+>O?A&GW'YM][K0``+0[;\I&1^
MW?GD]D?M'ZB_$GXUY]/*_P"9.[C@````M_YB#$]\2UF9W[_MNQ-K(+6N,QO+
M7XUYO,1]XVN;'T+N`````````````````/--YPZ^TOE,[*;OLZ13Q27)AD<\
M<ER(9'D12/(BD<\/-36?:JJEXUJ7-50`````````-!;32CRP?K!\N]3WY0?3
MOE1PT5]D_*>FO`AXY_LSR\?2?R\NG_0'^<;MOU]^?W+SP\5%GX</._ZW=M[?
MYY>I]9\-=Z[WY4+<[+\NOR3Z/Z$ODGT;J753^6KS#V>ZUFQR9];;),B&2Y$<
MCR(I)D0R.>*2Y,,CGCW]]M5+Q5?75=JJ``````````-%-%*;;5&E;;1.0U?E
MS\L?.)KG3Y\/>_LG"3^G/Z^3+:8X````LP^B_?[$_J'I/(+\F\N^R;\\?P+O
M=^:>=M##G\%U,.P+<WOHG<:@'C&\!<E:-PV+Z`?3N\SX^F=V````````````
M```````/--YPZ^TOE,[*;OLZ13Q27)AD<\<ER(9'D12/(BDD\/.3V?6EQ76Y
M56[5<``````````!M9;;#OOG/_G@?T<>?/?3_/E]XR5>8>B^NIR+(^3].>`G
MQQ_9R-[?C9W_`+G^5/LU]C?S;<#!M?SB/SK_`++^CM)]1]^_O7^2O,)]=_.H
M`#J753^6KS#V>ZUFQR9];;),B&2Y$<CR(I)D0R.>*2Y,,CGCY"^FM+JKZU+P
M```````````!2LILIHICM^=:#SC>;N"O^^A=%F8]1_>K6/5WJ?O'JM:```.`
MFCVF1O?-][#_`%GLY^A?>O3IXL_'KT8>0_RCY_$UF-7Y'K_)OXEYB49EWN&_
M17L>Q-K(!Y0?$_,QW%M]'_K'?W0]CD@``````````````````#S3><.OM+Y3
M.RF[[.D4\4ER89'/')<B&1Y$4CR(I+/%SD\?TI?K55=?JJ```````,:?ISFL
MEGF/I0``,1GL'D<)/N7B?*E^LOROTM?F'])S,>*.OS8>">ZLUXGT_P"`GQQ_
M9R)GF\KZ5?1_XM^L'U5^!'4>H^A?FR?G)_:1&L;=^Z+V_P#RT9Q_MWY=#@98
M^>BD'4NJG\M7F'L]UK-CDSZVV29$,ER(Y'D123(AD<\4ER89'/'R%]-5U=U^
MJJC5=K2I4````````%-*TT6JM%*:64VTVM*6\<]!V'LMC'()/)G[H\T6:>GO
MB6XOM'QMK12H`@.BV_H`POZ(H;U'HGU3>&_Q;[ZY;YF!;7R6/Y8/&'-9>/NF
MUS=^B-P``````````````````````!YIO.'7VE\IG93=]G2*>*2Y,,CGCDN1
M#(\B*1Y$4EGBYR>/Z4OJOK4O"E=5VM!4````#I7M\'Q^_LE\?]MGX;?;@`-*
MTT6JT'A[_=7XA[@/PG^UT5LX6&2RKE?2O@P\?_V,9SOK7XX\#^C7\YV/+W)X
M=YW)@4KP?F?]/&XXO?\`V7Q;]-SQ0Z_UF?Z>/-_V_P!/'Q/ZIU+JI_+5YA[/
M=:S8Y,^MMDF1#)<B.1Y$4DR(9'/%)<F&1SQ\A?2JM]=;U%5+RH``````````
M*4UL54TLHMMVM*1N"6/X\L<@D\<GZ#^5*O4?PD```6W\MT/O%\0>K;_.4Z$`
M`````````````````````````#S3><.OM+Y3.RF[[.D4\4ER89'/')<B&1Y$
M4CR(I+/%SD\?TI?7??JKK2NM+P````!U_P!#C^</]*_F_G5_2'YUCR]&<[Z+
M/S>^C>GC\M/I^0_SET0`&E;=*VV+_>=#?)\#W5%;.%ADC&-/TMJ^^DLW$^8K
MVAYWM/\`:WFJ19..``!TUHMO?W\&^O>YOS%]ZZEU4_EJ\P]GNM9L<F?6VR3(
MADN1'(\B*29$,CGBDN3#(YX^0OI56^NM^M+M:7`:K@````````4T4&E::5LI
MI;1;9M:4C<$L?QY8Y!)XY/T'\J5>H_A(```MOY;H?>+X@]6W^<IT(```````
M```````````````````'FF\X=?:7RF=E-WV=(IXI+DPR.>.2Y$,CR(I'D126
M>+G)X_I2^N^_6E:J2`:JE0````,2?KWD?)1^OGR/]!;^=WT)+=1,`4T4`IK'
MI6E%EE%;.%ADC>/)&X)HYCR^8KVAYWM/]K>:I%DXX``'36BV]_?P;Z][F_,7
MWKJ753^6KS#V>ZUFQR9];;),B&2Y$<CR(I)D0R.>*2Y,,CGCY"^E5;ZZWU6W
ME=5=:7ZUHJ````````TMKHMTK:*:QTK:+;-K2D;@EC^/+'()/'+^@WE1ZD^$
MZ@``%M?*]%[TO$'JV_/E>@```````````````````````````\TWG#K[2^4S
MLIN^SI%/%)<F&1SQR7(AD>1%(\B*2SQ<Y/']*7UWWU4NUI>*J7ZUJK0````#
M;R4\X'Z6?-O2/^9_TH`*-**:V#2MM-;*++**V<+#)&\>2-P31S'E\Q7M#SO:
M;[5\U23*QP``.E=#N,B7P3Z_[B?,OWCJ753^6KS#V>ZUFQR9];;),B&2Y$<C
MR(I)D0R.>*2Y,,CGCY"^E5;ZZWU6R:JZTOUOHJ&JH``````*:`6*5NBE-;*5
ME%MFUI2-P2Q_'ECD$F$/T1\GPH^HOBGQNM^-*QV*O'5L[+V4,KR;!<WS.]]P
MOF'[U*X)@``````````````````````````/--YPZ^TOE,[*;OLZ13Q27)AD
M<\<ER(9'D12/(BDL\7.3Q_2E]=]]5+]:754OUN+@U5`````BNUAE6JF`T4"U
MI:IK9I6VFME%EE%;.%ADC>/)&X)HYCRXPOKW`^>OV5Y[V63!\K:Q*RW[74[M
MW..!VKI]GZ\O/'VC()R?1=2ZJ?RU>8>SW6LV.3/K;9)D0R7(CD>1%),B&1SQ
M27)AD<\?(7TJK?76^JV2JEVM]=:M:7ZTJ`!!I[,5O2:J+R6_"M.PH)+V-1FW
M0:W*``TK32MNE*:6*:V4ULI646V;6E(W!+'\>6.021O'FC>/-',>^-8\UDG/
M2=)RZ_/#]RYG(=]!U0````````````````````````````'FF\X=?:7RF=E-
MWV=(IXI+DPR.>.2Y$,CR(I'D126>+G)X_I2^N^^JE^M+JUZ]K2ZI<H``L.W>
M!9?ML/D;:[ZVO>V'/D7T.QY6RH`5:+::VK5-+::V4ULHLLHK9PL,D;QY(W!-
M',>6-XTL:@FCF/?&\>;&_I\*5Y\'JS]2\2``.I=5/Y:O,/9[K6;')GUMLDR(
M9+D1R/(BDF1#(YXI+DPR.>/D+Z55OKK?5;)4OUO54OUI4`=<Y$>(?J-1O*5R
MT<QM>RL>40:>S&7T.L[KPYL@6CV``"JFMFEE*%E-;*5E%MFUI2-P2Q_'ECD$
MD;QYHWCS1S'OC6/-9)STG2<NOSP_<N9R'?0=4```````````````````````
M`````!YIO.'7VE\IG93=]G2*>*2Y,,CGCDN1#(\B*1Y$4EGBYR>/Z4OKOOJI
M?52^JZ[5=52X`#&-T6LMNV&->'JLS(+H]A51L;J6U;#&Q6=+JL^G$[^J@`=(
M]S@]V\/F4K:;;::V4ULHLLHK9PL,D;QY(W!-',>6-XTL:@FCF/?&\>;&_I\*
M5Y\'JS]2\2``.I=5/Y:O,/9[K6;')GUMLDR(9+D1R/(BDF1#(YXI+DPR.>/D
M+Z55OKK?5;)4NJNNJI>"NJY1BIZ;4WUZ7/[KPYP`!@:[709U.,WW(VU5%-%H
MTK;3;;0LIK92LHMLVM*1N"6/X\L<@DC>/-&\>:.8]\:QYK).>DZ3EU^>'[ES
M.0[Z#J@````````````````````````````/--YPZ^TOE,[*;OLZ13Q27)AD
M<\<ER(9'D12/(BDL\7.3Q_2E]=]]5+ZJ7U775)-:"NJI51A)[#1YMN/W@``Q
M?='JKAL')N[U68J*:*>3_P#6[Y'ZI_R?^L<MA4IMMIK936RBRRBMG"PR1O'D
MC<$T<QY8WC2QJ":.8]\;QYL;^GPI7GP>K/U+Q(``ZEU4_EJ\P]GNM9L<F?6V
MR3(ADN1'(\B*29$,CGBDN3#(YX^0OI56^NM]5LE2ZJZ^JEVJ[6EPXB^WSU=U
MSG=F'D<E;70V5U+^]'L+P=5FXCNIT^/+>ZV\S4YJE>WL6;*IS6VTK319I6E-
MME"RFME*RBVS:TI&X)8_CRQR"2-X\T;QYHYCWQK'FLDYZ3I.77YX?N7,Y#OH
M.J`````````````````````````````\TWG#K[2^4SLIN^SI%/%)<F&1SQR7
M(AD>1%(\B*2SQ<Y/']*7UWWU4OJI?5==720K52\"T_9X>#'L]#>?J,ZD^IR5
MM<S7);OI_+AP'=MSW.V77"8&3%);,M.JVEBGI;G/#]^Z7PCTB?FE]+SN>!^[
MNW^.[6FME-;*++**V<+#)&\>2-P31S'EC>-+&H)HYCWQO'FQOZ?"E>?!ZL_4
MO$@`#J753^6KS#V>ZUFQR9];;),B&2Y$<CR(I)D0R.>*2Y,,CGCY"^E5;ZZW
MU6R5+JKKZJ754D%!@A[700.>/T.\)TH`P?=CH,U_(;W"_P!;I/H9KN0WI3"U
MUNCS2\CNQ36S2MM-ME"RFME*RBVS:TI&X)8_CRQR"2-X\T;QYHYCWQK'FLDY
MZ3I.77YX?N7,Y#OH.J`````````````````````````````\TWG#K[2^4SLI
MN^SI%/%)<F&1SQR7(AD>1%(\B*2SQ<Y/']*7UWWU4OJI?5==7235?K2HM2V>
M)@_['19E^4W=ZVGSP,5/2ZB^+3Y^-7H-7D?T&SLEV^!E9YK<6?;7!QT_?>=M
MS]5<[Y&OV!^.YOO#'<YQ?"?<9@_&?83G0R4ULHLLHK9PL,D;QY(W!-',>6-X
MTL:@FCF/?&\>;&_I\*5Y\'JS]2\2``.I=5/Y:O,/9[K6;')GUMLDR(9+D1R/
M(BDF1#(YXI+DPR.>/D+Z55OKK?5;)4NJNOJI?52]6N$[L-)D!TNTQT[W5YI.
M4WTACOIJZ`S<7%AT6GSE\AT.$WK-!V%#)DXY_;S2&3!7V'.YWN+WRVW2MM-;
M*;;*%E-;*5E%MFUI2-P2Q_'ECD$D;QYHWCS1S'OC6/-9)STG2<NOSP_<N9R'
M?0=4````````````````````````````!YIO.'7VE\IG93=]G2*>*2Y,,CGC
MDN1#(\B*1Y$4EGBYR>/Z4OKOOJI?52^JZZNDFM+]5>CL^/$+U.FR8:#;6]9N
M+D_Y[<"%31XP.AT]Y6JS[']OK\J7.;G$/T^CS8<ET&,KH-1<=K\BZC59'C@_
M9_XMZYOQ^^O331R4VV4ULIK919916SA89(WCR1N":.8\L;QI8U!-',>^-X\V
M-_3X4KSX/5GZEXD``=2ZJ?RU>8>SW6LV.3/K;9)D0R7(CD>1%),B&1SQ27)A
MD<\?(7TJK?76^JV2I=5=?52^JE^&OK=/W]B9>171;3J/*@Q1])IH-+%T#FXV
MIW?B9'8T$W2F5CW:ZW-ZJR88;+'EKYK=W%X&3K%#I6VFME-ME"RFME*RBVS:
MTI&X)8_CRQR"2-X\T;QYHYCWQK'FLDYZ3I.77YX?N7,Y#OH.J```````````
M``````````````````\TWG#K[2^4SLIN^SI%/%)<F&1SQR7(AD>1%(\B*2SQ
M<Y/']*7UWWU4OJI?5==7236E]MVQQ\4'3ZK.%R/0RZ*3%MT6GZ/S,:U38X=9
M,8I.Q()9G%)H==3Q=Z8>1]#,/RV]ULCM&^O:.[?Y!M:*V4VV4ULIK919916S
MA89(WCR1N":.8\L;QI8U!-',>^-X\V-_3X4KSX/5GZEXD``=2ZJ?RU>8>SW6
MLV.3/K;9)D0R7(CD>1%),B&1SQ27)AD<\?(7TJK?76^JV2I=5=?PEU<*/7::
M!9-)3'?DFT&VN[U>P&%7K>>RY<QO9Q#(.+OMPB==SO?.%E6J[+!E,=_;>+-V
MWC3Y$^>SM[2VFME-ME"RFME*RBVS:TI&X)8_CRQR"2-X\T;QYHYCWQK'FLDY
MZ3I.77YX?N7,Y#OH.J`````````````````````````````\TWG#K[2^4SLI
MN^SI%/%)<F&1SQR7(AD>1%(\B*2SQ<Y/']*7UWWU4OJI?5==722S3;8N&OK-
M-=MK<^DS6\GT*E>G<O'QP;W4Y@>7WP&'KJ=#=7K<VPG=:SK^:+O'$G[$@FO>
MTV;W[KY::QT5LIMLIK936RBRRBMG"PR1O'DC<$T<QY8WC2QJ":.8]\;QYL;^
MGPI7GP>K/U+Q(``ZEU4_EJ\P]GNM9L<F?6VR3(ADN1'(\B*29$,CGBDN3#(Y
MX^0OI56^NM]5LE2[$OU.LZRR+>J<F+/[QG45KL.'4:+*[S>[L4W.MQ:]%ILQ
M?+;Z^+3[+>4J,&'8<WG,X_HZU:%(G+';_G8=@VXU6:;D=S36RFVRA936RE91
M;9M:4C<$L?QY8Y!)&\>:-X\T<Q[XUCS62<])TG+K\\/W+F<AWT'5````````
M`````````````````````>:;SAU]I?*9V4W?9TBGBDN3#(YXY+D0R/(BD>1%
M)9XN<GC^E+Z[[ZJ7U4OZ2SH\0/4ZNYW6Y<0R*Y@^7WN%GJ]%FHY/H;)=OKL8
M70Z;OC"RLI7.[GM7&G%O&=B6E[/!R=\]N1Q%]L%FQ\,W5:'-3Q^XGT-:*V4V
MV4ULIK919916SA89(WCR1N":.8\L;QI8U!-',>^-X\V-_3X4KSX/5GZEXD``
M=2ZJ?RU>8>SW6LV.3/K;9)D0R7(CD>1%),B&1SQ27)AD<\?(7TJK?76^JV2V
MO80V@;?&RL\SM\,O6:?MF#*XJY)8Y+9-AAW@:O8=:Y$'>V%E8WM_J,_?%=1N
MJ5Q@=#IKR-5G][8>2"E-;,,'4\]F?Y+<4ULIMLH64ULI646V;6E(W!+'\>6.
M021O'FC>/-',>^-8\UDG/2=)RZ_/#]RYG(=]!U0`````````````LUX[TA=1
MU/P>&X?2;2S(MUY[[%U?K.YO)[#SAT-HOJT-P^DR%?0/(/(R88`````````'
MFF\X=?:7RF=E-WV=(IXI+DPR.>.2Y$,CR(I'D126>+G)X_I2^N^^JE]5+\%W
M::?.+QV]A,M,'O9Z6_33;.Q_;X&7GE][C4W^HZ\GBR_<OOL:G0:BY;7Y>072
M;70PB]=SF;OD>CT4&E;,=V\U7=N!==%KIZ*V4VV4ULIK919916SA89(WCR1N
M":.8\L;QI8U!-',>^-X\V-_3X4KSX/5GZEXD``=2ZJ?RU>8>SW6LV.3/K;9)
MD0R7(CD>1%),B&1SQ27)AD<\?(7TJK?76^JV3$'U.LRG\[M;!]WA6[YT'1>=
M%$Y;<BFBVW7LUF6#FM[@4[3ELY_'=-C&Z'39.N=W/8,,UN>?AV9;7796>;WN
ME;-%M-;,)O5\YFRY#=4ULIMLH64ULI646V;6E(W!+'\>6.021O'FC>/-',>^
M-8\UDG/2=)RZ_/#]RYG(=]!U0`````````````\2/BS^G*_SO/)>0SZ#Y`B>
M)T&$OXM^F_H-^_\`Y$7D]AYP\E/E#^@;-W]K_,/'1\\]C^J+U%^#P```````
M``'FF\X=?:7RF=E-WV=(IXI+DPR.>.2Y$,CR(I'D126>+G)X_I2^N^^JE^R7
M89NOU66;F-QAZZK4<#(ZARXNY<3)YFR_-7R728M>BTG<6+D9`-)M<+'6\YFS
MY'I!@I['F,XW']+R%*Q/;XTIU5^+SHM->1ILGOG"DHK93;9%=MCR;5W46645
MLX6&2-X\D;@FCF/+&\:6-031S'OC>/-C?T^%*\^#U9^I>)``'4NJG\M7F'L]
MUK-CDSZVV29$,ER(Y'D123(AD<\4ER89'/'R%]*JWUUOJMDPG]AJ<VG([O"O
MUNHS6<AO=)9R_P`C'TWAO43\[[7N/'R(I+9@<[#E[@,/+S'<MT`&"OL.9S5\
MCT<HBNIK9:WLL"P'<:G-!R6YIK93;90LIK92LHMLVM*1N"6/X\L<@DC>/-&\
M>:.8]\:QYK).>DZ3EU^>'[ES.0[Z#J@````````````!Y"/)']#W-3ZS))]&
M\7R?)T?G]^!_K?DC^C>+_0QZ!_('QG^._P"D:\;L/.-Q_1?&?1IZ(_&T````
M`````#S3><.OM+Y3.RF[[.D4\4ER89'/')<B&1Y$4CR(I+/%SD\?TI?7??52
M_J[(MQY=!A=MXF1W1AY-T>!G+I<1_3:7J3)BSH<ATJK$?TVAZ4RL?*USF\N!
MPLH6R[##LRVFNO"ZZ;'=Z-Y?,-XC[;!1V/-Y^>&WVX645LIML\W?Z7_-/2!^
M:7T6BRRBMG"PR1O'DC<$T<QY8WC2QJ":.8]\;QYL;^GPI7GP>K/U+Q(``ZEU
M4_EJ\P]GNM9L<F?6VR3(ADN1'(\B*29$,CGBDN3#(YX^0OI56^NM]5LF%/K]
M3FPY+=X4.NU&;/C][I+/K2_S"_0N/S]<9U5PV%FE0`!UM/!AYZCG>;CKP5]E
MQ^#DY*N<V'(VVTULIMLH64ULI646V;6E(W!+'\>6.021O'FC>/-',>^-8\UD
MG/2=)RZ_/#]RYG(=]!U0`````````````\A'DC^A[TU>E?Q&\2OBW^F_TR^D
M_P`2L3/RGW_Z^/6_\\(\@_DC^A[UZ>MOYY/%YXV_I4]H_LK^:@`````````#
MS3><.OM+Y3.RF[[.D4\4ER89'/')<B&1Y$4CR(I+/%SD\?TI?7??52^W_-CM
M7VN/M%UZVGV'<N/E+I;#MQK\<F_U7H2XGK-5X``&++I-#YM/TX^56J_<]'Z@
M_P`9/L>3KE=KW_KY::QT5LZ+[G7?G!_TK^;?TEOYFO2':/(ST5LX6&2-X\D;
M@FCF/+&\:6-031S'OC>/-C?T^%*\^#U9^I>)``'4NJG\M7F'L]UK-CDSZVV2
M9$,ER(Y'D123(AD<\4ER89'/'R%]*JWUUOJMDQJ=#@=L8^19%M\/-QQ^^TEG
MUI?@([7F;^]-ML@>DW``XB^W#5U/.<;=3LS'FR+:/;=L8<M-;*:V:QPZ+*:V
M4VV4+*:V4K*+;-K2D;@EC^/+'()(WCS1O'FCF/?&L>:R3GI.DY=?GA^Y<SD.
M^@ZH`````````````>='SS^QWHN]#?CCYH/-O[8Y3/J'A+"_\;_2GL+/Y#+[
M]<_._"!\4_3^;9O,7@]=YVS>?:_S"``````````\TWG#K[2^4SLIN^SI%/%)
M<F&1SQR7(AD>1%(\B*2SQ<Y/']*7UWWU4OX*ZN$#LM1W[A9.1_G]KV1%D+I>
MC\N'SS=SRWJ0^>=QK2H`LLVVMQY;O4=8]SA8;/TK^<8D?T2^?]:=3B>C/\W/
MIGJ'_+#ZK=S\<VO&Y4."?WKP'F]_2KYK@6]_\#Z$_P`Z_H/I2_,;Z/F=\2]?
MP\$D;QY(W!-',>6-XTL:@FCF/?&\>;&_I\*5Y\'JS]2\2``.I=5/Y:O,/9[K
M6;')GUMLDR(9+D1R/(BDF1#(YXI+DPR.>/D+Z55OKK?5;)\ZW>?SN='W'B9&
M:SD-[I+/K2_"EUO/2FR;+[S'1=#YF+U1DP=&Y>+C]W>I[.QY^],/)R8:#=8Y
M=[IH9)#FFY/?TULUCAT64ULIMLH64ULI646V;6E(W!+'\>6.021O'FC>/-',
M>^-8\UDG/2=)RZ_/#]RYG(=]!U0````````````````````````````'FF\X
M=?:7RF=E-WV=(IXI+DPR.>.2Y$,CR(I'D126>+G)X_I2^N^^JE]5+\3'4:RS
M';XOH5X7I)-;,NEX*YY%/IW#>PGYA]"@$T71>9C=59,%GVTUMMV=B7&X.9D\
MY_==.Y6-Y_/:WSSNGZ_C>HW\L/K&EL>MD=-8Z*V4VV>`S^@_S][[_P"?+[W1
M9916SA89(WCR1N":.8\L;QI8U!-',>^-X\V-_3X4KSX/5GZEXD``=2ZJ?RU>
M8>SW6LV.3/K;9)D0R7(CD>1%),B&1SQ27)AD<\?(7TJK?76^JV2I=:QM(,!W
M:Z/+)S&XOHU>U[2Q<G"IUO/=NXV5UED1=UX>9VSC9'6V1#S5EV0_1[C&3T&C
MN)PLJZG79F$?J^:S:<EOZ:V:QPZ+*:V4VV4+*:V4K*+;-K2D;@EC^/+'()(W
MCS1O'FCF/?&L>:R3GI.DY=?GA^Y<SD.^@ZH`````````````````````````
M>?OT']O]`GGSX@``/--YPZ^TOE,[*;OLZ13Q27)AD<\<ER(9'D12/(BDL\7.
M3Q_2E]=]]5+ZJ7[6^OFM^@<_=]JLV^_3[.ZG7["+2,&78<YVECY'9$&1W=AY
M?;&-D8M^BT.?3B^MVE:8.>PY7.=R'3VW]-K,9?WGE\WWE_L=+8];(Z:QT5LI
MMLQ;>J^3RB^5NFHLLHK9PL,D;QY(W!-',>6-XTL:@FCF/?&\>;&_I\*5Y\'J
MS]2\2``.I=5/Y:O,/9[K6;')GUMLDR(9+D1R/(BDF1#(YXI+DPR.>/D+Z55O
MKK?5;)4NJNOP@]?I\FG/;6QK=XG6>1'VWBY&6GF]_4OJI(,5?1Z"_#3[;N3$
MR;&-QJJ:V7RZC98*.NY>X/"R.J,K'[2P[LJ7-[/2MM-ME"RFME*RBVS:TI&X
M)8_CRQR"2-X\T;QYHYCWQK'FLDYZ3I.77YX?N7,Y#OH.J```````````````
M``````````'XX_[)_JM^AI^=_ACT">?/B``'FF\X=?:7RF=E-WV=(IXI+DPR
M.>.2Y$,CR(I'D126>+G)X_I2^N^^JE]5+ZKKL,G6:K*IS6WM!VV-:/M,7Y59
M9>:W_=&-EU4DUI70P>=?RV<3D.I&#GK^5SA\ETUG.SU=@.ZU,UAOX*^/)?SF
MQ[UPY**V4VV4ULIK919916SA89(WCR1N":.8\L;QI8U!-',>^-X\V-_3X4KS
MX/5GZEXD``=2ZJ?RU>8>SW6LV.3/K;9)D0R7(CD>1%),B&1SQ27)AD<\?(7T
MJK?76^JV2I=5=?@S['2YS^,Z!+/K2^JE]=UU2^JDE2_!WU_*YQ.1ZN+7QX(N
MQY'/CQO5;^EOFG[SC,[G'=)W%C28[]SJ.XL2^\#5Y5-ME"RFME*RBVS:TI&X
M)8_CRQR"2-X\T;QYHYCWQK'FLDYZ3I.77YX?N7,Y#OH.J````````MUZ/??E
MD?JE^CP````````````````MGZ?H9#C0?H:?G?X8]`GGSX@`/--YPZ^TOE,[
M*;OLZ13Q27)AD<\<ER(9'D12/(BDL\7.3Q_2E]=]]5+ZJ7U776H;.#I7*CR.
MZ/;+I:J7UI*KKJJ254NMPS\2UC9:_)QS^^Q@=!H)W#??]IMIB^Z#0P>6'*3S
MNWY&RW"GU?/9P^/W5%;*;;*:V4ULHLLHK9PL,D;QY(W!-',>6-XTL:@FCF/?
M&\>;&_I\*5Y\'JS]2\2``.I=5/Y:O,/9[K6;')GUMLDR(9+D1R/(BDF1#(YX
MI+DPR.>/D+Z55OKK?5;)4NJNOQM;_7W`X.7=/@[+6E]5+Z[KJE]5)*JWX,>P
MY3.5R/5X$.QY'-'R?2=F020B:#RR?1.&SJ<=TE^VFV'4TV'C[WFKRM\UM*;;
M*%E-;*5E%MFUI2-P2Q_'ECD$D;QYHWCS1S'OC6/-9)STG2<NOSP_<N9R'?0=
M4```````!;/TW0_D??KM^G@`````````````````D.-!^BY^<O@_.Y\&^,@>
M:;SAU]I?*9V4W?9TBGBDN3#(YXY+D0R/(BD>1%)9XN<GC^E+Z[[ZJ7U4OJNN
MU28-NQTF<SC^B72U4OK257754DJI?B$ZGG<F^@WMKFPP.E<G#RG\[O::V8%^
MQY3YK<WW(]!)X:83NMY[-AR&YHK93;936RFME%EE%;.%ADC>/)&X)HYCRQO&
MEC4$T<Q[XWCS8W]/A2O/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MMDF1#)<B.1Y
M$4DR(9'/%)<F&1SQ\A?2JM]=;ZK9*EU5U\8D>>SN>?[PQ<O?6W;^V^,2VYI^
M4Z6=09-5;\(G7<M';[,HO.[ZY;7Y=-;+2-GK>II\7IW+QHW)'&KH;^=)FW<:
MS*IMLH64ULI646V;6E(W!+'\>6.021O'FC>/-',>^-8\UDG/2=)RZ_/#]RYG
M(=]!U0```````%L_3=#^1]^NWZ>`````````````````"]CB.1_3#_,K\^;O
MN/Y8#S3><.OM+Y3.RF[[.D4\4ER89'/')<B&1Y$4CR(I+/%SD\?TI?7??52^
MJE]5UU=),)G7Z;[+^-OKNZ7?>EUR>#G9)-#O*J7V([O566;363V*7,)RO14U
MMIK9@ZZWE\KG-;G#!UG/7CZG,MRSL/.-QVZHK93;936RFME%EE%;.%ADC>/)
M&X)HYCRQO&EC4$T<Q[XWCS8W]/A2O/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MM
MDF1#)<B.1Y$4DR(9'/%)<F&1SQ\A?2JM]=;ZK9*EU5U]5+_*_P#2>6]/?S[L
M)/%-52^RG<Z^NE][6HVU5;ZZW%::6T4CIK9@F['E<TW(]!+8Z]>Y&/&F/W+B
M24ULIMLH64ULI646V;6E(W!+'\>6.021O'FC>/-',>^-8\UDG/2=)RZ_/#]R
MYG(=]!U0```````'4NWVGB4]N^NP```````````````!Y:_5'HZ]CB.1_3#_
M`#*_/F[[C^6`'FF\X=?:7RF=E-WV=(IXI+DPR.>.2Y$,CR(I'D126>+G)X_I
M2^N^^JE]5+ZKKJZ28WM_K^@]A'F>Y3H*J7UI,)/7\YFZY'J:J7UWW56WTW64
M664UMM$V>LMGSL#*9SNXVEUEN>;@W&:V7<+**V4VV4ULIK919916SA89(WCR
M1N":.8\L;QI8U!-',>^-X\V-_3X4KSX/5GZEXD``=2ZJ?RU>8>SW6LV.3/K;
M9)D0R7(CD>1%),B&1SQ27)AD<\?(7TJK?76^JV2I=5=?:MLL?#KU6HS%<QO[
MK=9L/FNPH==SV6OFN@[1QLNJM]=;BM-+:*1V\9^#8;N=/ESY;>TULIK9K'#H
MLIK93;90LIK92LHMLVM*1N"6/X\L<@DC>/-&\>:.8]\:QYK).>DZ3EU^>'[E
MS.0[Z#J@````````````````````````!^3?^M'Z9?II?F/^>UWW'\L`!YIO
M.'7VE\IG93=]G2*>*2Y,,CGCDN1#(\B*1Y$4EGBYR>/Z4OKOOJI?52^JZZND
MF"WLM'NJR9R>0Z2JE_3.5%C&Z+3YIN4Z>JE]=]U5+Z:V46645LP-]ER><WCN
MEY&VW2MFEL>MD=-8Z*V4VV4ULIK919916SA89(WCR1N":.8\L;QI8U!-',>^
M-X\V-_3X4KSX/5GZEXD``=2ZJ?RU>8>SW6LV.3/K;9)D0R7(CD>1%),B&1SQ
M27)AD<\?(7TJK?76^JV2I=5=?BGZ767Q:78X&NWT,TAEZ(S,?.CR'3\Q;)87
MN-9S=LEVNNV-Y6KV7/Q244CP&]IR.>7CNG^\=M-;*:V:QPZ+*:V4VV4+*:V4
MK*+;-K2D;@EC^/+'()(WCS1O'FCF/?&L>:R3GI.DY=?GA^Y<SD.^@ZH`````
M````````````````````64]MUUZW$\B``/--YPZ^TOE,[*;OLZ13Q27)AD<\
M<ER(9'D12/(BDL\7.3Q_2E]=]]5+ZJ7U775TDP@]AIKKM;FXB^IT_6T\62_0
M;G*SSN_QA;_31B2WO#%R[U=5M.\L3*ILMQL[[1]F027J:C/H6:5LTMCULCIK
M'16RFVRFME-;*++**V<+#)&\>2-P31S'EC>-+&H)HYCWQO'FQOZ?"E>?!ZL_
M4O$@`#J753^6KS#V>ZUFQR9];;),B&2Y$<CR(I)D0R.>*2Y,,CGCY"^E5;ZZ
MWU6R5+JKK\*O7:?-7R&^P:=II,YW'=+8)NM;CSWNKX^YZ&.'['A[ZVB[378U
M=]H\^G&=?P5T.)'IN<S*<MT.%/JN:X6^/N#&FRR<MM-%E-;*;;*%E-;*5E%M
MFUI2-P2Q_'ECD$D;QYHWCS1S'OC6/-9)STG2<NOSP_<N9R'?0=4`````````
M```````````````````!YIO.'7VE\IG93=]G2*>*2Y,,CGCDN1#(\B*1Y$4E
MGBYR>/Z4OKOOJI?52^JZZ.278G.EU?;V-/<EA;#M3&R,1W3:2T_9X6:WD^GO
M`U6SZ.SL;&SOM)=-KL^_;2;;!?V')YS.1Z:S/::O'7O-/LZVYF.3W?9V)6FL
M=%;*;;*:V4ULHLLHK9PL,D;QY(W!-',>6-XTL:@FCF/?&\>;&_I\*5Y\'JS]
M2\2``.I=5/Y:O,/9[K6;')GUMLDR(9+D1R/(BDF1#(YXI+DPR.>/D+Z55OKK
M?5;)4NJNOQ$]1JLE'/;;$WU.JS;<CTE5+\<F_P!3U#E0]+Y4%ZNIVG>&)EV(
M;C4V?;36W(8.;ENYK?68[76=G8M]YNJSL771Z2ZG4SW-:_(IK93;90LIK92L
MHMLVM*1N"6/X\L<@DC>/-&\>:.8]\:QYK).>DZ3EU^>'[ES.0[Z#J@``````
M```````!YI/U,XGT-?FOV%B'H/57:_'-AVMR&1YP?T\XOTQ_E=VX````````
M``'FF\X=?:7RF=E-WV=(IXI+DPR.>.2Y$,CR(I'D126>+G)X_I2^N^^JE]5+
MZKKN+NOPS]7I^4MNS#<ST/,62UI,%'9<S52[N7%RKJ-;L)#9?@,[/D;OM9L;
MRM5L<A^DVN!KL>5SR\9TD:EBPN]3SF<;C=[36.BME-ME-;*:V46645LX6&2-
MX\D;@FCF/+&\:6-031S'OC>/-C?T^%*\^#U9^I>)``'4NJG\M7F'L]UK-CDS
MZVV29$,ER(Y'D123(AD<\4ER89'/'R%]*JWUUOJMDJ7577]'9D5A^YPND<ZS
M.GQW2U4OL%WFLG\.1=MJ]G;AGX73&7C<A;6W/.P\OW,=%36S"/UO,9M.0Z&F
MMD7EAQ)]'H<R7*;BFME-ME"RFME*RBVS:TI&X)8_CRQR"2-X\T;QYHYCWQK'
MFLDYZ3I.77YX?N7,Y#OH.J``````````````'YZ7])OQ_*?Y&WW>/`Y66KQQ
MT-A'HC4^<_\`33C?>3_/3]6[AXK)``````````'FF\X=?:7RF=E-WV=(IXI+
MDPR.>.2Y$,CR(I'D126>+G)X_I2^N^^JE]5+ZKKJZ28*.ST=YFJV$UCR+V=1
MLZTF%'KN<S9<EU/6<\-N>?APB6*R+;ZO/;QG6:5I;EGX%K6?K\E>@VNE;,*/
M6<]FNX[<TUCHK93;936RFME%EE%;.%ADC>/)&X)HYCRQO&EC4$T<Q[XWCS8W
M]/A2O/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MMDF1#)<B.1Y$4DR(9'/%)<F&1
MSQ\A?2JM]=;ZK9*EU5U]5+\-W5Z?A);[S-5L;Y--M,*O7<]F#YCHL6/0Z6-R
M6;BCF;;Y3'?E6YO?4ULPH=9S6:OD>@IK9QU\>&KI^=S2<ENJ:V4VV4+*:V4K
M*+;-K2D;@EC^/+'()(WCS1O'FCF/?&L>:R3GI.DY=?GA^Y<SD.^@ZH``````
M````````>(_]Y?F$GU,G>GS_`"LZ7Y_]5YQ/TZXST:_F1V6(CV?SWJ`_)[N0
M`````````!YIO.'7VE\IG93=]G2*>*2Y,,CGCDN1#(\B*1Y$4EGBYR>/Z4OK
MOOJI?52^JZZNDG2>7'B7ZG5\=<ST<9T\*EIBQZ32WHZK9V&[C6;^E91'?;'L
M,'T(\1V%-;+6-E@='9.'D2T>STK9A1ZSGLUW';FFL=%;*;;*:V4ULHLLHK9P
ML,D;QY(W!-',>6-XTL:@FCF/?&\>;&_I\*5Y\'JS]2\2``.I=5/Y:O,/9[K6
M;')GUMLDR(9+D1R/(BDF1#(YXI+DPR.>/D+Z55OKK?5;)4NJNOJI?MEV&CK]
M18YN-?=_JMA<)AYO6\\5_6FVMQF#F6=;378ANFY^[?6;#,ERW1#$CTW/W\Z/
M9=WXDUB^YU>D<5\^GS::V4VV4+*:V4K*+;-K2D;@EC^/+'()(WCS1O'FCF/?
M&L>:R3GI.DY=?GA^Y<SD.^@ZH``````````````>(_\`>7YAZT_QP^@_FH_U
M*?%/?=_.K]:\H/[!\!EZ\7]%C!]7Z+WO_P`[OUD``````````>:;SAU]I?*9
MV4W?9TBGBDN3#(YXY+D0R/(BD>1%)9XN<GC^E+Z[[ZJ7U4OJNNKI)K2^S+<8
MN&SK-+WOA94CLDR,Z/<X\MWJ<X/(]-UMD0XANFY^PG<ZKU<_..['#WVX4.KY
MG.#R'0_*MF#'K^:SI<7O::QT5LIMLIK936RBRRBMG"PR1O'DC<$T<QY8WC2Q
MJ":.8]\;QYL;^GPI7GP>K/U+Q(``ZEU4_EJ\P]GNM9L<F?6VR3(ADN1'(\B*
M29$,CGBDN3#(YX^0OI56^NM]5LE2ZJZ^JE]5+])9\5W1Z>ZS6;&ZK`S\/W3Z
M&`31?8N1P,S(UHMSAAZOF\V')=*([)%@;[#EKCL'*Z=RL;.?Q>\K64ULIMLH
M64ULI646V;6E(W!+'\>6.021O'FC>/-',>^-8\UDG/2=)RZ_/#]RYG(=]!U0
M``````````````PJ>Z^9S5^%.FP'_HCR=T'R?.N#^;YEYOP[981/>G+YK/"?
M3[_'J`````````!YIO.'7VE\IG93=]G2*>*2Y,,CGCDN1#(\B*1Y$4EGBYR>
M/Z4OKOOJI?52^JZZNDFM+U\D.GKAFZK19S^/ZBW788F*;H])SMET[AER.Z+<
M8M>BT>;OD>F&E:8P]_H^D<O$@LT63OG=I='JYZ:QT5LIMLIK936RBRRBMG"P
MR1O'DC<$T<QY8WC2QJ":.8]\;QYL;^GPI7GP>K/U+Q(``ZEU4_EJ\P]GNM9L
M<F?6VR3(ADN1'(\B*29$,CGBDN3#(YX^0OI56^NM]5LE2ZJZ^JE]5+])9^%N
MK@ZZ_GL\G'=/K<4J`,*76<YFMY/HU6E*?"VG6N1C=F07ZQPZ+*:V4VV4+*:V
M4K*+;-K2D;@EC^/+'()(WCS1O'FCF/?&L>:R3GI.DY=?GA^Y<SD.^@ZH````
M````````````````````````#S3><.OM+Y3.RF[[.D4\4ER89'/')<B&1Y$4
MCR(I+/%SD\?TI?7??52^JE]5UU=)-:7KY%TN'/J='D@T&Y[QQLG6M0!AWZ?G
M\K?.;R6QR:*(ZP2?'YRVG-16ZV1TUCHK93;936RFME%EE%;.%ADC>/)&X)HY
MCRQO&EC4$T<Q[XWCS8W]/A2O/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MMDF1#)
M<B.1Y$4DR(9'/%)<F&1SQ\A?2JM]=;ZK9*EU5U_5&39BUZ/67A:[97QZ;:8G
M>ETEV.LV-VNMSR@`PD]=S>;;D>D*Z4:+=*V4ULUCAT64ULIMLH64ULI646V;
M6E(W!+'\>6.021O'FC>/-',>^-8\UDG/2=)RZ_/#]RYG(=]!U0``````````
M``````````````````'FF\X=?:7RF=E-WV=(IXI+DPR.>.2Y$,CR(I'D126>
M+G)X_I2^N^^JE]5+ZKKJDF,CH==UGDVY7><WGVI?@L[#G,^_%=376H`QD]!I
M;O\`5[#O?#RE&BE-;-*V:6QZV1TUCHK93;936RFME%EE%;.%ADC>/)&X)HYC
MRQO&EC4$T<Q[XWCS8W]/A2O/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MMDF1#)<
MB.1Y$4DR(9'/%)<F&1SQ\A?2JM]=;ZK9*EW&2W8'^STF=CB^@QC]+K[BL#,O
M+U6PP/=ES6:3DNC[$@F`Z+S,;&YO]/F7Y3H04IK:4IK9K'#HLIK93;90LIK9
M2LHMLVM*1N"6/X\L<@DC>/-&\>:.8]\:QYK).>DZ3EU^>'[ES.0[Z#J@````
M````````````````````````/--YPZ^TOE,[*;OLZ13Q27)AD<\<ER(9'D12
M/(BDL\7.3Q_2E]=]]5+ZJ7U778H>FUUR>NR^_,/+P\]7I\[?&]-:#M,"TW98
M>7+F-Z!\*L$79<S//3.LS4>,^Y&E::*:5LTMCULCIK'16RFVRFME-;*++**V
M<+#)&\>2-P31S'EC>-+&H)HYCWQO'FQOZ?"E>?!ZL_4O$@`#J753^6KS#V>Z
MUFQR9];;),B&2Y$<CR(I)D0R.>*2Y,,CGCY"^E5;ZZWU6R5+K`-]A3V">\C4
M9_SFGPA];H,X/(='"IH\3/2Z/@K[=395I-8I,OW+[WD;;@`4IK9K'#HLIK93
M;90LIK92LHMLVM*1N"6/X\L<@DC>/-&\>:.8]\:QYK).>DZ3EU^>'[ES.0[Z
M#J@````````````````````````````/--YPZ^TOE,[*;OLZ13Q27)AD<\<E
MR(9'D12/(BDL\7.3Q_2E]=]]5+ZJ7U7781.PU&;_`(W?+Y,3O3ZG(3H]OVWB
MSX\-YJK8=CA;.HIPU],EFBVWA[_H3\\_H5?SL>E`!36Q;'K9'36.BME-ME-;
M*:V46645LX6&2-X\D;@FCF/+&\:6-031S'OC>/-C?T^%*\^#U9^I>)``'4NJ
MG\M7F'L]UK-CDSZVV29$,ER(Y'D123(AD<\4ER89'/'R%]*JWUUOJMDJ78H^
MHUF1C0;7LK&GTEGPE=;S^;?D>C*@````4UL*:QPZ+*:V4VV4+*:V4K*+;-K2
MD;@EC^/+'()(WCS1O'FCF/?&L>:R3GI.DY=?GA^Y<SD.^@ZH````````````
M````````````````#S3><.OM+Y3.RF[[.D4\4ER89'/')<B&1Y$4CR(I+/%S
MD\?TI?7??52^JE]5UV%/KM3FPX_>KY+!]Y@]@P37<ZO8`#ALV/SZ_H=\W\K'
MZO?(<4_K+D,]7@+Z'ZMOR9^P9@O&_;:5MT6K;-;(Z:QT5LIMLIK936RBRRBM
MG"PR1O'DC<$T<QY8WC2QJ":.8]\;QYL;^GPI7GP>K/U+Q(``ZEU4_EJ\P]GN
MM9L<F?6VR3(ADN1'(\B*29$,CGBDN3#(YX^0OI56^NM]5LE2ZP3>X<TAFO-U
M&?1+-A*ZW09M^2Z`J````"@&L<.BRFME-ME"RFME*RBVS:TI&X)8_CRQR"2-
MX\T;QYHYCWQK'FLDYZ3I.77YX?N7,Y#OH.J`````````````````````````
M````\TWG#K[2^4SLIN^SI%/%)<F&1SQR7(AD>1%(\B*2SQ<Y/']*7UWWU4OJ
MI?5==A`[#49P^-WVMTF);J-1D5T>U[3QI@`!"MY!^<3_`$F^8_TH/YG/46[A
MJ`%MFMD=-8Z*V4VV4ULIK919916SA89(WCR1N":.8\L;QI8U!-',>^-X\V-_
M3X4KSX/5GZEXD``=2ZJ?RU>8>SW6LV.3/K;9)D0R7(CD>1%),B&1SQ27)AD<
M\?(7TJK?76^JV2I=QDMV!;L]'G3XSH,7'2ZNZS7Y]Y.JSP`````%+-8X]*VT
MULIMLH64ULI646V;6E(W!+'\>6.021O'FC>/-',>^-8\UDG/2=)RZ_/#]RYG
M(=]!U0````````````````````````````'FF\X=?:7RF=E-WV=(IXI+DPR.
M>.2Y$,CR(I'D126>+G)X_I2^N^^JE]5+ZKKL672:[NC#R;AL#*Q#]7J<[?'=
M&```//K^AWSCT%?GC]'`!36.)2E-8Z*V4VV4ULIK919916SA89(WCR1N":.8
M\L;QI8U!-',>^-X\V-_3X4KSX/5GZEXD``=2ZJ?RU>8>SW6LV.3/K;9)D0R7
M(CD>1%),B&1SQ27)AD<\?(7TJK?76^JV2I=5=?U=D68Q>BUUX^IS;R-7GZ77
M@````!2W6RP4ULTK;3;90LIK92LHMLVM*1N"6/X\L<@DC>/-&\>:.8]\:QYK
M).>DZ3EU^>'[ES.0[Z#J@````````````````````````````/--YPZ^TOE,
M[*;OLZ13Q27)AD<\<ER(9'D12/(BDL\7.3Q_2E]=]]5+ZJ7U775TDQQ;_7]7
MY$>4_F]MS])2H``'$YEG+8=X!36VU2A2FME%;*;;*:V4ULHLLHK9PL,D;QY(
MW!-',>6-XTL:@FCF/?&\>;&_I\*5Y\'JS]2\2``.I=5/Y:O,/9[K6;')GUML
MDR(9+D1R/(BDF1#(YXI+DPR.>/D+Z55OKK?5;)4NJNOJI=K2_54```````"F
ML>E:4VV4+*:V4K*+;-K2D;@EC^/+'()(WCS1O'FCF/?&L>:R3GI.DY=?GA^Y
M<SD.^@ZH````````````````````````````#S3><.OM+Y3.RF[[.D4\4ER8
M9'/')<B&1Y$4CR(I+/%SD\?TI?7??52^JE]5UU=)"M5+P```````-*VZ+:*V
M4VV4ULIK919916SA89(WCR1N":.8\L;QI8U!-',>^-X\V-_3X4KSX/5GZEXD
M``=2ZJ?RU>8>SW6LV.3/K;9)D0R7(CD>1%),B&1SQ27)AD<\?(7TJK?76^JV
M2I=5=?52X:TOU5```````IK84TK;3;;0LIK92LHMLVM*1N"6/X\L<@DC>/-&
M\>:.8]\:QYK).>DZ3EU^>'[ES.0[Z#J@````````````````````````````
M/--YPZ^TOE,[*;OLZ13Q27)AD<\<ER(9'D12/(BDL\7.3Q_2E]=]]5+ZJ7U7
M75I%&J[6EP``````&E;=%HHK'3;;36RFME%EE%;.%ADC>/)&X)HYCRQO&EC4
M$T<Q[XWCS8W]/A2O/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MMDF1#)<B.1Y$4D
MR(9'/%)<F&1SQ\A?2JM]=;ZK9*E]5]:J7J`5``````!0"FMFEM*%E-;*5E%M
MFUI2-P2Q_'ECD$D)I=C4^L\+"I8N&AEMIU%W6DF)E*^G:6[KK<$=G865E1X7
MK/K2H``````````````````````````'FF\X=?:7RF=E-WV=(IXI+DPR.>.2
MY$,CR(I'D126>+G)X_I2^N^^JE]5+ZKKJE^M*@`J`````4`&E:4K*;;::V4U
MLHLLHK9PL,D;QY(W!-',>6W_`'.OL,^D\?P4=W#126=:[&YW*BSM_<N:`O,Y
MS=7L<UO1U+JI_+5YA[/=:S8Y,^MMDF1#)<B.1Y$4DR(9'/%)<F&1SQ\A?2JM
M]=;ZK9*J7ZR-:75+E````````&E:4ULTL4K*:V4K*+;-K2D;@EC^/+'(),!O
MIOXWA`]R>995F8H``$"UN=[)?)'H[-O\T[H`````````````````````````
M`#S3><.OM+Y3.RF[[.D4\4ER89'/')<B&1Y$4CR(I+/%SD\?TI?7??52^JE]
M5;M;FM+]:5````````TK32MNEM*:6TULIK919916SA89(WCR1N":.8\OCH_1
M'R9U#]^^3_2M```.O>7W_P"B]XI]37!ZG8]2ZJ?RU>8>SW6LV.3/K;9)D0R7
M(CD>1%),B&1SQ27)AD<\?(7TJK?76^JV356I<O:JJ5```````!32M%K2VE-;
M::V4K*+;-K2D;@EC^/+'()/-[ZW^$X]O<OF"99V&``!U7I]GZ8_(/I3T1?(O
MI```````````````````````````'FF\X=?:7RF=E-WV=(IXI+DPR.>.2Y$,
MCR(I'D126>+G)X_I2^N^^JE^M+JJ7ZWE6M*E0``````"FE:*-+*TUCTK;36R
MBRRBMG"PR1O'DC<$T<QY?%?^F?C7LW[Y\D```%JW']/[W_$WJ>_OE>AZEU4_
MEJ\P]GNM9L<F?6VR3(ADN1'(\B*29$,CGBDN3#(YX^0OI56^NM]5MY6JE^M2
MXJ````````6M+5-;!36.E;1;9M:4C<$L?QY8Y!)YO?6_PG'M[E\P3+.PP``.
MJ]/L_3'Y!]*>B+Y%](```````````````````````````\TWG#K[2^4SLIN^
MSI%/%)<F&1SQR7(AD>1%(\B*2SQ<Y/']*7UWWU4OUI=JKK2_6ZBI4!C#]2<O
MDC\T=+S.%>````%"C2VNE;-%-*VTULHLLHK9PL,D;QY(W!-',>7Q7_IGXU[-
M^^?)```!:MQ_3^]_Q-ZGO[Y7H>I=5/Y:O,/9[K6;')GUMLDR(9+D1R/(BDF1
M#(YXI+DPR.>/D+Z55OKK?K2[6EPUI=JJ5```````%NG.:W&5\QYG+W]AZSL/
M8Y!2FZRFEM%MFUI2-P2Q_'ECD$GG`];?"<=WN7S#-\_"```ZGTVTO"Y']FO0
M]\B^DYJ/.'Y\:J``````````````````````````>:;SAU]I?*9V4W?9TBGB
MDN3#(YXY+D0R/(BD>1%)9XN<GC^E+Z[[]:754O&JNM*E0!Y+?UY^1YI/$G;9
M+O,/3`````#2MNB@Q>>J>5R`^>=[/.;EHK9PL,F-[AO:=@?&^OLRWT_\E/&3
M^FWA_L_[]\C`V.E[)6F^W/'`6H\=U'OI\3^IK]N5Z'J753^6KS#V>ZUFQR9]
M;;),B&2Y$<CR(I)D0R.>*2Y,,CGCY"^E5;ZZWJ*J2`````````#R1>1?D_16
MBPLYGW3MLPWV/K]*V:5I32VBVS:TIU!J+,?GSW37R][T_1GTOFMQ]]^>?:ZT
M``#KR>&?;KV'YE_=?[\SO5\UZW/!'X<WT_,?-XM-XC%Z#YF')=]=V```````
M`````````````````\TWG#K[2^4SLIN^SI%/%)<F&1SQR7(AD>1%(\B*2SQ<
MY/']*7UWWZJZTOUI4`"Q_P"ZZ/RY?JK\M\[7Z/?.KB_F^Q]*/YD_2_2Y^8GT
MOMKD,P`````:*>5']9_E&3#S!TF7GQMUE%;.%AD\_'QG]D/)GYR_I%N$W7PW
M*;[:_GO]!WJC\8Y)DZ;#/\&_5+SH^*?Z+8OH?HWLI_3K^,Z\7L_-8Z8R\;/A
M\I^A[JVO4NJG\M7F'L]UK-CDSZVV29$,ER(Y'D123(AD<\4ER89'/'R%]*EU
M5U^JJE:J7%0```````!YPO-WSJI7.3]T[;O'?9FE;112RFVW:TIY4O*'S6VO
MF==>7[<]JX8?WK_I2WTM@````V$N3U[M^IG>KYKWH_EM_-#VKYW\M>,7P#R6
MBGM?_0GL+@^HG`%@OS+!PC^>-/Z!?3^\NM[7*```````````````````'FF\
MX=?:7RF=E-WV=(IXI+DPR.>.2Y$,CR(I'D126>+G)X_I2^J^ZI<HU7:TN``X
M_(M\1W[F?$,SGBCM,\O@+O0`````+1/L6F\M7ZL_+/,G^H?S/M#E<GU)_E+]
M0]-/Y=_2.S>#V'GX^,_LAY,_.7](H%[_`&WF#]+3](?XI+/.0]&?FC_FY_:[
M<]TWP_\`2Q_2+^*:7Y?.@`=2ZJ?RU>8>SW6LV.3/K;9)D0R7(CD>1%),B&1S
MQ27)AD<\?(7TUI=5?=4N"@KJJ````````"FBBH:*46V:4IM:4\KOE/YMQ,+.
ME][^B\Q]7P^AO2_RD```<++'<MM?=GE)]]?OI=Y\_P#A7K/\&_B%=/P_Q>U7
MB\;QS^#.3R,?5MAZJO:/2@`>([\\./M^YB#T,^I-[G9]);H`````````````
M``````>:;SAU]I?*9V4W?9TBGBDN3#(YXY+D0R/(BD>1%)9XN<GC^E+];E5;
M]50H*@`8(_?/"9A?&?8=K\EE@`````HJ'D)_8OY%DM\P=%G%\(=O\ZV<-#)Y
M^/C/[(>3/SE_2+(9M'>[ZS_$GT#>T/P`N:Z7XEBQ^7>[\,OFS]B.I]3]`]4/
MM3^;FY_IOAPE4$N<[YAWHZEU4_EJ\P]GNM9L<F?6VR3(ADN1'(\B*29$,CGB
MDN3#(YX^0OMUI?K55==JN```````````&BE-+-+6E;=K:Z_P*_)DQV"3SF^L
M?AF,7W%YDG6PP@``.J--M,BG$?K_`.B?XYVF6;X-XA`$:P[9+F7``#SY^7M%
MMK&;[T3N.U]W*```````````````````/--YPZ^TOE,[*;OLZ13Q27)AD<\<
MER(9'D12/(BDL\7.3Q_2EQ6J^NJ[54``".;&*1ZZ4````=9]/B]F<QE`#13#
MC[/XW)!YEZ+NOA\WYULX:&3#[\S_`$CQ,?./T7]`GV3\//)=^H?YIRO[Y\E^
ME:```6M\ATOZ#OB7U1>CSF\ZEU4_EJ\P]GNM9L<F?6VR3(ADN1'(\B*29$,C
MGBDN3#(9H^1DLJI(-:M;JZK@`````````!HII2W2T*:V;2VL=@EC^/+'()/-
M[ZW^$X]O<OF"99V&``!U7I]GZ8_(/I3T1?(OI`````````T.#QK>=R;@````
M````````````/--YPZ^TOE,[*;OLZ13Q27)AD<\<ER(9'D12/(BDD\/-S6?6
MM=:7#6YK6[54```````#`W[]X3)%YGZ.\+XUN`4I6\;-;R.-=I6WYJ<-#?',
M>6-P31S'E\5_Z9^->S?OGR0```6K<?T_O?\`$WJ>_OE>AZEU4_EJ\P]GNM9L
M<F?6VR3(ADN1'(\B*29$,CGBDF1#SL\?*26UFM+P-:@`````````!I0!I6VE
M3C[+N"@DX""6.02>;WUO\)Q[>Y?,$RSL,``#JO3[/TQ^0?2GHB^1?2``````
M``.F]!#Y%_#?+UGL3]Y=7-MC>````````````````/--YPZ^TOE,[*;OLZ13
MQ27)AD<\<ER(9'D12/(BD,\7,2V;JZVJEY4#6H```````=.]GA^*C]P/C%\?
MPC=^IC\H_J,^Y^?2@`I36S;VW</'?P&/)&X)HYCR^*_],_&O9OWSY(```+5N
M/Z?WO^)O4]_?*]#U+JI_+5YA[/=:S8Y,^MMDF1#)<B.1Y$4DR(9'/%(<B+F9
M8^3DMW5UI6JEX````IHZ%T&#WYT&<``````-*VZ+?A2O&QW\/%?P<$L<@D\\
M?JGXCB0]P^9I=FX@``'7&KV/K,\D>C<^'RKZ$```````!B@^)ZSRV>->;N"Z
MB?VS?H7U^ZOJ````````````````/--YPZ^TOE,[*;OLZ13Q27)AD<\<ER(9
M'D12+(BYR:/E9+.0DMK4U7:TN````````M"^QZGSI?I+\[\Y/Z4?.^]."SO0
M5^=W?^C'\V/HG>/"9HTK;HMI5X^R[BXK^$ADCL$L<QY?&+^D7D'8_>OE&J@`
M`'0O+=#^A[XF]3W9:'<=2ZJ?RU>8>SW6LV.3/K;9)D0R7(CD>1%),B&1SQ<W
M-'RTMG(R6;Z^W[5IJ%=50``!YGO,?SVQ;A--Z'_1?=Y*_IG0`````%-%!\J5
MV-EVPLNXJ*_AHI(_!)TOL,7#)Z$^51:^SC([^B];=!K\:_\`[S5W(=%B">8N
M1Z$ODOT:3P2@```````<)CTQ+_$-7D]^P['L;;2`````````````````>:;S
MAU]I?*9V4W?9TBGBDN3#(YXY+D0R+(BY^>/F)8^3DLWU]N\NI76@*Z@`````
M``'F8_4+YMD:\V=#E-\H=0-`H*%=K97867<;'?Q$5_`PRQS'EL:[[EL:OV#@
M>,BNXR.^V;"AY?(CRX?5]$!>OS>\S/?..W'4NJG\M7F'L]UK-CDSZVV29$,E
MR(Y'D123(AY^:+F)K.2DLY"^W>7V[JZGVK2NH```?&E/'GXW^5\7%;Z>O47T
M2ZSK-F`````*:/C2NVMKL[;MC'=QD=_%17<'#+'()8WCS1S'OC6/-9)STG2<
MNOSP_<N9R'?0=4```````````!L(J6%?-,*ZGM,GMO>2@``````````````>
M:;SAU]I?*9V4W?9TBGBDN3#(YXY)D12*>+FIH^5ELY"^S>WV[N^FXK3ZUIK4
M````````+(?NNDN\^.;>1:V0#2CYTKMZ5VMM=C9=Q\=W%QW\+#)'H)8YC2QJ
M":.8]\;QYL;^GPI7GP>K/U+Q(``ZEU4_EJ\P]GNM9L<F?6VR3(ADN1'(\B*1
M3P\U-'RLEG(R6[Z^W=WV[FM/K=3Z&M0```MOYK7]M[?*FN=,`````-"BCY4K
MM[:[2V[965XZ._C([^'BOX""6-X\T<Q[XUCS62<])TG+K\\/W+F<AWT'5```
M`````````>?3R]HL#'FK2Y./K^Q]77M?I@``````````````/--YPZ^TOE,[
M*;OLZ13Q27)AD<\<DR(N=FBY>6SDI+-_);O+K=S=3[W4^E52@````&.OTISN
M13S7T0````%)12OPI7;6UV=EVPLNXV._B8K^"ADCN-+&H)HYCWQO'FQOZ?"E
M>?!ZL_4O$@`#J753^6KS#V>ZUFQR9];;),B&2Y$<BR(N>FBY>6SDY+-_?;O+
M[=U?;]ZT^M550`````````Z<TN'C]^>:#)S]1Z669DVE'SH^%*[6V[:65V%E
M_'1W<3%?PL,D<@FCF/?&L>:R3GI.DY=?GA^Y<SD.^@ZH```````````#S>>3
M>?Q!_"]5Z0?6/09?ONNU```````````````\TWG#K[2^4SLIN^SI%/%)<F&1
MSQR&>+F9H^4DLY"2W?7V[NZW<74^U:5U`````#PH?T`?"?=?_/\`_=@````!
M11\:5^%M=I;=LK+N/CNXN._AHK^`QY8U!-',>^-X\V-_3X4KSX/5GZEXD``=
M2ZJ?RU>8>SW6LV.3/K;9)D0R7(CY^>+FIH^5DLY"2W?W6;N^FYNI]KJ?2M-:
M4`````````'EJ\J_+K?^>P,U7V[M,M?UWK-*UHI7XT;:V[:V5V-EW'V7\9'=
MQ$4G`P2QS'OC6/-9)STG2<NOSP_<N9R'?0=4```````````!'L6WCXJ3'/O`
M``````````````'FF\X=?:7RF=E-WV=(IXI+DPR*>/G)HN6ELY*2W?WV[V^W
M<W4^]UOUJK4````HN8:O<'%^?O\`1WYYYUOTO^<^@O\`.'Z%GL_._P"@9PO`
MW<[R"X```"A7YT?"VNUMNV=E=A9?QT=W$QW\)!)'()HYCWQO'FQOZ?"E>?!Z
ML_4O$@`#J753^6KS#V>ZUFQR9];;),B&1Y$7.31\O+9R4EF_OMWM]-U=;][J
M?:M*C4`````````'G*\V_-OE2F<+[IW7?&_V`H/G2NWMKMK:[.V[81W<=9?Q
M45_"PWQ^"2-8\UDG/2=)RZ_/#]RYG(=]!U0`````````````````````````
M```'FF\X=?:7RF=E-WV=(IXI)DP\_-'S,MG)RV<A?9OKZ;NZW<WT^U:5UI4`
M````6]?2M=^=W_3+YO\`T*/YJO1ET/R7:@````:'SI7XTKM[:[2VNRLNX^._
MBX[^(BOC\$D=QY(WCS8W]/A2O/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MMDF1#
M()X^8ELY22/D9+=]?;N[Z;FZW[UI]*JJM5`````````!1174!HKI1\Z/C2NV
MMKM+;ME97CX[^,COXB*_@H9(YCRV2<])TG+K\\/W+F<AWT'5````````````
M`````````````````>:;SAU]I?*9V4W?9TBGBD61#S<UG+26<C)9OY+=[=;N
MKZ?>M/M6E=0`````'G%_47YEZ.ORZ^F@`````44?*E?A2NUMKLK+MC9=QL=_
M%17\)#)'X)(WCRXW]/A2O/@]6?J7B0`!U+JI_+5YA[/=:S8Y,^MMD4\7.3Q\
MK)9R<EF_DMWEUNZNIN+J?:ZE:FH````````````!0?*E=O;7:VW;.R[867<?
M'=Q4=_#0WQ^"6R3GI.DY=?GA^Y<SD.^@ZH``````````````````````````
M``#S3><.OM+Y3.RF[[.D4\7/3Q<O+9RDEO(26;V^W=W6[FZGWNI]*JE`````
M`(CNX9=I)@`````*3YTK\;:[:VNTMNV5EW'V7<9'?Q$5_!021S'EQOZ?"E>?
M!ZL_4O$@`#J753^6KS#V>ZUFQR9];;ST\7,2V<G)9R,EN^OMWEUNYNI][K?K
M54:UH````````````%*T'SH^%*[:V[:6UV,=^PLNXR.[B8K^$AELEYZ_I.77
MYX?N7,Y#OH.J`````````````````````````````\TWG#K[2^4SLIF^SI!/
M%S4MG*RQ\E);OK[=[?;NKK=Q<^U;?I4-0```````````#0%%'QI7;VUVMMVS
MMNV$=W'1W<5'?PT,D?@DQOZ?"E>?!ZL_4O$@`#J753^6KS#V>ZUFRR8=;9S4
ML?+2V<E);O[[-Y?3=W6[BZGVK3Z555H`````````````-*5^9\;:_"VNUMNV
M5E=C9=QUE_%Q7\-%?93S\G2DNNSP_<N9R'?0=4``````````````````````
M``````!YIO.'7VE\IG92][G<Y/'R\MG)R6<A?;OK[=W?;N;J?>M/K6E56H``
M``````````!H4GRI7XVUVUM=I;78V7\?'=QL=_$17\'#)CAT^#*\^#U9^I>)
M``'4NJG\MWF'LZM7LLE_66\O+9RDEG(26;Z^F\OMW5UOWNI]JJZTU```````
M``````!H44K\J/A;7;6UV=MVRLNX^.[C8[^)COLIY^_I^?6YWON7-9#/H&J`
M````````````````````````````\TWG#K[7N8S<E&WV$EGCY66SD;[-_);O
M+J;N^W<74^U:?6K534`````````````T-%?G1\:5V]M=I;79V7;"R[CH[^+C
MOX:&_&[J,"9Y\/JS]2\2``(CB2>5OR]VG6G.[3*[V5.4DLY*2W?R6;VZW=7T
MW-U/O6GTK2I34`````````````&A2K\Z5^-&WMKM;;ME9=L;+N.CNXN._'WS
M-W&[75Y^?O',7L]IK@````````````````````````````/-MYSZ[I+2Y%UU
M-MVEFV<I+;O[[-]?;N[J;JZW[W4^M5=::@`````````````&A32OQH^%M=M2
MNTLNV5EW'V7\9'=&<>^QN#52/)L]3?I_BP``/)QY5[CK/4964GH\KE)+>1DL
MWM]N\NMW5]-Q6GVNI]%-:E``````````````5:%%*_&E?A;7:VUVEEVQLNV%
MEW&1W8H^.IWSUFJ](7HGDNYMSC@````````````````````````````8-OB7
M26C<GG?30;J[_>4Y&2S?WV[V^W=74W-UOWN?2M*E-0``````````````4GRI
M=\;6VI=M;*[*V[8QW<='=;;JKH/M]-W'M\?T2>@^4```\MOF+L^QMC%\>9W]
MR.VMW]]N]OMW=UNYNI][J?2M*S4``````````````&A2?*E?C;7;TKM++ME;
M=L8[NNL2MK<FIAN)?ZV?5W#`````````````````````````````"Q[B=EAY
M^1;ZT?A=WE6Z^O(7V[V^W>7V[FZFXNI]:T^E:5```````````````%)12ORI
M7;VUVUM=G;=L;+MA'=C!Y)=KWNAR,?0]3DY^EZ<``#&I\XV^//Y_M;#OG6\R
MK=;+RE]N\OMW5UNXNI]JT^E55::T``````````````!532OS/C;7;VUVU+MG
M979678PN27]_3N<E659GA^Y\R`````````````````````````````/A;7R/
M^3^YN%Z#%Y'G][<7M:;V^W=W6[FZGWK3ZUI75J:@`````````````&AH44?)
M7X6UV]M=I;=L[+NE=?7HK+U'7N!)ZP_5/$2+(L```^-'E`\K]O>/U^!8W\SZ
M3(OT[=7TW-U/O6GVNI6I54```````````````-**%?E1\+;MM;7:VULWT=>Q
MNNT%MW.9?J@]0\7/,Z(`````````````````````````````#%M\QW5@W![.
MR[B-KD-W67/\FFZOMW%:?:ZGTJJ````````````````*3YT?&VNWI7;6W0_'
MKC,YN#))]-T/;>V@S5?9N>````MDYK,\Y7GCK+H.FP[//GO09%NGKR]]/M=3
MZUI55JH```````````````"M%'SI7XTKM;5CG/UE_2Z7C(ZY?/K>AR-?0]2`
M`````````````````````````````-#S*^:^PN3Z/$Q:?*M_?GN<GN7.I][J
M?6JNM*JE*```````````````*UTHHI7XT?"E>JL*N/G1097OK?.V1<5L?4QZ
M?XO>WT````%C?$[+`+\&Z>_3NM9C+^7[ZXC*R;I=NDDM*C4`````````````
M``&AH<+96W35K1-3'D@^G\_;#S.9E6^I:7*I]1T@````````````````````
M```````````X6&[S)^:^Q[PW6-;MSV7U)RVWO(WE>X,Y]*M5-0``````````
M````#0*_.CJS#6>Z1+M_JKS^SUMGW(Y_IV]+\=-,R,`````=&Z3)\ZOGOJYO
MFQ_>M.K=7/UCI\N,X<WRH````````````````D^7'V)ML3MK;X_)26]#Z/*]
M`?WKEKQ^PP````````````````````````````````!\:,,GQWH<97S7<7/=
M+A=7ZR?J339,.UV3Q45P```````````````&^OI,MCC]T[W#FV;'T%H<J_7N
M]7G`^U\YR4E```````+0>1S\8WS7<6?\CL/E1N;J`````````````````;"R
MMS?28>2[Z3I[]>ZUGTJ``````````````````````````````````@^%)B_^
M9;FP'@]IU;JY^5EM`````````````````VMM9EF1WZ]UK,J/U#2=B[&(````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````````````````````````#%9\NW5FW'[#YTKK6F;C[1SO<^YQP
M````````````````````````````````````````````````````````````
M``````````````````````/'QX^^@Y6.OCU+=]3)W+W.BSH_;^;`````````
M``````\Q?FC]P,AWT'Q]EF^K>```````````````````````````````````
M````````````````````````````````!Y'?(G?^BCZQJ*ZK-N<RNGMEAYX?
MN?,@``````````````?GG?G[_7[B:^4^_P#++]6\`>LOU9^`.6;ZMX``'0.A
M^M=M[;Y]U?J^YL.X7U9>CV?FJUSE_NF3+Z5XEMNYS[1JIW/N?FL,P^E[@V_S
MH``68<;Z3CF/N>!Q]M(\G3<-#LL@W?\`D0`=%:/ZI;ASGV7()W_D8```8R?F
MGMV^GN?+/5.J[VZ/I_A8%KG,?=+H^G^%@"TSE/0%V?5^?P``````````````
M````````````````````````!Y'O(O?^D'ZYK_I66QSF'3NQP<\/W/F0````
M``````````/SSOS]_K]Q-?*??X'K<]8?SZ^KKU1^!H&%3XQ^F,?Q]O'X-O:O
MRWW?)K]+\1XLOE_NWT+^@/R"QT?//8^[OQX3A=/+\OG=O;-<WTOQ"RKC/2]S
MO3?$+?M!]<S0?9/S6\_GP/\`6_*=]0\)8-/B/ZC]@[#D;F>E^(WL]IYD'5^L
M[GLK8\59]R/HOKK7=C>;V7FR?Y_)6T\W]LZ8TWTFX'?_`"/A8=GR,F%E_P#K
MGYW>6#R]^[UXW7^<^Q=CQT8Q=WVQMN`ZEU/T'E)<"2Y.E@>!U?9VSX?L;8\;
M;]H/KF:W[/\`F:```````````````````````````````````````/(_Y%[[
MTA_7<?[W9UBW+8'3NQP,\/W/F0`,;ADC````+#"_,```````_/._/W^OW$U\
MI]_WM=IYD]77JC\#<^/WC\G.1DPP,-OQ[]'^5EP+6N8^Z\K+@W1]/\*Z$T/U
MBX_H_C/3.F^DRK*T,LR^?L:XCU):QR_W>]KM/,>0SZ#Y`PC?%/T[R!]_Y&R:
M_2O$>(_Y-^@V6/ZMX"QM?.?:*B6Y?/P7!ZGIW4?1MM;-D"[[R/;9S?VJ_GO/
M)E@7!>M>G=1]&N<Z7XA2K%,7?]3:GO\`?7XWH*^_?D5YG_-O[9=F;+B.V-KP
M'56K[ZV'F?N&1/Z%X[ZTUO:VB<EZ&Y.3![PW?R_/E]X_)S#C\?\`T<S=_:_S
M#```````````````````````````````````````'D>\B]]Z1/KN/N[MI8ER
MVJZ=V.!GA^Y\R`!^84>H8[%),6(%N1?*14N7,:Q<(7U@LV+/BXD]=(````/(
MKY,_H4OH[?RUGQ^\?DYR,F&`!&<;=R7)TL.P^CZKU?>=H;/AH+@]3WAN_E^/
MK@/75W_7>=^QMCQL0Q.B@.!UD[SN5YF;6[:V;J_5]UWEO/EO6FM[;CH\R:YO
M,C53Y4DBV+O93E:*BEWVK'*,K113%W\6Q=[+LOGAHKC@^<^S<@'?>2.QMCQO
M16C^J=P[?YSQL>;UWKNQ[9VWS_J#4?1.RMEQ6WMFZNU?==J;7@Y/DZ/&_P#.
MO9N23Z-XO```````````````````````````````````````'D>\B]]Z0_KN
M/N+LVQ;EL'IW8X&>'[GS(`'YPQW63PZ>.),W!VZ>.$SV%T)80=6FR.W2<FI[
MA```````````````````````````````````````````````````````````
M``````````````>1[R+WWI`^N:_Z)+'>9NZ=V.#GA^Y\R`!CD.X#I4[L.BR[
MTMR(J=J':1$3JTG1S!O"DNE`````````````````````````````````````
M```````````````````````````````````!Y&_(G?\`H7^J:GZ567<WE=<;
M?"SP_<^9```````````````'$Y-O+8UP````````````````````````````
M``````````````````````````````````````\>?C_Z#>]N6IT;K;[Z_J/.
MYM/M'.@``````````````#SE>[>-]&'A3LOK:```````````````````````
M```````````````````````````````````````````M*Y3.M,Y3.')24R8_
M2=/)<FP```````````````?G;?N;\?\`:!^4/TG(3\0VX`'2G=XO:G(Y$#Z&
M*'[J*X/YOF0#HX>E.[QNW.,R/G<[2Y*<``6^?2,.X/YOF`=#?0\2,;6RZ#Y/
MG=#?0\3OGYYE@=#?0\3OGYYEP/H8H+T$/>WS[+``````````````````````
M````````````````````````````````````````````QK_?-+Y#/T^^>^9G
M]`>)OV^,;;UO_F7]`]-OY]=M/]),!@'_`$6Y+:RTF&EDQ.>P^?\`4=^2_=XU
M/4FDN"^<9F(KV;SU^?GK:SSGIKB/FF9C>]/Z6\OX?LK7_K&#DS\K;ORG?KWP
M7IY_*/N,=GI?3VT_5,&]KX-M(1OHOK:N_P#BVQXO*IUGU4&(_P!E\]G$\#=1
M#-Y'>-\2V.-;U)I<]OYW]8``````````````````````````````````````
M````````````````````````````!X'OVA^4>SO\I/I%TWSG/``P6_H#RORN
M8\?2NGN?^49WVC3[G9KS/A^RMV^EX>/KTAJ-S$[1Y/(O_P#.6W\Y'Z<<9Z9_
MRM[?SE?IOQF4_P`C;ZP;T3J<U_A+I\>WI+3]W\%E474A.]CDNKOC6TL^5]-[
M!7MGCLCI?N<;.;X!ZG#K[9YST!?G)UP`````````````````````````````
M``````````````````'FB^S_`"_'7V'-`#[TKZE?AOUB]7F]X```````````
M```!AF]6<WF9\I](``.MNH@[!YN:USZU@W5_(<_JOKL>W+Z=A\[K[KK/D&PZ
MSZJ#I;NL;OSYUE\QA7<3FVVN?6L"Z/Y+G]G\G/;%]7P>Y.'R8_LK.J.PQ^[N
M#RK>?I.'W_\`.<N-;6S@MA;PN=9VCR4_7W21;B-:S];P,F?E;>``````````
M``````````````````````````````````````?G9>R_,6[^R?,0!UAJ-EZ;
M_(GI'T1?(OI`````````````````````````````````````````````````
M`````````````````````````````````'@2]:^<]/HO$@#K7#RO1+YL^Y>A
M/Y)]&``&)$E)-#(B````````````````````````````````````````````
M`````````````````````````````````"S#I-)$IX0!$<B&X?4;*Z/1[4`>
M9XGIXXB,&8(]&P.N2>$N,*1F5.TCH,P]$H,LIA^/4D7:@```````````````
M```````````````````````````````````````````````````````_.P]D
M>98C]6^=@"!:W.]47D_T3Z&/D?T<`?E\'IX,:0!&2-F\+Y2+G31;P=V@[N)F
M8GB]HR3GI[```!11TESL/86UOEV=>```````````````````````````````
M`````````````````````````````````!^=?[*\QT?8/F@`ZUU6Q]/?D?T=
MZ(OD7T@`8D#NHYP%)TZ2`[`.',#Y>.9PC$J7MD@-\8+CJX]6I*@``"SO@\3S
M1^1>>L_X3%O9^AYGJ&]C='<#U$X%IA9`8C#.<=E'2)W$0T\IAZISLHMV+ESQ
M2'O\+!CLHZ1.XCS?%QIC$/2H64&<PQ\&+`O;+TB"F8(`````````````````
M```````````````````````````````\^GUKYUCMZ[FP!O[;O2]\7^H78:';
M@`````````````#Q5_GSR%L/'XX[<WDOL1]X]7<+U,X'E=.OC'T7WF,XA9<D
M=;E)D=,9QU@=]D7/?,>48QG$++DB"G<QT23XZ8)Z=\&.@]"YYJSW-F4,````
M````````````````````````````````````````````````````````````
M``'D[\2\QC1^1Z^<[&_*]]LV?I;]<]"`,0!T`65';I.#N0D!90?0Y<G!W(2@
MPQGLP/-.3@[D)`6GG8A,C%D9=3GC%(9"2HD!9$>KL```````````````````
M```````````````````````````````````````````````$2P;<?GS#`R%_
M4<^2YEP`````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`__:``@!`@`!!0#P]YYUUVX]P$2#'LC-E:@UF6F9><E_]5Q:=/09#QYFJ>F9
M.P"5@NS,U;M%@6[1/]5YFQ&EO;*_'ES4"4NBANX0O2+6[4PA;M#B?ZKM>TKD
MO.J[F<5I6=JTY)3E/F?]I'75?>O.R;IQ[<)(1Y:5G<3;B=JMHKCO>EM?K[M;
MK=)MNCY+WO[2)F5RWF/;]>+OC:WJI/1:E_JW*/\`_67;MQ=>><>W3Y7=J>R/
MQQ<G_P"&N#_5NT^ZZ1*WS>=IU>Q+LXY"RVER[9/'%>I;E9H]H51^JT+_`%9#
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M0/Q9V=E:=*W7D&IW)$I./).FR=4R3YM`>EJM58L&A0D':3(.HE.DD/5\F>KY
M,]7R9ZODSU?)GJ^3/5\F>KY,]7R9ZODSU?)GJ^3/5\F>KY,]7R9ZODSU?)DS
M*2T%_P!7R9ZODSU?)GJ^3/4]+YOJ^3/5\F>KY,]7R9ZODSU?)GJ^3/5\F>KY
M,6GR2CU*D'B)0I9XB4V?DWZ)DJJR3LS:%L7?*T2Y[BL:?H=>IMPR/^@;TR'*
M6Z4JW[FOVH1JC95@O5>Z;ENF)`H49X<HLDZ.TR10]7R9ZODSU?)GJ^3/5\F>
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M>1@QHC!@P8,&#!@P8,&#!@P8,%05")#<BN2TS.VU6,@4^4K5,QC7UJ]`\>Y&
MK<:OW)<TTY8UJT:011$$01!@P8,&#!@P8,&#!@P8,&#!A0:[6[6K.?=U^0]Q
M]H,&#!@P8,&#!@P8,&#!@P8*@J"H5F1YCMB5&7N6D6G4IBSKN_`R_6'XU2K\
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M=M/FDGI#QWE^?Y%"EWTHF,*#`3NH@B"((@B#!@P8,&#!@P8,&#!@P8,&#!@P
M8,&##`5C_,C-G5RLCU5EY@P8,&#!@P8,%05!4%05"N0._+TQ]*UC;#<^JP>U
M'B<F!C?N.W13E>FJF@@B"((@P8,&#!B#$&(,08@Q!B#$&(,08@Q!B#$&(,08
M@Q!B#$&(,08@Q!B#$&(,0>5QQV3GY*HPV#!4%05!4%05"O0T=C7=&6=MRQH[
MTQ:/CO,<PKU6O.+YO1J9"Y4DB"(((@B"(,&#!B#$&(,08@Q!B#$&(,08@Q!B
M#$&(,08@Q!B%J63>%]U.R>G/NOO1W:5TX:_@O*6\K:G^ZFRKUZ7.Z"V$R!@K
M,>*W&(,08@Q!@P5!4%05!4%05":AI&E\=Q4B3V)8ZPKI[5;?6'1K+>Y:T%UL
MR@B"((@B"((@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!A<%8A4*F3U4J-2
M6B5N<H4Y*1TFY14&"H*@J"H*A7W6R\^O-L7&3ZOV9X[S!\2WU%YD_`=[L)$$
M01!$$01!@P8,&#!@P8,&#!@P8,&#!@P8,)69FI&8LG>'N<Q\;->H7E?+&8-]
M>ZFY=L%EWMO_`-U][EQW;==X3K!@P8,&"H*@J"H*@J"H/&.W^3>N,/C'M5[V
M'9_DZ!Y9U!U!$$01!$$01!@P[IW3NG=.Z=T[IW3NG=.Z=T[IW3NG=.Z=T[IW
M3NG=.Z=T[IW3NF296)$HA:],G9^KL&"H*@J"H*/%?]$FO@/&'P=X[S!\2WE[
M5=T001!$$01!$&#!AW3NG=.Z=T[IW3NG=.Z=T[IW3NG=.Z=T[IW3NF&+S7'.
M6^K)>SM<S9W3NG=.Z=T[HP8,%05!4%05!1Y"SORO;&'QCVJ][#L_R=`\LZ.B
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M((@P1!@P8,&#!@P8,&#!@P8,&##*=3C/5`L>EQJI<+!@P8,&'=%05!4%05!4
M%04?'BO^B37P'C#X.\=Y@^);R]JNZ.CNKHZ(@B"((@B#!@P8,&#!@P8,&#!@
MPM>DT6L5C#.T#9I>1B79EMNQ+5+_`,=V5E.V<P[`-EM"@YDQ1A2Q%8,&#!@P
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M'=0[J'=0[J'=0[J'=0[J'=&#!4%05!4%0>'Q[5\>*_Z)-?`>,/@[PG/,W,1[
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MN`JW.NVK8]N6;!\/S!\2WE[5=T='-7!T=001!$$01!$&#!B#$&(,08@Q!B#$
M&(,08@Q!B#$)^I3]45B#$&(25/G:G-=-7%=?QO@S=)AB[\9YF8,&#!@J"H*@
M\/&#L94R]9N4LBDI+^Y$B>Y$@.6+3H;\*QZ?`?2WHSJ>[\<]WXY6[1ID_`]R
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M,8^N^_KVN&V:_:E1\`S979FC6:4FG1*O4Z'3GZ11O$68/B6\O:KNCHYJX.Z.
MCNJ")X3M;S0F'X?8I]H5FIVB*@I,18<"#2[JM^N1'C;+\)R7H7;N#T+_`-TR
MO>P[/\G0/+.CNCH[JYJX.#O9[I^1^1^1^1^1^1^1^1^1^1^1^1^1^1^1^1^1
M^1^1^1^1^1W149V'D*G7J/2':)<U)N%'S#.2Z%2;&<SW;R._/RW#Y^6X?/RW
M#Y^6X?/RW#Y^6X?/RW"%E6V[@BX+S7;%N5&NV[:60*)DG;!7J"1846!%_!N.
M\[:M)VH[AY9V:HM:IMPTSA?MJ/7E;=/QM>]2G[*P9!I,WXCS!\2WE[5=T='-
M7!W1T=U=$["(T8A^1^1^1^1^1^1^1^1^1^1^1^1^1^1^1^1^1^1^1^1^0Q!4
MX;?\,/7!T[11[2\E5+6<??AO4#)U:IAMFS79<*0E\[V[`@_/RW"/N#M65@RV
M_P#LJ9R#E3?);-A3EN;H+$NNE?/RW#Y^6X.Y?MRX)GWVD_F,5[V'9_DZ!Y9T
M=T='=7-7!P<XHC33PG45&<;VK\2WJ(\\\\]3)R>D)[!UI2.0LATS9[B:DN_M
M4QB?M4QB?M4QB?M4QB?M4QB?M4QB?M4QB?M4QB?M4QB?M4QB6-BFC8\?,AX:
MLO(T/)F,*SC&K&A<&?+?D'K"S<]6*EKV,BW',W)=AM]HU7A^*<P?$MY>U7='
M1S5P=T='=71!>")X3`@QYF-9VU+<;?IM[Q"]CG;G?NR3<W8,U5*15:)./%Y_
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M].H%,O2X)BUK9K-8J5P5.;DYZF36$;XK%VT+A"@1XZ\*][#L_P`G0/+.CNCH
M[JYJX.#@HFO%O@K>P\(/$I;M$I\RNKYM\M^1D+&<MUSN^[L`]W8`MNPV^[KA
M[NN'NZX>[KA5Z5#@&W>IV-:-0R/N<MNW4NR];GO>H\;XMCWPMJ4QI>T]5+-P
M3`ILSXOS!\2WE[5=T='-7!W1T=U=$T$T\`QG:42_<C=6.QW(UA?@[7<QI1NG
M5P>TO%UY^UY22FY^/0<3S,4VI61;M(ITK078T#W=@"VY`5)'9GBVFY2S)M4L
MC,\[;V/*%:E%]W7#W=<*E2ED7/=&G_,\KWL.S_)T#RSH[HZ.ZN:N#@X*.^&K
MH@\/"ZOF"OIA^!<7^=\_%OC?,'Q+>7M5W1T<U<'='1W5T33P"UJ')7%6<-]/
MW%.0UQ!L(V^X;N3*>*+$S1:&2NE[@F3DLR8+M#%R]NT<O1+;P`NH]I$1%24I
M=-IKKQME^$Y+T+MW!Z%_[IE>]AV?Y.@>6='='1W5S5P<'!1."]AHT:-&C1HT
M:-&C1HT:-&C>TNB#P\+J^8*^F'X%Q?YWS\6^-\P?$MY>U7='1S5P=T='=71-
M.TT:-&C1HT:-&C1IM5W"9*L;-'4@R[<V*\(5JX:_<LXT:-&]I=1[1\>'C;+\
M)R7H7;N#T+_W3*][#L_R=`\LZ.Z.CNKFK@X."B=IBG=.ZAW4.ZAW4.ZAW4.Z
MAW4.ZAW4.ZAW4.ZAW4.Z=TT[*Z(/#PNKY@IY/E@BHJ=NXGD6+>[SKUV^-\P?
M$MY>U7='1S5P=T='=71-."]ABG=.ZAW4.ZAW4.ZAW4.ZAW4.ZAW4(,2)+Q>H
MUEZ%DU_NH=U#NH=T8O83@NH]H^/#QME^$Y%462[=PO)YIS'/FJ5[V'9_DZ!Y
M9T=T='=7-7!P<%$[&HB,\$5&=A=$'AX75\PSE^G6E*0LMV,L/YN62?-ZQR+F
M2P8+JYCL)V6D\EVO4)?W^H1[_4(N#)M`I\O-3,:=F?&^8/B6\O:KNCHYJX.Z
M.CNKHFG!>*)^-5JY5:XO95.*<%U'M'QX>,/Y0AX^J4GE^P8D#YNV0?-^QB!F
M.PIJ8D\P6+4)CW^H1[_4(]_J$5?(]M2<#WOJ'O65[V'9_DZ!Y9T=T='=7-7!
MP<%$XJ(GY=N!+QIJ)`MI'7%I=ONGJ"F12):TPA.TJ=D4[>IHO!=$'AX75\?T
M>U?'BO\`HDU\!XP^#O'>8/B6\O:KNCHYJX.Z.CNKHFG!>"(W\&1H4Y.(M$I$
MN)2*%$'K8<?2-;=0ANON/PWNRW@\G!."ZCVCX\/#P\/#Q9_QMC#XQ[5>]AV?
MY.@>6='='1W5S5P<'!1./Z]J5EHLW'2D4BGI$KE/DX<Q-S$V_P`(<Q,0BF5U
M_O5RFNR,?MKKP71!X>%U?']'M7QXK_HDU\!XP^#O'>8/B6\O:KNCHYJX.Z.C
MNKHFG!11-.U3J%YS!2/;<BM0KLU./<'7GG%EJM/RS\9R7K\CV;(L*L7XZ@NB
M"<%U'M'QX>'AX>'BS_C;&'QCVJ][#L_R=`\LZ.Z.CNKFK@X."B<4U[#>%KN=
MZ<J$58T]VH\&-4+>>=?<>&C>*#VO!=$'AX75\?T>U?'BO^B37P'C#X.\=Y@^
M);R]JNZ.CFK@[HZ.ZNB:<%%$TXMXU]L"F]JV8K[L]5I.++3G!O#IA8KE+SI-
M2I\W2:BNB"<%U'M'QX>'AX>'BS_C;&'QCVJ][#L_R=`\LZ.Z.CNKFK@X."B<
M4U7LN./Q7Z!3IF2<>H=,@O>;6Q"7OVJXKL.UYAZK4U:;'*)3H"09>J+-R25^
MGS;J>ZBE4I$JY*<4'M>"Z(/#PNKX_H]J^/%?]$FO@/&'P=X[S!\2WE[5=T='
M-7!W1T=U=$TX**)IV9"E3<Z]5:9"GGEIUNPD[MJN)S+5>)BC2$U*$E*/SLRD
MS)4N/4:TLA.+-6S-+#D+>J!3K6N*M52SMC&Z:]5V6[?Z]MSP]N2Z>&=:ME*]
M-ON<,>B"<%U'M'QX>'AX>'BS_C;&'QCVJ][#L_R=`\LZ.Z.CNKFK@X."B<4U
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M!49P00>UX+H@\/"ZOC^CVKX\5_T2:^`\8?!WCO,'Q+>7M5W1T<U<'='1W5T3
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MNS\)Q]UYQ]!![7@NB#P\+J^/Z/:OCQ7_`$2:^`\8?!WCO,'Q+>7M5W1T<U<'
M='1W5T33@HHFA3Z--SZOI*T"02YG'R=DY*H23>$C+K-S=QS3'N-MS3RQG9N:
MH\X[4*15")3H,U#>M=]!ZV9PGJ?-2*\/T03@NH]H^/#P\/#P\6?\;8P^,>U7
MO8=G^3H'EG1W1T=U<U<'!P43BFM+I$'DQ+ADI=*+.3$VC[SS[[K>]=/=[\O+
M1YI]RVZ@\D2FQ?54S0JA+CSKSJ\**J3M*5&<$5@['C.DM5IZ5?KD*#.2""#V
MO!=$'AX75\?T>U?'BO\`HDU\!XP^#O'>8/B6\O:KNCHYJX.Z.CNKHFG!120D
MHT_&BQ*-14CUV;GHMS1?_&*`B^8$O0ZC,.TBBQI"8GZ#/3$>8DYJ57A38_FT
M_<D#ESO!U]]P=FYIPI-0>J;LS`66F#]$$X+J/:/CP\/#P\/%G_&V,/C'M5[V
M'9_DZ!Y9T=T='=7-7!P<%$XTJ42=G[BGUB1BW(L*)+Q+;GG5E:!.N35R1>_/
MT-QZ3IM/J$Y,5"X9B8=GI6N3\L.O2EP2RHKJEM1%=GJBX[#G^Q$55M9!![7@
MNB#P\+J^/Z/:OCQ7_1)KX#QA\'>&5V_[.MF=E)N5GY6M5JF6]3*'7:3<E-K&
M2;'H%0^<6-2@W'1+HDJQDFQZ!4);+..9J+"C0IB%X+F#XEO+VJ[HZ.:N#NCH
M[JZ)IP44DGG:11'WWGWI6*[`FJG27JI$6W:B.P8E*H5.EWIJ=K]2F(,U!F(_
MN["J$[`>E+AYJURGPY&8&E;>Y](XH6][2J_M,_1!."ZCVCX\/#P\/#Q9_P`;
M8P^,>U7O8=G^3H'EG1W1T=U<U<'!P43C:SB+'F(G.CTFD09F"C]KP5<G*.(L
MM%>FJ5'];7%.=UZ#$>@Q9F6E*_"F9:-*1K7AO^<3+R/S)3)I).=N*26''[$^
MV#;B"#VO!=$'AX75\?T>U?'BO^B37P'C#X.\,R]2'J_F#`5T3,`S=],,$?36
M;H]-K^XCY.XU*#;E$M>2FZ/3:_N(K&#L?5&0VY5FHJO@N8/B6\O:KNCHYJX.
MZ.CNKHFG!1UU7WKE>2%!E9=^;F(DA;]/(,W;SJ^<4^(E0D8TS)4Q'*;28L6)
M'B4.=EN14Z)%D7777GWKC_Z)7A(HY5:*\Z\X\5VAU6V:TA;;G>GJD_S*@?HA
M%HE4@4074>T?'AX>'AX>+/\`C;&'QCVJ][#L_P`G0/+.CNCH[JYJX.#@HG&W
M?^B04>58=K</UDGTF96=B/1YQB$&+$@1(L>BU*%-U>4@2S$&(,0I3[E2IL:#
M$EXB<)2ESLXMS17'(:"#VO!=$'AX75\?T>U?'BO^B37P'C#X.\,O?[@LR4B<
MLB\<IUB2K^&<$?36Y*O5:%G;YM94*%.SE2HMP5R;MO/-RYOO1:1M[@6M+47P
M7,'Q+>7M5W1T<U<'='1W5T33@I)N]^<N=[_S=NN]ZIUA[OU-WA;,94F+D7DR
MB(,0HM1A)"<BV_3EGYV)/S#$&(4R;62F[AD>[%P;9/S'S'U$K-6T=T\&#%CO
M4F3B4J755>>/T0R?AI^C].874>T?'AX>'AX>+/\`C;&'QCVJ][#L_P`G0/+.
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M9=%A734LPF8,052Z*MBVVZG:=E75C[)4')?_`/$F6![]^JKJQ]DJ#DM^5W(S
MCN,L1N6;-^"Y@^);R]JNZ.CFK@[HZ.ZNB:<%(<1^#$G$AUJDVNG_`)N;5'II
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M,NH/:</T0SYF5*ATYA=1[1\>'AX>'AXL_P"-L8?&/:KWL.S_`"=`\LZ.Z.CN
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MP^#O`;/A0H]W>Y-F'N39A[DV8>Y-F'N39A[DV8>Y-F'N39A[DV8>Y-F'N39A
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M*_Z)-?`>,/@[P&ROC+Q)-RDK/RN<,1N8YJ7','Q+>7M5W1T<U<'='1W5T33@
MHHFA5/\`\C1'>*:BBELPD>CS499B8I%-6>CUJJI&5.%OK#EY"=H<.?BQ83\"
M(]I2O^NWS]$$X+J/:/CP\/#P\/%G_&V,/C'M5[V'9_DZ!Y9T=T='=7-7!P<%
M$XIJI!BO0(M1I;M7?5+?IR^NZ3%&6Q&(=/H,Z3$%^7C"$*I4J<E8<W;TD5&H
MQJA$X4>&]%J-PO\`?J=(J,N]+Q[;5XIM"?E8U8G79Z=0>UX+H@\/"ZOC^CVK
MX\5_T2:^`\8?!W@-E?&7B2_K^H6/*%?%\5V_J[QS!\2WE[5=T='-7!W1T=U=
M$TX**)H6\^[,R<*B2$C#]<4B559RW9HY5KH5>F091Q12CU%RGQE>M=Y9VMPG
M(0G!CTO;,E-Q)*8C2=.K8];4_P!^HOR])IA^B"<%U'M'QX>'AX>'BS_C;&'Q
MCVJ][#L_R=`\LZ.Z.CNKFK@X."B<4U7A2H$Q"ID6$_!BBE"[WK*N>U1!>#VG
M"G(Y2Z1&C19B*09F8EUF9^<FQ!![7@NB#P\+J^/Z/:OCQ7_1)KX#QA\'>`V_
M4(5(KW[L+-/W86:?NPLT_=A9I^["S3]V%FG[L+-/W86:?NPLT_=A9I^["S3]
MV%FG[L+-/W86:?NPLT_=A9I^["S3]V%FG[L+-/W86:?NPLT_=A9I^["S3]V%
MFG[L+-/W86:?NPLT_=A9I^["S3]V%FG[L+-/W86:?NPLT_=A9O"_K^H6/*%?
M%\5V_J[V,P?$MY>U7='1S5P=T='=71-."BB:%NP8[\_<T%_O\$UF%;;2B]E"
MD2B3D[7ZB_%C#JJZJ56HPX:JKRGZ()P74>T?'AX>'AX>+/\`C;&'QCVJ][#L
M_P`G0/+.CNCH[JYJX.#@HG%-5*1+)-5#SM8MPU:%$AU`8JK09&)+$W'6:F1!
M>#VA3Y&)/S%P34)'4XKJ@@]KP71!X>%U?']'M7QXK_HDU\!XP^#O&E]WS1<?
MT"^+XKM_5WLY@^);R]JNZ.CFK@[HZ.ZNB:<%%$T(+RTRWJBX_%H'"3DIB<BU
M^-#@2ZB]E"G0':/(Q'GGWQ![3A^B"<%U'M'QX>'AX>'BS_C;&'QCVJ][#L_R
M=`\LZ.Z.CNKFK@X."B<4U4MB&V<C345VH4JHQ9^#`K%(CQ9Z9?I\.=K,Y/.2
M%)FI\]V83J/VN^B1J'4H)$AQ(3SVAWG:+1U57E3BNJ"#VO!=$'AX75\?T>U?
M'BO^B37P'C#X.\:7[?M=R'7.UF#XEO+VJ[HZ.:N#NCH[JZ)IP4430N1>3)4F
MK3DNM1J$C(O2\62FX4Y7YR"^OG$[,0;8B*[[LPWTC6Y.N$>0G)9.%O2B3$Y5
MZ@]/33VH@]IP_1!."ZCVCX\/#P\/#Q9_QMC#XQ[5>]AV?Y.@>6='='1W5S5P
M<'!1.*:J6O\`]+JJTCKZOM\D*Y-23KCE-KD":YZ4155Y8<6)"6#7*C!&P+@D
M8CKSCT&#$CQ;GB?];&DK2).2E_6U#?6I4>$[!75!![7@NB#P\+J^/Z/:OCQ7
M_1)KX#QA\'>.\P?$MY>U7='1S5P=T='=71-."BB:07>]%NIY>=;<ND:=JLPL
MS/2TU'E(L&O2LVDK(2TC4JNLXDXU4(-1G8!(7!$B1:S3O,8Y0G'I>GE,I<2H
MQ7YJA4U78-'K+LY+192-P_1!."ZCVCX\/#P\/#Q9_P`;8P^,>U7O8=G^3H'E
MG1W1T=U<U<'!P43BFJELQW$BSDNLI-5U%?IPI;L98<^_4'Z15(M-IM7=BV[4
M7!ZD5)PHU,J4O,S\E1W)A^OR4J[-34:<C6_*),3E8GGIV<+?G>5'JLIYE/((
M/:\%T0>'A=7Q_1[5\>*_Z)-?`>,/@[P[#/2ZO',F'[PM*O6'=6T/;+%W69,R
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MY\36=;`MU2#-S4N.5RJ.#UPU)YRE1XT>EB%,AI%J%R1%?J`A1%6-3.'Z()P7
M4>T?'AX>'AX>+/\`C;&'QCVJ][#L_P`G0/+.CNCH[JYJX.#@HG%-5X46J<Y)
M5R)2:O7)=V7J"EM0DAPHC[\>-`MF+$A>ZSXMKQ&0K<FX4>YGD6=X4Q%C4%.#
MKJOO76\BO((/:\%T0>'A=7Q_1[5\>*_Z)-?`>,/@[P[+/_:(Z>F0K?W%8`Z9
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M@\/"ZOC^CVKX\5_T2:^`\8?!WAV6?^T1@_+5?P;E2R<?6E=^<,^635LD[X=W
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MW1T<U<'='1W5T33@HHFG!T@QHDO%J;D*J4Q-:=-I(SD9RWYV*LY09`B7,\B3
M4_-3JVW_`-<#C1ZI#EDF+<2*LK2I6E)59]^H1^'Z()P74>T?'AX>'AX>+/\`
MC;&'QCVJ][#L_P`G0/+.CNCH[JYJX.#@HG%-5[#C[T*)59=*K(HO:K+O,I'!
M5_)%5%>FYM]T75!![7@NB#P\+J^/Z/:OCQ7_`$2:^`\8?!WCO,'Q+>7M5W1T
M<U<'='1W5T33@HHFG!WA;TPY$<G9*-(3&O9MA]$C1G>Y&X*K2%,3$%'XD2*K
MVG#]$$X+J/:/CP\/#P\/%G_&V,/C'M5[V'9_DZ!Y9T=T='=7-7!P<%$XIJI*
MR<Q.Q'+6_P"F?HTU(NEN3BPX]4IT60F&J=Y3O*=Y3O*3BMMSO*=Y>"<5U00>
MUX+H@\/"ZOC^CVKX\5_T2:^`\8?!WCO,'Q+>7M5W1T<U<'='1W5T33@HHFA)
MVY-3#L2V7T=C0HD")"BQ(,2J2RU:1_-!JC5&J-4MI7O6%13NS[5["#VG#]$$
MX+J/:/CP\/#P\/%G_&V,/C'M5[V'9_DZ!Y9T=T='=7-7!P<%$XIJXX]$?FXS
ME`I\2+$C/T:K1'(M8D$D9M%5%ILVY6)69EHLK&XR4C,3T6X(T*!+\&=A=4$'
MM>"Z(/#PNKX_H]J^/%?]$FO@/&'P=X[S!\2WE[5=T='-7!W1T=U=$TX**)I;
M\C#?6IU://Q9.;F).).N0ZS32F5.+3XM>I[K6#!@CJJM(E/54ME;#[]O;1F#
M.*#VG#]$$X+J/:/CP\/#P\/%G_&V,/C'M5[V'9_DZ!Y9T=T='=7-7!P<%$XI
MK;\%(M2K<PLQ4>%559RB$"/%EHKMQPHKB5"WHIWK6?$A6RX3-P0X<-YYY][M
M+J@@]KP71!X>%U?']'M7QXK_`*)-?`>,/@[QWF#XEO+VJ[HZ.:N#NCH[JZ)I
MP4432>59&@#I;4=79F=@I+S93ZY'DH:5BC1CSBV8AR[7B'G]#IQ-ST[5H^[O
M#[DCL0[+VG#]$$X+J/:/CP\/#P\/%G_&V,/C'M5[V'9_DZ!Y9T=T='=7-7!P
M<%$XIK;'=\\FVK-</_2WXRZH(/:\%T0>'A=7Q_1[5\>*_P"B37P'C#X.\=Y@
M^);R]JNZ.CFK@[HZ.ZNB:<%%$TN-6R@Z4#VG6494^Q3H,C,3V&<`[&[G3%6T
M;:)08-6I-*KU,S%LXV-2TOFK$FT^T7.+VG#]$$X+J/:/CP\/#P\/%G_&V,/C
M'M5[V'9_DZ!Y9T=T='=7-7!P<%$XIK;\9(-2K<!8%1$_,JJ>9T;\9=4$'M>"
MZ(/#PNKX_H]J^/%?]$FO@/&'P=X[S!\2WE[5=T='-7!W1T=U=$TX**)I.IY]
M;XZ6U`;,3D;SB:[5NW)7K3J^['+KM-V;S$Q'FHW8>X_H@G!=1[1\>'AX>'AX
ML_XVQA\8]JO>P[/\G0/+.CNCH[JYJX.#@HG%-7'WH;\Q"A7!(18$:`_1J0^C
MU7G_`#^:_%>7@@@]KP71!X>%U?']'M7QXK_HDU\!XP^#O'>8/B6\O:KNCHYJ
MX.Z.CNKHFG!11-*!/PX3U4H\>2BR<E,SL2>B0:/3?P,VYC2Y-BW856"JWC^B
M"<%U'M'QX>'AX>'BS_C;&'QCVJ][#L_R=`\LZ.Z.CNKFK@X."B<4U4E9N8DH
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M1[5\>*_Z)-?`>,/@[QWF#XEO+VJ[HZ.:N#NCH[JZ)IP4433P5=$$X+J/:/CP
M\/#P\/%G_&V,/C'M5[V'9_DZ!Y9T=T='=7-7!P<%$XIKX,]KP71!X>%U?(,M
M,3D>4P%DN;A/;=<DJ/;<LEJ57;-E*;@1]M&48EK61A*^J%;ORJNT^55VD]C>
M[9&"J*ZOC?,'Q+>7M5W1T<U<'='1W5T33@HHFG@JZ()P74>T?'AXMZU+ANZ=
M3;QDI]U[;GDM1[;CDQ2WMM&4:;<MD;;<G4*XOE5=I\JKM/E5=I6K0N"WW.%>
M]AV?Y.@>6='='1W5S5P<'!1/"EUX+H@\/"ZOFVF@R<U4I&B0YF6]WI8]WI8]
MWI8]WI8]WI8]WI8]WI8J5(<DX.5:9+R%R^-\P?$MY>U7='1S5P=T='=71-."
M\'?!GA!."ZCVCX\/&$[=E*3826]+L]WI8]WI8]WI8]WI8]WI8]WI8]WI8K=)
M@(GJU/7I7O8=G^3H'EG1W1T=U<U<'!P43BHBLXL&#!@P8,&#!@P8,&#!G%5$
MXKH@\/"ZOFV+T&F>@=NN^@9B]N>-\P?$MY>U7='1S5P=T='=71-."\45O!@P
M8,&#!@P8,&#!@P8,&<%5@OY\$X+J/:/CP\8F^"_P+@]-_P#6Y7O8=G^3H'EG
M1W1T=U<U<'!P43LHK!J+X$KW971!X>%U?-L7H-,]`[==]`S%[<\;Y@^);R]J
MNZ.CFK@[HZ.ZNB:<%['>&IV-FV*93,F>ZE3YNDU'\)J"O"JWBG!=1[1\>'C$
MWP7^!<'IO_K<KWL.S_)T#RSH[HZ.ZN:N#@X*)V6<6J-4:HU1JC5&J-4:HU1J
MC5&J-7A7KJH]N$QEV.LS2JK)5F1XKH@\/"ZOFV%4\RI;R/4_MUUY$D*?A*EY
M/J.1]MUV6@*BHOC7,'Q+>7M5W1T<U<'='1W5T33M,[/26LOSJ\MYMF^XNY[\
M?95CZ6R7N5NZW9NS[L74>TOFZ(EJ4J@Y9IL\L*/`FH.)WW$LCC1[CH%PO1;C
MH,"O<:^\BSK4]]BO>P[/\G0/+.CNCH[JYJX.#@H[X/<M6CUFM&):7,PI?BNB
M#Q4:K3:6Y'R?1'9N%,0)J#BV[ZO:5P.Y9O%Q/FY>A\W+T/FY>A\W+T/FY>A\
MW+T/FY>A*9=N9V:M3.UUVE<N/,S67D:'D?`]F9!3(&([SQS&X5_(MG6V]:.8
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M9Z6V8KLO6F[_`/-%XW'N)_%Q3;F%*_.8;VX]-NLKCO&.-<8TK+&$<%9+A9FP
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M(I<G+>9>:RQYK+'FLL>:RQYK+'FLL>:RQ6Y67=E);-4#%=5R3N`O&_>R[3Y!
MR;[64L256:JUN;?II]^@6[1[8I_BC,'Q+>7M5W1T<U<'='1W5T33AK^#2*O4
MZ#4/PK*M"M7]=G9Z?][P;(W1Y-NZ+?\`D;@]IDV@5&O42@8EJ$R4F@4BA0<2
M2D"'8B2DJZGFLL>:RQYK+'FLL>:RQYK+'FLL5N!"@3GFT#WN*][#L_R=`\LZ
M.Z.CNKFK@X.]A%8:^$*O84>%U?-L7H-,]`[==]`S%[<\"T):<E)USQ'F#XEO
M+VJ[HZ.:N#NCH[JZ)V&HHSP+IJV8]=&Z#<192X[SIP8-1"3G)NGS8@H\/CP\
M8F^"_P`"X/3?_6Y7O8=G^3H'EG1W1T=U<U<'1T3LM4[RG>4[RG>4[RG>4[RG
M>4[RG>4[RG>4[RG>4[RG>4[RG>4[RG>4[RFO9>%%U?-L7H-,]`[==]`S%[<\
M!N:XJ?:M&KV0;ON1;(O>J615*14H%9I7B+,'Q+>7M5W1T<U<'='1W5T1>RT:
MHU1JC5&J-4:HU1JC5&J-4:HU1JC5+3QUD*_(W3:VYY%P_#ZA.U7+MW9KN*T[
MKM"<:HU>RJCRCX\/&)O@O\"X/3?_`%N5[V'9_DZ!Y9T=T='=7-7!T01?Q55$
M1ZZK==GO`%%'E%U?-L=0E77Z=5I*%*>N::>N::>N::>N::>N::>N::>N::5>
MI2LS+9=FH,:X_`<\R\U%LHLRF1:K=$.'#@P_$68/B6\O:KNCHYJX.Z.CHBB+
MQ9X%BC-E?Q#.6/U9ZK)0MN>Z''FYJD[CM[V,-MUQY#ZJMUW+)9`R#5,C5K@S
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M>'BS_C;&'QCVJ][#L_R=`\LZ.Z.CJB"*(HBB*-&C1HT:-&C1HT:-&C1HT:-&
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MC1HT:-&C1HT:-&C1HT:-&C15%4515%4>4>'BS_C;&'QCVJ][#L_R=`\LZ(((
MHBB*(HBC1HT:HU1JC5&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1H
MT:-&BJ*HJBJ*H\I7_1)KX#QA\'>.\P?$MY>U7=$$411%$4:-$4:-&C1HT:-&
MC1HT:-&C1HT:-&C1HT:-&C1HT:-&C15%4515%4>+/^-L8?&/:KWL.SD57*`J
M<]T11%$411%&C1HT_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,
M_,_,_,_,_,_,:-&BJ*HJBJ*HJBE?7_RLVBNV'C!%2SO'>8/B6]8:N5.&]WG7
M5$411%$411%&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HJBJ*HJBJ**
MH\64CT6],8?&/:GX7/D;`A^<U:B/]V==411%$411%&C1HT:-&C1HT:-&C1HT
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MJ8=EH&.*7ZSN:`CUZWUX\R'3%JEJ8]?<JTA3WXE/J"*(HBB*-&C1HU!HT:-&
MC1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:*HJBJ**I6IGFS%X0DMRT,54QZ1M
MCMY/H:U:WK!F):X*)#29H=3=>1411%&C1HT;X>T:-&BJ*HJBJ5>;\XC5&$MB
M6)A^BKX]?==?=G(,U8EXY)H\%^+3)U)N`BB*-&B*-&C1HT:-&C1HT:-&C1HT
M:-&C1HT:-&C1HT:-&C1HT51HT515)^<=E(&/+>]<U>IS,U?=X2DK!DI7MO.N
MONW-2INQKINFF2U\46DU+EB*(HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1
MHT:-&C1HT:-&BJ*I5*DD!W'EMR\-R>F:ED*ZZ93I:DT_Q[DZV7JS2;`K4G49
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MT:-&C1HT:-'XL.&D>LRD)'8E5K<Q2K'I%L0+HO2IW='L7'\*@I_H"8EX$W`O
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M"=RX3N7".2URQB#9]Z5`@XTFI9V%4\=6N5.[+KO*/:^*'7%@P84O"_'K=CVW
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MSTUQS9+P9NDXSFYFU*YCGX5QAD?'-`L;*L:6F<57%?>.IS&5G24Q3K4R:_ZQ
MNO-T*'&MG'<>-9ESXO?BPYBKUC,-*I52O6*F-X]X93FK?J^2Y:1LNL7+E:T)
M"0G9>I2-_5NBV]E^U;SLJZIBEKDU<L9`6^/FE?/K7UC6KIGZ;?5X73/V]57;
MYG*1>]AW-5[NEL],]SLWQ+6BVA%N:MTFY[PNF?MZJUJ^;MAWQ`O_`"#)5VW+
MNNN6O*MWS=L*^*)>%UTZ\2P;RLFVH^%(<".YC)42X:?=V0+X>MK)"S--IUPY
M<KE-O^(\]=T#(TY4ZE*W%EFK4>KY(B?*NU:O?U<GW'O4V<O](+\9NBZ7=["P
MOX@S=]3RT\?77><6SL!6U0R%!A2\+CF/T'*]"G7Y+$\]#J=B8BO:T*1CS*50
MD:KBIR\L7PK"PS)U:1Q[D)/-,CYJ^'<K6[.SU*QC<$U'M6-,VY5\>?\`]N__
M`+5SSD>0Q[D3(-J3UE6C2X]$M:[ZI3J-FBEWE:E;FZ']=+W^K&3OB+(M0EZ!
MD.]KMHEP7GD6GQLIW)BVY7*[;>?''8EF47'ME6],Y%J$O0,AWM=M$N"\Z7];
MICZ[5SZZ3ES4JV,US]5I]Z9>,:W%:5&CXY?DZGDS'\N]-U7$MWT"W;52FS=]
MN6GE"R9:R,H2DG<-=B.U:D6_:4'&T_;5[2-N4_!,AZ#/IY]G?_2"_&;HI=WL
M/"_B#*&(KSN:_;.P%;5#(4&%+PNS,R4G.IJ2E.I\A`]TK5$IM.=DH%M6Y*Q3
M)-KSET6XDM#J4D2=/D*<Y!MNW9::]74_S+S>7\WA2DI`EI&V;;IDR3U&H]3?
MDZ!0J=&=DI-R:BR4G'F(\E)S3\[(R-2EY>AT64@2TC(R;T&0D9>8FY*2GX9.
MR,C4I>7H=%E(#LE)N32R4FLV])2;\U!M:=C9+IM(I-&A$:V+:F(L&!!EH4"2
MDY5^H6Y;U7C0H,*7A+;5N+/QI*3F8LQ(2,W&FK5M>>FH\C(S4JB(ZEGVW4Y2
MX_\`2"_&;HNEW>P\+_[4+\9II^1=WL/"_P#M0\K+R28<9YPX77%1^BX7\0RL
ME-SKW^PU8YE+NSWIDSWIDRJUZ7G9+#<G&AR7B#8SB=W)M3?<?AO_`.PMPV90
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M/8DM=7;KMR/:]6\/VJ9;=Q14^U:U[7=9$:#&C2T:/N`S?-7:/W_>T2R]L&8G
M\#9UR35:-C[.U3J4_6:C<&2\A77;DGN8W`T^RJY?EYW-7+HNJY+VK]U7W>=\
M5N?W9[EZI;<E?=YTVT1,Z9D2MVO=5R637[:R%?%FW94]P6;:S>MOWC=5J0+F
MW*9]O*T9*]KNIUJX^RCD;%-6R/F?*V7IG'.><RXBD8M_WM'M;&V;<MX??BW3
M6\OY'WDYDH6:LX?ZAL)$6@\F"<F"<F"<F"5N%"=D<Q>W/]I;0KM&I=O_`#(L
MT^9%FGS(LT^9%FD[?-JU.%F%]QZO_P"TLG:]S563]QKM/<:[3W&NT]QKM)2R
M+P=FKC@UF#6?]I;$A./V]ZDIQZDIQZDIQZDIQ5:9*2LIF)UU*]X>JHZEQ79;
M]JRM,J<A69#_`&#L-YUV@>>R1Y[)'GLD>>R169F6BR68O;GAU_W;`MJWZGD^
M\*S0HDQ'C.6)D6KVG4K2NZD7G3/]@K1R:]0Z?\XJ&?.*AGSBH9\XJ&/YCHZ.
M7)<$W<U4\.OZMP+BN[A;-&6X:_:-H4FRZ7_M/EZVYR0O$I='JE;F+6P?<L>)
M_M14Z=+5>G6YA>T:$_*4^0D'?_T3O__:``@!`P`!!0#Q!&JZHLK4XJ1$5'D_
MU6D1Q7_'E3>>=E!U.\]!A)!A?ZKI53Y]V>/(\%V/"]5S*Q9>EP82_P"JYB9E
MY2';]1Y5QNON/N_[2RDW+3T`?=>><J5"N.:)ZT[A@$&#%F(M/M"YG7J92JW*
MKXV@Q'E?_P!6T[_\57>.I;E-Y=W>.(__`(4;_5MRRT5Z3E)F%.2W&1IGF]P>
M.(T-(L.6B<R%_JQ414H*K3ISQZ[_`.%-=F)'@P4@U"7CQ/\`4UQN/RCSC[D1
MSLQ8CL&%1)YZI4KQ#!D9N.0Z#./"6\^SW>?/=Y\]WGSW>?/=Y\]WGSW>?/=Y
M\]WGSW>?/=Y\]WGSW>?/=Y\]WGSW>?/=Y\J=!BP)27HGG,#W>?/=Y\]WGRHT
MI:?(OOO1'T546FT.<CR7N\^>[SY[O/GN\^>[SY[O/GN\^>[SY[O/C]`FD(M-
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M/5HD:)!H_?>APG(;K$/R/R&C1HT:-&C1HT:-&C1HT:53_P`C4FC1HT\RD_.6
MC1HT:-&C1HT_(8@\ZCR3-'@1%<GYV0?F9*4J<*9E8TI$_P!`TZDOS9'FY.EP
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M!AP88T:-&C?`HU/F:=$FJA#5YQU''/Q&C1HT;P>=1YV(Y$HLU4I1R?E?'TE*
MOSDQ.S4*FRM+D%@HGY#1HT:-&_CU^W9&X(%=FJI+4NQZL_<5T=B0DH%.DOP6
MC1O!HT7\RITY)MRFSGGD&HR3TE'_``)"6\[FJK->;0*=)I)R^@JC1HJC1HU/
M`IRD2DY'_$:@T:-&C1O"8@0YB%2HL27C5J5Y$UX]I$L[*R<FXM3GD%%&C>#5
M&IX!,2\":@V_:=.MN<_&:@T:-$4004J<%^3F)Z"[4)#\"@2Z.P95WSZJ(*HH
MO!HW@T:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT;P:-$411!#4K$-Z"]5(
M3LW3_'DG!\XF:Q&6'*RDN[*RZKP5>#1HUHU1HT:-&C1HT:-&C1HT:-&C1HT:
M-&E#J\.MTYHT:-&C1HU1HBC1HW@A'@N1X5&??AI4H'F\[VX?_DZ528'(D5%4
M45111JC1HU1JC5&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1JC5&J
M-4:HU1HW@W@BB"$Q!=F(-(?YLA%<Y47QW0(7>FGT\YK2"BJ*HT:-&C1JC5&J
M-4:HU1JC5&J-4:HU1JC5&J-4:HU1JC5&J-4K\^M-HF(YY8M':HU1JC5&J-4:
MHT:-&C>"*(*1T\VJ]PPO^KM.IWGJNU9)QU'444515X-&C1O!HT:-&C1HT:-&
MC1HT:-&C1HT:-&C1HT:-'GG74EIN5FW6C1HW@BB""D@[RYRINHY/^.[?=9`I
MSO?F/T45115%451HU.#1HT:-&C1HT:-&C1HT:-&C2;GI.0A3N1;3DB[<CR]=
MI=FW5[JSLEE&UYDI]=HU55HT:-X-&C1HBB*()PJSK(5==[TEVI9&S%11H@HH
MJBBBJ*HT:-\,JE0<IDG,SLW.+3JE,4R8EXW/@-$$X(((?I"_Z:G6494?'=`]
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M..0W6B"+P0000_1SVI6O:'CN@>AT_P`@HHHHHJ\&C>#1HU!J#4&H-0:@U!J#
M4&H-0:@U!J#4&H-0:@U!J%+I\"E2;4&H-0:@U!HT:-&B"*(H@@Z5/T&M>S^U
M*^DU#44445115%4:-X-&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1
MJC5&J-4;P:-&B*(H@@BB'Z.>U*U[0\=T#T.G^0%%444451HT:-&J-4:HU1JC
M5&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1JC5&J-4:HT:@T:((((H@@Z5/T&M>S
M^U*^DU#44444451HT:-&GYGYGYGYGYGYGYGYGYGYGYGYGYGYGYGYGYGYGYGY
MGYGYGYGYGYGYC1HT:-$$40000_1SVI6O:'CN@>AT_P`@*****HJC1HT;P_,_
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MJS12X+L6/X?0/0Z?Y`70>T>%4451HT:-&C1HT:-&C1HT:-&C1HK%2P:2M+1H
MT:-+^K"TQY%:C1HT:(HT11!!!T35T=*GZ#6O9_:E?2:AJ**/:/BBBBKP:-X-
M&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1HT:(HBB""":9+O>I2$\
M]<LPCWO/'/>>.>\\<]YHS5K4)5]<P3US!*'==2IL23FH<[*>"U"2692#28KQ
M`E8,LGA]`]#I_D!=![1X444515X*HT:-4:HU1JC5&J-4:HU1JC5&J-4:HXXY
M"&J-4:H_$=ANY$J<"HUJVJQ*U&D-&B+Q11!%$$,E7E.6[`F+FG>=[SQSWHCB
MW-&5%N:*\BUJ$J^N8)ZY@E*N2>E(WO7"]UB5])J&HHH]H^****-\.:-$$403
M3)OQG^!1%_Z+455MSQO0/0Z?Y`70>T?'A15%X*O@M6I%3GRJ8_N>*]4*=.4N
M9I=F7!58-(LZY)(EH46#"$&B*(H@Z.F9/;DWZ5VZ*O\`YIJ_+\E?2:AJ**/:
M/BBZ**+Q1!B#$&(,08@Q!B#$&(,08@Q!B#$&(,08@Q!B#$&(,08@Q#N\4$$4
M0=TR;\9_@43_`!M/X<\"BU:"Z2E3YK_B.@>AT_R`N@]H^/#PHO%$:=T8@Q!B
M#$&(,08@Q!B#$&(,08@Q!B#$&(,08@Q#*,DKE2IDHDA3F(=U!49P:(((.ZNF
M9/;DWZ5VZ+Z5_P"WY*^DU#444>T?%'M%T47@B,\+5&BHS@@@@[IDWXS_``*)
M_CMYP/E;.5+OW'5\8ON#P"IQ7H4L0W%B1(3BPX?B*@>AT_R`N@]H^/#PHO!$
M;X/<U'];+V(LU!A38@A2*54Z]5LN;3]Q.")!TS)[<F_2NW1?2O\`V_)7TFH:
MBBCVCXH]HHO!$[#%.ZIW5.ZIW5.ZIW5.ZIW5.ZIW5.ZIW5.ZIW5.ZIW5.ZIW
M5.ZIW5&+V%1O!"//2DHDA4Y2HCNE_P!DU:IW*]A^LJ]\GZV?)^MGR?K9\GZV
M?)^MGR?K9\GZV/X]K=&A].7<UC?`]#O6P,6YVL[<-TV[XL@FI69DIG\&-,P)
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M[>6`LH;>\WW)MTRY@7.EA;C,934S2+<I/42WHP-U^1>S*^DU#444>T?%'M%%
MU=U$1OA:IP>+@E8DQ)%%I,^_-X[ORX,8WC4>H[N9EC^2?<\?R3[GC^2?<\?R
M3[GC^2?<\?R3[GC^2?<\?R3[GA[J6[F'(EO=03=[=M8P#3=TT]+7I?-GXZM_
M<+U,ZO5EK5;K%QU4J<5Z%+#CJOOPG.7"XU&5?@QH--F8I*RSLK"\44#T.G^0
M%T'M'QX>%%XHC/`;;J_K9.W5K+I%86<Q2\5"1C4V=D<6SL1VF6!1Z:_#<2&Y
MLQ^[#A>E\V;CFWMR/67M6AF2,C7GEN^-LN'Z3GG-^-L<67B"Q;?N.U[XH75&
MVLXYV\97X1(L*"G"5])J&HHH]H^*/:*+J[P3\DX=T8G@;$.Z*C.P]HA`I\E`
MBH.Z96JLS-7*]6WN]Z[BGKN*)6WSUV\>NWCUV\>NWBFU!^,=*_)F':#:>X/J
M08]L!,HYAR/F:O\`&:@><P79&:?B2U*1Q[Q?0/0Z?Y`70>T?'AX47@B<41HQ
M/Q:E-I(4[%4ZJ3_98@J<;GI'-R"?JALYF9>4W5WC>UGX]H&XGK`VO13=YN"S
M#G"YIBL/0HWKN*.UV,Z]7NK[NEN7:KLNZG.;ME-%R+F"^,M7MZ[>/7;Q(U%)
MM[WDG/<(E?2:AJ**/:/BCVBBZNGZ\$1G@^HJ,X+J]H@@@[IDWXS_``*)_C:?
MPYXWH'H=/\@+H/:/CP\*+P301/Q9J._+P:Q?U5IY5[[K]8EJ759ZC3=-R;7'
MWZ/7)NI]I4X3E)28KI^J$*)$A1+VREDO)L=TS)[<F_2NW1?2O_;\E?2:AJ**
M/:/BCVBBZNB:CJ<41IW3NG=.Z=T[IW3NG=.Z=T[IW3NG=.Z=T[HJ*G%4_(>'
MM$$$'=,F_&?X%$_QM/X<\;T#T.G^0%T'M'QX>%%X)HGYKQ[IW3NG=.Z=T[IW
M3NG=.Z=TNFWJ;/4;'-(EJK6X,K`EG.Z=T[IW>PJ,5=#]4$'=73,GMR;]*[=%
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MHQ1BC%&*,48HQ2%+PH`Q1BC%["HW@]HNA^J"#NKI?UEO75)S%@7.[%]P;B4^
M7]QC]A7##=B6)<$)SW/JQ[GU8]SZL4VR*Y,Q?=N2]WB5])J&HHH]H^*/:*+J
MZ)KP=T-1$[42+#A.1*JJO)-U)3UC-N#M7A*0)R!,=I41149P7075X>T000=T
M0=$T0_1SVI6O:'CN@>AT_P`@+H/:/CP\*+P31W1->")VYBH0("^L)V(+.U!P
M2K*Z.566>5UYUY.RKO%=7M%T/U00=U='1-71TJ?H-:]G]J5])J&HHH]H^*/:
M*+JZ)KP301&=F-%<@P_/9V95VGS,=^%!A07>#T*$^3=.=93YI9B'VE1G%=7A
M[1!!!W1!T31#]'/:E:]H>.Z!Z'3_`"`N@]H^/#PHO!-'='=1$[4U4.4_RZI,
M$M3X4%."HBI%DY:*ZX]%ILQV9Z?@R`\G![5[1=#]4$'=71T35T=*GZ#6O9_:
ME?2:AJ**/:/BCVBBZNB:\$T37@B*IW4&(5=60):&CDNQ!B#$&(,08A#?ARM3
M3NO(Q#NH=WB]Q75X>T000=T0=$T0_1SVI6O:'CN@>AT_R`N@]H^/#PHO!-'=
M'=1."(T[HQ!B%-1(DTQ!B#$&(,08A5H;JR\E&AQH#$&(=T5&&3ZJ_)18<1R-
M#'M7M%T/U00=U='1-71TJ?H-:]G]J5])J&HHH]H^*/:*+JZ)KP31W@B<7GG7
M':G-0IAY*C./ISJN^G=K+PK]8A))3:3<,J$W$YD63Y,PM,F8*KZZ0DYV,]&%
M1O![3@NKP]H@@@[H@Z)HA^CGM2M>T/'=`]#I_D!=![1\>'A1>":.Z.Z\$1O8
MF9R!+I)3;\LB354?&UEX[M90A3\S!CDQ&=EX*PIB<A2M/29@<FKP4>F:I+"S
MLJY+SM]6K)%ZW!+W'6+;R)0H5+D[@HE0'M7M%T/U00=U='1-71TJ?H-:]G]J
M5])J&HHH]H^*/:*+JZ)KP31WLSD59Z8<EG'*IW7CNO'=>.Z\2KOF]4>177:6
MXL>8JJ=R8[KQW5)A&5;@NKVG!=7A[1!!!W1!T31#]'/:E:]H>.Z!Z'3_`"`N
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MLO`I\@DTD_++,2M)FDB0N$2+"A)4IR7BRE/1DE6G%1(3Z185&7NQ2KS#L.7D
M8"PI0RM37XTW*R[DK++J]J]HNA^J"#NKHZ)JZ.E3]!K7L_M2OI-0U%%'M'Q1
M[11=71->":.B:DW.Q8L22ICDLI,0')F#ZFC.D66J,K#<<J,_#]4SHE*G8#KE
M6F("QXO>CQXT*J2DK54@0XLQ-U1^4E(<I"5&H/:O:<%U>'M$$$'=$'1-$/T<
M]J5KVAX[H'H=/\@+H/:/CP\*+P31W1W7@FDU-.2D.!*3%2>APW(+A-4EV-%]
M5SS@_&J$*,]2Y]Y85&FGU1^I4U(E0@S\&2GUE1]Y^GSL6LNO.2=.B/Q!]"L4
MF'5>"ZO:O:+H?J@@[JZ.B:NCI4_0:U[/[4KZ34-111[1\4>T475T37@FCHK[
MKB3=554E:0L>!$D)R3=I\SYY`8@Q"KOO1H\*##@PV(,0><<>2GNI`J4S1W'G
MGWJC#1RKK`==KD(AUB4B/-1X>U>TX+J\/:(((.Z(.B:(?HY[4K7M#QW0/0Z?
MY`70>T?'AX47@FCNCNO"8GX,LD-(U4FEHCSI*S,U*33$&(345)>7HLNUUB#$
M&(5N`ZD-9>7J,LLG49$=G(LN^[7'1*W+$&;@33BZ"ZO:O:+H?J@@[JZ.B:NC
MI4_0:U[/[4KZ34-111[1\4>T475T37@FDU.Q.^Y3(\5:A`A05==1UUB,H+>[
M&CP9=UZMR;JN3T/UA`JTG&$5'DX5-%EJAQ>@PGB-3Y6.[3WGY>:>U>TX+J\/
M:(((.Z(.B:(?HY[4K7M#QW0/0Z?Y`70>T?'AX47@FCNCNLQ'<EX;CL]/K"IT
M&7<HCG_1J5=4\[(U5DX*U&IPYN#*5:5@PH,S`F$X3T+G2E%C=^5X*XZ\/2TN
M\5"3=DEA1$BP1=7M7M%T/U00=U='1-71TJ?H-:]G]J5])J&HHH]H^*/:*+JZ
M)KPFHW(EZ9+HZXFM5<?=BN5J55(]7E7I>B0^[*51Y)F=G)*7@R=&@0GI6/29
M2./.S-&CI_U(Q2N0VRDDKS\HQ>"Z",]=/:O:<%U>'M$$$'=$'1-$/T<]J5KV
MAX9BG:'N0S?;%P6_7+3KF,L97SF.^<J8HR!A.]\<;)]TN6[/_C>WM&6L+Y0P
M5<^.-D^Z7+=GUGI[;SZ#(5"G5"DSW@M`]#I_D!=![1\>'A1>":.Z.ZQT6<GD
M1'4BN+$@2,^[(NI6),>B.S]6G8SL"5I$C!BP(L"%ZYB24M%=F**L,I4V_-P6
M*,4I;O*J+%XO:UCT.2]#%U>U>T70_5!!W5T=$U='2I^@UKV?VI7TFH:BBCVC
MXH]HHNKHFO"J/?\`AP7>Y#G)V)!B*[6(@]+5$9&<2!4(7J^BRK4B..Q8<"/,
MT>)`CPYB%7WW>3`=5V`3\NLS*T2:[\(5&"Z$!D2KO:O:<%U>'M$$$'=$'1-$
M/T<]J5KVAX9TZLB0<1]./JY8'HM47I<??9U8/O:MW)%[XBZ-O\D.]HRUFC*&
M=;GMW)%[XBZ-N..J=O!LV[.M#C6S7'/!:!Z'3_("Z#VCX\/"B\$T=T:B%+17
MGXT5V#"<F*G,CT"JO)R9QQ9.:AP)J>[T]48<-R$Y5I6/S9"JPYMY51U*)_U3
M'";5ZGU1UY'G51I+S$&:@/:UIYDK*N]V5%U>UYT)Z,NA^J"#NKHZ)JZ.E3]!
MK7L_M2OI-0U%%'M'Q1[11=71->%0_P"J.Z.IWJQP32:=6!'E(;L*5(D-R,Y#
M@U21B2U,F8T?C47'Y&?AQ'(SCVBZ3$]+2Q27'GGWM7M."ZO#VB""#NB#HFB'
MZ.>U*U[0\,VN?]G[IL9%MK=%MMV$8YN?$74MZL'WM86QY8.5NE!_'GL%,K6Q
M;5E9,Q!BV@9JZ3.$^EKMD=R'UAZKGNLY.\%H'H=/\@+H/:/CP\*+P31W2*K(
M-*3_`,&IJR4D4[LHX)K78:+!H:<V8X561B+$>AUJ=23E').#PGY9)N6HLWWH
M=?G_`%91,;3OGEI18D.$E0F7)Z*Q$=%U>UIU82-D-=#]4$'=71T35T=*GZ#6
MO9_:E?2:AJ**/:/BCVBBZNB:\)S\YYTEO^JJ\$TJ[G<GI%_F2:(,08@Q!B#$
M&(3$O"F87JZJ23S;@066J\T0*/+PSNNNCVKVG!=7A[1!!!W1!T31#]'/:E:]
MH>&;7/\`L_;?<S7!M^S%7,0V]D7=WU8/O:N;_L<\+F_[',.)$@Q+SJ-5RST;
M_!:!Z'3_`"`N@]H^/#PHO!-'=)A62],]&JRLEI5&2S@FM7<[\C07U291&C$&
M(,08@Q!B#$*A2N_$O^O17:)CBMK)PH-*>F$A2<O+.KH+K.U.G4]*+64@W;+3
MTE.NGZH(.ZNCHFKHZ5/T&M>S^U*^DU#444>T?%'M%%U=$UX3\MS84A,<^#(_
MG4N":5UQ$CT5Y'I'L/ONN.S-7CS$3SRMRY!KT)5A34M,(]HN@NKVKVG!=7A[
M1!!!W1!T31#]'/:E:]H>&8'W:8&LGIOG3AZC-BX)Q]OSS59&X'<Y@/>#LCJ>
MR#__``E&[Q=J/O\`8#W@[(ZGL@E:[T4;:C[Y.HC,;E:!X+0/0Z?Y`70>T?'A
MX47@FCNBNNONP%>D9NKK_P"#`1D%P36<=[\I2'^Y/IIV)^IP9)')JN14J,[4
MIB%4[(J-6*]9]<MR%0[<JUQ1J3B^X)5^ETN:IL-='W5><K-GU6I+/XTN276!
M`BS4>1QK<41:/:]2IQ^J"#NKHZ)JZ.E3]!K7L_M2OI-0U%%'M'Q1[11=71->
M#&NRZK(3E-8LYP32O)^5OQ'>6KSKJ/S\E#'JO3G2+7Y1U(LW/5=Z%3JQ*)+U
M2:@3$>4EIDCT&$V3FYB4F5T%U>U>TX+J\/:(((.Z(.B:(?HY[4K7M#QW0/0Z
M?Y`70>T?'AX47@FCNCNM3@O/NS<PDQ*PT9#<$U?1KDK$2%,NJBNOS$"$/52G
M.C];I[I,7`\I#I=2CJ]%KDD[)S4*?EYBC248ORA3"6WB*2Y5&>U?T7075[6A
M4?EY#70_5!!W5T=$U='2I^@UKV?VI7TFH:BBCVCXH]HHNKHFO!-)F4<FG)68
MBRK\*K2[Y#F($832N+WWYJB0XT5*"^^KEOR3H[1J<Z5*7E920H<N["DBO2R1
M92FQUF))XJWM%=!=7M7M."ZO#VB""#NB#HFB'Z.>U*U[0\:9:Q+,67,=J@>A
MT_R`N@]H^/#PHO!-'='=51%2?E'99^'5GG"!4)2(.JCQ&?1R%3)&'.2J4*,A
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M_M2OI-0U%%'M'Q1[11=71->":.DS_P"5J'!-'1->":5;_P`U52+%AP8;ST6N
M3J.NN(\187K"JPI.6@.HZZA59=V)`D8JQI9[3@NKP]H@@@[H@Z)HA^CGM2M>
MT/`;6APXUS^Z5JGNE:I[I6J>Z5JGNE:I[I6J>Z5JGNE:I[I6J>Z5JGNE:I[I
M6J>Z5JGNE:I[I6J>Z5JGNE:I[I6J>Z5JGNE:I[I6J>Z5JGNE:I[I6J>Z5JGN
ME:I[I6J>Z5JGNE:I[I6J>Z5JGNE:I[I6J>Z5J\)J5EYV7RUB68LN8[%`]#I_
MD!=![1\>'A1>":.Z.ZD]"YTM2HO,EG!->":.Z)K4HWF\C;\'ER15JH[+I29!
M9.772N14=E*938*0N7#=(CKJNRR>:5$75[5[1=#]4$'=71T35T=*GZ#6O9_:
ME?2:AJ**/:/BCVBBZNB:\$T=*I"[\O(Q>=*B:.B:\$TI;OG56541)F+%K4[+
M2T*5A+K,/\J#*K,0'I.J0IQXF418-(\@]IP75X>T000=T0=$T0_1SVI6O:'@
M-H_%?B2:E9>=E\OXQ=L2?XT#T.G^0%T'M'QX>%%X)H[H[KPDU\UJ#@FO!-'=
M'=;CBJD&6@I+R]6J"2,"DTQ82/:+I6D?CSDM57Y1QV(Y%<?TG?\`IJ8NKVKV
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ML[$A/S<-]V)#31TJW=\PH_LX31T73@NL^KU0J3D*'!A+I$@PHR0Y:!`5[5[3
M@NKP]H@@@[H@Z)HA^CGM2M>T/`:)/0Z76OW*VH?N5M0_<K:A^Y6U#]RMJ'[E
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M(ZCVBZ"ZO:O:<%U>'M$$$'=$'1-$/T<]J5KVAXTO2]*S?%8[5`]#I_D!=![1
M\>'A1>":.Z.Z\*4G,CS<A+QDDI.:FDC0YJ7B2M&EHKJ<B4@1+AANO)<41Q85
MPR;Y`GI284>UKLTL"5IDD[*2PNKVK^BZ"ZO:O:+H?J@@[JZ.B:NCI4_0:U[/
M[4KZ34-111[1\4>T475T37@FCI5_S4A?^<JZ:35)@32O/SU)C2W)6K(B(CT.
M'$=C46GQC_QJ%.N/.ONQ8KD&';SG_0\3%2F9N-ZOJKJ251?6(NKVKVG!=7A[
M1!!!W1!T31#]'/:E:]H>.Z!Z'3_("Z#VCX\/"B\$T=T=U'U8Y1D3EU6,L.5I
M\%(,K&@0IAR+1YB668G)B;D*4DHLJB(I%D)..3U"APX5(J'GL![6LONQYY=*
MA/N24-V!5IT>B5*FO0XT.8@KH+J]J]HNA^J"#NKHZ)JZ.E3]!K7L_M2OI-0U
M%%'M'Q1[11=71->":.E6AO*Y`BI&@TE>[.)HZ5N$C\D[).U.G0Y^?I:PJ](/
M#M5D'BK5&0F)>2G*J_`<HDW,/2\M"E(5;F5@RM.E$E95=*O+<R%)Q_.9=[5[
M3@NKP]H@@@[H@Z)HA^CGM2M>T/#JC>LO3ZA+QX4U`K]92AR<A-)/246(Y!AT
MJ](-2J'@]`]#I_D!=![1\>'A1>":.Z.ZCR=YVE/K"C5E%[KBH\G"3AN0ZK%D
M9ZF1(%PP51RLT]]'ZM(..O3J0J@LM6Y\DJ-!DWU5$23A^LZ@NL5QV([**])3
MRZ"ZO:O:+H?J@@[JZ.B:NCI4_0:U[/[4KZ34-111[1\4>T475T37@FCI,P^;
M+TF.ZL%]4E*PFCI67T=D*4XKE/5U'DB4V0B#U#I[PE*DI:%;OD!=:J[SZF]H
MND1Q(D.C/*KCVKVG!=7A[1!!!W1!T31#]'/:E:]H>'1Z>Y5+MLFHQ(:W]['H
M'L2])_S.CUBD1*-3I.9<G)7P:@>AT_R`N@]H^/#PHO!-'='=>$RJ2M1J+B1Y
M&EQDC2O"4_\`&KCND66EXX]1J<\.T*GH]4H,*#4A[2H1%AR5#<[LFNKVM51(
M<XN@NKVKVBZ'ZH(.ZNCHFKHZ5/T&M>S^U*^DU#444>T?%'M%%U=$UX)HZ)K4
M)/ED=YRH4ZE1GHTFZ5V(K[[CKL&%&N&'#B>\;@EQPVQ:]*Q(-O.JDHJLX5%4
MA5A[1=%5'4HJ*Q[5[3@NKP]H@@@[H@Z)HA^CGM2M>T/#I#X]NN4BTFJWE-PI
MZW*![$K"^N[MK\CZQI%B3_/IW@U`]#I_D!=![1\>'A1>":.Z.Z\(\O#F84C%
M?DYF619&JD:*D&#0(:J[.U*#(.I<B'O&X.7%+J1)J%/U=J"JTJ;JOR%$>[TB
MNKVM78_,KH+J]J]HNA^J"#NKHZ)JZ.E3]!K7L_M2OI-0U%%'M'Q1[11=71->
M":.B:JB*D6CQ'7H$:=D(WG-8FED:3RHU6F(L>/(R4*2A*B*DS/2$LC_G-5>M
MY5Y?"O0%6%*S#LU++I4YA($K38*P95[5[3@NKP]H@@@[H@Z)HA^CGM2M>T/#
MI#X]J4A"J<C,S<>7IM+F8<G;5`H#]PGN+!*9#>MJ[/!J!Z'3_("Z#VCX\/"B
M\$T=T=UX)I-2$.<2:DYR5(=3J3[B2%2GE>Y-+D:9)/3D0BOR\))NJ0(CRR\Q
M*S'!]U'W*3$64FEU>'%\^J:Z"ZO:O:+H?J@@[JZ.B:NCI4_0:U[/[4KZ34-1
M11[1\4>T475T37@FCHFO"K2G?ATV96:E=%GY.<<G5CUZ()1IV,0*'*0E===<
M=M]KKW"*X[%<>=FJ-&>KL#N2\M'J$==7M7M."ZO#VB""#NB#HFB'Z.>U*U[0
M\.@6X[`KQ6[2E*Q-3M#\YHE(IL.D2!7K:=K<=U%1WP6@>AT_R`N@]H^/#PHO
M!-'='=>":.$2$Y&<D7HDA/$[+>>2L)ZMRD-)6LS@Y;[JK+2<M*)7_P#HC<%4
MJE/?CK!K2N)'J$>?65E'92`N@NKVKVBZ'ZH(.ZNCHFKHZ5/T&M>S^U*^DU#4
M44>T?%'M%%U=$UX)HZ)KP><2)#I\9:?-F@U1JC5&J4M[EU)JC5X/(BHDO+NJ
M+J]J]IP75X>T000=T0=$T0_1SVI6O:'CN@>AT_R`N@]H^/#PHO!-'='=>":.
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M*+JZ)KP32HOJY*T^'RY;A3__`"U3(L*''AO46)#>\SK#@RO.BOUUX@4=]]]U
MUUUWL+H+J]J]IP75X>T000=T0=$T0_1SVI6O:'CN@>AT_P`@+H/:/CP\*+P3
M1W1W4ET\XJ2:.%:A(L"5B<Z7)RE0II_U;4H9RJXX=^O.'FE5G25DH$BY9M:6
M)D#L+J_HN@NKVKVBZ'ZH(.ZNCHFKHZ5/T&M>S^U*^DU#444>T?%'M%%U=$UX
M)I56\F!Y+@GY5Y%;^(JMX+J]J]IP75X>T000=T0=$T0_1SVI6O:'CN@>AT_R
M`N@]H^/#PHO!-'='=2E_E&31PJWH-,>;(]B*]$=AUNXK]E2KWC>4P]!C19>+
M1;UOUYZAUB[YQ15X/Z+H+J]J]HNA^J"#NKHZ)JZ.E3]!K7L_M2OI-0U%%'M'
MQ1[11=71->":5%Q7Y6G1$B2PB_E(+YS4AJC5&J-4:HU1JC5&J-7L+J]J]IP7
M5X>T000=T0=$T0_1SVI6O:'CN@>AT_R`N@]H^/#PHO!-'='=277S>I)HYK6H
MK(4O#Y,`:HU1JC5&J3,M`G(-H4=8MZNHCCK5[#ZBZ"ZO:O:+H?J@@[JZ.B:N
MCI4_0:U[/[4KZ34-111[1\4>T475T37@FG=1YV$^_3)ER)#B.SU03N4^4\U@
M?BO*S@]J]IP75X>T000=T0=$T0_1SVI6O:'CN@>AT_R`N@]H^/#PHO!-'='=
M2I2[SR24]#F'(TS"EG95R)49W\"A47S6_NPJL%5JKH+J]J]HNA^J"#NKHZ)J
MZ.E3]!K7L_M2OI-0U%%'M'Q1[11=71->":.D6!"CNO49Q5EI"!+*CRH=Y#O.
MG>=.\Z=YT[SIWG3O.G>=.\Z=YT[R"O\`%[5[3@NKP]H@@@[H@Z)HA^CGM2M>
MT/'=`]#I_D!=![1\>'A1>":.Z.Z\(U+@1EAT>$ZKCKL-WOG?0[Z'?0[Z'?0[
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MDW%145/&]`]#I_D!=![1\>'A1>":.Z.ZB+V&C5&J-4:HU1JC5&J-4:HU1J]A
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MO'>.\=X[QWCO'>.\=X[QWCO'>.\-7B]H+J\/:(((.Z9G])G_`$SMTCTS&?LK
MQO0/0Z?Y`70>T?'AX47@FCNG8[RG>4[RG>4[RG>4[RG>4[RG>4[RG>4[RG>4
M[RG>4[R]E[1=#]4$'=72_/B#\"B^B_\`I,E?2:AJ**/:/BCVBBZNB:B:"*WP
M7056\%U>'M$$$'=,S^DS_IG;I'IF,_97C>@>AT_R`N@]H^/#PHO!-'>"*SMW
MC57Z-08<1R+#_%5>#VBZ'ZH(.ZNE^?$'X%%]%_\`29*^DU#444>T?%'M%%U=
M$U$7\N'>&^`S]5DZ<1+NB<R6FX,[!XO#VB""#NF9T7SBH(J3O;HZ*LWTX-FM
MN[D;3W!]/3*6*$5%=7QK0/0Z?Y`70>T?'AX47@FB:\$5@U!J#4&H-0RQ.]V3
MLV=\^MEJ#4&H-0:@U!J#4&H-0:@U!5;QO2H/4ZW)68<FY0_5#8SM5D=VF6=P
MG2'R?8\.NV]7K5J]]NO+<7&[\=WY8$*5QY?<[8O&C(J2C%]U"5])J&HHH]H^
M*/:*+JZ)J(K/!:C-/SDX6K+1'88J\%U>T0C34O*H]=,B[&@Q(<6'>%NT^X::
M]CNV7CY<VN?+FUSY<VN?+FUSY<VN?+FUSY<VN3..*"]+[5-Q]\[4)G`>[W#^
MX&!N#V18ASPF=MJN7MOTWPC3DM`)>HP9B)XPH'H=/\@+H/:/CP\*+P3016]J
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ME6;_`)R,L"755>5&MEDBI`[$W/.2JOU2:>>E9J'-.>**!Z'3_("Z#VCX\/"B
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MGIO0A[:K2W#;[<LYP[/<<1[M3]/B/1(-(>(,&'`<\44#T.G^0%T'M'QX>%%$
MT$5GX,6##CP_PIR;@R$KV;\DUG;9ILHDC3UX(=,3<#C?`&=-Q'5]Q]:B9DW#
M9CW`5J_9B*]<JS,PJ^<3!YQ,'G$P><3!YQ,'G$P><3!2HT2-+<^+[MDKZ34-
M111[1\4>T47@BMXM&H-0:@U!J#4&H-0:@U!J#4&H-0:@U!J#4&H-0:@U#O=A
M?S5!!!W3,_I,_P"F=ND>F8S]E>!NO.O>)*!Z'3_("Z#VCX\/#VBB+Q_-#O#4
M&H-0:@U!J#4&H-0:@U!J#4&H-0:@U#(TZDM;-OSJ5"B-0:AWC\U'W'8C@\O!
M!!W5TOSX@_`HOHO_`*3)7TFH:BBCVCXH]HNB\$5GAJJW@@@@[IF?TF?],[=(
M],QG[*\!CQG($*+.3,8E9J)*OPWTBP_$5`]#I_D!=![1\>'A1>"*WP2:J$A(
MID2X*?5EL*YZ5*4:7FI6;<["JS@@B"#NKI?GQ!^!1?1?_29*^DU#444>T?%'
MM%%%X(K!%;^%H+4Y!(WXN@JMX(@B""#NF9I2,KL[3IJ),^JYX]5SQZKGCU7/
M'JN>/5<\>JYXILA,0)C&\O%A43P&K(\LJ2SBQ(Z(B)XBH'H=/\@+H/:/CP\*
M*G%'O`JI1H%6<G<60GUN"VI^VXMO694KBEZ?C&5EGY"0A4^#P5[BGY""#NKI
MD&1CP+G6ESS?5<\>JYX]5SQZKGCU7/'JN>/5<\4N4C08/FD;U`2OI-0U%%'M
M'Q1=%%%&<6J=Y3O*=Y3O*=Y3O*=Y3O*5>IQ9R9+?GIB9@=Y3O*=Y3O*=Y3O*
M=Y3O*=Y3O*=Y1J\4$$$$'=*G2Y&LR,7"U/?B?).5$PC*J?(^5'<+2JS4]B>7
ME)GY80#Y80"5QI3X<6!`@RT'P%YUU]URDP'7X<*'"=\1T#T.G^0%T'M'QX44
M49V&J-4:HU1JC5&J-4:HU1JC5&J-4:HU1JC5,G2BQJ-9DHLC;35&J-7L(@@@
M@[JZ7/9=(NMQ,)RHF$I51,'RJDUA65EY>>PQ+2DM\L(!\L(!\L(!1+%IE(F.
M$KZ34-111[1\44449P9Q8,&#!@P8*C4F(+T"/"A1(S](EXTM(,&#!@P8,&#!
M@SBP9P00031!T31#]'/:E:]H>$JJ(D:HRL$@QH<>'X?0/0Z?Y`70>T>%%044
M8,&>"7'37JO18,)R!"[#!$$3@@@Z.CHFKHZ5/T&M>S^U*^DU#444>T?%%&"H
M*@J#!G!B#$&(,08@Q!B#$)RF2<\]!EY>7=8@Q!B#$&(,08@Q!B#$&(,3BP8(
M@B"((((.B:(?HY[4K7M#PFK3#W>*8]&28\/H'H=/\@+H/:/"BB\&#!G!GX<Q
M5T@W/^(P8,$$0000=$U='2I^@UKV?VI7TFH:BBCVCPJ"BBH,&#!BC%&*,48H
MQ1BC%&*,48HQ1BC%&*,48HQ1BC%&*3<_*2*1+I@)%@1H4S"8HQ1@P8(@B"((
M@@Z)HA^CGM2M>T/":M`>2*Y#?B+3I.++KX?0/0Z?Y`70>T445!14%09P8,&#
M!@P8,&#!@PK%8Y>16#!@P8,&#!@P8,X,X(@P01!$'1-71TJ?H-:]G]J5])J&
MHHH]H\**+P8*@P8,08@Q!B#$&(,08@Q!B#$&(,08@Q!B#$&(,08A4YM^<G"U
MX$=V&Q!@P8,X(@@@@Z)HA^CGM2M>T/"7G77W7(;D-WQ!0/0Z?Y`7045!14%&
M#!G!@P8,&#!@P8,*Q=[]*)S*-8BDQ,1IJ9D\GUN`E'O9^JCJ]YU@P8,&#!@P
M8,&#!@@B"""":NCI4_0:U[/[4KZ34-1111114%&#!G!B#!@P8,&#!@P8,&#!
M@P8,&#!A7*;%DIJ3H%0FEIM/<ILLP9P8(@P1!!!!!-$/T<]J5KVAX[H'H=/\
M@+H****,%05!@P_(_(_(_(_(_(_(_(_(_(_(G*/2:@5>C)`NN3H5&IY^1^1^
M1^1^1^1^1^1^1^1^0P8,&")P00035T=*GZ#6O9_:E?2:AJ*****@J"H,&#!@
MQ1@P8,&#!@P8,&#!@P8,&#!@P[K1@P8,&#!@P01!!!$$T0_1SVI6O:'CN@>A
MT_R`NBZ***G!@P8,&#!@P8,&#!@P8,&%2HW-R.P8,&#!@P8,&#!@P8,&<400
M1!T='2I^@UKV?VI7TFH:BBBBBBH*@P8,&>%L&#!$&"((((((?HY[4K7M#QW0
M/0Z?Y`45!4%%05!@P8,3\9Z7@O3'XS.*((@@B"#HZ5/T&M>S^U*^DU#44445
M!G!@P9Q8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&<&#!$$01!!!!#]'/:E:]H>
M.Z!Z'3_("BBH*@J"H*@P8,48,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#%&#!@
MB"(((((.E3]!K7L_M2OI-0U0445!4%045!@P8,&*,48HQ1BC%&*,48HQ1BC%
M&*,48HQ1BC%&*,48HQ1BC%&*,48,&"(,&"((@@@A^CGM2M>T/'=`]#I_D%T4
M445!>#!@P8HQ1BC%&*,48HQ1BC%&*,48HQ1BC%&*,48HQ1BC%&*,48HQ1BC%
M&*,&#!G!@@B"#I4_0:U[/[4KZ34-4%%%%049P8,&#!@P8,&#!@P8,&#!@P8,
M&#!@P8,&#!@P8,&#."((G!!!#](:MJE:]H>.Z!Z'3E;!45!1114%&#!@Q!B#
M$&(,08@Q!B#$&(,08@Q!B#$&(,08@Q!B#$&(,08@Q!B#$&(,08,$3@@P01!!
M"IJR0K7L_M0GN[%JJ]R`@HHHJ"H,%08,X,&#!@P8,&#!@P8,&#!@P8,&#!@P
M8,&#!G%@P8,$00004E5[]0JSW>J'CNWU_P#*4Q6+^BBBH*,&#!BC!@P8,&#!
M@P8,&#!@P8,&#!@P8,&#!@P8,&#!G!@S@@@@A6%_\G6WF2';FT\ZI4E&Y\JH
MHO!1@P8,\/8,&"(((@@B"(//(ZE(;$@S;_-FO'=O1/\`J@/<FKBBBH,X,&#!
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M8@Q!B#$&(,08@Q!B#$&(,&<&&A,3$*7AN.QZU,5">AT^`\JO+^%3JB_(OQH$
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MIWZ*=^BG?HIWZ*=^BG?HIWZ*=^BG?HIWZ*=^BBU&EP$BW!`=)FKSDPFO^AH4
M:+`>@5Z9<(5=DGSSJDQD[]%._13OT4[]%._13OT4[]%._13OT4[]%._13OT4
M[]%._13OT4[]%._13OT4[]%._13OT4[]%._13OT4[]%._13OT4[]%._13OT4
M[]%._13OT4[]%._11(]'A$2MR,,CU^.\1H\:8>__`&?,C1GYJ'[O03W>@#]O
M052:EHLI&_VGEU[DGYP><D*-WW[B=3O>'[-^EYB[<5MBW(]-W<=MW_V'<]`:
M^I_UDFKRQ[B\0=+C[$S<CTW=N.X@W(]-W<=MW[.&L&95W!73<5O5RTJ]>F%L
MG8\K2=+G?6\B[>,QIFFYNG!O8M&EQ(<2#$V\X0N'<3ES'^![^S1DVZ[5N.QK
MDO[$^0<7RO:PCM"W%;C:+F'9%N@P'9V%MGU:RGC+"FT^Z<UW/!VD5&LSW8P]
MA/)^?;PR1L.W<8EM[\"@]./>A<]K9"QM?N)[HR[@6X\.VMQQ;@6X\K8^[&;L
M!5/#E%_T@YZ!"<[SJPE0E?2;B\0=+C[$^/6#QMMBM:@<>F!6*G;V0=\%OT3/
MV+=YWU]WU[*]Z&6MU.P.F5RB[_,-[4=Y=M[X]R%S4>\]P.QR62S-O_2XG9RF
M9QWE4FF;E\&;[I>2FZ3CS''3@OV_;*VPR3V]6D[;]A-#R_CK9#6KJW,XYPCT
M_P#<7=MV6Q6;)NK:1C#)V8>G+GW;1N>P#2+\<V-N]/O:$YM8387M7]PO<S&.
M![1O7:EMPP/:68;`C;5;:R)M;W9X.QUMUK727[_[D>EK*9YD=QE/P?C#(&#=
MN&![2S#8&,=J^WF=VL5;:)L]N7%.9]NV`*WMKQAM6V]3VUG*.W';_>>V\W;[
M:MS^;J3U/YVJ4F:WQN/Q,.WCMWVA;6(6;=E$.B7K>>'.G=BV]MHLE!@[=JKL
MOMJQK)KF&NGSCS)&.ME,FN_C/V.]I.*[2F(/S)Z5O^D'/0)/\R(YW7);TJXO
M$'2X^Q,W`[P<`;9Y'<CU=,WY2*A4:A5I[CTV?BKI_97MB7N7J"6O-V/NOZBF
MU[<5D7>/L+M"Z+"W^1]M6^V=W:=2ZY<>W7O$V>/)<.RWIC?638!F6VK4O[?1
MB&A4K/M.HF:,>;Q__F2__OZM>9I=U[Q-FFS[<!:FYW<3?E,RCGG;I8=Z9*Z9
M5][;,_8PH&5/^U1M;_[?>QGZ-[,[0K&7=G.U_;SE'$&VC9G=].V$84WZ80F<
M59KZ2$S'DMR^3-X6YS,-$V9VA6,N[.=K^WG*.(-M%]_]KFCJJ]*#%?\`VJ+<
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M%7HD2)&B;C<UV-7\+_Z0<]`DU8/OM=EO2KB_VH<]`AO]UWFDI^<S<7^U$-&R
M'<?0[CY)NJD:XO$+S[KG^P\HKL63\W0\V0AP4<>N&(ZL3Q!>%2]7PT5%3_86
M4J,S)IZ_G#U_.#U>G7DB1'XK_B"_9QV/5*#-NSM([,W.RLC#<?<B.2\U+S21
MZA)2L8F(\.6@2]1@1J?+3,O.079J7?F.U#J$E&FN,Y/2E/@SM0EY!X?GI2'-
M\5GI1)PCQ>1`D9R#4)3_`&%J<I6IA*G;MX129E9F3C4VA5V;2F4:[X!`=C.0
M^-X0W(TI;D:+)1[4\C491^N1*7.NU&GW?$?]67"X[#M^AO/4.?DOBR+.W(^M
M/J[E1I,M7JW4I2!<,I$HC]6N*'+.566B4J!`BTIVN5-:1)35>K$I!NR///Q*
ME/3<O2;MC)+I,5VL4\F)R$[7:C6(\&=EZS/0*A+1ZZES>=N^\$W6)U^H4V9G
MH[EKKR(G^P^0I;N3M+EO,Z;V;K\C<LK%AI1ZHY*6_1Z1792G6JL20CW?_P!$
M"Y?84W3%JENVQ/OU"L2$T]5I.U?A:U?A]8,6+9LS7*5ZL6%,NVY4*-7)NG3D
M^M0L^ZOA^X51RGW7&@QZ/=L9R72Z:E(S-#BPWH5R.QX5/N^LQX-1K4&-!EKP
M>5'KRI4>#3[@EIZ4G'K=_P"NK?ZAN>^YFG5#YC7`?,:X#YC7`?,:X!W(U?1;
M>K<&OT[P^Y*8M2A]J/+2\RBHBHE*IKL`\UEDF:U3TJE,DW(DW3'''(;D*3E(
M$9ZC4I^9A2LO!A0($&6A0)67EH;M"HSD9Z5EWY@]64_EQX$&9A1I26F(#E*I
ML.6BR\".L&CTN7F'I:7?CS4E*3T.3ITC()-TNGS[R2LLD><ILA4$2!#D).WJ
M?%IU-_U#=ZJE6YT4YT4YT4YT4I,2(]-XS]E?[2W)2*I4*Q[C7.>XUSGN-<Y[
MC7.2EI7!(1,:./)2/]I9FO4*GS/O9;A[V6X>]EN'O9;A,75;3TO1(E,BTO\`
MVENZ(^[6?6LZ>M9T]:SIZUG2G3\S,3.-'E6D>((TQ!@.N/N1'/\`8.[T5ZK^
M:31YI-'FDT>:312X$>'-XS]E>'3<PD""_/3,6$JJJ2DY$EWY>8AS+G^P5R6&
ME6G?EG5CY9U8^6=6/EG5AS&=35ZAT:6H5/\`#IN*D:8X0(7.C2\O#EH?^T]1
M@O.3)#AQ(JP*7&5?]J'W'8CD&F2\)77''?\`]$__V@`(`0$``04`\/BQ84O"
MSEUH9VEU;:5U8<ITS*-#KE&N:C?ZKE+IMV?N3QYU5[LK]K[,RW:7!KEP82Q5
M2<'XF_U7L-WM/9/Z_/CS/>&;;W"8B@=)7=1/Y8VY=)3"&)9S_5>7LUXJP-9O
M23WCO6'UDZ'7Z%<]*_VDBQ'(,/`V?\.;GL8ER4ZJU>@[U.EUUE,VN[HN@7U?
M<:Q<?8_O3*U\[3/Z]O6SI%8V3[%>IE@J+XVV2[A,L7%G;_5NS]NP_JC\8L*%
M'A='/9A%M'^P9XXWW=S:UO5_U;UHL,WO5]O&!\T61N+POQVQ[)GL3]6_QQO&
MV^4W=/MDZ9.X2I[BMH'^K)F6EIV6Z5$W'V?[B_'N+O\`^$3JM=G*6X/"F%:?
M@_J2;;L\Y1_U-UC;<K^`*O;-R4"\[;[-[7A0\>V9TR=T53WG[#O$.2=V>VW$
M<:\>L#MHH428ZU5H.QOYJ[8/YJ[8/YJ[8/YJ[8/YJ[8/YJ[8/YJ[8/YJ[8/Y
MJ[8/YJ[8/YJ[8/YJ[8/YJ[8/YJ[8/YJ[8/YJ[8/YJ[8-_O44IV=+2HO7!LVO
M4C^:NV#^:NV#^:NV"N=:ZEN4:^[UN#(]Z2<Y-TZ<PUUBZY:F-OYJ[8/YJ[8/
MYJ[8/YJ[8/YJ[8/YJ[8/YJ[8/YJ[8'.M7:JO6OUD-OE3CX[WS[4,H1H46%'A
M?Z'N^^K)Q_2[[ZH6S^R4K76CQ?`?_FKM@_FKM@_FKM@_FKM@_FKM@_FKM@_F
MKM@_FKM@_FKM@_FKM@_FKM@_FKM@_FKM@_FKM@_FKM@R%U;L6Y4L+I;]72>V
MZ8._FKM@_FKM@_FKM@_FKM@_FKM@ZI/6@I]=V#?U^NJM+[>]E_\`-7;!_-7;
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MNK?V=;QZSM`N:R^N+M/G'\6[U-IF6I+YW[;SYW[;SYW[;SYW[;SYW[;SYW[;
MSYW[;SYW[;RE9WVEP5D<J=.JY'Z5MBV"9EAW]T]]WN"8N!NJKGO%,[M]W487
MW,43\6][WM3&]J;MNHEE'<Q4\1].BS,:69E'J8^Z]`E,19_S=5K6V76U*N2.
MV7"TD[!P=B6`Y\E,4'R4Q0?)3%!\E,4'R4Q0?)3%!\E,4'R4Q0?)3%!\E,4'
MR4Q0?)3%!\E,4'R4Q0?)3%!\E,4'R4Q0;G,:V'A+.'R4Q0?)3%!\E,4'R4Q0
M?(_$G?\`DIB@^2F*#Y*8H/DIB@^2F*#Y*8H/DIB@^2F*#Y*8H'\(XGB.3NV[
M"\ZE=V9X_G7;GVW9@QQ.8/ZFF6K(E[EV<[7=XUJ8-W2;C]A]_P""<^XTW%V+
M_H'>QU%[2VY/8FV[[G^H!D&L9*V0]/J-E'<KNKW@5>SMF=SSY1]I>'J=#E=O
MV'I-?DIB@^2F*#Y*8H/DIB@^2F*#Y*8H/DIB@^2F*#Y*8H/DIB@^2F*#Y*8H
M/DIB@^2F*#Y*8H,R;2,*9EQ5TWTM+)>!_DIB@^2F*#Y*8H+BVQ[>KOE^LQT[
M]N.*]K_0]V.X4W-.VGM*VRV)#^2F*#Y*8H/DIB@^2F*#Y*8H/DIB@^2F*#Y*
M8H/DIB@F\!8@G"M;3L/55+NV75:6=L7-&ZC:/6*9N5V9[XI/<'M"SULDN?8K
MU):;F:+^'=%T6_95N;KMUV4-\V4+:M;`G2WQ]=UX9YWH9-Q7MSLC'4)V&)#$
MAB0CE'*.4<HY1RCE'*.4<HY1RCE'*.4<HB\N!"RW9]F[I]O>,,^SMS;"]J%!
MG*#MJY1RCE'*.4<HY1RCE'*.4<HY0L,6&/0S(V%[$R5+5^S<O[7;TL7*N$^I
MWC>U[HW!=.?<%A7,ED9[QQX_ZA&^^#MRI&S+9E/;@9_=WU!%O.D8>VGS]92@
M6U0[8IKL,2&)".4<HY1RCE'*.4<HY1RCE'*.4<HY1-U>B2%3RTZ]M'ZC.3:O
M7:YUC>4<HY1OGQ,N:MGO0QQ7\OM@/*.4<HY1RCE'*.4<HY0L(6&/0BJ4>FUF
M2S!M*@O.;0M^5UX`C[SMD]O6U;W3=W\5'*\7\+JP[LIJY+GP)9EE=.G;O2J;
MDS=CEJS;+MZQ:$Y#'88["$A').4<HY1RCE'*.4<HY1RCE'*.4<HY1RA^7=?=
MO#;KD?;G<>4]P=NQZI1:++T*C<HY1RCE'*.4<HY1RCE'*.4<D6$/0AZ&/PRK
MT>FUNGYIPY6\(7)9UR69U2]ONQS<7=6SW<"X^[$=\>[I=PMN[9<.[5<!7[OM
MW!;_`#>)+90J&W;;U`LR6<ACL,=ACL(2$<DY1RCE'*.4<HY1RCE'*.4<HY1R
MC=ILTQ;N]M?=->6<K*P7TML^5#>5OJY1RCE'*,3XMM;#.-.4<HY1RCE'*.4<
MHY1RA80L(>ACT,?AF>-OU,R3([(=X%:VKWQOJVR1-K^2MD.ZNF;J,1_@;O,\
MP]N&`^G=@*#G3,&ZO.MR;T]QF.\?T''%LN0QR&.PQV&)"$AG*.4<HY1RCE'*
M.4<HY1RCE'*.4<HY1RCE&:]EF(<TW_RCE'*.4<HY1RCE'*.4<HY1RA80L(>A
MC\,?AC\,K]"IEQ4E^9OO:'GGJ&8[M#-F+NEQN!B9AV_>/>I/G*L;@MRVYZZI
M38CM.VHX6@3$.'#'(8Y#'88[#$A"0CE'*.4<HY1RCE'*.4<HY1RCE'*.47;9
MEK7[;6T+IX89V49'Y1RCE'*.4<HY1RCE'*.4<HY1RA88L(>ACT,>AC\,B0S=
MAAQ*S3MA&2;=W.8>VC9-N#9IO!_`ZQF8INMY-W`5)W:5L"V>8TA25(A.$-P<
MACD,=ACL(2&<HY1RCE'*.4<HY1RCE'*.4<HY1RCE'*.4<HY1RCE'*.4<HY1R
MCE'*.4<H6$+#'H0]#'X8_#(CA$<-RV-X5]8[Z9MX4K)5O[`\@5G;7O/\>;E<
MIIA3`O3&QK3KSSU?EWUW=]NBIE.E*9)0W!QP<ACL,=AB0SE'*.4<HY1RCE'*
M.4<HY1RCE'*.4<HY1RCE'*.4<HY1RC:CN"H6Z7"_*.4<HY1RCE'*.6+#'H8]
M#'X9$AD1PF8$.+#N)VX]K&X3J>VQ;=V538GER-FC:WV[O1=T'4)W]7].9UWF
M6U09"VJ'"<(<,APQR&.PQV&)"$A'*.4<HY1RCE'*.4<HY1RCE'*.4<HY1RCE
M'*.4<HY1RCE'*.4<HY1RCE'*%A#T,>AC\,B0R)#(KA&AHJ/5JI[8=T/4IM9;
M`W?8[NJ%?>/_`!WUC+]>H6!;;GG,&]+3999L)R2A.$-PAPQR&.PQV&.PQ(1R
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MUOP[GL?IR59VH7UTAZ[&I6ZSM9PFXU/PMLGF/,(FRF2=B7W`=(+A"<(;A#AC
MD,=ACL,2&)".4<HY1RCE'*.4<HY1RCE'*.4<HY1RCE'*.4<HY1RCE'*.4<HY
M1GG+5-PCCF],F9`R+%PUF:[\)79:E:2ZK5>AC\,B0R(X1'"*X1W3>S(.OV-?
M\3UKL,Z7TZ]-;*O'?62^YW?E4_/[_M2321MV"Z0G"&X0X8Y#'(8[#$AB0CE'
M*.4<HY1RCE'*.4<HY1RCE'*.4<HY1RCE%0I%/J\EE?I>;`LT'5)Z).W+;=MB
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M<(SA'=)E":-['TPNC[`^EG]F/COK)?<[O.^K$J2NLNA`=(3A#<(<,<ACL,=A
M"0CE(<I#E(<I#E(<I#E(<I#E(<I#E(<I#E(<I#E(<I#E(=,3=LFZ^5Y2'*0Y
M2'*0Y2'*0Y2'*0Y2"PAZ$/0Q^&1(9$<(KA&=)A":)HVI??WTL_O.[6??H3LW
M]G[(OBN4)0ED_*`Z07"$X0W!R&.PQV&)"$A'*.4<HY1RCE'*.4<HY1RCE'*.
M4<HY1D"^;5QA:&5NIU196%M)W847<10^4<HY1RCE"PA88L(>AC\,B0R(X17"
M.X3"$UK-&]CZ871]@?2S^S'QWUDON=WG?5B5)365(#I!<(3A#<'(8Y#_`"=A
MB0CEG*.4<HY1RCE'*.4<HY1RCE'*.4<HW4Y4AX'VT?U?\OQ:5N(Y1RCE'*.4
M<HY1RA88L(>AC\,?AD2&17",Z1W290FR:-J7W]]+/[SNUGWZ$[-_9^R+XKE"
M4)4EW2"Z0G"&X0X8Y#'80D(2$<HY2'*0Y2'*0Y2'*0Y2'*0Y2'*0Y2'*0Y2'
M*0Y2'5"R/5XU^&R;&%8R=N"Y2'*0Y2'*0Y2'*%A#T)@_#'X9$AD5PC.$=TFD
M)K6:-['TPNC[`^EG]F/COK)?<[O.^K$J2FLKI+(0'2$X0G"'#'(8[#$A"0CE
M'*0Y2'*0Y2'*0Y2'*0Y2'*0Y2'*0Y2&2*_=UIVGNXZJ?5OQ*FZ#JX=07=#;6
M#L]9?VUY%VH=<?J]7M-[2MRV\'-:<I#E(<I#E(<I#E"PAZ$/0Q^&1(9$AD5P
MC.DPA-:39-&U+[^^EG]YW:S[]"=F_L_9%\5RA*$J2J-2`Z07"$X0X8Y#'88[
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ML#Z6?V8^$]8NY*W5]UYTEL*VME+<5X?UDON=WG?5B5)365TE=95&I`=(+A"<
M(<,<ACL(2$)".4<HY1RCE'*.4<HY1RCE'*.4<HC2D&9@]`S:'&VR2G*.4<HY
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MN$9PCNDR=4+\]_?X&>'74GNEQ%BQNGQXWZR7W.[SOJQ*DIK*Z2NLH2J-2`ZU
M(+A"<(<,<AB.HG@F[S:#NBS^;I?Z\G5'NJJ;A-N>:=JN4-JG15ZA6[2S-H/1
MCZEN$86-;4N>RK15$4?AD2&1'",X1W2:1A-:];/Z_6A\)]O.3KJVKYW-?P+&
M??H3LW]G[(OBN4)0E24)725UEW?R@N$-P==1U!@SP=@S@J(J17",Z1W281B3
M6O5!^_S\#/'I?2T_[>W@,6+"EX67NLK@ZU'=EW5;7+M\>(^LE]SN\[ZL2I*:
MRNDKK*$KI+HU(#J$)PAN<6#/!/[3V%9JF;E]LF)9?`NW(9Q?<0BN$9TF$)HF
MM>MG]?K0^$^WG'X3_P#@:,^_0G9O[/V1?%<H2A*DH2NDKK+(0'2&ZQ!$\-?1
MJ1G291A,Z36O5!^_S\#/'I>T;>%MTVC]-[#N<,2;@;,\`ZL&7:]BW:X8XLB>
MR7D#$MDS>-<7>(NLE]SN\[ZL2I*:RNDKK*$KI*Z2[I!<-!$\'ZG.SE[=M'[%
M?RU9]M98(SA,.ER5JD6U1<,;U-K6Y"I36O6S^OUH?"?;SC\)_P#P-&??H3LW
M]G[(OBN4)0E24)725UE=)=&B(Q$[#!@P8,&#!@P8,&#!@P8,&#!@P8,XKPF'
M3)^<L28HE\-;EL4[@(,UKO'Z5>YO==NWENC!U#X4O_#'U"#^&/J$'\,?4(/X
M8^H0?PQ]0@_ACZA!_#'U"#<OTC-_]CS_`%#>DIG.Z<%8IS-N$V@90V3==?$N
M620J$A59'\'.>Z3!&VZ%?'6VH,O<.*<JV+FNP^&\?;I%W28)LO8ANTON\MJ/
M2*IN-KE\1]9+[G=YWU8E24UE=)764)725TED:0D8B=A@P8,&#!@P8,&#!@P8
M,&#!@P8,&<=^F\2%8?\`8*4BHUV91B[_`.+%@[*Y&>G:9.;8NL?N$P\FX*WJ
M'U:\DT'HH=0VBTK^&/J$%=Z0&^ZV*+0LHOU_,&[^A9%V8Y&VY=/;=+NNQ7_#
M'U"#^&/J$&Y?I`=06SK`_C$R3_#&9]^A.S?V?LB^*Y0E"5)0E=)765TENPB>
M$JG%3>KG>>V_86CQXTS&QK=][V)>^Y/,61<0[1[0ZX>\ZRH?\_F^@_G\WT'\
M_F^@_G\WT'\_F^@_G\WT'\_F^@_G\WT'\_F^@_G\WT&ZO?\`Y)WCRILWZENY
MK9?.['=]F,]]&/A51U,S]93"MFQ]G/5FBY.OQ%1Y..^'.->SKN/.BSB[)4B[
MXHZR7W.[SOJQ*DIK*Z2NLH2NDKI*CB,=3@P9X1.SDE3I3+_5)Z>&"C?WNTA[
MA>H7@OK1=-C.U,MRZ[7O6C36O4#^RKA3JE4*//[,^OYNFP`;:-Q..=U^#]W.
MV.S-X>W[=7M=RKL[S7(R5PWC7^C_`--J:V%8?[.??H3LW]G[(OBN4)0E24)7
M25UE=)71.")X6J<%.I5B>X,EX-1%5=H^UC.54R3F+%]J9HQ[B?HU[#;KC?P1
M[`3^"/8"?P1[`3^"/8"?P1[`3^"/8"?P1[`3^"/8"5#HG]-BDUR]>BYTSL;V
MQO,KO3SI,]BO$>3<WWGLIZ"%LVXEK6I;%C6\=5O*M=Q?M0+'M2<OR]<16-,8
MQQ7QZEFTF\L)YHP=TP=U&8IG:/M=MW:1BOQ1UDON=WG?5B5)365TE=90E=)7
M24'?\>">`]-S=^N[66[>[;HK[1-XLYF+^J-4G'MP.$+TVUYMP;_5:S7<M.VQ
M?U[]F6VBK2%)E:#2>H']E7#'^.;]RO=FS/\`KBWW<YAO#N-]O^,=[&X:O[5M
ML>9\R9)W#91NVS;XQC=/0VWTYBW>X%X5^ZK8M.!PS[]"=F_L_9%\5RA*$J2A
M*Z2NLKI*Z)P3BSP5G844F-+8V^85Q_<4SI-:]7O+%UWINOE<$R?(^1-)/D32
M1_`\@KWR'E#Y#RA\AY0^0\H5FF7'AV[NIO)[LMX>`-E?0NS5F5[;YMCP9M;L
MWCNWV_\`[G,$6UL+W8W9D+:WT@*18E<\7]9+[G=YWU8E24UE=)764)725TE!
MW_$3BP9^+N1RM+X)V]?U5LUQI7.G98,X]3?:"]=_]A(?TF]=_,I-3VS"Q<?W
MQDZY=L?0^O"MIU2[5L7;K#MO#$O5:-\B:2?(FD"[;J([/5#;E3:@]"P%(0(?
MR'E#Y#RA?F.8UDP/Y#LN_P`&)GWZ$[-_9^R+XKE"4)4E"5TE=9725T03PU12
M8TFR9TFM>J#]_GX&>/2^EI_V]O&_62^YW>=]6)4E-9725UE"5TE=)0=_Q$T$
M3\7)U[5C'MG[P.O?NEV_)NUZ[6_K>!CO:_NGSALXRUMQ_LT[XJQ6=H&]_+.Y
MQ.RJ<,L[2X&1-^8_I-ZST*%'AV-AS$F(H$UKUL_K]:'PGV\X_"?_`,#1GWZ$
M[-_9^R+XKE"4)4E"5TE=9725T0343L,&#!@P8,&#!@P8,&#!@P8,XKP44F-)
MLF=)K7J@_?Y^!GCTOI:?]O;QOUDON=WG?5B5)365TE=90E=)724'?\>TP8,&
M#!@P8,&#!AU1M@6W'-NSC^NOM,QMNAWJ69C^Q,<TA@P8,["\7])O69)HFM>M
MG]?K0^$^WG'X3_\`@:,^_0G9O[/V1?%<H2A*DH2NDKK*Z2NB":\43P54["BD
MQI-DSI-:]45%A;^77G7G>WG>-">J/2^DYF1Z??C?K)?<[O.^K$J2FLKI*ZRA
M*Z2NDH._X\$\`FY26GY7^O%M(F=MD'\!>+^DWK,DT36O6S^OUG/NOVEV\YQH
M3ML^IZE_`@9]^A.S?V?LB^*Y0E"5)0E=)765TE=$$UX)X.O!=5%)C2;)G2:U
MZF'3PN[/UQ/[3=[='5[;+O9='MMN])TN+#>ZNT9.-C'<O+VO9>TS?=D:W_V)
M]1\_8GU'S:YT7=Z&X6_[#LJW,:V1XWZR7W.[SOJQ*DIK*Z2NLH2NDKI*#O\`
MCP3@GX]JV1:UDN?@+Q?TF]9DFB:UZBVR6:W8VE-[/=ZUHS+VVK>HZ/;<=YSI
M1,7;FKEN>R\2[HLC7!^Q/J/G[$^H^?L3ZCYAWI(=07/5Z?QV8@_8*9]^A.S?
MV?LB^*Y0E"5)0E=)765TE=$$UX)Q9VLB9*L7$UKW[U5HU3K\EN[ZE%37^1W=
MC9D2WNKUC&9=P1O!P7N'B]IG!>"ZJ*3&DV3.DUK,DUI-:S1O8^F%T?8'TL_L
MQ\=]9+[G=YWU8E24UE=)764)725TE!W_`!X()Q9V]P'4*P;@V=@]0#>QD99C
M>EU$+8A4OJTU:BQ[,ZJ6VVY)^B5RC7+2>RSBHO%_2;UF2:)K6:UFM)LFC:E]
M_?2S^\[M9]^A.S?V?LB^*Y0E"5)0E=)765TE=$$UX)P3LY9RE:F%\>Q]ZV]+
M<I/6YT_=R^;KIQGA[&.':-PN7&&-;S?W7=.V@19#I_;J*AN$Q[^"NJBDQI-D
MSI-:S)-:36LT;V/IA='V!]+/[,?'?62^YW>=]6)4E-9725UE"5TE=)0=_P`>
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M0ZKMHT6L;?\`9KG&T,IX.8@Q!G#^S'NBJV'+KMROTJZ[>%%XOZ3>LR31-:S6
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MK2:UFC>Q],+H^P/I9_9CX[ZR7W.[SOJQ*DIK*Z2NLH2NDKI*#O\`CP03BG'=
MWN8MO;?B]S;S(T[9WT][(E[*VI<>K+CV4KF$]LEZ1\@[?.J1<M=O6_;WQU1K
M4VO](^MK-8+-_4&''VB;9>FQL:W=;7<P_P!7'9+>*]238?<73IW,;"?ZV%)W
M([?\0?UX>E_BHQOB['&'+07B_I-ZS)-$UK-:S6DV31M2^_OI9_>=VL^_0G9O
M[/V1?%<H2A*DH2NDKK*Z2NB":\$$$UX=0/(5QYCSYM=VB8YVP4/=K+79M+WG
MVG==O7S;0\\ZX[=VZS;?8T>T*_0LK=66/`A3,#IWS4QA;='U>:!YSB[%59BW
M'B^<G)2GREC5U[=SU*."B\5U44F-)LF=)K69)K2:UFC>Q],+H^P/I9_9CX[Z
MR7W.[SOJQ*DIK*Z2NLH2NDKI*#O^/!!.*:&XW+M*PEAS9/LTE]Q\CO,P1-YH
MVX]-#<93K[QIPO+)&/<=2N_G<[A')>VK9!3_`%9M0ZLEI3U-DL>W;(9*QSTI
M(L2V\AG4_P`W42RL'[*<;U+%6V0_M'[<ZO=^5,9V)2,6XX447B_I-ZS)-$UK
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M>*I!S'U*L`5_$?2GLZ)0-M_4*K-/S?NIW*;9\&XPVR=+[&.,:MMYR[T\=M.5
MG:M3LU],G+,E.2M2DV*=6"W)*I;==K]:GKBVY]B@0I>#U@%%XKJHI,:39,Z3
M6LR36DUK-&]CZ871]@?2S^S'PS//4(V:;8[WM*[;7OVU\V9LQ?MTQ?@G/6)=
MS&,\R=2_8OM_R'_,KTS3`.Y'!^Z6R<R=2_8OM_R';G5SZ;MU5:D5>DU^E^"]
M9+[G=YWU8E24UE=)764)725TE!W_`!X((9PD*CO4W[4BD4N@4G,=HS]_XCVA
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M<#UCOZ_.ZBY*$G7*_P"UKT$O^V;=^&L9[@O[&G\-73-,`[;L'[6K)N_#6,]P
M7]C3,?0KZ>.1[!_K;9HR-$B^"]9+[G=YWU8E24UE=)764)725TE!W_'@A5*E
M*T:F=*2G3MUWOEW)M!PWC6W-Q'4EW+.W9A;J;5.`_C3<]:T3;3N"LC%6?]W4
M_6]V&]6SK0MVP;5ZAF!LHI?^TS?_`&?N$JM2J,C1Z=TL>_6\O<-Q4Y6MF^_2
MDU:F5ZE*6->]K9*LU3JQW`E-V\;6J#[M;;A125O2V9Z].#^DWK,DT36LUK-:
M39-&U+[^^EG]YW:S[]"=F_L_9%\5RA*$J2A*Z2NLKI*Z()KPZF#ZUW<4A3Y>
M6N3J_<'G77W,_4>;Q+E_;U9U*L#!I>]D6MD:U;1QOO[VJ7C@_8QF_(N5^.]:
MW*[M2W963>ELY$M1>&:=XV`,%P>E/:-?K]RJ+Q75128TFR9TFM9DFM)K6:-[
M'TPNC[`^EG]F/AF^3_[#G6>P]>FQS>;U6\QV1N#Z+'02_P"V;N4R]E?`_7L_
MEWZKQ@:][TR5A7<+G2[-M?7VW,=<_>R]B#^NW0=J=MX1\%ZR7W.[SOJQ*DIK
M*Z2NLH2NDKI*#O\`CP0SE4?4^$^D93N5A?J>U1^G[4-E%+<I&U-1->KC8TM.
MXQZ54K%O_,_#?]M6O*>NVMV3U.MTDGMJV]6IMKQEPW=8)E-P6#NE]N!<K5F;
MWLTKMUV?_P!>W,*99Z7EYWW9>.Z-O5SM;&\C*,C)2E,D113;1O`@W;_8:X/Z
M3>LR31-:S6LUI-DT;4OO[Z6?WG=K/OT)V;^S]D7Q7*$H2I*$KI*ZRNDKH@FO
M#?)%@3N_Y#;]$B5SJE\$TZD=JI;.[/:=<D&[-M#.WES$UE9ML*%LWWX;:*A"
MC]9"6?F,`]2[<3,8AZ66#K'B4>C4BWJ6HO%=5%)C2;)G2:UF2:TFM9HWL?3"
MZ/L#Z6?V8^&;Y/\`[#F[;;A:>[3;M:^X2[\/]/GH)?\`;-LK_P"SYPLK_P"S
MY&@PIB%CBCT+`7]C#P7K)?<[O.^K$J2FLKI*ZRA*Z2NDH._X\$-U\W$DMLW2
MG1Q-LG5BG%E=M6W*G.TC;ZHFO4IMKW@VD])"YXM/S@B?@;K.G[-7M>W5YWF[
MDJ3M@Z+&[[+N-+;QSTT;JRTN%=L.$\`0."F7]S>W3`$ELGWDP+-ZM6,LZ83S
M7)#^DWK,DT36LUK-:39-&U+[^^EG]YW:S[]"=F_L_9%\5RA*$J2A*Z2NLKI*
MZ()KPZC^V9<K8\V&[BH^X/"FRCNU?J*<$TZO%O0)3*W3(K,*J;2>Q7J]1+7H
MV9NH?DS+EW1-Q75!P^8SZLMA5&?QMGG#>8)=>PHO%=5%)C2;)G2:UF2:TFM9
MHWL?3"Z/L#Z6?V8^&;J-@>ZG)?64.LCT=,I;ILM]*O;5DW:5LEW6]/'J:47J
M<_\`_3(=/A-^?RHW6]/'J:47J<SUK?V6[TE>F!T@9/9==G@O62^YW>=]6)4E
M-9725UE"5TE=)0=_QX(73:]"O:VL%SMQ;$-Y75UG'',-8:E(LAB!1-=S=#]Y
M-NO3IN/W=W=)IV-U6]O&VV63MK.'5(ON4SIO5W:UJW\Q].2^=W[V]'I6[PMA
MMJ[,M@>Y_?Q=6U;^MOOGQM5-K.VO)6WRC%5DYBHTS>%TA]U.XLSC_6OZD%@1
M+#L>Z\G7S@O^M%U%;CG=GO2WW,;;W&*ZY-ZS)-$UK-:S6DV31M2^_OI9_>=V
ML^_0G9O[/V1?%<H2A*DH2NDKK*Z2NB":\(\%V9E\#3M0Z?\`O&Z>$.6G]W?!
M-.L3)OO2W2'O6C/6+4*G3:1*W)NSVT6D_5^HOL^I+MY]6?`M'D<@;@MT74(J
MM@;0^HI@"5Q%OMSGC#*^3\!89S-"R3TF+&FHNV+<3F/;SGGBHO%=5%)C2;)G
M2:UF2:TFM9HWL?3"Z/L#Z6?V8^.^LE]SN\[ZL2I*:RNDKK*$KI*Z2@[_`(\$
M$.JC@ZY[QL[=QN*I6?-L=D2;M.LQ1-;L@PIBUMO]XR^/,WRTQ+SDO=>7\3V(
ME6WY;1J*]<'5"VGT8ROU=:W-/6=L=WGY2FJODGJB[:Z7MTSM8^[/$.5.FWMC
MR0G6"Z<V7L1;+_ZK>)(5M[3%$XJ*;$MGSU!_L-\'])O69)HFM9K6:TFR:-J7
MW]]+/[SNUGWZ$[-_9^R+XKE"4)4E"5TE=9725T037@ANGVGV3NEM?:[G;)NV
M&[,7]5/`=WI8N;<09-5-.K5/^\=R9[Z7UHY&O.0Z3EQ7',T#I/[:J64KIR;/
M:6_O&Q5@[`NU?IF8JH]B;:CJEX?@WQ@791E68S!MJ4Z@B)^]?BHO%=5%)C2;
M)G2:UF2:TFM9HWL?3"Z/L#Z6?V8^-.B[UHK7WYVOVNLE]SN\[ZL2I*:RNDKK
M*$KI*Z2@[_CP00J%/D:M3]^VTFVMMEWV+U4JY:,S8&^;:WD26I]0D*M)Y,N"
M0M/'.Q#:?9&Y/`TOTH<E4N);/2%Q)*.4;IB[2:8Y;FQW:=:S]-L6S<V=3DJ$
MA(U60VB1)G:YOO-XE`IUU[2OZ^F.JGB[IZ*)Q44Q/L]?LOJT<'])O69)HFM9
MK6:TFR:-J7W]]+/[SNUGWZ$[-_9^R+XKE"4)4E"5TE=9725T037@@ATMY]VS
M\VY*VC[<LLKDGI+8ZJ*2&W7J?8IEMO6Q'*LQEU.QU;KGA4W`FW:VIBSL"'48
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MZ9LWN(ZCJ7M>UJ8ZM>KU:^^IWN+I%(IEOTE2\;!_>1U`,<;8\#8IH\M1*+)1
MNI?@NBWY@;8CE.:RSME7BNJBDQI-DSI-:S)-:36LT;V/IA='V!]+/[,?`=W]
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M7%OOOMYV693^;NVL31!.*:;(Z5%S5ONCQX$K`S1>E\=13<=B#$%BX-L5=<F7
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M_$TO#:7O1P'F>X\)=4;<`FV+:S8.URTA==]5UTZT=JG3!H#M'VG[U]K&4I#)
M^.^J[+4J)NGZAM!RY96R/!-5V^X#7BNJBDQI-DSI-:S)-:36LT;V/IA='V!]
M+/[,?`=Z?V<>)-AFPS./4(SCLCV1X.V$8.X]9+[G=YWU8E24UE=)764)725T
ME!W_`!X()QZF-$J6+,XW3OXW([@+HB;&-\>78,'!_5+P\_#NKJ^S;^QS=]?>
M:KC00WZ[4JUN=L&7DNLE3I/;WT[[QN"]%U7A-3U-R3U<\^88MS/.+K!SWNBZ
M?!+=5W;G&MO;#0,E;Q=V8HHO%_2;UF2:)K6:UFM)LFC:E]_?2S^\[M9]^A.S
M?V?LB^*Y0E"5)0E=)765TE=$$UX(()KO#R!CF[MUEEW71K[M!-$.HE#I439]
MTZGHK^S831!=."Z[JH]=WB[VK#L.T\8V>7QBC&63(&,-O&%,,QU%XKJHI,:3
M9,Z36LR36DUK-&]CZ871]@?2S^S'P'/N/JGEK!/_`!2=XY_Q2=XY_P`4G>.?
M\4G>.?\`%)WCG_%)WCG_`!2=XY_Q2=XY_P`4G>.?\4G>.?\`%)WCG_%)WCG_
M`!2=XY_Q2=XY_P`4G>.?\4G>.?\`%)WCG_%)WCG_`!2=XY_Q2=XY_P`4G>.?
M\4G>.?\`%)WCG_%)WCG_`!2=XY_Q2=XY_P`4G>.?\4G>.?\`%)WCG_%)WCG_
M`!2=XY_Q2=XY_P`4G>.?\4G>/PV&;#,X]0C..R/9'@[81@[L=9+[G=YWU8E2
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M28TFR9TFM9DFM)K6:-['TPNC[`^EG]F/C38=L-P9T^,(=KK)?<[O.^K$J2FL
MKI*ZRA*Z2NDH._X\$$X]+F"]?N=-XNRC"&4Y7:UMCW![A:-DVT]P.&KSP1TT
M,&W[1W7<6[>\8WSU=[5E*NO5QNJC3%C=6/;]7W,<[E\!Y:FA=>IWF^>Q?@S8
MWMEI&WG$?!1.*BB\7])O69)HFM9K6:TFR:-J7W]]+/[SNUGWZ$[-_9^R+XKE
M"4)4E"5TE=9725T037@@AU>'GJC5(4*'`AX[EWMS_4T33<GT],19]GZO<&Z_
MIYY`PO&QY,]0:4DY2GRU>L^TKJ@9!Z=^U&_WEAY!Z8>XNBUFDW'1[[O>W,<V
MGT?[<BNV[&BPX$++N]O.VX#)*[+.H;0)+:?OMO"H7X*+Q75128TFR9TFM9DF
MM)K6:-['TPNC[`^EG]F/COK)?<[O.^K$J2FLKI*ZRA*Z2NDH._X\$$X7K/K2
M[-Z/]/EH=D]4K*,U9.WS9UC&6Q+MPRGB3'N:+4O;IO9DPK-Y>W)Y<W#[3]D,
MO@:/@F-`@3,*^MK^WG),/<GTR;4M6R=@NZW]Q>-U.HO7J3E+=`;Q-WEN[7+2
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ME-9725UE"5TE=)0=_P`>""<+@I$&X:#TQKHJ6+LL=86F3T6@V_4*=5J'PVZV
M9:]G[][_`-K&YG91>6-^K5CR;EJ%U!]H=><N/?#M4MFBUC<9(6-NJB8<ZEFZ
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MR2]6>G9L_K+].Z7NU&1K6\7'MB8ZWC"F[JZYBRMLW2JM:!1=M`IU$):5L;=C
MP447B_I-ZS)-$UK-:S6DV31M2^_OI9_>=VL^_0G9O[/V1?%<H2A*DH2NDKK*
MZ2NB":\$$$UWX[1G['BYFKEL;VMCG3OR?5LH;8T.J_=\[<]R6U1*%CBQLD]6
M^RK8NZ%UB;?6%`ZPUJ/1;SZJ>#[NQQTCJ;,2^`N&[R<E[#ZCZ\*I496CTSH\
M4V<A4Q1>*ZJ*3&DV3.DUK,DUI-:S1O8^F%T?8'TL_LQ\.VN__:IZ\N"+ZV";
MYO[%>=K%W.='WI1_]M7J&S2]3#K[]57;`_N_V!?U;-U"9/V?^#=9+[G=YWU8
ME24UE=)764)725TE!W_'@@G'/6`,>;BK'VHW[=FU7/&%*;-[0NHF9+OBFXTQ
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M2:TFM9HWL?3"Z/L#Z6?V8^';7?\`[5.\O:Y8^]#;-F+.V4L4[--CV8K8V]=&
M?I4=*FY>KF__`,77'1LLM>I=&7KS^#=9+[G=YWU8E24UE=)764)725TE!W_'
M@@G%--V^S*S=TM.W";4MT>WB!8V_O?9<%KR^T3>YNQFZXN-]B6V'9+MHJNY*
M\$1'4O>XL1V%)[A-]F+[SK-1Q#E[!68^%P4.GW/0.GE><WM^SZ1HL.!#QC.1
M=Y/43X**+Q?TF]9DFB:UFM9K2;)HVI??WTL_O.[6??H3LW]G[(OBN4)0E24)
M725UE=)71!->""":\.I3MLB77:VS'.$WG[`"&[';7N2MS<M/Y4ZKEXN0.FUN
M<R8[BKI;;?;$GZ/1J1;U+Z0L6:I=3X79:]!O>VIZEY^Z964:CU>,4.6]A3`V
M9=\&784*'`A*+Q75128TFR9TFM9DFM)K6:-['TPNC[`^EG]F/AV,.CI3L;=5
M,ZE/0(P1U"LU[C.F8F8NFML`V8VAL#VKG54Z,5%ZE&3*7`GI6F>"]9+[G=YW
MU8E24UE=)764)725TE!W_'@@G%-%,@V';64+*VCUZ[]H6[@W680C[AL'V#6^
MISM]M:3P/U*-R*6STC:+-36&]M^&<"2/5E;0,A\%-^NT"Z<HSN,NJG.VC(Y<
MWF9DWF3.TG;51]LF+N"BB\7])O69)HFM9K6:TFR:-J7W]]+/[SNUGWZ$[-_9
M^R+XKE"4)4E"5TE=9725T037@@@FO"Y;>IMVVWL[R5.[,]Q7!JC5&J-4V&3B
M6IOA:HWA,0($U`IV$\-4>K<%%XKJHI,:39,Z36LR36DUK-&]CZ871]@?2S^S
M'QWUDON=WG?5B5)365TE=90E=)724'?\>""<4T437J@8UK5JUW;WGNR]Q>.>
MSU@*!%F;#L&KI7[%XW9C'&U^/T&VK<M203BHHO%_2;UF2:)K6:UFM)LFC:E]
M_?2S^\[M9]^A.S?V?LB^*Y0E"5)0E=)765TE=$$UX((9BS?C7`UJUOJ[/1*G
MMOW[8<W#U)-.JA@R'<V.MH.YZTMR&-NS@ISS3JJ<5["B\5U44F-)LF=)K69)
MK2:UFC>Q],+H^P/I9_9CX[ZR7W.[SOJQ*DIK*Z2NLH2NDKI*#O\`CP03@JHZ
MF;^J%B+&U9LOJUT!^L65>UIY%MJ\+1MR_;7V@Y6E-E>XB'$<BN=CJP0Y9_;-
MM=J,>J[;NPHG%11>+^DWK,DT36LUK-:39-&U+[^^EG]YW:S[]"=F_L_9%\5R
MA*$J2A*Z2NLKI*Z()KP0KE;I5LT3#UCUOJ-;DK6M*U[(HN_#97;-<M/8MN-C
M;BL+QX$":@;K<*5K8YEK%64;/S'8K4&H-0SYN'QOMVLWII6/>60LD-0:@WLJ
M+Q75128TFR9TFM9DFM)K6:-['TPNC[`^EG]F/COK)?<[O.^K$J2FLKI*ZRA*
MZ2NDH._X\$$X=2O<'=%"EMINS?'^W:T,NX6QMG*U=O\`7;MV&;L3=SM*LW<S
M9G3@W*U!Z7:-&DS-2TE+;U\S/[Q<L;+MS5-J?4_:-&\%$XJ*+Q?TF]9DFB:U
MFM9K2;)HVI??WTL_O.[6??H3LW]G[(OBN4)0E24)725UE=)71!->"'4PO><L
M[:QL(QM+XUVND2&Y%<V;2T'!._\`,B8]M+*MF5?I7WI9];B[9.IY:;ZTKK#T
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MFC>Q],+H^P/I9_9CX[ZR7W.[SOJQ*DIK*Z2NLH2NDKI*#O\`CP03AU(]NMR7
M53=HV]JP,_6CF?/>+<"6UMSMJ^-\NZS\#99L^7'/7$_`447B_I-ZS)-$UK-:
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M6:-['TPNC[`^EG]F/COK)?<[O.^K$J2FLKI*ZRA*Z2NDH._X\$$XIX$O!11>
M+^DWK,DT36LUK-:39-&U+[^^EG]YW:S[]"=F_L_9%\5RA*$J2A*Z2NLKI*Z(
M)KP03BWP!5X+Q75128TFR9TFM9DFM)K6:-['TPNC[`^EG]F/COK)?<[O.^K$
MJ2FLKI*ZRA*Z2NDH._X\$$[#?`&]A1>+^DWK,DT36LUK-:39-&U+[^^EG]YW
M:S[]"=F_L_9%\5RA*$J2A*Z2NLKI*Z()KP3M-4:HU1JC5&J-4:HU1JC5&J-[
M"\5U44F-)LF=)K6XZU2+=I-T=539G1:A'ZL.T*(L?JJ;2HAN4Z@>W7*%DUO>
MW@J?VI;&^L9LKP+MR_GPZ>Q_/AT]C%W6EZ>V4[D@1X$U`\;]9+[G=YWU8E24
MUE=)764)725TE!W_`!X()P3P1>"B\7])O69)HFM<V9VQ+@*W9WJQ;/4BQ^JS
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M'9FQ;JA7YL4V][*^M?M[W&JZ\Z\[XUZR7W.[SOJQ*DIK*Z2NLH2NDKI*#O\`
MCP3BT;V?[6F8_5F(.CMF%<W]-#\-HWCUF,^U+;ATX<3Y"I.6\5C^DWKU(-Y]
M2V283VS=</$61HM%N:V[RHF[)Y)+?!QDJG3JDK]3IT.H<<W1H46[^1'_`(OC
M/OT)V;^S]D7Q7*$H2I*$KI*ZRNDKH@G!/!=R66:[F7,QTG<8W%2[=%X**3&F
M1<GX[QC)5SJ986@713*]1;GI&9ME&)]\46!T'=@<J[_!/L,/X)]AA_!/L,/X
M)]AA_!/L,/X)]AA_!/L,,J=`+9W=-BUWHF;9KAVH;R.F?N;V83FRSJR;F-GK
MVT'J);9]Y]-X9EWQ;8,$Q]M?5`PKN)R3XPZR7W.[SOJQ*DIK*Z2NLH2NDKI*
M#O\`B)H)VMVNZ//.WV0W7_V)>I78%1W8;T]RN]Z]]F_5TWQ;%[1V=]=7J+9P
M,+Y#O3)EE?B*?VJ\PI0=NW0DS$[F+I>C^DWK_8%^V\P'NHSSMFK6"L^=-W=_
MFJT.BITWK[MK^"?88=97ILVWM!Q)CB\*=9=V3E:J,Y5-A71KQ'E?:_\`P3[#
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MU6O[%\SXEV^[J+`O^S,J65V<^_0G9O[/V1?%<H2A*DH2NDKK*Z2NB<$7L-&C
M1HT:-&C1HT:-&C1HT:-&]A>"DQINVP7<.#LP8LVJ9TR[,;<<,3F!L4Y4W98R
MV84+_D9;)#_D9;)#_D9;)#_D9;)#_D9;)#_D9;)#_D9;)#_D9;)"X/['6T:6
MIFXOK+;:,.X%W<;_`/<IO.K6R;HQ;A]SAM=V8;=]GML&]7"-1W![;*ACZ^*7
M>FW3I5;DLHS?9W6W?7+[W)'1;P?0Y>W?%'62^YW>=]6)4E-9725UE"5TE=)0
M=_Q$[+1HT:-/[%N#9S,O3AP/C*1PGA!HT:-&C1HT:-&C>Q_:SPE*1++_`*\V
M$)#$_3/'O\9O7^P+]MY:MI73?->M[:[BO!>0MM/5MZ2.T.V/^1ELD.J-U`>G
MYU#L;[0I;:U1\MWS;6-$RQL\ZPG3AV6X%_Y&6R0_Y&6R0Q7U^=H>5,R<,^_0
MG9O[/V1?%<H2A*DH2NDKK*Z2NB<47PI>"DQI<UL6U<SDPB.NS6O7.JL_ZXQQ
M:U`2T/=RWCW<MX]W+>/=RWCW<MX]W+>/=RWC+]MT.6MG8)TTJ[U`MLVR?I`[
M;]I:=B7LNSI2Y>UU"NFOD2X<DX-Z+=P3,SAG".,]O]E>*.LE]SN\[ZL2I*:R
MNDKK*$KI*Z2@Y^;J<$7\&Z[2MN^:#^%F7+5FX(Q7V>O5A>;S5TQMMF)Y;`^W
MD>_QFM>L/MBRQN;VY;7^AOD^\#"6V+!6VF@;RIB:NG>_"M>VH,/W<MX]W+>/
M=RWCW<MX]W+>/=RWCW<MXR[1J;1;I]]KI_CM,^_0G9O[/V1?%<H2A*DH2NDK
MK*Z2RL[+1O@K1HWL3"DV3.DUKUS?BW'GP5V\R?!7]<'[6O`E5'4H-T6U=4MX
MCZR7W.[SOJQ*DIK*Z2NLH2NDKI*D)6NIQ:-&H-0:@U!J#4&H-0:@U!J#4&H-
M0:@U!J']CO,+F,NF;T^\S)N"V0M0:@T:5>D4NX*4*/JQV9UF2:)K7=1]\GX&
M<?BS_P"+<S[]"=F_L_9%\5RA*$J2A*Z2NLMI`>'%:B>&JHJL2.\TFE)G2:UZ
MYOQ;CSX*[>9/@K^N#]K7@.?,WV7MWQ=F+>IN:SH]M,W9Y!VF9!QK?=(RCCWQ
M%UDON=WG?5B5)365TE=90E=)7277\H+WY"+X)E3</@/!DG_8PZANWW=Q&Z`W
M5%VH8FV9X^RMB[+5'["KPC/?E,*3)-$UKNH^^3\#./Q9_P#%N9]^A.S?V?LB
M^*Y0E"5)0E=)7677\H+Q"?-1OX;[[D)R9W2;>I:]OQE7A$?(SY,*3.DUKURK
M1KL:%8N3+3IUK_->P#YKV`?->P#YKV`?->P#YKV`?->P#)^0+:KUO?UX+#N.
MV=F7@/6,HMQ5+:F;5["G\B[@I&1DJ9)>(NLE]SN\[ZL2I*:RNDKK*$KI+*Q(
M#Q"?''FH-\"W3;,K$W94?-?]5.UJQ-=0SIF;@.FS=?3PZ*^Y?J*X\V_?U=L6
MXYK&!,!VUMZL[@W@\]W4BOD=XF%)HFM=\U`K6.M[;F6+">=^:]@'S7L`^:]@
M'S7L`^:]@'S7L`^:]@%_55R_[S^5%W_L6,^_0G9O[/V1?%<H2A*DH2NDLK"`
M\PA/D-\AQ!%1>#1HT:-&C1HTWJ[K;KS3E%UYYQ[IK9XR-ES'C1HT:-&C1HT:
M-&\7XB,B1"*^1WB.K4FM<OXIL3-EAW#T3<=Q*G&Z*UL0B-T9K9A&<^F/0L/V
MK5>GO1Z;MYVG]"*T]R>$O^-59!_QJK(,<?UP\#4"Z;*LNU,<VEX#<=MV]>%#
MLGHT;?Z#?&,\0XPPU0?$?62^YW>=]6)4E-9725UE"5TEU_*"^0GR'$'7T5.#
M1JC5&J-4:HU1JC5&J-4:HU1JC5&J-4:I_:,Q`]=^R_HK88^1W3*:HU1J\7GT
M0B1"*^1GB.\31-:[M-DV'MVDG%Z*%KPB-T8+9A$7HX6U#,1]/"C9-W"[3^F[
M1-R>;?\`C560?\:JR#_C560;->B/MLVHW]PS[]"=F_L_9%\5RA*$J2A*Z2[Q
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M9HWL?3"Z/L#Z6?V8^$]8_`-U4[*MCXYO[)E9Z8>R?,>VFH>']9+[G=YWU8E2
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M*Z2Q`>(+Y"?(<0<B#L0=BB13FG-.:<TYIS3FG-.:1([SD/=SU?*UM?,N?V?=
MX%U&0,A7;E#(>'O[-N]JRH6T7K5US=`_3J@]/T_FG-.:<TYIS3FG-.:+%'HH
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M5)7665A`>(+Y"?(<0<B#L0=BB11(IS3FG-.:<TYIS3FG-.:<TYIN$VF>\O\`
M80YIS3FG-.:<TYIS3FG-.:<T6*+%'HH]$'XA$B$5\BOD=XF5)LFC:E]_?2S^
M\[M9]^A.S?V?LB^*Y0EE_*`\07R$^0WQR(.1!V()$$BG-.:<TYIS3FG-.:<T
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M.Y"OXGV)X=VMT'=/O7RAO`KFPOIXTO`<+_0%QVY0;OH.]'87?>UNY,,[W,.[
MFK!W$].S+V%XE@;O[KH3MHYZQ;>,-R.Z^YS3G'..<<XYQSCG'..<<XYQSCG'
M..<<XYQSCG'..<<XYQSCG'..<<XYQSCG'..<<T>C(ZETYLQA:+F1=XE8J"[=
M]A>X#=/4<@;L-N>Q>QMJ>S#+.]6\L>X]L[%5G?B9WVZ8FW'6KGWI];D=KUQX
MLZHMW>H*WA;IQY[B5[IF;G:?#G,1[Z,?+&K^[:6B^\N[`]Y=V![R[L#WEW8'
MO+NP/>7=@>\N[`]Y=V![R[L#WEW8'O+NP/>7=@>\N[`]Y=V![R[L#WEW8'O+
MNP/>7=@>\N[`]Y=V![R[L#WEW8'O+NP/>7=@>\N[`]Y=V![R[L#WEW8'O+NP
M/>7=@>\N[`]Y=V![R[L"1LO?/=\2VNFWO,OV:E=H&S/"96NI!8N';>Q1MEW7
M;[KNVL[(L/;6)#_04Q+P)N!NVZ45O7E$Q[N#W?[#KEJ^X?I_;MRI].ZWKY6J
M;+M]&,7I]-YMO.^\N[`]Y=V![R[L#WEW8'O+NP/>7=@>\N[`]Y=V![R[L#WE
MW8'O+NP/>7=@>\N[`]Y=V![R[L#WEW8'O+NP/>7=@>\N[`]Y=V![R[L#WEW8
M'O+NP/>7=@>\N[`]Y=V![R[L#WEW8'O+NP/>7=@>\N[`]Y=V![R[L"3F]XE;
M)+:;OMRJ4CIC73;$M2LG=-_:L[E'=WNVWGU[:OTD9>2?H]&I%O4K\?..Q7;5
MGZ:R9T7Z[!BUCIV[Y,93TI8_4\HT'W<ZI1[N=4H]W.J4>[G5*/=SJE'NYU2C
MW<ZI1[N=4H]W.J4>[G5*/=SJE'NYU2CW<ZI1[N=4H]W.J4>[G5*/=SJE'NYU
M2CW<ZI1[N=4H]W.J4>[G5*/=SJE'NYU2CW<ZI1[N=4H]W.J4>[G5*/=SJE'N
MYU2CW<ZI1[N=4H]W.J4>[G5*/=SJE$#9-O\`<NS&/.C-E6J1<(=-O;!A:-"A
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MW$.H=]K/1+\0=<K_`+I7'^O#F?>[?-U\>N!;U%N[$G3%NRY=IV<^F]]J'2VZ
ME/3;P!L2ZL5:MBY>D]N,WZ].*\^F#LULJXL;[2^I].+D?=GURJ93ZUM@Z<E>
MK>RO=#TL9NIT^OY>S)UD\4XIR7O=J;G34KV\GJM71MZS!U.+;L391F+<UU9]
MGF/[!O>W,F6+U`,WX2V[=8O:AO4V1;L;@Q7$ZG[_`%;>H3$WU+U5M]GS6^8^
M;MU.0,:;\MY&ZG(&WC+,OOOO3$&^;8+N>S#O!MOK\\O]FG7.G]JM3V=U?<]F
M_$NZ#>1NIR!MXRSF[?9N\IN^J@=0;J(67GC;?O`W96SO0S=OMW=TS?3@W>-N
MSQOO*.G]O1V0;9:]T0*;0Z_(],")#A;B<=[O^H3OKC[9NI;&N;&F.-Q75^SI
MC/J"U*9F=X%"ZD=YY0R7:^X[JX9=PUF'J65%.E)M/R_U`,[7_*3'R9Z[7^D+
M*_[@LO\`FX\ZQ.H=]K71+[6V'JM[/MWF[/\`!J'4ZV*4O>Y^/URO^Z4;2NGC
MNQWJU39G_7VVQX,*12*30*7QZSOP)U:<"WM-V7TDKXD,G;">C[OBV?8?Z='5
M6R%8^5>D[*[T>EE3-@717LO+MA].SJ(N+:/4FZV_VY=6;;C>E^8HZ7.X2Z:]
MM/K%S;;<O=.G_P#US/\`XH;XDZ[873MZCG4.VEWYLCV?XJK>#MJV\/*N-L+]
M;'%F\_:=F^[,$_\`?AWS?]VWJA?<;U'LA6]M\ZBV^#=Y@W<-O3ZC^/:QU6MR
M_2IW.2>=]M/]@.2E:ELKPKT[]DFWBYNH]D*WMOG46WP;O,&[AMZ>+?\`ODW$
MZZ[U[,[?]^&\-S^)]KO6\OW*^/=[/6'.F5N/VA87K_3;GK+R=U.NGO;T>[<K
M=(G>)M]VY;47,9W9OWD]I'5+V/VQL:ZIMH69N)SO4)?+N']O6T.B]-"_=LN^
M&Q-MF.^@M8/P)?L)Z_.OA_I"R_\`N"R_^,33J'?:UT2^UM`WSYMV1]>_H]=?
MN_\`>_NGWG]3GJV4G=#T8>MM7>I7D3*/]C7=[G[=AUP>IEO5W`]#?^L_N_WR
M9?VVWKU]M\NZG<[LDZ_5$W>[%-H/]G_>SOKO2Z-S.U^%_:PV@=8F]]S7663K
M$WO_`#Q=0+^R1>&QGJ869_;&W$83S1LA_L9;J+LZCGX75+Z/F]3<_O\`]F?]
M?;;'@PI%(I-`I?9N>R[.O:$\ZZ^[:..<>X_HG[1=J!"QICB!9%"VR;;;7JIU
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MG)]I[DO](67_`-P6!^3BO-3J'?:UT2^UTK=\^U_8U_9`V9Y2L3J'_P!P/(/4
M'W6[_.L%_60?I5V=97^JSOGVJ=."8ZXF[/"N_G^N%_7;WC[8\W],?H<XWM>R
M[IP!L@V*[?ME_P#36E)6!TE;R_\`O&;=-U^%.GM_;'V@;O<,;YO[?UZN./\`
M]XO?/*2LQ_<BZW$I*N?V=/\`9*R_^X+">8YWSJ&_:ST2^U>G2)Z:&1(>T783
ML[V&6QN=Z/\`TT=Y64L&["-F6V7)FY?HZ=,?>%DVV-M&WFS,$[2.EKT_]B-[
M[H>CYTS=Y]_X4Z<^QK;EA/;5M4V[;.\<S.QC:+.;J-VG2NZ>N^F\;$Z>VR3%
MV6)G8QM%G-U%T[)]J-[[E\H[)=J&:LZ_[)6?$2%U`(5RRO+]Y90W^5>#/;7^
MB7XAK%>HMOPO]ALB5.=PMO23J!8F1/Y`L3&XK>%8V4L5=%NSJO3;)\0?V(]Z
M,3:/:4"/`FH'^PNXK9/@;<[-_P`-NV(_AMVQ%(Z/>UBFU"S[.M?']L^(/[7&
MXBAY5WO]*C<#2]RG3U[.>-QV"MK]FT"OT.ZZ#BO-N)LX2F4=UVV_">1C*V3;
M/PMC+%&[O&N0=I.'\T8GW`V!1<VXFN/+':L_==MOR!FWCN+W/8'VE8_W([N,
M5[6:N7-N>P/9V?>,SN>P/)[AS*5\/8QQGMDW$8[W98#_`-A=Z^!.I+EF!O;Z
M/G]B&]G,U8*S)MRO_9CTN^J9N!DME73H_L-XQ,8T7(UO69Q_L)V=;^0\$]'3
M)%Z;:,E="+Z>;OL%5_J;7ALBW'TS=UM)_L%7A7$V5]72WJ-:/27Z858JG3)W
M1;:/^_3?>Y#K(UR:VD[_`*W=W^PG"W5*ZEF\O;_C+JZ8)NSIH5W?SU@+2PU;
M^^K"MV;%<98VO/8U0^IIO9J'3_VTYKZJ'40V_P!@=>C)>YFO7AO,W/Y[Q'L%
MZ_-_RF)Y++/4_P"H3M(A9;W!V/2^J)O`ZA.4+!W)8DZCFZ#&&[3#V3^I]+=:
M1W/M*<ZM6?.H3N.N?=GLZS#N>RE;/1!G8F,;I_V'_MY85?H.Y'8]A=[;KLW[
M/7=^GG6@P9?MFR73WWP6[@CI-=/;8#U/MO\`L\Z$\Q>.U;*/]@B&_0<8]9C_
M`+7.?-D\;?%T@.B?NIN+=QU#=JN;ZOOUV_="UUYSH:="G_M.36/;SOC^NEF/
MJ>;&7-DU0L/,U,Z/.[3IR=3//>T3<)NBC;L?Z]G76_[3G5UFY2W]I_7ER1CO
M)G3MZ^60*!B67ZYN\S;1FCICWI:M3L3K&4?)5E[2/[!G46R=CG=YU'L>Y#L#
M#W]AZLU"0JW]BK8GE/'6U'JT88W.X"W$U3I#PW[FW\?ZAZDG6_R'M]SQ_P`A
M+?D?\A+?D?\`(2WY'_(2WY$I_86WV0)K8-O.M7?3M\\/ZR^R:+O/M+M9+P[B
MO,DI-RDI4)22V+[-:;BTA8.P[`R_U(=IL'>YLJV]VQ=N==E%NV]0[2M^QMN^
M!\8Y`JW3LV*5W,%F83Q%CNS,;8SQ]ARR,:84Q'AJSJ)TNNG9;>0:OA3$=P94
M%V6;2EL[).,\?9CLC(F",,Y;Q?;FQ39S:6'[[Q-C+)\[COIY;',294K&'<5W
M!DS.NVO`.YRU]OVT7;%M4I^?]D>TC=169;!N')+)6X39SM9W709;&MG;4]OW
M21VE7IL_V9_ZAWWN.1.HYZHI)ZHI)ZHI)ZHI)EZG4^7LW^N#]K7^TN\';SN%
MR#U`OD/NO/D/NO/D/NO/D/NO,MX!W1/6)_7(IE0EMI?:S)UU.E?@7<]O;ZSW
M37Z=U_VEU7^G]?>ZC_9S(>^?9%@;(G\I?3V/Y2^GL?RE]/8_E+Z>QD#JA=.:
M>L/9A<&VRY-M78W5?V%;KHV[[:3_`&!:'NZVX=##<+'G>HO3][%^98_L#2],
MHU%_NJX3ZR--S+UBKPZR%-M+K5_SG2-C]8WI]=9>3ZCN][K1=7.C]'G!&8O[
M=T7&]R=2'K.XSV,].?>)U.J?M/Z469^M;2L1]&/)O]P=RD6AN"_MYVI1J+G3
MKBXCQ[T=\F_V\:O`L#8QO.P]U!-K'^QW4!<]=]17Y16*?**Q3Y16*?**Q3)&
M/K8MVV?ZXDY-1-I_8Z0&.-R$IU`.C9TR,?;9>HK_`%)OO[VG_P#W1KR_^\9B
MC/\`B3:;_<5LO==@3>)_<Q_M,4^5W[=2'^FUGS"%6V0_W:/L%ZS74=Z>&7OZ
MWO4CQAD:R?Z?75.ZH6QC(G]8?>3_`/2YR+1J/+?TL=M5K6W_`,-/_P#TEL-]
M1WIX43^J)_41L6]+.Z.7X$2)#@P\W;D,+[=:!85^V?D^S_\`8/?E&@R_49][
M[3/>^TSWOM,][[3,L7#0*C:']<'[6NQO6Z&'2_Z@62-B/2TV+]-:G;2NFILE
MV+WY:734V2V-O1G>FCLDJ&^'?7T7>G'U'[ZQ)T>>FS@;->&^F?LCP%NJP]TL
M-AFW_=E_</P-G'/>QC#?]<+I(UZ%FC`V'=Q&'L1_UP>C?ABB7GTT=DF0=EM3
MZ?6T*L;+[<V&;3[2V;]<CIZ67@7H"].S^N?TW=P>PZQK&LW&5F]O>?N3I&!<
M+7]U`-SV4\13U:K-3E-H&^/)6W"^=MVY;&FZ>P..\+?5M)V"8XQ/_8#Z1>9L
M2="O^RW0=Y[V]?K']-KIZ7)LBZF6QKJ,T.\>N'TJ,?3NQ;J?;&NI)0M\75^Z
M=?3DN&@;DL+;J?[AV]?K']-KIZ7)LBZF6QKJ,T/)W7AZ3V'XF0^I%LBQ-M'_
M`+/W5/V*]1SIZ8I??B8NWK]8_IM=/2Y-D74RV-=1FAWCUP^E1CZ=V+=3[8UU
M)*%,?VH<5RO6$_L'U_;)NDV@?W`(D6W*A:G]@GH^WON(_LTV1B>\,'9%W#X$
MV<[;MNW]AOH^;I,K]4W^R/3]H/4MZIFXO:%O[Z.?3VOC">V?I2;:^OATE=W.
M:O\`4/4-Z'<MNER__P`<'=(?\<'=(?\`'!W2'_'!W2%*_K>[D(U1V6[0\?;)
M,$^';R\M4?.&Y;A@7%K^;,R[:=L^.-J^/>/]D[I<[P][%7Z1N^O9SU*,Y?TQ
M-M6W+*V&-[&^7:M"ZL_0DELAVC_9JZ2&S#;+O%_LD])[#>.]KG]LGI^8,PMU
M`?[2F/-KVW7:+_<SWL;Y=JT+JS]"26R':/\`9JZ5>Q3;'OC_`+(G]E7%F.HW
M4*_M[=/'8GM8V\XF^E>]C?+M6A=6?H22V0[1_LU=)#9AMEWB_P!DGI/8;QWM
M<_MDS&T#:7.?W!/[I%FVACO99_</I=.K=N_VI.F/T^-GO3*_LU7A>>0^BS_9
M&FXV;-^_]M[89LBP-TY^H'BW&V0M\_\`9EPMAS`/06ZN.4;^MS^MAB/I'=+^
MQK3_`-ANIG@FY[.W/&/\99"RO6]O?21SQ5ISL=2GIY[N-V&0.EET.9O8ON8V
MF_UG<N[%MZV[G^OUF>ZNH?TW_P"OM-;`.H!T_NB?"V*]2+!_1LA89ZR74-_K
MD77N'WU[+?ZS-L[->HANY_K]9GNKJ']-_P#K[36P#J`=/[HGPMBO4BZUG18Q
MCUA\595_J396W2X\M6AN6Q;&[G^OUF>ZNH?TW_Z^TUL`Z@'3^Z)\+8KU(L']
M&R%AGK)=4/\`KWWIO+WQ=2SH-7/U)-E'5OZ$UH]628C?U+,@9.RKUINBM2>K
MIA3JQ]$?!W5;P%2/ZO\`N!W"Y%ZS/0GMSJD&3^B_FW<+TA<J]!_">>.D?LO_
M`*ZFZ[!^9/\`8:_K)H.2K'P9TK-M&(9NW++L^SH'_P"B=__:``@!`@(&/P#K
M\J49`6DFX"'*7FW1).!93RKY*DK2+)I;04$3-H)<-DIIF9#D.=[P?I*@@8\"
M$&G)/?\``0,38%BDF9`X23,%*T55*M+C3B0I*DD%*DD3!!%A!%Q_TL9S1UI2
M:>H6XVVX1)*ULALNI2=.`.MXM'"`OG+W<J44R5'EUM-+4DD8$%>)2E2^*K`&
MB+CRDC9T&Z=:L`<6E)5*>$*($Y"^4YRTQ39)3J*T4R`@*5>HWE4M$R20-`LT
M?Z6>SCG?R4JA-35.O*`E-O.@NJ96JP$@,TE,A),Y%5EBO=VHR&N4I+=0`"I/
M?)*5)6A0G89+2DD&P@2TPYEJ$(13(4K#4K6D-J0#P5!*2MS$H2X&&Q4PI0`Q
M0BMSA9KZA!2H`S0RE23,20"2O1/&HI,N]`)'^EC>3<V*)ZMJ'%(3A9:<=PXU
M80I?)I44(!M*B)``G1&:^S[F^PNH<RJ@I31H;0I;JCEBF5I2VVG$I2W&65M!
M("B<9"052A5'F#2V'D&2D.)4A:3J*2H!0.L1_JE"$WDR&W#W-3GG1+H,P82V
MIQEPI*DI>;0ZV<2%*00IM:3P5&1)2J2DJ`AJHK&!4M(4"II2EH2XD7I*FRE:
M9ZJ2"(:3SF]E37*(EBJ$U`S=2B/CII\UPH;5I`2](*`*<-DF,DR;,ADCCB@E
MNFJ:-RD0%*(2!RC2%T:23(2Y<3T3D957.#/JA%+1432WGWG#)#;3:2I:U'42
MD$V3)N`)D(5E^:TZN=J`".23E:'FB381/,Q3ME.J4XQ*>'%<74\QO9JSE#ZI
MX:K^H5+<B?\`ZQI>3I1*PRQ*%X$A[KYADV:JQ/4SF)!D$XF%B:)`6<$7\8`D
MD$_Z7<WO;&S\YG'-,HYOYT0"5.4PX64UB];"HT[KJR5.ON`3D@#I`M!D1:"+
M""-(BGYTMN`/<ZJ;*F0?_*5(;JJE%DA,-L5#:M%A]V:#G(FQM9]6?.C`NU"C
MK)5,D_FI'^EU7[+.=Z\.1<^:96454Q,-5#L_Z=5`32.48JE)2A9(#8>6L][,
M9CS-SY&"LRRH=IG1;(J:64XDS`)0L`+;5+A(4E0L/2<Q/9HEW&]E%9FQJ`3P
M@E"VU4)(G<&JU]M)D`$M`"9Q>[-1EJKW$G"3H6+4':4`3K0TX_/EFIM.@WAQ
MNPSUR)*.N?\`2U+K2BE22"""0009@@BT$&T$6@QS7_S+Y>D*?S1I.4Y[A$L&
M<T#82EY<B0DUM(E+C:?BM-(GPE'W>?H38QF:>61J!Y$^4`UU":SLI'3%W.:M
MM@`A,BJ:IJ$P,"9KM%O>W6W0O):1:VECR2W0E"'K0)-\(JQ&<TH4$J4-$YI'
M^DW.+_+AG[B44_/"E*\O6X>!3YU0I4_1N3F,"7DI4TX00IW"TS;CE#^5YDTI
MFHIG%M.MK$EMN-J*%H4-"DJ!2H:"".FI<ERY..HK'FV&DZKCJTMH&VI0$9_S
M"H@H4U#438"C,^KOMMU#`F9DR:=0)DDV6DF9]PBBOK&T*%Z0<:QLH1B5V(PT
MK;SYU0E*4[JE!7ZL<&@61KNI'8P'?C[`KZ4?5Q]@5]*/JX^P*^E'U<?8%?2C
MZN/L"OI1]7'V!7TH^KC[`KZ4?5Q]@5]*/JX^P*^E'U<?8%?2CZN/L"OI1]7'
MV!7TH^KC[`KZ4?5Q]@5]*/JX^P*^E'U<?8%?2CZN/L"OI1]7%,Y3TBF7Z9U+
MC:RX%"R])&$6*LG;H$%)H%6?^5'U<?8%?2CZN/L"OI1]7'V!7TH^KAU]B@/*
M)2<.)T%.*4DX@$@D8I3`()%@(,/YG6JQ.U"U.+/YRB293G("<@-`D(2ZT2E2
M2""#(@BT$'00;0888SVF545200IS&E!4)G"5)P&2L,@K5(F;28^P*^E'U<?8
M%?2CZN/L"OI1]7'V!7TH^KC[`KZ4?5Q]@5]*/JX^P*^E'U<?8%?2CZN+:!?T
MH^1&&J8?:UP$+&W)0.XDP$4U:@*/Q5S;.P.4"03L$P%),P?]".6KGD,H_*6I
M*1NJ($$(?4^H:&D*.XI6!!\*/^7HG5#\Y2$[V./L"OI1]7'V!7TH^KC[`KZ4
M?5Q]@5]*/JX^P*^E'U<?8%?2CZN/L"OI1]7'V!7TH^KC[`KZ4?5Q]@5]*/JX
M^P*^E'U<?8%?2CZN/L"OI1]7'V!7TH^KC[`KZ4?5Q2<X<FI%L5E"\U4,.!U,
MT.LK2XVL3;EP5I!D;#*V.;/^9#FGET\E]HU#ZXYR:P$4N=4Q#&;T2I!?#2^`
M[B4075K>*4R;5+[`KZ4?5Q]@5]*/JX^P*^E'U<?8%?2CZN/L"OI1]7'-3FZB
M@4EJE?<S!U9<"DMIR]ERJ;44X+<50VRV/SE@V"9C)^<0HBXUGV5H*G`L)Q5%
M&\XRX)83,IIUT@GKQ]@5]*/JX^P*^E'U<?8%?2CZN/L"OI1]7'V!7TH^KC[`
MKZ4?5Q]@5]*/JX^P*^E'U<?8%?2CZN/L"OI1]7'V!7TH^KCY^B=2/S5I5OA$
M`./+IR=#K9'91C2-L@1RN7OMOIU4+2J6S(F1UC;UDJDRT"KJ!89&32#KK$\1
M&D(LT%23!I6U..!7[E@*2@`_E!-XUW%&6K`J><=8QES9_+4%+V)8DH)V%DZV
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MJ%H("G"DF8N4"-6"VL2(L(@*"<"=55FX+SO:\)0K)VU$``J-14S)`O,G`)F^
MP`:D?@K7\15?6Q^"M?Q%5];'X*U_$57UL?@K7\15?6Q^"M?Q%5];'X*U_$57
MUL?@K7\15?6P,62MR^\U7UAWHPO9%*<[4UC]FI(&8W3M:(D\FKH%:H(<0-N3
MBR/T1!>YK9FS6:>34<"QN%5O&2@0`>5IA.X\)E?C-*VN$-40FFS]OU=9LY5$
MRV3^<FU2-F:QJD"V$O,*"T*`(4"""#<0180?]!/6<T=")SPI%JUD:$IO.N3)
M(G:1!8R9/JC9LQ6*=.W+"C]$%0T+CUUY"@E5I>J%%,QJ\*;BAKA)&O$L\S?E
M7-**9(40=3%)P>$$;$2I\NJ:J4[77N3G]&HV:;@=40>1R-*=3%5U*MXI[4?@
MK7\15?6Q^"M?Q%5];'X*U_$57UL?@K7\15?6Q^"M?Q%5];'X*U_$57UL?@K7
M\15?6Q^"M?Q%5];'X*U_$57UL?@K7\15?6Q^"M?Q%5];'X*U_$57UL?@K7\1
M5?6Q^"M?Q%5];'X*U_$57UL<\?\`*I4Y8VK,J5MSG/S8:+KRBYF="T4U]`TH
MKY7E*ZBL9;2I+25)?><!,?@K7\15?6Q^"M?Q%5];'X*U_$57UL?T/(J/)J%<
MT@N9IGS.5M35,)"#75K*WU$B6"G0\L$B:1,38S7GGGN24=([)0.5N9AFN)%\
MDN./4#.(W8D*=0GOARDL)?Y\\SW:RLSBHI'*);U2XDLH9==9>7R+`22VM2F&
MP5J=<4$8D`@+4#E=%[1S5-.Y*JH51O4KJ6UH-4&0^E84A8<0OU=DE/!(*`0H
M6P]6^SOG!EU0VD%26\U17T8;2!,\I54U16!0`!)<%*V`/B63/J'.1GF_F)QE
MN>5<XF<P6E0!/SE*S5^O,IL(QOTK:)\'%B(!_!6OXBJ^MC\%:_B*KZV/P5K^
M(JOK8_!6OXBJ^MC\%:_B*KZV/P5K^(JOK8_!6OXBJ^MC\%:_B*KZV!RV1H5Q
M:NI3OJ5&&IRM^F!TM5"G"-IPI]^C5PY/FRZ9PW(J4IOT#%)M.M8I9V8%=0CE
MTIM#E,LE0T@A(PN;:00-6!3YN/6VP9'%P74ROX4N$1I"P2;L0CE<M=FI(X3:
MN"XC93I'YR24Z)SZLNMK5AMIL34HW`=LFX`6DR`!)@Y9E`4S3*.$)3Y5Z=@"
ML,S(Z&TSG.2BJR7]:Y\/"F9$B&0>$K2`HB9F?]VV"O\`.201'],YG4Z:&G%F
M/"GE#K@6I23I*L:S?B!@U56I2U*O6ZHDG;,U=J)OK*M86#M]J/)SV2>['DD[
MD>23N1Y).Y'DD[D>23N1Y).Y'DD[D>23N1Y).Y'DD[D>23N1Y).Y'DD[D>23
MN1Y).Y'DD[D>23N1Y).Y#:\"<$Y$2LMN,>23N1Y).Y'DD[D>23N1R_J[>/\`
M*PB>[*/))W(\DG<CR2=R/))W(\DG<CR2=R/))W(\DG<CR2=R/))W(M;W"1VX
MFVI23NCN]F`]3DDIM"D$A0U[+0=B<&ASY(KZ97!4EP`K`T\(@A>N'`2?RA"\
MQYE.AE](FJG69#8PF9;)T$%31-@PR)!H*I"N22?G*=RP<9!MPDWA29H5>0H2
M,"ORU>)-RDFQ2%2GA6-!&V#>"1;_`*!*R_+P'ZS2#WC6H5RO5J(!&JHBP*57
M/J)23PWW.]'YJ`)3EH0B24Z2D&<&FRID9C7I[YU1!2A6IBD0D@_%;&*]*U@B
M"BI=46S^Z;FEH:DQ.W6*RHZ\3?4$ZPM/<WXX0*MDGM2BQL;<S'DD[D>23N1Y
M).Y'DD[D>23N1Y).Y'DD[D>23N1Y).Y'DD[D>23N1Y).Y'DD[D>23N1Y).Y&
M2^TSFRD(K<EJFJE`'!#B4F3S"B!/DZAE3C#DK2VXH"!SXYD,)/-CGQ3-9_E2
MTI2$);KARE33202A"Z6I+B"P""RVIE)2)B?DD[D>23N1Y).Y'KW,G-:S)WYA
M7*4-544B\0N..G<;5,2$C.=D)]E?M3YPU&<Y?F&7U9I$5096ZBMI^2J`OUDM
M"I<'JC54"VIU222%RFF<<U^9WLIS=S**O,T5M36N-(84X6&RPU3)2MUIQ;>)
MPU)*FBVKYM(Q*!(27?:#GV8YV2<4JVMJ:E((NPH><6A('Q0E(";@!'DD[D>2
M3N1Y).Y'DD[D>23N1Y).Y'DD[D>23N1Y).Y%K8VK(X(*=@GMSB;"YZQL[([@
M@"C>6TG\@\)M6KP3--NJ)*U"(32\Z&!1U9L%0B24DZ.';(?FNA2!^5.$9G1N
M%;(,T5#4P4SN"P.])V2A4Y3-HA&59V0W5&00NY+IU"+DN'4[U1[T`R3U1=75
M+"&VTE2E&X`6D^^TW"$9?EZ%<ABDRR.^6J[&N5F*7Z*$SM[Y1369B!59LZF:
M4#XD[)),N`@7*<(Q+,PD2F`:JM67%:!:$-I/Q4BY([*KS,S,!1&->J=&P-&_
MK];%*3,*%AU]'9@N'OD@@[(';A`.H.S;UB>43)7Y0O\`AVX16T;BFU(/!<39
MM'9N*3,$6&8G'](S@)I\R;'S;@`X1$[4:2/]XT3=PDW324+&%:;%H,^3>;G8
M0=(-I2H":3,$3Q)AO,J!4T+%QO2H=\A0T*2;#H-X)!!/N_\`TW+B%5C@G.\,
MI-RB-*S\1)L^,JR04O/<]66Z%LJ6M:C(ND6JX1N3.>-<]5*3BF4C(N;`-/1(
M&#$D8%.`622!(H;.I8I7QI`E)#M7P1^3I.SJ;^Q&!I(2!H'6=1F5+3NN4])@
MY=U+:U-L\JK"WRJP"EOE%`I1C(QJ$DS,9W[,E_.\XO9BX[GV5#@EQ[(ZI0&<
M4B/C8*5T^O+(F5*4PTD2$<\^<C].VJIS7G7EV7-NE"2XCU2F8K9)5AQI&%UP
M6KPD+4``2<71YG<\UN<DS29I2I?7.6&EJ'!351GJ>K/.SU199&8Y4VK$US?H
MJ'+DD&8F6S7._I)=K5MJTS;D;NK%"P"#H-H@N4>VGN'M?[(_I6;@U%`K@J0H
M8BV#8<(5>G\ILV'1(SF.<W-97+4+G"(02>2M[Y)OP3L,^$V;#9WHR+.5SJ`/
MFG#>X`+4JU5@"8/QQ.?"$U=2_P`-T2OFFI%XCXR[PCBHL)&E=XF@0><F;)"J
M^I3)EHV%((F$ZH)$E.JO2)(%IDIRMK%E:W#B6HW#4`T``6)2+`!(6"`TT)`=
MG7/6Y=I+M*-!V-0^_6AQ#<QRLK#>%3$P>S`2-'610L3!O!A-52J*0""E0-J%
M`S%NL;C[R<OK2EO-:030N[%<,4A\1=B7$CO585`2D(5E^8S0PXODWDJ_=K!P
MAS6*38J5Z)WD)E,>[SF9/2*AP6T?EN&>%.Q85*.A()%LA"ZO,5%305RE0X;)
MSN0G4*I2`%B$`D7`$<WLDDB@IR$\"P.%-@E+]VD]X+B1C,^#(/OCAFX?D_#O
M7=:U=7S;13U^5YLA#&:Y76M)>H<RID<H`T^V;0I`==Y)U)F@N*"@XTMQI>6_
MY@O\HJRQ5T:B></,:L<2NJ_IU2"SF7](6N2,QI>2<*FF%@E#J6C-IQ3-&G*O
M9+EZDFCS'GEF.;T?"FKU(4;K=,E04<86RS4MLN<$`K3B,BI,^DS/GUSD<Y2N
MS6H=J7E"[&ZHJPIMGA0)(3,DX4B9)F>L"XV).#];6.OJ&#09@,5$\9.((G@)
ML*P--EBT_&3H)`AK.,F412/D+96DSY-??!(4-$I*;,[4S%N$DA]<A4M22\D?
ME2L6!^2N1(U"%)MPS/4'LR3(N`!+8.EQ5B=D"U1&D),.9WFIG3TAY5Q2KEN6
MJ&(F\"16O8`-BH+K4^12<#*3.Q`/?$:%+[Y6D"2;<(@--Z+SJG5/7*738I)!
MF-,C<>[UH6W!,&PPW74:I+:.))T*3<4G64)I4-0F6B*?GUE(X+P2E](^*KO4
ME6NE0Y)1TG!*!1/JQ/49"#.\MF9;.T`4?H3T^[W],HYK;ICR2$IMQ.D@+(U2
M520-9((O,,<U*!0]:JDE3ZQ>`JQ9_2/S:3^0@Z9&/6WAQ1^UW-W4ZWIN<7-N
MK=H*^C6EUBHIW%-/-.)N6VX@A25#5!%DQ<8YK\WO:*AIRLYM&MQ5K7S:JX5:
M:-*%U%.D!I#[(I5S<9PH<#QDRV4DN=:^MM#A)[[7&KLC3K;$/<QLY,Q@*F%_
M&3*V0G\9L\-.JG$D\$2CU>M.%&-3#XT2Q2"]A*@%@_DSEWW46,E;5P&$\HH?
M^47,"?%0`1QS%)S>:.&IS#YUZ5X29*4#I'Q&]0A"QJP:I=ZK$[&D[9LVO<\J
M`X2+1VQMCLB*WF;7'YJK;4IO\U8$E8=>6%8U"V3IA-#5\$.*53.#45BDG<<2
MD3U"?=VJS,&2FFR4SNQG@HW5E(AS.:X_,T""\M2KL9GA*CK26N>J@0[7.3D\
MLR'Y+:;$IVD``ZJIF\P$I$@+`-8=?O>S_-BI3U/2Y<^I2@!-=9E]-5.A,K,+
M;SSC0%I')R45$$GJTC#==2&2FE!:-<3M2=8B:3JC9BBYTT(^:KVABXZ0)8OS
ML!"2-5LQ2U3AFXA/)KU<39PS.NI(2H\;J"D'A(?J@C_S2%!,_HTSA]+9FEI0
M81^AP5;1<*CMPEM%R1(;7N@W7,7L.!8`TITIV"DE)VX75TYD*A+;Z"-4B1(V
M5H*MN&*U-SS:%^&D*[?NXQ0),C4.S.NEM))'A*0=J''DV.YH\4`Z>302#M?-
MK!\Y"ZDWG@CL$]K<Z_YJ<QUHY1K,LTHVGA*?_+\NA5292,PFG2XH@V2%LA;'
M-SGZRW@;SC+%TRR!8M_+ZA14HG\KD*RG1?WK:;+R>KI>%Z#;L'X9;L5N7+X3
MF6N)>;UD*))[!>.V(K<L4>]4AU(XP*%G]5'3K>LX"2;;K!.W6A-8[:*=IYT[
M39!,]'?7V[L<LZ9DE2R=4F9GNF?N.5K(``F23(`"\DFX""Y0NI=2DR)209'7
ME=K:HM%G44.CXP(W#\,9#F"C-2F'6B=)Y!:4"?=O)))B@<5H:"=I!*!V$^[E
M'2SL0R5RXZR.SR8W(R/*!9@I`^=E\SW04JV)PVG5$]VWM]>_T7F1E59G%9+%
MR-%3/53H3,)Q%#*%J"`5`%1`2"1,VPE]SF^C)F%W.YE5,4Y'&IT*>K$ROX5,
M`=!)!$9;[6N??."DKJK*T5')45&P\MKE:BG=IN4-4^6%$-H>64I]4M64JQ(*
M`3EN1T.:(RC,,HJEU##SE.:AMQ#K*FW:=02ZTMH+4&7.53RLN1PEI6,*0MW(
M&<NYP-IM'J=:EITIE.UNO11C%^:AQ9)L25&"_P"T3FSF.4,!00'WZ5U-*I9N
M2BJ"33K4?R4.J.MU9;9TI.]%;E"^]K:1YO\`2"9@[2<>["FQ<ZPXG<*%?L]G
MIZM:;TLND;2%1FKHO3EU3*V5I+:9[6*<+5J)END=SW&77.`J,PE(&E1G*>H!
M(DZPLM@&O>6[*9&(S`G?(7#:$"JI#,&Q2#/"L:A&M>#>#K$@M5024<JA*\)O
M&)(,CL3EU!"M14MT'N1EZC^ZJ:A'A!"[-;M[$4J?R2Z/_3+/;]W&/NJ/2O11
MI_(HJ5/ZF+:[[MZ82G4`[`Z]15T3JV76S-*T*4A:3JI4D@@ZX,(3S=YZ9D6T
M=ZU5NC,&@/R4M5Z:E"$VFQ`3*\2,C&4^R/VHL9>\QFJ:A#=:PPY3U(?9I7:A
M`<"7C3*2Z62V`AALA:Q:18,FK.95+256:YU5/-(%:EUQENGIV<3S@;9>86IP
M..TX3-S``I6)*IB2VG^=3N6,*N:RUEBBPSOPOM-BKT?&J%2T2F9_U'G;FE7F
ME09_.UE0]4N6VGAO+6JTVFVWJ](DW$NI(V6G!N3D=J*?BN^C5T];YA[T:HS?
M^W/^.S#FP-_W&;J$E4FG!,`&1Q`@$VV2-@/YTM/0IW*=@NMMN(*R4S;"003B
M-W>@R!M.@&)#J">./%5%)]\>]$W%/QG?2*]W&/NJ/2O0U]UI/Y=OW`YL\^\1
M2C*<SHJES79:J&U/H-]BV<:%2MDHRMC).95.K&UDF5AU4CWM17O+6M.I+U=B
MD4#IQ2T"?6%)*SY\_M13\5WT:NGK?,/>C5&;_P!N?\=F'-@;_N,4+`*3800"
M"-<:854*0IZ=R'%`H3;.P!*2=3AE5F[`:82$)2)`````:@%W44\<>*J*3[X]
MZ)N*?C.^D5[N,?=4>E>AK[K2?R[?N"YSVS\DU3U-0,+FK%,T5!346(3NY3U?
ME2-"EF<S,GK"D\^?VHI^*[Z-73UOF'O1JC-_[<_X[,.<4;_NBGCCQ512??'O
M1-Q3\9WTBO=QC[JCTKT-?=:3^7;]TJ3SY_:BGXKOHU=/6^8>]&J,W_MS_CLP
MYQ1OP.H6^Y">./%5%)]\>]$W%/QG?2*]W&/NJ/2O0U]UI/Y=OKWF*E#/)?U;
MFQEM14V2_P#:*0M-:FX3*"IFT\(XAB`ZUI//G]J*?BN^C5T];YA[T:HS?^W/
M^.S#G%&_`ZI?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?"Z^M7@:;$R;3>9``"TDD@`:
MIA363,E:K)..6)U^`+3*X34+;9$7EE^3=4V)K2+$J$^^1,DRNQ`F8.J+8OB^
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MKT-?=:3^7;ZZ;H><&:-Y/2J[^I<9J*@($P)!JF;<<4J1)`DE,@9J!D"TO._:
M^UF;KF$BF8%/DCJE'XB49KRU0Y;8<++:Y3L02)4G.WF1D@=S*F.-BN?JJBJ<
M25)*<;86Z:=)*5*`4VRDR4;;H>YF^T#+V\SRRH*%+8<*P"ILXD*"FU(<0I)M
M2I"TJ&@PY79CSB<YDF6)*7<VIBR`;OFLSY6H<G<E**@*49`%1L+H]G/M'IN=
M3J"),(RNNIE2)%@J9/4;A`G:EX`RM"9V=7]^O!Z%)Y\_M13\5WT:NGK?,/>C
M5&;_`-N?\=F'.*-^!T/?J]=(S.@FIVF2H%L`E2TD@\&5N)-IE\8&RT2(6A@L
MMSD5N\#4G))X9E.\)E81.<>NJ<4]4%)23(!"9F9PIOG8!,DV3L$Y=6GTB>./
M%5%)]\>]$W%/QG?2*ZZ_JU8@O%2@A#:2$E:C;>9R2D`DF1E8)6PIC)DHR]G$
M""GAO$`=ZIQ7`D3;P&TJL`Q$3FG)LZ6$9D@2!,@*D`*)4@``!:0GAH%XX:;,
M01U^Q]U1Z5Z&ONM)_+M]><UJVFS&HI\L7F=*U6,I?=13KIZEU-.^IUH+#;F!
MIQ3@"TD8D),Q*8R_(^;E:]0UV=YDVV5T[JV7#24[+SM0`XVI*Y%TTR%)!DI"
MU!5EA4^^I2UK,U*425$F\DDDDG5/25!RQA;WJK*ZA[")\FRV4A;BK>]25)F=
M?JOOUX/0I//G]J*?BN^C5T];YA[T:HS?^W/^.S#G%&_`Z'OU?<Y/''BJBD^^
M/>B;BGXSOI%==)IW4E*&*=M*)SDL**UJ6!=WRB@D?[O6L@UM2ZI"\O2EY"$C
MOS/#-2M"4DIFF4UXI3`!!Z_8^ZH]*]#7W6D_EV^O`ZT2E22""#(@BT$$6@@V
M@BZ/9TEA86G_``Y3YJZ`1)%3F^`NM*`-BT)HVYBX!0D3;+I/:2X\V%!?-Y[*
M&5*%B:C-@X6W$S^.UZE.8GAQ"<L0F4+!!!D0;""+P1H(ZI[]>#T*3SY_:BGX
MKOHU=/6^8>]&J,W_`+<_X[,.<4;\#H>_5]PK.H#GASC9%5C6I-.RL3:`;.%3
MBTW.$K"DA"P4`))*5%22D%&6L2E9\RT+-B4?AK'T3/<C\,8^B9[D27E=.=EE
MD]J`T<KI\`,PGD69`F\RE*>O&%%*D#4"4"/LR=Q$?9D[B(539A3AIZ7!<0D)
M6DZ#,=\F=Z533?<;0]E[_?L+4A6I-*BDD:QE,:W6R<XR@%684Z`VE!4E*76\
M95AFJ02I)4HI)4D&9"C=)+_..H31)G:TB3KL@?RDJY)).@A3DM(G9"D9(R4K
M<`#CJU%;CF&[$3P1;:4H2A,[</N`Q]U1Z5Z&ONM)_+M]>LG,'E/>KM(9;Q&>
M!IL20VG42D$R&OTB*'+67*AYPR2VVA3BU'42A(*B=8`Q65_.S+ZC+<PSK,GG
M^1J67*=X4S+3+#&)IU*'$A2TON()$E(<2I/!()YT(J,GK*?*%YE6/4=2NE>3
M2N4KSRGF>2J"CDG`AMQ+:E(60%H4#A4"D=2J,YYP)+E'1J2A+0)2'75#%):A
M(X&TR)2""HK3,X0I*D(I,KITM)`"0&6@`!8)#"+(_#&/HF>Y'X8Q]"SW(#K>
M5TZ5"T$,L@@ZLP)P'&,L80H:4LL@[H$XPII4@#61'V9.XB/LR=Q$&FS:D3)0
M,E80%`ZJ5IM!&SL@B/\`"N,X,6+E)6\CAQXKI8L/`NP\I9=T*WS#WHU1F_\`
M;G_'9ASBC?@=#WZON5E6S4?SC_46CK*WQ%>!_O3O#W88^ZH]*]#7W6D_EV_<
M!O\`QQ[-LLYTK1>\]69@RZL3GPVG7:R@)%HFBB;F)`B\E&5IYM5',Y)"0I-+
ME](JD2!<`:$H>4$ZGJ@D.]!NACGM[/:].9994*6E#R4.M34VK"M*FWVVG4*2
MJPI6VDZ92(BLYH\Z,U=JLUHC@J**DI'GUH44!7)J=4ENDQ$*`*34329I6$D$
M0\,K]D%'F3KH(%97FFR^ITR*SES3KZM60KDX23A5.TNYCDV54^34Z^\I:9RK
M=:;%MSE=4U=0HG25/$66)%L^H9A][_X+4,\1'BCJ"#^>/%5$Y?\`T&>WCE/<
MLV.A6^8>]&J,W_MS_CLPYQ1OP.A[]7W*RK9J/YQ_J+6PKM17^=.\.LBI1D!:
M2;@(+>2,.5BP5#$KYINP<%0)"E*23HPI,@=40<IYTH;IW'E?,N-@I;MF<#F-
M:BDW!"IR,Y*D9%7N&Q]U1Z5Z&ONM)_+M]0LZZYT\R*MP)_I->U6@J(&%FNI^
M3-I,@A"Z%:E&Y)<))X0C/^?#BBK^KYC658G.Q#]0XXA(!M`0A24I2>]2`-'4
M3T,P^]_\%J&>(CQ1U!/''BJC_H?^)T*WS#WHU1F_]N?\=F'.*-^!T/?J^Y!Z
M&5;-1_./]1:V%=J,TI^:M&JI+#DW%8D-H1B`PA2W%(3B5(R2"5$`D"0)"LIY
MQ4CE)4)^*L7C\I"A-"TG0M"E).@]8\E1N+:<JW4-8D&1"9*6L%0D0%!.$RM(
M)%T^A3Y4RM+:ZEQ#:5+)"`5J"05$`D"9MD"=:*7*W72\JG:;;+AO64)"2J\D
M3(L!)(%A)O\`<-C[JCTKT-?=:3^7;]PN?27'>3_K/-G,*2GME+,"6Q1KE\8H
M"WY)E,XKP)]+F?/6C1BHLIJ**GJ%6S0JO35EA6IA)HW$FV>)29`C$1T5OO*"
M$(!4HFP``3))T`"TPIK*ZI#JQ\7A(4=<)6$J4-<`C7Z&8?>_^"U#/$1XHZ@G
MCCQ51_T/_$Z%;YA[T:HS?^W/^.S#G%&_`Z'OU>I6];V=-BS"H0V3.0)FHROD
MD3)U+KY"\B'/Z>LXFY8DJ&%4C<93((,KP3+3*8Z",GS(K#U$ZM*4I3B*D.K4
MZ%`\%(DI2TD%4Q($3!``"VGB=7`!/_TD>1>\`?+CR+W@#Y<>1>\`?+CR+W@#
MY<>1>\`?+CR+W@#Y<>1>\`?+AQQ;I8Y%!5)Q.$%(OPD*5B5:.#WQ^*#&9Y9S
MFQ4K>951J&J@C$A&(!`;>E-20`E.%8!2"58\";832YNRSF%&\,3:P0H#$+'&
M7D&:21<MM0F+)D60YFO,92LRI!,E@R]:;'YH`":@#\P)<N`;7:J%,OI*%H)"
MDJ!"DD6$$&T$&\&T=2;.?U(8+L\"<*UJ5AOX+:5$"T#$J29V3AL93EZELS^<
M+JPA9$[D!&-(X-LU$VF4I"9:S?*7.58=%AD0009%*@;0I)!!!WI'HNY*VX&7
M"I"T*4)I"D&<E`6R(FF8M$YR,I%>7,9<ZE;1X:G!R;8D<,^464H5J@(*BH`J
M2"`3#&<<XZCE7V5H<0RU8V%).(8UJ&)<E83)(0)ID2H&7N(Q]U1Z5Z&ONM)_
M+M^X_M%SM;,ZG,WG*Y@RX2F,A2Q4)*3>27&ZYH)%\RD6J/29B1_N'/%,!;9*
M5`S!!D01I!T&$L9G_P`XR+)J,G0-9?QOTP2;L0C,,DJ'RAU:DU#;93\XHA(;
M<0$W$@!"@0HIEBFH$6I9+3R@D2!Y,`R%W[R/(O>`/EPNIJ6W&VVP5*4I*0E*
M0)E2B7)``6DFP"/Z`:%:,D*<":]1DLU$["6IR33$32'"O$#):DI1/#2Y7D>7
MJS*J4XA54VI0:#-,1,D+!7-]8*2V@C#AFI92"C$WG&2!UUE=AX`"D*$IH6GE
M)I6F=H.L02D@GR+W@#Y<>1>\`?+A%$I2J<6D%Q(2B<M*\1`LG*<AHG,B/ZW,
M^J2Y#%_Y/#AQRGWO*</5P:,70K?,/>C5&;_VY_QV8<XHWX'0]^K[A6](JJ8`
M+KB@VB9E(J!)59(G"`3($6RME!4HS)M)-Y,-U66DAY)X,AB))LEAD9S!E*1G
M&1\U.<X6VS7E0?#*@E:5)IW'2$*4E8$EH`M!LGLPM-*Y7G'(G%4-FZ<I2IQJ
MQY2M^G;^HCRE;].W]1'E*WZ=OZB/*5OT[?U$>4K?IV_J(\I6_3M_41Y2M^G;
M^HCRE;].W]1'E*WZ=OZB/*5OT[?U$*'-VNKN07,JIW7FW&%$_&P%D8%7<)LH
M49242+.@I_,F?5ZZ4DU;("7;K`X.]>2++'`5`6(6B9,(R[-'F:AMX%33C2TX
ME)!O6R3RK9V06R9A#BY&43,%C(Z==:L*4DJ4>2;D+E),EJ6";AA1,6XA9']+
MYUH;8+R@&76P4M@F?`=QK40#8$K%D[%R[Z)CI*NI<=+C+3BVV`1():0HA(`T
M3EB)-I)F=015YZIV5"X"T&YGA/)4A7*8;A@3-`,YG&1*0]R6/NJ/2O0U]UI/
MY=OJDSURFGID*<<60$I2"I2B;`$@3))T`"9A"N;/,W,UH<EA=J*<T3"@;BE^
MM-.R4ZJ@X4C21&1>R/G,RD.MY>XU7M)4E:0]6EUZL;QC$A<G*AU&))4A4II)
M3*'A5<TZVOID+6$/T"6Z\.-I)PN<G1K?>;"DR5)UM"D_&`E"LNSJE=HZA'?-
M/MK:<3QD.!*AMCH9AYASQ3T4NM**5)((()!!%Q!%H(T$0BDSX?U*F$A-9D^D
M:SLCCE?)P*4;L:1#&?945%BH!("AA4DI44*2H3("DJ24F1(,II)20349!7*4
MA#X$E(,BE22%(5*8"@%`$I-BA,67AW(\W3A<;M"A:EQ!GA<0=*52TV@@I4`H
M$!+384XZX0E($U*4HD!(&DDF0`VH6_F"BJOK`DO)"IMMA,REM(%BE"9QKMF;
M$G")JZ6M\P]Z-49O_;G_`!V8<XHWX'0]^K[ARZ*'*1M3KC#@5)-IPD$*.$6F
M5ALM`F;I]"FS0M%EEIQ*RI8PE21(D)2>$0H6!4L-LYV12<[,@4A-91J4ILK2
M%I!4A39FDV'@K.W;#R*M^E*T82`*9(X-Q-]TRD:Q(U1'EJ;^'3W8\M3?PZ>[
M'EJ;^'3W8\M3?PZ>['EJ;^'3W8\M3?PZ>['EJ;^'3W8\M3?PZ>["GVU,*0B6
M)0I04IF9#$9R$S8)WF&\MRD,U-0Z9(;;I`M:CK)223JG0!:;(3F?M%JZ=K$)
MII&&48Q,?OG@5)!!^(UBT3<O3"\VS^I;I*9N];B@D3T)2+U*-R4)!4HV)!-D
M.95[.FS3M6I-8ZD%U0NFRT9AL:0MS$LB7`;4(<K\Q>6^^Z<2W'%%:U'54I1)
M)V3T%)I'%M.53K;(4BPR(4XH%5A2%);*3*TSE+"52AC+FE)0JH<0V%+,D)*U
M!(*B`2$@F:B`9"=ABDRIQPO*IF6VRLWJ*$A)5*V0,K!,R$A,W]([G#:0NCKW
M5K04)/S:U$*4VL`84DJ4<$B<:0=(("''V/4J=4B7'SA,K)X6A-PF5J<24I/Y
M8@Y12NJ?QN*=6M0"9J4E*;$B>$!*$B4S;,SMD/<AC[JCTKT-?=:3^7;Z]YEI
M;9Y(9WS9RRO>($AZ\X'!5H.JM!#95HX:3?.73IH^;=)DCU.F0P+R>BIB4Z0I
M[+44#SA5:2MUQQ9)))-T(8]H?,]23\=_+JP*GQ:6I;1*6O6&<]$K<J]H'-OE
M!0YQ3-53*74I2ZA+J0KDW4H6XA+K9FAP(<6@+2H)6I,E%ZB]GO-:KS/`I2`_
M65+-&VHI)&-"&$UJEMDB:)K:4I)!.`\&%Y2]EN1T5&9A*#EC68*`,IXOZH:Q
MA2K+TT[8E+@S$X>KGPA*WEJ6H-M-LM@J)40AEE#;32`3P6VD(;0))0E*0!&8
M>8<\4]%&7Y6RNH?<[U#:2I1U;`#8!:3<!,D@"$5O/-_U=%A]79(4X=9;MJ$:
MX0'"1\9)AG)\I:#-.P,*$`DR!))F2222HE2B222229F*K/*6F55.,(FE"03:
M;`I<K0VB>)PBT)!NO#V;YJX7JA]6)2CV$I&A*1)*4BQ*0`+!!I:YI;#R)$H6
ME2%IF`H$@@$3!!&L01#E)G+2UN4.%`J2."\"+$J4;WD"6,B<TE*E249JZ!2P
MA2RD%1P@F0%I)E<`+S<.C6^8>]&J,W_MS_CLPYQ1OP.A[]7W'75T=,AMQ9F5
M`6WSX,YA-NA,A=J"#T&LZ:0/6,P6X5K^-A:=6RA$]"04*5+5423<`.4<,],@
M)1Y16X(\HK<$6.G<'=CRI\'X8\J?!^&/*GP?ACRI\'X8-*_)UMU)!!%A%Q!%
MH,9]D^:5%/1UZ:GYM;ZT-J72@<!"''%`'"J:EH!!,TJ(4!P5Y9S+"<TK!9RT
MSZHV=7$)&H.LV0V9SY4D%,?U/G-5KJ7!/`"9-M@F>%ML20A/%$S*:B3;TC^1
MI<#*W,*D+(Q`*0H*$Q?(R*21:`9VRD7,I8R]P+:)"E+')M``RQ!Q>%"@;TX"
MHJ3:D$"&<TYS5'+.M*2M++5C84FT!:R,2P#(R2$"8D2I)]T&/NJ/2O0U]UI/
MY=OKS(>9#0).;YA1T=DY@5-0VTI5EP2E943,!(!)(`G'-+GU2-!*<MK'\O5A
M$I(K&$O-#"+`A!H5A-@"2L)^,!U+G%FO+2J>:S.<4+9)DI+U0GUBBMOERN8-
MH0?S2A)FF0Z.8)2)GD'>P@F!2T32G7%7)0"H[@T#2;AI@5'.%SDDW\DV05["
MEVI3L)Q3&D&,PSVAID(>2XFG0J4U)2$!:SB,U$KQI!)),DR$@2"EYUP@K`,@
M+@;1?'E%;@B1<.X('M*HPI*$?.HR\H2:5NLQ8A4($QA2GOD4^$H0[):"E*4M
MIH,SSBH<HZNC6E*WV$)Y1^E!454RBHX1PCB:=*5EHE<DJ"R(I^;W-Y":2CI$
M!#32$22E(VR5*425+6HE2U$J42HDGRI\'X8\J?!^&$N!6-*C*Z4CNF^V/4>3
M'JN#UGD_B][+#?WO*VRNP\&4NA6^8>]&J,W_`+<_X[,.<4;\#H>_5]R#T,JV
M:C^<?ZBUL*[45_G3O#W88^ZH]*]#7W6D_EV^NFLIK\TI,G;=L]9KO6O5T&8`
M"S1TM8\F<YXN1*0`<2A9-IVL]J^59BXO#.DR<L.OS5HQ5%0EY!G8`N@"CJ"Z
M*/GCDM/6YCFV7JY2GJ:ZL4HM.82G&&:9%+3J.%2@`ZRX$S"@`H!0=YC>T2C-
M=ESJT.X`ZZRM+K1);<0XRM"TJ02?C%*@2E:5))!=SC)^=M9S9:$R5Y@NDJ:1
MO;<-"L)`_+J5'3BAQ61>T/(.<V$R2S0+JW:E9G_Y"GJ:)$K2<=>FZ0F2`>GY
MX>R$J4?\1UV3/(2`<*6Z-=2]5*492X3C5`D))F93`(2HCHD&T&%)RZG;8"C,
M\FA*)G7P@3UM06"SH9A][_X+4,\1'BCJ">./%5'_`$/_`!.A6^8>]&J,W_MS
M_CLPYQ1OP.A[]7W(/0RK9J/YQ_J+6PKM17^=.\/=AC[JCTKT-?=:3^7;Z\YJ
MT%1SBS`Y&_F5+355&Y6OKHRQ4N)IEK73K<4S\TESE`K`%`H!!!`BC8YE9D_E
M>:9QF35.'Z5U;%0BF:9>>?4V\V4N-DK2PV2A05A<,C!S'G%75&85!O=J7G'W
M#I[]U2E=GJQZ&8?>_P#@M0SQ$>*.H)XX\54?]#_Q.A6^8>]&J,W_`+<_X[,.
M<4;\#H>_5]R#T,JMN-1/6_YM\Q,=0:3I`/9(EO&*\IM^=4-L2![(]V&/NJ/2
MO0U]UI/Y=OKQ+[*BE:"%)4#(A0,P0=!!$Q'LY9I'`IMSF^UG"PDB27<XY.:%
M@7+;31C@FU&,B0Q&?5CT,P^]_P#!:AF7Y"?%'4$)TE8.XE4]\1AG;ZE+;QXI
M;EO0K?,/>C5&;_VY_P`=F'.*-^!T/?J^Y!Z!YL<YIHI"M2VGT@JY(JM4A:$@
MJ*%'A)4D$I453!2J:`6\^ITIE8/6`F7Z)((V"!'X_3_Q*?E1_P"\%-_$I^5&
M)WG%2I%TS5)%OA0FL5SBI0TI12%^M)PE0`)2#BE,`@D:\"JH<Z9>;5.2D5`4
MDR,C:%:#9'XLW]/_`-J/Q9OZ?_M0IRE?%;4$<%*"5">JMRX`:0"5&X"\ARLJ
M#B<=4I:CJJ422=T^[#'W5'I7H:^ZTG\NWU>WJU.<U?4]ZHPU3,XOW;#((;;3
M^:F9ELGJYZ#U+FB%.4%9AY3#:MI:;$N)'QDR)"TV$C"I)FG"H.4V>,(0;0%.
MEHVVVH7@4-M(.W'_`+P4W\2GY4?^\%-_%)^5":2FYQ4JW5&02FJ25$Z@&*<X
M%+0\X:9YQ4Y)15)4HR$S8%:!;'XLW]/_`-J/Q9OZ?_M1^+-_3_\`:@OKK!5.
M`<%#9+BE'0,5J4[*B):YD#_BN0Y7'/!\7!AP<G]'P9WSX5_0K?,/>C5&;_VY
M_P`=F'.*-^!T/?J]9AIA)4HZ!V]`&N8Y2N="-82LV5&SL;<8346^<1W)1_RU
M1/;0K>E'S3J3L@C>Q1B>3-/Y0M'=&V!K=8'ID\<>*J*3[X]Z)N*?C.^D5[N,
M?=4>E>AK[K2?R[?6X<5\V@Z57G8%^[(:\2J:BT?G)3V)$]F)-U-O'1O$3C%3
MO@[(GV0>U!4@I7K`D'L@#LP4.`I(O!L(ZA/J!Z/OUX/0I//G]J*?BN^C5T];
MYA[T:HS?^W/^.S#G%&_`Z'OU>L4T[/?*W!I).L!`5F+N)6I,C<2GA'=VH+>5
MM<(Z92&R?C&6O+9C'4+*CKW#8%PVNC)IQ2=A1&\8%+F'#0JS$;Q/\K5&J3;I
M,X#C/DW)R&H=(V-(W-'5STR>./%5%)]\>]$W%/QG?2*]W&/NJ/2O0U]UI/Y=
MOK45=6ODVS:+ID:I)L`W=J/FT\HH:Q5N%7!W(*&26V]0&T[)&\+-GHS22#K0
M%I<4H:BB5`[1NV1(Z\&H93A>1NS_`"2=(.@Z#M]-G"LHE_[%RRJS1^8)_P"7
MI"T'+KC\ZFTV=2/1]^O!Z%)Y\_M13\5WT:NGK?,/>C5&;_VY_P`=F'.*-^!T
M/?J]8K</Q4=DD=H&'G#I6K<!D.QT[:@DEQ$B!*TX24[<TVZ\%"P01>")'JQZ
M9/''BJBD^^/>B;BGXSOI%>[C'W5'I7H:^ZTG\NWUK3TP,A9,<5(';Z=38GA6
MDSV1:"=32-N'%8"$%1(,K)&VPW:9=+[1,TS9,F*_+D9&%2G-NO0^NK&CO4HI
MC(&W%;*0BHRJO06WZ5Q;3B3>EQM10M)UPH$=1/1]^O!Z%)Y\_M13\5WT:NGK
M?,/>C5&;_P!N?\=F'.*-^!T/?J]8!ML%2C<`)D[4.+J!A*\,A.9`$[Y;,$UM
M3;IM2FW8,S'#<Q?I*/BB+!/Z7MP&T'"I5UK@[*N"("4DJ0JU)/9!UQVQT#F=
M=+`F>$&ZR]1U;;`-6=ET/U3"9<EBP@Z0E((G+5ML%VK&#,&-N04.S(C:G&I]
M-_L@9AERIMZ1.8E.4P;[#80>UU0],GCCQ512??'O1-Q3\9WTBO=QC[JCTKT-
M?=:3^7;ZT"VT<"=JC8->6KM3A#E0[R:$`ZFF6DF0NU(X;^+],'Q1$B9_2]JR
M)%,MISM&<*JLJ424S,ID@RO$CP@=2>Y;/H)ID68KSJ`7G<W39#65TR>$LI"C
MJ3N*CI4=30#L"/5G6PM!2#8;;9W@S!NUHQO-X#L*'HS*"U1JPKE9(KGN+OUY
M0K)LAH:C,*E)\G3,N/N$:"$-)4J1F)60A='S2J:%I4B7,P6S08`=*FJIQNHL
MG:E+*E#\F%<SN=;E.[FE;7/UU2JE6MQH%QMEEIL..-M*44-,(Q`(P!:EX2H$
MK5SBY]>S>DHLTRW-ZZIKF6&JMMBI:]9<4\MM;=4FF9!2XM80EIYQ.#"`0>"%
MGGES4S2A;;O>51O+IMJI:2NG5+3A=,IB=XZ@>C[]>#T*3SY_:BGXKOHU=/6^
M8>]&J,W_`+<_X[,.<4;\#H>_5ZO(0O,*P2618#>!H&L5&_4LGIA=4\>&X"++
M)`JP@#:MU=?I6JE7?(PS.P<!W3;`0D6DR&W#&7M7:=<)``W29[(BI8OUN,DC
MM=%X'05=H]4/3)XX\544GWQ[T3<4_&=](KW<8^ZH]*]#7W6D_EV^LPF1Y,&:
MCHEJ3U3<-VX0C+J:0;0"5REH!DD:@!E.6Q9*US43)(V@)]F?2+8-RTSVTW=@
MF'6TB0"C+8)F.Q#]>Y\42UY`8E;MFY"*ER\N)4?"!W!"%C2B6XH]WH,[)\4P
M<L]G_.:KHJ1&$IIE<E4TR;!,(IZMM]I`)M(0A())-YG"&>>.4Y7G;:936E#U
M%4*U9N-..4XF+I4HEIG=#?M%H*`Y8KUAZE?I2\*CD7F0A1`>#3.,*;=;<!Y)
M!DL`B,Y]G',?FRS6NY-4N4BZVJJU\FMYF2'0FE9:2H!MT+;F:J:L,RE!LA;=
M'F]-DC2YS;R^B91('0EVJ%74HEH*7@K548=YP\[J^HS*N?,W'ZEU;SJM0%;A
M4J0T"<AH`Z<]'WZ\'H4GGS^U%/Q7?1JZ>M\P]Z-49O\`VY_QV8<XHWX'0]^K
MU=W,:A%HM3,6R2)\&?Y1,MJ.'P4"Y(NV3JG7W)0K+E&2T7;LTG:-AUMF"TX)
M*29$=&;;2B-64ANF4<DZ,*KI$6VN3TZT3$,5Z=:>L%"W<(EMPZWJI!W#+]J'
M$#XJE#<)@)2)DP6'+%N62UU7C:38=<:_5#TR>./%5%)]\>]$W%/QG?2*]W&/
MNJ/2O0U]UI/Y=OK)#,I@D3UDZ3N1ZE1)"3(3(T3T`73E*WL0E]TV*F%'9T[M
MICUQ%J'+]97PWC;Z,F4*6=8$[T)=?;*0$JM-UTK=VXP\?SI;@`AZD7<H3EV#
MOB%LF]"B-PRG##\KY]D`RZ'K)'`;G;JJ(D!M3GK6:L..HNG(:^$2GMRGT.?7
M-;-W<%/EO(9PD3_=\BZS6+`)'>IIZ6W3,3(D(S'G1F/VC,JE^J=MG\Y4.K>7
M:;3PEFW3?U$]'WZ\'H4GGS^U%/Q7?1JZ>M\P]Z-49O\`VY_QV8<XHWX'0]^K
MU;^HYE=*82;@-!(TDZ!NZQ8:&!KLJE=/4&L-T]!-0U>+QJC2#[[[8^=I^R#O
M@0&$TW"5^8G?!G("TP)I"%J&@$F79EVX[\^">Y!IZA!Y,Z2)C;`M&L1,[$<M
ME[HD='?#8F+1L&9@Y+7F2E3P$7*$Y\$G2E6@B<I:(#E0)M*!25BZ1E*>I:!,
M;DX55T3B2%F<C=,WR4)SF;>W`J*Q06Z;M/@C]HRVHY1RQ([U.@#MG5.G8D.J
M'ID\<>*J*3[X]Z)N*?C.^D5[N,?=4>E>AK[K2?R[?6/))L2+5'4'=.@1ZI0H
M!<TG4.JHWJ.L+!K70IYXS4JTGH"G?;Y0)L!G*S0")&<M&M'S]//]%"M^4>N*
M9"$7S(PV#3(&[4U=R,*%2`T!)`WH^:"EG8D-T]R,2#R;I_143K@\%6U;KP*U
M"@XA$\0$PK#*T@7&5\IZ(.89>H+QVD:NB8U]4&V<]-D)HW%8'FI`@BT%(E=8
M9$=G8@JK%@-IML-^R2!A&K[S'J66<%(L*A=+43VU;FKT)QSG30XO_P`XLBK\
MF7+0FM+/#UBD-F2AP@%$`C$3U(]'WZ\'H4GGS^U%/Q7?1JZ>M\P]Z-49O_;G
M_'9ASBC?@=#WZO5`VTDJ4;@!,P'Z^TWA&C](Z=@6:I-T*IVVPL)L)G*W2+C=
M=LS@,5;(25V`F1$S^=($'WSCDT6H4)IGJ:FT>Q+HO9BZ+I@;"1,RV3(;4*?=
M,U*,_@V!<-;HXT$I(T@R,,UJ+TX23I$Q(_K2CD*Y/*HNG\:6N#8K;D=4F.5H
M:@L*.@*P[J57[5D%T5)63I("NR%".`ZD[(([L%:<*Y:$DSW"`-J<%*Q(@V@V
M'J1Z9/''BJBD^^/>B;BGXSOI%>[C'W5'I7H:^ZTG\NWUAC`P-_E'3Q1IWM>"
MIE,U$@6WJ5KZP$_]IC"\Q,:>%/L%/;A689>,*D3)$I3E:00+`0+9B_7T=!NG
M_*-NQ>>Q.$9>U8E`!,M70-H6[8U.D72.&:2F8!NLO`V0>Q#C+)X*5$83:"-!
MV92M%L#UU/).?E3EN+'[5D<BBM4I&H5)5O$3UIW1P'@=E,OVC'!6@[.(?LF,
M+Z;)V*%J3L'M&1UNIGH^_7@]"D\^?VHI^*[Z-73UOF'O1JC-_P"W/^.S#G%&
M_`Z'OU>I^OYC8V!,`V3&J=8Z!IWRF@8D=!D$C<%LM:S:A^MJ53P@`"X``$F0
MW->R^"M5I)).R8`3?.&=62MS@R[<<G3I*CK:-DW#;B9*$[)/:283ES*@DV8C
M;*^:I;*MBR)A/*#53;V+]P&,*A(C0>B]0JO$P-;$)C]8$Q(]"8C@K4-LQB2X
M5#2E1)!W;MD2AO-6A)1D#L'5UTFSWCJ1Z9/''BJBD^^/>B;BGXSOI%>[C'W5
M'I7H:^ZTG\NWU8,L[).@#5/:&F`Q@Y5R\V`G;)[W6`V9:8334_S25D)LM5:9
M7Z-H`Z\-4XN2DJW3(>+T*DJ[W_LF?:Z`6$80=*C+L6GL07Z@I)E(823?>;0-
M%FV874I4E14296BS0)D2L$AHB50@IUR+-HW':/1:=T!4CL&P]@P'A<XGLBP]
MB71X)(V#$T.K&PH]V%T%<`J:;Y7BXSUQ,$$2W873GXBB-F1L.W?U(]'WZ\'H
M4GGS^U%/Q7?1JZ>M\P]Z-49O_;G_`!V8<XHWX'0]^KU)#*N]O5L"WLW;<>HM
M&2&[Y:5:FPD=F>H.@]0K.%2YD:X(D9:X[>S'`4A0V2#V1+LPVMX#`%`F1%PM
M^"`V/B)`VS,[Q$/5JQAF"03I"09=DD#5AI+[JBDJ$Q.0.H)"0E/1`;"BE(2"
M`"1?.W9T;42*N43J*M[-_9EK0O@8'D"_2";K=*21(@W;A@I581T%(!L4@]@B
M7;AY";`%JW^E3/5_XAZD>F3QQXJHI/OCWHFXI^,[Z177HR[/*]%.^4A6`A:C
MA,P"<"5`3D93(,K;H;K:)Q+K+J0I"TD*2I*A,$$6$$0[G.<N\C3,X2M92I4L
M2@A/!0%*,U*```)F8;SC)'N7IG,02O"I,RE12H85I2H2((M2-R%Y5F^8(9J&
MI8T87%%.(!0!*$*`)!!E.=ML?BK?T;WU<',<AJ$U+*5ELJ2%"2P$J*2%!)!`
M4DW7$&%Y5F^8(9J&I8T87%%.(!0!*$*`)!!E.=ML!EK-F03^7C;3MJ<0E(VR
M-6$OL*"T+`*5)(*2#<01,$'01ULQ]U1Z5Z&ONM)_+M]6];E\X[:-OO1L`35N
MP5K,R3,DZ28;>5<A22=@$&$UE(XDS2!;.1D29@B>K=*)`)/Z7P0ZEZQ:L5@.
ME4DBT:UL-M)$QB!/%!MGM=R!3TSA2`D%4KYG7ONENPM]*E*<MF223WTC(SG8
MFZ,;;J@=DD'9!F#`I\P0%)582+K?RDFPC5EN0%,B2'`2!J$7C8M!VY=&GJ56
MJ.']9!)[(Z4<56]#W&ZD>C[]>#T*3SY_:BGXKOHU=/6^8>]&J,W_`+<_X[,.
M<4;\#H>_5ZD\\?BI`W23^S"W3\91.Z9PJLK586DZ\IRO).@:-4ZVG"!BUY+/
M9/:B350M&MB<EN*F.U`Y"N4";AC0>P1.&VGE%P/&>*XD#O@=<`:++KK@G+6;
M$)`*@/U4[`$CMC4A+R+TD$;(,X2_3N87$B4M33)0OON(LV8+#XDH>^8UH<=^
M*$RVR01V`8<6FT%2B-LGH-OJ[T&1V")'<G/:@5S=J')3EH4!VQ;L@]*T@V8L
M/9FKM=2/3)XX\544GWQ[T3<4_&=](KKUG)$*P*JD4S04;@I8(!.L#*>M%5[/
M,YFBHHE+4TE5X`7)]K9;<.,`3)"UZ$QF?_3?S;$4?G*CTRX>RC.&@_3.N+QH
M)4`K#0%:;4D&Q24FPB[4C\*;^D>^L@Y=D-.FF94LN%*2HS60E)42HJ))"4B^
MX`0]E&<-!^F=<7C02H!6&@*TVI(-BDI-A%VI#E/1T?JCQ!P.MN.DH5*PE*EJ
M0H3E,$73D4DSC,N;-4LK9IL#C8)F&R5+2X$SN2LX52%DPI4IJ,^M6/NJ/2O0
MU]UI/Y=OJH0F\F6[#%*BX3.X`!VX13MWK,MC5.T+8#=8HJ6+YE4]Q%PU)[IC
MYE2FC^;RB?%LW8DBL4G],#QDF%+8J2^E%LN"097VITZ0(7F*DS6JZ>I.21L$
MVG5&Q"G73-2C,F',MJS)*YR),A:)$3T:HU]>4<NT<;>KI&SK:XW!`2D3)L&S
M%.TKOA/L``]GHFBG)QNP;Z3L'O3MP4+$B#(C4(Z%5S>SUA5-643JV7FE=\AQ
MM12M)E,&1%A!(4)%)((/04O\E!W20.[#ROSU=@R[724_.-UE2:*K?J*9IV7!
M6_2-TKM0V#^4VW64RE#0'4ZO3'H^_7@]"D\^?VHI^*[Z-73UOF'O1JC-_P"W
M/^.S#G%&_`Z'OU>I5+OOL23V^@`+,7;<)WND9J7!-6$6ZY$E;LH=<5>5'<!D
M!M"SH!UHX5)M!]_9ANHK%`*`M$R"-4&5I$[OA@T>5)D#>J4A;?*=I.B9NT:.
MD7ESQM2+-CXI_1/8EJP6G1)23(CW]CH@M((2?C&P?#M3AFB0>]M(U`!)/;ZD
M>F3QQXJHI/OCWHFXI^,[Z177N6><HM^*'VEY$,(<<2'0+$\LA-H5+XM0R%)4
M!>4K)M5%7G67*Q,U**5:3I$ZMB:3J*29I4-"@1%'YRH],N*K-<DI%5U4TX<#
M"4K4I>*CP*DEL%9PH4I9D+`F9LG'_NF_]!6?5Q2YAF+!I7WFD+<:5,%M:D@J
M00H!0(-DB`1<;8J<ZHJ-=>ZRX<+""0I>.BY,R*4.'@A169(-B3<+0ZFDYOO9
M:I22GUATNK#<Q+$D&G92%"TI*E$`VE)E**C^EU7+Y@\4*J4*24*;2D$(0A))
MQMI*E3<29*4H!03)(ZV8^ZH]*]#7W6D_EV^JM)U5I'ZPAM.HB>ZH]R$G42H]
MB7;AXW\*6Y9VNBY3FY29[8,MX]B&*5L23/Q0`!V>Q%O0705JAR9!D3=(WIU@
M;QMZHCE6>&L72FH[4^"-F^"\Y8+DC4'OO.KK=%+MR38KBGN7[4"N:$TK[XBX
M'0=A0[.S'-CF,M'*-9EF5(R\)3'JY>2JI)&D)82XHC2!:0+8SNI;1@9SEFDS
M%L6V\JPEAY6OBJJ>H599,D:(Y-E)4=0"</5=9))(NF+`)G19,D@2@J5:3TG,
MCGD&95;6:O5[Y(M%-FQ?9;6#?):*?++-,YSX(!Z4]'WZ\'H4GGS^U%/Q7?1J
MZ>M\P]Z-49O_`&Y_QV8<XHWX'0]^KU*J6+^'V&QW>@RG5P=F9Z1`_))'9GO&
M'D_GJ.T3,=@]0#[)DH;A&D'6,#U]O"H"^1.XI/"[`B0L^FB=,CE%;!)W5W;4
M86`&ANJW39N#;@K6223:3:3U(],GCCQ512??'O1-Q3\9WTBNO<L\Y1;\560U
MD@FH00E4IX'!:VL:Z%@'7`(N)CG#[-L\X#U.MI;*2;E)K&`^VDZ18'42L(Y1
M5QBC\Y4>F7!\X[_X<OHGSCO_`(<N"E0F#>(-#S=`2PI\I4A'>A+E/C?1(6!+
M;A60FY!0)`81ULQ]U1Z5Z&ONM)_+M]58!_+3V#`X@WU0HZB#XR1VX>5JK5XQ
MZ*!^4%#L$[XA#GY*Y;H/<'44T%2V74JDE(`Q*,[`G#\;4`OT6V13>T7.\AK:
M"@RFDJGF:FJI*IAAVI>0*1#32WD);<<#52ZZ`@JPAO%,'#/FW[0N;&35F;KI
MV*FCJ_4Z9^J4RVAQ#],IQ%.A92V5/50QJ2$)(`*IJ`"\N]453NMF2D.H+2DG
M44V0%"R1MD9:(_YA<QJ"P;@WS,](FGYC9#7YN5JPSI*1]Y`-QQN(06T`?&4M
M24I%JB`)QF?L9R%GUE_+\DIV:-IM)4IU_*FF7:9MH2Q%QYRE0VBXE2Q.\P*;
MGIDU=E#A,@FMI'Z51(T`/MH),K;)V6]*>C[]>#T*3SY_:BGXKOHU=/6^8>]&
MJ,W_`+<_X[,.<4;\#H>_5ZEZJZ?FW3N*N!V#<=J)-B3:[4ZVJ-H]@B*9%WD_
M1F?9Z1QO44#NCX(4?R@D]B7:Z4-M@E1L`%YCUK-5``?%G8-DBTG6'9B;+N#6
MQ2["Q.,=*L+&H;#M&T'L014-E.O*S=%AW>K'ID\<>*J*3[X]Z)N*?C.^D5U[
M0<ZJ.G"Z!E5,I;O*-##R1)6,!6'"=3"@@S%M\H1SCYK(0I]Q(14-J4$%12`$
M.I*I))PC`L$BQ*2)DJE2Y+FX2FH075*"5!03C<4H#$+"0")RF)W$WQ4<]>:+
M39)4%-+4XU9BIPRL*0Z1;(K%H(N(,[OW'_XE#O\`C[D_6N5/)X.3\E@1*?)<
M#OL4OC:MDHJ.>O-%ILDJ"FEJ<:LQ4X96%(=(MD5BT$7$&=QIEO,L!=A6#2`@
M;*4J4-E(F-!$+S_/'Q69FX%#$,10WC[\I4N2G%K^,XH),B0!:HJZU8^ZH]*]
M#7W6D_EV^JI=;,E)((.N(%8V/G6YS&QWPW.$-K5,.*U$;ZAW(=(TK5OGHLKU
M%IW)@'L0Y^;([A':GTV/O&Q>HZ=8#2>P.Q`I75<,7F:I[9'!!UK)1_5*W(\N
MYR(LDSF*JQ3:)3F4BBK:1)*IVA]#Z+!)%\VV:GV6L9%A&%=1D*:)2EV$%7(N
M,4+@F"00NI<)M)<,Y0_D/L^K7SF5,P:IVDJ:5UAY#"7&VE.8I*IU!+CK25!M
MY:@5I,I6BES?VFURZ1->IQ%,VU3O5#CZV@E3@2&D*2G`%I)4ZIM'"`"B3*%Y
M?1<P%\Z$`%*1G+="TS.VT-EO,E*1;/"4MJ5:#@G,"IYO<S<HYK@+Q3RXUP6H
M$&:%I=JUTF&9F"S1LJ$@,6&8,-U#S**A"%)4IIPN!#@!F4++2VW`E0L46W$+
MD>"M)D0TC./9%D%0MN7_`#5,7/64$?&2O-$YHZ5$Z!4M\:P"&:'.QF'-Q4DH
M_P"9I`[3IN`"'*%=2H-B[$MEH``S2$@$UO.;/WA34&74[U54ND*4&F*=M3KS
MA"`I1"&T*40E*E$"0!,A#N79'1YCSD"Q+@TB&*5P:BS6K:>`_P"D7L0ZG(O9
M+S>RPKF.74:@5)G^\4O*U91-RXCE"\$]Z<8$S,"71/1]^O!Z%)Y\_M13\5WT
M:NGK?,/>C5&;_P!N?\=F'.*-^!T/?J]2!@/TXX:#.6F8'"3MWC5LBF01;P>P
MCX>D?3Q/VH;?`X)3AGK@SMW;-N))$SK1-#*ML2WY1Y*6RI/=G`Y524#9).Y(
M#LP:EU1F;,1MVD@#3MV:90/6@3*Z85V,)^&#5Y4K%+XLYSE>!/A!6L;X_P"7
M<*=;1N&SL1AJVPL:HL.X9@]B/ZEEX"9`E0`E,"^8%@4.R-6SJIZ9/''BJBD^
M^/>B;BGXSOI%>[C'W5'I7H:^ZTG\NWU95(Y9REH.N-&WHW-(BH!'!4`4G1(D
MF6R+O]HA:M4G?Z*2-4;\.LIM*DD#9E9V8D;"(^:;4K823%C)VR!OD1P@E.RH
M=J<!56Y,ZB;!ND3[`CU0&8'!DD&0UIV=B<<FR<"S=+$D[6*:3M6QR<]=*A9,
M:NL=6)*4'!J*OW1([LXYOBH'(C,^7R]9F.'ZTTH,H!L-M4FG,B")#5`CF_S)
M:7B;RC+%5"A.Q+U?4*"TRT*Y&CIU$Z0I.IT]/SQ2]_S?.+*\KH"9SQ5#RF6L
MP1,VGYMFM%TS*9D)D=*>C[]>#T*3SY_:BGXKOHU=/6^8>]&J,W_MS_CLPYQ1
MOP.A[]7J94@8DJ[Y)TRT@Z#N[$-H>7R9O3:+21:)&_:@E@AP>"K<-GZT3>;4
MD:I!ENW=!^H78D2$]@$G<$H#-2CE`+`9R,M>\'L:\XE3,`;)EV`.W'!"$[`)
MWR=Z/*2V$I[D-H>=4I())$S+@B=UU\H4U/@MR`&N0"3LSLVAT.0)X+HE^D+1
MV)C;$.-IL23B&P;>P9C:Z%3^EXG53TR>./%5%)]\>]$W%/QG?2*]U59]D*5/
M9.\K74JE4HV-N&\MDV-.G60LX\*G.F8^ZH]*]#7W6D_EV^K!23(BT'7A8?`"
MF\,R+C.=LM%UNC8@NT+P(.A5H\)/<@A314-5/"'8MW1&%0D1JPAM-ZE`;IAH
MLV\$XDFX@FS<D9'M3C&NGFH76@]G#/L1\TVE.S,[V&+%!.PD=N<<)Y6U)/B@
M0'<1Y1S222>$=4_FW;O0"DF1%H,-UP[Y$B=O@J&[([`Z&4<Z,N^T9;6TM4U;
M+YRG?0ZBW1PD".<'.S*G>5I''&V&%#O2U2MIIDJ3HPKY(N`B8..8)G,]-S0]
MC8=F[E>>9L\XW.U+*&V7J5Q0_)<=S:N0@Z#3N"0$B>E/1]^O!Z%)Y\_M13\5
MWT:NGK?,/>C5&;_VY_QV8<XHWX'0]^KU1BH:M;'[0!2=P'=B33IEJ'A#<,Y;
M48:E`6-46'M@]B,;S6$\67B&W;@T66HP)583*5AOD+YFXDVW[/2K<E8E'9)$
MNP##K@N*U2V)F78Z"#H1-1VKNR1"Y6A,D[@M[)/0<#225.8@`-,Y(B;BTHUK
M2>P)=DQPGA+63_VH4XPL.2ME(@G8O$]ON=2/3)XX\544GWQ[T3<4_&=](KW5
M<H:YM+S+R2A:%@*2M*A)25)-A!%A!A6?9"E3V3O*UU*I5*-C;AO+9-C3IUD+
M./"ISI6/NJ/2O0U]UI/Y=OJ[[,Y*4$G:M'8)[,*0A2D*22#(D6BS1'#4%@?E
M#MB48*]GL!0[,B-J.6I6R5Z)`SW5&S9$*J'+)W#4`N'OO-O2T]+I$OU$R[?1
M0T;%.2_6./>LZ#0U"3N`G?A2VP$H`2,2C8;)F5Y-^I*>F.$ZD;`)[8C@O">N
MF0\8QR3\K1,$7$=2/1]^O!Z%)Y\_M13\5WT:NGK?,/>C5&;_`-N?\=F'.*-^
M!T/?J]4<HS:I$P/&3V;-@=1?K+B9R_1$D_K$]`-,C$I5P'O[.B"I1"GW.R=0
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M"T+`4E:5"2DJ2;""+"#"L^R%*GLG>5KJ52J4;&W#>6R;&G3K(6<>%3G2,?=4
M>E>AK[K2?R[?5VUDV*.$["K.P9':CE1<Z)[8L/:.WU!ILB8Q3.P+3O0&@;&T
M@;9M/8ET!5U-C2;9'XTOV=4Z;M<8&C\VBP:YTGM#6V>@7A<A)GLFP=O<A5+3
M**$H,B182=-MX`UK],34LDZY,8TD@ZH-L(K3:MN4]W"K=,CU(]'WZ\'H4GGS
M^U%/Q7?1JZ>M\P]Z-49O_;G_`!V8<XHWX'0]^KU3D3<Z);8M';&W#C8N)Q#8
M5;V#,;74&:1-F,)!V@"?UI1(0:NH$W5W#3;<D;ZCOR$%]\S)W`-0:@'OMZ"&
M?RU`;IE"LN=6$J4D$:M]A&K:+1J1RV(+1.1($B-28MLV[^@T1>%I\80V?S/V
ME=1/3)XX\544GWQ[T3<4_&=](KK+*/OM+Z=OW%<H:YM+S+R2A:%@*2M*A)25
M)-A!%A!AO,LI<"LLK5J#2%*'*LK`Q*:()Q.-@6H<$Y"2'#BPJ<Z+'W5'I7H:
M^ZTG\NWU@W6BU2)$^*KLR.P.H.OGXB0/")^3"WS\91/9LW!&)P?-H[[7U$[>
MG6VH]1I#)I%AE<J6@?FCL[$NB[5.V#%:=9(';)A591NCAVRO$]68.G8,*9=$
ME),CT*E*M'*2VD`[_4CT??KP>A2>?/[44_%=]&KIZWS#WHU1F_\`;G_'9ASB
MC?@=#WZO5$O(O001M&<,U+2L*2FTWDI-J9:]IT_#A5\ZL?IGM(&_')OT_!T<
M%)EW-J,<\.MPQ\&Y!9I%$+`T%6[PK#KR[$*87>@D;FG;Z*&<S$E(&HJV0E,%
M-MND&"_2C$L7"2R=K'8-<P%NR`3<!H[IU3V.BT$BXS.L!;"D_DI2.Q/MPK+L
MP/`5<3=(Z"=%MH/9%D<I0N!23=B[2@"#N"!65ZDI#9F!/2+B3<`+]^4*=;[Q
M("4ZX$[=LDRUNHGID\<>*J*3[X]Z)N*?C.^D5UEE'WVE].W[BKSG.5S49I99
M21RC[DK$(&@"PK61A0FTS)2E3F>9XY-1X+;:9\FRW.8;;!N`O)/"6J:E$D](
MQ]U1Z5Z&ONM)_+M]8/Y>X;YD;"A([A&Z8#V:.6GXLY#8$N$K:EL1@IF)C2<(
M$]VT[<?/-\F3^:1XD_??'?3VW.U"*JD)+:[-65DP0=0B?O/15RH.!8$Y7@BX
M]DQB.GSH[`LCU3+4X42(Q2E9^:.V;=;3TAQ"15^TOMIMA+Z-!M&J-(W-PVQZ
MS3.87"!/_M)OUI@RV8"`4%)-\S8-B4]R>S'],95B<7?JR-I)&B8L`U-674CT
M??KP>A2>?/[44_%=]&KIZWS#WHU1F_\`;G_'9ASBC?@=#WZO54,OGA$&6JD&
MX'5([%VB%,N=\DD'9'1:P_G3V,)AV7YOB)Z@JO6)K7:-Y(V-)UMB%//'$I5Y
MZ$V%J1L$B)5#A4!HN&X)">O?U(],GCCQ512??'O1-Q3\9WTBNLJ+-7TE2*6H
M9=4$RQ%+;B5D"9`F0F0F0)WF/PVMW&/K8_#:W<8^MC\-K=QCZV/PVMW&/K8_
M#:W<8^MC\-K=QCZV/PVMW&/K8_#:W<8^MC\-K=QCZV/PVMW&/K8_#:W<8^MC
M\-K=QCZV/PVMW&/K8_#:W<8^MC\-K=QCZV/PVMW&/K8_#:W<8^MC\-K=QCZV
M/PVMW&/K8_#:W<8^MC\-K=QCZV/PVMW&/K8_#:W<8^MC\-K=QCZV/PVMW&/K
M8_#:W<8^MC\-K=QCZV/PVMW&/K8_#:W<8^MC\-K=QCZV/PVMW&/K8_#:W<8^
MMC\-K=QCZV/PVMW&/K>@O.<Y7-1FEEE)'*/N2L0@:`+"M9&%";3,E*5.9YGC
MDU'@MMIGR;+<YAML&X"\D\):IJ423TK'W5'I7H:^ZTG\NWUARK5B4`XCH(-R
M=DFW6E/6ANI!FF6'8-I&Z-[I$8[^#+PNYU!+:N]3PE;`T;9D(-$T9-HOUU#M
M"Z6K;J=":3(B"A+RI&R^9VB;1M$1B49D]2/1]^O!Z%)Y\_M13\5WT:NGK?,/
M>C5&;_VY_P`=F'.*-^!T/?J]4;;5:D'$=A-O9,A`IY\%M!`&@J(!/8LVH=*P
M1B42-<'4U>A(6F%U]6"@!)E.PRO*I7BP6:LS"Z@_&).P-`VA9TX918+U'4'=
MU!VIPC+F+FY3UI"0&T+^K'ID\<>*J*3[X]Z)N*?C.^D5[JN9[G"IRX+30("W
MG#WK:)[JE2(0D%1!E(N9YGCDU'@MMIGR;+<YAML&X"\D\):IJ423TS'W5'I7
MH:^ZTG\NWU@7DV+=M!UU6`[21/9BG+8)PALG8"""=WHA#*203:96#7)N]]D-
M9:U\4`G8`DF>N;]K7Z@NNJK%K`DG3K)V3>=0#6,%:KS:=D]6/1]^O!Z%)Y\_
MM13\5WT:NGK?,/>C5&;_`-N?\=F'.*-^!T/?J]4<<_)1+=([AA=6TJ2L:B#M
MGL2LEJ0M=2@!*+U:#I-AG<)$VZ8Y(H"-0J2D`[DY;<HY5A@+3I*2!+9`!,M?
M=E!;5)"#H3IV2;3V!K1C1)*/RC=M:N]KP`Y42)_-`WU1-IX'93+L@G>B>#&/
MS2#V+#V(P.I*2-!$CV>BDH\J[+PB)_JCL[,%2C,GJQZ9/''BJBD^^/>B;BGX
MSOI%>ZJLYSI<@)I9923R;#<[$(!O)O6L\):K3(!*1TS'W5'I7H:^ZTG\NWUA
M3THN^0D#MPFD0`XDD``V$$G0=`GJ@PE-0C&I0G8`;-><M>6Q!>I$I61HD`0=
M`-DQLRV)P6$LAHC\JT[(N&Q>(TN.+.V>X!N`:T8JAT).H!/LDC>,?-U$_P!$
M'>5$VE)6-F1[-G9C$^VI(&F4QNB8[/1+RQ-+0G^D>]WB=D00#\V@D)&^K;WI
M:_5ST??KP>A2>?/[44_%=]&KIZWS#WHU1F_]N?\`'9ASBC?@=#WZO5*APZ,'
M8Q$Q,PEM-BG0`?T[3^K9T`TKYQL:";1L&VS6,QJ2AQ;+>%T#8()G(V&2A,:>
MQ#?].L`2,4N^E+A;<^^TWZ\349F)MJ*=@D;T2Y3&-10GV;^S!,@E]OL'1^BK
ML'8M*%B1!D1J$0&F@25&5D,LC0%'=D!O&)"!5YL;3\6V0UI"U1U1=LWQR2F)
M)NG@3NV&8VK=:/7LO.)N4R)SD-4'4&D&T=3/3)XX\544GWQ[T3<4_&=](KW<
M8^ZH]*]#7W6D_EV^KI3JD#LPRG0$J.Z1W(+JKFQ/;-@[9AQS0#(;";.S*>W`
M=IU83V#K$:1`8S%H6V3L(GJR-HVB8):&'&C@B9T'ARG^B=W1"TU9-\T_DX=&
M'6[=]LXF(^:=4-:<QN&8[$!BNPE"K)RU=47$&XV1C;\FN<M8Z4]S6V.@_4K$
M@9D3TA*29[%O0MX+:>^5VAK[PMU`>0;;#BA83(*MUU*[5FQ!33CDG=@`[,AP
M5#5E;L06'A(C<(T$:Q]]O4ST??KP>A2>?/[44_%=]&KIZWS#WHU1F_\`;G_'
M9ASBC?@=#WZO5'*5?[P`C:G,;AGM&%TY^(9;6@[8E%.ZGO;.RF8WNB&]#@(W
M!B[1AYH#$TI4RG4Q`*F->W8.X1ZQ0K"%FTC7_.3>#KBPWVWQP`E>PH?M2BUE
M6U;O3A-2H!";B%&T@ZPG;I$Y6B/7*XR*M$[#+3(<(FZ>B.3R]G;D$C<%IVY&
M"^^9D[@&H-:.56)I:M_2/>]L[4*D>`B83J:YVSV)=#U-RU#MT]"O^U<=>4+9
M3WMZ=@]RT;74CTR>./%5%)]\>]$W%/QG?2*Z_P`I]J=#SLHZ%S.:950Q2.4;
MSB4C&M+27:E#H*<>$%913N<GB(`<E;F/,KG2P:;,<JJ':6I:-N!YE9;6`18I
M)(FA:9I6@I6DE*@35^SMO.AD0H\M?S%50:0UA4EFII*;DDLBII;5*JTJQET!
M*4'@J)$9_P"S5ZJ%:K(ZZIHC4);+0>]7=4WRH:*W"WC`Q8,:\,Y8U2F:/F[D
MK2GZRO?:IF&DB:G'GW$M--I&E2UJ2D#5,9A[5J#G4C/7<I0R[5T2,M53865K
M0V^XS4&N?+B:<KY16.G:Q,H6X<"DX#UNQ]U1Z5Z&ONM)_+M]7"QH(.Y#.8M6
MB4CL*M&X9@[,/HTD).YBGOB"E5X)!V>BQ7(,G$%)Q:=*3NF4X%-F0"%BXW">
MJE6@ZQL.O=&*E6%IT3L.Z)@[-D6M$[!2>W.,`:4-FP;IL@4F9$$I^,#=*XS(
MO`L)E=LQ\PGE%C2!B/A*L'Z,%A">30;[9DZQ-EFL!MQ(0W1LF3B["1^L1MF0
MUKKN@'6C)23,&$9B@<-%^Q.2AM&T:T]7J9Z/OUX/0I//G]J*?BN^C5T];YA[
MT:HS?^W/^.S#G%&_`Z'OU>J-.SD`H3V#8>P3`K$IX"@`3J*%ENR)2CDT#$MN
MP#3-)G(?H&0Z*%#XH43N%.^8=4-4#<2`>R(Q),B-2.`\K;.+QIQPE!6RD=J4
M(0M>%)(L3P1?N]F&A^:=_HU%2+YJEM)$NR>BET7I(.X9PR[I(4-P@CQCU(],
MGCCQ512??'O1-Q3\9WTBNO\`F-[4\N27!E@R?UAH2F]2/9FEBK9$[`MRG<<#
M:C8AS`OXL9'_`)L/9VE-3E>?L4S.8/,@E"U+92O+:]1`GAJ*:5,M:L*4EFE1
MY1VW//\`X9K/_%<FCG__`'W,?YA<4O.>O:QT'-)A>9+)`P&K)Y"A0;SC#RU5
M2)2MI#,BP'VQ>Q;G.Z*O)<Q6Z<N:Q32YEC3*<DKN2)F$HJ$(I*I*4@R74OKE
M>8SKV>YX/^;R6LJ*-PRD%EAU38<3^8ZD!Q!TH4DBP];L?=4>E>AK[K2?R[?6
M"Z06J3,#:(4GN;4!IT82J:"#9(WCL@#;A9EP5G$#JSOW#/HM-JO5A[,U]#YE
MQ2=8$@;ET2Y6>RE)[4XP@I!U0FWLS'8BI=J%%1X=I/Y@W!T64&[$#N6]J`C0
MA(&[,]L=&IIC:)&7Z22.UU,]'WZ\'H4GGS^U%/Q7?1JZ>M\P]Z-49O\`VY_Q
MV8<XHWX'0]^KU7^F5W#2L223XI[1T7:DO5?W3UT^QM@\'7GKB%!`D%@*W;Y;
M8/\`LZ#M8Y8`)3UAPE=J%.&U2R3MDP%O.<FH_%PXI;)Q"WWSBQX>#_VHL>'@
MGNPAPJ04A22;3.0-MDNW"$ZB!V5'HU#0O&/Q01T0D7DRAA&D!9W</</4CTR>
M./%5%)]\>]$W%/QG?2*Z_P`C^ZY/_P"*MQSF_P`F_M.>Y13%*Z:`JDIS^GO*
M!FR%=\[E5>6ZAG$;$NL)2G`PJ7//V<\Z48*_)\BS&F=D"$KP9MDV!U$[2T^V
M4/-*^,VM"M,<_P#^^YC_`#"XYU^W.H_Y?.^=J7?4E7.@+*LLRJ23+%R3SE5F
M*93G3N8KA9S6Y]U3H:HFZM--6J)D@45:#2U*UZH9;=-0`?CM).B,M]JV7M$4
MO.FD"'U!)D*_+DML+*E"P%RD528`9%1:=4,4E2ZV8^ZH]*]#7W6D_EV^L.68
M.R-!&H>[>(3FM&)+3:97R%X.NF^>IM0*M0FXBVS009*VBFV6QT$,IO40-WN0
MS2(N2)[M@WC!P\%`O41/:`LF=NS3HC@O_J?]HQY8>#\,?-NI.R"-Z<5#3Q!)
MQ&RT2*0G2!J:G19)_*EN@CMP5?E)2>UVNC4OFX?LI).^.IGH^_7@]"D\^?VH
MI^*[Z-73UOF'O1JC-_[<_P".S#G%&_`Z'OU>JA23(BT&$HS!K$4R.(`&T:9&
M4CK@[`$)JG3)(!DJ>&0TSG981INCE'G`Z=`Q!7ZJ.W9!I:-')MD2T`RU`!8!
MN[4*S:JN3/#K2L)V2>"/AC&NQ([U.@#NG2>U$TF4`MA24_E*)`[IVIQ.I?6M
M9%Q43N(G9LG=AE6DA78([IZ*Z1=S@F-D7C;![$+85<#9KI-QW.S/H)7+@MD*
M)V+AMGL`PK!<V,`VIS[)(VNI'ID\<>*J*3[X]Z)N*?C.^D5U_D?W7)__`!5N
M,E]J7-SA/Y4^%K:Q%*:BG6"W4TRR)R2^PMQO%(X"H+`Q)$99_FYYA.H71\X^
M:KE"^H2"G^5J\KK,N?*1.3J:=FHIZ@*.)'(T[1`*%".<WL_R,?\`-YUSIJ*-
MHRF$JJ*TM<HH3'`;"BXLD@!"5$D`$QS3]BG,?F_19RAG+$*4Q5J4E%+24^&C
MH,*6TD%;G(5.,D`I#:2!PS'_`/;S(O#=^KASVJY=1(I\XR4N9D:9I6,4[^6.
M/,U[(4H!90O+ENU+:!:LJIY@J``ZV8^ZH]*]#7W6D_EV^L2D#&A5Z;K=4'5W
MX52M(P%8)*2``J8D;C:9;<HX;O)RO25IVKQ,049>WC5JB?94;3M"4`.'A+-N
MH$C4V!=JF\P,LH>"4CA$7@:D_P`HWDZ^J;(P,!2MB9WHY>N>4T!;)*I2&NJ<
MAM3V1#S;!*TH24DF=O!.DVG9Z(<3>D@C9%L-9DQ;(6\4_)-AV3J="0CU=5CC
MMA&NKOMQ/!V9=3/1]^O!Z%)Y\_M13\5WT:NGK?,/>C5&;_VY_P`=F'.*-^!T
M/?J]7]0>M0X;-8D7;"KMG9,*:1WIX2=@Z-HS&UT/Z;7\$"<C;(C%BO%Q!VI1
MRI<Q`:"HGL`3.]$J2GNUDIW@3&%H!L:HM.Z>T`8*UDDF\FTF&'$W'%V<)'1#
MK9DI)F#KB$I<(0^G=&K('ODG4O&_)3B<.J)SEL2EV8-#0&;AO-\CI)/Y6H-&
MG4))ZD>F3QQXJHI/OCWHFXI^,[Z177]!_E5/-M+`HDTK9S3UXKY1%+5>LIE1
M>J)P*60E!4:M8`"B$\(!,*]F[V4,<X<K:=6[1I>J'*9VDY4XW64.);>2MA3F
M)U*"V%(<<</*%*@A-9_F?YR<WFLWK*JHS&K30MU2J-IFHKTNMXVWET]8HAEM
MYQ*0ILE1(7B2H`QF?M5SJF%":[D6V:1+I>12T[#2&FV4NE#97WI<<5R;86ZX
MXL(2%81&>\R,QYN)YS95G3J'PPJN-$&72R:>I)/J=8EU-2REA"DX&RGD1PE!
M4DNNTC?(M*6HH;Q%>!!)*48R`581).(@%4ID"?6S'W5'I7H:^ZTG\NWUDE]H
MR4DS'OU#<83F30DM`MV)R4-HV@ZD]7H)J%":1,$:9&RS8O@OK=DI=]I'8(LC
M"PWRJM66+]97[-D8:9D)&B9GV`!OQ.H62-`N`VA_MA]K8[(4.UTAHZNUI>DV
M@$W@_FGL;9CE:!Q.!5H!M&TH3F-K;,>N9@L%2;AHGK`VJ5J667RTCE38D6)&
MH-?7.G<T=3/1]^O!Z%)Y\_M13\5WT:NGK?,/>C5&;_VY_P`=F'.*-^!T/?J]
M72XB])!&R+8;S"E$U)%HUM(V4F<M6V6B)=-3/C1A[*.Z.DF(P*=64ZA49;D^
MJ'ID\<>*J*3[X]Z)N*?C.^D5[N,?=4>E>AK[K2?R[?6;F6O6I6"1MB2AN2.Z
M8++NR#JB9`/8NT=,ZWJI!W"1VX6C441N'I/F5J1Q5$;QC$XHJ.J22>SU0]'W
MZ\'H4GGS^U%/Q7?1JZ>M\P]Z-49O_;G_`!V8<XHWX'0]^KU3DJ=,SIU`-4G1
M[Y0.6?`4=`3,=D@G<$<IWZ-4:-D:-FT:_0-(XK@K$P#^59OC=D(((^;424G1
M+4V1\/3-$_F]OK$],GCCQ512??'O1-Q3\9WTBO=QC[JCTKT-?=:3^7;ZP#CZ
M@T#H(FK<LEMF>M!53.A>L1+L@F"T\DI4+P8#K1DI)F##=;2B:DB9`O(-X&N#
MHV=/3'B'?3#R1^6K?/6)Z/OUX/0I//G]J*?BN^C5T];YA[T:HS?^W/\`CLPY
MQ1OP.A[]7J8;0)E1D!KF$TU/+EEZ=?2HZNHD'M$$N.J*E'23,P*.J.)M=@G;
M(FX:X-TC=K"<%*.\7:G6U1M;THF(7E];:L"PZ2-7C`[N["F'A(I.Z-4:QZ0-
MLBS2=`&N>U>8:RQGXDB=8`2`.N;2=HZ>L3TR>./%5%)]\>]$W%/QG?2*]W&/
MNJ/2O0U]UI/Y=OJZLPJ)8&[IW3`F5'BCLVZ((22EH7)U1JG5)[%PCE:=6$]@
MZQ&D>\0*YD2=;G,:;+5)U_RD_">@+9MJ/"3VQKCLW'6&8THFA=JI:IM"M@Z=
M?9Z20M)AS,*W@DB[2!J;*C*S8GK>SOVJ<CR;V;YAG)JC*14:M:/49ZLZ?+75
MI.E+@&CK$]'WZ\'H4GGS^U%/Q7?1JZ>M\P]Z-49O_;G_`!V8<XHWX'0]^KU-
M)5;@!5VAV3.'#.Q!PC]&P]F9Z+-6>^3AF=G@JW52Z"7F3)2;O?J0$5K`5L2(
MW%#MQPV,/Z`'BF)D2^E&]'*8@9:)K/8O.]'(9:W@&J0!+82+-L[D%:R23>3:
M3UB>F3QQXJHI/OCWHFXI^,[Z17NXQ]U1Z5Z&ONM)_+M]7:ITV%R4]OA*[FQT
M5TYN6F>V/@)AQD7)40-B=G8Z`86D.(%ULB-@VV:Q&W'S]-(G3A0>S88X2,/Z
M*AXL22K#MN#QHG1HQKU0#XRKOT9[$):`)Q$!#:03-1,@`!:I1G(63-P%L)YF
ML(!>YH464.H%AX5`&::I7B'QC3N5*RH=\9@R"B1U@>C[]>#T*3SY_:BGXKOH
MU=/6^8>]&J,W_MS_`([,.<4;\#H>_5ZFYJX.QB$^U#I-^-6^>C[_`/?=<GID
M\<>*J*3[X]Z)N*?C.^D5[N,?=4>E>AK[K2?R[?5Z<INM\42Z*-A6\8>EJC>'
M2M,YD\JGIU*`<=2WRJD)-Z@WC1C(_)QIGJPTKGK[575OJPE3"J49$A!([Q=1
MF"*II:0;UMNH$M*-#&><Q<CR_.5-*2I-6]4G-07$\)*QRKS],A8L(Y)ML`@*
M`G;%1DF>4S591U;:FGF'VTNLO-+!2MMUM84A:%I)"DJ!209$0Y7<\!2<SG%`
M_/,YJG+[[1@IZMURDG.>$(IIJGADJ20'E^S#VEOYO4(Q8:,Y2[4`WRGF39I:
M61NFVTY/ON")`]6/1]^O!Z%)Y\_M13\5WT:NGK?,/>C5&;_VY_QV8<XHWX'0
M]^KU-(59C!3VQV1#FHLXA^E?V9]%FC/?*E/:$U?K$=<GID\<>*J*3[X]Z)N*
M?C.^D5[N,?=4>E>AK[K2?R[?5VWTVEO"3M<%7=Z*ZI5B4)EMGN`&>S#CXN4H
MD;$[.QT[&>\VZMVBJZ=:5H=9<6VL%*@H<)"DF4Q:)R(L,9I[1.;[ZJ=S/LNH
M4TBVUJ2N6;%@$H6G"H*32O.K"@0>!9;9"JFJ6IQQ9FI2R5*4=4J)))UR>EEU
M,]'WZ\'H4GGS^U%/Q7?1JZ>M\P]Z-49O_;G_`!V8<XHWX'0]^KU-+B#(I((.
MN+1"7F9!Y&C7TI.L;TGX8Y-Y!2=0B7^V!6UPP(1:`JR<M)G<!?;?L7E2.\18
MGMG;WI=6EU,],GCCQ512??'O1-Q3\9WTBO=QC[JCTKT-?=:3^7;ZNJ@J2.3<
MNG=,V$'64.R->"MM)4T;01;+65J2U;CLV0&Z=,]4Z!LGWDZ!`R]DS<6#,Z;>
M^4=2=R?@ZC[,.8_*SJ?7*Y#Z0;D9+CIJ=*K9A*F*^G4`0`5(5*?)SZQ/1]^O
M!Z%)Y\_M13\5WT:NGK?,/>C5&;_VY_QV8<XHWX'0]^KU3E:=6$]@C4(TQ)QD
M%6J%$#<D=^.360A'Y*=.R;SO:W5K.J'ID\<>*J*3[X]Z)N*?C.^D5[N,?=4>
ME>AK[K2?R[?6`;=`=2+IV$;>G;!.O$F&P@ZI.([5@&Z#!==45*-Y-\6]0:RU
MUU2J=A;CC;9,TH6Z&PXI(T%8:;"I7X$ZG26=5/1]^O!Z%)Y\_M13\5WT:NGK
M?,/>C5&;_P!N?\=F'.*-^!T/?J^Y!Z9/''BJBD^^/>B;BGXSOI%>[C'W5'I7
MH:^ZTG\NW[F'H^_7@]"D\^?VHI^*[Z-73UOF'O1JC-_[<_X[,.<4;\#H>_5]
MR#TR>./%5%)]\>]$W%/QG?2*]W&/NJ/2O0U]UI/Y=OW,/1]^O!Z%)Y\_M13\
M5WT:NGK?,/>C5&;_`-N?\=F'.*-^!T/?J^Y!Z"*2D0IUUPX4H2"I2E&X`"TD
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MB`_3@)%2V'%`6</$I*C*[A803JJ))M/NPQ]U1Z5Z&ONM)_+M^YAZ&7)I$@.U
MR4ON+E:I;MJ9G40@I0!J)G>23PG%$[0[N_'?J['<COU=CN1WZNQW([]78[D=
M^KL=R._5V.Y'?J['<AS+JH!UIU!!!%Z53!!U[#;MB4?T?%9R_(XO_.8)]OH5
MOF'O1JC-_P"W/^.S#G%&_`Z'OU?<@]#./.4_BO0UQ>H'C)BE\Q_Q%^[#'W5'
MI7H:^ZTG\NW[F'H9!]WIMY/44\0>,J/^N_\`6.A6^8>]&J,W_MS_`([,.<4;
M\#H>_5Z_LZB>AG'G*?Q7H:XO4#QDQ2^8_P"(OW88^ZH]*]#7W6D_EV^M<LYG
M9JC'0FGKWJDRQ86T43R6U2^\N,"\2G,&<@:C*J]!;?IG%M.)-Z7&U%"TG7"@
M1UL>AD'W>FWD]13Q!XRH_P"N_P#6.A6^8>]&J,W_`+<_X[,.<4;\#H>_5Z^0
MG,ED+<!*4I25*(&G0`)V"9$S.5QD@TE&D,COPM1*R)_%*9)39JA5L(S"@5B;
M7M$$&1"AH(([8F"#U`]#.$SM"Z:S92]+>.Y#4M26X>H2.E0E"LWSRK=8IJ9L
M,I0Q@#BEDJ65%;B'$I0D*3(8"5$FU.&U>9<W<6;4";3@3_S+2;_G&1/&!I6U
M.P%2D-B)'W68^ZH]*]#7W6D_EV^M>=OM"=1914=-E[:CI-8\JH=PZZ!1-3LG
M)P`&1,<\<F;1@;?KU5S8'>X,Q0BNDF5@2E50I``L3APV2EUAS:YOYBURM(TZ
M[65`-P11L.OH)OO>0T@:,2TSC,^:68>7RNKJ:1RR7SE,\ME=ELN$@V3Z1-:P
MV'7''`VD*)"1P5**C*TRPRD"+3?9`8SQOU5P_'3-31V?C(V\0TE0@/TRTN(4
M)A22%)(UB)@QD*YB0IZ>9V`F>Y*WI*I&15K-8:%Y5/4<BXESD7TI2I33F$G"
MXE*TE23:)R-H(#7-=ZL93F3[*WVZ8N)#ZV4*"5NI;GB*$J,BH"5A_)5+H@`W
M(`.ZH[Q$8M'KW_K'0K?,/>C5&;_VY_QV8<XHWX'0]^KU]45CJU*3C6&PKXK8
M4<"0+DR$I@7F9,R2>A49LISYIWYL(!^,@S*E"X$3DG3(F=DI],',Q?0R%3EB
M4`3*^0O,M8'1JPAEEMQ;:I8G)!.&V5B3:H`6F[6G"*BF6'&UB:5),P1K$0M>
M6%)34M*0M"P2DX05(5($<)"A8?R5*'QIB2'6QL-R[<>61X'PQY9'@?#'ED>!
M\,>61X'PQY9'@?#'ED>!\,>61X'PPA>8<F\T",2<.$E.G"J=BI73F)W@Q49U
M1I0[2U13RE(LG!A0)(P+`Q(<`)FL`I422IM0PI"6,N>]6KI<*D>(2[.4R6C/
M"\D2-J#B`$UH1,"%UP1_3\Q5;ZRRD<,_^7:FE+NNJ:';`.4PC"2K.:?E*0F2
M*IF:V%3,@%&0+2C^0X$DGO<0MZ*FLQK4%U"@A33?SCB3IQ(1,ID+3BE*Z\@%
M64%M5&M1^9+JD2=M`";#P7%3F$<(&1`43('W08^ZH]*]#7W6D_EV^LTM<\>?
MN5\U"I>$-U=/F#KLIVK*TT[67I2?BA>8)4;<247E.8*YZN\\,%JCEM50M4JA
M9WR*<UCR1:+JI,B9&'N;OLPRP9;35+@>>F]4/K>="`CE%N5#KJYX4@!*2EM-
MN%"9F%<YN?>6N_U4M(9]=IJI]A[DV\6!);QJIE%.(R4NG4J4@5%(E#JJ+VK4
MV1O-SE2YJJCJGS*<TX:5VEJ!(@\)-(X1+"4S,PO+,@SVDYP4Z9RJJ-NN:;-L
ML)374E(YBU2VEQHBU+JA;U;G1S]=1-.69>S1H)%SE>_RI*9_&2W0*22+DN2,
ML0GSF;;3A8S-;&8M&[%ZXPVM]5W_`-5BH39.>&9,Y@=&E\__`,-?0Y7+'U-@
MWIO0KC(/!.S*8T$0US2SW!2\FM1;?*%.-A*S,MGA%3:<94H32L"9FM*0!"*J
M@JF7F5B:5M@*0H:J5)401L&/+(\#X8Y#F^_R%+4314U3$TU#*3()2A0M:2Y,
MI+R3B!DD%M2DE3F=\UGN#4)P5#"R2T^D$E)4-"T*)+;@X29J3:A:TJ5[0\PS
M%[^K\J'45"5E*FE(/S:69'YMML<%"$\$)LD9F=+5\[.39K%)$^!)2TR&%QQ`
MD&W%CA*0+$SN1/`GRR/`^&/+(\#X8J&JQ"%O+3)IQ(PE"C82H3(5(3*;CB`G
M,&S',XISGIGJSU>A6^8>]&J,W_MS_CLPYQ1OP.A[]7KY>84Z"ZQ5N+4G`DDH
M4HS*%`"0M/`EWP!T@PERN`I&C(DJ,UR.H@7&6A93+L0,NHR5`J*U*5>I1`!-
ME@L```T`7F9/3.U#B@IMM2FVL-W)I6K"=<JG,DVF>@``1DM;FCH9R]+KN!3J
MPE"5>KU(44E1`2DDR5.0*B)3,XPHS.D4=05+)/CQ^(4WT[7RH_$*;Z=KY4?B
M%-].U\J/Q"F^G:^5'XA3?3M?*C\0IOIVOE1^(4WT[7RH_$*;Z=KY4?B%-].U
M\J/Q"F^G:^5"6*:M8<6HR2E+S:E$Z@`423L=!ZIYP.--4820ZI\H#6$V$+Q\
M$A4Y83/%.4C.4%SV:4[K+$U<JHG#3K5.PT[*ARC:+R<2DIN"&FP.%59O3*2E
M](2EK$)@N+4$BS20"52-G!MLG"ZE\XEN**E&RU2B239(6DSLLA"J<D.!0*2D
MD*"I\$I(M!G*1%L[HHF^<RBJN"/G"2"KOE8`LB]8;P!9F25`DDF9Z5FD=854
MU#P*L"5!(0@&04HD$\(S"0$VX53(D)MU%*MJE0V?)H;"DKM/E"X5K/!X)P*0
M/C`!4B!5T9#=0D?.L%0*VS,@&X8D*E-*I6@R("I@>Y#'W5'I7H:^ZTG\NWUH
MBLH75LO-F:%MJ*%I.JE22%).N"#'.GF-STS:JS-S+S1U5&:NH=J7$,NAYFH;
M;6\M:D-(6VPH-@A(4ZI0`*E3YP\T<LSFM1DF5&GHT4:*I]%+RK5.T:I1ITK#
M.,U2G4*64E2DH1B-@`ZKR?M:YS5_-]"5?_1LI%<VM%G[Y%8EUI=]GJ+R0)$$
MDD!I=%SJ1SC?5+"SF>:_T]Q2M&"D0C*ZA0G\10<T!4P9%>7^S3)Z/*:6I*'%
M^J-(1RY"9(6XX)K>(23@4M:Y`G";3,YQ[6\CR^L4RV&C65`##[;(4I26_76U
MLOH;2I:E)1RP2E2UE(!6J;KF7<_',GJ$X@EG+:LYXT%?D*;;8K7\0/!DNL:`
MM#A!!4DTGL\S>JSFA`\O59>C+E3T!#2:VL*T@6%:RR21Y,`]"E\__P`-?2-L
M<T7'5.NJ'S"05H=.HIJU)LL*Y!21,A2;XMOBHKN<"4NLK26PRH`\NI23)H`@
M@X@#B)!"4S4;!"W64!M"E$I0"2$@DD)!-I"19,VF4S;%)FV=TPJJ=E<U(/Q=
M`<`N4ILR6$JL41*PR(:S'+W$O,/)"T+29A23<1VP9$&8(!!'35OF'O1JC-_[
M<_X[,.<4;\#H>_5ZA/K]U"VPAEU:U,R,P6RJ8`T@I!"2#;/5!!(]6IU);/[Q
M8P(`U052Q2U$!1UH1E[CG**FI1(GAFK0D&V0&Z9F0G#-!E"`I24K4XI1*4-M
MRPE:B`HWJ2``DE2B!9,D>7I?#=^ICR]+X;OU,>7I?#=^ICR]+X;OU,>7I?#=
M^ICR]+X;OU,>7I?#=^ICR]+X;OU,2?J:=*;;4EQ1UK"V@7W\*R^VZ*FA>6FC
MI:%Q*'WU<.94,02R@2Y12D$+FHH2E*@5&9"2$Y%3!521)=2[);Z]48Y`-I.E
M#80DV3!(G#F6Y(1FN8ILP-J^8:5_Y5X3!*3>VWB5,%*E-FV/6^<M47$I,VV4
M\!AKS;8,IR,L:L3A%BEGH5>4TJ$K?4`MH*,ARB%!0D9@`D`I!)P\+A<&<+RI
M;"_66U*0IL)*EA29A0DF<Y2-TQ*VZ$569)_IK`*3-RQXB=N!H<)*A*SE.3T$
M3'39C65:%-K4^YP%]\@)44I0>*D`:EEEG0JN=?*E3JBJE"`)!"1R3JB3/A*5
MP)6#"`;3BX/N0Q]U1Z5Z&ONM)_+M]3EU)BCK7>2ILYR^OI'2H\`<DT,P2I6H
M0:(I21PN&4BQ9!SKGI53Y3-JZKK%3,R#4ON/2VL<MKK#G;[-ZEY2D.T]+F-.
MV532CD'5T]4I"9V8S54N*0O2F=IMS;*4/*<I<C9I*%I.(X$J2PFH?DDF04*B
MI=0H@">#3TE+Y_\`X:^@FGI4*<<58$I!4H[`$S!S_.7D9?0I5A2DJ/*O$=\$
ME*'$H2FP%1"N%-($PK#ZKD"*-B8DI>-U3B^.XIDK5;:`3A'Q0!9'EZ7PW?J8
M1R=73,UM,%<@LN/<F<4BI#B>1-BL(X:1B29'A":36+Y\4O\`3J7+G"T6WU+;
M-4[*<V5MI7C82"%%Y!PK)2E"E</`WS.RMI+U#4`NHS#A^K-,A4E)?7@2>718
M.22G$Y-*T`(*BAK(<MJ6%H;F2I;CQ4M:K5*ER,D@FY*0`-<S)\O2^&[]3'EZ
M7PW?J8=KBXTZMKA<FV5DE`!*B"I"9J&A,K1.1G))Z%;YA[T:HS?^W/\`CLPY
MQ1OP.A[]7W#ET@%2VEP),QB2%2.J)@R.N.CG%3AX>*F3/3AD\9#9-IU9#4$(
M6I"2I0F20";]>/)I\$=R/)I\$=R/)I\$=R/)I\$=R/)I\$=R/)I\$=R/)I\$
M=R.50@)4"+0`+#HLAS+JZA55L5C:'9MK"%H<2I:#,*!"DJ2$Z4E)3\;$9+R^
MB4<LRY5G(LK.-Q/_`)=X!*E@Z4)"&Y2"DJ(Q'I%9@AAL/K$E.!"0X18)%<L1
M$@!(G0-3IU<X.:[:JDU;BE/-32"VM4N$G$4S0HXBJ9F@RO2>"BHYT5:4(L)9
M8FI6@E*G%`)21:#@2L3[U4K8&5Y(SR+(45$34HE1D"I2E$DD@`6FP``2``]R
M6/NJ/2O0U]UI/Y=OK5&:Y.\JGJ&@H)<09*2%H4VJ1_.0I23K$]3R_F9S=;Y6
MMS)Y##*3.6)9O5($A*1-2B`9)!,NFR!VL=2S2YFFJH'E*.$2?IUJ9!)D`#5-
M4X,[`+8S[GP\23F^85E9;H345#CJ4RLD$I4$@2$@`)"72-MY6CE'&70LHF`2
MG"I)E,@$@D&6D3E;($5&?N>KHOY-!"G#LJM0C]<Z"`8Y'*V$M3%JKUJXRS-1
MV)R&@",CIVTX4K89)`U7.$L[:E*)US&$-)D/S1W(\FGP1W(\FGP1W(\FGP1W
M(\FGP1W(\FGP1W(\FGP1W(\FGP1W(`9`2%)!D+IS([4>IX?FO7,&&WO>6PRU
M;K+Y]"M\P]Z-49O_`&Y_QV8<XHWX'0]^KU*SKBSICT,X\Y3^*]#7%Z@>,F*7
MS'_$7UG,P7*-U#J4DI)0I*@"+P2DF1&D7CW$8^ZH]*]#7W6D_EV_<"BS=:`I
MK(:*MKE3NQ*;%"WK%0<K4K2+YH*AWI(YV<S4HY-JBS.K#*=2F==4]2V7"=.X
MT9"P3LLZ5JOH7%-/,J2MM:"4J0M)!2I)%H((!!&GICT,@^[TV\GJ*>(/&5'_
M`%W_`*QT*WS#WHU1F_\`;G_'9ASBC?@=#WZON0>AG'G*?Q7H:XO4#QDQ2^8_
MXB^LG<ZS(D-MR``$U*4HR2D"RTG7``F20!&',ZU?)S40VW)M`Q"1&%&'$`+!
MC*B`3;-2B?7:+YQER0>9)`2ZD8I#%A44J3B)2H"PV$$$@TV;4P(;J6T.I"A)
M0"TA0!UQ.1E,:A(M]PV/NJ/2O0U]UI/Y=OK_`-7YD9'7YNN<I4='45,N,66U
MA(%I)40``22`#'.;G;[3\I<RJJS)-'3T;;RFB[R#9?=J5*2VXM386M5.`EP(
M5-HF1$B'?:?[->;]3G%!F-#2FJ72!MUU-93)73*0:=*S4K_Y5FE4E:6E)5B*
M$DE!`_IW.W+*O*ZC_=5=,]3.>`\A"NQU(]#(/N]-O)ZBGB#QE1_UW_K'0K?,
M/>C5&;_VY_QV8<XHWX'0]^KUG,V`0C+C5MEYR02`<0)-PQ)!0"=`*@3HZT/0
MS;*E*D\L,.I3I4A/*(61Q2M`/'$(:>5A4FRXG;L!CRGZJODQY3]57R8\I^JK
MY,>4_55\F/*?JJ^3'E/U5?)CRGZJODQR-.K$20381(#9`AJG;,U,LI"]8J4I
M8&SA*3L$=9(>87A;:J&U.)MX22%)3=J+4DR,AIG,`&*&D33&J0I]KE$2)26\
M8*\9%R0@*))LD#.R$LLI"4)`"4@```"0``L``L`%@'N&Q]U1Z5Z&ONM)_+M]
M?>N9/E.2YF<86!FF4T=<I*A_NZA;::MH&0X+=0@"](2226Z+GWS-IW$)`!<R
MRJ73)0!^12U#=0")7)]:0!*^VS,,RYC,UE*YE2F$53%:VTAQ!J$N%I2"R\^A
M;:RRZ$JQ)5P#B0FP0US,YPT-?F>;/4K=6EJD2P&4-N..MH#SSKZ"VLEE:L*&
MG3A*%$`*$.Y5S7YF98Q3N#"1FCKF9A7YQ90BB;G*T)5RB4JOQBPG.\THLMH%
MF?S>6Y=1Y<S-4L14BE:;+JB1/$\IQ0)401B5/J!Z&3U-,K&&&FVUC2%LG"M)
M&@S3,3O!!N(B?*?JJ[D>4_55\F/*?JJ^3'E/U5?)CRGZJODQY3]57R8\I^JK
MY,>4_55\F"^@R0A,BHV"0F2;;@)Z=2/ZG,\EZURL].#E<=VK+H5OF'O1JC-_
M[<_X[,.<4;\#H>_5ZS6S3J6U3LXFP@*,ER)"EJ`D.$+)&<DB4[3$Q#M+7@K%
M+@2ATSFH$*X*B3:I(`M&@C%;(GK1K.LE=+-0R24J$B"")%*DFQ25"PI-A&O(
MPE%9E3+C@O4AY;:2=9!2X1X9C\&;_B5?4Q^"M_Q*OJ8#HR-M4U2EZTH:"?\`
M<'4AG._Z&V2Z\MK!ZTJ0P)2K%/D;9XI2EMPWFR\K0T5E8PA]2I85%-_)"^4[
MH^P(^E/R(^P(^E/R(+=%2MLK/QRHN2UPF21/4G,:H,+JJI9<<<)4I1M))O)Z
MR71UK:7FG!)2%I"DJ&H4D$';$.5->^[4TY,T,GYO")SDMQ"L2[+.#R9MG?'J
M>34S=,W9,(2`52N*U=\M7YRB5:_N(Q]U1Z5Z&ONM)_+M^X&<<S7E2;SK*U+0
M)]]443S;B!+S#U4J=XPRE(DCG;F+:\3-%5#+FA.82G+VD4C@2=13[3SFRX96
M2'57$Y64/4SQ!6PZ"4%0`&-)20I"Y6$@R4)8TJPIP_@S?\2KZF/P9O\`B5?4
MQ^"M_P`2KZF&<G5D;:`ZY@Q>M*)%]LN1$[KIPWE*\D;:"PLXA4J5+"DJNY$7
MRE?'V!'TI^1'V!'TI^1'V!'TI^1"J!I":5EP26$DJ6H:4E9E))TA*02)@D@D
M=&M\P]Z-49O_`&Y_QV8<XHWX'0]^KUD4S(GI%^U#U"\"%-+4GA"1(!(!VQ:"
M+"#,60FFHVU.N*L"4@D]C1KFP:88HLP2$.IQDI$II"EE0"B+"JVW4NT=<IXX
M\544GWQ[T3<4_&=](KKI3]0M+:$B:E*(2D#5),@!KF%,^L&K>20"BG3CO$Y\
MHHI9(&G"X53(LODWFV4.8VUBT$C&A6E#B03A6-(G=(@D$$]?L?=4>E>AK[K2
M?R[?N!S=]HM=,TU!4+2^!_\`4]2R[2O&R<\+;RE"PVI!`)`BKSS,E8ZBM>=?
M=5^4X\M3BS:2;5*)M).OU;WZ\'H4GGS^U%/Q7?1JZ>M\P]Z-49O_`&Y_QV8<
MXHWX'0]^KUFV_F2"5M"0*5%)*9SPF5XG,Z")F1$S')9>RAE/YB0F>R1:=N?7
M2>./%5%)]\>]$W%/QG?2*ZZ:YG4V'D2A#[Q!.(KQ+"&S(R```<(())4@V2MA
MMC)0I5*LCUM/[ODP%`*692"DDDMR(*E<&T%7N`Q]U1Z5Z&ONM)_+M]<\Y_;4
M&BI>59YE=(ER5B&"P^FK3.[AOU^6$SNP)'Q^MO?KP>A2>?/[44_%=]&KIZWS
M#WHU1F_]N?\`'9ASBC?@=#WZO7R#FCX:+D\(PJ43*^Q()`US(:\-II*9:F?C
MJ64I6+?BI25@R%MJA.Z2;X174*^4:<$TJ`(G;(V&1!!!!!$P1U9/''BJBD^^
M/>B;BGXSOI%==-\Z*=DFF=:0AUP&<GDE21B$^"%-X`DRD2#IO%+E=.Y4.$@8
M6T*4;;IR!D-<R`D23(14YIGBDMFI;2A+*58B)*Q%3A'`"A<D)4KOE3(T]?L?
M=4>E>AK[K2?R[?7-;S34S.LS[+,SS1*9$XZCE'*G+S=/A-TM%P@#*](5(3ZU
M]^O!Z%)Y\_M13\5WT:NGK?,/>C5&;_VY_P`=F'.*-^!T/?J]?/U+JRM"5J2U
M9*384<`EHF+3.TDF?0?KW%RIG))2B<YK2>$J7Q9"S55/4`ZLGCCQ512??'O1
M-Q3\9WTBNNET->TEYEP24A:0I*A?:#980"-0@$6B$T.5,(IV4S(0A(2)F\V7
MDZ2;3I/N"Q]U1Z5Z&ONM)_+M];!)(2";S.0US($R&L"=0&&EO^TGFO0<J$RI
MVJU55F`*M"J-P4=N@87E35,&5A*7N>F>9IG+B;TM%BA85LH2BH?V,-2F_3?%
M#S1R-D,Y?EM,S24[4RH(IV&DLM()5,JDVE*25$E5Y)),.5/-#,\TR-U9)2CE
M&JRF1,SL;>;34$"ZVKN`TS)=6W[3.;+ZF@3ZO6U1R^O<`O#=(VJO*E73FXD`
MV8IR!<IPM+@;4I.-!)0O"2,2"0"4JE-)(!((F!=UG[]>#T*3SY_:BGXKOHU=
M/6^8>]&J,W_MS_CLPYQ1OP/<!=5A'J]2M:FRFY,SBP$``)(GP1I`F+C)*U-^
MKM&1QNV6:R._)E=,`'\H0,O:6725%:E&R:B`+$S.$22!*9U9V]63QQXJHI/O
MCWHFXI^,[Z17NXQ]U1Z5Z&ONM)_+M]&?6J?\#<Y<RRI"9?-TU;4-,D"X*92Y
MR2TC0E:%)G;*8$99[;\\>%0_39$]55CJL(#M3EK+S=8M01A2DKJ*5TJ2D)`)
M(`3*04.>O.K,\Q;7>TY6/^KVSGAID+2PF_XK8LLN`ZV/0I//G]J*?BN^C5T]
M;YA[T:HS?^W/^.S#G%&_`]P+1U@GCCQ512??'O1-Q3\9WTBO=QC[JCTKT-?=
M:3^7;ZYYY<T>6PUE/FJ,L83_`/6V:KIZE8LD>&A&:6763)()2.MCT*3SY_:B
MGXKOHU=/6^8>]&J,W_MS_CLPYQ1OP/=!/''BJBD^^/>B;BGXSOI%>[C'W5'I
M7H:^ZTG\NWUS4\TVGB*"KJ::K=:T*J*1JK98<UBANMJ4V7ARVX=<TGGS^U%/
MQ7?1JZ>M\P]Z-49O_;G_`!V8<XHW_=%/''BJBD^^/>B;BGXSOI%>[C'W5'I7
MH:^ZTG\NW[I4GGS^U%/Q7?1JZ>M\P]Z-49O_`&Y_QV8<V!O^Z*>.-Y44GWQ[
MT3<4_&=](KW<8^ZH]*]#7W6D_EV^J?#'PQ\,?#'PQ\,?#'PQ\,?#'PQ\,?#'
MPQ\,?#'PQ\,?#'PQ\,?#'PQ\,?#'PQ\/5*3SY_:BGXKOHU=/6^8>]&J,W`$_
M_9U1V%M$]B'!^:-_W12/SQO*BCQ?&JWR-<!M`)W8IY_E.^D5[N,?=4>E>BG4
M?CTE*?\`T*4[?>P%:HZG\,?#'PQ\,?#'PQ\,?#'PQ\,?#'PQ\,?#'PQ\,?#'
MPQ\,?#'PQ\,?#'PQ\,?#'P]4HRFTEXG:`43V`3%/Q7?1JZ=YC\MM:;IWI(NT
M[$5%#_\`5%)4M>$C1N1A_*21V^U[HMM[)W@.W&2,?&<]:=4.,X@(.VD>^R*%
M-MJ5FW\YU:MRVS6]W*=W0JG2-M+CI/C",HKTW/4#`/&0#BW,0&UKPVO52.P+
M?=`K.@$P*S13,ONDGXH#91/=6!MPVJW@-NG]7#;K<+=EU!MI7!2W4K8.PM2F
MMP8@=2R<5%(1A2T\</FU'$G=;4/=$,,C$K@H2!I)-PUYF44>2MF8H:5IH\>T
MD[8PF**D(D6V&@>-@&+LS]W*',4CO5+;4>,`I/BKC+LR1:NA<<97+0E:B1/8
M`;\*.2-Z#V#:.W[H*U5\$;=_8G&=YVNR;0IT'\YR85+7!6V8JZ^5C;0;GKN+
M"MYOWZ>G57-<%-2$NI(T+3)*MO$G%^D(R_GE2C@U+8;=EH6`2`=<$.()_,`@
M`]\C@G:N.YV0?<]3RM`LUSH&[":ZI$VJ0%Y:C=B$\$SJXN'L(,!9$T5+^(@Z
M&46R.N&D2V?=VI0@36R`\G_S=JO_`$>,;<9ES0?4`*IOE&IW!Q$K=<SY-4M1
M!A5+4C`J90H&]*@92.N%"1]T`PBT(OXQ[EV[&7<UTV/.DU#XTSE<K6Q*PCS0
MTP*IP255.*<U\`DA.UP5*&LJ?4#5LB;M&2X-4H(DX-H`+/$BLYCUZI%P%QA1
M^*H2)`XJP')"U0+EPG#E%6I*%(44.)U"#>-4:0=(-E\3%Q]SA3,VA)T:57;<
MKAKS@9<2$U^9GYS\I*".$-A"2$<9:B(J,_>3_P"1;.XIPC]1((_.'NZ4+$P1
M(@W$&\&,38,J=P+1^>RK1/\`.02A1T*Q"\0SSNROA4U<E)41\5PIF"=3&D6C
M0M*IVF)*[]-AU_SMO3K^YQ7\8V)&OJ[`T[D'-*V0I:,\HXI5RECA)29Z)C&O
M1A$CWPB5-.3ZPVW/XC2;E$:R07%#5*I0W1TXDVTE*$C42D`#L#J!2H3!L(-Q
M&H8349>2E`5RK"M&&=J#JX;4*!-J2">^A'/#(4_\PVG"^T+5'"!.Z]2!=9PV
MY2M`$"E?-GQ2=&L=;4U-B[W,-.R>&;S^2.[O7POGCGDD4M+-3>*Y2DWKUP@V
M(`[YRP6ID0E@$<JK`V#:&F4Z3L":U:JB0+P(:RVC$FV4A(U3JD_G*,U*.DDG
MW>&9T:<5123)`O4T;5#7*3PTC4Q`":H=YCYX?F:@'D5'XJC;@!-QQ<-O\^8M
MQ`0:2I$RFU*A,)<0;B-XBW"H$6RG`=:.R-(.H?<PNNF0'9UA#=#1)FMPR2-"
M4WE2CH`%JCM"9D(;YDY,J;C@G4+%\C*>*5RG=2?!;`3:%`PKG'5IDMX%#(.A
MN?"7^F1(?FI)M"^I*H7^"XGA-+_(7+LI-RAI&N`0Y35:#A!"7VIB2AH4DW3`
M.)"A809$R)C_`!9S0`>8=!4XV@6I/QE)3??W[<II-H!!.$,55J="M(UCJCLC
M>"T$$&XB[W)F8+-(9G2K0-C5.O=VCG6>DLT#<U34<)=E?)1E)L?&7I[U)G,I
M1D61)**%DA*$(3+E5"Q)PCXHN;1*?QB)R"35U@_YQ\#'_P"33>&QKZ5FXD`7
M)!/N^<ZRQ,J5U0/!LY%PF<K+DDVH(N/!LX,QD.=J#>8L`EIW2N0[Y.J2`.5;
M^,!C3*7`-+6H*%:#>AQ.JD_&'92;"`9B.`9*TI-^UJCWV=-\,?#'PQ\,?#'P
MQ\,?#'PQ\,?#'PQ\,?#'PQ\,?#'PQ\,?#'PQ\,?#'PQ\,?#'PQ\,?#'PQ\/3
M8G#:;@+S"**B05K5<!WJ$Z5*.A(TJ.L!:0(5242DOYL^D8E2GAGI(^*VF]"3
M:XJ1(E/"K,<S*C3)5B=<),W%7X$G23\8CO4ZA*82TTD)2D```2``$@`-``L`
MZF%((:JFA\VY*PC\A<K2DZ#>DVBPJ"ET[B"FT<HROO'$Z%)(_5<3/4,Q-)5F
M/-UQ-+F!&);*K`HZ2I(U3^];F+9K3B-G(U[2F2;IB:%\50FE7Z)F-,HPU`P'
M5%H[H[.S$VE!6P0?<7$XH)&N0((;FX=:P;I[4X314;:G%*N;;!,]<RT#238+
MS*$YWSX>0"+4,`X@57R,K7%?F)F@7J4I,X3E66MJ;I20$,H$UN$=[C";Y:$#
M@IUR`83FN;`+K"."FPI9GJ&XKE>JX6A.E1_T`72U2`XVX"E25"8(-X(C^J92
M5KI<6)*DSQL$&8Q$6R![US:5)4BK^@<^4B?Q*BZW05$=XL?E@8%"Q8%N+U_*
M":VD/"2XW:M*;P5)3.8E\=$TD"9PW1@J!C`TW'N'L;,<%8!U#8>SVIQ9[B_.
M.">H+3N"9C#2C"-4W[EV[.!5OSIZ95I=<!FH?F),BK6-B/SM$*R;F@E+U2;%
MO&2DA0TJ5^\4-"4_-IGLI*LSKUJ33J42X\JU;BM(1.\SL*CP4VWD88104"`V
MTV))2-\Z22;23:3:;>J^JYFT%2[U8L6@ZJ57C7%J3\8&/7LMQOM(,TNM3#B-
M=24\))&E29IE:2)RC^G<YZ=%>P;"2$A<M<$8%D:)A*IVE4X+N3Y@<N<5^[?'
M`'Z2B`-2QU0&@:O+9=R58WH6RZDC]8H[$XDNDJ0!J(<4G=`*8*5-O@C5;5\F
M/)O?1J^3'DWOHU?)CR;WT:ODQY-[Z-7R8\F]]&KY,>3>^C5\F/)O?1J^3'DW
MOHU?)CR;WT:ODQY-[Z-7R8\F]]&KY,>3>^C5\F/)O?1J^3'DWOHU?)CR;WT:
MODQY-[Z-7R8\F]]&KY,>3>^C5\F/)O?1J^3'DWOHU?)CR;WT:ODQY-[Z-7R8
M\F]]&KY,>3>^C5\F/)O?1J^3'DWOHU?)CR;WT:ODQY-[Z-7R8\F]]&KY,>3>
M^C5\F/)O?1J^3'DWOHU?)CR;WT:ODQA:I:I6PVX!MG"`-LQC>8#*=*W7$@#9
M`*E_JP%\Y,V2ZL7M4W",QH*AC5;KI;V1!H.9="BE0;"ZX,3BM<B9F1H*UKL^
M*(]??4HH4>$^\3AE.Y`O5*V24#"DV$IC'3CE:@B2GE@8M<)%R$ZPM/QE*D/]
M`RE0F#80;B-0PJOYN29=-I9-C:C^8?B$_DG@:F`"#1+"FT@S++R26SKIM$I_
ME-J`.DF,6?TRZ"I-[S5J2=512DDDG\MI4A\>,7-G,Z>LG\12@VYL89JF>,$;
M$'_DW;/]V0O<Y-2C[]6)/,5")6<)IP6[:8\F]X"ODQY-[P%?)CR;W@*^3'DW
MO`5\F/)O>`KY,>3>\!7R8\F]X"ODQY-[P%?)CR;W@*^3'DWO`5\F/)O>`KY,
M>3>\!7R8\F]X"ODQY-[P%?)CR;W@*^3'DWO`5\F/)O>`KY,>3>\!7R8\F]X"
MODQY-[P%?)CR;W@*^3'DWO`5\F/)O>`KY,>3>\!7R8\F]X"ODQY-[P%?)CR;
MW@*^3'DWO`5\F/)O>`KY,>3>\!7R8\F]X"ODQY-[P%?)CR;W@*^3$FF:A6PV
MLW["8D*-_P#\Y\WZ4ICEN<5=3T"/SEA2]H32G8DLG6U<67,KS6I3<MP2;!UL
M20!(W$-K.HO3'].8Q8%V!A@$`C\Z]2AJXCA%\A":SG,<1L(80;/_`#BQ?Q4&
M7YQ$Q"6&$A"$`!*4@``"X`"P`:@ZP+U6Q@=-[C9P+.N9<%1UU)48*LGK$J'Y
M+R2DC]-`5/P!!53L%7YS+J;=K$E?ZL<FV*](&A*W@-J2I;D7YCX;_P`J+\Q\
M-_Y47YCX;_RHOS'PW_E1?F/AO_*B_,?#?^5%^8^&_P#*B_,?#?\`E1?F/AO_
M`"HOS'PW_E1?F/AO_*B_,?#?^5%^8^&_\J+\Q\-_Y47YCX;_`,J+\Q\-_P"5
M%^8^&_\`*B_,?#?^5%^8^&_\J+\Q\-_Y47YCX;_RHOS'PW_E1?F/AO\`RHOS
M'PW_`)47YCX;_P`J+\Q\-_Y47YCX;_RHOS'PW_E1?F/AO_*B_,?#?^5%^8^&
M_P#*B_,?#?\`E1?F/AO_`"HOS'PW_E1?F/AO_*@>L,.JUWG`)7?[Q<]P$ZUA
M@*S.J;93J-A3BMBW``=@J[4!TM&I='QGI*`.L@`(&L2DD:L!*1(#_08TV8LH
M>0="T@RUQ.T'4(D1H,%S*WG*4GXI^<0-@$A>ZL[$$TA:J!HPKP*VPX$I!_2.
MS$F&JMLC_=K6>RVHC3JZL7YCX;_RHOS'PW_E1?F/AO\`RHOS'PW_`)47YCX;
M_P`J+\Q\-_Y47YCX;_RHOS'PW_E1?F/AO_*B_,?#?^5%^8^&_P#*B_,?#?\`
ME1?F/AO_`"HOS'PW_E1?F/AO_*B_,?#?^5%^8^&_\J+\Q\-_Y47YCX;_`,J+
M\Q\-_P"5%^8^&_\`*B_,?#?^5%^8^&_\J+\Q\-_Y47YCX;_RHOS'PW_E1?F/
MAO\`RHOS'PW_`)47YCX;_P`J+\Q\-_Y47YCX;_RHOS'PW_E1?F/AO_*B_,?#
M?^5%^8^&_P#*CDGDUJQJ+6Y+]=0$8ZH-T\[3RCF)6S)L+MV2->`O-JE;Y'Q4
M`-IV">$HC7!0=B/5\L80RC\T2)UU*[Y1UU$G7_\`P/I664#/K+Z._)5A0@WX
M;`2I0%X$@DV3)!`^Q->&N#AHVI\9?P;\`U5&TM&D(4M!W3C'8A&99>3A584G
MOD*%Z5#5$]@@@BP_ZJ*AM[A!=2[.>GYQ5\>21X(CR2/!$+>;;"5)D00):0.W
M&8LD\%)84-E0=!["1N>X#F04%*RY3TH;Y3'CQN%QI#IPJ2H!``6`)H5:"3,$
M"$4W*^I5:I#D7R$XCJ-N=XY;<)I6?R!_J'=^].^D5%T70\KBC=4D1F7_`$__
M`!_<#,_^F_E&.@BFY7UVD3(<B^2K"-1MSOV[+A-2!^0813<KZE5JD.1?(3B.
MHVYWCEMPFE9_('2IS+G!4"G96L-A12M<UJ"E!,FTK5<E1G*0`,R(;KJ)8=9>
M2%H6DS2I*A-*@=0@SBJJ\O?#C=$ZXR\K"M(0XR`IQ/"2DG""#B3-)G83$OZG
M_P#B]7]1'^+O61_3L&/EL#G>XL$\&#E)XN#AP8IZ(%/3YH@*40!RC;S29F[A
M.M(2-DF0TWB`I)F#<8?SZL27$LA(2A)`4XM:@E"$SG:2;;#(`F1E#6=<YE^I
M-KY,*!"W"AQ:9\G\VA2E$$$3"96$V"&LPR]Q+K+R0M"TF84DV@CN&T&P@&*I
MO*WN551/+IWAA6G`\WWZ.$E.*4^^3B2="C+IVZ3G%6>KN.IQI3R;SA*9E,_F
MFU@6@@3E.1E=']*R&MY>H*5+P<D^WP4RF9N-(39.Z<]06&$<W*"AJ<RKBURR
MFJ=*3R;4Y8EJ41(DW)`,R4@D%29T+KU+4/568D)8I4('+J44I4I*DD@(Y/$D
M+M)23*1M(RK^I4%32NYI4&F2TXE*5M+!EB7PK4&]*DSFD@RZ7^JY^_ZNQB2C
M%A6OA*G(!+:5J,Y$V)L`),(H,LS)M;SAPH2M+C14K0E/+(;FHW)`M4;`">HN
M9=59D$/,K4VL<C4$!:24J&,,E!D01,*(U#"<RR=]%2PN8"T&8F+P=(4-*2`1
MI$9C0TS:T*RU\TZRK#)2A/A(D2<-FF1UNDRW**AM:UYFXMIM2<.%!0`HE<R#
M(XK,()Z7,*`M&GJ,MJ%,.MJ4%$B]MU)`'`=2"4S$[#K$_P"B#OWIWTBNA=#N
MRGQTQF7_`$__`!_<#,_^F_E&.D>HZY3KV4MM'`MT$I0Z%("4-.*M/!QXFP2E
M(`,DF6+HY+2U*0MMW-Z-"DFY25(?"@=8@D&*WV6YLLGU8E^@6J]VE<))2+IE
M!))E/A<J!P6XYU?W+,_0M10Y3GU4ANK:Y;E$FF?<(Q5#JT\-#*TF:%)-BC*<
MC(@@9A4T1!9<996@@804*=:4D@$`B8(,B`=40CF^TXU45[E*RTA`:*2A\(0G
M&IU:$MHY-7"*RL7&1(G&6T%6L..,TS*%*2K&DE+:1P5"84G0E0L4)$6&.:W-
MA1^;?K%5+B=!%*E*D@ZH4%+$O@BA9=`4A>8TJ5`V@@\H""-0BPQ6^R_,5$L@
MJJ<N6H]^PLE2V@3WQ0<1.JI+Q[T".=;C*.46G-ZTI3,)Q*!L3B-@F;)FP3F8
M?YRU#&6H8IFU.KI9OK=#2`5+FZ"&RXE()X/`,K`HV%?/G*FTXS3)?0AR:DA1
ME-"L)05!))$P4SE.#SSRV@HV:%IKEN0?+IJGFDIQ+=`20AL$`K:05%6&TE?!
M"J'G-14RGZC-.2;IJ:<BI]T=XI4N]0005`<(A($L0(_Q'S@IJ"KHD%)?:IB\
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MB66*9QHOT50D*2E;:`I3J'2I:QRB$@DD8!)!.'AH$56>5+*&,O6Z4T(PK#SC
M2"4J==*E%,EJE@2E",,E`E0DHTT[O7J?><A5&SR*\R6ZR*5+6`OXRXC%A".&
M`6\0/Q2HH'?%,<W.:E2EM?\`4&'C4K4%%P.4]/CFA07AX2P<6)*YBX@VQDE#
M1H;6C,JL4[I6%$I00+6RE:0%6WJ"AK0_S*YN4+-2YR#3C;CA6AMG%/E'*A25
M&;8X*4(0A*U*5+$3))>YBYAE]/59NI*5T[K*EHI>25/$Z_B)<"&Y2DD!2U#D
MP)E*E'F/SV:IN6>8-13OTO*!M:02%(4EPSQ#"JX)(P6A04%Q4<RN;E"S4N<@
MTXVXYC2VUB\HY4K2HS;3P0E#:$K4I4@HF0+?,OGTU3<I6-J<I:BEY0-KP!2E
MMK2X20H)2?R9$`27C"NAG]-SHJ&VG%YE4K2E32W"43E9A;7I!$K]:,[SS+L+
M=#75JUT[*5));0"JU3:20T5!20&S(A*1(8,!/.LFP#,E[RH?S'F.U1TV6LN*
M;:=K.64Y4J1>I*6Y!#9UQB!LF2%!.;?XK8%%6Y',U2$$J0I.%2DK:F9G'A(2
MG$KXI"B%@!'.G*Z.@32.CE&J1Q3PJ7&3:D\K,-)6M,B@D)3(@E.@\SWGT\F3
M4O%220<)Y)LD$BPX;B199.*S-,K;;'-W*VW#45;B5E;[C:5$HI)+2D@&0Q*2
MH*T2Q(G_`(MRVEH&J1:"\U2.%]50XS+$DEQ)#86XCA(L2FU.("9A7M"R%M'*
M86B&W<2DI6JI0PZA6!3:CA)7A(*9R2J4C*$YOF-+34N45"5*:;)<-:E-A:6Y
M^['*"TI%J9@$`B96TW8C-\N2M0T%YA92#+52TT1/\XRT_P"B+OWIWTBNB[LH
M\=,9E_T__']P,S_Z;^48Z`&24I+4Y*?7P&4ZLUD<(C2EL+6/R816<XE?U*I$
MCA4,-.DZS<YN2NFX2E0MY,&$L,)"$(`"4I`"0!<`!(`#0!TF1?WFB\5^*;GM
MD(_]HY(KEDRO=8_?-&5I&&:I?D\HD":XYQ9DT"E-175[H!O`<IV5`'7`-L9?
MEV:9E3T[[?+XFUNI2I.*I>4F8)F)I4%#6(,9E7Y:ZE]AQM!0M!"DJ`?;!D18
M9$$;(AFDSBII7Y4;2'&4X%NJ6&4@H"4A2@O%8%$#`KA$B4Q1,9P%(6>44A*Y
MXDM*62V"#:`0<20;DJ2++AS2S-SR9>J&"=1;J4)0)_G%1D-;<R_^Y4F^N&>=
M&1"69Y,OUAD@6K;3(NM&5J@I(Q!-N+"42X9CG7SIREG$\Y65E4RT;3B4T'4)
M(%JI$@$"U5PM(AW/<\YPU-7FM53N@4Z:M0`J%I4$L"C:E)L*PA8*,"DDJ)"%
M`1_T/[<?_8K_`-3CF;SLP*<ILJ>:<J`D3*6U+$W)?FX,(.A2QHG%5E^2UC5=
M59BWR###"@XZI3LD\)M,UHP@DR6$F8P@%1E&7914^5IJ=IM<KL:4`*`U0%3`
M.I&35^:OHIV$T+P*W%!*05%\"9-EI(`UX%#E&8,5+Q!4$-N)4J0O,@9R&F,[
M^XL?^KQS3_ZST8CFI_<D;PCFOSBS,\G1MFL:6Z>]0IYG`G$=`X6*WXJ5'XIC
MFW09&Z*M--7M*=>:X;"5+E@;#J9H4M02I4DDR"3,SF!_@G)BA+>4MK>J*DB8
M34.(*6:8*T!1`+LB;E68F9%&75#8IZ[*Y4M2P`$\FIH8$D)%@2L)LEP0H+2)
MA,XIVUB:55U."-4%+H,"MRC+66GD]ZN16M.NE3A44F5DTD&4Q<3'-?G%F9Y.
MC;-8TMT]ZA3S.!.(Z!PL5OQ4J/Q3'-N@R-T5:::O:4Z\UPV$J7+`V'4S0I:@
ME2I))D$F9G,#,_[:SZ1$,?V8_P`VY&2?<7__`%B*RHSI998?H66N5();;65)
M4GE%`'`E6$I"CP0J4R!,C)D<W74U3.4M/NU#S2L32>43A2@+3P5'%@!PDCAR
MMPJ`C/V.<-53L.JS.I4D/*0%%,P)@*ME,$6:9QG>><U$%.3+9;;*DI*&7:H%
MLXFTE*18`[BD+UXS8X)\\:5*L)=KW4`ZA4A0GM3G'^$^<E2UE]=ECKZ'6WUI
M:*L3JW`I!60'._*9))/!!E(I)YZ<Z,E0LT]:TTS2G"0:@TJ4%90")D+Y%(39
M:7,)DH$"B>KZYIAVEIVFG&"KYX.-("%)2SY10)3P2E)!!$R+9<U:*J2KD*QV
MH2H6H5@<9;F++4J`.T8S3V,YH2IXL+<RMT`)]::"N5Y#4Y6:5)PSX4U(G8@K
MI7LQSZHHZA#24/,.9FXP6W$)"5I2TM:3@Q`X`D$89`6V15L<TU%=`>14VHE2
MBJ=<UB,U@'OYRL`E=9;#/FT>*(H4,V^HY:M;DM'*+=0`=3RB#^E_HB[]Z=](
MKHN[*?'3&9?]/_Q_<!_.,F:;<IJP,_.*=0@-%#+;2@XE1Y0VMXIMH781IF(1
M6<XE?U*I$CA4,-.DZS<YN2NFX2E0MY,&$L,)"$(`"4I`"0!<`!(`#0!TR$UC
M2'0VH+2%I2K"M,\*TX@9*$S)0D1,R,2,&FH6&V&U$DH;0E"22`"2E(`)(`!,
MK0!'X92?P[/R(_IJ:=L4TI<E@3R<B9D8)89$VRE*=L)?ILOIFUIM"DL-)4#J
M@A((VNAR.5$"NI'6ZFF)(`Y9HS`F9`8DE2020`HI)L$,_P!7ID%<D+4VL)<2
MVZ!,R)!!*"2`L;(-O04WE[#;"5'$0VA*`5&]1"0`2=4VPNNIZ"F;?<F%.)8:
M2M058H*6$A1Q"PS)GIC^F\@WZO+#R6!/)X?R<$L,M:4H]4Y-/)8<&#",&"6'
M#AE+#*S#*4K)2@4;#2$,@80VE("`DWI"0,,M:4H-9EN7TU.\9S6TPTVNV_A(
M0%6SMMZ"7,RI&:A21))=:0X0+Y`K29#6$>LY?1,,.`$8FV6T*D;QB2D&1TB<
M*KD,H#ZP$J<"4A:DBY*ERQ$"0D"9"4-U;S*%NLSY-:DI*T8A)6!1$TXA8<)$
MQ?#;E2TAQ3*L2"I*5%"ORD$@E*M<2,*H\Q914-*O0XA*T'92H$';$-4U+1L-
MML*QMH0TVE+:_P`M"0D!*OSD@'7AQ=&RAHNJ*UE"$I*U&]2RD#$HSM)F=>'*
MRG8;0Z]+E%I0E*URNQJ`!5+1,F4!FN90\@$*"7$)6`H7*`4"`1.PWCH*H\Q9
M14-*O0XA*T'92H$';$-4U+1L-ML*QMH0TVE+:_RT)"0$J_.2`=>%5R6D!]20
ME3@2G&4BT)*Y8BD&X$R@5Y:1RX3@#F%/*!$YX,<L6&9)PSE.V4X37+907T`I
M2X4I*TI-Z4KEB`,S,`R,XS'.LPIDN9=54+;`*RVM*UA:2I"FB2J4@3-2,)T$
MF"QE%*S2MJ,REEM#22=4A"4@G7Z"GW\NIEK62I2E,-%2B3,DDH)))M)-I,)8
MIT);0FP)2`E(&H`)`;4..4S2&U/*Q+*4I25J_*60`5*US,P*C-:"FJG$V!3K
M#3B@-0*6E1&["6&$A"$`!*4@!(`N``D`!H`C^J'+Z8U4\7+<@URL]7E,..>O
M.<-OU#2'%LDEM2DI4I!-Y02"4DZ2F1AJHJF&W'&3-M2T)4ILV6H402DV"U)!
ML&I!KJW+:5Y\F9<73LK7.^>-2"J<]>#0U+*'&"`"VI"5((204C`04R!`(LL(
M!%T!*1("X1G7.O/4!%17O!ME(4%8*1D86IE,P%."16F9D4@WD_Z(N_>G?2*Z
M+NRGQTQF7_3_`/'_`-5#OWIWTBNB[LH\=,9E_P!/_P`?_50Z?_KIWTBHMB^'
M0/S/'3&9?]/_`,?W!6BC;4Z6T+<5A!.%MM)4M:I7)2D3)-@_U#U2JE)!;J'%
M$:9%9((V4D$:H(BY>X.[%R]P=V%4S05-4KP`!(@ZIU(KJY8(0ZMM*3H/)A95
M+5ER@&S9[@\]TO(QH1S?JZ!LGXE5F@+3*P=!2AA^5AMMT6EMP%*DD@@B1!%A
M!!M!!O'^H9+V8(4EU(D'&SA7+4,P0H#1B29:+)QY>J\-KZF/+U7AM?4P%K<J
M'`/BJ<0`=G"TE6X1"*.C0&VFQ)*4V`#_`&VDWDS)M]P<TYSYDPMA_.<P.`+2
M4E5-2LH0TN2@#(O.U(%X(`(-ICG/D*V5-,#,:EVGFDI2:=]POLA!(`4$-.H0
M2FS$#==TSG-OV;Y14YS7M,+J5LTK9<6AAM2$+=4!8E`6XVB9-JW$($U*2"_E
M.;,.4U52N+9>9=0IMUIUM10XVXA0"D.(6DI6A0"DJ!!`(BAI^>67/9<O,Z-G
M,*5+R<)?HJ@K#%2@3,VW2VL))D3A-D9KSSYG9'5YCE61H*ZZI8:*VJ9"6U.K
M+A_,:0IQ>$**$#&L!)!,9;S+YMM<OF&:U+%)3HT*>J'$M-@D`X4XE`J5*24@
MJ-@,5GL.R);?.'.:2L-`G^FAYQM^J2`'6F0ZTRX2RYC9<*FTI"VG"%*;`67^
M://O+:C*<SIL/*4]2VIMQ(6D*0J2N^0M)"D+22A:2"E1%L4/M`S#+GF<ES-Y
MYBEK%)DR^]3F3S;:IVELS"K)3"@"2DRZ;+_:?GN1U=+S?S58125[C133OK4'
M%("57C&EIQ3>(`.)05(*DV](KFC[,\L<S;,4LN5!8;6TA09:*$K7-YQM$DE:
M!+%B)4)`QSDK^:JJ=*.:N45>=5O+N*;)HZ-(4\&`EMS&\0>`A10E6E8Z&9^U
MG*LL<>YNY,\U3UM:%M!MAYY;+;2%(4X'5%:ZAE,T-J2"XG$1;+HN>V!K+'#S
M:9JQ0KKL37)IJBE*@S@Y3EIR6GA!LHF98IS'0RWFP:MF@_J-4Q3>LU)6*=CE
MW4M<L\6T.+#3>+$X4H40D$@&,W]F7/!"4YCD[ZF'2@J+;@DE;3S14E*BS4,K
M;?:*DI46W$E24F8'^H5`]J?,VJS]0,RZC-G&$IU)4C33(6-9=7(VA04#(-?T
M'*6>:E2)`+J,I0'<0NG64B:M5ELENNITDE),-\X^9N8,9G0NE24O4[B7$8DF
M2DDI/!6D]\A4E"R8M$5'-3VFYO1NOLE(>H5,+KEI44!:4N,-,OA"BA0(Y4)`
M"@20##HR#V<O5=1;)UA2,B:*M"D^INN$STEVDTS*"8=JN;=$YE](LS0P[4>M
M*;UN6Y%@J$I2Q(G>23.0Z/M!YQY,YR59E_,3/:EA<@K`\Q4Y8ZTO"H%)PK2D
MR((,I$$1S<_SI^SQ@-4'.YM%+GE.W:*#/J9')NA4B<**E+2@@J`+A934*X58
MD1[,?_N><W/2YC'L:]@V<H:P>T$U.:\YFW$B98SYO^GY.AV<RA"$EL5(60D>
MJKQ)$R6^<?LQJP9916NM,E7?+I5$.T;IUWJ1QET\>,Q]I.:M!UCF1D.:YV`H
M**2ZRTFF0))!)4$U+CB!*PMXD\-*8YF9QF;A>J:O..6=6JU2W74O+<6==2E$
MG7,9_P"U'*D!7/'V49MF.59NVA(QU60IKZGU*L"4S)%*@8EJ,O)YBZJ0#8/L
MM_ON?>F?BAR3GW[0\XJLUK4,%VIRO*D)RK+G7DI*FWW*I2JBJ33J5\Z[3(2D
MA*L*<5@_^T7GM:*I"JJB;:K&V\'+4M<IKDW@TI2L#B4N%#C94M*76UI2M:)*
M+_L^]MOM$K&JJJ>PT;66T;;ZJ"E<`]7J\[>4%-LJ>,U^J,-EU#!:>4X$.30C
M_*YD50UF%;4N-KIJT@M,*H7&/6C6/)!<4TEAA+A>;27%%QI3;)=*FL:?8KEG
MM)S7_$SCYHF\R5E;/]!=K\7))81)WU@H6_\`-MO%[D%V%+Q2I"BG_+EF2$HS
MM6:,99B2"ILFH<;#-4F>`FG6PZBJ2I6`\@H*5@ME[5/\D'-M"%4/-+):)OFN
MVD)"A7<VDH;K&@H"1=>JEHI2;5\@V\3,$A"O9M45JZ!2Z"NJFG$!!F]3-8VF
MUE=B6UK("UVE*9D"'O8AS2]H[];[0$-/%IU%"/\`#U554[2W7Z.E?)]9?2T&
MG#ZX%(;=:27F67)%J/:32\YLSKJ?G`CF[G5'F]*FD0MBDRQ"VT/5%.]B)?J4
MJ21R!`22-(`)3S1_R]\^L^H<O_H==5.YFAHY9F`?92ZIVB2&7TE5*XVE@K65
M#$5K04'`%'VK<T::H8HW,TYD9M1I?JG.2IF%5):92]4.A*N38;*PMYS"K`VE
M2L)E*,P]G'L.Y_UN9\^,OIGGV4UF7II<IS=5,)NMT"\1?:!/>+><6ODYO)96
MTEQ:.?G/M7.#,:&FR;-<LI7\E;=<105CKSS2.6K&.4"%O4ZL):*FU*0I`M$A
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MS.G+P#].JDKZ!U#BFUTM<R>!CX(6VZW)#J#-*<`0XY[+/;LL?\SSNYK4J*U<
MC\]7Y:EI%2ZI7QED53;1MF$--S`)F?\`4/SDYDN+FK+ZYFL2#?@K6.2.'52E
M=$29=ZI<SWXGSBYX(7C;S',:Q]HSG\RM]98`-MB6<"1K`=-[3O\`[GG./TN7
M1GG^4WVFNX>;7M$;Y"G6JU-#GB0/4*IM)L#CKJ&6Q^74-4060VE<>QWV%YLD
M+Y'FED-/F1;)*!39=4YJO,"E8%@4S3NH:40`7%MB]0$9SSAYR<S,XS>HHWS0
ML5E+S@324SC&7DTS#M)3IHG`PRZ&^70E+A.)U2S)2B!S!_S><SF%M4?.BB5E
MM>A2PXIC,*!;@0A]U*4!Q]:!4LXPA`6W0I6$)"K?:+S/8^UYQS+SAFF&A;N*
MG`19,E1"RH2'>H5ID#S$_N;?HW(YSY_G:>7YO9IG6<Y;G=,H8VWLMJLP?0\I
M34E!Q5,<-0E&'$X&UL3"7EQS']GN3U3;N5)YQ9S44#X47$?T^O4NKI"I:<16
M6F'TH6L`\H6RM((4F>4^PGV'^Q[+>>KU11TBQG&=T%?FSF;/OIFX_3\C5TU)
M2,-*X#N%0::P+6LH;&-64J29@_X>],F.>_WJE_\`#J.,MR_.GTTJ\ZYITN74
MCY5AY*L?HDK9*%62<<Y%3+0Q)*W74(2<2DI5E_LO=YN5]-F%-F+*'J@TSXI6
M&FGT%RN]:P):-*A`Y9M]*Y.I*`T5..(2KVK_`.;FK2FKR#V99:VRVM*TI%9G
M'J",M2RTX4EM2E*:K*1M4UR<72NW+2!EGM.RCF7GE#F8JUEZN?YQ"J2A-;C8
MK'WV#0(]8')/NN*05I*E6A2524.<^0T",&6YCE&<9K0$=X:3,*8OX6I7ML/E
M^E09F88G,WQS(^]57_AU9'MQR#+T*>K:[FYSF;IV$`J=>6:U*`AM`F5K*G$)
M"1,DJ$A'JG.C+JK+77^;V<O-HJF':=;C196T'4)=0@K;+C3K>-(*<;;B)XD*
M`]JW,[)BWZ[F_,C-:&GY5:6FS45BFJ9A*W%<%"5.NH25&P3G%+SQY^Y)69%E
MG,UC-:C-*FO8<IF*="LLJZ4#EG4I;62:A+H+:EA5.A;R26ACCVTY_0`I8KN=
M65U#8(((;>K6W$`@DD$)4!(DG5)CFK1^S*E<S.LYCY[F/]8HZ5*G:E**QRKJ
M&:PTZ`7%H;:J66\:4KPH+JP0AE_D_;%[3_:90OY1EF?9(<ARYNK;73N5]?6H
MJ6$JIVG0E;B:53R5*<""DCEL"_F'\',*BYG9?4YJ]1\Z,P2^W1L.U+C1<.8E
MOE$,I6I(7RK022)%3C:9XEI!S>DJVU-.M>T4(6A:2E:%IR.D2I*DJ`*5)((4
MD@$$$$3CV-<^_9I0OYK0<W*.ORG,F:-I;ZZ*L"Z5!=>992I;8J32+6MQ3:0,
M5,5+7ZPT3E=9[0,HJ,H&<LKJ*1NJ3R3[C#:^3+JJ=1#[*5+\GRS;9<3\XV%-
ME*C[`^9]395TW-ZKKUI-BDM9G_3G&)IME8PX)SF2#-*92_TB1FV=.+`>$VT-
MD)DG0I1*56JO`$I"1)),AWS_`-(GZN.^?^D3]7'?/_2)^KCOG_I$_5P0%O@Z
MO*)LU_)PK+G58TD!;:[L2"2`2-!!!!&J)BPCW`YW/NN\GZ_S=S)NG$Y3KVD)
M>I+=!FEU(E;PYZ.GK*CFAF51EJ\PI7:&I53NJ:+]&^4%ZF=*2,;+I;05MF:5
M84S%D(J*=9;<;(4E224J2I)FE25"1!!`((,P;1`Y^U/.S-7,[32&A37*K7S5
M)HU*4LTR'ROE$,E:UK*$J`*UK5WRE$PGV<N9K4JR%%1ZVG+R\LTB:G"4\NED
MG`'<*E#&!.2CJF.;OM.7B-+0U."L2D3*Z&I2JGJP$_'6EAU;C23^^0V9@@$9
MQGOL,SI2J"DS!ZHRC,*/EJ=;;+I+K(;*T,NH73H<]74<"05-J*)H*2:C-\U>
M74556XX\\ZXHJ6ZZZHK<<6HVJ6M:BI2C:223&6\S^<V=UM?E63)PT-(_4NNT
M]*G"$!+#2U%#82A(0@)`P(&!,DV0GV=T//'-FLE2WR*:5-8\$H8EA#"%A7*H
M8"1@#"5AH(X`1A)$4W.;G!FE369A1H8;8J'G5K>:12@"F0A:B5)2P$@-@'@2
M$HJ>=/.^N>S+,JPI4_4U#BG7G5)0EM)6XHE2B$(2D$FQ*0-$(YR<[\TJ<RS!
MM#3::BH>6X\EM@290EQ1*@EH6(`/!T2@\TLPY\YP[0*;Y)2%5KN-;9!!0X^%
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M22A4P2`=$#F'SIYWYI790$I0JF>JW5(<0B6!#YGC?2F0(2\IP32DRFD$5O,:
M@S*H9R?,7&GJJC0ZI-/4.LD%IQUH'"M;9`*%$$I($H5GGLWSNLR6J<2$.+I'
MUM<J@&80ZE)P.H!M"'$K2#:!.&:KVF\X*[.S3`AE-4^M;3,P`HM,S#3:E@#&
MI"$J7(8B9"*K+/9ISEK\EIJU6-YJF?4AI;F$(Y7DS-"7<`2GE4!+F%*4XI)2
M`_S(?S6J<RBIK#F+U(IY:F':]2`VJL<;)(74*;2$%U4UE(D3#Z_9CSAKLE%5
M+ED4SZD-.E-B5.,F;2UI%B5J05I!(2H`F*"O]L'..I=%=4T[%7F=<Z_5+I:5
M3J4N.7/.<G3MJ4M#32"E(&%")6169SS,43S<RBGI\IR<26D?T^A04(6A#@2M
M"'GE//H2M"%I0ZE+B0L*'^D65`_[MG]F.\3N".\3N".\3N".\3N""4I`.(7`
M12^8_P"(O_5-E2LPJFF9--*DMQ""0F0,@I29R((U)B4?;V?IF/K8^WL_3,?6
MQ]O9^F8^MC[>S],Q];`HJ2M94XM20D<LR23.P`)<)).@`6Q3(!F4L"8U)N+E
M_JF;JZ.E<>9D4H4)$2"B2$S-@Q%1ND23IG'V!W<'=C[`[N#NQ]@=W!W8^P.[
M@[L-*;HEH4%I(4H#"DS$BJTV"\V&R'TY_,U15-9,N%9P2DBS!*6&4@!(`"4A
M_JERMHC@J;:!_2E/=G'>'PCW8[P^$>['>'PCW8[P^$>[!=920H$:2;]F*98%
MIIQ/:<<EOGW`*E&0$(J\]J`REPR0)*6I9O.%*`I1`LFJ6$3$R)B;69Y8Z'F'
MAB0M,Y$3(-A`((((((!2000""/\`4)E2E&0#;))-P%D>61X:>['ED>&GNQY9
M'AI[L>61X:>[!0TXE1F+`H$]@Q2^8_XB^OZMRDJF&\P2WB9;<<;QDE03B2TI
M0*RD$J`D02)$$6%W(,TJ0\TZI)4O"$N229X)HP@H)D2%))L`F!9"&G5J4EH$
M(!)(0"2HA()DD%1)($A,DWF*5%34.KRUK$%TZ9*&%>)1P(44I"L:L8.))G,$
MR)!.:9.5A"5E"DN)"5H4`#)0"E"T*!!2I0,Y3F"!_J"3E6:,J>;:L;4@@*2F
M_"09!0&@S!`LD='V5_\`]'\N/LK_`/Z/Y<?97_\`T?RX^RO_`/H_EP2W2/%6
M@$H`VR%*EN&%9G5@)F`E"!:$($Y)!-IM)).E1)D!8.OJW-Z5*TMN+``6052;
M2EN=E@!PS"9G"#*9Z-)D@7R?K+B4%0$RD'OE2)$Y`$RF(_I>4XBE2L:UK,UK
M60$DF0``DD`)2`!LDD_ZIZNKHZ!3-&L(6EQMM7)*);!<45":$JY3&%`8;`%%
M-N)4&DRBG74NA)44MI*E81($R&@$C=BBS;,'T4:<8<6V<7K#82N:0`!A"E``
MVK!1,3!((_U4OY76`EJH;6VN1D<*TE)D=!D;#H-L.N5B3F!<D$A]*2E"09\%
M(`!42!-1O'!``*@K!0L-L@`)DA"4#"D22."!8D6`:!=_]Y/_`/_:``@!`P(&
M/P#W`*64W&\Z=H=V)5)FDZ;!+<T0%),P?]+"V#PD@$C4!G+=D=SW=5ATD#8$
M_>-OH`&R<):%N$?Z65]+/@X4@;+4DD;JE'_9[NEI=Q_VP4`##^4;I=DP%.<,
MC<W-.W_I87:A80D3O(%VI.\PW6OD)#JU8B3(?.3%IU`2#/6@+000=(,Q_JF%
M32+"T*G(C6)!OD;QT"E)PDW&PRW;(/J^9&1^+AY+:Q-VG<W84\ZWRP%ZDK"C
MN$A78A+#*2I:R``+R3<(QMJ]6.KRDC_Z/$=Z`:S,"Z/R<"3^NJ:O==;3EZ39
ML&[_`$N?RHV-5,WVM0*_>H'C`"P)&OTDC"J8BRF4X=I,TI.ZI)]V4/Z#P3L&
M[_2Y.8TH^>HU<JG72._3L%-XTR`ANK9,T.)"AMB<CKBXZAZ2LS"4@ZAO#M@X
M^R@';]V2C5W]$`F\6'9'^ELC%1S?7<V>59UVEF<AQ%3!UR?=XHT.6C9T]--Q
M0'OU+X+23(Z)V3V/])V,^9$U4JI+`O4RO@K&O*<QJ6G1`<;,TJ`((N(-H/3*
M=78E().P!,PQ6K[Y:;>,"4GL@^X4VFR1JW#=,A$UE*=N9[`EV8M='@_#'E1X
M/PQY4>#\,>5'@_#'E1X/PQY4>#\,>5'@_#'E1X/PQY4>#\,>5'@_#'E1X/PQ
MY4>#\,>5'@_#'E1X/PQY4>#\,>5'@_#'E1X/PQY4>#\,*JD+"BUPI2E8+].@
M6[4(J&W1A6`1P=43U8\J/!^&/*CP?ACRH\'X8<K%.`X!.4I3-P%^DD05JO)G
M$Q"':M7)K(M24V@3LG:+2)67C3;'E1X/PQY4>#\,>5'@_#'E1X/PQY4>#\,>
M5'@_#'E1X/PQY4>#\,>5'@_#$T*2K=':[<36V9:HMWI_Z$X6DE1U`)[T6I"1
M^<>T)GL1PW$C8!/<CRH\'X8\J/!^&/*CP?ACRH\'X8\J/!^&/*CP?ACRH\'X
M8\J/!^&/*CP?ACRH\'X8\J/!^&/*CP?ACRH\'X8\J/!^&/*CP?AA3#K@*5@I
M(PW@B1%^I%5S?JG9/9>O`)BU3*N$TL6BPILD+@!.\1Y4>#\,>5'@_#'E1X/P
MQY4>#\,>5'@_#%34EV94`V!*4^4(2=/Y))VH>9Y3"6'92E/@K`(TCXP5'E1X
M/PQY4>#\,>5'@_#'E1X/PQY4>#\,>5'@_#'E1X/PQY4>#\,>5'@_#'E1X/PQ
MY4>#\,<!P'9!'=BQ(5L$=N1C"ZDI.N".L@X]\VG]8[6C;W(QD`2^,JT[4^T!
M&"D;4Z=82';/8$3"4-#7F3V)[PB:ZD#8;2=^+:D^`CN1]H5X"/DQ]H5X"/DQ
M]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X
M"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DP4*J"0;",
M"+C^C#V5<L4<@K@C"DS0JT&T$Z;=28C[0KP$?)C[0KP$?)C[0KP$?)AUCEBX
M2)A)2D34+0)@"5HU9:MD%IU)2I)D0;P=2`H(Y)'Y2YC<%YW):X@#UE1E^:CN
M1]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ]H5X"/DQ94'
MP$=R)IJMUM,<$MNC;![0[,8:UE3>N+1VNP3$QA7V%#>(WH*Z4XQ^2;]HW'L0
M4J$B-!_T$P,)GJG0-D^\QBJ#RAU+D]T[=FM')I(F/BH$]ZP;L?\`+4^$:JS+
ML6=B<<-Y".*F>^(X523L-H'=C[0KP$?)C[0KP$?)C[0KP$?)C[0KP$?)C[0K
MP$?)C[0KP$?)C[0KP$?)C[0KP$?)C[0KP$?)C[0KP$?)C[0KP$?)C[0KP$?)
MC[0KP$?)C[0KP$?)C[0KP$?)BDYT)>/)K(IJE6%(DVLS0LB6&2%WDB=J0(^T
M*\!'R8^T*\!'R8^T*\!'R8Y=]UY8U&J<NFS5P((3LJ($*:HVGUK%GSJ6FI'8
M"7#NR.Q`HJS"EE*PL!(D20"!-6D24;)`3D=`AU>6E,GL(6%"8.&>&6H1B.["
M49@TXDFR;7)KGL)4E&YB.S'*4SE0W9/YVF+8EK**,!V$J)C[0KP$?)C[0KP$
M?)C[0KP$?)C[0KP$?)C[0KP$?)C[0KP$?)C[0KP$?)C[0KP$?)C@U)&RV@]R
M)H?2OC(`WHG4,!8U4'M6GL".3<X).A8LW;1NQCI_FSK6I.UHVMR,+R;-!%H.
MP>T9'JP;;$U&X1RU1)2Q;,]ZG8GJ:IVI1ZOEJ<:ORI6#8[ILUC'+9@LN+U)F
M7=/8$8&P$@:`)#H71=UE3YH+$J^:<V%6I)V#:3K`=+ZWR2.5_+D,6I??=9/4
MLZK(VB.4ICR2Q=*[<T;6Y`:S%.))N6.[I[!V8Y5LC$;EC>.KL&T:T<D\)'0=
M!&J/?L_Z!!UW@M]E6QK:^YK!I($]"1?LGNFTZ\8WU<DT?BB\C8T[)LT@1\TG
MA?E&T[NC:E%O63^65(X#R"DZQ-RAKI5)0UP(]1KOM5"HT[PTDMV)5;:0M,CB
M^,0H])@K6&WDZBTI6-Q0,'-LJIDL.-N(QE!(!0J:989X1PRBT`'1IBJK<V9#
MR&BA*`2H#$<142`0#(8;#,6Q*@IFF>(A*3N@`G;ZI9'SZ`3JW'=%O:@KHE<H
MW^0;3N=M,CK067!)6E*M.QJ[X[,%^FM1I&E/='9&G5ZH&T"9-@$%UTC%+A*T
M`:@UNR3M""VS-#"3:=79U3J"X:8Y)D2&DZ3KD^_6Z&KUI,PMII04EQ)PD$$3
M%H,QJ$6PNH78XTA:5:N-((MUS8=N&$JM.!)MMO$^WUC;!;=`4DZ#'+T\ULF\
M:FSVE;1UYBT&XZ4GWWC3N&"RZ+1V1H(UC_H!RSWDP?".IL:IVAK"FIA-TV`#
MXNI9JZ@VS9?ZS6\-PVR-H!U]4]@:-6+>AJ=9):4H!2YX02)JE:9"\R%IE=#&
M:"RFS0"G=U$OH'S*SHFL?-C4&(F**F2HA+5(XX1.PXU*1:)R-H&B=@VNC644
MIE;2RD?G)&)'ZR1#;I$C4+<<.[R8W0@$;/5=7H61RS'`=%LQ9/9U]0[L>IUH
MPNBRWXVL=?L&/6:<<#XPU)Z1K;VQ=U+UQP6J[W6&KM[VS'J;!DTCOCH.OVDC
M2;;K@TT))3[]WI],:8TQIC3&F-,:8TQIC3&F-,:8TQIC3!J\G[TVK9/>JUT?
MDJ]]W!-2Q33`J@DX2)%#F(!8(UQ,SV!H(@($Y``;D:8TQIC3&F-,:8TQIC3&
MF-/3D*$P8Y5N987>-36V1H.D6:L!UFU0$TD:1J;>C7V_=\,INO)U!I/<UX#;
M0DJ4D#MG8[)CUNHM=7;;HGVSIW-7J&F-,:8TQIC3&F-,:8TQIC3&F-,(14E3
M;K)*FG4&2VE&5J3J&0F#?(7$`AWF]SO&)"Q_RU>@$(Y1-K7+`6MKF)%0O!-X
M"EP[F[@.-NB;97J8\8*B)62*DDC6,M$:8TQIC3#5!3`AMI(2G8`[=YC3&F-,
M:8TQIC3&F-,:>GY1NQU-QU=8]HZ#"J>H'SB;%`Z1=,CL'7V8PCO%6I.MJ;([
MAZBEDW7G8%^[=MP*9COW."`-`NLWA\$!L]\;5'7U-@7=G3TMO6J*I0PN(4DS
M'Q@"#)6KJ3O&Q9U:SIU,N6A0_P!AV1"\L?O3,IV+S+9'"&W'*)'!<MV]/=V_
M=[EG+"OA$ZB='8MVX57.CYM!DD'L;EYUSUPJGJ4!QM8DI*@"DC4(-ABJJ,N)
M"*G!P#;R>#',)5>4G$+#,B5YG9UA;&KTJ<SI]62AH.SLW'7D;XQMVF04G<G+
M;%FSL=154D6J,AL#NG>ARK5:AK@IV;NZ=L=2OB^+XOB^+XOB^+XOB^+XOB^+
MXOB^+XOB^+XOB^+XOB^+XOB^+^I-Y@UWS9`.QH[8VX+B+9`+&Q*WL$^[J&="
MC;L7GL3@4[7?.G"`-33VAMPA@:!;KG2=WJ-\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%
M\7Q?%\7Q?%\7PG,&K$J6XD2U$.*0-LI`.W%\7Q?%\7Q?%_0NBSIE,KN4)>_8
MARA=[YI5FP=36G;MPM`N)F-@V]@V;74`;BE$_P!(B>^80-*N$=N[L2Z:WW$L
MC4Z93*KE"7<.T;8#:_BDI/OV#"FS\4D;AE[N*=/Q4]DGN`P$GO6$SVS=O@[7
M3V=<U=<#(MM+(XV$A.ZH@14T!,RRZ%#62XFP>$A1V^I6].V\+G@4G9%W[,-O
M#3-)VK1OGIPG5,%M/QU)3V1W("1<+.H6]"Z+HNBZ+HNBZ+HNBZ+HNBZ+HNBZ
M+HNBZ+HNBZ+HNBZ+HNBZ+H*E2`%YU(*Z986`9'"9R.O[[>A;U"J:%P4E7A`F
M'0/RI[MO;]W'%ZJI;@^&*FH.E93X/^T=/;T9RBZ+HNBZ+HNBZ+HNBZ+HNBZ+
MHNBZ+HNBZ.6K74,H_*6I*1/4FHBW6@I#Y>4-#:%*_6("/UH<RF@IUMI=*9K6
MI(,DJ"I84XKR!/AW:LX=?<:+S;R0E20K"009A0F"#(3$K+YSLD0'RY3D_EHF
M-ULKW2!&'+JEIY5^%*TXI:I3WP&R(NBZ+HNB[HV=.V^+VW$G:GW91/\`)4#O
MCM].V#I4G?$,)U7D=L]KJ%O7ZJE8F;@-51NVM)@&J<4N4Y3-@G?(7#:CEV#9
M\9)N4-?8T'1NPA^4L:0J1T3$Y;7471^4A!W"1"]?#XH]W%<<^*F'#JN+WY=J
M)=-9UN4+`(-X-H.U!-11-S.E`Y,[K923MP[F^5J<2IK"2A2@I.$J"3+@XIB<
M[5&P0\BM4M+3*03@(!*E&21,A0E(*G9.ZT0"FE#JAI<4I<_T2<'ZL<G2-(:3
MJ(2$C<2`.KN2T2/ZPA>RG?'3M\9.^(I_/)WE>XZ7$DR0L3&BT$3.QV^@TIIO
M&E*TE1(X(`,S,W77#3J'H6]07YM/C&%["=X>[BN.?%3"N.YXYB?36]&_K:IH
M;RZTM(V2DX3M&1A^M587W9?HMI`'ZREC:Z>_HV=.[L0O93OCIV^,G?$4_GD[
MRNJ7]=E*I$'08+I25SN2HS2-@`"?Z1,!#8"4BX`2`W.I+\VGQC"]A.\/=Q7'
M/BIA7'<\<]3OZV%%3]X%.*'Z:U+EM8I;737]&WJ#NQ"]E.^.G;XR=\13^>3O
M*ZE;T;XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOZ%T6=27YM/C&
M%["=X>[BN.?%3"N.YXYZEJ]&^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^
M+XOB_HZG4G=B%[*=\=.WQD[XBG\\G>5[IK\VGQC"]A.\/=Q7'/BIA7'<\<]>
MUTS/DJEQ*?-F6`[=NMUJ[L0O93OCIV^,G?$4_GD[RNIZG6:JA\R2F\]CLF"B
MB;F="E7>"+>R(P+`2ZF\:"-43.Z-'6:_-I\8PO83O#W<5QSXJ85QW/'/4K.A
M=UA45W^Z;6H;(22!MF0BJH5'RK87;JH5+>6=F6MU&[H6]2=V(7LIWQT[?&3O
MB*?SR=Y77R*5)(2$XB-!)-FS*7OMZ","L/)D+.J0DBP:YW)3V.GLZHOS:?&,
M+V$[P]W%<<^*F%<=SQSU&76)6PT75:$@I3/;40!!#.4EL#XRL3PV9M84C=(V
M8725KTFU6*0E*4B^<C(8CL$P*R@<+;B9R4)7&\2(((.H1`0W3BMU9-*Q;K<D
MC7FF4#^H9<JE!^,7$*_5L6-L=1LZ:SI'=B%[*=\=.WQD[XBG\\G>5U6^+^L$
MU+%JFP9IE,D$B[7%MFG?F$8$SE-5G8O.T):\<L5%;DI3N`G?(7[9/37]"R+(
MGU%?FT^,87L)WAUURBA/0!$F^`-T[OP1R;EBQ^ML:^J/>.OU<<^*F%<=SQSU
M/5ZQJD*;2IP-**"4@J"DC$F1O$R)6:##CU0@+0RV3)0!&-2@$V&R[$0=!$84
MV`=(GE%2Q$)&N3<.QT;^AJ1;U)W8A>RG?'3M\9.^(I_/)WE=7OB^+XOB^+XO
MB^+XOB^+XOB^+XOB^+XOB^+XOZNOS:?&,+V$[PZZPFX`2WY]K:Z&)1D46@:O
MN`KCGQ4PKCN>.>K7Q?%\7Q?%\7Q?%\7Q?%\7Q?$C*,PQ6?\`,*:&NEJ<CL'&
M=R+XOB^+XRX)-U0'3+\EJ4QL''V(F#%_26=2=V(7LIWQT[?&3OB*?SR=Y75[
MXOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+^CJQ9TW^'\H<+.%(+KB;%S6)A
M"57I`20HJ3PB2`"`#B(56N3T_..'LSC[:YX;G=C[:[X;G=C[:[X;G=C%ZXY/
MCN=V)E\G;5'ESNJCRYW50'Z-XN-SX2%$E!U1(]Z=<2-UXL+58UWKJ4K&PH`R
M.N)R.OUMRC??@2EJB)O'#K"T]S?B30M-YTGWZWN`KCGQ4PKCN>.>J6]&^+XO
MB^+XOB^+XOB^+XOB^+X/)@#$2HZY-YVXOB^+X*W%!(%Y)D!MF$(I7$N-LMA,
MTD*&(DJ5(B8N*0=0B44Q2\A3H;0%I"@5!0`!FF\3(F)BX]3:R_*B$5%0%**Y
M`E"`9<$&S$HS`)GA"3(3(*5&HK72LF9)<<)F=4S-L?;7?#<[L?;7?#<[L2-8
MX1QW.[$E5CA''<B9?))UU1Y<[JH\N=U4<OEU2J:;TS)2=92380=C8,X_Q#A&
M.4L$_P![BP2OGAGPM7!;?T&^,G?$4_GD[RO<ZNV&OY=KJ+@UQVXHY_[L;Y]V
M%<<^*F%<=SQS[@'U/,7*8'0$-D#8("%[JS!<]835\9Q6/]>8_7A5'7H+;B93
M!(-AN,TD@@ZQA%53-!+2[4K6H)!MO`!*MO#L0.4S5;8'Q$8G$[7*$)'@&`V\
MZIY0O4H(!.TA*4]CJ-+YC_B+AWCJWSU!0_-.^F)3_P#I?[$]^WH-\9.^(I_/
M)WE>XUG4*[8:_EVNHN;([<4?FQOGK.30*CN".3?D";B+M@V[GN(KCGQ4PKCN
M>.?<*FK4#RK919JH5/=(6!M0Q1`>2;0C;2D`[IMZG2^8_P"(N'>.K?/4%<0[
MZ8_ZO]CH-\9.^(I_/)WE>YU=L-?R[747-D=N$9?[,<I7F)HV4*?<+C+#+(65
M!`6]4.--XUR5@;"BXH)4H(*4J(<YK<_\L?RJN;M+;R9!2;@MIQ)4T\V38'65
MK;409*,CUC))(*C*S=Z`;%A496Z\);)GA`$]CW#5QSXJ85QW/'/N%12$^1J6
MUJ\W;C&W)/2MT:CPW4K4G7",&+QP>DI<CR5A=565KK;###22MUYYY:6VFFT)
MFI:W%J2A"0"5*(`M,,YO[5.:M7EE$]*52E3%72I*C)*':FA>J6&'%'O6GG&W
M%:$F70I?,?\`$7#O'5OGJ"N(=],?]7^QT&^,G?$4_GD[RNIS]P)U#@3K3M,M
M07PKU<F:;P1([.N/>>@K,*$)+=0A)*E*D$J0E+921:;0$D$"5X-TR2EQL#4Q
MGY$>5;\(_(CRK?A'Y$>5;\(_(CRK?A'Y$>5;\(_(CRK?A'Y$>5;\(_(A"$MA
M[E5A,T'$<1NG8))L-MPTD16>RWVD+50LYA4-/LYC@*V$.AA#"VJG#-QI!*$J
M;="%H25N<L6TC'",MYUT=)GV4U2.48=2I+@`6G@OT=4RK$VHI[UZG<22FS$4
MD@O\YO8LXYSARM)4I5"H#^IL)ODV$A**Y(%GS26Z@DI2FG=X2PY1UK:F7FE%
M"T+24+0I)DI*DJ`4E0-A!`(-AZD.65*=UYWH')HF-,[#M2G`<;,P>B6@9&\0
M4!!F+YV#=/:@./*F09R%VWJ]CW$5QSXJ85QW/'/N/E[`/!;`0KC/S3O%!_V=
M)[.TN)"@,_RPR(!$TU3:DFW2E0!!O!`(M$.4->TA]AY*D.-N)2M"T*$E(6A0
M*5)4"0I*@009$2A_G![+%?X+SE<U8*=OE,J>6;9+H<2?5IV)"J-;338FHTSJ
MK#3YCSRR53F6))8&:4BC49:H%1+:C4)2%,%9*DAJJ;8?)`PMJ29P70MM.(S(
MQF\W_$CRK?A'Y$4^2Y*CUNLJW$,L,,A;CKSKB@AMIIM#96MQ:R$H0D%2E$``
MDP?:GZ^FHY\MJ%4[S:90%X,NP$K:14@GELU;,G%4K:"TM(4PRX[4!`<S;GYS
MIS7_``MD:&'VLIJ5,E]689FVO!+D5<FH9>PI+C=54)5CY<!EA+BVZCD:OV<>
MT^D309C2\)/#*F:EE14&ZJE>"`E^G=PG`XF1!"FW$MO-N-H\JWX1^1'E6_"/
MR(75!*7K@0A14J4]"<()MOE,ZT@8_I4AZSY67Y^*>&Z_!P-3%IET&^,G?$4_
MGD[RO<:SI"X@34HX1MSMVHF82[2DA8-DA.^R4M,[I1S?YA<[.511YFXXA_D%
MA#HP4KSTD+4E8'#;`,TJLF->`7'\XLU*UC3_`-''E\Y_C6/^YQY?.?XUC_N<
M>7SG^-8_[G'E\Y_C6/\`N<>7SG^-8_[G'E\Y_C6/^YQY?.?XUC_N<>7SG^-8
M_P"YQY?.?XUC_N<>7SG^-8_[G"T\P<ZSD43I)<H:FK8J*):C\<,JI`6G)@$N
M,+:<5()6I2)I,+K.<-'_`$_.L,F\TI`ENI!`DD5"9<G5MB21A?!<2@%++K.(
MJAK(.<M925S%6E3E*_3O(Y1QM)EB=I%*]9IU7`E2%,*5-+3[I2J70DT"KL#M
M]J.3J`!.XB[8-O9Z52B9@$@;'04[/@FR6O9;M=OW)5QSXJ85QW/'/N*5*,@-
M,$5-8V"+PE6,^"C$>Q#^:TQ,BX"@FRQ$@@RO%B097ZML#!5(0H@32N;<CJ36
M$@[1,!QE06DZ001NCH>SO^_9;_,M]%V@S!I#[#R5(<;<2E;;B%"2D+0H%*DJ
M!(4E0((,B)14<X?90K_!&=N8E8*=OE,I>6;9.4.))I<1DD*HEM--B:C2NJL.
M;>R7G\AI.:90XA#BF%\HPZAUINH8?964I4IIYAUMU`6A#B0K`ZVVZE:$Y1[7
M.:K#-54Y6XK$Q4)"FWV'4*:J&<4E*:4XTM24/M\-I>%8"@"A5![4O9V^7:*L
M!0XTX,+])4MA/+TE0BT)>9*@#(E#B%(=:4MIQ"U/5]6MJBH:-MQYU:L+3++3
M:5..N+-B4(0D*6M1D``5'3%/E7-!A#7-3FXMYO+GEM8:JM6[@2_6.J6.4:9<
MY-(IJ;@E+8#CZ>666V>E;XR=\13^>3O*]QY]$*:25*0J<A;81(V:='0:JL)0
MA"@9JLF!;8#:9BR<I6WQ0\^^:JD(S#+E*6R7$!Q`4MI;2L2"0%#`XK3?(Z(0
M6ZK+P%3%M`W??+O]29VCJ1]JR[^`;^7'VK+OX!OY<?:LN_@&_EQ]JR[^`;^7
M'VK+OX!OY<?:LN_@&_EQ]JR[^`;^7'VK+OX!OY<):76Y:%+GA!H6P3*TR&.9
MD+Y70QS>YKHI<PKJE6%JGI\K#KKBKY)0@E1D)DF4D@$D@`F&^<7^8#-:&E"T
MS1E5%2,\JF:;/6ZL*6A*DDSY&FY06`FH'";A[G3SXS%C*\OIQ-;SZPA,]"$#
MOG'%7(:;2MQQ4DH0I1`A_FQ[`&%4%--2%9M5(2:EQ,I8J2F4%(ITFTI=?Y1X
MI(/(T[@A_/.<%4[75M2HK>??<6Z\ZLV8EN+*E*,@!,DV`"X=#@D@J(%F[VN@
M$"R9`MUX2V3/"`)['2%T6I62=@ZA[6K`)&$:I[E\<FDSF9S]^Q[DJXY\5,*X
M[GCGKVLFJ?(U+B$\02P'8-LMCJ!74+>"CI#RU=APK`V``(*LOJP=1+B)?K))
M\2':"HEC944F5Q(TB8!D;Q,`RT"`NOJD-SMPH25G8)44`'5L-NK`=#CRUZO*
M%O<Y+`K]8P$)G(`"TDG;))).N22=,>SO^_9;_,M]%_G;S]S2ER?+*83<J:Q]
MMAE)/>IQN*2"M9$D-IFMQ4DH2I1`BHYM?Y:,K_K%2,2/ZOF+;C-$DW8Z6AFW
M55-AFE=2JD2E8M8?0;<Q]HWM"KE9CG.:N!VIJ%I0@K4E"6T!*&TH;;;;:0AI
MIMM"4-MH0A"0E($9![*\]SEC(:3-:@(=JGUI0<"05J8IL8*%5E0$\C2(<DA3
MZT`XK$*R[V><P:)O+\IRID-,M(`%@M6ZZJ0+CSJRIU]Y<UNNJ6XLE2B8;SWF
MO74V;9;5!:4/TSK533NA"U-.)2XVI;:PE:5MK`)DI*DJM!$4?.#V;5U-3TG.
M@/5*LC0H!_+G$J`6ZRTD2;RVH65"G2HIY-U#S+(4RV$M=`%U02"0!,@3)N`G
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MU196=A/!7V&R3LST])[/'ZI:6T#/\L&)1`$U5324B9LM40!KD0]SJY]9G391
MEM./G*FK>;8:23.2<;BD@K5*2&TS6M7!0E2B!#_-S_+AEG]7J1-/]6S%#C-$
MDW8Z:BFW55%AFE=2JD2E0M8>0;:6M]J6?56;N85NI0ZO#3M8EE(13TK813T[
M8PDX&&FTE1Q*!5;"FD(GA)$R=2R.\&Z8"DH`(M!!,P85_EFSBH2X^Z!2/<X`
MZX,UJ,GY/`K+GU2(6ZY8V]F&,/OTLV'DK<<=J',_YK\S*6GSG*<X:<<8H:YQ
MSU:AS4I0AO,FDM@+5\V@-U5*EQE-4E+)4ZVIE*HS+VC>T:M=S;.LV>4_553Z
MYK<69```)"&VVT!+;++:4-,M(0TTA#:$I'DQN_!'DQN_!!04X5`3OG9V(];Q
MGUC%R&/3??=?R=D[Y\*<^@WQD[XBG\\G>5[G5VPU_+M=1<V1VXH_-C?/NPKC
MGQ4PKCN>.>JS/52ZVTMXCXJ,.([&-2!V9P0C*G6P/CO8@G<2D@[3D+HWE(;:
M<$E)0B4Q?*:BI0VB-R!79>O`X`1.0((-X(4"+=W4@,O4B*DZC86E9W,8W$[4
M`/Y?44T[RX$!(\)25G:;Z:?0I,VE]G0\"==82$C<+G2)=:44J20002"")$$$
M6@@V@BT&*>H]HW.#,<^72(#;)S"MJ*LLH``PM\NXY@Q805E,BM4UK*E$DQ2^
M8_XBX=XZM\]05Q#OIC_J_P!CH-\9.^(I_/)WE=5G[@UVPU_+M=1<V1VXH_-C
M?/NPKCGQ4PKCN>.>O*IQ-.WRZ6U*2L(2%XDC$`%`3ME*_3"S6MI=:9;*L*@%
M)*B4I3,&PV%1MU(Y.G0EM.HE(2-P2'6%+YC_`(BX=XZM\]05Q#OIC_J_V.@W
MQD[XBG\\G>5U>WK^NUPUZ!J)'J#BM!([$^[%&#_NQV9D>["N.?%3"N.YXYZ\
M*56@QF)6)$5!9&PS.T:QQWZ9=8TOF/\`B+AR?Y2M\]04K0$[Y'<,8I6>M3VL
M,M^SH-\9.^(I_/)WE>XL^HC.LFDJH"0E;9(3C">]4E1D`H"PA1`(`D01)1QY
M6Z3I/)3[(!!W8_"G?H3W(_"7?H#\F/PEWZ`_)@MC*G<0$Y<B9RU;HP.Y:XDC
M06?@C\.7]%\$?AR_HO@A**AHTK([Y2@`9:B47DG1,`:9Z"BF9$D-I"4C4"1(
M=@>["N.?%3"N.YXYZ]5R2<.-14==1O.WUBV]1*":JGQ8<5B5I-Z"=!F`4JN!
MF#8J:2A_+'%J%DPV%C:4G$#M&/PEWZ`_)C\)=^@/R8*UY4Z`+R63W(QNY4ZD
M#263W(_#E_1?!'X<OZ+X(_#E_1?!`913&G03:I8"`->5A5M`[YC_``],\GAE
MBTXYX\?AVRU.#=T&^,G?$4_GD[RNM\;AD(PTZ,6SW!$PU^JKNQ\ZUV%#?G'#
M01L2/<B39MU#8??L=;K\VGQC"]A.\/=Q7'/BIA7'<\<]86].4CA*U!VS_MB;
M35FP3V;HX37ZJN[$G6Y;?:([<25-.R+.P>U`4DS!Z:SK!W8A>RG?'3M\9.^(
MI_/)WE=:EU=P@BE1(:M_9-D!56NP:)S/<$86D@>_2=/1X:0=D`P7J;@J%LAV
MM0QA7WR;]<:O=ZV7YM/C&%["=X>[BN.?%3"N.YXYZO/IN193B5V)ZEEICA'"
M#KRWK=V,3@"U:]PV!V^C(VQ(I`.J!(^_9@-K,VU;FSK$:?\`9TS/+?OW4M)X
MRYRWHGU=W8A>RG?'3M\9.^(I_/)WE=:I2-*MX&$)_-&];TZP2`DSGJ"8GV#9
M&)-H/6J_-I\8PO83O#W<5QSXJ85QW/'/6KKIMO[)Z<+TI._?VH0,0*@+1.VS
M6Z7+FFCPFW"_MME(1V2J$NMF:5`$'5!$QV.KN[$+V4[XZ=OC)WQ%/YY.\KK&
M?1*E&0&DPE+1F$SGMR[D`4[5FP3O2$6(EM#MF+3+P.U&)5H'%.];$R)*%X[>
MP>@*2F[XWROMT:VJ3\,-LN&>.4R-$S*S8C%2N;X[H,?_`+$>JU0DK1HUY'1=
M<1UFOS:?&,+V$[P]W%<<^*F%<=SQSUH4J5PI7"T_!MPI+2,2E2[&L(X+<OT2
M-\Q,"7@=N)@S\#MP&:T2GINEKV6$=`NJT=DZ!"ZQY5B09;6@#0![]6.50K"H
M$C6[HC"VK$-D'QK8"WQ-.PF6ZFZ!4O+2V@Z5*"1KB9(%D$+JTN$:&P7)[!2"
MG=4!'KE(%!I"$H3B`!L*E$R!-Y496SE*<KHIZ#,EK:=90E!44%23A&$$%!4J
MX"9*1;/9@>IU;2R=`6`KP20KL=6=V(7LIWQT[?&3OB*?SR=Y76B:2G,TSOT3
MTG8`[<)8;%B97ZPG,]*M@7*G9M8AN""HW"V'*I0M[OP60TX;/@(/;Z+>B[M]
M9K\VGQC"]A.\/=Q7'/BIA7'<\<]9E4^$>]&OJ[`^"%5CTRI1X.V;2=6=N_"#
M+OK=T]SI$NRM2>P?AE"'-4#=N,-TJ;U6[9,AVX4TD6!)'8A2=16^!W.@Y/4&
M^(#N8TJ'%F?"$TJ-NE2"DG;,%5&ZZP=286D;1`5^O!RUQSE1A2M*\.&85,=[
M-4I$$7FZ&<RKJE2`\D+"$($P#:.$HD6B1[W3I@%;*GR-+BR>PG`D[:90*>D;
M2VVFY*0`!M#JKNQ"]E.^.G;XR=\13^>3O*ZRLA%&RJ^^1TDZ=@6[<<&U1O/<
MU![S":P6I5?N2(W+1\$!:#,&T'HR6XF>S/>C&@S3JC61+?B1AVE.U^B>V#.$
M+U%2W1\$(6=(!W1$S='*)M0C3K"[=/8ZS7YM/C&%["=X>[BN.?%3"N.YXYZR
M4ZJ\`RUSHCUJI)4)V#5EJG4G.R"TW>)$#8T;D>KJL4CLCX+MSHS=4$[)`A2&
ME@F8L[,-C6WS.&ZA-Z3+MC>,)<%R@#NB'6IW2[!(Z'(@\)>\+SVMV$)-\IG;
MMET*"K9$U.8F=O$"@;94N&Z5OO6TI0-A(`'8'5W=B%[*=\=.WQD[XBG\\G>5
MUEZG17FPD;P.B6DP'7#B7V!L:NSV.@6EZ=.H=!CYMWL$;Q,%TO<$?G*WB(L)
M4D:ID)]OM1WHW1`>94,8T`R[)L.N-^.3K&[=6X[EQVI0,SI!,"6(&\&ZT#01
MI$%#-C@MPF^8U-6PGMR@4]2D@ILGO3!E='(TXPMZ?^T>T.S&!%YO.J??<(EU
MDOS:?&,+V$[P]W%<<^*F%<=SQSUCRBK3H&J>YJQZQ5*DC0.X-`U]^^`VV)`7
M=`O-*P$WB6G2;Q?'S3TMM0WIQZL'"I6L9VG1;[Q$U"9U<0[L?.$(&[O=V,*A
MC;&V-V\;=FM!IE`H4KO2;1/1;HG==ICU.K&'#8#J;.MJ$?#"JE(Q-N3,Q=(F
M=]TP??;`33))6=71N7ZWO$>M5UJKP#OGN;NIT)Q2E?\`]&?;>'Z$[-N?6#NQ
M"]E.^.G;XR=\13^>3O*ZPQ+,@-)@MTUGYW<[L!U:\)5<)3LT:1??L1RM.Y,)
MM(M'8F08QJL4#(]W;Z+=$WID3LDR&Y?MP&D"Q(]^[T<*A,:\.TJKE3`&K*T?
MJSCE:0\FK4T3UI6CL[4<G5,AT:I3B_63V[8#?(80-`,NQ*.$@C8(/<@).),]
M)`EV"=Z,23,'K%?FT^,87L)WA[N*XY\5,*X[GCGK"1X2M0=O4W]:,*S("W6`
MUHFV[([$NR#VH%'6&85*1OOL!!U)V6W=%;WY(LV='9A56Y:I1(';.V=[I$U"
M!(@R)&O=V1V80XX+2!:+P=/9T0?5CRB-3NI/:CE%TP2K5"2G?G\,<)O<5\`B
MU*NQW8FT;=(-XVO>.L7=B%[*=\=.WQD[XBG\\G>5U?U:EM4;"=?4';.B`:ES
MLDGLV;\-L,B4YS.DW`>^Z`E-PL@DW0[J<'MQC>4$CWW:3$@%'8`[9$*K'`2+
M9#L">P.S$BK`?SK.S=V8FDS!Z+=6+C(G]&P]B723*0=H1A*`DZH`!^';A=$L
MS`G+9&ILBWK%?FT^,87L)WA[N*XY\5,*X[GCGJV->T-4P7,6!.R0-H"_9.[!
M>=X92";;K-;NPXZ=)`W+>WT&`+_^T)=OH82K$1^2)]F[LP&F0H6S,Y:+KB82
MP4J`2`)V7Z=.K$V5A6_N7]%QO3*8V1:-Z"T;T'L&W?GT>$`8DI"3M#N0FJIB
M4VW:AT2UKYB$NCXPGU@[L0O93OCIV^,G?$4_GD[RNK%8ON&R??./6%]\J[8^
M'H-U*1,)OVC.W9CA!0.P#V^U"TMDXB"!9I-D%9^,H[@D-\&&J5!G*PZQ41VH
M<4TVD$)-LID;9MG+3!64@DJ,Y@:UD3"<!U4V=B[L0GA8FE'_`&V:#KB_L1,6
M@]`+(M"AV0?@AM1MFD;W2JE[^".L5^;3XQA>PG>'7J^>GLLYJ56;Y6AY;'K"
M'*9I!=;"5.(1ZP^RIS`%I"BA*DA1PSQ`@5?-GG-2.T&84#JV*FF?0IMYEYM1
M2XVXVH!25I4"""(H/9M[-J`YGG>9EU--3)=99+A99<J'?G:AQEA`0PRXXI3C
MB$A*#;.0-5[.?:?EQRO.:(-*>IRZP_A2\TAYI0=I77F%A;:TJ!;=4!.1DH$"
MEY_>SSF=59CD]=RGJ]2':-E#H:<4TM2$U%2TXI*7$+1CP824G"3*/_<&K_B\
ML_[[#?,WVM9.[DN9/4Z*I##RFEE=.XMUM#R5LN.MJ0IQEU$PLD*;4D@$&*7G
M][/.9U5F.3UW*>KU(=HV4.AIQ32U(345+3BDI<0M&/!A)2<),H7F5=[/LR6V
MB\4YIJQTR!/!8I*A]]=@/>MF9DD6D`O97FK#E-4TZU-NLNH4VZVM)DI#C:P%
MH6D@A25`$&PCK97'/BIA7'<\<]6Y'XJ.U?NFR`E-@$*;%Z@1NB%,/H-\[+]L
M&43.+<AM35J4RW$\(]FR%N$RL(&R19V8+SR`HDR$]0:UU\X2R4A*+)```=[.
MZZTQA6V#M2[(M@O4:B"FT#N$6SU-^"ERU2+SJ@W'?'1>83<,784`.P>E.R(1
ML=8.[$+V4[XZ=OC)WQ%/YY.\KJR$:I)W/]L!&H`(##`FL[<IW6:L3)EK<$>_
M;CYQI*OT4?LR,?.4@(U<*QV086XTG`6Q+#J$W'8)[<&N=M4HD#MG9)F-W5A3
M:KE`@[=D*9>1B03?VP;KM&]`=:,P??(Z\(1\8JGM`&>^(0E5X2!V.@ME-YM&
MR+>S=!I%V*1=L3[1[72N*&C%VAUBOS:?&,+V$[PZ]S'VGU+!JFLAJ<ZKG&4F
M2G&J=:''$(-P6I`4$$V!4B01,1D'^<;V:E-5E'.9BE8S!UD3;6M=.',KS"8$
M\-52)%,XI6%*54]*/*/F.8W_`-FO_E[-HYQ_=,H_\,IHR[VA^SFO7E><Y?24
MWJ]4A#2U-<OSL;IG9)>0XV<;#SK9Q(,@LD24`1_[_5?\)EG_`'*&^>7M:SAW
M.LR9IT4J'WDM(**=M;KB&4H9;:;2A+CSJY!`)4XI1)),9=[0_9S7KRO.<OI*
M;U>J0AI:FN7YV-TSLDO(<;.-AYULXD&062)*`(I,YYR\X_\`$66H<0:F@K*2
MA2BH9!X:$/,4S-0PX4E7)N-N`!>$N(=0DMGF5[<<AIFZ;,<[]8I*U:4A#E6V
MABG?HG'@FQ3M.@NLEQ1*RVIIHJ*&FPGK57'/BIA7'<\<]5).B''3>>W,GM07
M57",3`DG8&^J_:CA`+&O@._VHFJF2K]$_LF`EU@-*59.T2GK'1":))X*;Y:L
MID[(%FS`;;$@D2$(KJ834B4P-8S!EIU#').#`YJ:#L:^MV3!4JP"'G$][W22
M.B*J7`7?O*&R+]R`I)F#:.@BIIU!2'`%)(T@B8Z"4ZJAO&$)_-&]TBJ<'AH2
ME1&HE94$G;*%;AZH[L0O93OCIV^,G?$4_GD[RNK-(]]IZ!GH^3TCK"+$XKM8
M&8W(;;3<$CNGL]`MN"8,+9I4DI)L,@1K&VP&5_P0*G,#,C1.9LNG*P#6'2(K
MFA8HV[.D;8[,X#C9F#=T9+5,Z@M/P;<H<J%:;-TS/:ZQ7YM/C&%["=X=>\^O
MNG.;T<<Z/\D'M66'545&ZJ@6N2W?Z=4.S2XT%7O9-F*V7V%*,DI>I4)&!DQS
M=]F?/-GD,SR6ISZF?2+4J*.;^;8'6S\9IYLH>97<MI:%"PQSC^Z91_X931D/
M,'VH<X6N:N15](WZSFC[U,PU2\ASE-2SB=JUMTZ>7J&6J=/*+&)3P2B:RD'_
M`/V#RK_\K<W?^^QGW-'F;FJ,\RG+:^IIJ3,&RV6ZRG:=4AJH0II:VEI<0`H+
M;6IM8.)!PD1D?LSYT<XJ?FG0YG2-\KFM4AMQBE]7YS>MHY1#U51-GEW&$4R<
M52W);R2,:@&UY>_S@]KV6\]6674._P!(H4T%,NK+:@KDG5-YOF+JV%G"EU#3
M3:U()2EU!4%#)AS\R$Y5S/R]-2SDM0T^FJ9K'G5)54U#[J$(]7JW6V6`FB=3
MB:::4II;H4ZYULKCGQ4PKCN>.>JK.HD[T*/YW:$$:I'=[4-C6W[8/00\+TF6
MT1\$.U"[52\8DD]CL]%-92#A@B<K]97=VHY-W@(-\Y`=CA&`TBTWDZI]]W14
MW\86IV1W;MN#2.&2D73OEI&T>QL15UX,BTTLIXV$A.ZJ4,))FIA2VSM*Q)&T
MA28Q.*"1KF4-L4\R`;]4GN#3$AHZ2MHY\`M);3QFL)(VBIWJCNQ"]E.^.G;X
MR=\13^>3O*ZLT#^;XQZ"SJ8NT.D4?R@#V)=J&E?F@;@D=Z+>G++HF#V-<:\'
MU->).I,#="K.S$S_`,./GU8$[('83?MQ-TE9W!N?#&%(D!H'6*_-I\8PO83O
M#KWGU]TYS>CC(?:US<*E.Y34I6ZT%814TBYMU=*HW8:BG4XW,SP*4EP<)"2/
M8Y_G9]EDJK+,XI:^FS!UM,L3+_-O-7,KK'4BU"P%*H*C'PFUBC8("DD1SC^Z
M91_X930W]TH/_G.GZ+?W2@_^<Z>$NM**5I(*5`D$$&8((M!!M!%H,(YU>V92
MGLT9RMM]JHJ;7U.T6<FERNI+BYK4]64B*=*GB2NH15+*E*+RB>M5<<^*F%<=
MSQSU5SBG>@\8[P@:ZAO&&Q^:-Z#T%'\D@]F7;A;>JF>X1W3U$U=*K`N\S,AL
M@BXZNC8A65^LMN*=4E*DH6VI02DXYG"2H":0+93G**C+%/H9"U)6G&M")D@I
M5(K(MD$V`SW(#S[V,&V:3BG^D;.P8^:3(ZMYW>DQ5S[;4A/AK2D[0)F=J^&\
MX?5A2X\I2R;))=*@HG6`42=B"JC>0Z/S%I5XI/4W=B%[*=\=.WQD[XBG\\G>
M5U;E4=\GLCX+XX7?)L/:.W#IXWC#I$+U4RW#\,)&H5#LS[?2E:S("\F/5\M2
M23\:5IV`;AKGL1\ZWC_1GV4&48:E!1KBT;8L._`+*PK6G;N7]CK5?FT^,87L
M)WAU[SM]@?.3.5T_.S,6<Z:I:$45<YRQKD)2PH53=.NC0DDG'RM0VI(2K@G@
MXHJ?8Q[>*BI8RNB=74916-,.5090^I3E31.MLA3R4<NHU%.M#;@Q/OI<+:4M
MXL]]IGLZ6\[E%4W0LL./M*86[ZK1,,..!I7#0A3B%8`X$K*9%2$DX1DW^6+_
M`#$UM:VEMI3.84K5)F'#+.;KS*F6U54*%'"5I86<+B56*;6G#/%_^]?_`.98
MR\?Y1A5_T+U!'K9JO7/MWK#^+D_7_P#F)!CD,5G)3(P<+'+)O\L7^8FMK6TM
MM*9S"E:I,PX99S=>94RVJJA0HX2M+"SA<2JQ3:TX9XDYW39=F>:N4YQ)IEHY
MP.)<4+0"V^\PPL?F/.<FJY25"R*;V1>RW*E\W.8]$MI7(N!I%36^K@"E2ZU3
ME3%)2TT@6J-EQU.-*'%N'DVD-]:JXY\5,*X[GCGJI0JT$1R*N]5[P>T82/SN
MT80-8;T'H.)_-5O0C7F.P>WTV'OEFY(WSJ;Y@U+:>`;A(2V@>$1KZ8Y%QQVD
M/Y300DG9Y5MS]4I.O!*,X4\3<BJY02UL04XG<2-B$U.8H3R2U8$K0M*DE1!(
M$K%"8!-J0+(6SE3866P"HE24A(,P)S()G(V`$ZT!QS,12F\\@7"K=FU;NRUX
MPU-:]5Z/G.3D-<20%SV5J&MT"E)*21>)3&N)@B8UP1JB%%G-ZA(/Q52PG6(:
MY(?JF"MGDZC3P5R4=D+";=@F$4S`Q+<4$I&JI1D!;9:3*V`X^MNGEJK*E#8P
M`C]<0"_FM0Y+XHPX=B3O*V;$MKJ3NQ"]E.^.G;XR=\13^>3O*ZM*"VX>"JR>
MMH/:.I;#JAK[_2-'C?LPMF=H,Y:Q$NU;M1-1D(X3J=V>]./*3V$J[D?-)4H[
M``W9D]B/5VDB0MD-\DG1M;$X_P"7($[Y%/;@4V9)E/XTI;=EA&N(^?0%:^G=
M%O9C%3+*3J&T;MA'9CU&M),R`";=B1-X/8.WUHOS:?&,+V$[P]W%<<^*F%<=
MSQSU8/)^+?L:L-F=HF#L@#?OA(UH/0(.H8;<-P4)[$[>Q$Q'SBTIV2!%KHV@
M3O"."I2MA)[<HE3(EKJOW!9V3'K)$B;9J(F=>5O9E'*.C&@7SD1^KPA&.6LI
M)MD>V(FE.`_F]R[<E#ZFU8T-X5RM$L)M)%H[TJ$XJ:XBUYT)V4MI$NRM0Z=5
M'+@4[KKFPD3+9W2CJCNQ"]E.^.G;XR=\13^>3O*ZO)5A%QA2FTXAIOW]$2<!
M0=T;HM[$?-+"M@V[G0:93>9]F0';@NL*P$VRE,3UKI=F)OO$[4^R3VHX14K;
M':`CR<]E2N[#BFFT@F0!D)VF5]]TX#LN$Y,G8!(`[>WT.6%[9[!L/:.U"%JO
M`D=D6=F_H,?H^-UHOS:?&,+V$[P]U59SDR5.Y6ZK74JG4HV(6;RV38VX=9"S
MBPJ7TRN.?%3"N.YXYZM(W&$ELS"IV:DI;M\8*ALB6I9V#W8L6`=0V;]D`BT0
MI:K@">Q#@<LX0D1>"!;OB8C"EZ23K'>G+LQ\XXH[$AW8M25;*CVI1P6AMS.^
M3!;PC`WH`D."-;\Z_<Z!2H3!ARC/>JN\9/8LV>A4T[G>N-.).PI!';AFF=$E
M`J4=E4E'<G+:Z>KSB5CK+20=4DJ"AM!I!/&'5'=B%[*=\=.WQD[XBG\\G>5U
M@XTOONX3/?CAH$]46'L1-A12=>T=H[\86EXALS\860*JN5B4+0+[=$SK:`.E
M2W.U2NP`>V1#2#>$IW96]!8TKDD;=_8G")WJF=TV=B7007#)*,-NQ-420E2M
M>P?#V(X+?ZWP0$N)*9Z;QVNL5^;3XQA>PG>'NJNCK$)=:=24K0H!25)4)%*@
M;""+"#"LYR9*G<K=5KJ53J4;$+-Y;)L;<.LA9Q85+Z57'/BIA7'<\<]7;7H$
M^UW("E`*!$Q,`P9`IV#W9QBI'>R4]T&.3?7).FT;R;]N`RBV5YU3I/2OU.@S
M_65/M=%3@M2B?ZHP[]O0<.J`-T@0E*R2HDF0OOE;HT;D<%L[H[AB1;D.-\`@
MK;T7@WCK!W8A>RG?'3M\9.^(I_/)WE=8)?%@5:=Y78MZA.&:2\"4_P!(S/ZH
M'0+KIPI%Y,!*04LH[`U3^<JX:FT3`0D2`L&P.@M"3($WZR1+M61A;0+-)$SN
MQ,""Z!PD6[6GN[4)4;Q8=KX)=8+\VGQC"]A.\.LLM9>2%H754X4D@$$%U`((
M-A!%A!L(C\,I/X9GY$?AE)_#,_(C\,I/X9GY$?AE)_#,_(C\,I/X9GY$?AE)
M_#,_(C\,I/X9GY$?AE)_#,_(C\,I/X9GY$?AE)_#,_(C\,I/X9GY$?AE)_#,
M_(C\,I/X9GY$?AE)_#,_(C\,I/X9GY$?AE)_#,_(C\,I/X9GY$?AE)_#,_(C
M\,I/X9GY$?AE)_#,_(C\,I/X9GY$?AE)_#,_(C\,I/X9GY$?AE)_#,_(C\,I
M/X9GY$?AE)_#,_(C\,I/X9GY$?AE)_#,_(C\,I/X9GY$?AE)_#,_(C\,I/X9
MGY$?AE)_#,_(C\,I/X9GY$?AE)_#,_(Z"Z.L0EUIU)2M"@%)4E0D4J!L((L(
M,*SG)DJ=RMU6NI5.I1L0LWELFQMPZR%G%A4OI%<<^*F%<=SQSU=2=(M&U\%D
M8#>@RVC:.V-J#T[C@,C*0V38-^"Z;W%$[0L'9GT#2T]KAL,OBS_:U!HOC&X/
MG%WZPT#MG7V.@&]*SV!:>U`J'P%%5H!M`&QI,22D`:P$82`1J0JG'>J[DQW.
ML'=B%[*=\=.WQD[XBG\\G>5UAC%Z#/:-A[6Y"%&\"1V19\/4'JM5N$JEMD@?
MJSB9@4K!DTB\Z-=1WDCNF`RR)`;I.J=?H*<_)!.X)P*UM)4`2#J76@[1CDL)
M2J4Y3F#L&S>Z#@/Y*MXPKC=H=8+\VGQC"]A.\.LLL^]TWID>XJZ.L0EUIU)2
MM"@%)4E0D4J!L((L(,(S#+%A67U:E!M*E#E&E@8BV03B6@#O7!.0DEPXL*G.
MBKCGQ4PKCN>.>L%4YN5,#?'8L@].VR/C$GP0/E0AD?%`'=[,86S\XN[6U3M:
M-?;CURJM<5:)WB>D_G'L;,^BW3MVG#8-<D]P0*:I;/!LG<9;![L!Q!F%"8Z#
M1&G#XQ'6#NQ"]E.^.G;XR=\13^>3O*ZP+:KE`C=AQE8F9V#7N,^Q$Q\VD_H_
M]J,;3UNRH?[=N,(X6OP#\.[`=J4@IGI"=S@W:TX2\BY0!Z*W<M,TK.JFR=LB
M%66:"(#-4<*#>9HEMX+3K""AN9*KR=/<&H.ST7"=(ENV0#^4HGM=J!6T8X0O
M`OLTRTV6$1@JD$$:G<-VZ8+%,"2JR<M!T`7VW0$*[XVG9/P=8+\VGQC"]A.\
M.LLL^]TWID>XJLVS94R9AIH$8WERL2D:`+UK-B!:9D@%><9PN9-C;8G@:1.Q
M"!H`TF]1FI1)/2*XY\5,*X[GCGK!NJ3[R#,;O:@MT*-N\]FP;<XQ/.R.I,G>
ML&U'S:\8V9^-'>]A$*IZD26C:G;(S&J#T4\D1C03*>D&\=@1(:/-'?MCUK,5
M8E3!PSG;^<>T+-?1T@E:$]I/:-D*:5IN.H=!CD7T31.SX%7:\B)[$3DJ>I+M
MSCUMP22F[:N`WSU@[L0O93OCIV^,G?$4_GD[RNL5.-BR8GKD7[OPPEQ-R@"-
MOHN8M;=Q"&_TO&5U!-&DR2BP[ZCVAK[,!IH22+AT).I"MD02TD#K%?FT^,87
ML)WAUE29D\"I%.^TZH"4R&W$K($Y"9`D)D"<?8*O<9^MC[!5[C/UL?8*O<9^
MMC[!5[C/UL?8*O<9^MC[!5[C/UL?8*O<9^MC[!5[C/UL?8*O<9^MC[!5[C/U
ML?8*O<9^MC[!5[C/UL?8*O<9^MC[!5[C/UL?8*O<9^MC[!5[C/UL?8*O<9^M
MC[!5[C/UL?8*O<9^MC[!5[C/UL?8*O<9^MC[!5[C/UL?8*O<9^MC[!5[C/UL
M?8*O<9^MC[!5[C/UL?8*O<9^MC[!5[C/UL?8*O<9^MC[!5[C/UL?8*O<9^MC
M[!5[C/UL?8*O<9^MC[!5[C/UO05FV;*F3,--`C&\N5B4C0!>M9L0+3,D`KSC
M.%S)L;;$\#2)V(0-`&DWJ,U*))Z57'/BIA7'<\<]88%VE1LVM/OU86R>^OVK
MNQV^D5ANMGX/=Z@I:>^5P1LG3M"9@53@FM=VL#VS?L;?0D;1`66Q/8EV!8=N
M)"P=8.[$+V4[XZ=OC)WQ%/YY.\KK!2A>;!MV0796K4#M3D/?KPWA,Y``ZQ'0
M),)HZ<XB2)RMMN`W3"&1\4`;>D[9Z<NKM-P&J>YJPJN>O<G+;,R=LW=:K\VG
MQC"]A.\/=5S.<U5.5C;8("W7-"$3W5*D0E,U&Z17G&<+F38VV)X&D3L0@:`-
M)O49J423TRN.?%3"N.YXYZPY,VI1VK]TV0Z%F4\0'A`]$K=4!*X3M.P(<KW-
M,P-DF9EL7;>MU!-'36I23,Z-<[`N&J=D0$)N`EN=:.[$+V4[XZ=OC)WQ%/YY
M.\KK!*=56\#W82PL3&$`[D)2RHDJT:1J6Z^Q'*!6+5"29C>GM1R;SV`Z`1.>
MP21;K;\!Q,U*&DZ-@7=O7C"OA+_)';U-_6C@,3'&)_9B3K1&PJ?8(&_$L>$_
MG`CLVCLQC:4%`Z09CHD*\FWO`R_6/8V(`%@'6J_-I\8PO83O#W55FV;*D!,-
M-))P,HGWJ1JF]2C:LVFP`#IE<<^*F%<=SQSU@Z\;_E&?:A3ZR4$"9(UM4?#!
M+*L(%EI(WIP&Z@J3/3,D2U1;;`>4Z7`=2S=O.\8T(0@;0]^Z3KQA8;*M<F78
MD=^/G&/UI?LQ)U*D'='8M[$29<2HG1.1W#(]$-(,E.&6T+^T-N`2.&L35W-K
M?ZU=V(7LIWQT[?&3OB*?SR=Y76#:1K]KH*6;4MSE^C8.S;T"M/`7JBX[([=F
MW"$N+Q-D[(D+Q;:#+4A?KUI).&=TYV;4N]T7:T2%@B3B0K9`._$\&$_FF78N
M[$`3*F5]D:?TD]G;@+09@V@ZH@NN&0`G#KITD#<F>WT#3Y>+/RM)UYFP#7OV
M(Y0.S5J8E=NSM1ZK5B2[@;IG4(U=25_62_-I\8PO83O#W<5QSXJ85QW/'/5R
M=0&%G7&]\,<F+UF6T+3VH0C3*9V3;\$<F\)CWW:D%VB<-FBX[$Q8=N4`.&>!
M?".R.#.7Z0W-,)53`76ZL],_?L61(Q\ZTDZ\I'=$C!>HBH+3;*>IJ:9B\6Q@
M<\HB_7&@]W7V>@S3H,Y2!EH*E`;MG0LM6JX=LZV_'*K7@!NM*=P#MP"\>41L
MDC=-H/8V8#K9L/8UCKCK%W8A>RG?'3M\9.^(I_/)WE=8(>3\4RW;CV.S"71\
M8?[>S#S9OM["K=_HE>E!!W;.W#3A.%P"0.KA)$CK6;4<A6H*T"X]Q6D:QM%U
MD<(E&R/DSBQU.W9OPJG!QJO!`L!V3N&4[#'JE&)A.F5HGHF;!IEICE*YW:F5
M'=-@VIP&61(#=)U3`;3>Y9M:>T-N!,<-5JNT-K?GT/6$=\C>^"_=A+AON.R.
M[?UBOS:?&,+V$[PZ_<H5,*4&S(J"@-2<A+MB>M"*E@XD+`4#K$3]XT0FK+?*
MXEA$L6&\*,YR5^3J0U6!.'E4A4ISE,3E.R>X(4\X9)2"2=0`3)W(10J8Y(.3
M"58YVR)`(PB4Y2O-LAK]<*XY\5,*X[GCGJY3JPNE7??MBPPVK0">S+N0%)N/
M1>I%B:%@B6C0H;@@U%`2I&D7F6N-(UQ:-:)5*"E0U+1V9$;%L>4`V01VHQ%U
M)V+3N"#59>"`K01?.\2!N)M`G?$WE8$G03A'@BT[<!Y:L:Q=9(#8%N[!)A=4
MZ)H3<#^J.V?AZ!;6)@B1A5&H\%5VY,';%AU^L7=B%[*=\=.WQD[XBG\\G>5U
M@M&J#NBT=F"P3P@20-;_`&SC&JQ*_P!H?*Z*@?C%([,^U#0.H3NDGMQA4)@Q
MPFD[0EO2BQ)3L*/;G"EH1-0!M5;HW.Q#A_.&]T66#=(3VU&?8'14V;E`C=AQ
M&@$'=GW.L5^;3XQA>PG>'7]31+LQ\I(ZB@B:3M$">M#N15=BVB2@&^P\-.T;
M9:ZM`AKSR?$<BE\TC>A3*3);YP#BWJ.X,)XT9?F+(PN(EC.HLGE$SV"5)V`!
M#=6UWKB0H;8G+:N/6ZN.?%3"N.YXYZP2^;$F1.\>[!6BW#)0EJ7;QA(G:FP[
M5W8Z+C@N3B[$D]#YY"5;($]V^/)RV"KNRC$0HC4)L[O9BG:82$C@V`?G]D]%
MU8_)(W;.W&+\I1.Y(=KHLO#6[!^'K%W8A>RG?'3M\9.^(I_/)WE=8^MTW!*;
M2!OCM[L<O^\;OEV=HBV$XC,IFG<N[$N@U2HM)MEKFP=N`@6)2`-H""AIO&!I
MQ2GL"1LBUH^%\$6M'PAW(6@)4%%)`L$IRLMGVH6K56=X=%EPW$)\8CHE1T0X
M>+V^[UBOS:?&,+V$[PZ_<XSGB&&><-$)34,6IC&KK+3,'8.DQ3U;!FEQU!&V
MVY,'7!L.N(I?-(WH8RP6ML2Q:GY:]T!*-D0_2I$U%,T\9/"`VR);<+H5GA,*
MF.*N9["L6Z.MU<<^*F%<=SQSUA@<&P=(@T-1WJKM2V[:5=L[<>KI/`59;IF)
MC<-D]GH*=5<D$P[4JO49=L[XCA<)1N2#V3J"+6?UO^S'DCX7P1\XVH;$CW(8
M=:!`&$6WS"BK0>BZ!J3W+>U`'Y*B.WV^BRWI[I`[76+NQ"]E.^.G;XR=\13^
M>3O*ZQD;C!52+D#H)(LU)B\;.W"F&Q-1(FF4YZDI6W:D8&D8-4REV5=JV!45
M2L:P9ZT]4DVDPG+:>]4L6W:!L`6GX(P(M4>^.J>YJ#MQ;!"R%'\D`$]P;<2I
MV4H3J@`;JI6[`W(=3HF-X]SHHJ47H,CL&X[1WX2\+S?K'3[]3H*3\9=@V[SM
M#LR@8KU<+=N['6*_-I\8PO83O#K]SC.>(8<HGKEB4]0W@[1D>Q"\AJA)3+X4
M-:25I6-B9!&K,F&:IWO6V`H[29RV[A#^8U+JFYK-J?C*/"5?J3&[K1]K=['=
M@4*U$MN21B.D+`*3LA<@3L];JXY\5,*X[GCGK&<\*A<>T8#ZU8@F4C,F5ME]
MPG'!;QSN(2>U9`56+PIU.XD6;ML$H%B=TDZNR8.85G"!-@.DZNP+@.T+8Q/%
M*=F0CD:1I+A.DIG/83*9V]R&EO#"I2@0!*RT:!8-CHE"KB"#MPY0O63-FR.Z
M+1L=$NCO$7;5VZ;>L7=B%[*=\=.WQD[XBG\\G>5UGZVW8I%^N)W[(WH#BN^%
MAV1W1([?0]?HN$3HLF+,-QO!&W')A&$G3(#LFP;\3J7K]<JWR(Q.3<.O8-P=
MLP$H$@-`AYLZ,/[0/1+:Q-)$C!4@8VE;FM/44.SO<%"L6U+=GVH]:JQ)`N&K
MK`:FJ=.]UBOS:?&,+V$[PZ_5GG+3Q8C@PW%2</?8K?!Z'K@<+2R`%2`(5*XR
MF+963G<!9"<E9=+:4A"<13B)")&T33>0-,(H6SBPS)5*6(DS)E;L"TV`=!JI
M0]R*VQ*>'%,3F/C)E(SU;X`49G5U>ME<<^*F%<=SQSUB8+3@F%"1@T+AFE1L
MV=!VQ8=?8Z"F`9&\;(]\H#*&YI3=8#V08Q/+Y,:DY=A/;C$^Z5'6$NR9[T28
M3(ZMY.W#+FSV"#V^D%53>43NF5TM<=F.3JT'$+R+]L&4O?9'J]&@@&\Z9:^@
M#5U>Q&`6J-I.OW!HZQ=V(7LIWQT[?&3OB*?SR=Y7690JX@@[<+HWS))-AU]!
MV%#M=.^UJXNPKX>DD8Q);2#JX1/>ZS7YM/C&%["=X>[BN.?%3"N.YXYZQ/01
M6MWI(!WP=VS<@.M[!&H=3X>F;7J$C='P0E6J`>QTGSB`K9`._&%``&L)=9.[
M$+V4[XZ=OC)WQ%/YY.\KK#&Z9#LG8C@-S&N?@,HP=ZK4.G8.G?Z`J$#A)L/%
M^`[\`@\-(&(:^KL'IG`/SNUUPOS:?&,+V$[P]W%<<^*F%<=SQSUA@;&,C:&[
M;.,+R"G7!GV+(#C9F#I@MN"8-AA=*_8DF4]<7'8([73"?Y0WC#1/Y"=X=;N[
M$+V4[XZ=OC)WQ%/YY.\KJY4JP"TP77>\3HWAVS\,84``:T&I8&%:;3+3+MB^
MR)J[Y-A[1V]^<2,)K*6Q)-HT`ZFP>QN0'6S,'L:QUQTF-T[`TG8[L.5[OQI@
M:Y)F=H7#X.N%^;3XQA>PG>'NXKCGQ4PKCN>.>KBF:O7?L72V_??`)`*])[0U
MH*'1,=D;!T1ZJX>`NX[-Q[1^#H:BQ<>T=;>@T509*38F>I^3LC1K;'23,(HZ
M7A`&_03W`)V[FOF.3`S2PTP$;"`>4_6=`.N.MW=B%[*=\=.WQD[XBG\\G>5U
M<@?&(';[4)U3:=OX)=%RG%QG+:M'8GT"TX)@QBIG2G9F#NCN1P7<7Z1[8BPS
M^C[<8)2GIDG?N[<<K7+Q'4F3/9)WANP$I$@-`ZX7YM/C&%["=X>[BN.?%3"N
M.YXYZNMTW)G+:L'=Z!A+PO29;1^$"$.F\I$]F5O9Z!=2<"C?I!VH^:?LXRAV
M+1'!5/;2=^)D3VD'>C_F584ZA^2GMR@E-^E1]]@]Y@UJCP:Q;P.PYB4D;&()
M$M&UUN[L0O93OCIV^,G?$4_GD[RNKIU,7:,(V!O='W_[OW`7YM/C&%["=X>[
MBN.?%3"N.YXYZNZ#?\)Z!A6R-\0W/4.^>E*FDXE`6`F4SJ3D9;D$4.4`)T*"
M_6"=<);*"-@@[<*8S"H<8"I@H2GD;#>+$I41LDZD)?844+004J22%)(M!!%H
M(T$0&Z+'6@?%4R7-U2`%[,U6:T`9KE:64F]?+!/_`*(XU[I&I;T+.LW=B%[*
M=\=.WQD[XBG\\G>5U<D?%(/:[<)_-LW/@ET)PY4BX3EMV#L`^X"_-I\8PO83
MO#W<5QSXJ85QW/'/5UMFP*G+;M'<Z$H2P+U&>T.Z3V(0U^2`-O3V>G53U2`M
M"@00H`BW9AK+:A(4*=QPK!$Q\SBO!T%:0-N`E`D!<!8.EEUB[L0O93OCIV^,
MG?$4_GD[RNKE*K0;#!0Y:A6]H.R-(^",2""-:#34YQ*582-&L-4GL;,85=\J
MT]S:WY]6D.LE^;3XQA>PG>'NXKCGQ4PKCN>.>KBH:[Y%^Q?/:@)60%B\73UQ
M[[(QN&6H-)V![Q'K;@DA-PV+AVS\/4<UKY<'`V4G7?DM6XIM0V#K]+,Q/K%W
M8A>RG?'3M\9.^(I_/)WE=88'1,;T<%P@:XGV9C>C$GA*U3HV-3?ZM9UFOS:?
M&,+V$[P]W%<<^*F%<=SQSUAC0<!UKMSN1-Q95K`2[9@);$@-`BWJ!=">$H`$
MZ2!.0.Q,RV>DLBWK)W8A>RG?'3M\9.^(I_/)WE>Z:_-I\8PO83O#W<5QSXJ8
M5QW/'/N%+K!W8A>RG?'3M\9.^(I_/)WE>Z:_-I\8PO83O#W<5QSXJ85QW/'/
MN#9UB[L0O93OCIV^,G?$4_GD[RO<Y3[Z@A"!-2E&0`%Y)-@$%M+ZW):4-K(W
M5!,]D3$=^[]$>['?N_1'NQW[OT1[L*?*W<)0!Y(W@DZNO"GFEN83*]LZ`!JQ
MWSG@&.^<\`P&0\4*58,:5)'A2PC;(WHF+0?=A7'/BIA7'<\<^YPJLV>2R@F0
MG,E1U$I2"I6T#+3$@XZ9:0TKMR/8COW?HCW8[]WZ(]V%M-K=FH2'S1[L*9:6
M[B,KVSH(.K'?.>`8[YSP#'?.>`8+5"\%+%N$@I5+5`4!/7E.6GHM\9.^(I_/
M)WE=82Z^I,J:)2AXK6N7QL&$)2=4345$&R82=$%EM(.'2?@CO$]GNQWB>SW8
M[Q/9[L=XGL]V.\3V>['>)[/=CO$]GNP6G$@&4P1!9>)46%E`)_)D%`;4R!J"
M0T>["N.?%3"N.YXY]SJQ3Y."E);0G0E+=\N,J:CLZPC@H3+;^".\3V>['>)[
M/=CO$]GNQWB>SW8[Q/9[L=XGL]V.\3V>["*U@EMQM5A&A0D01[]:/ZG+]SRL
MOT,<NUT&^,G?$4_GD[RO<[+^*[OMPYL]0&P8J/._L)]V%<<^*F%<=SQS[G9K
MYU[?5U%7'.\F/^D_X/0;XR=\13^>3O*]SLOXKN^W#FSU`;!BH\[^PGW85QSX
MJ85QW/'/6KM8T9.8FPG7)6DG]4*A+K9FE0!!U01,=6EU+-?.O;ZNHJXYWDQ_
MTG_!Z#?&3OB*?SR=Y7N$D5),U3(`$S9O;?=@<DR,&F9M.Q*0%FL8%0P9I5NC
M6(U>I9>=&%[?;AR>KVNH3&A)C/>=O/7-*JBR[+ZT4C;5%R*7W7S3MO*6IU]I
M]M#;:7&P$AE2G"I7#;PC$]SAY@8^=&1HFHEELC,*=%YY>E1B+R$"PO4V.8!<
M<983=(V$>ZRN.?%3"N.YXYZUI,O2>_6IP_H#"-W&=R*-XF92V$'9;);MUSAG
MKSGUA4OMF2R`A.RM02?U23M0W5M]ZZA*QL*2"-_I*KF3GF9NY5EN6T#E?4.L
M(0M]P)?IZ=MAKE)H0I:G\9=4AQ*4M*3@*EI(=YP^PFO'.N@0,2J%_DZ;-&P+
M3R9FFEK``">"JF>)(0W3NJM+_-_G/1/Y=7TJBAZFJ6G&'VE@6I<:=2E:%:RD
M@QFB96EUZ6V3+=Z3*WN?&3UF4)SJC1F%`:NG=I_6Z%QQQINJ8#J4EQAQ;3@0
MXD85!.))*2DFJ]IU'D]6[S=H:MJAJ,R33N*HF:Q]M3K5,Y4!/)H>6VDJ""H&
M11.1<1BZ))TJ,MP#M1+3ZI_P>@WQD[XBG\\G>5[A./*)(Q$)GH3,R$M%G9MZ
M#E65<%7!`UQI/:V3T)=*%5"P@&Z9E/8U=J$H0E2DF]5TK=2\]B`XT0I)$P1:
M#"&Z[$"RL*2I,@H3D%)F0;%"_7"3HB:FUG96>Y'DE>%\$>25X7P1Y)7A?!'D
ME>%\$>25X7P1Y)7A?!'DE>%\$+11XVG"."K%,`Z)B5HU;CJ&%L<TPWF&5UA0
MJNH:B:6ZA:9CEFW$S73OA*BA#B0M.'"EUMX(3)%%S?J_Z?G6&:\KK%);J9A,
MU&F5/DZML24<3)+B4#&\RSB`A[.@S_0N<#EO]1HVT_.J_P#KVFFANJGI<FU4
MV)'K&!.`J<YWT/K&5E6%K,J7$[1KFJ2`XO"%4[BK`&JA+:E&8;+@&(]"2U6Z
M@M,<G+"=$]/PZWNBKCGQ4PKCN>.>LR:.@=JI"]"FP-B6(N;,FY:DX+8HA1S_
M`-XA95M%6!/ZA@5&9N<HI(DFQ*0!.<@$@#;OU3'JU"X.2F58%)2H3-]L@H3U
ME`0,>5*?!^.T%I3^L%)_7$!VH873J_)64$[J%K$MF1U0.K4U"#:ZXI9V&TRM
MVU]C6BF)/";"FS^@HA/ZF'I.=7]@/_B%%T/Z5[5<B8S!:$E+-4!R-=33F1R%
M8UA?0D*X1:*U,K('*-+%D57/KV#UBN=%`4S5ESRVJ;-&PG2VJ2*:N(0!,H52
MNJ("6Z5U1F:CF]SJRVJRW,*510]352'&'VEB]+C3J$N(5IDI(.F/)*\+X(='
MMEPUV=Y>E%1DN35B4*R[,%H#BWW70LE-8]2!"7$Y>XA+:V\;ZDU+;3J&6N8?
MM(:535-`YR^6YE3I3ZWE[I`2X&YR#E.^A(144RSR;@2VX,+S++K;?^7;F_S?
MI?\`"":1=&]0/-(=;JVW4RJ'*S$/^8J*E1+C[Z^&MTXP4D)EGO-O_+[6O9GS
M<IW2$+4O&TR^5*Y>DI:@E2JRDIE2:9JE\)P`C&^E*:E_R2O"^"/)*\+X(9<I
M5*0VE4W$$SQ)%H`,K)F0/YI,I$6X)672T2U)=!OC)WQ%/YY.\KW"4^V,2'5$
MC"#829R,A9?9JP%/R:0=7OI:R1IV91ZNR21,DDWDG3N`#:BSIE.*,TI)2F5V
M$$RW;Y]#FQ7YJ\BGHD/O_..K2AM)]3J@3B60E()(!F0"HB5L35GF7@??*;ZR
M/QW+OXVF^MC\=R[^-IOK8_'<N_C:;ZV/QW+OXVF^MC\=R[^-IOK8_'<N_C:;
MZV/QW+OXVF^MC\=R[^-IOK8_'<N_C:;ZV/QW+OXVF^MA%#E^<4+[SADAMNK8
M6M9U$H2X5*.L`3T*S,>?;]+392ELBI76J:32\FK@E+O+?-J2N>#`J>,D)`)(
M!54?Y=J"II**:_65J);H7G"JQ=!2.H]8IVCPB0XMM%J4M4K"$36IQ-^C9,%1
MO,##?"0_WTK>UMROZ4)(Q$Z-:`4R2!H`OV9S[48DV'2-(]R5<<^*F%<=SQSU
MH4+`(-X-H.U%+74;26@YC2O`D)!(D4D@`3)!5;?("*>K=907G<2RLI252*CA
M&*4Y89&4[)GJT\IID5!_.=P$'BE$B/TQ!QTIITC2VUR@`UUDNIV[-:`YF3RW
M5)F!C).'5`%PUP`(Y'*GW$!1G@3PDDZN`@I)D!,RG8-2`'*$/).EQ/(F6J"5
M(3N(.M&.O:2RO\E+A<W3@1+8$]GH<ZO[`?\`Q"BZ2MS3_,314+-#0,.'^K/*
M12U5`D`D+8KAA=3)1"DTY4XR^X$H6P[/`2&R2F9D2)$C02`3(ZHF9:IOC*>:
MGL?==H<RIG6ZQS,FU*0,I89=1CS!;B%(4DL*4GDDI6EQYXMLMG&L12T.95*J
MVH99;;=J%(0VI]Q"$I6\IML!M"G5`K*$`(2584@)`CG%[/O9AG:LASG,:8H9
MJ$V!T`A3E&XX.&PU6("J9Q]HXVDN%4EIQ-KKN9O/&B=R[-,M>73U-,\G"XTZ
MV9*2H6@C2E22I"TE*T*4A25'I6^,G?$4_GD[RNJ2Z_4%)DA1)1*[#.[:G(S@
M<DV0D_&58F6K,W[4S`IU*Q&9).BW0-;MS,+K,P40DD)2$B:EJO"4@D"X$DD@
M``G6/DG_``6_K8\D_P""W];'DG_!;^MCR3_@M_6QY)_P6_K8\D_X+?UL>2?\
M%OZV/)/^"W];$VF'E*U"$)&O:%JWMR',WR2J;RW(*-:$55:XDK6%J!46*=@$
M<J^$B:PI;;38(4IPE2$+#?,G+PYF"T!+V8U.%VN>LX0Y7"`RVK2S3I:;,DE:
M5*&**CF[S-*.<V?MS26F'!ZE3+M!]9JTXDJ6@]\Q3XUX@6W5L*M`S7VB9DJH
M;;45,4C0Y*BIIS'S-.DE(5(E)=<+CZDV+=7+H*;3?HV1!;(.(62@*7P!KW[G
M=ETRU*L,S8='0543M[V6X>Y[DJXY\5,*X[GCGK52T":F7&UC5M/)R_7[$]$,
MT:;FD(1X*0.UUA29BD2(4IM1U<0"DSV,*I;,-.D24\5K.K:K"FWBI!V^DYU?
MV`_^(470?YR<[:^GRS+Z5.)ZIJGFZ=AI.JMUU24)$[!-0F;!;#O,WV!9<OG1
MFN$@YA4(6SE;!M`4ADK9JZTS!LG2-D87$/.H("OZY[6\YS#-2A14S3D--45-
M.8E34;3B*=DX>"I:6^5<`!=<<5PH\D_X+?UL5/K66.YES9SM;(S2G0S3BL2&
M0XEJHHWE.I^=9Y59-.ZOD'TE2"67"E]&3T?^6#.6<^S_`)RL(JTUC"&GV\HH
M\9"A54[\L&8NJ0ME-%4-ARG2''GT(/JZ7GO;1SX?]3YT9;AI*GFXTI'KU9F)
M:Q(7E[9<<(RVI(4OUMY112)2XR\IQY#8J,P]K'/6E]7JJP(;;8IF64-4],R,
M+#.+E.4>4VBQ3[RE.+.E+8;;1Y)_P6_K8\D_X+?UL-TH0XVERS&L)`"B9`$)
M4K@G\J=AO$ID=!OC)WQ%/YY.\KW+`<2%2NF`9;O1R]F?!D\J6O-L3W+MO5A:
M4K("3(`$C1K1WZO"/=COU>$>['?J\(]V._5X1[L=^KPCW8[]7A'NQWZO"/=C
MDUJ*@0;"9W;,9YS5S[*%YKEM?6)JFRPZAIYA\,MM.`A:"EQMU"&_CH+:D$@+
MY0X7LARA9YN<WUS3ZG2NJY:H1:#ZY5@(6Z%`F;+:6J<IDE;;JD\H>DQR$]65
MN[T_+,#%B-HU#W(!?5+6'=C`T)#W)5QSXJ85QW/'/6I:>`4DRF#K&8[(ZFY6
M5!DAL%1V!TSX0)J;*7`.*H3_`%2J&*(?NFT(\%('9ETF8YC[4ZW^FY;G.5.4
M2*M2''&V:D55+4-!X-(6M#3B6G$<KA*4.<GCPME2T/\`-W_+UE_^(Z\33_4J
MQ+M/EC:KL33!Y.LK)$$$'U-JY;;KR;#_`%OVKY[49H4**F:<J#='33$I4U&T
M$4[)P\%2TM\JX`"ZXM5L9F\HS4EQP#81P4C:"0-J)EQ7A'NQWZO"/=COU>$>
M['?J\(]V._5X1[L=^KPCW8[]7A'NQWZO"/=@EPS(41,WRD#VX]:G\YZMBG9W
MW)3GJ7VZG0;XR=\13^>3O*]Q;.HY?Q7=]N'-GJ`V#%1YW]A/6DTD'8]Q%<<^
M*F%<=SQSU*726]9+:!M?6A'9QGL(D=F6F*6K)F5M(Q<8"2OU@>E*%B8(D0;B
M#>.A+ILU\Z]OJZBKCG>3'_2?\'H-\9.^(I_/)WE>YV7\5W?;AS9Z@-@Q4>=_
M83UD75W".&HRU!8.QVXQ)M!O&K"7$W*`.[[AJXY\5,*X[GCGK_%6O-M#\]:4
M[Y$4U)EKH=2WC4LB<L1PA(F0`9`*NG?`RW,7TLN-K5A"I@%"I*GB(PCA%5D]
M?3'*4KB74ZJ%!0W02.J9KYU[?5U%7'.\F/\`I/\`@]!OC)WQ%/YY.\KJ$NKS
M,"GY5.)5P%M^N+)[)ZVH*X";:>503J*5@4D'C!*I<4PIQI.(*MO`WR([S]9/
M=CO/UD]V.\_63W8[S]9/=CO/UD]V.\_63W8[S]9/=CE7AA`!T@SGL$PX\L22
MZZ2G7"0E)/A`C:/64P;`1/H(3AQ"8F-;3V(D/<-7'/BIA7'<\<]4MZRP/.O-
MV2^:=6@'92#@.VDP5T-8H'4<2%3V5)*?%,-MUI0H.A12I!)!PRF#-*2")C5O
MO@UE.M#;044S653)`!,@$F8M%I(MGJ0':FL<4H?[H!O:F2L[DMJ.1:6XL:KC
MBW#NJ)EL"0W.C9U#,&'AA+JUJ2=!2X,22-HVZX(O$=Y^LGNQWGZR>['>?K)[
ML=Y^LGNQWGZR>['>?K)[L=Y^LGNQWGZR>[`94)K4JX6F9D`++S9HCU"7SGJ_
M)ZV+D\._T&^,G?$4_GD[RNMRE!*6TS3*=AM,R0-7;LZ"FWK0W(!6K.=AU2);
MAMU^M%Y=F*`XTY>+B#,2((M!!M!$$T]<XA&@*;2HC94%(!\$1^(+^A'UD?B*
M_H1]9'XBOZ$?60JF_J"K$A4^2&DD2\IK06!6J5*5O)`7B?Y<?;%?1CY<?;%?
M1CY<!=54+=0/BA(1/9,U&6K*1U"(33TZ0A"``D"X`7#K(I4)@Z#!4HE0T"[=
M.GL1A;2$C6]]ON(KCGQ4PKCN>.?<!FK%[+DCQ5@@_K!,4K9$BM/*'_SA*QN)
M(&UU5!K<3;S=B742"@)SPD$$*3.V1$P9X2)JG^(+^A'UD?B*_H1]9'XBOZ$?
M60MX9@HX1.7(CZR"^,P4J4K.2`O,O]Y'VQ7T8^7'VQ7T8^7'VQ7T8^7":QQ:
MGW4&:2H`)2=!"1.9&@DF1M`!MZ+?&3OB*?SR=Y76TH6RL$%)(MW]N`VTDJ4=
M`$X0T^`%"9E99,DVZ_\`LZM;U1?FT^,87L)WAUU,V")3Q'4'=N[,!QLS![&L
M?<!7'/BIA7'<\<^X%1EZ.^6D8>,E04.R(2RW8E`"1L`2'8Z74ZH[L0O93OCI
MV^,G?$4_GD[RNK:.HI74)M39,&5FH=:,+"$H&M9UVOS:?&,+V$[PZZ%,FZ0)
M[-G;W.@`UWI[[4E[[O<!7'/BIA7'<\<]6^#J=-D\['67%RU58DE)VDMN;NMU
M/X.K.[$+V4[XZ=OC)WQ%/YY.\KJ=G6X]:7AQ7"1).T`=VZ$AIHE&DD@':`GL
MVFVZR^$OLG$E5QZ:?45^;3XQA>PG>'70?`X)`!.O_LE&%L$G6A2W;,0N[ON`
MKCGQ4PKCN>.>I6]7153X##C;6PF02YV5+ZY=V(7LIWQT[?&3OB*?SR=Y74[>
MA=UJMQ1FD$A.B203+NG7Z"WU'YM5@$](O,M&IK[75U^;3XQA>PG>'712L3!T
M&,#8`&M[@JXY\5,*X[GCGJ5G1NBZ+HNBZ+HNBZ+HN@@9=4KE\8HPM^&,>]$J
M-AID:IQ+5NS2G]6%U;YFXXHK4;IJ49DZUI@)JVFGP-,BA1VP</ZD`'+:E,_C
M(3RB!LK."6Y`5*4]!O&S%T71=%T71=%T71=U5W8A>RG?'3M\9.^(I_/)WE=0
MGT;.MU.R')NJ)3+1IPFRR4[-4;<`E/)I.E5FX+^P!KQZNA6*TDDV3)D+!;(2
M`TGI;.I+\VGQC"]A.\/=Q7'/BIA7'<\<])+IK>K'UVF;=)TJ0DG:,IC:,.9*
MP,*5/A*`-"7""@">HE0O@>ITK;9&D(3B\(\([9ZKJ=3=V(7LIWQT[?&3OB*?
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M8<.N!N)`]W%I_/.\GN14-'XKJMP_[.GLC4]PM7J')_EJ2-FV?:@C5*1V9]KJ
M!4+24!6X`J&W=4">R+#V9]/9[B619TI4JX6PY4G]ZM1VO?.''!I4K<G9[N.,
MG2`1M6'?$/,FYT!0V0/]NYTVI[F4U,/RL9V!=O&&VM54]P2[?4`VJTHFD[%X
M[!EM0[E[EZ#-.Q[Y';Z>WHW1=%T71=%T71=%T71=%T71=%T71=%T71=%T71=
M%T71=%T71=%W1LBV+8MZ0MI[YS@CM]BS;B0O0F7Z1_[1]W4$W*X)V[NS*&:]
M/Q#)6P?>1MP%),P1,=KIK(M$7^X-T6].]6GO4\!/P;0G^E&`7(`&W>=\#:ZA
MR:CP7+-O1W-N&\R:%UBM?_:+-:R`X@S2H3'26^XUG3<M>TS=J$SL.V;=@"<(
MI4G\X[P[9W/=V8B1^.)'64.X;1K2A5`]8MJ<MB?:/8(ZC;[AV])R+?E'+!JR
MTGM#7.M$U_%$SKJ.C=D!M07%WJ))V3U"8@H=M,L*AKZNW>-?8@Y?5'@&U*M%
MO:/8/3W>Y`R^EM6NPRT`Z-O3J#9B:OBB9_.4??(:T*><O49^_8N'N]R+AX+G
M85HW;MR$YE3=\COAJC5V)6'6V(#S6V-(.H>GNBZ+HNBZ+HNBZ+HNBZ+HNBZ+
MHNBZ+HNBZ+HNBZ+HNBZ+HNBZ+HNBZ+NG+SID![Y#7,',J@6#O!L:FLGLFW1`
MI&S8FU6SH&UO['4@ZFT&PC5'=U("VS;>E6IJ@[Q$>H5_!4FP$Z=0$[QT[_N9
MZO3<)T[>'NG4&V=<U-29NJF22>]&FW5U3M;/)M^31=KG5[FML_Z`>KO'AI&G
MXP[HTZM^K!JJ<395>-36/[)VCK\JR9C2-(UB/?K19[DVQ;!=>,@.SK#5,<HX
M"EA)L&KW2=)T"S9#+,L9$DC4&J>UJG;@J49DW]3D>$A5X[8U]_<D%@SU%"\'
M4/;![%\!FK&-JX*&@:Q[1VC*,3"@K?&R+Q[DE;A"4C2;(--EJ3KJNL[0US;J
M`&"^\05Z5&X:LI]DWF"PQ8WI.E7<&MNZG^@(6@R(M!$<@_(+E(@W*V.V-RR[
MUK+#LH[FJ-:\:-;DW_FG!9(V">L3O&W9BWH71I]PM/1L@H!QK_)';.C8OUH%
M17DI1H3=9K#0-<VGLP&6@"L"Q(N`U^Y>>S!==,U&\]5QLJEJC0=D>\ZD<D])
M*C84JN.P38=@VQRU$LM+VY=T=D:T8:AKEAJIOW`/V1&%W$VK44D]J<<%U/A`
M;\3"T[HCOQNB._&Z([\;HCOQNB._&Z([\;HCOQNB._&Z([\;HCOQNB._&Z([
M\;HCOQNB._&Z([\;HCOQNB._&Z([\;HCOQNB._&Z([\;HCOQNB._&Z([\;HC
MOQNB._&Z([\;HCOQNB._&Z([\;HCOQNB._&Z([\;HCA.I'Z0[L6+Q'4`)[@[
M,2HV"D?E+L[%@[)CE<Q=*S^2+`/?K`;,<DD">A*;]O4V3;LQ)?!1H2+MO5/O
M`'^@<Q`:K.$/RM(V=79OV8Y02)_*2;=ON$1*E6'4?DJ[4S9M$;$2K&5MZX$Q
MNV=B<<%T#9F-^4<%Q)_2'=COT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT
M[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT
M[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT[HCOT
M[HCOT[HCA.)'Z0[L<)U)V.%O3C#2-K=.L)#MGL1)Y080=`O[![8V(Y54ICXR
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M?6&_V8\HK<$6N*W!'`<4#K@'N067;QN$:H_U4-D620G>$7Q?&&&E:3B&YA[O
MN!1>USG=GV946<9\JM]3]5]7-+1(HZZIH07F'65.52G'*9;BPFI8')K0A!0L
M*6:C._4/\3\WF9J_J65H6[R38MQ5E'(U-+)-KB\+M*B[UI1_U#IXB=X1.+X`
M,,_I_L^X',;_`.S7_P`PYMT*C._4/\,<X7IJ_J65H0URKAMQ5E'(4U5-5KB\
M+54N[UI(BHSOU#_$_-YF:OZEE:%N\DV+<591R-32R3:XO"[2HN]:4>E>YE>R
M#*59SF=/2N5KC*7Z6GP4S3C33CI<JWZ=J0<?90$A>-2G$A*5&*SFOSFI7*',
M<N><IZFG>24.LOLK*'&G$FT*0M)21K661D7-WGAE2J.MYS4-%F66M<M3/*JJ
M+,7%M4;P+#SJ6R\XVM(:>+;R"GYQM`()"AS%O_\`XSS?'8.:S&W'_P"KP<E5
M_C'UCU7^G>L4A/+%GUC#ZR*CU/#R'SO*^L<D$6E<.9QF_,*J6RTA2U"DJ\LS
M!W"B6*3%!75+ZC;8E+94H`E(.%4E-.I*5I)"DD$$$&1!!M!!L(-H,95[)^;;
MR*1W,5.*=JG4J4S24U.TM^HJ70DIX+;;9P@J0%N%#>-)6#%;[,?8;3'G/5TQ
MJW&5H73T2:BCI7,'K<ZVH::92XE3:@VMXK!<2V,:KZ[F?SNHW<OS/+7ET]33
M/)PN,O-G"I"A=?:%))2M)"D*4D@G(JWGUEQH&N<N6T^;Y:HO4[OK.754S3U$
MF'72UR@22&GPT^D2*VT@B?35G.+V-<W#G%%E[XIGW?7<MI$H?+:70V!75E*I
MPAM25*+86$A2<1!4`3S_`/:QS7.590EYJG-0,PRJK`=>Q<FDMT5=4O`*PD8R
MV$`R"E`J2#4>VCG;SIR7F3S6;KOZ8Q79R^ZWZYF!;#G(4[33:RI*4S+CJE)"
M4H=4E+B6'RWSIR_+,\RC+<BYF)6[FV?552K^EM,)==::=8=;;4NH%7R#KE+)
M"$NMH)*T$H2KGZ.9?.S)<^R_F'DZ,Z>KJ)U]VGKJ9;8<Y&F(9FBJ;)+;S3_)
MAMU*DE9E,](.87LDRLYOFW(.U/(!^FI@&&2D..*>JWJ=A(25H3)3@*E*2E()
M($5/.OGUS)JZ?+J-!=??IWJ+,$,M"94Z[_3JJJ+;38!4ZXL!#21B<4E-O4:+
MGID7,I=1EV8TS-73N#,\F2MRG?;2ZTL4Z\Q34)*VUI4$+:2X`>$@&8A[F7[2
M<IJ<ES2G"5+IZILMKP*G@<03P7&ER.!UM2VUR.%1D8YF<Z\\K*:J9Y[92C-Z
M5#'*XV&%E(#51RC:$\J,0GR96C\[I.>_M$R:LIJ:EYBT5/75;3W*\K4-U#CC
M244^!M:,:2T2KE5-ID1(DSZ7F?SL;S!O-\FYZY0SFE#5M-*:"7+$UM`ZA2UR
MJ:!U2&WB%%)Y1!$B5(3_`*()XB=X="<;1AG]/]GW`YC?_9K_`.8<VZ3+N<?-
M9G+\L]H59F#?K%-0J0V]4Y>MBH6]4UU&R0A!Y84_)5;C:'GE*4@*>2%<ET?:
M;G^2O*IJRA]G?.*H8=18MIYFIRIQIQ,YC$A:4J3,&T".;'^?/V?4Z6SGB6\I
MYUTK(FFASVD;2VE]8!44-U3:4MI*P@%H4#BIO5AG[`O_`(*YD?\`B-='.GV@
M^R;(JBLYOYA_3?57D9SE=(E?(91E],_*GJ<RIWF\-2R\DXV48RDK3B0I*E<T
M,EYS)4G,:+,LPIZI*UAQ:7V*"O:=0IQ*EI64+0I.)*U),II41(Q4^U_,*.NR
M?FG29_F>85%4JN;=34Y4NJJ7C3,T--4/U=2:U@AIMA%*H@K25)2H)$<]>=G-
M^E<HJ+,<[S.H99>:-.\A#M8ZH!YA02IATSQ.LJ`4TLJ0KA),>WGVY-)E6Y7S
M<9R6C=!&)M>>NO,O.(O*5M*9I5A1`O(!ECESIS++W%,U%/S-S]QIQ!*5H<;%
M(I"TJ%H4E0"DD6@@&.;7^>[F:RE.8K2SD?/*G92)4^:TR$-4]>XE,PTW5(++
M:9R"67LM;M<4X3[`*3,ZCU2F=]G7-A#K^!3O(MJ1)Q[DD<-SDTDKP(X2\.%-
MI$97[$<HS7GO4YIG56SE]+GY;RNFR]==4K2S3%.7J;<K&Z-YY3;8#P]827"7
M%-('*-TW^5;G_6/&E3G;N5U%51%MIYQE'*%NH8Y9NH;:4ZVEMP)<;=P8R@@D
M3A/^6?GISLYQ9GSKKJXY<,VRQ.7HR/+:]U_DJ6@<4^VJHJW$.*33UU2EI#/+
MC`A-+\ZICG7[#N<V<M97D_,45]7G><X,2&<KH5#_`)EIG%:[4-J;4EI2SR*5
M.N+Y3D%(6?8M['\ZYV\W^<U2AY.4YAG:<L>RW,:AI"W.2>8I$(?8+J6U*8&)
M@E,TJG4<G3N9GS,YQM<AF&45=1153<P>3J*5Y;#Z)BPX'6U)F+#*<>T7F'['
MZ1=;GU5SHH%LLMU5/1J4AEO*W7B'ZE^F93A:0HD*=25`84A1(!H*[V\96_EM
M'F;JVZ8N9G0UZ7'64!:Q@HZZK*"E"P0IQ*`9D))((',4YV.?(YE*YP9@:`TX
MR#^N',/_`&@'S7<I*@-)8\&>1/+X0P%FQ<>U)S/QSIY`M9(.=9IQE'*ET5CI
MHQS?+G!Y(*/_`#`S+A`%7)6F/\Q__P!J[^H?X?\`\'U/J']5]7_J/(8EX?6_
M5)TW+3G/D>`1*4K1'M.]NF:5-8WFW,I_(&Z)EI;(I'4YKF"*2H]:;6PMY:D-
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M&8M4]3GXS!K`&<ORKD$)I7*BLQ!04^IQFG95ZVMPMI=881_FE_RO5V<C+,OS
M1.49QE>>^JKJZ5YQ"%,U#3M$@-AI9=8$E*<2X:@87&EM.,1E/^9SVS\Z<QR2
MC_JE?15M)1BF?JLPY$#U.BR:G=82&ZQTAUQ^HJJAVG::;*E,H1C<;K?\S/\`
ME4KLY%)S<K&*//LHSTTCE73"I4TU3U=.[1H2A3*G74`@EW&E;B\5/ZLXT8]D
M6=>PG**NOHJ;F3DE.\\Q74U&VW4X"X`LOU=/(AM;:N4EA`(X4Q(>R_V5\\R_
M6<ZN:W-BGI\XS%UEY**RH<2R`EBK?;0K,$LK9>4NK07&UNOK"G/6?64(_P`O
M[;8*E*YETX``F22MH``"\G0(RKF7_FFK^<N=<]LPI&*RMH>;ARYFDR5JI!*&
M7GJT*54UB0"9-J#2D\(MH0IEQ[V?C_+_`)LOG+S7]J7)IR&JJD)9J&7RZTT_
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M(S"FHC(5J_5'!@;?4`V^4J6E:DJ"$4^85?#JO9USQ=IV%$$J;R[-*=MYQL*(
MD$NUU<E12#>RDD6IG_H@GB)WA$H)C=AG]/\`9]P.8W_V:_\`F'-N@ISVGYXV
MC,"C&UE=+*IS-X$33AI4*!90L=X]5+IZ=1!'+3LBHYN^QMK_``3DRYIY=I8>
MSAY%TU5F$(H\0DH)HT)?:5-(K7$P]FF:ON5-34+4XZ\ZM3CKBU&:EN.+)6M:
MB25*422;2>D]J_\`]S7G/Z;+(SG_`"O^UER?,SVGL#+7<9!119J9C+:YL+FA
MMSERAKE`!)X4;SB@BE$O8SS*KW$NOY/S7YI43BT3P+<I,XS%A:T3D<*E-DIF
M`9$3MCGASRYB<RLXS?*JS^D\A5TM"^\P[R629:P[R;B$E*N3>:<;5(V+0I)M
M!CF7S1YZ4#^5YI15E2E^EJ6U-/LJ5E56XD.-K`4DE"TK`(M2H'3&9\X/9SDN
M?94%\Y:ZII,R>]8I:!JF5F3KB:A;SKC33E+R!Q*92I1J626FVW"L(5SGS3V<
M.,U%,D4C-4_3E)8>S!FF;;JUH4@X5J0M(9>6FQ;[3JB5$E:O\P_,>C^V(RW*
M,T2FPE=-0OU3]4H)LD&4,I*U3,@X+"1)7.[_`."N<7BTL9C["/:NH.<Q_:53
M_P!'S%"U`(I:MT*1E]>DJFEI;3R^24_P>1#J:DJG2HE[`?8-[0LQ#&74G-WF
MWD685S9#:0RS7*H*E]"G`4M!24K4EQP%#0(6X"E*A&7^RCV5^QW).;_,'(<W
MR]2\Y>YOM.+7E%.^PX_FKG.6N"@JL4R'5TZFZCUEIY*6$A=2TM1__2O_`-6C
M_P#R!_\`U%'^97_+[ZRU1YUS_P`LKJ+*''EAM+M:S3+PTG*2)`>%1RKB0.$S
M3N2FH)!R/GA[3.;==S4R+F;6?U/-,SS5E5%0-,4&-TAJL?":>J#JVTMXZ5QY
ML-K+REI927!SQ]HF2`BASG.,PJZ;$"%&G>JG%,*4#:E2FBA2DZ%$C1'M)YH\
MP,KJ<XS1_G3EJFZ6D:6\^M+2<J<<*6T`J(0A*EJ(%B0285SJ]HG,_-LERU"T
M-JJ:RB>89#CA(;07%I"<2R"$B<SHCV8?_%>:[^;Q_F"__1W^=7'M_P#_`(*J
M/&<CVZ^QKF,D5G.2M1S=KZ6A21R]2QE^8FJ?Y!!(+BI,\D`F?SKS"#(NHG[:
M^=WM3R]?-]W.^:-<U0Y=7`TV:/-4N(U-8J@=":AFE:<=99#CS:"MQU.%.'"I
M8_S/^TM-0]5^T*KI<NRC)6W.34_D])4H=S'.G&B9+4TVI:*`K2FU;0"^0S'E
M$5'//)JQS..:W/O'GV2YHI:W?6V*Y7K+S:WE\);].X])162ZMARG?<"5/%(S
MBLI58'&N:^;K0JS@J2[1*2;9BP@&T2ASFU[1.>F8YAESP`=I0XBFIW@#,)?8
MI$,-OI"I*"7DK3B"52Q)21[=?8US&2*SG)6HYNU]+0I(Y>I8R_,35/\`(()!
M<5)GD@$S^=>809%U$_;7SN]J>7KYONYWS1KFJ'+JX&FS1YJEQ&IK%4#H34,T
MK3CK+(<>;05N.IPIPX5+YC?_`!KF7\E51FH)N]I2):W_`.;]&=\DQ[3_`/XK
MRK?RB.;F4^S.F3F.:95SIS.N]02XA-75L(8>:>%$TM234O,AU+JF&YNK:"RV
ME:PE"O:74>V:@>R',O:%7Y5091EM:T6*YP43P>?J'*9T<JR@-&H4D.MMN`TX
M5)(?86J/9'F?L>R#.<VHF.8V2LO.9:S4.,H?P*7@<4SP0YR:D*X5N$I-T>R_
MV5^W^I2_[2J7,JNK;9>?159C0Y"XBL2&:QY+KJOG'%4`;"ERPTXITS51N!/^
M6_/GV@^BAYJ4%0ILR(<2S4,.%!!L(6$X;;+;8_\`U@O8GD=?SQYK<^:'*ZJA
MJ\IIGJ]#1:H*:C4S4(IT+72_9TNE3Z4-@NJ27`XAYMO_`"S>PCVF55.C..:]
M=7YEGR2\VM&4(SU^I33HJG$J+:%4PS%UQXXI-MT@>25M.-K5SGRSFIS5K\UH
M<\SBMKJ+-4-$Y8Y25]2Y5-//YD94C"D-O`/I=>2M*TK"4JX,_;WSFR!UD9MS
M;R_*'F7)(J&#4T69512J2A@>9*V](DM!LE.<<Q/_`/I=S#2EG+$YK2TG/K+W
M%*>_H%<XR*$YJ2>$,O"'6G2[A`:PLU.$ERH139]EO,SV3Y1SDR>JKWZC+,TI
M.9%)FK=5153RGJ5Y^OIZ5U!J"TXCUE;RT+Y8..*X)"CS?S;_`#!L)I>=B?Z@
MU6,(;8:2R&^:E>&&\%.I;8(8Y,JX:EA1(60L%(S/[W4>F7'.FHS+@'G1SVI:
M6E!LQBDI:*I4XC\J9HZELB0`Y(F9N_T13Q$[P@=#=AG]/]GW`RKV<^TFOJZ3
M/.;JLQ`HVJ&IJ%UZ:K,:O,&E4CS:#2(.&K#)365-+)QM1)Y,I6:CF[[&VO\`
M!.3+FGEVEA[.'D735680BCQ"2@FC0E]I4TBM<3#V:9J^Y4U-0M3CKSJU..N+
M49J6XXLE:UJ))4I1))M)Z:H=YMYA4Y>NK8<I7U4S[K!>IG2DNT[I:4@N,.%"
M2XTN;:RE.))D)!23(BXPWG?.O-:S,ZUI"&T5%74O5+R$-J*D(0Z\M:TH0I2E
M(2%`)4HD`$F/_?CG!_\`EG,?^\Q_C9W-ZU6=!8<]?-4^:WE$I"$N>M%SE\:4
M`("N4Q!("09"4.95G?._.ZRE>&%QE_-:YUIQ)O2MMQ]2%#64".@,R]H"5N<U
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M4Z\XY4J=204NJ?6HNEP$`A95B!`D;!">;?/;GAG><9<G#AI:[-:^KIA@EADP
M^^XT,,AADFR0E*0Z#M)S)YP9ED[3Z@MU%#755(AQ8&$*6FG=;"U`6!2@2!8#
M*#DO.[G/FV:T:E)66*S,:RI9*T6I46GGEH*DFU*L,QH(ACFK59A4N972N*>9
MHU/NJI675SQNM4Y66FW%XE8EH0%*F9DS,5G-[+,PJ::@S'D_6Z9I]UNGJN15
MC:]890L-O\DHE3?*)5@49ID8K*+(\PJ:)G,&BQ5-L/NLHJ63>S4);4E+S1F9
MMN!2#.Z&N<7,W,JK*<P8GR=515#U+4-SOP/,+;<1/3A4(KL[SWG'FE;6YFQZ
MK65#^85;S]72V?\`+5+KCJG'V+!\RZI;=@X-D4=-SCS*JS!O+V4T]*BIJ'GT
MTS"``EBG2ZM0992$@);;"4```)L$4?-W-\SJZK+\NQ>J4KU2\[3TV/OO5V5K
M4VSB^-R:4STSA>8\U<QJLLJ'&ULK=I*AVG<4RY+&TI;*T*4VO",:"2E4A,&0
MZ#7.+F;F55E.8,3Y.JHJAZEJ&YWX'F%MN(GIPJ$5V=Y[SCS2MK<S8]5K*A_,
M*MY^KI;/^6J77'5./L6#YEU2V[!P;(:YJOYA4KRMAU3[5&I]TTK;R@4J>;IR
MHLH=4DD*<2@+()!,B85S11F%2,J6_P"M*H@^Z*153@#?K!IL7(E_DTI;Y4HY
M3``G%A`$/\U:7,*EO*ZIQ+SU&E]U-*\ZB6!UVG"PTXXC"G"M:"I,A(B0CF;[
M,^9^=/T7//(N=5;FJD4R:RG?I:9RE?;9J6JY#:&0LK<"0EFH+R;2I"4VPWFW
MM$SW,<_JFD<FA[,:VIKG4(G/`ARI==6E$[<(($[9=!G*LJYXYY2TM,A+33+6
M;5[;33:$A*&VVT5"4(0A("4H2`E*0```(=S3.*AVKJ7CB<>><6ZZXJ4L2W%E
M2U&0`FHDR$4=%GF85-:SE[08I6WWW7D4S(N9ITN*4EEH2$FVPE`E=#F3<P.=
MF<Y%1NDJ6QE^:5U$RM1L*EM4S[:%$B\E))TP]FF:ON5-34+4XZ\ZM3CKBU&:
MEN.+)6M:B25*422;28_P$CG?G:<B".2_IPS6N%!R=W)^J<OZO@E\3D\.M%;E
M639A4TE+F2$MU;++[K354V@DI;J&T*2A]"224I="D@DD`$F*W)\AS.KHJ3,T
M!NL8IZEYEFK;`4`W4M-K2A]`"U@)=2I("U"7",T\U>;'/7/LNRM*2E-'2YQF
M%/2A)`24BG:J$,A)2`"`B1``NA/.K(\RJJ/-$*<4FL8J'F:I*G4J0ZH5#:TN
MA3B%K0X0N:TK4E4PH@J==45+425*)))),R23:23:2;28]F?^7_V4U#E1E'-+
M+G*O,GU,N,"IS_,G"]784NA+CC-&HK;IWBE.)+[B0"A"#_HBGB)WA$X(C=AG
M]/\`9_U4)XB=X=':,,_I_L_ZJ$C\Q.\(D.@"=?>AG]/]GW!!493(&V;A_J';
M*3,%([`EO]'%#;8O2"3MREO>X-)(R/+I6==+=I&Z1$Q_J&*6B"DZ#:.T1NQW
MJ-Q7RH[U&XKY42`0-<`]LD=B"XX9J-Y/N"W3MD$-(ME^4HDD;@3%.\#-6!(5
M;\8#"9[)!/3!ZL<#:20`5&0F9V=@G8!@.-D*2H`@BT$&T$'4,*-.L+"%%"I:
M%"\'7$Q"*>H=2A;MB4DVFV5FW8-4]!=0\9(0"HG6`F83F3LVFU)Q<.0(3H)D
M2+1(BVXC39`?I5AQ!N(,Q[]:%4J%@N(`*DZ0#<3L].NB:=2IU%JD@VB[>F)Z
MG2<O6+#:)@3,[S<+`=2&4OSF^XEM,A/A*NG:)#7MV.@B@6L!YP$I3;,@3)-T
MM!TZ.D&7E8Y8IQ8;9X=6<I:-6?06]A*L"2J0O,A.0G(3.BV&ZVG[QP3$[QH(
M.N#,'7'^H8_TZJ2QK%H']8DRVDP>6=-2G42Z9>"K#N`06*I!;6-"A(V]J$U.
M7M+`-R\00+Y6$D3M&B!RU>$IU%3>/ZX'85MP$OK"U"]03AGM3._TE(RX)I75
M-`C6(6#V(>YNU9FJG.)HGXS1,QN3VIR^+%;][>WD1F&:-SG220R1JM'&X1LV
MRXVZS6I_>)!.LJY0VE`B$4:#(U+J&]HF9W@-N*AM`D$MR`U`)`0U1+^SUS:%
MMG0EW",2?TNV@:L5OFFMX0IREI&TH23(+6<:P-(";$ST`F/ZFTG"<*B4DSDI
M,YB>I98=0P*O+:1)2D<(K41B4+TMB\R_*)D3,2F(_K3H*$I!FF\X@<.$73F9
M2-EAF96R_J*Z-'(@8BC&>5";YFR5@M(E/6C^KH/S>`KU[`9IV004[,4/.1Z>
M)]Q1?/YKUJ3L!/"V2-OUP)Q<-*2-8FT[(T0,R?HPFE)$P5?.I22`%*%PG,<&
M\&PD7Q1J90DM%UM3:L1FI9F0"-`UX]8S6F:4OE4I""<:)&4E6CO@9[\XH7R"
MH(J6U22)J,IF0&DF5@U8169E2I13+(!PKQ.-SN*M!V`!;9,&4Z6EY)"BXA:@
MX0,:0`;$F5@.FW3"<JRQH/5"DXS,R0A.JH]JR\:H!;RW.64MJ>GR:T*)0HCX
MMMH.B^\BR1!BI6VPV7RTG$DK.$)X,B#*TW6:YA%$ME'*&GQER4UCAD%`5*>&
M8GVH5E>3M)=<;`+BEJDA$[A9:2=;M&2TY@QR+B#*PXDJ$IA23J:"#=V!799\
M6G?5AUD+F4C8X).R3_J(IZL"Q:"G;09[R^QK0Q2D2+;:0=D`3[,^FHOO;.\N
M&L]HA\]2&9'Y37QDG6`).P5:8S#,V[)ONE$_REI1@LV2"=:<-M,U#;84,12I
MK$05VD*.(3(G*[1**K(*@S4PK&G1-"Y3D-`N-YM5?%)4'O6ZALG8MM[$57$.
M^(9:;L=0VVMLW$+2@2MT3NUIST14U;B2%\BV%"[AIDE6Z1/6G*',SS+,%TP"
ME#DVU);#8%P,TE2B=&DZ)FR'/_.[T4W%5XZH6ML8N3?4M0U4A4CM"<SK"<+K
M0\E2"@R$QB)(L3AOQ3L(E9;.P&*'(4\%VM62?S6\17,B_2E1UL0A=$Y4-J1A
ML2&L/>R*0#BLM`$X9=4>&AQM"M7$@RMUR)*VXJ>*GQTQEKJ[$I>9))N`PWG<
MC$RM*P'6P2D@R,P9&6F1!EJ$10U#D\+=2A1D)F29DV;`A5/2N)=74%`0$D$G
MAI5<+=$K=,A?&7-*O2PL'9"2(?56*"$U+2.34JP32$@IF;`24DZ+9:2)Y?14
M:@XMISE5E)F$I3(VD78I73U)WB=4JH6$!3*)%1`!E@G(G8.X=2&U),P:2P_^
M<5&84M8H(4\I+B"H@!2>$9`F^6(`">K9886FE<#G)D!13:`2)RG<=>1,KC;&
M:5`[TNI2-E&,'?'^D2LNRM"26C):U@F:M*4@$6"XDWF8`$IFYKP#\N+FO`/R
MXN:\`_+BYKP#\N`2EDC4P*M_7A-:VG`H$I6F_"H`$R.D$$$'4-MH/N!2I`G@
M?;*N(3)7:W.G2*A`6$*"DS$Y*%Q&N)F1B1M!CU4,(#>+%APC#BU973EIZ'K8
M0GE2,..7"PZD[Y0[1?&4)IXPM3V1(ZQ,-M9FWPE(`<0J1F189R)!!E/;@-H$
MDI```N`%@`V(74,MI2MSOE``%6FTZ;;=F/6U4[9<G/%A%^KJ3UY3G!9:0$H5
M,D`2!*KYC7TP&*=(0A-P`D!IL$<C3H"$$DR`D)F^S7TQRZ*9L*G.>$6'5`N&
MT(35+0DN(!"5$<(`W@'1.9Z"F>11@4K&1A$BK\HC5UX+%0D+0J\$3!TVB/57
MVTK;D!A(F++K-;1J1ZHAA`:GBPR$L6KKFP6ZT(4\@**#B3,3DH:1J&/6F*="
M7+\02)@G4U-J4)J5(!<0"$JE:`;P#KQR58VEQ(N"@#+8U-J"FB:2W._")$[)
MO.V82NL92X4W$BV6I/4UKH%2$)#B4X`J0F$SGA!U)Z('KK27,-Q(M&P;]J%)
MR]D#""4H2`G$J5@T"9.DG;A+=1Y9PEQR[OU7BRRP2!E9,6?Z19B1^6[VX[X[
MICOCNF.^.Z8[X[I@!2B1(Z3%1YW]A/\`JFS!-'3N.S<<$TH6H`JF1,I!E,$'
M8C[([]$[]7'V1WZ)WZN/LCOT3OU<?9'?HG?JX-54TKJ4)29GDG``-4DH``&D
MDP^LBPO&6O)")_ZIETU34(;=L*@;YD"1,A:<(&O*6M'VQO=/<C[8WNGN1]L;
MW3W(^V-[I[D.)75(4"E4PDF9$C,"R\W#7AI63R%.!)(&C5!G;BG/%.TFV9G/
M_5-7N`VI6X1M3EO1WPW!W([X;@[D=\-P=R.^&X.Y')NF8D=`$/IT!X]E".Y[
M@A3ID#=[Q`6@S!N/^H3,$I$R5N]N/)+\$]R/)+\$]R/)+\$]R/)+\$]R`IQ"
MDB1M((WXJ/._L)Z_44J`7*P$B>YI@LN&8.[L6:(`)NNA(424"\;.IMVQRC>Q
M;?\`Z@U9A0.AI;G?I4"4D_E`B9!.D2()MLC[0S^O\F/M#/Z_R8^T,_K_`"8^
MT,_K_)@!RH:`TD!9.Y(3W1":"F)5(E2E&PJ493)&BP``:``)F_K]3B9R.KK6
M=%+5V(RCDV]DSTG_`%4*4E$DV6@676ZU\^AA;!4=:$N+.'21I%OOV/\`526U
M7$2.W!*N'/5T1P0!L#_[R?\`_]H`"`$!`08_`/V>JNNJFB@BF=5994Y4TDDD
MRB=1550X@!2E`!$QA'0`Y1J8M[!>+8AS[D7"]CD[PR&^>R$=-13%4S87C"V+
M=59*HF7.43H'5DCZ)[HG2WC"0A8CB:N1&[<=7D^;LAGR0L#!.,:OG3LI$IE-
M.WV2(NHLA!$CQLH!E4R@"Z)Q,FHBXB[AMZ483<%-L&LI$2\6Z1>QTG'/40<-
M'K)VW$Q%$U"&`Q#E$0$!_P"%DW9[*88NKGMN*M^;GH5%8%'T3%W4N_;6Z\?)
ME]H5V>,?@B`CO"")AT`HE$?IY?3:!CY-R%W3UGVG-RD8LJ@-NP#J:)+2$@_.
MCRBV=BR3AUB".Z?RT"FU*(@-04*X?DBV\Q,QD6O)J(*.4XY&0>D:*OU&R0@9
M0J)3BH)"B`F`-`'4:L/$T'(/I:-L:WVT*E*R.Z#R26(8SE\_52()BI`LNHJH
M1$IA*D42IE$0*`C_`,*_G4,'>[!5K7<X\QU;UI,E5163;3G"2NUQW=<:Q/O&
M*1124NFXG:R9`+O`G[,!,C]/;UP]=KN2CX.\V+%!>0B%$TY"/>Q$NWN"&?M^
MN*8A^I>M&ZITCANJ%*9,=`,(A.6*VBH.-L>-EI%./RS<$S'M[=E8!NMO1TDA
M#Q"KV2!TZ0$@@S\ET35WDU54R%%4(BZLG2;[,-ZQ3YA*LDG::L#9$9(1S@SE
ML=&WFJIU'H`?JQ.61<*HJ;@:MRE,8H_\*Y6_,NW]:=@VU%1TG(F>W5<<);P2
M(13(SYPPB/=MPW*Y=&*4"I-TSB<YS%*`:F"L.\363;BBK9B\RYJR6VRK,3TP
MSBK>:)\0K27BWTA/3DAU**#5E+RS214<*F2(46X&4$J>\%,YVVIJ)N&$D$BK
ML)B#D6<M%/D#!J59G(,#J(JD'F,0XA_Q2J+*&W4TB'44-H([I"%WC&T+J(Z`
M&P`J#S+@:_(G).,[C>3\?#77#)2+9H\>VO/N;8G6PM)=!LZ2.@]:+I:+($WR
M@55/>243.:I:,@[A=6G,/F*[>-N1DPBY1W"NU"Z(R"$=-)+M%C)CR]6X2,0V
MP0J85Q)\\M<@QSTR_N?8KZPU>%UBR:G#4D4]OOALZ]V]1'0$SG7B1,9,3%4!
M74V_<60;\Q0ZX@(Z+:N7T[D/'^6(/)DDLS9(G>+NC0MRO&EU."$("IQ,$.8"
MZ#O;HF+O6CC/'-MRMXW[?MQ1%I6?:T(W%U+3]Q3KTD=$Q;%'4`$ZRRA2@)C`
M4H")CF*4!$&=S6;<S#@G?+*IN!N-]Q(25IW&FBF!5DW)$N'I6>>D6Y`!))P9
M$X'``4%(/9!$+<1'SL5W9PM]J9M[H8Y-@FP9T'*;?=`Q#YCR(:0N)43EWRB8
M$$1UT.;?'D#Z;<9W"SQ#7"E<&4<&Y7_*JPIHL1$V^2X^'[(K-.0QXHTC89--
M$QXY(J17JH`8Q3/$4E#J+$44-_PMXGN!5\?W-P9QI(2_'-PCH**()1L+D-<W
MD/$]B>')J&ANO0)/1T:V3(BSCFQC;HF6,8?14163(LBL0Z2J2I"J)*I*%W%$
MU$SZ@8I@$0$!#00JYL.NHY56"X-K_P")FZ%DCAO%/!6"X?XXQ[,B943FZL[Z
M:@GJ)A$3#J340$1^G/!SQWLM(VS+EE'/"-Q(O"'(V:&LF_U3R>/;CF3$)R(1
M4D5P]>.5#:F!HQ0`=`*'_"ZR^,3"##RGB,^;OR"SXI,<E25\G7N.Q+<(3_'?
M'+E<$U3F8S-M(K+NFR29CN3L46Y0'K!*.+<[XW?>Z%C9;L6VK^MI<YT#.48Z
MY(M.1+'2)6QSD3>-#G,T>H;PBDNFHD;V1!#TGSC'%FK$F80N;\4<,B%B.4FX
ME9KNY:*?1V844UA3*'6&D[0AWZQ2J',*CLQC[@"D`_3C,F"9`C8'-]V<^;VV
M[=B)4(N]HDY)VR)=50H;Q2-I9LS56W>4R8')L,(#CB;NTSM/*6-_+L+9@CY(
M5/=AAD7&1B04BK-`KH8';YH#*47*(>Q.Y,3:4?\`A:X9O&Z#MF[05;.FKE)-
M=LY;+IBDNW<(*@)3D.41*<A@$!`1`0TKB^^:8N=TNA;^'[F>\3_!D61="J:5
MX3LW3ZDA(VM#=:4AU26C<Z[AD]<"&JKMXXW?M:0?3[*V(U!&/Q)Q_6<?...T
MC%4)',<]6$DK_B;!L3G'JP7DFHO)EZ8.4148HAL*'IEI'*.2K6M%%!XR8*-7
MK\'4N#R11%RS0+`QA5WQA.D4RP"5N(`F`J"($`35*XKMJ2G+>E$U%$[3F;T;
M14!"7^HFY(T\EM@ZKP[CRI4Q^L:LW:"*ZR7LBD!0#I%_X3<+GSJF-HQX^N?@
M;R,WBLZQ$,GK)WUPA9B?H6;E>%%$A3^5+1*SEO(1Y52"FT!9X^$2BCK5OWA:
MLLQG[7NN$BKDMN=C%RN8V:@)U@G*0\M'N2<BB#ENJFLD<.0Q3`(;?37=?USN
M3,[:L>V)^\+A>%*!S-8.VHI6:EG)2&$H"*;=!0P`)@UTVA7#5Q)3ZC-6Z<AV
M&HG>1V"94&Q[VLV?>V'>*I4$RD*F*DE%NE!(0A"`)OM9"DW2A](7#2_\R63#
M233?\JA&DD-PW"V$FNH.+<MDCQ\01T$"@9N`B(:!J-*-[6M[)M\K%UZMVS@X
MJ`AU``#:`+B>>I/"B(@7_P"0::"(ZZANBH5K@*Y%FX&T25<7Y&-ECDYC*()Q
MBI2C]0%#=-?)^GOC#C_Q17R?I[XPX_\`%%?)^GOC#C_Q17R?I[XPX_\`%%?)
M^GOC#C_Q17R?I[XPX_\`%%?)^GOC#C_Q17R?I[XPX_\`%%?)^GOC#C_Q17R?
MI[XPX_\`%%?)^GOC#C_Q17R?I[XPX_\`%%?)^GOC#C_Q17R?I[XPX_\`%%?)
M^GOC#C_Q17R?I[XPX_\`%%?)^GOC#C_Q16)<B6)B&3LK+O#)EFWLSV#=+JZV
MDRD+2(5+^5=K/FK=@V4%C((IMUG92J^S\E(0P"41"HR:8X`GC,Y5BU?MQ'(D
M<)@3=(@J4A](GD,77=,',("%?)^GOC#C_P`45\GZ>^,./_%%?)^GOC#C_P`4
M5*FA,!OF\U[G/`AUY:^F[R+1E3-S%CE9)HTCD%56Y5A(*R22Z9S$U*50AA`P
M77?UU._+;CO*X)6Y)IR'6`D>0EWIWK@C9-4QQ(B03]6BEO"!$P*0.0H4UD&#
ME=F^8N4'C)XU5.@Y:.VJH+MG+=9,0,0Z9R@8ABB`@(`(<M6Q;N5,9RN1;XB&
MJ[.6O1O=,;;XSR1'B@QCEW%DC52E<%:BBDX4`_VU0IE1`#'$`^3]/?&''_BB
MOD_3WQAQ_P"**^3]/?&''_BBOD_3WQAQ_P"**^3]/?&''_BBOD_3WQAQ_P"*
M*^3]/?&''_BBOD_3WQAQ_P"***!^'^X"D$P`<Q,@QQS%+K[(2D&**`B`;`$P
M:^J%$;W1864[6ZQ0"`\;,K<N&/0((Z"JZ,@_;N0``T'1)JH/U/509VSFFU&T
MDX*7<B[L.^LA\98W_P`E0)=Z+(BZH#R;K8ZFNTHB'+2:Z"B:R*R9%45DCE42
M524*!TU$U""(&*8!`0$!T$.4/^!!IN^[OMFS(<HF+[J73.QD`P$Y0U%,CJ45
M2(8W*&A2B(CJ&@<M.$V=\3-_/FP&WF%B6O*/Q4.4=-QO*SH1T<H(Z<AB/1+_
M`-U1@M["U^RB8'*!#34];T"<R?+O&,1B$D`"')H4#"`ZCRAIR_)^GOC#C_Q1
M7R?I[XPX_P#%%?)^GOC#C_Q17R?I[XPX_P#%%?)^GOC#C_Q17R?I[XPX_P#%
M%?)^GOC#C_Q17R?I[XPX_P#%%?)^GOC#C_Q17R?I[XPX_P#%%?)^GOC#C_Q1
M7R?I[XPX_P#%%?)^GOC#C_Q17R?I[XPX_P#%%?)^GOC#C_Q15[8QOOAGEY^R
M,B6E<5CWA!N<B,BMYBV+KB%H*=C%CIQ(&*5=JNJF)BB!@UU`0$`&I+@GR;CR
MXLB75PHW')619UROKU91LM+X+DWBDOAX[Q!2+,506$8H6*(9`"ID;MVI=THF
M`!^3]/?&''_BBOD_3WQAQ_XHKY/T]\8<?^**^3]/?&''_BBOD_3WQAQ_XHKB
M8L.WL13%I3N5L=O\2,)Q>]VL@1HVR2LG:=P_R-O'-S'$8IR_T`%B^KRZ;HW+
MP_7'CJ4OY:P,Q7/-V\]:76VA$8BTK\BV,PWB/(W#%T(C[KI33H5`4`!Z[3=`
M2B)OD_3WQAQ_XHKY/T]\8<?^**^3]/?&''_BBOD_3WQAQ_XHKY/T]\8<?^**
M^3]/?&''_BBOD_3WQAQ_XHKY/T]\8<?^**^3]/?&''_BBOD_3WQAQ_XHKY/T
M]\8<?^***$_A*^(Q'K#`8\/<D!.*`EU>I3E2>IQP"83^Q$N^``'LMX1]C224
MA=]R8_=K[H)-KYM*20+OB&HD5D;8]U&26@!RF5<E+S`81$`H)?'M\6G>\;N$
M.=W:UP1<ZDAO\@$=>YRJ@HG`0$IDU0*8I@$I@`P"`?L`3&$"E*`B(B(````:
MB(B-2-HXQ;M\P9`9F5:NSQS_`,FL6WWI!%,Z<E<*!5!?+)&T$[:/`Q=0,FHY
M04*(`M:L;(7I<39^</\`Z7&*XV3BK59M5QW0"5:19C'5;%$##Y1-.U@(&HBJ
M4H<B%T<268L5<.MNJD%04K@GHV>N+5-/K5FY&J3II''4TW2D(WE5CB8=`(([
MH&!![??$'GZ71U3<#9K&&MBUSKE2$/8GFV\8X!/?'45$'K@.0N[O!O;QVUM<
M#\]/@/7=7)W9Q$9$A')#"!>IZR-M\[A(Y0'>U*"Q1T`/9#K[$QF7!%9C=N(%
MW$G6<L\/%BB!?9B9=&70*.HZB``F&@<G+MKY%-A_'1GS\>U\BFP_CHSY^/:^
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MHKO5DD@(J[62:32:13J&`3F*F0I`$="E`-`KY%-A_'1GS\>U\BFP_CHSY^/:
M^138?QT9\_'M?(IL/XZ,^?CVOD4V'\=&?/Q[7R*;#^.C/GX]KY%-A_'1GS\>
MTF*_!-8ZB(*$%9-+-N>D53I`8!4(FL>:4`AA#4`,)#``\HE'9743'`89$5"K
ME/(PO$UECKF^\F((*-H^2(H0QRFTU%182\XE'3=%-*88\1V`Y`P@)UV<C&7M
M;2!A+N%U<*-I:15(`COG`&:1N30IN72EI?A2XGL89CZM%1RI:4TNG;5U-4B%
MU*B=-DJ\/UI]H>7,V1`YS:<M(HK'R)C!KY64I&+T?=[&5Q*%$QS(I%$SR">G
M$F_J9`PKIE,(E,F8=:86SQ"6XECR6<"DW)?5ME>R5E+N#%`N_+1*@K/XTIC\
M@'(=VF&N\J=%,HG!A-0DBQEXB4:HOHV4C':#Z/D&3D@*MW;-XV,9-5,Y1`Q3
MD,("'*`_\!"W+E2Z4(<'15PA8%H3W0N>Y%T`#K&T%"(B"BNZ)B%47.)$$A,4
M5E4P,`TY@<+1B>(;:5WD/=C>;3E_R*9PW!$)!9,6L>!@'D(S1,N0>4KOFK\M
M9F'G6<=)`5RYR+FJ?D8I-PV4U5\N(,UY1+.T-W>."[9FJEI^W#4->JSOQB*7
M9<0%`'%J8(AF<NX9.2_PK-2:*G-H@8``1WGJ#,>4`W-=-[J;<X<\X90.@=</
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MGX]KY%-A_'1GS\>T,O+\";671T5,5M9UY\4EXN]$0`RAG!+=DW!&Y0`=>L=*
M)$'0=##H-.XZU?FT$I.2;"9$Q+RSGFRRP27`=T3*-&TW)K[I=NX<J9C;!W-H
M1ME1'#OB'`EF1%S-;H01L&X<S71=,HY:1CJ-08W%.Y'N>48K-B@Z46*5G#M#
M]84@F.8"Z#<\PSQ+C/,D)>3:&:3UJY,>Y-C69`@U7*C)[#2.,;AM]RBZ`':Q
M-]R=RENF_@=>6FK2^/FRX)DN<Q$5'5E\0F;YX[E4X[I1:PTO,,!*)A$"E3%X
M<1_Y7+I0O(+@*7A"@W!R!;SNGBDMANJD8P%#R68?RON<X-R@/5MWBAM.730!
M$/D4V'\=&?/Q[7R*;#^.C/GX]KY%-A_'1GS\>U\BFP_CHSY^/:^138?QT9\_
M'M?(IL/XZ,^?CVOD4V'\=&?/Q[7R*;#^.C/GX]I/W;X$[?D``R@JA%<1.;8<
M3E$@@D"8NW+[=$IM!,(@;>#4``NNH`A<W"OE?&B*J2:9WV/<QRE\.&JIM\BB
MR;>^%6Q#;NI3`(@.HAIU8!J!RM\-\6L_C>Y7`CY/;6=(>*1*=RH43H1Z4H*<
M&U'>'[644';HX#H&ZH80`R-\V*U5OB,8`D^C;VP=<$@_F&Z)P!PV>-8MH5K,
M!H``<RK-NJF337K=-TPI6YF)H.7;:9+BR=^[6Y"9#ANH4ZE<B<\FEH[.F;?%
M1*4046.8`)Y2D`<AY3&-SD<2C)!-:<LZ83)%WA;XJ:`'NC$&.<%$M1`H.VBB
MS8QO8E6$X&*'T6<OB^)QC;EJVXQ4D9B8D5!3;M6Z8@4I2E*`G555.)4D$$BF
M454,5-,ICF*45\88@9S]G8RE7P0[2%B"K*7[D<[M4&C5M.&BA44(DY$P$)#L
MC&*<3[JYW([@$+FOCIO9OC6SFP(N&>-V4F5*?E3J%Z]O'SLDPZU<'"Q2F`(B
M((H[$H[QEVYTSI@IB[@SQQ!X-QZU*=NE<BL+%GO"1$P=6L_:QI.N9M%50UZQ
MRZ,]=G'17KD5=0`UVW6O/2#N3$.ONW),W(K/W*8&$Y!UDQ7D%$_9"*8E1%/E
M]B(`-)K7?<\M,N``ICLX5)"(8%-^V246<`X65+ZAB"B/U`V4`%LM-R<`+O*O
M9B?=&.)1U`135==6'J#ND`!Y]:W"8\M<Q=1-JM%(N3ZC_P#='&\;3ZFNE?Y=
MVC_4;+][7^7=H_U&R_>U_EW:/]1LOWM?Y=VC_4;+][7^7=H_U&R_>U_EW:/]
M1LOWM?Y=VC_4;+][7^7=H_U&R_>U_EW:/]1LOWM?Y=VC_4;+][7^7=H_U&R_
M>U_EW:/]1LOWM?Y=VC_4;+][7^7=H_U&R_>U_EW:/]1LOWM?Y=VC_4;+][7^
M7=H_U&R_>UP_YX1M&WF^.YF:/AG+4::,:$AT8^Z-]>UKH=(;FX3R-QURKAP;
ME$J*"0#H;2O\N[1_J-E^]K_+NT?ZC9?O:_R[M'^HV7[VO\N[1_J-E^]KK?\`
M#>S^L_Y?N"QWMFFW<]2O\N[1_J-E^]K_`"[M'^HV7[VO\N[1_J-E^]K_`"[M
M'^HV7[VO\N[1_J-E^]K_`"[M'^HV7[VO\N[1_J-E^]K_`"[M'^HV7[VO\N[1
M_J-E^]HQ#8[M0"G`2B)(9JD<`'_DJ)@!BC]4!`:-UMBLDA.(#O,Y&;8"42EW
M2B0&3H@!ZHAIH(\H@(TL>"G+E@G!]>I*LHRF(]$=H?R95-%<P=+OMTG/VR9>
M;"-6\J93-FNGC:>CSI?P;@K!/JW9%=H@+0RN[SF"EK#S_%H<0&,WJ814U$WH
MW9.KM;,BB"3A$\I))'))@`@)E6\RFL=0P`7RA(-1J6R/P178ULZ_&")W\]AF
MY'1V35)50=X&QXIR=PXB#JGWB(.6ZSB+.?1%(4"E.<KG']V1,Z:V(R2$MVX<
MO`RK9L4JQ]592U'ZA5O(552ZJH/&0J-'0"50Y'!.K,#2_<9S7NC'',1M+13P
MB;:?MF6%`JZT+<$<0Y^I<$`P:&(<Z2A?9HJ*)B!Q_P"`+['>.D(Z^,S=3N/6
MZZBBELV#UR0*(+W*HV$IG+PQ3`9*,05(8H?;'"B0=6FO(7[.RLF[C';T$+FR
MW>952P,>DDJ)CPUM,$`3*X.W*8W41<:1-!#4I5#-B'*85[:Q1:"/$7Q`Q0"E
M)WS.N8Y[$VQ,)@!%6Y)I--5NR504WM6D,V,N`;S=V^*J7D=14I-3TE!*J%,%
M@V6FX@;#C4C&$[<))HFIU:VZ(&ZMS+N5E`Y0*H`<E).;UN!C`(#NF-&Q)/=>
M2$NGLDE71A3;)&U_;$%</J4!'T9,SYP*`&5E9U\W,)N74P%@Q9E#HTY@^KJ!
MDK`A#B!M_P#E17;X-=--!*]54`0_[D0T^I7^7=H_U&R_>U_EW:/]1LOWM?Y=
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M2T$[Q>6JI-LHAY8]R"ZMM5F-M%=#%MS>Z[R(.1PDT(<``4@-NJ:5G/(V>\>1
M^0H"R'UD6Q8\;+/IYM&)STBB_EKH=.VD2Z;).12;DC"$2=%6)HL<=T@@`F*G
M96`<1VF!2"GO6]8-N1"IRF]OUJ[%N0YQ-^V$YA$><1K_`"[M'^HV7[VO\N[1
M_J-E^]K_`"[M'^HV7[VO\N[1_J-E^]K_`"[M'^HV7[VO\N[1_J-E^]K_`"[M
M'^HV7[VO\N[1_J-E^]K_`"[M'^HV7[VC==C^!)O;NODB"[#3=V;OD*B>GU=-
M->?6A\DB9>WU#"83*PLV\.83&,)A$$IORQ,H<N@%*0```#0*4<61=+:1*4!,
M6,N%`S!SH4.4B<FR!1)0QAV`=!(H<YN>D&UNW-=UF,BN#'&VI0_NW84P('*=
MSU<0\%>-5,<`W3N6FZL4!'=5((ZTPM7BHLEEAG+[A$C)AF"VUD(N(7>$2%)N
M=>YUP.=LEIKNLYY)RS3V@Y*<2B$5DZS+CDIBRVSY-U:F7[&.\8.(<ZY]QFTN
MA!J8XL%%R&*0!%55FY*?JRJG,8Z)8C$N<7$=`956\GCK<NM,B4?!9%<[IBD:
MN6Z92H,)=3=*!4B"5!TH82MRHJ"FW-]#F[NNN6:05MVY&.YB;EWQQ3:Q\<Q1
M%=RX5$H"8="@.Z0A1,8="E*8P@`PN.\=PLZ6Q"SI8_'&.(\N_*W'*GWD$[GN
M=-`PIG>'3$YBE,<4&"`G`#_=#A6,O')#:,RAQ:W7$+.X*WF2Q526XDX3,V40
MBG2I#ECHY,PF0=2YTA<O#`JFU3%(JJ:;NX+FDG=P2(J*=2551=G9EAP[E;>2
MC8MKJ=-FV*!="ID`Z[@Q!4.*ZV^<6K]RV2N6ZDP*H><DD"G2:+Z!J$/'G$R:
M`%'VJH[RVWV8`.Z'9K6SNUSC7M>[7M>_7M>_7M>_7M>_7M>_7M>_7M>_7M>_
M7M>_7M>_7M>_7M>_7M>_7M>_7M>_7M>_2BRQDT444SJJJJG*FDDDF7?4444.
M(`4I0`1$1'0`J\[8MB<@KG@[[MMX%K7%$R#:2B"W#&+>6V_()OF9CET;23='
MKRE'4`*=,VFHA5YW_-+N6=_XOQGD"RKR2=*+)RC3(-B6\M&MO+3@&^1T\'R%
MT8=/8*+Z"(;HB&#6$BNZ=/SXRM*3>*O71WCD',[$IS:R"CA0=1ZHS@4BAJ(%
M`H%`1``$?:]^O:]^O:]^O:]^O:]^O:]^O:]^O:]^O:]^O:]^O:]^O:]^O:]^
MM@A7J]X?06]W8A-"7%+<;7%'%(UF6Q@#1,3N"AHN0NP$G!3ETUW0`>4(J^+1
MGY2)7BWV_;M^VVHJUT.8.5C)MQ$Y2=<35-=FY!1!<@G3'KDQ.%)X@S,C#8\X
MFH&/4/9=X,FZ"/NV[;(J+&>VSUQP.LB8`$\M;RBWLBB9RU,`I[[5XT=LSQ\M
M'G1;W%;KA9P>SLF6<=P86KMHZ`H`LW6`#G8OB$!9LL!R'(4Y7#<;>R=8$@+R
M#GFX=:U7`A)*#ED2@$G;\RW()@2=M%!ZM4H&$A@W5$C'1.FH;Z?CC+&J[9[F
MBY(P5SO3`BZ9XZA7A=Q":>MU`,5617+J:.:*%$A0#RE<!3ZI)S+YYSQ*N;<P
M-;SN3N*Z+GGY%2/>9"?,ECOIQ-.:>&*=-B10%#2TL)]=[?00/U_6JMD,!<+#
M1SCO"D*A^3HR5O-5;?EKUCDOY*C%P[%L1->.B%0UU;Z%<NP-HY!,IE&YFMP9
M,(XBXPX$6;6LDH=O+/2#[(HRZQ-#-4S!I]J(/7"&H&%$0Y4(BWXIC#QK<H`D
MT8-R-TM0`"BHIN!J=0VGLU#B)C#RF$1Y:V>*OK5L'MU[7OU[7OU[7OU[7OU[
M7OU[7OU[7OU[7OU[7OU[7OU[7OU[7OU[7OU[7OU[7OU$PKZ6BF4S/^7^X42[
MD6C:3FO<IN#N3]R6"QP5<^3)&!5?J2&ZL@@8^@#K6+\X)Z,<-\<L9%</N7#B
M+E./A<\VFU,IA6[GIB_:NNEF9?<!$IM"D(1TN<=1"N&JR6LK)(0EB<(63,E2
M40B]=)1KP;PNB0L8JKMH*H(*CUK1L8-U+K`,F0QA$I2[GM>_7M>_7M>_7$?C
M5)GY=(S^)KM<P#3<ZT5[JMR/-=-HD*37;[ILF@@(<H#R@`B&E6=<"S<Z+_+U
M]7[DET14FXL5`DH6P(D=1Y1359P2#E+FW5=X/;#7M>_7M>_7M>_7M>_7M>_7
MM>_7M>_7M>_7M>_7M>_6P>U7B&ME.(V7CV<I'NB"FY8OVR+QHN0>7=5;N"F*
M8.?E"G-P8M***I"G6=6@X6,=-<0U.8T&\<&$2&]1LL82C^T.70"";$F9&#W(
M&"'PKP4Q:4\T+)RUD(+F%L_)"L98!*JRY3@\A'`=4;V1D>J4%0%FW$]PJODK
MNP//)!-2+&WG:TF>PQ%82GE8M?45S11%2F37(K]OCU2F(MHF`BBVP/FB7(ZR
M"T8A^0%W.QW7-[1\:T$[N#G%C#]LEFZ*9ETW(\KM(J@J_P`H3WW'T(>&>QY,
MQ+8M99H_R>Z9JZ%G+K+H[CK7442'V;:,**:[A,1$#/#`4Y"G9E$5N)C+L8WD
ML_9-B#L<:V,]`49*):R#<KIG"`DI]L;G.0R+R?=[H&;H[C,H=<82.)Z[KNF7
MDA(S<B:7O"ZG*9SM8QLJ;=;1L:AKU:92)E!O'L4Q`B:9```*DF(@TMZVH])A
M'M"@)MT"BX>.!*!57S]P``95=3=#?4-S`!2@!2E*'J>$:V:>&MG=KG[E;/#6
MRMG>K9WJV=ZMG>K9WJV=ZMG>K9WJV=ZMG>K9WJV=ZMG>K9WJV=ZC$.0IR'*)
M#D.4#%.4P:&*8HAH("'((#4OEW@\1;N822<FE<C<,LBZ,VL^[2%)_*Y/'2I@
M,$1*[H:IHI@"9M`(F`I$(R5XF+'QLWF8EAQ6Q]DOCV)<$<\C9_&^;FU^,8C(
M=M3T:'LDS/FON@[4<)E,10QFZ6@F342)$PC,/Y)#QC"*:Z@.OD\>U(T0UUU_
M:D#GK9WJV=ZMG>K9WJV=ZMG>K9WJV=ZMG>K9WJV=ZME;/#7/X:V>KLVULU#U
M!VUL[7.'13N)EV+62C7Z)D'C)XB1=LX2-R[BJ2@"`Z"`"4=H"`"`@(!47>MD
M/91"`2E6C^$F6ZYR2EJ3S5?RMB@9ZB('`2'("C1SH`\FZ81.4#'=X\O9:(M_
MBMQ+&+R5NS_5I-"3J1P30--(MT`#_P`WR)B(M9MJB42M7/4NDR%(9%&GV.\D
M"]@[%N*XALO)\!*"<B=HW"T>#&-+N*ER@FHP6^UO3IZ@JS,<=%#IMQ(4Y#%.
M0Y0.0Y!`Q3E,&I3%,'(("'*`A]/KBR7-`W>2:10B+,M]94R9KEO!^B<T3%`)
M!`P(E!-1T\.4=2-TE3%U.!2FF[OR)(2$A:C692NW,=X+JF;J/"/%C*-+5B54
MM`27>E2,W;D2W2-&J9SD``222.WX=,'%;PN!<?.&<$@WMM(6K2^92"$&30C9
M!F($-#,E"`2,;D*)5CE!V;?'R<$6EZ7BT(O>#I$JT='+I@9.V$%BZEWB'VOC
M%'[8<0^U`(D+[+?,.SL^K6S7P!7./1L[M;-.@*V"-;/#6SO5L[U;.]6SO5L[
MU;.]6SO5L[U;.]6SO5L[U;.]6SO5L[U6_'WHYN.TK[Q\^>3N),MV+*N(2_<7
MW,\%NHM*V\_1$"G37.S:>6-52B54$B&(9%=-%=*]N#[YQ5LG*6]<C9%/AJ^<
M!LJ.=,;0_P`3;95";Q@.:6C`16MF7%VV(B[D$3`55`[@NBZ1',D:_P#B%EVZ
MZ=PV7P/XQPU>QA;@DT&^E;V:25TNFIVI10,B]?13IZU^V"()J;A=X$S[NSO5
ML[U;.]6SO58V*;*:"RM6P+:BK8A$#Z"J+.+;%0\H7$H`'6K&`RRNZ`%WS#N@
M`:`&SO5L[U;.]6SO5L[U;.]6SO5L[U;.]6SPUL&OKA6P0\%;-/J\U;/K4O.0
M"+:-OEHD)DG(`5!M/IIEY&$H8-`!30-$'(\I1T*<1)H))'&^2VSE[ABZY5:*
MOVVI!F+Q6TI1?2+=W,SCS%.8Y2$*"4FR*4P.$`U*0ZR:0#:>9,*2"Z&);\D&
M=V8WN&`?&7)9ET(B6?:Q,9,-C&U0W`)(0CGK-XZ`'(`J"V.J=M..SM&>2+3\
MC@\D0C;=3(G*F0$65Q,&P<I&4H1-19$NFB:A5VX&/U.^;Z!>V3$"MUKA;MT(
M*S&;K=,B[N^=/Y'$"JB;^%3:_;'ZZ6H"=%!0H"`B`A<F<<M.A<XYQ$Y4OZ\)
MB?5,+.XKR445G6B<N]<B!5$4#)+2LH)S&`2D336**;G6@4M[RD+3;/36AC")
M<=>DDQME%T91Q<DBU'^"</=#/WH[N^1,$T!$X-R"+&VH%`I4FY`4>O3ID*[E
M7YB@#B1>F+M.<0Y`UT(4"D+H4H!6SE]2OJ^K79KZ&SNU]8*YZV&K8:MAJV&K
M8:MAJV&K8:MAJV&K8:MAJV&K8:MAJV&K8:K$RH^CAMO(-EW?:5QN;@AFJ1?R
MPB[:FF\FK;UU,P%,KGKD41;(OM0<(`)/9*))@@.PU;#5L-6PU;#5L-6PU;#5
ML-6PU;#5L-7/7UPK9W/K>AV:UX^<*[.6I"#F6:3Z+E&RC1ZT6`=Q5%0-!#>+
MH)3%'0Q#E$#%,`&*("`#4'=EGOED9"V)-*>M=^MKY-/6\Y.=L[B94J.[OI.$
M!78/TR[HB`F,3=WB&K'G'EB1MNQ=Z,H>"RK&(=4LK%2I2>Y$9)2JJ)2@#EFZ
M2&!?'-R',5D*90`3&,E9,](*/;TPRX:VJ^4<J]:[>VB[(HM94@H8PZB":*2T
M:'/HT`QA$3ZC]/28NLT[B:MO&DD7'EJQ,8(N?=^_)%XFTN9ZV03UZQ=1\"44
M@!1$#%;%,3053ZV-PEX_>MD\KY1AGD]EBYHQ7JGS5A*B"%PKD42$#ZR!RC#,
M%1V,6BNH%5,0])Y/NAB"H`J);.9.DP,F!D3B5:X3I'`=1`X"FT$=@@94`$>J
M,'9R4'J>&O%S=NMGUJV:US!WQKG'H"MAJV&K8:MAJV&K8:MAJV&K8:MAJV&K
M8:MAJV&K8:INS+WMR'NVTKDCUXJ?MNXHUI,0DS'.2[J[*1C7Q#I*IFY!W3E'
ME`!#E`!K/5Y87<S+2V<W$L,S>Q9<?=)#'JEGKS:[UC;=Q.3F>+Q[T99$2-GG
M6*H"V#5RN"A2H[#5L-6PU;#5L-6PU;#5L-6PU;#5L-6PU;#5L-7/W*YO!6S3
MP=WT.3UJ'OAZE#R4?)=O-1&6AVQ27,V1)[)_#-P]A*`4H<JK0.141Y10Y1$`
M1`!O3@/S0MUZ![??3&);B4%-:5BDV"P/3QT<*^@BYAUS!(L"[P[[7RELIHW2
M`A@MN]G*D7"$N>5Q'E1L*ATX\&9Y08QM<`]=H446+XC>03<@43&:@J5,=U<=
M?H%BX1CWH#!V1`)7C/M$C<BEW7,95"/3>D']LTC$TU4!#30KU3774-,2<.T2
MMY#DCB"1&_\`)HH'`CYI!OB-I238/0+H=(YQ&,A0T#<52:/":F`3:O,E22`&
M>S`N(NW=\-1;Q;9849%X0!_;+KD%$!V@5(=!T4&@[7=KPCXJV>IVJ\=<@=L=
MM;.[Z'/6RME;*V5LK96RME;*V5LK96RME;*V5LK96RME;*V5LK96RME;*V5L
MK9Z'UZV=RO5\(5ZH=\/0V<G@H>S4/5J0>-6I5;BM1)::B%2AHLHV1*"DQ'@(
M<I@5;D$Q"!M5(F`<]9MX+[\>?_0MENT)F<M'KC`<\7<S5D5I-&BTCC[)QU!6
MLHB7VI31YSZ:G-JQL6[1]S4;DG)K!U[M#B846LXK,!'PZ@=<4N@I3;5JD*Q@
M*)45%=@&,`_3S*N3R*HHOK5M"17@SN`**!KGD=V&M5%4IM0$JDDY:IB73EUT
MYZN#-%]NBA9V`K;D<D7!+RBIU$"W$Z1<!"O9-RKJ/\G(E(2W6F/KUC0HCO`)
MJG+JD!=)MKWNI55HV6-J>W[!AR]5&1P;@[A5&T8@FF82;I5'`F/R&4$:9QL>
MW2:,6#9!DR:HEW$6S5JD"*""1>8I"%`H!Z@4'>^J-=G<"@Y.U7J^"OK5L"N>
MME;*V5LK96RME;*V5LK96RME;*V5LK96RME;*V5LK947F.W4VR,7,7?DZ`:M
MFRBJ@(L[)R3*V?%*KF6'457+)DV>',``4PK;Q2E*(%#96RME;*V5L]#GKFKL
MTKU/!6ST!Y.D/'2B2I"*I*D,FHFH4ITU$SEW3D.0VH"`@.@@(:#4%>-FJ"V5
MMN=87M9YC'4!%Q%'='!Q!O#%'>,B8H.(YR41U.B(B/\`"5A7BML)J!+6X@+"
M8JRRB12F,E=$&R0.A[K*)B)2O#1ZZ+%1,-AX]77V0&K%MTR+ORRX8J(4LNYU
M#GZQP::L]<83RMX8``.N>-4VK\^G_P`?]`DF)P&0BK\X@6]O:J`*_66-;\ZG
M`E7.0FT"0C`#B0!T``W=[0-ZKTBXIP+AE`3T5B"V"&4%=)$UON0B),4S)\@I
MJ3"K]<-T/:G#E':,3;\6D",?#Q[6.:$Y-[J6J()%.H/.<VF\<P\HF$1'E&@[
MWU`]`.3M?7KU?0V:=-;!'P5L"N;N5S=RN;N5S=RN;N5S=RN;N5S=RN;N5S=R
MN;N5S=RN;N5S=RN;N5S=RN;N5S=RN;N5S=RN;N5S=RN;N5S=RN;N5S=RN;N5
MS=RN;N5S=RN:M@]JO5\-;/KUXZ^KX:[._7@^M0@(`("'*`\H:<X5%W?;I%2%
ML6]HVZHQJB?J@>VX^,5X\@P4U#[6LR77CE1$>4HFJ=NZVW!FK/($/9N6+:?L
M]Y/=7?,P8.))JJ(!J8\C'.70&YA/]2K&OA`$RH7E9ULW4B5(Y5$BI7#"H2Z8
M)J$$0,4`6#0P#H(<H?3RQ;!;K&2=7_D)-Z[(!@`KB"LV*4>/$#$VC_+GD8H`
M[`W---1`0N.8;G\GNGBHRBXMIFY24(F\+:%O.3QTHF8@>R,@)(>3:GU__?PY
MC!5T7XX2`7#AR2V(M0VH&3;-R)R,L8H#R"54YVQ0-S"D8/5KLV5V<E=G)7U.
M^/H;/K5X@K9W:YJYNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY
M7-W*YNY7-W*YNY7-W*YNY7-W*YNY7$-EE-T#1_8^(;[F(-8#]4(W/[@+-+40
M*IJ42BK)*M4@$!U`3<FHZ!6;\0.G@N'F,LM,;J9(J'*)V5O9-MM-!JT1(`Z@
MEY?!2:^NGMUC\H\@!S=RN;N5S=RN;N5S=RN;N5S5L`>BO4Z:V?6KLTH?!]:O
M!71V:4/9R>I43=K=+><VI*`@[.4G*$3."1LH=0X<H[KDC4"@/(&^;337ES;C
MA\`O+CX9[TB,F6D`G$3,;:GW:KF0*4AN7=*F>Y3FW3::G3U*`@`FS=BYPOH1
MC)VS?T.VZP1WS2K5:WKC7!$1T#=!E%%$Q0Y=X`-INEU]-,RYC(%+%1,C)"9R
M?JVQ08LSNA,X4$2[I`W?9CJ&@:CJ%1EYRI1<-\?6!E"^G)E2J'#1A9[E@LLJ
MN&O5^Q=F'K3$/H;0`+O"`A'3DP<7;HCJ>O&45,7E7D#D45*X'0!`!\L<)J<O
MJ:;=*#LY-HT':]:@Y/7&NYK6RO"/UJV=L?K5ZM;.]7K5ZU>M7K5ZU>M7K5ZU
M>M7K5ZU>M7K5ZU>M7K5ZU>M7K5ZU>M7K5ZU>M7K5ZU>M7K5ZU.'CQ=%HT:(*
MN73IRHF@W;-T$Q57<.%U1`I"$*`F.<P@```B(Z4YD++N>$NAFR<F9O%X9^W?
M`T<E$=$G)41$Q!,`"9,3``'+[(@B40'T-G;#;7JAWPKQUV<E#W^CU:'LZ*'N
M]S;5G7(F00&7AG\2N8`]B*D(\*Y2,<0_;"5[N@([0*&FNG)P#Y!=*I.Y)]BV
M_P#'[Q^8RAGS@N*KA86T@F]$P:&W-\X@H(B<YC*&.(Z@(X#D'`B*C>QD($HB
M?K!ZBUI%Q;#4-[U`29D`"_M=G-]/,/6J*Q3(0V.)*X$T`.43IJW-<ZT<LL9,
M`U`#A$IE`1,(#N"``&@Z\#&'D2K()0O#U'95?(F*8A3O\L.2NA*J!BE'K$%6
M#HHE$-2]8(<NNHV2Q,3<7>11)QUJ&AS+3RII8H*?]T1-4B6G-N@'-6S;X.:@
M[5=G*-=G<K9VJY>X%>I]0*V=WEKD\%>M7K5ZU>M7K5ZU>M7K5ZU>M7K5ZU>M
M7K5ZU>M7K5ZU>M0W5EC(ECXSMGK_`"4L_?UU0=HPZCOJ3N09HR,^NW2.L*:9
MSE1(83F`HB!1T&G#1'-#W)\NVU$\3BBS;BN<APT'=%O<K]%C!JZB`AHG*F$.
M03``"`C?/#?B##5[6G`7\]M@9F_+YN*"93`0]LW.SNL(M&T+>)()@+MPR0(J
MJ$T`%3`Y!(H"@@%]W9+8^D,E69DJT6-L7!`Q5RHVU(QK^)FTY6'N9H9VT=HO
M#MTC/FP,U.HWO*>L!P3JQ35:M[QD\I88>K;J:QK[L%S,Q*;@QP(!4I+&Z\X<
M4Q$=>M7;)``:B<"`%%:X2SWBS),L9JH]/;EMWA#.+N;,TN51V]LY95.4;I!S
MJ+LR%Y!Y>0:]:O6KUJ]:N7P5L"O$->I]2MG+ZGH#W_KT/9VZ'NU=L`H3?]U+
M?E6J(:`82.C-#'9*E`>3>(L!#E^J`5F[$#PPC&YJX=<H6EU6\8A`EVD,:09N
ME5">R`$V?NB4!+H("<!`=0T%[&$,;J;FQ9=L4LGO:$$6<E&SZ2HD$>4Q?(Q*
M40#4`,;F$?3Y??MQ*#AEBZ_W:`G+O%!9M:;M9(3%':&\4-0KBPEB=<#J+X+<
MX*L3HK=09)W(N8>!(X$^Z8?M179E0*&@B8H<H;:NM^(%$S6U`:%$1-O`#Z7;
MJFW0#D_^3AJ(\OJ<@C0=GU1H*\'104')T!ZOU?1V=L:YQZ`K9WZ]KW_7KVO?
M]>O:]_UZ]KW_`%Z]KW_7KVO?]>O:]_UZ]KW_`%Z]KW_7KVO?]>O:]_UZ]KW_
M`%Z]KW_7KVO?]>O:]_UZ]KW_`%Z]KW_7KVO?]>O:]_UZ]KW_`%Z]KW_7KVO?
M]>O:]_UZ]KW_`%Z]KW_7KVO?]>O:]_UZD[V?LG,@XZ]&'A6+<"_RF;D$E#,2
MN5#B`)HD!,ZJIQU'=*)2@)A*`MU;XN^>N<6BKE=FE*OUG#5DH\,!G(L66H(H
M@;0H:)$*```%``*``"5SVLXZU!8@-YN`=*K%B;@9`!@3;R"20^W2,<3MUB^S
M3-KH.Z8Y36U<X,5XT+CM^&G@CG(ZNH\)B.3D`9.1T+JHEUG5G'=#E`>0*[-?
M0'LUKL[E=G<KL[84/9LY*M22W`$S2[?(2G$0WBED(=RN8@!Z@^2E$>@*X>'1
ME#[UK9NS3;22:B9#?:IF,B;C.+=8!U*0##[(@E]D8PCJ`%#7%2!B%($;(Y$9
M$,`B(JE4R-*R(G.`[!WG`EY.8`^GEB?`/;'Z0;HK#+7_`/`O"U@6,_ANM_A;
M5&8]IH'5_=?M.77V^OLM`@&(`4`9PL4T`"%W2@#=BFB`%+S!['D"@[.B@[-`
M]`/5\`5X^<?0V:UZG16P1Z:]KWZ]KW_7KVO?]>O:]_UZ]KW_`%Z]KW_7KVO?
M]>O:]_UZ]KW_`%Z]KW_7KVO?]>O:]_UZ]KW_`%Z]KW_7KVO?]>O:]_UZ]KW_
M`%Z]KW_7KVO?]>G,;*Q[.3CGB8HNV$@V0>LG20CJ*3EJY`R9RZ@`[IBB%.5+
MWX5L5)/G>\9Q+V1#KXPFEEC:"#EQ+8U6B5UE`$`]DN<^H!NFU*(@.2>);A\E
M\H1<KCQQ:[V4L&X;BC+HM5>WIV[V5LOUXM5PP)*I+,P?E<F,XDERBDD;V(&`
M3&RC%Y6N&]K>QSBFSX.8?GL%W#1LW)W-<TZ+6`BEY*=8R**351JRE#K`1MUI
MC$)N*$`#"+9PTX>(F_I=#=ZR7RO/7%D'RO<UW/*;<FG0P@;1UZJ*)O<F]KH7
M0L'C;']E8]A2@0I8>Q[6@K3BRE3*!$RECX%!ND`%```H;G('(%>U[_KU[7O^
MO7M>_P"O7M>_6P0Z*^N'CK9IX*[-*[.2NSE]`>[VN<*'ZE#VZQ6P.4XMU)3(
M=NNFX"FJ"J;FP9EBDDMO<AB%6ZHY_5`O)KL''GO#D#S*>^GS5\$N1_,YY7&!
M^I;ESSGMRKV]X8[\(C0=G/0=KO[:#D[.:@[-1]#9ZW37C'9VJ]7IV5]:ME<U
M<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U04XV<O@:
MVW>3)5^P;HJJLEDI1BLP1?OQ(8"I]0H)4TE#%-RK"0-!/RU8SV!LU>Y("$O&
M`=7,]?1BCFUH^-:O2/7Y)I\J7R8IA;D4,D@<PG4,`%(0XCNCH````&@;H:``
M!LY*\85X!^O6RAY/5U^O0]G;H>WZ]#4#_;^+\W92L3_K+Y.\Q(>L>>_V0//5
M[]/+$^`>V/T@W15L?`/P\?H9AJ#M>@':]:NS;0<GJ=L?0^MMKQ!7J5LKFKFK
MFKFKFKFKFKFKFKFKFKFKFKFKFKFKFKFKFKFKFK/F'@0*X=9(Q%D"T8HH@`F1
MGIBV'+6WGJ0"(!UC=\+==/>'=WB!O:AJ%9:RR^;&;R.6,RKQ#,3D`/*+7QG;
MZ$?'+B<?9:A*24VB)!#V/5@(#J80#FKFKFKFKFKFK96RO$-;.U];T!Y/6^K0
M\G3]>A[OUZ&AZ/KA6-RH_:2ES--I%*E]K`J0N'R0IE`FFA1*(E$-FG)LK'GO
M#D#S*>^GS5\$N1_,YY7&!^I;ESSGMRKU]X8[\(C0=G/0=KOT'9RT'>K9ZU;/
M7K9]:MG;&MFO@KF[0:UL'N5SUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUS
MUSUSUSUSUSUSUSTNS>MD7C-RD=!RU=(IN&SA%0NZHBN@J`E.4P<@E,`@(;:?
M3RT--725RH=5G!77)MWUOPXF<^4%*Q8L6[4ZI2AHD!7RK@-SD$!,(F%K%0L8
MQB8QBBFW9Q\8T08L6B")`221;M6Q2D(4I0`I2E*````%;-?#79WZV=JO!]:A
MY.SGKLV4/9]0:'LV5`_V_C/-Z5K$_P"LOD[S$AZQY[_9`\]7OT\L3X![8_2#
M=%6Q\`_#Q^AF&H.UXJ#L^I0=G17>^N/H;/6KLUK9V?5KQ!6P`Z>6O6KGKGKG
MKGKGKGKGKGKGKGKGKGKGKGKGKGKGKGKGKGKGIAB6RTR)V[%79DNY(\J;<C<4
MD\@Y)EL@`S4`NN\+4),&93B/*1(N@`4`*'/7/7/7/7/7K5L`>]7J=-;*V?7"
MMG+X:[.Y79LH:'LV4;H\=8Y^&J:_G;ZL>>\.0/,I[Z?-7P2Y'\SGE<8'ZEN7
M/.>W*O7WACOPB-!T^.@[5!V;:#M>L%=G*-!VO]%!R<OJ>I7J^"O5]#96SOUL
M[];._6SOUL[];._6SOUL[];._6SOUL[];._6SOUL[];._6SOUL[];._6SOUL
M[];._6SOUL[];._6SOUL[];*V=VOK5XP\=>/F&A[.W0\G3]>A[.@:V=G/0]N
MA[.:H'^WT9YO2M8G_67R=YB0]8\]_L@>>KWZ>6)\`]L?I!NBK8^`?AX_0S#4
M':\5=N@[5=G-0=KNUV<M>.MGUQKU.BME;!K9WZV=^MG?K9WZV=^MG?K9WZV=
M^MG?K9WZV=^MG?K9WZV=^MG?K9WZV=^MG?K9WZV=^MG?K9WZV=^MG?K9WZV=
M^MG?K8-;*\0UL[5=G)Z`]_Z]#R=G/0]'@H>D/!1NCQUCGX:IK^=OJQY[PY`\
MRGOI\U?!+D?S.>5Q@?J6Y<\Y[<J]?>&._"(T'3XZ+VJ#LYZ#M=_90=G2-!V:
M!6SUZ[-*V=L=E>KW@K8%<W<KF[E<W<KF[E<W<KF[E<W<KF[E<W<KF[E<W<KF
M[E<W<KF[E<W<KF[E<W<KF[E<W<KF[E<W<KF[E<W<KF[E<W<KF[E;`K9IX*V=
MRO6H>3M5X/K5V=L*'LY!H>YXJ&AZ/%4#_;Z,\WI6L3_K+Y.\Q(>L>>_V0//5
M[]/+$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#M4'9]2@[.D:#LTK9VO4#T-G:"
MO4Z-O=K9W:V!W*YNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY7
M-W*YNY7-W*XR5%I0)$,8<9V8+5M'5?KQ_P`)G:[=SCEZ&IS[A5RI/P`A/8`)
M!W!,&HUS=RN;N5S=RN;N5S=RN;N5S=RN;N5S=RMG<KZ_UZV<OU?%0\E;.7PU
MV=L*[-@UV<U#T>M0]JC='CK'/PU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC`_4M
MRYYSVY5Z^\,=^$1H.GQT7M4%!VN_LKL[5;/4UZ?0#DZ`]3IKU?!6SZU>M6P:
MV#6P:V#6P:V#6P:V#6P:V#6P:V#6P:V#6P:V#6P:FKYO22")MN!037?O.J6<
M*;SAP1FT;-VS<ICJ*K+*)I)$*'*8P:Z!J(2$9ARS'$H\%-L5C=5XB9I&)J*`
M!W9BVTR,#A7<`=Q,RCM(-_4PD,0H`HI$32;.#RA!M?*)V%:$40BY5F+@R24Q
M;H.555#)@7JP<HG.)DCF#E,0Q35L&M@UL&M@UL&M@U]</1^KX:'DKL[M#V=N
MA[??H>2AZ#4/1XJ@?[?1GF]*UB?]9?)WF)#UCSW^R!YZO?IY8GP#VQ^D&Z*M
MCX!^'C]#,-0=KQ5V_%0=KQ4'9LH.U79RCZ'C\05ZGA&MGUZ^O7K5L&M@UL&M
M@UL&M@UL&M@UL&M@UL&M@UL&M@UL&L_9G.<4U<88>R)>S`H&*0[B8M^U74A"
M,43&Y`4</"(();V@;YRZB`<M<2.%7SXPHY,Q7`Y&:D<G,H9S.8PND8A4J"A]
M=%56MSN%5=.50J(";7JRZ;!K8-;!K8-;!K8-;!K8-<_<]'ZGJ<]>`:'DH>_T
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ML\-;/#6SPUL\-;._7UPUK9VPKQULKP?6&NSMUV=JA[=#V_!K0]!J'H\50/\`
M;Z,\WI6L3_K+Y.\Q(>L>>_V0//5[]/+$^`>V/T@W15L?`/P\?H9AJ#M>*NWX
MJ#I+04':]:@[.7GH.S0*#DZ/K^AXN>M@!WZV#X*V>&MGAK9X:V>&MGAK9X:V
M>&MGAK9X:V>&MGAK9X:V>&G\S8N-Y7*MRH:%C[-B+BM:U7#\XIG.!U9R\731
MF@F`E*0QM\Y]3%$$S%`PEE$K/^:HG<=QS(72:MWW,I=G$I#-6R!MTTDZD\'^
MYT2T'=U,059%=$#:>S6*40-=&+LQ9A6C\?W`0L=<N,[7LFT[*AW239X5Y[GR
MJC)B666(55-,QD7;]0-2%U+KKK$Y9P;?4MCK(4(@^:1UR0Z;!PNFSDVXM9!D
MX92J+AJX063'=41<('(;DU+J`4PA[?P%&<8J0KE:/74)@F\"W$H=,H`J89G#
M7D42S$O\(NJO$F33+O&,!"AJ6-'/_P`W]>'#3'.T3BI<S_->,[Q:]:0@[AUK
M.`\=<#4#F`NJ:S`PD`>0RFFH[/#6SPUL\-;/#6SPUL\-;!\-;->]7B&MGK4/
M)Z]>#ZWH#V_7H>SFH>CZU#VO!1NCQUCGX:IK^=OJQY[PY`\RGOI\U?!+D?S.
M>5Q@?J6Y<\Y[<J]?>&._"(T'3XZ+VJ#H\04':H.SGTH*V5XZ#D[7UZ[-*^M7
M-X:YNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY7-W*YNY7-W*A
M\D6.521N/'<1*-WUJM6#A[*7-#.WB#DI80K0ICF<LQ!PKY.)#=<4P@F)5"@5
M5-RULIU9T"#X&3J>OL#VT1$2F3\H5;0KTH2+DI"'$P*(-#)&,4R?6`<!*`7H
MYN*1N^_W$(O#KOE$&["WHQ)ZN1=X,)&%*=<#F*F1$5UW!Q$N]ND3ZPQ0YNY7
M-W*YNY7-W*YNY7-6SQ^A]7O#0]_ZGH#R>KW>:AH>V-#V?M:'H-0]'BJ!_M]&
M>;TK6)_UE\G>8D/6//?[('GJ]_91\CW+$O+D<NIAC`P%KQKYG'OIB2>;RJAA
M=.]_JFZ"*9U%UBHJ;H[A-S50*=Q&+V<)A>VA?MW+1]$$//7ZJV01,11A(W%*
MZLBI*J"5409Q:"H;A2=>8@J`HQQ;E6291&<XE`C=DY<*-&C?*S1%JN]<RT*T
M:HHI(/VJ*!C/V!0T,71PAO$%9)M^S[$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ
M#I+0=G-0=J@KN=L?0^KSC79J/H;.[7-W*YNY7-W*YNY7-W*YNY7-W*YNY7-W
M*YNY7-W*YNY7-W*YNY7-W*XF(B0L&TY[(C7"E\S>/KC>6M#25U1EW6?"*W7:
MS:$G'"!W;45WK-%J<S=0#=6J<``P")1ON\K_`+.MR\[,PWAJ4F$H^Z86.N&)
M3ON[+D805JJJ1<JDJ@*B;(DTX16,43)JI$,0`-H<J#-DV;LVC9,B+9JU13;M
MFZ*8;I$D$$@`I"E#D`I0``KF[E<W<KF[E01;BF&40-SW#'VG``\,8GNI<<JF
MJK'0[70!U66*BJ)"CH`[H\M<W<KF[E<W<K9W/7]#9KX:\`_7H:'D_P!-#V=-
M#T>M0]G,-#T?6H>UX*-T>.L<_#5-?SM]6//>'('F4]]/FKX)<C^9SRN,#]2W
M+GG/;E7K[PQWX1&@Z?'1>U0='B"@[7AH.S;0=G1Z`=[Z]!6SZP5LU[P5L#PU
MSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUSUL#MAH-;-._0\
MG;K979R_4K9V<X4/9T4/)0]NA[/VM#T&H>CQ5`_V^C/-Z5K$_P"LOD[S$AZQ
MY[_9`\]7O[*80<BQ=L(FT\7VJPM\RQU_)9EO*/GTW(3S-)0`(&\Y74CE#)Z@
M(LP`1U*(%I>[)ZXI2.D\-1\=?EO6_&H=66XG9WIHDZTC*"(]4V9J*MQ4;%)O
M..M`N^5,BA3_`+/L3X![8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#M4%=G;H
M.S0*V4')]<:]3PUL[OUJ^L%<]<]<]<]<]<]<]<]<]<]<]<]<]<]*MW")%VZZ
M2B*Z"R9%45D52B15)5(X"4Q3%$0,40T$.0:^<#.^9*M%@XQ;OP5"*KE/OR=F
M\/QW+>!FFJIR!OMW*MPNP3/KJ84C:E+H&O/7/7/7/7S=K=F^7;J-N+FWL_W`
MW:*&*N]M#`JC-"7B78)@(@W>A<FX)#"'6=68"@;<-NIK(G*JDJ0JB2J9BG34
M3.7>(HF<NH"40$!`0'00KGKG[8<E;->BO5^H.VMGUZ[.6O!XPH:'LTYAH:'L
MYJ'H^M0]KP4;H\=8Y^&J:_G;ZL>>\.0/,I[Z?-7P2Y'\SGE<8'ZEN7/.>W*O
M7WACOPB-!T^.B]J@Z/$%!VO#1>B@U^H%=G-R:>AX1\04'>#T/$%;.[6SOUL[
M];._6SOUL[];._6SOUL[];._6SOUL[];._6SOUL[];._6SOUL[];._6SOUL[
M];._6SOULKU.GT/%S#79R4/9VZ'LY:'M\U=OQ:TKPY8;GW5D^YL#&260KQAE
M%&MUKO;B9B_C[;A)0H`>/139*MG:SMH8K@YU2$(JB1)0JY7877DM4'(=<"B]
M[3*:JG6#O;ZA'#T#@([?9!KSURW-D0>F]Y+[^KEN/(0]-[2'W[14)&3O600(
MH"I$7MUN72152E$A52IKNS`!@`Q@`P!KH(ASTE$G=W<>+;N57J$::YE31Z+Q
M=,J2SM)F+KJRJG*4I3*`4#"```CH`45LQ7NIFW()A(W:7&HW0*)S;QQ*DBZ`
MH:B(B.@<HU_2-Y_G4X^^Z_I&\_SJ<??=1;^W[]NJ8M=-PV<7'B2_)N2N"Q+I
MB!,":Z23%\JL#!P<I-U*3BS)+D,0I3F42`Z!\<9;M45/R<R98]K7W"$7,07+
M>.NJ$1FVK1X!.0JZ)5@27)R"10IBB`"`A^QH_)N-$UG6:+-@VMMQ]OKRL=&1
M-WVN295D_<PSJ6%-!N\:J.W:S551RBF?K#D5-_!B1A+YQO**Q8R,Y,+VTH,K
M&\KO%JBJ)#)GE(]R:(;&6*`&253</-T!U.EO`)*>M,3VNNREIADQ97'=DW)O
M)JY[B+'ZF1._=N#`@@4QA%0[>/;-FXG]D"("`?2"Q/@'MC](-T5;'P#\/'Z&
M8:@[7BKM^*@Z2T7IH.UX*#LV4'?]#9Z]>/F"O'Z&P>SIK9WZV=^MG?K9WZV=
M^MG?K9WZV=^MG?K9WZV=^MG?K9WZV=^MG?J5+`Q+**+.3DE<LP#-,$O=&>F%
M`5DY5UI[99<Q2B<X[=`]2MG?K9WZV=^G<U<,M%P,.P2,L^EIJ1:1<8S1*&IE
M7;]\=-),H<YCG`*M*!Q7?=J9"L+#N&;?M@+@LFXXF[+;<7I<4[(73=`,IV"7
M<-%3HMEXIFY(FH)DED%$U-#E$I>&==AEO',_EEIAC'MO9'LMA?-LOKWB+YMJ
MW$+=N,)VU&[D7[)1TZ:*O$47#<IA153.43D,4YMG?K9V=KT.S6O`/BH>:NS;
M0]&M#KV<E=JK2QQBATVBLA9"92,M(72J@@]=VG:C%<K!-2'9.RG1\LD'`JI)
M.52'!!-!;<3ZXZ2R*MPJ7MD^65EEU7BTF\O><Z]\LLH)E7)U';PIS[QM1W]@
M\PZ5RW)D,>F]I$?_`.-KEN'((]-ZR'W[2<LQ>7>RE$5S.49)I<ZS>02<F$1,
MX3>(NP4*<=1U.!M>4>6DY*$?WE#R*)5"(OXJZ5X]ZD58@I*E3=-'9#E`Q1$I
M@`W*`B`\E+.7,O?#ERY547<.%[N=K+KKK'%159951X)C',81,8QA$1$=1Y:_
MI&\_SJ<??=?TC>?YU./ONHB[;`RE?]K.4ERK'@Y.=?3UE7&V17*LYC)ZV7ZR
M[!VD?8<#)@J3>WTCI*;IP_W]_P`FH_\`*CW`_)__``Y\O)Y)_C/^4_Y!>X6]
MU_7^YOE__GC<ZWRKW(^V:==R>AFKX)<C^9SRN,#]2W+GG/;E7K[PQWX1&@Z?
M'1>U0='B"@[7AH.CQ4':[]!V;*[.V-!R=%;*Y>Y7)^RN3D\%;.SZE=G+7@\8
M4/9RT/;^O0]G-6;/_&<5_HAMWZ#;AP`-\S61*8W.)2+)"4!Z!,/=KA0.LJHJ
M<,3Q20&5.90P)(/7"""0&,(CND(4I"%V`4``.0`^G%B?`/;'Z0;HJV/@'X>/
MT,PU!VO%7;\5!TEHO30=(4'2-!V<U!0=F@5LKQ_6K9^Q'X85^<6S=PQLGI=\
MEM6YCC$UP04>L"0I"$9.PC&W;K(F;V)A*XN9P)3;QBB`"4I'5RJ<1MJ<7BR1
MW+AHYOS+-_,\@NESAOJ'.AE,KF/2.L/)O?E`;4?;B`<M3.&<_6*\QWDJ`;1S
MV3MMY)P,UU;*6:@\C7K68MAV^8.45DQ`Q%6SI0@\H:Z@(!:.5\9XP@[8QA>*
M)9.T\CY!OZVK6C))FD^49^ZK*%9+O)_J2J(F,FN$1NJ%`#HBH40$8@US?.TY
M#QU&1JJ"Q\>8K)>>6K-`2[IEDHY+,+YA%(".FZ*A[75`X`4#IB'L0C;?O#)]
MVY@N!H41?WW>L/CZ!G)50Q"@(*16,H6!B44RB`B0J4>!@WA`QS\FG*%>KXJV
M5V<H>I0T/9MH>SFH>@?#6*O@@3\\Y2K7_L["?@U+Z!&G$`WRW`V*4W.!3QSH
M3`'2)0[E=3Y2XZG_`'\_).JZY3J_)?R"\N\FW-=.KZ_[=N::;_L]-[E]#-7P
M2Y'\SGE<8'ZEN7/.>W*O7WACOPB-!T^.B]J@Z/$%!VO#0=%!]CX:#HKLV5V=
MROJ]G)^S=*[.[0]ONA0]GU:'M]ZAK-G_`(UBO]$-N_0;;_\`%I/_`*5&N%'X
M*X_\)NOV$JNNJFB@BF=5994Y4TDDDRB=1550X@!2E`!$QA'0`Y1IRQQ-:%SY
M0E$UY=F$C(&"S;:(=J@4(R3;K.DW#QTW76,(;@MD#@0AA'=$Q-5,;<0T=:UF
MS5RR14[!NFUVCR+M/K%4UEE+>N@TY(.E&ZHF*FFP=E,)%1-U:W5G`JBOTCL3
MX![8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#I"@Z:#M4'9S:^A]0._\`LCAD
MS3%QSA8,JXGFL9+)LFZBYGEQ8PNX95OO)HE$3.7#:Z6R"1=1,H5``*7V`ZX(
MPHW121#%&(<=8_7!(4C@L_M2TVD-)/%%4/8**+N$55E5"^W.<Q]1UU]+KV!7
M9MH>S;MH>@>]0]G-0]`^&L5?!`GYYRE6O_9V$_!J7T"/_M$T_!KNO_7[_P#K
M<>AFKX)<C^9SRN,#]2W+GG/;E7K[PQWX1&@Z?'1>U0='B"@[7AH.B@^Q\-!]
M2@[7>K7N>/\`9_9LH>W0T/2:AK-G_C6*_P!$-N_0;;_\6D_^E1K@TF<^Y(8V
M2G<^-$6MMQI(N=N*?G%&,@N=\JP@;9:O'8H(`HF"[HZ142&.0AE`.H0IF60<
M,W_;N0[1?#U9)6`>"H=FY`H'/'S$8Y*F[8.R`("=H^026*`@)DP`0_8)V%KR
M\Y`S>1KSAK,+*P:RK)PA$`S<STVW5DD3$.B1RBS\F."9MY0JAB"'5BII5E8[
MBY*(B).^+I@[3CI.><+-(9B^GY%.,:.))PW354(D514N\)$CFYBE$=`K'>/7
M\\[NE]9-EVU:SRXWP'*YFG4%$)1R\D=-0ZAB`J9,3$3.H<Q2B!3'.("8?I%8
MGP#VQ^D&Z*MCX!^'C]#,-0=KQ5V_%0=):+TT'2%!TT':\=!V?5H.SI_9/!`H
MVC"R'^#_`!M8BOV\-6XKB?$B2;Q3(<:)RZ"D5R=M&;Z@FT`":;IC"33TF.,-
M2SWR:\LJ6IDR[K/;&$G5R++%+NWV]TMB!KO]:0EQ-%RB!=S<(IO&`PD*>A[.
M2A[.:IBX[@DF4-`V_%R$U-S$DX3:1T5$130[Z2DG[I80(DB@BF=550P@!2E$
M1'0*?0F&<RVQ=T\P,J"MO+(35K7&X31)OK.XRW[Q:Q[UXW('MW+1!5(O)O'#
M4*'H'PUBKX($_/.4JU_[.PGX-2^@1_\`:)I^#7=?^OW_`/6X]#-7P2Y'\SGE
M<8'ZEN7/.>W*O7WACOPB-!T^.B]J@Z/$%!VO#0=%!]CX:[7CH.U6GT@'MT"U
M_7[;UOJJ$?';1R[Y-Q+O!CT.N=)LXAIUCA0Q>0FA4_;F(37?.4!F?\/Y5Z,A
M!'3&2A)MC[ERZ35R<Y&T@BW$ZA%D#B0P"=)0PD'=!4"&.4!&KDR%@Z-M9:UK
MMM.VI6X+JNNY"6]$6[<MMPZ%HIP3I,A7;U99TU8MG#8[1D9/05`5%,2;ZB2;
MD>&]TL0A2*.`R-=B`K&*&@J&2+`"`".T=WDUV``<E?P/#A\9=V_W?K^!X</C
M+NW^[]?P/#A\9=V_W?K^!X</C+NW^[]?P/#A\9=V_P!WZ_@>'#XR[M_N_7\#
MPX?&7=O]WZL-_+V%:V04[TNF.Q_!M<0SSVY@A)F8ZQ=BI<B,HT9*M&JA4E3K
MRBA/)$"I_P`H50`2;W"PI@]2-R)/<-?#];N(;SL5HX3BI>Y'$('NI)W?8R+T
M$V[E1P\7?'78JK)N#D!`$`<K"8E.IW'-RWKA[(]O/1BKDA7+5W%+*J,'&\XM
MR^;.G$NI=)$4#[8QDFAP*<-[<*<H&"*L+BJ:1>%,@*E;M&V0FAU_\)+C=CHF
M9237=&4<6ZJ<1`VKQ19D``<QWC?V"0M).+>M)*-D&R+QA(,'*+QB]:.$P5;N
MFCMN8R:B:A1`Q#D,)3`("`B'T*$/F2_FMIKW(5\:!CDXBX+@E9,L<4HNE4XZ
MVFCQ5)(!.0@.'!4TA.(%W][4*AD\;85EI2U2+`:XG5[3;2#GG"'EFZ9&#9P8
MOVZ1O)PWP5<+'^V&W13`I-X\#DG&\XE<%I7$@JJQ>D26;+I+-ES-7T>_9.2E
M50<-UB'2624*`@8-0U*)3#Z%Q8I93K:VIIS(PT];TP^;'=QS>8A'G7IHR2*'
MVT$5T3+(&41]FF)P4`J@%%(\O8\1A.[V$I`+*)3<C<[5.U+98D2>@Q.LE<UP
M&;LG8"814238++JK)%.JBFH0AC!:.3LXWN%Q79:LW!W3#639Q.IM5E+1"HOV
MQ+@FI)+RF1!-R#=0$FR+4F\D)3G<)*"4/I'8GP#VQ^D&Z*MCX!^'C]#,-0=K
MQ5V_%0=):+TT'2%!TT':\=!V<U=H/K_L[YO>RT9<Q+=QQ;<+C&YV_7;S9K<W
M%:ZD[0=)/4A]BFF5F[M=\=4PAN@0IS:%3`?1[=<4QTE#I&'!N1DA,F<Q#"DO
M;:Z*R8B70=TY#&(8-@E$0'D&FLC&O'4?(,7"3MD^8N%6CQFZ;G!5!RU=("4Z
M:A#`!B'(8!`0`0$!J.MK,)/\>;$;]4W\JG7OD.28IJ70F^SO#<4"0W0U.8DL
MBLJH(`0':)>4,(R7!_==MR%_%M^7M*]<=9(FF%@W39D8S65N9G<;R/?J*C(,
MDQ5=(.EH/R[<4,W*`'%0P)LXI1;AR?$8()M6RZF1+K05\F0(":":H)P`E,)"
M@!0,`!J`!KJ.HC_`\.'QEW;_`'?J7N2Y)'A>@+>@(U[,SDY,Y9N6-B(>(C6Q
MGDC)R<B\@2)(-T$B'5665.!2%`3&$``1IGBI&Z<3QT<_N=2U&F5)F>NB,Q>9
MUY29FTG',XXC`>-HIPH!2D?.8Y,J93E6<`B@"BA&>)LB2N';LOT8MG-ST)C2
M[YVY_P`DF$F@F\AT+E>.XYDBW=OFRA';9J0ZB@-S$75*FFNW,K!YBP?=/#+=
MUFS6\W5,3)-WM9BWIIND121MFZ8=:W^N8R+7K"=<W5#0Q3$62,JW5254_@>'
M#XR[M_N_7\#PX?&7=O\`=^G5[R%GV!?<-;:[95W:N(+CFKMO-3RU<K`LBUM]
M]&LUWP)&4*4R+$%%BE,8_5&(4YR?[K_D4?\`[P?E7^/?N%UQ?)_R^_*+W?\`
MR(\IZG^D/R=_\Q[V]U7NA_W_`,D]GZ&:O@ER/YG/*XP/U+<N><]N5>OO#'?A
M$:#I\=%[5!T>(*#M>&@Z*#['PUVO'0?8_2&0NB#;,W=S7!)-[0MXCQZHU*R>
MRK)PNO,$2;F(LL+5%`YRD2.40.)#"8"@.JSERLJX<.%5%UUUU#JK+K*G%159
M9501,8QC")C&,(B(CJ-6_<V.73UK>3%X*4+[GLBR;ETL^1,P5CPC3IJ@X*X3
M4.B9$4S;P&T`-=!"Z,QMHR$CLG6]9-H3#Z'D6KA_!Q]R2TC&L)V/4;)KIJ'2
M1.Y<)I_;P'4I1$PZ#J_3AXO"ABR)T%''EMCSZX@9N!RI]6*<V33VXZZZ\U?T
M1@;XO[C_`!]7]$8&^+^X_P`?5_1&!OB_N/\`'U?T1@;XO[C_`!]7]$8&^+^X
M_P`?5_1&!OB_N/\`'U?T1@;XO[C_`!]7]$8&^+^X_P`?5_1&!OB_N/\`'U?T
M1@;XO[C_`!]38^9,5X$/=3`J"49D6T[)N"VK_8M4##NQYYYO-'*\:[HG*5I(
MH.$4]X3I$(KH<*:1EE7+^6>*_*BJRF(+W6=25IG345%1VK;+@#>4PCHX&4-U
ML>H5$Z@E.Z;.@(4E2%Y6';-[VC*VVX;1UX6]=,$_&.BY5PCUH-X6^&J/N5*)
MCH82E16([(3=.Y9MP43WJ$QA`I2@(F,(@```!J(B(TYBL1V7<.5Y-M)R$<XE
MG[U.R[3!NU**2$Q%/3HOG;Y-17E31,T;;Z8";K2:EU-CSB,C+6M!U=,HW;6+
M=MJ,GL7;+%TY%430EW#.2+HZ)#FZE)F](82@81*XW0^W`!BB!BF`!*8!`0$!
M#4!`0])DB=?W"\F[8MZZ)VU,?H+H"S:15H0THHT8(LF.@"GUPD%RL<X=8HH<
M3'T$=TM9%R^O/%;8FG6+JRF=J`^<'/+WO&2$?)#<YXX"]4F5DT%9F183[Z@N
M#EW=U/7Z4V)\`]L?I!NBK8^`?AX_0S#4':\5=OQ4'26B]-!TA0=-!VO'0='B
M"@_9CE_(NVS!BS14<NWKU=)JT:MTB[ZJ[ERN)2$(4`$3&,8``.41IVGD?B^P
MDT?,.N!]"6I=:62[E9*-_P"%0=VMC,DQ(IJ\Q4CM0.;]J4:S;Q7XVEWRL6_R
MW%SN+)QZS=1CP]N8S;L+;QU+FC7'5KMA.RB&3D$52D5)O:*%(H!@"'-%\5.-
MK'N1['1Z\I;65W,IB9:)E72!3.88)?([:,CG:B2HBD!V+Q8AQ#4AC`(4WN&S
M;D@+M@'FODDY;,Q'3T.ZW=!-Y-)Q2BJ)]-0UW3C7;\5<4OP(9!_`"WHLI6)?
MO8N4C72#Z.DHYTNQ?L'K50%FSQD\;&*HDJF<`,10A@,40`0$!"HJT,]I?[S.
M-&O4M?++DD!C,N0C(NB>^POSJU0E=P!,H9.<0775$"D!\W)RA8.?\4.)1:R,
M@QSQW'(3C$(R=BWT3+.+?GH.:8$.J1-TQ?M'+5445E43B3K$%5D#IJGR#P_7
MW)S<%"WPP;`WGK?<JH24#.Q+U.6M^8*V*<B;M)N[12478N!ZI=,#)F$@F*H2
MZL&9?BT65RV\=-Y'2C!07$'=MKOU#A!7?;CL0`5&3TB9A*!RE424*H@N1-=)
M5,L;%1Z$K<MS7%)1T-%LD"N928F9:073C8N.:)!OJK+*J&3013+J81$I2AL"
MI:=R#*.WV><QM(1_D:'9RQG-IV0QBA77@[-BD&AQ;.WK8'*AI*3]F!UA%%J<
M6R8*N/2YJ^"7(_F<\KC`_4MRYYSVY5Z^\,=^$1H.GQT7M4'1X@H.UX:#HH/L
M?#7:\=!]CX/I#%R-IP$S<D_8]V-9D8Z$2.]>>X3U@O'S+@(Q`IU7'5&%LH8$
M2B<A0,H(=64X@```B(B```!J(B/(```5CO)RMM/+-L^VKIAI]S,70@:*<RL6
MR4)(+MX6'?$\I<$>H"*"3HJ((_;-XJNI>2Y\87ND^7M6[&S5I,)1KT\>].BS
MD491$&[Q,!$@]:@F(B`<H:ASU)L;BCK^))%5;!$LR9(>LUW:?4K+.P;I"EJL
M)"I[Y@)J)2@)A``Y:_V=RA\9<G_$U_L[E#XRY/\`B:_V=RA\9<G_`!-?[.Y0
M^,N3_B:_V=RA\9<G_$U_L[E#XRY/^)K_`&=RA\9<G_$U_L[E#XRY/^)J"MF5
M/>,;<ET>7_DU;\AF,S.<N+W+;"\D_<*)<E*N[\F1`55_)TS]60-X^A>6I:]<
M@.+QLNT8%L+N9N2Y\P*PD+&MP$"@=U(2!$TRB8P@0A1-O',(%*`F$`%Y9'!A
MCO(D^9JX%%]F6_[VGBPS@4'`"<MDV4LF@X624*&[Y=*BB/*8"LA#<6J+Q[B2
MQ[BR!><PH!&4#;<>J^<@D!@*L^?+!HBT:(@(&</'2B:")-3JJ$(`F"(R!QF3
M"%WS@$;/VV%;1D%TK5BG`'!<K>]KN9F36E%"AND69QHHMBG*8/*GJ)N6)M&S
M+>A;3M:!:$80ENV[&,X:$B629A,5K'QD>1-%$F\)C"4A``1$1'E$1]!^E;4Q
M/0$SD&];<L1*4@#':KI,7#9W<<PU<2B9B';I.6L:LW/U)NL4`XI;HHF6,6K/
ML>/?1D8_O.Z;?M1C)32ZK6'CWEQ2R,0V?2SI!-4Z;9(ZQ5%U")',4@&$"F$-
M!QSCEW..;E=6+9-LVFYN!V0R:TPO`0Z,8J_%$YCF3*H9,3)IF4.8A-THG.("
M8?1N/)[)DWDL9YANV>N"">0<>\(G;<S).$Y"1MJ?110*W;*G<.51C@(J8'"1
M3&`"J$4(6,?2UI)XILYYU+A>Y<AKA&/19&5)UWN;:+?K911<R1A4;@Y;-T%-
M``7!`'6G&,[>N.5NP9.ZI6\9J=E6K>/.\F)-@SB!!G&MC*`W13:L&J8)BLH(
MG`YQ-[/=+]*+$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.
MCQ!0?L3C&4<3)I,^&>-C-F*K:254*HL7&40JS6L"12`FH%;N2F>D0`1U`43A
MIH`"/IW,OD6ZN)J(GG)E5ADXWB-R1>C=-X;^!6:V_FEU=4:T33`"$(V8-&Z1
M2%`I2%VT[?</_%TQ<D$O\AMC,6.G#$R9@':[OJRGK@#@8!V$MTN[IM-O:%RE
M@/(AHE6]<2WK.61<+J`<O'D!(O81X9L66@7<BW:.%6+Q,".F:CAH@J9%0@J(
MI'$Q"Q,QG[B=L#&WEK1L_<6UCBR;CR-+MB.4BKA%OY2YUK91:NDP,)'`IMW2
M9%"B4@JET/36ZVF1.)Z\;O3ZD[J31S7/XD9J*H"<$@9!@TMN2B20;XB!%IA<
M=X3:'W3"6HR$8JR2[.(8M(UHM,S4Q<<NJW9-RMT5)2X+A7=/WS@Q2@*SMZY5
M75-J=50YS&,/%+\"&0?P`MZ,18F-+/N.^[RGG2+.(MNUHEY,RSU==8K<G5M&
M1#F*0#'+UBI]"$`=XYBEU&HJ].-2]_\`#R&/U+O_``<QL_C9F^'1.13R2ZKZ
MW7,5&\H;JJ$8G(&.F;V+IJJ')9^',16PUL['5B1IXJV;>:.'KPC)NN]5DWJR
M[Z246<N'#ETNNZ=.7"QU5EE%%%#&.81'*^=;6QQ.Y4N"Q;?.\BK4@V:[Q(KQ
MTL5DC/7*5H8JZ<+&F4![+K-]5"-4U#!NZ"H2[LO97N1_=U_7U,+2DQ)NU%5`
M`ZH]6RBHML83`W9-$03:L6:6B:")$TDP`I0"G=K7Q;%SV#><&=@X>P%S1,G;
M5R1*CMHE*QB[B-DDT7*`J(*HN$3&(`B0Q#E'00&K@M+,ULW/+W!@]:&M=MG5
MV@HI"9)8.6HG91,W*N3[SBYHY$B8R2B8'ZY!5LY<"5PJ8R_H,G5TW'`VTVDY
M1A"1KB?F(^&0D)J47!K&1#)6143*JZ<JF!-!NF(J*&$"D*(CIZ.:O@ER/YG/
M*XP/U+<N><]N5>OO#'?A$:#I\=%[5!T>(*#M>&@Z*#['PUVO'0?8^#Z0]JI6
M[+.QM;$'<4PX4=/)1NR,LNFJHY%Z?W,([,H1D451WNK9$2)R%#=T(4`'I-0U
M+XL=2+K\D\31%K1T#"`;JX_W8NZUV-W2\V9,#"!W"Q7S=J*IP#1-`A2E`-XQ
MT_+9]R+D2@*ODK1(B!3"&HD)UIC&$`V;PZ:[=`V5_3TC_P"3-J_IZ1_\F;5]
MKN)V0NFP\>BH;7G]D50O@K_:1S_5B7\=7^TCG^K$OXZO]I'/]6)?QU?[2.?Z
ML2_CJMZ>MBXY&.F8QRUGK;N2)57B9:*E8QR"J+AHX;'$R:R*@$.10A^<-FRN
M!'.]HVED'(^-[JP+!2=\P>.H.;N*.A<WNB`6[)^:M>WFZAT4W7(WCGBR9DR=
M6JB0R9E-%XJ^>)QQ*8&QPH9-RG9IFR(YAN5KH`]4I$O2G1MU,PB(">424=E$
MHE&/*4Y%@)8^#L>PMD1"@-CRSUJD=W<-S/&J75)R5T7&]%1X_7T$PE%=8Q4P
M,)4BIDT*'HW?B)&=1MJ3F5(>3A)MRR\O:,I>!EDI5J5XW*(*=2N"9VRIT3`<
MA5!.`'W13/-XXB<-76C+6Z\=-I69G6@6U:"*#1Z#(T@VNN>%NQ=)*;P+-RLE
MEE5DM5$4U"E,(6SD+/EYDN:X;?E8JX(ZP[-ZQO:K>0C5!>((W#//TRNI`I%@
M0.*+9%J3>3,0RCA(XA],+$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0
MH.F@[7CH.CQ!0?L/.>:G1T2)XFQ%D;(I07,0"+N+.M%W/M&A2J`('.NJ@1%-
M/=$3G,4A2F$P`/%=@^6DG#ESD7'-JY>8@]5.L9Q)8ZNE2VY]<KE81,=RY)=+
M914!$3J%0$XZ@F80^@\/MK!#BI;O$[<'#GDZ93(W%PS=P%I._P`DLD`"8:DZ
MP&%H/'+A,=-.M!4X;JH&-0]G/7V7BKBD;LVZSIP;!N1U2HH)F55,FWMEPY7.
M4A`$1`B9#'-H&P!&F%FXZM&XKWNJ4,)6,!;$2]F9-8I3`"JXM6)#F(BGJ!EE
MCZ)IE]D<Q2@(U'73Q3W7^148;JG/^&-BO&$K=BY>0_DUPW=HO',>4-%$F!'I
MCD-R.&Z@<F)N&["%GQ..L>/+;7OZZVT(FH,E>\R275@X%>\9YX95_)FCRM7!
MT!>N%-TRXB'\&GN1TI(3:R*DDS;ODV[1LF)$$720+(D.JL;4QMPQ1-H4H`.H
M<NFH_P!/2/\`Y,VK^G9'_P`F;4#M"X'A"`&]Y.I'H*D!?>U!4@E4)H`<Q=!Y
M>77FI(Y[F=)G3,`&.2+2$QTMHICJOW!Y=/4HB25Q+D3(&A2A&):`'^NV^J-?
M[2.?ZL2_CJ_VD<_U8E_'4QD6\F9^U<.?)A.+<6JS9T"8KHZ"0YP$#%(<0'4!
M`2[!VA_BG^5TE_CG^5G^[%_B'UX>[?6>[OE/N]UW4[WNC^1_\D\MZSKO*OY?
MUW7^P]#-7P2Y'\SGE<8'ZEN7/.>W*O7WACOPB-!T^.B]J@Z/$%!VO#0=%!]C
MX:[7CH/L?!](>U79ZE#TFH:S9_XUBO\`1#;OT&V__%I/_I4:X4?@KC_PFZ^G
M%B?`/;'Z0;HJV/@'X>/T,PU!VO%7;\5!TEHO30=(4'30=KQT'1X@H/V#)75!
MXQR!EY]'%%3\B<8FL3\L'Z)4CJJ*QJ61)RWHY42[H$ZKW1!4QC%`A#!O"65;
M1/S6>>,>,F@N_)\@<1B=RP-L]4U-H9P#&SHE>.=)@745%&MU"0O,8P#K5WX@
MO*?QGC_%M^L1B;OLS&&/6C%&>AO*DWA8MS<%Z.)R703ZQ),QS,I!`YP`2',*
M1SIFC,V\/EWDLO(,9&2<&$DX@X&XV+Z"FB%2EX>1A[C;.FRJ*Y2$U'JP4(8I
M5$CIJ%*<(NT;NX4\><2,J<Q$DHW$C"_[)OZ9+N@01%*++=#4RIC:CO-H0A.7
M0$^>F*5\<`'%IPV"X1.N\N#+$784+9L<0I-XH":YY>&N9P)Q$I4P:VHIKJ)C
M;I2F,'I^$7BS*W:)EX>L8<1MN2;U51(7;J6R*PA;;LABV;B;K-$F;V[%3*E(
M)2@?<.8IE$P-0]G/7V7BI5%9,BR*R:B2J2I"J)*I*%$BB:B9]0,4P"("`AH(
M5)M<5XQL#&[>9=G>RZ5C6A`6J64=&.94%9#W$01ZX2;XE2!34$R:$(!2`!0'
MH'PUBKX($_/.4JU_[.PGX-2^@1_]HFGX-=U_Z_?_`-;CT,U?!+D?S.>5Q@?J
M6Y<\Y[<J]?>&._"(T'3XZ+VJ#H\04':\-!T4'V/AKM>.@^Q\'TA[5=GJ4/2:
MAK-G_C6*_P!$-N_0;;_\6D_^E1KA1^"N/_";KZ<6)\`]L?I!NBK8^`?AX_0S
M#4':\5=OQ4'26B]-!TA0=-!VO'0='B"@_8?%#.Q_#[B(F:H+#%]WE8F0HC&U
MJL,BH719,,K>46PC[LC&J4C_`"Y9EY&HF+@2'*L8#E,`B`W@\S-CJU<G8SQ%
MAJ<NQS;%\0,;=%I/[TF[CC;:M5O,V],)K-712MEI5VFFX2.3?;E$2CR42W\>
MV5:5B0*9@,G"69;</:\00Q2[A3$C81%!$!`H``"!-G)]#'LYZ^R\5#VZ'LYJ
M'H'PUBKX($_/.4JU_P"SL)^#4OH$?_:)I^#7=?\`K]__`%N/0S5\$N1_,YY7
M&!^I;ESSGMRKU]X8[\(C0=/CHO:H.CQ!0=KPT'10?8^&NUXZ#['P?2'M5V>I
M0])J&LU**`*9#+8M5*<X"4IDRXCMXAE"B.T`$I@$0YP$.:BF*8#%,`&*8H@)
M3%$-0,40V@/,/T"WD`.45DF3Y51,!]D1-=<A$CF#U#"F<`Z!KA.1=I"BJ?$4
M&\*0PE$1;2"ZS]FKJ01#11%5,X!M`!T$`'4/IQ8GP#VQ^D&Z*MCX!^'C]#,-
M0=KQ5V_%0=):+TT'2%!TT':\=!T>(*#]AN6+Q!)TS>-UFCMLL0%$7#9PF**Z
M"I#<ABG*(E,`[0&OG"W<JP6;2+#BXN#AS8+.TUNL=07#N9X5&1CUW'*HV=K7
M&?1<@;JPHE$3'W"[OT,>SGK[+Q4/;H>SFH>@?#6*O@@3\\Y2K8$ABG`+?AR"
M)1`P`9./3(<HB'.4P"`AS"&GT"+;B<H+*SJ*R:>OLC)(1[@BQP#U"BH0!Z0K
MRWR4_DO^_3[L=;OI:>YOY(>X'E6F]KIY9]HTTWM>73=Y?0S5\$N1_,YY7&!^
MI;ESSGMRKU]X8[\(C0=/CHO:H.CQ!0=KPT'10?8^&NUXZ#['P?2'M5V>I0])
MJ&D,Y83*SD,@HP[*#NZQWKQE%C=C.+WDHJ:@Y:0.DW(_01$K9=!TJ1-9!-(4
MU"*I"1P,<3#.<FZ;,>H*E'Q%PK,B`0.0K9:/,=$Q/4%,PE]0:]EB//8=,+=E
M>RQ1G@.F'NNDI"Y[&S)`L5G1&23N49W*S04=J)'73;$46$`$XD34,!=NA1'F
MIC>J]JY91M&3F'EOQ]QJ(W$6'>3<<V3>/HIN^$VX9=))5-11,!U`I@$>0::W
M78>$N(:[K:?*ND6<Y`6_=\E&.563@S1XFB[;`8AA35(9,X`/(8!`:^3;Q/\`
MYH7M^]KY-O$_^:%[?O:BS9?LNY<$8T*[*K=U]9'*@A=1V2"NZM'VQ9CU;W2=
M/5@`2H+.D4FA`U4.N(@1)6SL=V>P"+M.P[6@+-MF-*<R@,("V8I*%AV?6&Y3
M"FW13()AY1$-1Y1^G%B?`/;'Z0;HJV/@'X>/T,PU!VO%7;\5!TEHO30=(4'3
M0=KQT'1X@H/V)<!+6AFD.%U75-WM</DI3%&5NFXUBKS,RZWA'55<2$`PAH&A
M0Y/H@]G/7V7BH>W0]G-0]`^&K?G+*D&45E7'Q)(D"G**"C#W3"28$6?6V_=%
M`1;+`LDFLQ="!DRF%5)4H%6ZY!>%+AG+[7R910#DMUJ^E8H3@H)#G;R%MK+M
M%0$0$0.DJ8!#0P"("`C[+$V>2],-=85[+%>=@Z8BZJ:65`6EEN8NU_(J1+*W
M(]"XW,NZDTC&*JP18I&$YE2B0P"0`U#0?4IK:EAV;E^[KE?).EF<'`-KDDI-
MRDR;F=O%$6C83',":1#*'$`Y"@(C7R;>)_\`-"]OWM?)MXG_`,T+V_>U\FWB
M?_-"]OWM14+/8>O/&\(=XBVG+^S(92VXRW8S>*9R]3CIE4).0$I3?:F\<U5$
MY^0PID*HHG_N"^6R?Y$_D;[F?E?N$]W?R]_*'\N_\0>IWM.L_*'^7^1=9U?4
M?R+>ZCT,U?!+D?S.>5Q@?J6Y<\Y[<J]?>&._"(T'3XZ+VJ#H\04':\-!T4'V
M/AKM>.@^Q\'T9[>61+FC;6MQ@)2*OY%0XF7<*`(I,H]FW*==TX/H(IMVZ1U#
M``B!1`!$#6WP^8>E;W5U."$K<99'RF0$@@4QV%GVX55R*.H@)5%79#B`AO(D
M'DI.69\,R`L#E*=-D?#N3&S5=,40,51,KR4*Z,0P"!RF(KH8?:CIR5KE#AA0
M9I)F$5B?DKDJPU`+R:!UEPC(@4?9%Y1(.T.3E"DANS$=^0IQ*7KRV]+6_<Y4
MS"'LP2/)&B!.`#L$2EU]0*5C;$N5=E<Z!#K*6;=35.$N8[9/E,Z9-@46;NR%
M`!%3R-RJ*8:"J!`,77Z+VJ[/4H>DU#0]NA[/VM#T&H>CQ5`_V^C/-Z5K$_ZR
M^3O,2'K'GO\`9`\]7OT\L3X![8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#I"
M@Z:#M>.@Z/$%!]&D;:9+N\DWY'',@ZMNU54B1L8\(.AFL[=*Y3MD#E$#%42;
M$<K)F#=42)K17&*.&ULM#NQ!5F]:6%D:\A*W,!%$C&G&CAJR$HE,&JAFX%$#
M%TW1T$4%;FX7&RS%,B@N'@8ERJB8_(;<%9^QDU6R0@.G(*(:E`>34=Z@89+X
M>Y&)=!OB=:+N=RP7]B.@$"$GXTAN3]L87GV--(Z>89!L0SE0J2DI/04;(038
M5#"4IE75N/7CH"AR;QA9`!==1'0!$&$];TK'3D)*MR.XV7B7C>0C7[53VCAH
M]:F,FH0=!#>*8>74-H?11[.>OLO%0]NA[.:AZ!\-#V<U#T?6H>UX*-T>.L<_
M#5-?SM]6//>'('F4]]/FKX)<C^9SRN,#]2W+GG/;E7K[PQWX1&@Z?'1>U0='
MB"@[7AH.B@^Q\-=KQT'V/@^B7+DN]5W*-O6PS3<.4V2)7$@^<NG)&,=%QK<Y
MB%.X<N%4D$@.<A`$V\H<B93'*_C^%[$A[;MY!R=H6X4HYC.OD3F_@DY.[;N!
M"`:JG)H?J.HWR:CHJ<``U0MP\6V7'+BW(Y9PN>WFUTO+FN5,%CD4<,(A+J1A
MHI)QH4%%VIU1`"`'4>U,4D#C2RH&TF/5I)N5(QDF$G)F1#=(O,S"V\[>*_\`
MW1TL<W,`@``'HF5O#'EC76H8@IF4N6TH"=.8AAWC$,>4;JB("/*(5)9:X:D'
M5C9`MXRUR'LRWUW+.*F#L`%Z<UE),M%8N3*)=YH@U,#<Y@*DFF@8=\9&V[V7
MZ[)V."L&<Z_,0$AN>$>]8E$7$=,```<ZHG;ORE#3K"D6]B"X)D^B=JNSU*'I
M-0T/;H>S]K0]!J'H\50/]OHSS>E:Q/\`K+Y.\Q(>L>>_V0//5[]/+$^`>V/T
M@W15L?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0?1'F',,V2;(N3V;
MA*-D'+Q)\[@8R9<)%42A6,/"&![*/";P%72240*F;0@'5."A$P"X[A<XMMN6
M;KH"T=3L7CMBFR<$W5VLC$V:1>;,0X")#$?(G,(")1]B.E,YN^6$3E/)`[BZ
MTM-QQ'=LP2X:'*A;,!(`=/>2,`"5\Z(9<3!OI@W`>K`I"%*0A"@4A"@!2E*4
M-"E*4.0``.0`#T#L96/8R;)7^$9R#1!ZU4Y!+[-NY*8@\@B'*'/3N&E<76I;
M;U8IC-+GL:$B;1N6/=`B**+DDA#H)@Y*F`\C=Z19`>012$0`0B\:WO<#BY,#
M7ZY2<@\T72B#1KQR#`UWQC-<QRL9*-4$@2K9(Y@61``,)P,U5(4Y#%.0Y0,0
MY1`Q3%,&I3%,'(("'*`AZ7$)+M`__P!.7-MCX)MD2+I(:7=?K=\O#"<%0'?*
M/D*@"0NAAUU`>3TX]G/7V7BH>W0]G-0]`^&A[.:AZ/K4/:\%&Z/'6.?AJFOY
MV^K'GO#D#S*>^GS5\$N1_,YY7&!^I;ESSGMRKU]X8[\(C0=/CHO:H.CQ!0=K
MPT'10?8^&NUXZ#['P?1+#MQ%7JS7#DUJ[<$`-17905N/S'2$1`0`H+N6YQY0
M'4H:<F]6&;;;H$;C'XUL\SQ,B1$0-*OH1&1F5S)I\@&5=K+JGVB)C"(B81$1
M]-E&/7N2%AL<7B]GXN<EEI%HA;T&O=L0VR`D@Z7WNI0\CF`"-'>$O4`8Y!$I
M0.`M9>"E(Z:B7Z15V,I$OFTC'/$#\I5FKUF8Z2A!YC$,(?1.U79ZE#TFH:'M
MT/9^UH>@U#T>*H'^WT9YO2M8G_67R=YB0]8\]_L@>>KWZ>6)\`]L?I!NBK8^
M`?AX_0S#4':\5=OQ4'26B]-!TA0=-!VO'0='B"@^B<3>4W;4CYVLK.O&4DH1
M$X,CWQ?3B24\FU#5,ZJ342$,GIHF!R>U-IZ>W[J<JL&\]9U]1XQ)G+MNW>O(
MVX6JD;-1D:@L('7,8Y63I5-(!,!&XJ#[`AJQ>Q+>MNRM_P`19D3#71;Q)IB>
MYV[^`:^Y2KV0AC'!R'7D0!P*O5;AMX1*.@#IZ3YOJV+67,:<L?+\CQ1+M2J@
MD9&6Q7)1<?CU<IO9:"HLZFB@8Q!W=SDUU,%05TP3HCZ$N6&BY^&>IB`IO(J9
M8DD8]TF)1$!*HBH0X"`CR#Z8>SGK[+Q4/;H>SFH>@?#0]G-0]'UJ'M>"C='C
MK'/PU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC`_4MRYYSVY5Z^\,=^$1H.GQT7M
M4'1X@H.UX:#HH/L?#7:\=!]CX/H<A<-S3,7;\#$MQ=2<S-/FT9%Q[8I@(*[Q
M\\,1),NH@4!,8-1$`#E$*QK;^,IE[<$)8:EVK3LN2-<QL?(/IM6/;MR1*DF0
MBJH(ILEOMO4E3-UA1(*@<H,6>"^%TP0:3=JRC7!+7O\`R(#:/03(U;:2L(2,
M9@!"BD`K*(]6`#J)0`0$#J0^,4;7!P*8)F2M*S8IPWZQ#JR[C>^WBXA[(04,
M*J8[I@T'0NI*W'LTE%`FJ42@+OA\9*GU+H)^MM](XB0->4IS;>4"CR#3VXY]
MDG==NV^Q%R^23B\-W'UC5$@*++BPM0$IM<4R@/6&3*(@&\8=0#>![+OX]C`W
MY:CUO%7C!,%U%61C.6_71UP12;@3*IM'FZL4B2ISF24243%10"E4/4)PH\/:
MTF2_;A/&H7;+6^Y(WFBK3S<5(RS8M]O%%F8S=1-](/`.F*:)D@!4A/**X>L0
M7Y=;F3)E="R#7O,0JC9F,'*75?+BV99&$=2:2I3H,T@0.5TZ2$53`H<R:91*
M0KF;X:>(!1),'0.RQ+N1F[%D'*8>Q3;O"QAGL;('*&Z4_E9$4SE`1W`Y""H1
M-P5XBW)R.&Q.&5;KB$3WA%,CE,JYS<VAD]XP[`'4-7O#=Q.0#:#R)U;H(.6"
M-0@7RTJSC_=@\+.1[4WD9_*66\Y8.V92$4`"E`JO7$.'T'M5V>I0])J&A[=#
MV?M:'H-0]'BJ!_M]&>;TK6)_UE\G>8D/6//?[('GJ]^GEB?`/;'Z0;HJV/@'
MX>/T,PU!VO%7;\5!TEHO30=(4'30=KQT'1X@H/H<U"W'>**F0/<9TI%V?`H+
M3$\F]<LC'C#R2;4.I8E,8R:A1>K)"8@@<@'`0UOBV<<8D#(]W7V_AG@.@7F'
M9VC:":N$&;3\GH)J=PX`%':R@G!VGIO;H!J.]1PM_AX3MU)R<GDPN<77/"D1
M3WR%*(.[YD"IF`P&+O*&]B(;QB[I2CNF<,X\D&W,J"0MQ9</31NAO&WA4*2=
M%9T8A0,`")3'Y`T#4VNJKQK<;>175)[)F#[!#HVIU]#%21F4"MR"`>SU*8-"
M^Q`=?85;^'^,6U6$<VN1PP8$N<\?%PLA#FE'GD3"X/+K=.>(D8L%0,BY.U*7
MJ]#*`L(HF14J[,GW`F=TA`,BEC8Q(PE6FIY^J#*$B$S@`B0%G!R`JKNCU20'
M5$!`@A66N+/*MUK-;5L^W[JEK.B3$<F9R:L"4R[V'M*)$QDV,4R!-1)9V.^=
M99,4S"HH"[A)#*-I9,E;&OR+NV;A#MWT81]!+*Q1&[MDNP>QBS=XS-U3DF^J
M/7COE'=(`"`A[@V-D=#($0D8B;9T6Y;$N91-N0NB)$W&9FJ+M(A"Z%ZI,VZ7
M30NI0`:CKRSE;[>=LGR]JW?HR</C->)4!P<4BLE9[%H`=BLKH(('<'$-_=^U
MJ`.X:TLVSMYVSCZR+LB22*<E?UQP=KLXUTD<[>3BGLG+KHMNM:.$ED%1*H)1
M$@F*(ET&GB4QQ667>\FU,JFE%8@87#EDS]9(!$4F<[8S1Y$``Z:%56DDTAY-
M#\H4WR]BQC>$9C&S\7VMC"SFM[QL9#3;E*'EI.Y)N76B8EX^22*X?RK@$3'<
M"L9`B76E3$`23X?L'\1=TY)QGD;%&+[)Q?<-USF/96YK,G3V7#)6U%S$;+6&
MM,R2A5&;=L9TL_C6ZG7]:82F)HH9H3$'%-@V]9%\;=;VXSR);L=>(B(:EZVR
M9M=M+I@;EW159%`VA@#42CIZ0>SGK[+Q4/;H>SFH>@?#0]G-0]'UJ'M>"C='
MCK'/PU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC`_4MRYYSVY5Z^\,=^$1H.GQT7
MM4'1X@H.UX:#HH/L?#7:\=!]CX/H1U53D333(91110P$(F0@;QSG.;D``#E$
M1V5C[AGPA-C+V='2ZB4U.1RAE;?F)T!%69N(RJ1MQU'0C%)4R"Q1W55#+BB*
MA3('-8^&[#C'+FT\>24!(OUYI565<R3^W[""^Y*4EE%!(GOF>"5`"I))(@8I
M"E2$/;^DRMB&,*5M;M[$NYK'12!3(,F31[$I9;MM-!N0-W^1L2J-$1'0`(<^
MFWEE9R35%&-A8U]+2"P%$XI,HYJ9X[5`@<H[J9##H&VL^<2USMD%9,7SA*'!
M50%3QLI?TDYDG_D*?*)`:,6Y&*9Q$-$EC$+O!O;O"[?RZP,4$UE459`=2@V3
ML^\8Z:56$YAW?M)9#?\`:AIKRB/(`>A@M8J9&QGC"Q%72IA`@.G9S2C!!3>,
M.@F$A$42Z;1*``&NWZ#VJ[/4H>DU#0]NA[/VM#T&H>CQ5`_V^C/-Z5K$_P"L
MOD[S$AZQY[_9`\]7OT\L3X![8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#I"@
MZ:#M>.@Z/$%!]"F94\FP/D2;CG;''ELG5(J_?S"Y?)B32S$/9>01XF\H<JGW
M2&W2H`?K54RC?W%+E169E,A7[/Q3#&B,P\?:"E+W0@6:O26$YRK/7C]N63,U
M%<QD@(!7.ZJ94ADL9F\F(E)76VE;PE%^I(FHZ&<F7#B).<2AO&`K`&I"B8P[
M!$-`'=#T;0R(BS(>9L2]F\<L^WC%,E;%VLE6S]$P%`0/K(-XS<WQ`"@)]T=3
M"!L.W<]<^62,K8%NEEG8J"J9S,QK$L3,KJ'$1'?,Z06$X"(B!M0'E"L!\-MO
M*&17NJ397`N1<ZB3%[,W/.#8UG=<</8Z-SED14U`1`%2CR?MKXQ9;3`XPT1@
M^[[.BV*!=UP[1)9#F-+O=5H)EW!A$ZA]=XRAS&$1,(C60($Z@G/#Y3=OTRFZ
MP12;35K1J9$RB(;H%%1HL8`*.NHF$0#4-:S04Z1%@)#0*Q2G("FZ=&\8Y4BI
M0$!T$@AO`;FTUJR+EX@N'*QKYNQ>0O9BO>38\[9MY.6Z%W/"-B/+LL1Y&2"_
M5!H5(5W!]TH`4/8@`4Z>8BRGG+#$BL53R=@YD[>R7:#,PE`$13BYUHTEC@4=
M1,"D\.\'(`EVU(</,]?+?)34UGVW?=LWRVMI6T"7#;MQG<LTUU+=5?28ME$7
MC)XU4(#Y8HF2$0/H-8>XB<V<2-R6=&9@LN&OZ,QO8>/H\)F,MRX2&D(!=S?%
MR/UT3J.V!VSL"D@]T@*:`=4``PM5Y?$]Y9GE&74F1E<OY(N*1WU4?;*NX"QC
M0$,XZS]NFO&'3]0@!47C_$]BVGCBR(0@DBK4LN!C;<@F._IUAT8V+322WSZ`
M)U!*)C#RF$1](/9SU]EXJ'MT/9S4/0/AH>SFH>CZU#VO!1NCQUCGX:IK^=OJ
MQY[PY`\RGOI\U?!+D?S.>5Q@?J6Y<\Y[<J]?>&._"(T'3XZ+VJ#H\04':\-!
MT4'V/AKM>.@^Q\'T+$G"SC"\5T$'J[:/O`(&7<GC0N"[Y0(TS.ZVD6KHJ6'C
MT#/545"ZD3<J:AJ.@+E@NLN*^9EJDWN:^Y-NFD_>ID."PQL0T*)P8L04`#^3
MD.8RABD,LHJ)$]RT^*B+9GEK)OURW2EFY#;WV]M;Z-M7=;BHC_!J+LBDD(\Y
MS;HK;V@"5N8*@[PM23;S-N7'&MI:&E&V^"3QB[3!1)3<5`IR&#VITU"E.0P"
M0Y2F`0"C'.8I"$*)CG,(%*4I0U,8QAY```Y1$:,TN7-./FKU)<K9>/87`UGI
M%HL<0T(]CX`72R&T!$5DR@`<HB`<M)W;:$JRNFTFR*C]I,Q#]%_&J-8C`Q8;
MREJ]CCG(9,LF8""43^V$2*%`V\2EFRZ954'"2B"R1N4JB2I!343-]00$0&N(
M+AOE'!.H6/*#$*K:E4?O\>SBK9@=H!]##Y7%OUG@AIRD2`>33EQ+=/4)F&&O
MZ3@/*1$>M1_*6W5)$4"!KINJ>Y.\8=-I"_5K&]PK"45IZPK/F51*<JA15E+>
M;OE!*H0"@8-3CH8"@`[0`*=/W[ILQ8,6R[QZ]>+I-FC-HV2%9RZ=.5A*1--,
MA3'.<Y@*4H"(B`!3:_;914?8ZQ<LE(,Y4!,DD6W[$9&:0LF54-W?"2GEBN6Z
M1M#^3JCO%$$E/H7:KL]2AZ34-#VZ'L_:T/0:AZ/%4#_;Z,\WI6L3_K+Y.\Q(
M>L>>_P!D#SU>_3RQ/@'MC](-T5;'P#\/'Z&8:@[7BKM^*@Z2T7IH.D*#IH.U
MXZ#H\04'T&^[\>R;!A*Q]NRJ=IMGCIJ@M+78NS.C`Q[)!R.JQQ<F3.H1,AQ*
MF4YQ*)2C3?B"SW<]Q7;#J3\FSA[8D7[QVXNHT.Z)U\E<%PNUE'!F(NSNT19H
M]6<ZB9C&6`AC)GN&P+,9-V\Y;P1-Q65#,TD&;)=Y:Y#)HV^U0)N)I`LR.NT:
ME#=(10R6NA"C2.#+A5!CD#%3)="/:."F26F[*3>]6V<ID/IHM&J+$8N4M`$$
M_)S^R,93<]!-[?U\VC9;9<JAFRMTW%$P0.^J+O'(S+)JIBL?DY")`8PCR``C
MR5=MIXXRA:MSSCB[;09O(=BX4"0<,V<J$LLYCT79$S+HIF;IBHY;;Z9>0HG`
M3@`X0;;JY.LL\)#1P7=4'W6E7,KO%#=+[`W7:I#IRD$HZCM'"6:8,AFTG:ER
MOK:<R:1`$Z2[D$[FM8ZAPY0!!9B^,0=F\IIJ`B&MEWN@@B,??-GP%Q^1F$KA
M))&X(=*058+`8-#=7UID5"F#:`E,&NH5Q(8\,_%9*/4@%46X^R*LI;DY)P;I
M^F(@&Z(@NB4^@!O:EU#V(:4YQ.TDT37KE%S&(FC&ZX>71]GQ4HG*RDN[(F.J
M:+E5LFP3!0`ZX%%P)O`DINXKM:;16;3:T,YN:6:."&278N[NDU[D)'.$#@`I
MJMD7*3=8@\H*$-KR^AP0Y/M*-!W/9$-<W#FY6$ABE-+A<;&X<;QJBZ1##HNM
M,3H@'*(;AA*4=35C_&5O@4L#CJR+4L2$*5$K<I8BT8%O;\:!6Y!$I`!%N30@
M"(%V`(Z>F'LYZ^R\5#VZ'LYJ'H'PT/9S4/1]:A[7@HW1XZQS\-4U_.WU8\]X
M<@>93WT^:O@ER/YG/*XP/U+<N><]N5>OO#'?A$:#I\=%[5!T>(*#M>&@Z*#[
M'PUVO'0?8^#Z"/"[PIG>+3CN1<VW<]YP[E%K(/Y1,11D82V)<YR%9-6FZ<KV
M4ZPAS'*8J!TTR=8O'Y&O28&^,M)-E1;.D2J(6S:3B09F:R)81!7[<[<"159$
MS]UN[Q#:IMT#;QC5<6-+N3W&4R@56.E4D$EWUO3K352*GHT%--%4%!T,4#%Z
MU(RB)C=6J<!TLOB230!,YBH:V]<-L:)*D$ZQM(J5=[@F/H`E#4!`1,(Z^Q&=
MR!(<5B2-GVVU\K7_`/IL9).HJL)DRM6#2!FF)FZCETX$K=NDF<W6"(`<2$$V
MCWR.XKJONR;>D19KA.W1%V[!/)90A7"C?JG*C5-^L@02'$5"J=0!P`!)UFAD
MTSV3;[<ASE*9=:^;5,DD`CH*B@(.3G$`VCND$?4`:ALGXMOR`'*<4=VHM;5K
M2R\3(M&;A$$00C+BF2H,GQU2'4([:.B(([H:$4<;VZ!+(XG\+OUII@F")Y=D
MV7LNXW1$3=69^YAI%([![U@@.ZNQ4;(&#02%,`ZC$\?G#9%.I&!MY["M,F0$
MPQ*RF[0N@8M6W%D[NBXE=8"QDY$[J*4FT<'2%45DU#D7T*>4M;&CM*+S/:S^
M.OV.Q5./D$)YU*P#1PTDF4*X.*24@DJP=O2MG")=`4%('";83:EMG"^><=WE
M&/<?QJ%K(3\8@4TJC'1@>2Q#&>M*=%FNW,T;%3;F.DNH8Q2%$$"CJ%.L98-M
MR6L[#;9=%&>7>NC,&;AL=4#)O\CW`TWTMT0+UJ$(S%81W1,!71DP4(A:UKH$
M>STDFS<WK=RR9B2%TS+=(2=>8ASGZAHB)U"LV:9MQ(@B(B=8ZJJGT'M5V>I0
M])J&A[=#V?M:'H-0]'BJ!_M]&>;TK6)_UE\G>8D/6//?[('GJ]^GEB?`/;'Z
M0;HJV/@'X>/T,PU!VO%7;\5!TEHO30=(4'30=KQT'1X@H/H"]YS#;W8GI-P>
M'LVV$UR(+3DX9N9<#.%!U,DR;%#K'C@I3;H"0A0%15,IF^;^(6^I"'QN=ZN6
M#BV.A'S]B1P7RB,LJ#4$S:(8:%W1?KD456$I3]4X$XN`@+#LF)2A+6MIB#"(
MC45%E@01%4SA915PY,=15554ZBRRRAS'44.8YA$QA'T);*&.LBEQ?(7"H+^=
MA$[85DF2\^YWPEIZ/D&4@S.V,\W@.X0ZDX'5,JKU@=8)`*;'_%"BS.F!");M
MYY/L_<(D(II`4T(1Z)=U,QMT`#DU$H<@B-&P1'YSNJ^\@>5-HD\7:=PO;Q$D
MQ),PWHCW2G6A%/*$$1*JX,4=QN.\<ZA%$U=QU*S=KLYJ4>*F5>2DID:V9!^\
M5':LX>/7IE5##_RCFUHJ=[R5GX[B2I+'5>*R9+JDQ5*!@01:Q<&;J3[Q@*)S
M*/4P*0=0WC!N"A$SD(ED[#<-_)F:HD<W9:;"-2T4,,=.1X(R\*0I1%-%.13(
MV*.NX@<``1EL!35M3F,,@7DM$A84K)O(^<LPE],9`CF`C)&?0!!RT3D%@"/%
MR>.%-,BYSJ'(!`$6?#!Q-6^_LK\C'CJ%AKK=(+G4@2.GAWS>*NMHGUN^SWEC
M>1RC,QD@0%'>(*`"Y"[\\VW;(9$PEF).:EHR<@Y%16V9>`O6;1N%PT97.U3=
M-47[!^D!4"*[PJ([N@@1QO!'Q.!\?W2\R?<AO<UNC=<:T7:6^^<*%;-S1\="
M.')Y9RH<P@T1#JR[VX94I^5N8W$%Q>J/+@NJ0=-YN&LB?=B]?J2!#%592U\%
M2'JR%0*4@-84GL"`!2."$*06H^APU*38-BFX?>*C%/$@P,OO`+ASC9&1*6-]
M@'VPBQGA!.B<=PPD*8P&$A0]./9SU]EXJ'MT/9S4/0/AH>SFH>CZU#VO!1NC
MQUCGX:IK^=OJQY[PY`\RGOI\U?!+D?S.>5Q@?J6Y<\Y[<J]?>&._"(T'3XZ+
MVJ#H\04':\-!T4'V/AKM>.@^Q\'IWUQW9.Q-MP$8D*S^8FW[:-CFB8!R"L[=
MF(0!$>0I==3#H``(B`5+V!PY>5QK)8Z\?(Y5>(F;2+MH(=6L%E1C@H*-04#4
MI9!T4%P*(BBBBH!%BVYDNYLCR%@S%X`ZE8:*_)1&?1"VU3@G"R;P%7S(XG>%
M*=VF!5-T4%$1U`PF"GF2,)9VE;HAK,9+S<Q$QAI>U'Z49&M1</7`6>Y>249(
MMT$BJ&5057$XE*&XBH/(5&Z9Q!DSO:W)5Q;%Y-H](Z#%:0;H)O&,NR;J&.)$
MG;95,YB;P@58JQ"Z$*7T<)\+5H/ENMEGT7*3C-N<RK5:X+OE@@+7]U$$]!_\
MWMB.78[Q@*";K?-IH!@MC'EGLBL;>M6*0C&*>A.N<&)JJ\D7IR``'<NES*.7
M*F@;ZISFY_1<P]PP\7/1#PADGD5-1[24CG21RB0R;EB^(HD<H@(@(&*(:"(5
MG?A_FD$D(.ZV=Y0D-"+E278RB,+(A=%L)N&JH;BA#V\J^4W#%'V)Q*)=!'13
M('#I<IL17JW<%E&EOE5?-K2"41/UJ3J!D8O5]"*;_LP%N5=$@@4J*"!>6B67
MQ"<-$3Q&03)+JFD]<N/%[]?LF)E2E2&-R+CP_6-E#F-[%1V87/LQ*;EY`C;.
M6X3HBS86-3%!I"P5P/[):MQ.8%SK)QS^$<"=0R9@.J8YQ.J<W6'4U-7_`)[Q
M#?,>;=..D5,P$P7?`X`F7>=^0\@EU$1TY!Y``0'>"-@91O?]A#(%*0T]>$+!
MDMEF[,``5NZD(&3?+ID,81`JZK0B0`&\J9,*9RT/(,96*D6R3R/DXUV@^CWS
M1<@*(.F;QJ8Z:J9RB!B'(82B'*`_0.U79ZE#TFH:'MT/9^UH>@U#T>*H'^WT
M9YO2M8G_`%E\G>8D/6//?[('GJ]^GEB?`/;'Z0;HJV/@'X>/T,PU!VO%7;\5
M!TEHO30=(4'30=KQT'1X@H/3JQ#QV:]\AF(?R>Q;:=M3N6)P*(D4NJ4$3I1J
M8B`!N'*HY,!@,1N<F\<K&-O.>+"6_#Q<G+N$HEJ4T18-F-W"*:[6#9+F`5W;
MMRHU0,NNH=10Y@4/JB@5,CB3L3B,<L)9-'=8$<V0[ASF4Y#&3<3T/-G53(8P
M`.I&9]-`Y!$-:M_ADXFIEQ=4!>#B,86Q<;V36N)RP>7$Z&.MN5B+F?`1TYBW
M+P@LET'H`9L;4Y2I`FHFKZ&1\EG,B5S:]LOG$.1QN]2XN-[I%VTT5`W()59!
M=LF8-!Y!'D'95Z\3%W&<R=V7G-35N6^^D"@JJ,>1VF^NNXB+J:B==_("9L90
M-#%!NJ7406,'I+&S1;D(RCK@@;M-!W-.12"+"2=,9UJ+J)?R;EN4IUA;/&A4
MT53'$Z9G`@&H&$2XSO6_8@"W'/V-"R+*]+?\GC;E@)9TR*:98(.@(HFLW2>@
MX(9FY(JB`@82%(<0.$DI@6YC9;Q@Y4<N'UI(,&THFY17+NN"RV-)HRV\LJ`%
M(=6$6464``WA(7V(*7Q<'`39EHWNNDJU=7!%8_O/&[C[>EHL9BTDVSQ)HLL)
MQ%RJW*4ZQ3;IQ$.42!/8(E6(:B"BD1?[.5$0!+4#D1>1++34_)NBH.A>7>,/
M((>ZF.\M,_M11'R!E9TE]O'3?3#RB7:>P#ET/M'D]B&O)[H8XN=)Q)H-@<RM
MH2P(QMX0:?6`D)I*&ZQ3>3`PE+Y2V460$1`H*B;D^@#V<]?9>*A[=#V<U#T#
MX:'LYJ'H^M0]KP4;H\=8Y^&J:_G;ZL>>\.0/,I[Z?-7P2Y'\SGE<8'ZEN7/.
M>W*O7WACOPB-!T^.B]J@Z/$%!VO#0=%!]CX:[7CH/L?!Z9+ANX74EIC)#V2"
M`N&YXA!O)O(^84$4UK7M8A]]$KM#0_NB^6#=:;IR!N*)J*H0\GQ%9[>N6F^9
M^_AT)FX;]GVJC@PJ+LT)2XCD9H+FWA!1PD5P0IM=TJI>4>'S!F*;<)$%N!_,
M3%Q3SQ<LA<=QOY*0C[;A5Y67<@!AZC1Z8B)0(W(*HBDDGJ?>B8"(;$91,'&,
M(>+9I!HFTCHQJ1DR;)@&PJ:1"E#Z@5)GD4A7CRQ[TSY$`WA69@V,+E(`U#7>
M)O!IJ'2%9\54(`1AY3'*;13=$!,^3:31I$@GY]U,S4=.;7ZM?E3DV[XFT(0R
MX-4',DHL=P_=B05?(XN,9$5=.U@(!CBDV14.!0$PEW0$0,W8QF5+E1`ZA0?0
MEJPB#4P$TW3E)<<M'KZ'U'=U1`>0=X`Y-;HXH;ZMJY+AC?+K@>61;[08Q&19
MZQQ;6M!.7%PL*"?DD3J*@HF5T<E(8@&]N#9B^NESC2<7`I?<W(C=*&8BIO`0
M_5W.V47C`)J(;@N'2)S!R]6&A@*VDHI\SDXYZD5=F_CW*+QD[0/[19LZ;&,F
MH0>8Q3"`^CA/B(8)'0C)H+=DI99`!!60?6+))1%U,3]6`B(+0;A@W]42F,`;
M`I-9%0BR*Q"*I*I'*HFJFH7?3434)J!BF`0$!`=!#T%$5DR+(K$.DJDJ0JB:
MJ:A=Q1-1,^H&*8!$!`0T$*,I(V1:#\YD^I,=[;4,Z.9'E^U&,NB81+RC['9R
MC3F'?XWMJT9,P"=A=E@PD/:EQQ[H$^K25.YC$")NTR@&GD[Y-9+3E*4I]TY<
MJ<'UVRQY."CUKB?6P+CKDRH3<"X3=`\AFJIS=2VF(I4T@LCJ;0R:9BZ"98Q_
M3]JNSU*'I-0T/;H>S]K0]!J'H\50/]OHSS>E:Q/^LOD[S$AZQY[_`&0//5[]
M/+$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0>E?7[>
MBRBP=9[GV]`,S%"4N:>51.LUB6.\`@0!`AE%W!PW$DRF,(&-ND/(Y`"_W6)\
M8*.7#&':$FKFM>UW3,QS).6EO0<$45I<42F,FN_?GW#FWTBKZE,D2XLKY'=+
M9@NNR+9G;O3:3#5..L=H[M^+6F`.2W1.J9V(=7NB:0<*I&Y#^3D,`:9AR8Y(
M19]<%XQEH$='ZL52$MZ)+/R!"`'*4%CRZ!C\FAA(73VOH<*;6/ZTMP-WC-TH
M=OU@.?)7-]L4X7J3)CO;X+HNQ)N@`Z[!'DTI[!N[U>7=-QRZC9]'6)$.)XC9
M=)44541F53-XTYR&`P'*F],)=!`0`=`&#QUC.%ON";&NAO.W6O=T=`1Q7S.+
M9J$BHUH$+)R(J%%PMY0KU@)Z&12W1-J8`L#$DA:.0+=A[3MF+BE;F*PB)1J\
MG#E\JN.4=QC!T+A))P]5<N2BB58X[^@D`:*[QID.V+N'J/*58^.D4TYQFAJ`
M=9(VZ]ZI^V#40#^4-B>CERSDT`</G5H/Y>'2T$3GG;8,6YH5),Q>4!4<M$TA
M$.8P@.H"(#+6(Y6$[_&%VO6B"0J"<26]=>]<$8H.H>QWG@R9`+RAH0!`>70/
M0.$O"1$H"B8(J>Z,:S?=8B`Z@D?RDAM2@(B(%'DHZ$YB7&<ND=,$3$DK%M=Z
M'5@?K2D`7#4PAH;V1=-AN4-!Y:LGB-X>Y26M))&]D6#N"&06=HV],NF:TE%K
M0:JH=<:.<$;.FSUH[75`=\B91%%0R9+#R*Q3(@A>EIP=Q&:$/U@,'4E'D</H
MTRG.9LN*C<X_\H@\H[?3CV<]?9>*A[=#V<U#T#X:'LYJ'H^M0]KP4;H\=8Y^
M&J:_G;ZL>>\.0/,I[Z?-7P2Y'\SGE<8'ZEN7/.>W*O7WACOPB-!T^.B]J@Z/
M$%!VO#0=%!]CX:[7CH/L?!Z6^K\BS$+<8-&]OVH)]P>KN.X7`1K%\!%`$I_(
MRG5?"F(:'!$2CR#3CB`O!F5Y?&1S._R7=OQ.Y>Q-G"N)%Y`%%]1*YEG!5%E%
M=3&,V*B('`%E2C6$>(>%A%9ZW+(\@82X(HKJMXJ3MZY_RIB1FE$BFZIL_P"M
M41(MH)2F2$IA`QT@.@6XK9R9:STQ"BZWH:$FHM%40$3$;O8Z0\H4*&@!O&9)
MB.H>QVZ9+A+!F+E&]9FS)R%MI*3M609MS2<RS-%)K^5>S3(9`JQG`==H013W
M1$1$"C)W,X1`JM]Y"GI1FOU8%,M#PC1K;3<F_M,!'C5_H.P!,(::@(C@G`=O
M/5IP\*_CH2Y6$:IO)1DO?,^U]U&YU4_:K(1K=!PY.([J)!#>$HE4`N89?'&&
ML=QMPP]A2'N=-.[::3DY&MM"-9*08S<P5R\3=I,S+G2=E6!0B@`H)]0$:?W.
M_M2W[AN:3ORXX^;D9Z`BY)TT28M&164,Q<O2*&!MU`I.3%#=`553Z@.Z4:6=
M-K1'&L\<@@28QN+2WVYC[V^7RJVQ24C#@(Z[YB-$U3`(AUH#NB6RNIOAQ>F"
MKXEE57T=Y.X3CI*+8NTT9]HZA%C+$CYENW<)N&SIFKHN($WA43*LW!I(L'"+
MQB_;(/63MNH55NZ:.D@7;.4%2:@8AR&*8I@'00$!#T+=GU&AE)&VLEPODKU,
M-3-6,S#OV4@@J.@Z)+*%:B;8.^1/ETU`<(3,DY!Y(/,86:+QUJ`F<.$(-%JJ
MLJ(#IUAA)JI_W6O(&P/2701L!"IC%G5,!#"8/*%\#,EW8B(B/**ICB8.8=0Y
M--/H':KL]2AZ34-#VZ'L_:T/0:AZ/%4#_;Z,\WI6L3_K+Y.\Q(>L>>_V0//5
M[^S4,;YUSS:V/[X<0[&>+;CV.NB6?(Q,DLH@P>/36ZP>)MP5%)02$7.0XE`#
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MV(=LYMNU<)K$;O6B^AT0`2*D,41`P#4[BC+W$1:EGY"MD(\;@ME6(O&8=Q!I
M6.2EV"+YQ;T:[;D5.V716ZD5M\I3E$Q2ZA3>&C.+7&K5XY$I4UKC2NBSHDHF
M5*B'E$]=T>Q8HAJ<!$57!0`NIAT*4PA'S<#*1TW"RS1!_%R\0];247),'28*
MMGL>_9F.DLBH00,FHF<2F`0$!$/V-8GP#VQ^D&Z*MCX!^'C]#,-0=KQ5V_%0
M=):+TT'2%!TT':\=!T>(*#TK'"OECQ'&V)"O(R<\F<:%;L8(R;N_I%$I=>J=
M/7YF\*14-[=ZMN<P>Q,%1D%",&L5#0S!I%Q48Q1(W91\<P;E:LF31!,`*1-)
M,A2$*`:```%90L:*4!*4O''MY6Q&J&5*BF#^=MYQ&,P65-R`F*BI04UY-T1J
MYL*9EQK>S5RSO*3G3N(9JP+.QSM_'-&*\9*0$\NQ`2E%J55-P1U[(A]`3$"E
M,9-51_?C0YP$3-W%G*F62T$0`#F:N%4^7;[$X\@^KR5B*8L-=>5LFTRV>[;/
MI".=,05B<?>49!E2NH]^0BA"'?J+,@!0NAS&*/*0P:Y,N^2EQAWH6I.0UK*I
M*'3>NKQFHI9C;+./%/4_6BZ,103D`>K3(=8WL$S"$UD[*F.HB[7\Q>,C%VHK
M<B#EZP"W85D@V<.FD:L8&JF_(&>(F5,D8V\B)0,&Z(59&.WUGVE;.-VZ]J.H
M6VH&V8N(@'XLK!/<S%N_B&C=-LX\LG2'0<"8AP4(;<.(Z"4"PMUXCL1\R23%
M%JHSM]C"23!,2;FY&S$&5L[;AII[%%8H#H&H#H&C[)'#+?MTP-SVR@\GXRUI
M)\N>2.X8-CN2M+/NN'*B[0<F`HI-DW)5!.<P%.Y(41&IN*OIY[IW_C9_'QTQ
M,BDBBK/0<VFNM;LJ\3;D(GY2'DSIJN)"^SZDBI]3JF$:$I@`2B`@("`"`@/(
M("`UQ/XGB^N:6W'-+^18,UCE3ZQ"RLH-8>W%#(@``8P,GZQB"70`*8P@&@\G
MI)?^VUF_SQ2L'?V(:_SQ;TX]G/7V7BH>W0]G-0]`^&A[.:AZ/K4/:\%&Z/'6
M.?AJFOYV^K'GO#D#S*>^GS5\$N1_,YY7&!^I;ESSGMRKU]X8[\(C0=/CHO:H
M.CQ!0=KPT'10?8^&NUXZ#['P>EPO9;<RQ_RBO*XIT&2('.9TO;,0A%M]$B%$
M3&*,P)2@`ZZFY`'FLBS$$R)I6G:-N6X0B8$*0`A8A&.'=!/V/**>NH;=M0>"
M\&6NA=>6KA9LEW+E9@ZF1A5)DYDX>*B8!INB[D%B!Y3JJ84DDQ3$R:W6&!,D
MD\DT[<21(8S:'"0P_"@[(J":*A'+&/*IU@&`QC"E(&T#=/H4HB0IUU[PX:L7
M7JJ8_6+2"6.<#.)%\45$T4U%Y#'@LWRIM4P-O+'%7=,85!W!$`=*7]\W79CF
M&:(F<R,LRQAE^#!JU16WEE7%Q1,JNV0*4`T`^Z7DY3;P#RY%O6PK2C\:2V%+
M?/!)6$Q72D8R+N"XSBSLJ5CU78`==D_DG.^H9R0514(Y`_6B`**W!Q3WR9W,
MWE=<S<,1:#^3/Y4H1EU_477=?E"HF,=X^>BY8BJ.AB$27#4P.#`%UV3,@<8B
M[[<F[9D^K`HJE8SL:I&.CH[X"&^4BHF((AR&`!JY,<Y.QN[N3%]RW*,@WF6?
M7L6\BX01!@-Q67.G*HS7.NT21.XC'.ZJ'5IE.=L.\)H7(5@RI96W9Q(YD3G(
M"+UB[0/U3V+E&8B)D'*!P$BJ1A'F,43$,4YL5VFHNW-<[V^G=Q-&P*`+M&!B
MX!S&R*YTBC[%-1P\:E*8P>R,0P%$=T^F,H630.UDH?'MEQ<BV4`0.V?1]MMF
MCM`X#SD4(8H]'H9#QU$&(6X)&.:2EMBH?JTU)ZW9)&=CV1U!]B4KLS<69CF`
M0("HGVE`0DN'ZY3'8WEBU60=PC5\/4O9&TW\JHL\;>3+:*@M%/ECH+D,'L$E
MFY0#V)@+Z3-5P-7`O4;32R(X\H`?8E-$>0X[63`0$`$J:C@42CH8!``'3]L'
MI^U79ZE#TFH:'MT/9^UH>@U#T>*H'^WT9YO2M8G_`%E\G>8D/6//?[('GJ]_
M9MGX19RB<&_RK;.%+&CIA=,56T9)W"S7CXUZ[2*`F,BFN=,RQ2^R$@&`H@;0
M0RO\W3F@KB$O_"DY=D_CR*F%=Q^R8L[B/'Y3QV)#CN=9$S!S22"28F.<KMZ;
MD2;!IQ0_]BG_`+1-HUAS^UN7_P!)TG5X8AS%:C2^,<7==MS_`)16N^=RC%K)
M^X/",XN>(ZUU#+MG).H?LFK@O5K%U%,`-J43%'Y*5I?G;D[\>4[QS@''D3C6
MRY"X7UV/H2(<RSU-[<<DQ:QCV7=O)MPZ<*+';LFB&IUA`")$*4``H!5X8AS%
M:C2^,<7==MS_`)16N^=RC%K)^X/",XN>(ZUU#+MG).H?LFK@O5K%U%,`-J43
M%&?MRS,.CB&\7,:]):]_V=>%]N'UOS)T=6+MY"3\H\CW[8%2D\H;.6PF,GOE
M1504,"I>)7AANN;?S5G8U"WKOLIBX=+/&%H23Z>D8.]8R&4<#O)-)!<&KPC<
MA2I@L1PL!04<*B;]BV)\`]L?I!NBK8^`?AX_0S#4':\5=OQ4'26B]-!TA0=-
M!VO'0='B"@]))2[TQB,HI@\DG9B@`F*U8MS.G!B@80#4"%$0U$.FN(;,$R3K
M)257AX[RTQ-XR[VZ9=]=%QD*N8-?X1!F<Y0'EWBB(<A:O#)URE65A[0B%))9
MJV,0KF0=*+$91<6V.K[$JKMTJBV3,?V(&.`CR`-/KDPI:L=:=CO%W+6/?,(B
MSFD4@BU<"V6*VN/)!E#OG!#`*3A1D7D4`PD21$HE*5.[K=M/++%N101;W:QX
M?[ZZI$HBY,1M^6J`NB")C&`@-#`H`\A-/8ZJ*SW`ICNZ3E!4RVYBB6DDU#)(
MZJ'30QO+-R:F$=XI$"@43>Q3+H&Y5MP61N$V`P'<]Z$):Z-TMFU[6X]A_=MX
MFS8*JVU>ZBI4F2ZR1&[ER@*8E'>4,82@H4;'X6X>?<-;'M%RV:S1XPQ'"#:7
M]QSW+>\\<!^UG=LX\`CFY5M2I+D43#0RRA30%EVG&HQ%MVS%M8B'CD-XQ&[-
MHF"9-]0XB910PZG55.(G4.)CG$3&$1QYQ3X6BW\W<N/D8=">BH>/&3DFAK9F
M59R`N=.*0`RKQ$IEE&S],A3"5$B9A+U0*F(CCV[X8N/LK"@L9M&"Y%:W;I59
MD$[U*WW+K1=%TF4AU3Q[D#&`@"*:RVZIN/Y:4=(L8R+9.I&1>N#@FW9L62!G
M+MTN<?:D33*8YAY@`:XE[MB2*_DN\-'>3JBFHW3.>:N>1DX@GDX@``<K=)41
M*/*0!TT]EZ,-GT&3M[CW*`'?R94"G'REF\8(P=^PQ%#:`=TU7!"703U`OVQN
M01T`PU&SD*^;2D/,,&DG%R3)4B[-_'OT"NF;QJN34#IJ)F*<A@Y!`0'T+7R#
M8\RTN&S[T@8RY;:FV)C"UDX:8:%>L':8'`IRB9,X;R:A2G(;4ARE,40"K7@R
M'$%[DRC"D.F!]T#L(F`DG[@PE`=3;J_DO)H(<NHB`@77!L0)=Q5/%MEO')-=
M[JWLM!(R[Y/>`Z@#NK+G+J4VZ.FI0`NA0]&X,>-99LM>-KVO9]Z3L&0X"\CK
M9OV6G(.TY9=/:"3UU;<TBB8=IFJ@!L'T1[.>OLO%0]NA[.:AZ!\-#V<U#T?6
MH>UX*-T>.L<_#5-?SM]6//>'('F4]]/FKX)<C^9SRN,#]2W+GG/;E7K[PQWX
M1&@Z?'1>U0='B"@[7AH.B@^Q\-=KQT'V/@]+PPV?[-P"@,S@R+]K$PW+?+:+
M'<7Y.57R0">V]CN@/)KKZ$NNL#ATWM]L#ANF<#&1;.8S!+>/U,4P&W4R.E3J
M$W1*`J"4VOLA`WH&(<I3D.42G(8`,4Q3!H8IBCR"`AR"`UG7%%N/%8ZSQO\`
M?M_<=HNJ+5Q!Q<NM+6BQ>;^@J"T1<)^V_P"^%U#70!K$]I0Q=&,38=N:J;@)
MF=/G\<23E9!1,!$"G<NEEG!R@(@!CB`<GH35EWG#LYVW)]BLPD8]ZBFJ0R:I
M!*1P@8X"*2Z1M%$%R:'3.!3D$#%`:R5C#!%KW'-6G+7`5Q&7&-MQ,U;T@W3#
MJX>XH][-AY`U>+-%$4I!,PB`&3ZM0#`@0Q8C.7&7<?NP^A%V3Z-LIS+LIV1>
MO(IR+B*9RXPHFBF46BKHY\@8*'*L8QBJD3`ZH*>CC_BIL:/4+;MWR:;VX6[4
M#)-'%R-418WG!.C%#<3]VHPXKIF..IUQ=*E#5(1J"O:SI9K-VW<;!&1BY%FH
M11-5%4-#HJ@41%-9(X&271/H=-0IDS@!BB`>@];W7?4=)W.T*N0ME6JJG<%S
MF>))"H1F^:,#&38&/R`!Y%5`O+R"-9PSU<#5P3\IG*,!'2*J2Y4)61EI=6Y[
MP,V55]B<$52,`,8!,.\<0$0$!U]/VJ[/4H>DU#0]NA[/VM#T&H>CQ5`_V^C/
M-Z5K$_ZR^3O,2'K'GO\`9`\]7O[-X7O[6<+WX3K!WSG&!FRC%&Y;TBF^06C0
M5&<6&2;?B^I7CI95J`;K*]+<1>L7Q"%$QS-WRIS=8Y+KE_-6.)'W3LK)-L8"
MN>"<&`"N4$GO$+:17<7()`(]6[9."K,WB.NJ:Z2A!Y2UAS^UN7_TG2=93RO@
M_$<MG;*-JW:__)C%4%$7)/2MT^[G#(6VYKR6)M%!S(J^0QSQW)'\G1-ND;F.
MIHD4Y@__`,1^6OBBXD?Q)6*L@Y&L-]B^_;SL*U[DO#'<FF_1D+,N*7B$GLK;
MKQO*I(.DE&RQS)F1<HD53$-Q0-\IJR=FNQ\/W#GNZ++NV3]R\36H\DF$_=?Y
M1\,`6F]\@=Q$5-N">0MWZTDKU<8MJFW.!NK*)E4[L:VE\WSDOAI?R46]BC9@
MOQSD"YF5H$D&QD!E8A"0LZVVB+]$F^JT7=NE4B*`4YD%`()39%-BK*A+[XA[
MN<6U-9NM^7@W%J3=F0\0V5;6S;\!$OEEAD(EJY>OA4FVAQ(NNN4BZ:!B()!^
MQ;$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0>DS%+=
M:9#W+Q9D&1Z\I.L,CY%:3MSUI2:#O"7=U`-!U]2LERW5&#RW*`QW7[^I5/<N
MU(]SU0$UY!)Y9J(Z<N\'*.G)/M"+@B6<O"RXM5,1$/*B(R@S8(!IMT,S*KR_
M\CU=*P<T(W2:E5LEK*"DB!`(8\V\6FE'`[G)OK&<"JIS[QAUY=?1QEDI!/=E
MK6O9>UCN$C=6K[E73$+2>\H(:"8$G,6B"?+J053"4-#&&L_9BN9Z@]NX8QEU
MXJE**[E]D>XW<]/2C8IQ$Q=U2,*F8Q1U`J^[KH;0?0LWB/X>K<DG&2H:<BS7
M1'6FQ25EG;Z-<`]MN^&S!(N\NY;K)D;/1`JACI]0<Q-Q)8]*VA?"9L>6#*]4
M280E"V]8T,HW4.4XMY%E$`M.O$Q`-XS<Z:J6I=#@4PAK'V#;J@R4@JL:6NRY
MED"H.[EN%PF5-P].D`FZI!(A2(-&X&$$TB!O&.J9553T+MLM)FV7NIDU/<5A
M.E@(55I=L2D99B@DX/R)D>DZQ@L8>0$UC&T$2ETD^'B]'_D-Z8]>/5;1CY8X
MM9*1M=591>3A46[K10SB(=`MUJ0^R(@JF4I`(@<2\2V;479F,GCG"V0;@MUP
M14J!_P`KR6ZNTLQ!-8WM#+2JK-$IM!$!,`@!AT`<,1SAWY;,8=N+(>'II03D
M,9(8.YU;HMIH8A1'=ZF"F(E(`-H(@4#;#!2MQ7W=4!:$&B8$C2EQ2K.):'7,
M`F3;(*O#DZQ8^@[B*>\<P\A2B-85PW@]:7N:,93SYJZEDHU^Q;RTS<CIJQZY
MBQD$B+]1&M&RZZCM5$I`(JH;3<3$PLXU@@1JQCVC=DR;)`()MVC1$$&Z"8#J
M.Z0A0*'+L#TG&KB`TOUMJR>!K;Q3:J22ICD<7G@-O%7%+1ZR0CN@9LYE[V'>
M#E+N;N[J<XAZ`]G/7V7BH>W0]G-0]`^&A[.:AZ/K4/:\%&Z/'6.?AJFOYV^K
M'GO#D#S*>^GS5\$N1_,YY7&!^I;ESSGMRKU]X8[\(C0=/CHO:H.CQ!0=KPT'
M10?8^&NUXZ#['P>EX2X9VF4&8'PZJX5%44]]"4S4^:N$S&#3<`I4-=X#?MN;
M3T,W/Q,8GN47(Z9BJG,J=1.-48VVF4A^8.4IB@/(4H;H;`])?;E/>ZB[(NU;
MJ1*8N[NBZ@DHIYNB!2@8!<LUC:AKMT$1$!K!DRB=10?\,K3B'2BH@8ZDC;<4
MG;DHH80T]LY:*B'3]`F\=7['&?P$TD7V:"@(2$7(-QZQA,1+K0W5.6Y]#IF$
MIBCRD4*=(YR&DO\`=IR8C=%KO'XK-HEC-0L2LJ43`!7LS9V0P&$*N`:%.H@Z
M6,8H<P"!`!=9LF[22`QSME0X8A35`"C[$09'35'U0`AP$1T#EV"FWRK?RV.;
M846,#AH[N>)@V*C80*@MNVKC'?\`*C`!!ZI.1W`$=3`H4%!.9M)9'E9G+<P@
M<BH-'A36O:13DU,GK!Q:ZCE;0VF\5Q('2.``!D=T3%%A!P,7'PL-%MDF49$Q
M3-O'QL>T1+NHM63)H4B:290Y"D(4`#U/H':KL]2AZ34-#VZ'L_:T/0:AZ/%4
M#_;Z,\WI6L3_`*R^3O,2'K'GO]D#SU>_LWA>_M9PO?A.LIX!O$B";&_[9=,H
MF760!PI;-V,A"1M&ZFI?;=9'R*3=R)2B'6$*=(1W%#`/SBGS9^=.LA+UQY=%
M@7)CJ+?K[X-9F`XF+3CLJV5%+'T*JB8Z:4_&]0`D53-(.BB)#%$<.?VMR_\`
MI.DZ>?VMO[_V*)+T7G]K;^_]BB2I5NX237073.BLBL0JJ2R2I1(HDJF<!`Q3
M`(@8HAH(<@TXL7AP3:QMCR&59&"E;<MH`)`MHN]\,%NG*UM$CF0E129P\LM(
M*),RE!)FHR2`A"@W(4O[%L3X![8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#I
M"@Z:#M>.@Z/$%!Z3/*R2I43'Q1>[03F`@@*;^!68K)?;`$-3D4,0.?4?8Z&T
M&I,2`4#&RI=0J"4`U$_N)$@`GTY]T"AR\VG-I5N(`F!PD<P6PS,83:=4!+5G
M9#K`#3EU%`"Z<FW7FTK!L:`)`9GB+'"*HH`)4E'`6@S%RL4!`!^V*"8XB(:B
M(ZCR^C?+LB8JKVK,V=<J!"@`F#<N1O".U"ZE'VC=\L<P@)?8@/+I[$;^M014
M\EN7&RTD)2@04Q?VW<#,&IE=0W@T1>N@`0'34=!`=0$OT!WG7`]YML:9(\J4
MN"?1?R<A!PSR6;IBLM<\3<,44Z\6^/NB9R.X**IQZTQD#]:=6XN&Z_N(K&E_
M-,A7/:MMW%:%EY(P#?UVA!VY+!>I)*?)8+AU<;-J+V):)&6D.I!4Q^I/O@<Y
M!R]PW6-F^P,/1=YW1"7[''OV^L78X2DII[$&MFX`@[GR0X:"#H6[*+#R>.7,
MX,!0,0@;@B,;D#//$*>\D98!>;UD33B^W4FU56U.9#(=Q'40`VI3%/U+%P3>
M]JH;=Y3_`.&MELXZ7<-A:O[ID55IBZ9!$XE,JBM,OQ,=)(YB$,=LU!)`3%`W
M5Z\OI'+_`#=G/$V*4FC07IT+\OZV;:D5T-S?(#"(E'*;ITHIL11;(G44,(%3
M*8P@`XUXP[ZF2V["7WQ.W9<N1)R6=I,F4!:V>IJ2@+SF9UP!A3(UCF<\X=NM
M!$I2(B)-1*6E)'#F8,7988)(E<+/,;7]:M\-D$#F`A55UK9=N2D`3"!=3B'+
MR;?0'LYZ^R\5#VZ'LYJ'H'PT/9S4/1]:A[7@HW1XZQS\-4U_.WU8\]X<@>93
MWT^:O@ER/YG/*XP/U+<N><]N5>OO#'?A$:#I\=%[5!T>(*#M>&@Z*#['PUVO
M'0?8^#TI,O6BV7'(V*HQ9=9-GOBYG[';N#2,BQ3(3V0N(XYUI!H)!`1*+E,`
M.=1/=:+7$^([R%8;A"UKS.=0HNI/=;];!70ND'*'E[<IBJG'0#N47(E`I=`#
MBIF/9O6R/^-BC-Z?K#E2\HS+'-V`%,IREU;`H1,H["`(```')Z.*[I31`B\Y
M8,A"N%2F*`+!;=P*.T=Y,.7>*$F("<0Y0W2ZB!-`M!BFN94]N7-?$,NF(D$&
MRJ]QK7"5`H$$1`!(_(IH8`'4XCINB`CZ23N*XY5A!P,,S6D)67E'2+*/CV3<
MF^LY=NEQ*0A"ASB/U`Y1HF(>#&VI5\^?NRM$;Y]QB/9^6(18I%74%"2J8MXU
M@&OVZ0E2:E2'?.5IN[]=5?V&0OUN@5$KE^K8!;C2(F8X*"J,OAUVDS3.)0%/
M?4`Q"B(;Q!.(:A#9EQU<&.G1#]2M,0:ZET1B"P&`#FDHI5%J_;%`!$1!%-T?
MD`-WEU!)?&V2+4NM55(RXQ;&320N!!(H"(J/;:?]3(-PT`1^WM2<@".SZ)VJ
M[/4H>DU#0]NA[/VM#T&H>CQ5`_V^C/-Z5K$_ZR^3O,2'K'GO]D#SU>_LW`/%
M=9F.6DM@.SYG",K=%]GO:Q8\89&PW:CB?05M>2DD9E=0H$*"0-(Y4IQ.70P`
M!Q)4-Q(\*T5;,E?-QQ3.W\P69+ST=:BTV]@FR4=;-\1$E,&39JK>0$)'R**S
MA(P$;-3H@J8ZV[B["F86T.PR#"25]34Y&0DLC.,HL+IO5]/L&!Y5J'4++)MU
MTNO%`QTP.(E(H<`WAR-QN<']LV0[5=RK:8Q[=<G=V.@%F69Q`CC2YF<G:E]J
MI@*I459!`!.W.30Q%4S[P!N__4E__MCJ[!^<#-:(Y1&_W86@2U?R,]C886_'
MB@:1&P@]SMX9`7P)ZCU^@#U@`3JM<C<;G!_;-D.U7<JVF,>W7)W=CH!9EF<0
M(XTN9G)VI?:J8"J5%600`3MSDT,15,^\`;JULO;OQA8K.6(9JZN5B[X>(]U'
MH*%$JAD9"!9/WR`B`\BS-OUQ1Y2&*/+4QQ!YROMIF'B=N5I*-O=N.5EWEL60
M6XSF4NIU$RUP%2?R\K)B<Q7<R];('ZHZB2:)>M746_8MB?`/;'Z0;HJV/@'X
M>/T,PU!VO%7;\5!TEHO30=(4'30=KQT'1X@H/23UH7/'HRUO7+%/H69CE]X$
MW<?((&;.4M],0,0VZ81(H0P'(8`,00,`"#[!USR3U;$^4WK%E#R+PO\`)W;:
M774;V#=0!H0A5T70FB9-0FZ0-5CB!BHI:8QCQ6.51UDT7A6X=9N*D8VJ^046
M-H&YJF+DI0WAU]F.[R;U8J8K[@K,L;V.T6%,1,056]L-45-PP@&H:@.@Z>CG
M&'*EUZSG%5]*LT=U,PJ2#*W'#^.*`*`(`/7I)Z&VAM`0$`$,7@H<$VL\2ZK<
M=")B%WO=&TGIV!`%0Q0Y7B38--1$=A0$V@#Z4T,H4+SR<\;%7C;&C7B:(L$E
MB;[>2NN1`%`8MS`(&23ZLZZVH"FGU8F6(\S)9MHNG5A3:W7QEM)VG9Q8@614
M0%L>VX.;.%Q.6HE-O$=HJJE6,(_;3[H`4MFY.;9@X9'BBKEN>Y\)0]N8]N!^
MF=,J>CK_`!RMB\#*]48-],T,\C3F`X_;M-P2K*1WSMET7_,/E`<Q^.^.E;)=
MILXI;K2F28A?49+W5!*@"A0%(S2.;C[4"M2Z`-0&1,Z6E:2V+[JN=K9EMY+L
M&_;=N^UIBY7\.\N!A&(MT%491(5V<>]725<QJ29BHG`#[V@#=%I\-5D1UU.+
M&8Q,G>LM-W9;5IPMKQ\ZX7:1#E\XGG**RXKJ-ERD18(.%?8&,)`(`FIK/S''
MK'\,SM59-R\4X:Y7*DW<W5E`I^H4E475EI)N!W03%4BC@B>@'#K@*!!&-O\`
MXP>(/B<64CR,Q)F-+%JD:R<)J%,23BWD#;S>X>NW2BF8LC<;Q,P&$PI[^Z8*
MD&#.6D(%T]9N6K:;BDXM:3B5UT132D8]*<;/61ED1$%$RNVBR0F``42.74HR
MJUH?.T<64`T>^4F/9%ZI1'Y&2)%]"@Q>Q^#5;%CR)%+J`'/"N-`Y-S4QA&6F
MK,/B7B%;&.[D1/9.0586[GQ1,===:0BLH-H9(SM00$XI-I%T)S&`"G.<1`+,
MQK8D.M<-\9"NRW;'LV`;+-&SB<NN[)A&`MZ'0</U$D$SN7CA%`IUE2)E$P"<
MY2@(A%W#>UX8?X=5&JP+"+Z_I2ZK\BE`*(%7C4,9-GL<8X:B`B$^D(<PC48>
M]_G6>+W)*3/J%C6LQ2M%6S43)B!ABFT;G-+(0D9@&J9P9E:&4Y5"@B<V@`43
M&.(%`!.;=`QQ#D$Q@(`!J.T=``/4"OLO%0]NA[.:AZ!\-#V<U#T?6H>UX*-T
M>.L<_#5-?SM]6//>'('F4]]/FKX)<C^9SRN,#]2W+GG/;E7K[PQWX1&@Z?'1
M>U0='B"@[7AH.B@^Q\-=KQT'V/@]*NW,8Y"KHJHF.3=WRE5()!,3?`0U#74-
M0$/5`:F,<9*D%4\?WNP2@27.KHRBGD+)2(.+*OQRD83%*1NLFNR>_;-UMUCL
M1,8$O9<5TTU=I.6WE-W)M5&YTUVSMM*Y-.[2=HN4Q$IB"5`HD$NH&`VH#LU]
M'A\D"D)U:*^46:RG("@G<IV^NV)ZHE`$E1^H(_5K*>.59)-&X65XMKP0AUW2
M::[F+E(1O"N7S!D<P'/U*K`B;LY":$WT`.(;Q*.^E9!C&,DOX1Y(.T&35/V(
MF]FX<F*0.0!'E'8`TJG-YQQN1=`N\LVC+F83[M+V!E-P[.`,Z5`^A!]@)-[E
M*&FIR;RFF6#2BY"E,#:(LN_'9E`,&H=6Z/&$;:^J`K@(<].OR+M+(5YS!2#Y
M$D[8Q5L0:Q]`Y'<HY<N'20<HZ;D<IKH.N@:"+/$EEV=&MH5BHM<;BTK4=GCV
MKANS4(DWD[TN.XG9$%4VAU`Z@GVA,RIBB"*BP)"5XKB!_;\<>7%L]E65N7+9
M*KAXX2;_`&EM(&O%!)%7J.4A2"J9(IC',0=#G.,1A;C/M-O`K32S1HTO8\8R
M@7L>K).A81\Q)FB3C#OH@ZY#(G?1Q4R(B"AS'5!,Q"D3R;CFV;L732ZA"4>,
MA:S[5#744&=QQAD'Z)!'E$B3DH".@Z:@%&F,,9)N2QI9`_E3.,N8A+ABDW)#
M[R)&4O'^2/V92\@@J?RLX"'U>1;A3XG):8N1&;EHN$LRZY21?S9HZ3DS`VMU
M6-FI4"N'<+*;R:"1E/9-5@*02)`5P1/Z%VJ[/4H>DU#0]NA[/VM#T&H>CQ5`
M_P!OHSS>E:Q/^LOD[S$AZQY[_9`\]7OT\L3X![8_2#=%6Q\`_#Q^AF&H.UXJ
M[?BH.DM%Z:#I"@Z:#M>.@Z/$%!Z6U,RVR9R^2QBC(,;GB&Z0&7:0$LX2<A<[
M8Z0`INM%DBD=A[+=3.58-PB2IAX:G:4@FXNV#DIZ%R*Q<J:RS:Z("W8]@,H<
MF]RMI,JIWJ*FA@'>%/?ZQ%4H6C'D.90C&V(%F10P`!CE;122)3F`.0!$"ZCI
MZ-RH+ID517@)E%9(X`8BB2D<H11,Y1V@("("%8CO=^X!G%6[D2U)"7=G,J0B
M,*E,HEG#B=(0'D:'5U#E#E]D!BB)10=M%T735TBDX;.6ZI%V[ANN0%$5T%DQ
M$IR'*(&*8HB`@("`Z4K^6F3+"M0Z(J%.C<%VP,4YWTAW5$B-7JY%#'`1`!(4
M@FUY--:6(\S;;JPH!J<8F+NB?(;[9U?VD\$P<E4Y0UT3$W)[+VO+2GN=.7I=
MFYO;OY/V7(MNNW=[3J_RJ-&::Z!IO[OM@UTY='3#"F-FD2U.FHDA<F15A?R@
M=842`NC;,"N5L@JGR&(*L@Y()M-],Q0$IB9G<Q#-C/3CQM>+&6R%<$22?G7C
MY<KQ*54AW)79T3@(@J"4BB@(%`-PFFX`K77?T6A?-B0Q04D5I1E9EWQ;5JD0
M"*NI%Y92K>:;(%*`"9=PH1(H^R,.HFU+<Y85A]M45MV_+'ETT)AK%S*2";AQ
M'N$WB0$=LUTU$UVZIDMTY#;I@!5-0A5W<1;;_&$VJ)SA(8_>%81QU!#5,B]L
MR!'$>5(!Y1(T0;F$.3?#0-,DS%N7U(9)Q9:\M"7N^BV3>7BE+<7A'^\>XIZV
M$UG3(R23%9ZV&0(J!B'5+J0A%1TX@<S+()I2.5,XLK/2/U9>N<V]B>SV[J-7
M,L'*)`?W)+)D(/M1(<?V_I[@Q"K%%+:G#]G3.>5TD"H"F5G9]MMI"?Q*_*BE
MJ5,!=25MG`!,!2[^@"([H#Z`]G/7V7BH>W0]G-0]`^&A[.:AZ/K4/:\%&Z/'
M6.?AJFOYV^K'GO#D#S*>^GS5\$N1_,YY7&!^I;ESSGMRKU]X8[\(C0=/CHO:
MH.CQ!0=KPT'10?8^&NUXZ#['P>FC8V=?.[;NJVCO5K2NZ/13=*1QI`I"OH^3
MCE1(5TS7%)(YT@434*<A3)JD`5"J9%G;#L-ID6%2;MXB]UUH><40C8V,DUA9
M2!)N,`1C06,570SHATS@'*F)DP$K-ED&*NC%DLL`%<N';4;JM5)4W(4B4S!$
M\M'4W()E8I,A0$!$^F\)03L#)=DW8Y$-1CX:XHQU*D`"=8(JQ(*`Y)['E]FD
M&P?4'T.'C&,,*3NY7[FZ7_N>!OY27\HG\7;]MCNE$1`CEP@\(`B7E%+D'D,%
M2V0,77VOC"8FGR\Q(P"L($K;@S#@_6N'<*JQ<-'$<5503+*)@"Y`.8W5%2)N
MD*D_RKQ&2TXNF51,J#"WGTJY*`B!2"E.7')G$H;I2[Q/(^7D#>T*&I#R\UE&
MYE?^^$?W'"Q[,P\H`":4+&-U2AH(".K@PZAM`!$*!4V*E)-4IS&(>5O:_7)"
M@=/JQ3%JG)D1,'*(AUB9A`>4!`0#3*4Y86(L?V_/2$?'6M&S#*UH0TVU/=4P
MA"/5D9QXF=V02-%G)B"FJ)BFTW=WE,6"O$C`J=T93>R=QSC]5(H.SQD?*N(6
MVHXBPE`WDQ&R/E:9!U`%'*I@$0,'H-\CL6I3W!B680D%%B)@9=:T[B<)0\XT
M#=#>$$W!F+P1$="$15'3V0B&-;HDG)G4_'1:EHW&LJ?K'"TO:BXPPO71^=5V
MW3;O3_56]#A5-H&\(8[`1TY1`,LKB`"/U-1T^A]JNSU*'I-0T/;H>S]K0]!J
M'H\50/\`;Z,\WI6L3_K+Y.\Q(>L>>_V0//5[]-8_!6=9"'M/B]M.'$3%`&T5
M"9VA(IMON[OM!H3<20F4$B"M-PB(```!WS$GDG7H1_IK$^`>V/T@W15L?`/P
M\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0>E?14HS;2$9)LW,?(L'B)'#1
M\Q>HF;.V;I!4!*=-5,QB'(8!`2B(#R#5FO+!EI)_;647%U*0]KOD#.G]LN+?
M5CNNC6TH4PG>(*#)D*U!1(%B%)NJ'7./6"UM7B$PE+04DQ;MTWSZTTEX:23(
M">ZBH:Q+LZC<`X``ZEDB%V[A`#0H-%([+%OV\^="!#0]\*&L^0;+F.!"MU59
ML$VBAAWB[HMW*A!UT`PB!@!O(Q;YG)1[LG6M7T>Y1>,W*>HEZQNZ;F,0Y=0$
M-2F$*OVYY4X)QMOV;<TR],)TTQ\FCH99VJ0AE1`N\8";I=1#41`*RXWOA)ZP
M4"_89G9]W1B:(2MNS$1`>5RH,SKZD61<)/FI'K10-TY03,`E5(DHFO"0G$KY
M%:#Y0BCY)"VY^/47,0QMPR]O-)<6JQB@/L1.Z#E$VSG2_*_*>0YY8I2]:-OL
M[<M9NJH`B(Z(R"$N<I!#0!+UHCMT-RAHF5[:ET7$)#D,929O>X$#K`7:FH%O
MJ,2@!N?<*4?4$*3/&8/L]T9(Q3%"XPE;P((D.)PZQ.[G+XIPU'E`X"`AR#J`
M`%2%H%MB!;8VQ>]>(C:T+#,8V#(WQS"@06KB/CTR("DK<2F^Y*<FZH4YDC:@
M8`]![%R;-M(1LDT<L)"/>H)N6;YB\1,W=LW;98!(HDJF8Q%"'`0,41`0$!K)
M_#F]77+:U\'D(V!*J=0J1U&+,U[8_D%Q,(E,<T4LY9FTU$5E@*!N00&N*"UY
M<$QC;CX>LS03P%"D.'4RV.I%@82E/H`F#K`$G+KO::<NE0]KS+,64F;*-VS;
MY(^[UGE4[;T+)N"*@'*!DCJ&0$#@!@ZO00#3T_%KQ?GC.JC,G\,.`;;B)@4`
MZEY<LC-2-N7U%M5M`T69,;!MAPZ+R@)7Z`@81WRD]`>SGK[+Q4/;H>SFH>@?
M#0]G-0]'UJ'M>"C='CK'/PU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC`_4MRYYS
MVY5Z^\,=^$1H.GQT7M4'1X@H.UX:#HH/L?#7:\=!]CX/3\16,KP0*QR&Y2:*
M*(BH*21'-C7)(1EW1R*1]T#G\HD&ZA``N\":2A@`"@:E5[RQ1:ZLDLH*RLY!
M-E+4GEEO_C'<Q;)VB[C_`."Y.H7ZE'D,29$N:RI1,170C;F2;W1"BNGH*"39
MZT!D]:AO!J*IU'1@'E`NP*&"L/+2-S0I3E(U*A?;*8;M$"`/5D:(9,:)J-2:
M>V1;:%U']M[:HCB`XK+Z)>-W0+Q&7@[:+*.;A73F6"PK0CJ8EU2D;HMX]41<
MLX^/**15`2'?(0AT3^DLFUDW9T7UT9.8.S-2Z`#V%MZW9!5^"G+KHF[<QQM-
M!#739H&N&;8>$.F^AL8V0SD4SB412DPMUN>23#<``T*N90"\FN@!J(CJ(U?3
M3RE-*6OY2,L.'1,J!%''NN[*YG-Q,/9&`L:@\UTY`$2Z[=!Q^H[;':O;N=W%
M>;E,Y3%,=&6F56L.Y]EM!:/;,U2"```E,'2-8I>7C/1\):V+&>/)"4DI'?*S
MBVUOJN\E'ZPI``QUE#KD!($P.<QS)D*!S`"=*,[5L[(-XH)'`HRODL5;T<X+
MH;51F21<'=B'M=`6:I#RCR!H&\?W(P*^6=")BIC(Y#;MFZ8"0VXL<&T,J8^A
MMW5(!+J&OVP!`-8.W;]L>X<<+S3IM'>[I)6/N2UXYXY4!)):6>B1BY0;"80`
MRY6BG5B("H`)@=4H&*("`@`@(#J`@/*`@(>G[5=GJ4/2:AH>W0]G[6AZ#4/1
MXJ@?[?1GF]*UB?\`67R=YB0]8\]_L@>>KWZ:V_>UDW!,6G=]IS$?<%LW-;\@
MYBIN!FXIR5Y&RL5),S$50705(51-1,P"`@`@-1^"LZR$/:?%[:<.(F*`-HJ$
MSM"13;?=W?:#0FXDA,H)$%:;A$0```#OF)/).O0C_2V)\`]L?I!NBK8^`?AX
M_0S#4':\5=OQ4'26B]-!TA0=-!VO'0='B"@]-P]7L9JL[MB"E;LCW75+=4",
MN[6BY9!J)SD,5,[MNQ6ZL^AOX`V\70H;UNS<Y:MJWW:MS0<9/PY+E@XF>;&C
MYEB1^T71(_36*0_5J%'>(("4=@ZA3L\+!W/C]\X,HJ1U:=SO5T$5S:&+I&W0
M$B@"6\'*DD5/D$2D$GL1*K-<.F>6Y42K^5%;GEK@L&5<BF&J39ZRCP?1ST-`
M`A_*E2)G#VR8%U`"V-E[)+"+L9P[14E#O[DM\8]VBB850,M%6*W!9[N&(4Z3
M=WNI]8)#")!`3DM[&5L*J/D(DJ[J5FG")6[NX)Y^?KI29<H$,<$^L/H1)+K#
M]4D1-+?/N;P^B)C"`%`!$1$=```Y1$1&N)K,:1#J,'S6YCJ+_:12*YR5D8+G
M9;W4EW=\Z<6N)13$"Z`;0!`0T]"\[Q8*DD+<QF>X'":J9_*&1D+(MI'&C1=F
MN`B44U)5<KU(Q!$I]1.41*.OH9A=")NME(B)MMN0G6:J'N.Y&<.N`F3$-`*B
MJJ<V\(`(%$OLA$"C;$'=<E*7!?$[-7?<SJS[.C$7TI'D<3!HJ-]WGSU9NT;G
M71:)KD(=?K@0,0_5"44Q.`16%KK>([R@">0NJ(C5`*!OM0@DV:NPU,'*8-_V
M(\@";;2I9;`[YI#B31!>.R$WD),IRG-[)5JYB&J0@<HE]B"P;@@/*IO!NKWE
MC]6313CWXQ,Y!SC5%G-0<D"!7)$'B3919$Y%$S`HBL@L<APU#4%"*$)Z8>SG
MK[+Q4/;H>SFH>@?#0]G-0]'UJ'M>"C='CK'/PU37\[?5CSWAR!YE/?3YJ^"7
M(_F<\KC`_4MRYYSVY5Z^\,=^$1H.GQT7M4'1X@H.UX:#HH/L?#7:\=!]CX/3
MXUS@V+[GVCD%>*E[@63#R=D5-R3\A\BI&#VJAR-%$I0^]R"LN4PB!M#`!BB`
M@(`("`Z@(#R@("'T#A\P(4YGL+#GM9I/-43`H=D>]KA))W<IU(\@"6$:,EQU
MT$0`->30:`I0`"@````&@``<@``!4O>=[SL?;ELP34[R3EI%8$D$4R\A$DBA
MJ=594VB:""13**G$J:93',!1AXJ+CY:V,`8Y7,9TY.70\;!N''6/9.16`3(^
M[DV5$C=HW()RMTR@8"J$1<K*Q<#"LD(V'A(YC$1,<U+N-F$9&M2LV#)N3F(D
MD0A"!S``>AD*V(.9]RX23NZ0;R<\N'6K(6UCN*0MR1=QB!]>L46*Q`C$A@`O
MVQ,5-TA3Z1\1:&,+014CTDBC.RD)'35SOETR@!GDA<,DDHZ44,8!/N@H5,@B
M()$(70H%<,XB+:."`8"KMF#1!8H'#=,!54B`8-0Y!T&I;)$;#M27KC%TUN#W
M2:-44Y"2METNE&7''O7!"@91)%(Z;\!4$1)Y,($$`.<#8^EY14R\Y;+=S8<V
MN<=XZ[FU#@QCW2B@\IU%H\62RQAY14.?77:/INU79ZE#TFH:'MT/9^UH>@U#
MT>*H'^WT9YO2M8G_`%E\G>8D/6//?[('GJ]_87%%-0LB^B)B(X=<V2D3+1;M
MQ'R<7)Q^-)-VPD8Y^T,15!=!4A%45DCE.0Y0,40$`&OE9\3/Q\93_&M?*SXF
M?CXRG^-:^5GQ,_'QE/\`&M?*SXF?CXRG^-:^5GQ,_'QE/\:U\K/B9^/C*?XU
MKY6?$S\?&4_QK7RL^)GX^,I_C6OE9\3/Q\93_&M?*SXF?CXRG^-:^5GQ,_'Q
ME/\`&M?*SXF?CXRG^-:^5GQ,_'QE/\:U\K/B9^/C*?XUKY6?$S\?&4_QK7RL
M^)GX^,I_C6OE9\3/Q\93_&M?*SXF?CXRG^-:^5GQ,_'QE/\`&M?*SXF?CXRG
M^-:^5GQ,_'QE/\:U\K/B9^/C*?XUKY6?$S\?&4_QK7RL^)GX^,I_C6OE9\3/
MQ\93_&M?*SXF?CXRG^-:^5GQ,_'QE/\`&M?*SXF?CXRG^-:^5GQ,_'QE/\:U
M\K/B9^/C*?XUKY6?$S\?&4_QK7RL^)GX^,I_C6OE9\3/Q\93_&M?*SXF?CXR
MG^-?0M^]K)N"8M.[[3F(^X+9N:WY!S%3<#-Q3DKR-E8J29F(J@N@J0JB:B9@
M$!`!`:C\%9UD(>T^+VTX<1,4`;14)G:$BFV^[N^T&A-Q)"902(*TW"(@```'
M?,2>2=>A'^DL3X![8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#I"@Z:#M>.@Z
M/$%!Z;)$$W:@ZFX"+_+FV@*EUS@LQ:(&E#H,R;>N=,RNV)-.7[>(<])V>]<]
M=,XIGWMMG(HKUC@UNRQC3MNN5`'E*0HJNF2(<Q6N@;/H&7KL0?\`N;)$M!]!
MP;H@E\H3G;H$MN1*C0AO;*)K.BK!R#N@03B&Z4:D;V=([CW)MY2DDV5$H%,>
MW[:`+;CDC!M'=>(R2@".@"50-`_;&J6PIB=92<S'<#3W(?OXH?*4K")+D!N4
MA?)]XZLTJ0X>2-4PU1$Q5E1W@3257N"\8\C;*60RM7T^BH!#N;:@D2]9#VJ*
M@:[JI1,9P^`HZ"L8J8[WDY##4+9*KA0)F_[TCA8M$S"4%8JU">ZLNZ7T$`,F
MDLHQ)NCK[-4AM/8ZA;N8\L0$'?\`<E\1[.?MB%F6@2EN6S;CY#K8XR\0]`6S
MM\Y(8%U5'")RHAU9$0*<JBBA6439UJQ;,@ZD:1UO1#)L00*"8"5!LB4@>Q*4
MO(&P`#FI6"E82)DH19(R"L0^CFCJ,41.42&2.Q7(9(2B!A#3=YQJ_L"M72[:
MP\@IR+:%9.%-]L9`T0:^[$7,L;E.NU0,YBBJ:^R.JH`AO"&[Z8>SGK[+Q4/;
MH>SFH>@?#0]G-0]'UJ'M>"C='CK'/PU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC
M`_4MRYYSVY5Z^\,=^$1H.GQT7M4'1X@H.UX:#HH/L?#7:\=!]CX/3IWLS;@K
M,8IN%G."H4!,L-MSQR0,^W2*',"IV#M0>8C<P[*QG<CEP+F:BX8MG7(8Y@,N
M,U:0^XJCET)>3K':":#X=.98.0-@>GSKF^57!ZVLV0O*0AE3G(91)U=$LO:E
MKH)$`QM44(5-X@40,;=W4PU'4!I9RY62;MFZ2B[APNH1%!!!$@J*K+*J"!2D
M*4!,8QA```-1Y*882QA(.8W"MB/UW$A.E(LM%*(L%A9S&09)!(Q2+'4WC-()
MN<X;P'`=Y+KUQ)$X^Q]$DC(2,)UBZZFXK)S<FJ0I7LY./2E**[M<2@)SB`%*
M4"IIE(D1-,M7_>I=S6S[)NNZ0ZPN^36WX)>6#?*&NH?:>4-*M_B@LRS92Z;;
MM>ZY:UIIZ5N_=Q+MV\@DSS,)..F15#MQ7:2)%$'*I1*5;</H<Q`*96PU+7E,
M?WP,6XE8Z+?RK.;BIM%B4%))K$RZ2350[A!,17%%1F03)%.H41W#@%9G9.TB
MKMG6*,AHKI&$P`=-2T7A3!O$$!`?4,40$!Y0$!#6LBH&,<6Z>6':J1!]H59:
MT(DC@Q1]42II@/0'I^U79ZE#TFH:'MT/9^UH>@U#T>*H'^WT9YO2M8G_`%E\
MG>8D/6//?[('GJ]_87%G^K/GC]%LK]);?O:R;@F+3N^TYB/N"V;FM^0<Q4W`
MS<4Y*\C96*DF9B*H+H*D*HFHF8!`0`0&IS&V5X-['<2F%[?BGE]7%$03E*Q<
MBVTZ<A$QM[-WC)+R**EEE@W)"%4.F54X'=QI#-@<-X_T;$^`>V/T@W15L?`/
MP\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0>F,0Y2G(<HE.0P`8IBF#0Q3
M%'D$!#D$!K*.!'`G:6O?:DQ%P"`B((`1!$;[QZY55/[8Q8M5PRY-=5EA+M#Z
M!B/'K4%>JO.[YZX7?5!J*Y;*C6[)NS.`<H@=6:(H!0#E,F4=H!6/<=M`+N6=
M:$%`K*%T_E3]C'D3DWY]T1#?<.>M7/N\F\<=-`T"AC[:=M5<KWLDX8VBT.!7
M`P3(NB<E=KYOLW6Y3`1F13D4<&*(E.FDL6D.(3-+9:8RY>`*3\"QG^N=R%GM
MYH3NW$U+&>B8YIR0!455SJ@*K8AA((E747*7T,0X=M%!29F`L-%2%ARK)(E4
MN*Z[@?$7;@JON$3.JWC68F444!,"[HG,0I3&JWL(YPQ#=!QL5%2%0EFZ_N-=
M+.)0<'.PCGEJSJ"":PMB&!!)8KY$!2(34IC:G-;M[VH_)*6Y=,2SFHAZ0!**
MK-ZD"I"K)&]DFJ01%-9(^ADU"F(8`,40]#A<?1Z)".94F%?+S:'^WB^RQ*6\
MX6-U8@.H-"%('+I[$-X!#4!],/9SU]EXJ'MT/9S4/0/AH>SFH>CZU#VO!1NC
MQUCGX:IK^=OJQY[PY`\RGOI\U?!+D?S.>5Q@?J6Y<\Y[<J]?>&._"(T'3XZ+
MVJ#H\04':\-!T4'V/AKM>.@^Q\'I[ML>8U]RKPMJ;MF0,4H'.FTG(U2-762*
M(A[,A5!.00$!`P`("`\M9OQ7=EJO;EGF5WD"W;?*[-&,&%X1JBUNW:O+OE2*
M&(W%-JR,4$D!44,D!/8E.*J0248X7PY8DP7>9*)')C&/*U7#K$W#1R!7%TN$
M%$Q+N+D%1(Y=!(/LA$5;CL#B406N)R<'<IU=\Y$MYW(N1#54%'G5.$W@B(%`
M?+!(4Q?;;`*(0Y&Y;K;)&,5M+`3#LZ99),`+RO%C).A`=H"\3!0=1]3DBKYS
M5:D6^LI],I-#HS,'8QF0F7WS!%+/<>K$<L#G(FIY,H\Y1,`#HJ'L#6?D2WNL
M"'O*WXV>9HK[OE#0'S<%%X]UN^QZYNIOH*[HB&^0V@B&@^CD.^>$20:.[:R'
M)/GPH-)"P&SJ.82,@>8+"2\'DC=9'\A7441:.6_6*"D(#JF*BA*88YS'-C`6
M)).`6F7[J7Q1'096K=5,YPEV6*A\L?Z#NG;LUTS)F4*!M4P*90DA`6DYD)N:
MN%PS>W7=<N5!-_,N6*!D6;=!HU`$VS-`5%C-VX&.8HJG$ZJAAWO1S"X?O&K9
M6<ME2U(Q)RJF11_(W*X)%E9LTSF**BH(G67W":B!$SGT$I#5`2)403&ZKQO2
M?.<"&+Y09O*!:X+"(^VT"-!/4.3V.FT!JWN*;AECSC>\"1HK<]OV\U;&FG$A
M&)G;M;GBHI0HDD!7:&!C(,2$,HH0A!*DMUBVZI;G$)B>X+;N:-5\DDGUEM_8
ME=%U`Y)"S[J7;.F)B>QWR@]7,.HB!"Z`493"/#K;]W7#-9':IVW)SRL.NV<*
MQ,LGU<I;]MP*(J/'+EVF)V2YU42$*F=7J@5$Q%"05HW(4J-W3TD_O6[69#H*
MIQDU-((-4XHJS?4ISM6;5H@N<#G**Q5-PXI[GI^U79ZE#TFH:'MT/9^UH>@U
M#T>*H'^WT9YO2M8G_67R=YB0]8\]_L@>>KW]A<6?ZL^>/T6ROTEB\-8:B_)V
M3?R64R-D:4:N#VAC"T#N.I7N"X%T=WK%E-TZ<;&IG!9XL&X3<3(NNC!X0PA!
M^3LF_5R5Y7E))MSW?DF[SMRHR%W7=((E+UBRF[N-VY-$6J($;MR$3(`#Z-B?
M`/;'Z0;HJV/@'X>/T,PU!VO%7;\5!TEHO30=(4'30=KQT'1X@H/3X#XD[=:+
M$6:N6+&1<MP,F@:<L2:)<,.B^5+H&^^:.%T`*(^S2;&*(;I1UE+'X/<8/$&+
M)59/\KG,8UG9TS,5#%9RSXTR4D)")K`4VXD_%<1'0"J@?4@?E#EO/Z</,%4(
MZC8%]=UR3(1[M'>,F?R6W"DC&(@;02F8"KM$>0>0=;*RF&1V30Y11:&OF-NE
M%9L/(9$K++R#<4P`G(9-$X"4=>J,)MTU%!&V2(>3@=RJ4\3A%L1PDFF)3(&.
M^6#>U$P&*1$04,)0`NH;P#?N(,U1$="93L0BSX@M&*L,XDF3&3]R)]A)PR@F
M(B[CG)T"F%(P`H17^"**1CJ>A;(V8[CVU^V!)2;Z!;RRYVL?+QD\@@C.PYG9
M0,"*RAFC19%4Y1)JD)#"0%!.5&/05=+MF3<C5)9P]X9Y%XLBW3ZHBJTA(G4=
MKJ&`-156.94P^R,(F$1IKG+BYN=]<=Z'E8ZXF]EEE4YA9608G3<,_P`N)P.L
M25(B8A4RQD>84`(0A17,EO(>DC"Q[Q&6B+2<@V,\8O2NFZ3ZS<2+/7C<#)B4
M"BVF`.T72*)M%2GWOVQ0NO'5P-V8*S$6Y)`S+AJFX<6Y<*0`XAYEFH(=83JG
M":0KE2,454M]$P[IQ"DL595QD6Z<7,I:0/"O#&?-F)ROG)G*Y[(OULFJT.@J
MH8[PS!XU,N4R@@<K4QC%I_*JP>2&<^T;$,VM9S!Q9EI-Z<-WJ&<NT>JM2)%-
MRG6<&2-N:F*D<^B8EXK;[MIQ;^.K,,5>VDS`N,2>0A&@L+7MJ">N`3.Z%HNH
M>4?.4R=7UY3%,"?7$3+Z8>SGK[+Q4/;H>SFH>@?#0]G-0]'UJ'M>"C='CK'/
MPU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC`_4MRYYSVY5Z^\,=^$1H.GQT7M4'1
MX@H.UX:#HH/L?#7:\=!]CX/H%Y7QC^).[MIC<$,2<6(XZMC=<Y;QDV4[+1PI
M$T;MWID.K(?V?6F`SK75;=+:]Z6ZL*\#=D!$7#$*&*!%!CI=B1\U(LD41W%"
MD.!5$]I3`)1Y0'T<MA*J)I`4EG*1QS%(9;W5)?D89FFUWBF$#''>3.)`UZHR
MFHE+O&##8JF.8P$OTH"H)C&!(F4)LB)0$W+N@0"@4-@%``#D^@6MPUPDD^C[
M'QZLI'3;MN0QD6;E!B$W?MR=2?4@K)(E3BF8K%W>O(`![%<1-!6'8T.C`VK;
M;0S*(BT%7"Y6Z2C@[MPHHY=G455566446655.8YU#F.8PF$1]`C?(-@6A>1$
MB`1!2XK?C)1TU*!M_1D]=)F61Y>=(Y1Y1#8(T]=XSQQ;MJOY$QA=RC9%P^ES
MIG``,U3EY91PZ3;CH`^3)*E2UY=S7E^@=JNSU*'I-0T/;H>S]K0]!J'H\50/
M]OHSS>E:Q/\`K+Y.\Q(>L>>_V0//5[^PLU8JA7K&-F,F8ER/CZ)D907`1C"3
MO.SGEN,'LB+0BBO4)*N2*+=4F8^X`[I3#H`_*+X9_P#792_N_7RB^&?_`%V4
MO[OU\HOAG_UV4O[OU\HOAG_UV4O[OU\HOAG_`-=E+^[]?*+X9_\`792_N_7R
MB^&?_792_N_7RB^&?_792_N_7RB^&?\`UV4O[OU\HOAG_P!=E+^[]?*+X9_]
M=E+^[]?*+X9_]=E+^[]?*+X9_P#792_N_7RB^&?_`%V4O[OU\HOAG_UV4O[O
MU\HOAG_UV4O[OU\HOAG_`-=E+^[]?*+X9_\`792_N_7RB^&?_792_N_7RB^&
M?_792_N_7RB^&?\`UV4O[OU\HOAG_P!=E+^[]?*+X9_]=E+^[]?*+X9_]=E+
M^[]?*+X9_P#792_N_7RB^&?_`%V4O[OU\HOAG_UV4O[OU\HOAG_UV4O[OU\H
MOAG_`-=E+^[]?*+X9_\`792_N_7RB^&?_792_N_7RB^&?_792_N_7RB^&?\`
MUV4O[OU\HOAG_P!=E+^[_H1>&L-1?D[)OY+*9&R-*-7![0QA:!W'4KW!<"Z.
M[UBRFZ=.-C4S@L\6#<)N)D771@\(80@_)V3?JY*\KRDDVY[OR3=YVY49"[KN
MD$2EZQ93=W&[<FB+5$"-VY")D`!])8GP#VQ^D&Z*MCX!^'C]#,-0=KQ5V_%0
M=):+TT'2%!TT':\=!T>(*#TZUFW6W+*7=>4U'JX_CD5TT7T;)P3DCB1NO?.4
M^ZW:ME5&BVA=5?*@1*).L,JGEC$SAH1G=J,JUOU)93>*ZDH/R9O;3]H=$P`)
M0C7)4!'7E$7NG[7TF0"0Q4R,?_HL<28-3IBD)G6/4%Y`RV@\IC2!P,H`<H*"
M.H!H.GI[JN:'5ZBZ[C50L:SU@4%-1I.7"V6%241,4#?;&3)%V\1U#05$B%-H
M!JBL^W?'B]R1?[1>1MER[7.L-N67)D$C55LD4PD%U*ICY4LX/O'!`Z21>J$7
M`*4NQD&C9^R=)&1<LWB"3IJY1-[9)=NN!B'*/.4P"%,[AD<'V#[I,78ODP81
M`0\:Y<F'4YI2#B#(,7I3#J)DWC=4@CRB41IM'1K-K'Q[)!-LS8L6Z31FT;(D
MW$6[9L@!2)D(4``I"%``#D`/3CV<]?9>*A[=#V<U#T#X:'LYJ'H^M0]KP4;H
M\=8Y^&J:_G;ZL>>\.0/,I[Z?-7P2Y'\SGE<8'ZEN7/.>W*O7WACOPB-!T^.B
M]J@Z/$%!VO#0=%!]CX:[7CH/L?!Z?)=S13E9I/2$6C:<`Y;B8J[:3NMR6%%Z
M@L7^#4;-U5W29QV&3#3E$*?Y'4B6JUR9*R7;=P/Y)8I0?1EHQ,NYMJWFB)P(
M?4AU^M<@4#$U*\U,81(4E8>1M^<C)5S;]BP,#.LV;QNN]AY>*:^0/&,FT3,*
MB!P.F82%5*43D$IRZD,41I9T[71:MFZ9UG#APJ1%!!%,N\HJLLH(%*4H<HF,
M(``;:L7AMPU-,+\F9B\HQ[<3BUWB$I'JR^IX>V;1;2+43-UUE7+HRSDJ2@]2
M=)$IC`83E+C_`!HS4(N6SK7C(AT[2(*:;^5(CUTU)$3$1W0<O#KK[NHZ;^FH
M^GDKXGS)/9AQUD;9EL@L!'=RW$HB)V[8H![(C9$/MSUQIHFD&@;RITDSY`XJ
M<C$4"<RJ>4;6V9ZBH1](L9:<">NBZ3%6$1*B]>)I)M!]L8B:AP$4E$S'^A]J
MNSU*'I-0T/;H>S]K0]!J'H\50/\`;Z,\WI6L3_K+Y.\Q(>L>>_V0//5[]-;=
MP7AZ.,CY28DI?=^/V3MS:V,K*05`LG=ERK-M`T*'VEBTZPAWCHR3=,Q1.)R0
M>$,(0?D[)OU<E>5Y22;<]WY)N\[<J,A=UW2")2]8LIN[C=N31%JB!&[<A$R`
M`^EL3X![8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#I"@Z:#M>.@Z/$%!Z=K9
M4F"<C8>*3HQ<FP<@91L[B\?(FE[BC7#;02B1W.KJ,%M1#>1,`B.H%+7$LSN6
M5C88URO\SQ,&+UTBS0>R4IE:/N5A'(*.!(455&B"IB)ARF$HE+KR:^A+7%?=
MTPK!XQC'+Z*M<THS)<URNDTQ\DC82'$PN%3K*"5,52I"FD`BHJ8B93&#,7%I
M>K?JE+ED9^'A#`DHFT>S]T3!+BNUY&%5,)BMV)"H,4--XFBRB8"!D#`'IA,8
M0`H`(B(CH```:B(B-65PXX;6\LL>R)606F[M1*+F*</"&3:7/>)E$_8FCXQ`
M!:,#[Q0<KJG!,QBN&XU$6_$H`VBX.+80\:V`=0;Q\8T(R9H`/_<)D*7M?0Q[
M.>OLO%0]NA[.:AZ!\-#V<U#T?6H>UX*-T>.L<_#5-?SM]6//>'('F4]]/FKX
M)<C^9SRN,#]2W+GG/;E7K[PQWX1&@Z?'1>U0='B"@[7AH.B@^Q\-=KQT'V/@
M]/CZV2G`B\_DU"2,74N\JRM^VGZ:Y-P0UT!9ZV,)@$-!``V#5D8;N^#;2UKG
MQ=:5LSL0N)R$=';0;;RIQUS8Q3IK@Z)Y21=(Q3D6`%"&*8`$+!@\4WQ=4[<E
M^*/'$;:#U%F:>@F9W243%KEN",.V%7RYTHNV:I^1%$015`RHB7V9+O2O:0OE
M1`IEIBV[$ON\I2X8IH"'7>4@RD$F@/-P0%-9-B94X&T$A5";QRA9F1N(Z1L.
MXQ?)MXB#NR-DKB+<;<A-_P`EA963E&S<C[KM],&:Q0,.H'2ZXV^F5G=L2VF+
MQOQB18&=V78Z07/$G<MQ;.C040P31:MA.0QB@JH15<I3&*58"F$!"#N)P_NB
M_%V97K:R+9*W5?MT%R[S1S/OW)BH,$E>0Q0.)UC$$%$T#DY:=+6WPUG>Q[8!
M,<R=Z2LJH@0@!OJ.EV$&0A/;%$0$H;NH!J.T4F]Z8,G8A(AP3>.K<O-C.."B
M7D5.E%2L?&@`@;4`3,[Y.<]$05OQY9+Y0N\5G?<$^AB@&H`('EV8.HXH@(AR
M&>`(\HAJ`"--KAL^XH.Z8%YO>23-O2K&9BW`D'10J3Z/.HF)BCR&*!M2CR"`
M#Z,XQF72JN%\1+R"'D::QRME[3MN5"-*V9&0'3K[AD?MRJH&*H#03:&$6Z9:
M:1T>U;L6#!J@R8LFB)&[5FS:I`@V:MD$@`I$TR%*0A"@`````!H'T3M5V>I0
M])J&A[=#V?M:'H-0]'BJ!_M]&>;TK6)_UE\G>8D/6//?[('GJ]^FL;AO"\49
M=TY,VE,B9$EF[8+QR==I$.J6G[B=(!H1%(#'2CHY(W4,T1W$]Y0ZRRWIK$^`
M>V/T@W15L?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0>GXD,PO"F6?
M.&Q`.X6!+K2K9)NYY<KDQ@UU`YQB_9"4--H"(:@`W5FJX9V7QI<-OVT\F+HN
M>"9LY./E8RW(P[@[R:MUP*0N7:;=(J*2B#M%0Y2D3,)]";MQR>,+_3LNT[9D
MD8==[-W1=<*V?RBC(STK*,8VX@[`QT$S(&<]8)`3*N02"H.I:961FRXLCV<T
MDW!4U98LY+7'&2$`9R5K(RT$+=\1M(D33/OF;%<D/RE35ZHQM`B<ARV=);,4
M#*#Y6!K-;M+;CG2YBE54CYAVZ6D7Y%B`8`<H&%LX(8=TP)F`0$VZ6"QSC&PH
MM100*!V\;%L^N%500*7K%G#EPNH(Z!UCARNI_P!\64]DK%XPP].7>T%8K=I,
MW)<2-L*/%NL(0IFEOQ[*25.14=\$NL<I*>T$R8"(I@D%T\-BC)NX(D9(!OF1
MB%Q(J4BX+I!(P2A50%(X'*4-W>`Q1WP`>4B5Z6[?E@/--5%3Q[2Z(4NO)NIO
MH90'9A]76.*'U1V4VC\?96L^X99XGUC6"+)!&7$X("8*G,C;LR5L^-N%'4X`
MW]CL-H(#Z+2R8!XLPN/+\@\@/*FZ@I.&]HPZ23J[3(*%'75<%V;`X:?P3E3E
M`P%J*=/F!?\`$V_(R,G;\D5R@+MB=PAY7'VBWTU!-&.(J*:P$,/6N.M5$PD%
M(J?T,>SGK[+Q4/;H>SFH>@?#0]G-0]'UJ'M>"C='CK'/PU37\[?5CSWAR!YE
M/?3YJ^"7(_F<\KC`_4MRYYSVY5Z^\,=^$1H.GQT7M4'1X@H.UX:#HH/L?#7:
M\=!]CX/3\.%NH.#)K.E\CF42.*H-@,_<6\Q8.%0+J!A*)5P#0!,4!'3VW*FB
MBF1%%$A$DDDB%33233+N)IIIDT`I2@````&@!5V7/*BE(VIAF1EWT6F0XJ,O
M(\;/B6S:AFBAMO63"I);0-0,/6"'L>4*>W;#+JXQR&^.*S^X8*/1>PLZX,(F
M4<W#;(J-R*N#B(B9VV705.81,L*P@`!C2$O7)Z]W8=G)L#ILF[M>XH>2M6'D
M&Q+DBVC2XVQW42Z3;.4U"I,C@4#F`2**@!]<CFXI$&KV6E+MNDEE#<R:;RT%
M;I=S:9K+<.COM$56*D4!201U$S-S;[4Q0`>I,"+)@U;,F;8@)-VC1!)LV02+
M[5-%!$"D(4.8"@`4HVNBUK<N1LJF*2K>?A(R8052$ADQ342D4E"B7=.<N@AI
MH80V"-*+_P"'?Y%2"A@$7^/I-U;92E`--Q.%#KHLH#ZH,-[ZM,$2OYFY^'K(
MKA'KU')4U#3$(W.FG(K&:MA(B2?A!6`Q3D*F5PB8H:)D7$J47/P4@UEH6:8-
M)6)DV*Q5V<A'/T"N6;QJL3D,11,Q3%$.8:G;SNN481$+`QKV1<N9!X@R35%F
MU.Z*S0.N(;ZRNX)$4B`8YS"!2E,(@%9PO=QOJGF)^T;<2<*B8YA5A6+V7D?M
MA@U$QQDFYE-3"/(4>3G4664(BBBF=5554Y4TTDTR[ZBBBA]`*4H`(B(CH`4_
MPMP7Q+P8]L9ZR>7PQ:L5)>90;KBU=SS.5EOY'"Q0\@-W:PE<'$Q#E414.1&@
MN^(XC%9&[$B*R"T`CEO(1WKE=;551B1W--B1RZQQ$`4*Z4(@)M[[:8H`8S?A
MYXGX=2V\E%?%M^&NAXP+"*RDX'L&\%=44!2(HNW(Z`S=M2E1<&,0@)E,<BBO
MT#M5V>I0])J&A[=#V?M:'H-0]'BJ!_M]&>;TK6)_UE\G>8D/6//?[('GJ]^G
MEB?`/;'Z0;HJV/@'X>/T,PU!VO%7;\5!TEHO30=(4'30=KQT'1X@H/37;)E*
M<PQULSS\"IGZLYA:12K@"D4#7=$=WD-IR;:S7*E+H\>W3:4>N?=3]DVC(EVY
M:EW@+O#H9VL.@F$`UY``1,(M+*C5`3?95N5M!O#@<"*IVW!%">F!1T'>U473
M8MSZ!NBDJH!A#4`'%EKD(F$B]MQK=<^L1,$U%YV[B^[[XBY@Y3BV!<C(AQY1
M31)R!IH#NS,D6TQN.$<ZJ(@X*9)_%O`*)4Y*&DD1*LU<$UT!5$X"(")#;Q#&
M*,MD+A>S1*D<1R;V03@'#A_:UU'CFQ3K)Q3>8A3*-)544Q$G5.F[5-3V0::F
M`HPC*\7QK@=8[RZ0M^3C2.8L57$?-VXM_AH^F6T0FBD0HK%G&AE"H%3.=)L*
M@BN<HGLR4PC'0Z*18EG'W:\\C:)7?^5R+1,T^A=[@HJ+^4F6$5"D,J9+JC)B
MW_D_54HW<HI.$%2[JJ*Z9%4E"[=U1-0!`0^H(4J2\</6')KK%$BDDU@FT'-B
M01UW2S\!Y*^+IS;K@-.73:-2N1.'!]>4?>]H')<;>U74X1^D^91A@=./R9?F
M32?-Y!L!!<MA,Z5%0Q.J(`*&(8%(*ZW1394QZV8,;G.<4R'N:*5**$7=R*9=
M`%144S)/RD+ND7`#Z$(ND0*X<,3V]-,YATP?Q<5)H1KMJ^3B9B^KU:1@L70M
MSJ=6Y!%FBHJBH0#%(9,P@(&T"FOD[9G<>2[E34_)*U%UCD;)MTS"FXN.X1;F
M*J1@B8!(0A#%4<*_:DS%*595%#(-RY0?XJMR43+(V]&O+EG;':N&#M(#LUXJ
MS[)2.J5+<W037E-Q8Y!ZP#J@?>/$R.3)=;,>)W3E-BLY?3TK==OJF6'?+'MK
MGET"2L0\`@&\F*Y2\G,(&`B3@I!`('(UC/A=PLVW#K6RP%)(PTHB4`D8*7;E
M$03=-5!W%``1*8-U1,QTCD.;TX]G/7V7BH>W0]G-0]`^&A[.:AZ/K4/:\%&Z
M/'6.?AJFOYV^K'GO#D#S*>^GS5\$N1_,YY7&!^I;ESSGMRKU]X8[\(C0=/CH
MO:H.CQ!0=KPT'10?8^&NUXZ#['P>GQ;F*'.=1''T^_@IE`$@5*T1N<[9W#S!
M]0T*FF[8@U4WA'>.X1``#0VM@9,9(E;$N^VV,FZ:%."A&,J4HM)J/(H'MBMW
MB:Z)3#H(@740`1T#BALF42,6X5C3S@JJX)%<$"U<@K1DRV-U8%+OG5?(&,4A
M0#[6(@``')Z#ZZU$B>Z&-[LMF=:N=0*J5I.R1+.?-`UVD4._;J&*'+O)$'84
M:P9>3Q\C:V7+=M!Y:T->:K,KDLRQLF;>V>VAKL!#15=LMY`59-P`F5;J'.H4
MJF^JDJWQGQ%V/+7]8D><(^`FWCI;RH(](-&PVG?_`%2K>2;$3T,1D^`5TB[J
M(G:@0$BI>[4O>5B*G*'6$N:T'[Y--3<U$H+6<:5U*(ANE,(!M`3`4-=-6F<K
M'1Y#C_YU=NX(?8"`&Y)M%OZO('/RB&N@U<&*HZ:D<A7:1RWE;5F;0BP7A+9N
MJ.`_D;YQ<$L9L@LW51.JT<&C_*1%)<X%T.&I&N$.':(<RT5;;UT0+K;0+)X_
MMUG/*"X0@G5U72H:)8H`<'*K0%4R+%`RG5J;B9`30NGB<SBY!P<W6&CF\E)W
M_<::)P#?9%DI51%@PTTT*#4'212@``7F+%X[Q]'J,H2.,JZ<.':H.92:EG12
M@^FIEV4I`5<K[A`,)2%(4I2)ID(D0A"I63!NS-;ER^]=VV"J2G5N&UH1R!'-
MW.$1`==5@5:QY@W=.K<J#J!BEUM\'D8DWR#?3)C=-]OE$1*_*X>HBYB+=5,I
M[,A(QLJ5`R(#N^4"X4`-5!]!#.5KH':WWB8A'$FY8;J#R4LL[PAW"JBZ8`H*
ML0L/ES<X*%ZM(SKVQA3`+*OF0<)+W,@@O;5Y]4"91"Z(`P-7CE5),1`AGB(H
M2`$#0"E7*```:!]`[5=GJ4/2:AH>W0]G[6AZ#4/1XJ@?[?1GF]*UB?\`67R=
MYB0]8\]_L@>>KW]GY/X9YKA@R%>;'$UWL[2N6_8B_P"W(MR[5!@V>S3R#M!\
MP.54$!7.FW(O*H]?N`)C(`?V-@Y@QK-HW'8.3+2@;VM":0*9,'\#<<<G)QZB
MS=30Z"Q2*`1PW5`%$52G24*50ABA:V>U\0K9J5NO,-N8C9VBE?1,=D;.)^SY
M^\#3CFX3P\X.XBE`JH@@5@(G.J0=\A2B(X/XAFEMK6<WS/C&S\C)VHXE"3:U
MN_E5#)2IX8\RF@U*Z\G,H*0.`;(]8``?JD]=T+LOZ[Y-O"VG8]M3MWW1,NSE
M3:1-NVU%JS4W)NE#"`%30;(*JG$1T`"B-6+PQ3?#-(85CLGR%P0EBY'D<RL[
MR\JGV$8YEK:AYZU$[9BRLU98K;R1+J)5T";Q5%`.M(<5B_L>Q/@'MC](-T5;
M'P#\/'Z&8:@[7BKM^*@Z2T7IH.D*#IH.UXZ#H\04'IIN`<*J((3D1)1"ZZ(%
M%9%&29G9**I`<!+O%*<1+J&FNVLV<,5XD3:3:$@[EV!`3)NFG[.=&@;E:INB
M^R4*X;F;.6VH[G5H*&*.I_98&F4Q-[FL)?(48[`#"!!?2[.(=QPF)KRB";)U
MH.@Z<O*&O+"RL/N^Y$G$QTA%[I2D+[G/&9'+'=(01``ZHQ=``1`.;T>(KAYG
M(EG+8ZR)#WQ$'M-XF5Q%+,E';2_K?24*7E`[-@9PBW4*8ITS&WBF!0I3!)Y2
MX4IF=O#'[T`-+VX@S)/33..26ZPL9=5IE()95LD!C=3),4@<(E%4PE;``K*(
MQV8L>779UQMS`UD7EJI-IZ!\J24ZIRJHQDEVK]H`#J(M]QR8N@E$YA#E2%',
M#"-64'=,VG;<N^&.B;03;JJ[Z/(AL#VQ%C%Y0#77DI2;=9IL^31(4@IL+<<K
MW'-.#JAJDDG#PQ%ERB.PQE2$(3_OAB``B$WFGA0B):#8W$Z71;6C<T0DHUF'
M5PD*C.1!H"`=G,HR>/0(]:-B."J)K=7N`04B``*9$NE_C"S9(3@I$3<J6Q8W
MR%345&KBR+13-(.-T/8D)+H[PB(:J`&I@C\@W#<3K)-^1:0FAG#J*0B+<MY\
MLF*:TA&Q`JN5%7)"F$B#E=P($_A"))J[IB+NG*I$6[9%5PX64'0B2*)!455.
M/,!2@(B-9&SM?L<X?XUL=^RD(>WI4.M:.=Q4S+'ML/V_*D=%%LU5D)!`@B11
M8NZJ4Z;DX&J=LR[(QM,VY<L8YB9>-=$`R3AHZ)N&$H[2*$'11%4@@=-0I5""
M4Y2B%_<+$Y)N'5F7F^61MQT^$I2JR2,4-PV1-"8`(F59]&G%B[*@30[H4D]B
M0:>G'LYZ^R\5#VZ'LYJ'H'PT/9S4/1]:A[7@HW1XZQS\-4U_.WU8\]X<@>93
MWT^:O@ER/YG/*XP/U+<N><]N5>OO#'?A$:#I\=%[5!T>(*#M>&@Z*#['PUVO
M'0?8^#T^7[-\F\L=2MASR\4WW0.*D]#-!G+=T*/.#YLW,`AR@(:ARU(85DIU
MLA>MJW).3$!`NE`27D+/ER(R2KB)ZS3KC(/SOS.DD]3)E.FH;V)^0;GG7:%N
MV'DLQY.1D%-UFP]S\@P*C%[(2"QQW"(IW*@9RZ6..@%3,H;3:`&*("`AJ`@.
MH"`\H"`AZ%Z1KDY2K7?<-C6['`8=!4>-KH;W8<A/J^3Q:YN@!K"D<^$@K.8.
M;GR;FSR.Z[OD;HC@'E'E!N\2`WU==E.(Z58LY./=DZITPD&R#QFY2U`W5N&K
MDIB'+J`#H8HA2IIG!UAHG6WQ55MV,/9RQS*EW3J"M:"C$^^.HCOZ[V][+7>Y
M:4!A:%S6R)]-TT'?%QN!2T(!?M?Y2+2`#J(";V0#RB/-H`7G.6_82%Q7+'6I
M<S]A<5^+%NQ\R=-X9=9JNS8OB!'HG2,`&3529%4`0`1,(@`AEY84S@BI?<,D
M142&!,ZB-O@=5,AQY!,4#D$P`.H`8NNT/1X:L2N3&7AE(RS`E6Y@.9--"?OQ
MZI<0%2,4`$QHYBD83`80'D*.FZ/HW9:#],BK&Z[:G;;>I*F$J2C2<BU8MPFH
M8"G$"B140$=T>3F'96<;2.(^Y\)<-DW&U#>$0!Y=,;(1C\0)L#4D.VU$-O/L
M#Z!VJ[/4H>DU#0]NA[/VM#T&H>CQ5`_V^C/-Z5K$_P"LOD[S$AZQY[_9`\]7
MO[/XT.&F>72CU<B..(4EJS2W6`E;M_P&%UKDL&?7ZD-\R#67:,U':1-!5;]:
MEJ`*#69_FO\`/B[J`R1@^Y+ON#%-O7"X(E)1[6-N!:/S+BUL10P%%6(F-^9;
MMDA44.1W)*\B#7DPU^N?CS]!^1:X&OU8\2>:3>KCQS"296=\<45RL,/1J*1U
M2/D[&33&Y,G226X)2B@=@V1A'(&$>23*`%'E,3YIKB^QS&*VSF"P&$(GE^=*
MQ%!Y#YGFKB5XD\9^[9$-PZB\6Y<3T&HLJ8-48]FB!@`"A6(L\68;6V<NX[M+
M($2B90%%F"-SPJ,HK$O!+IHX9*J':.2"`"55,Y1`!`0_8]B?`/;'Z0;HJV/@
M'X>/T,PU!VO%7;\5!TEHO30=(4'30=KQT'1X@H/3V#F5Z9Q&6A>!("XYUZU1
M672182$>MCZ]#>3(`8ZIDT4Q?+)$*8PBJ42%$XE"I2[[5>L[A;6@_M_)D#)0
M[A)\TD8E+K(>5=-7;7>*=`L>_<.CB!MW[4`CRE#2P6A)%NXN+'L:E85R1X+E
M.[CP@1,RMQ5=$3"H";B,(V.FH8`*8P*D+J*9M/0S3=4<!E6-G(7UON$0$6XK
MPC9CC143*:Z"!U5%#$TUWM-XH;H:A2BE_8RL2[G*A`3&0GK7AY"53*```>3R
MRR(N4AT``U25*.G)KI1UC8D)&KJ&`15AKOOF.(4`.)Q*1DC)>3%`==.1#730
M`$``*2E5X6])5HD8##;TC>+P(540#0`5/'IMWPAKRZ`]`!V#J')7"?9>-K2@
M[58$/C-S[B6W%HLQ=.7N6EV:#QT#8O6.7"W4"GURICJGW``3#H'HYLN!HJ*#
MM*P)J*:+E$X';N[C2"VVSA(4RF$#IG=E.01#0#`&\(!J(.Y_J0*[O+(5QR2C
M@0]FJSBFS6WVJ(#_`,A-1LX,4/\`E'/ZOH\+64VFZS?*O;>&0<)*=694ECWX
MVD4EG!#$$G\$_,D8YM[>(4"&+ND`!]./9SU]EXJ'MT/9S4/0/AH>SFH>CZU#
MVO!1NCQUCGX:IK^=OJQY[PY`\RGOI\U?!+D?S.>5Q@?J6Y<\Y[<J]?>&._"(
MT'3XZ+VJ#H\04':\-!T4'V/AKM>.@^Q\'T!3BKX?RGL^Y;0D$KFO>*@!%D!%
M$G15/RYM]N@7<2614'K)1``!)5(3N!`#%6ZX^9E6S,F9L(("XN9M#H%,Z:'0
M721NA)9IO=8G%OV(!,HF'>*D9$R93FZI?6U%Y^52EYJRI&2L!XY`BA7B;2`(
MBK`H29S@`*+DCG#0!6+KUA=TQQ,L*@C6#\"6Z/ELO)R"]T.XQ(W6*KRDV[+:
M-EI`DGJ(',89(N@E$1`Y=WGU@;<;KMHVV[%M6,AD73M5-FS8PMM1)&97+I=<
MVZFFF@COJ'.?0H`(F-R"-2T'C_%3W(UN1;@S-*\'-Z!:+:6<)&,15>,C!AY$
MXM3"4106653.H7V0I$#35,5L#3":PD(*J:6062R1%1+JH1-4\003%`=0`PD*
M(AR[H;*3!S@VX4D!-]M40O>-<*D+ZJ:*D<D!A^H*A>FK^MUC:.4H2YYRQ[MB
M8-1Y&6PI$%FI&"791)'$DRE%5TRF74)OJ`R,!`U-H;30;[DU=P$)++,DDV*!
M@$XA'VG$E55,`;`$RFZ4!Y?8B.F@@(^APV7D^.1*+DX_&Y'KI4I13;=?>LI;
M+]50I3@;=00426%00Y`'D*?=$H^A(R[XX),HMB[D7B@F3(";5BW,Y<'$ZQBD
M#0A1'4Q@`.<0#EK/\P=(0CWS_&<:V7UY%'D4WG73Y(`_[@CUN/V7T#M5V>I0
M])J&A[=#V?M:'H-0]'BJ!_M]&>;TK6)_UE\G>8D/6//?[('GJ]_9^9/[:<0/
MZ#'5<.WSMG#E$>0MIB]X1#*3=B"C:*#+%N-#I&2GU&H:I,+ZM<KR(?@D34QV
MKU10_7/2;W"-Q`8U>>6V5EGB;Q'>,+OJ)J.H_P!TL#Y$]T8&3ZH1*5[&NRKQ
M[Y,!^UN$52;2UP-?JQXD\TF]<,G!<PWI_#O"XXA@R.SW2N(116/02S/G0RKI
M'>%('S!G"6BKUFFX^0!,`WC!KQ*84C8T\I>#ZP7=Y8X:MTP.^7R/CE<E\6='
M,#"`B0\B[8EBE#%#44G2A=AAK(7#%.2!%;DX:+Z4DK9:K.2>4'QAEMR[N1BF
MV;'`#J%:3Z,[UZA1,5,KEJ0P$WB;_P"QK$^`>V/T@W15L?`/P\?H9AJ#M>*N
MWXJ#I+1>F@Z0H.F@[7CH.CQ!0>G7LN_HX3]4*SJWK@9@1*<M>641ZHDE$NC`
M.WV(+-U`,DL4`!0H[I1+<G!KG1TS>X]NUXZC(1>1."EOH2=P-MZ(D8X[K>`(
MRX$3`V7:&Y$W2A=\$U`=`=WAF'EWK'&=_NDH9)&5!5PG+Q-PVXI.V*F502_;
M'+.64+%)O``!U\H*(@5136KUR!+J(DC[.MF9N%8JZ@)$<GC&)W+9B0VT5'"H
M$02(7V1CG*4H"80"LVYJFQ,YD;ONEE;*#U0!*HJY8)GN>YEPU]L5=:29ZB')
MO)&#:`TT&60&[KZF`WX*P8V208/EVI!T5EII^9-QY`S`?8$6,W4.J?V*21P(
MJ9,X2'#X\;$`H=69GD]!\8QM>4#D7@&X%#3G`P]%?Y$SGY^L/Q50?E/BC(<1
M[+E]P7]MW'H7V7*'N@O%:CR$Y/JCR^Q#>X9+QLEG.1\%#+8ZB5$+H;-X^2"6
MMB\Y.]#`="-<.$@T,X13)N.#E,8HZB)1T]'.+%H1115"RUYHY4B`<P-;;?H7
M$].("(>Q*BU4,<=>0H"(`.F@QK!,2":V;ZO*#6W-W>!5PX1N0`5T.8=[<D";
M0(.FGL1#0QO0X6<?-U3#+.5V_E"*9@!5-I>-\,H2,5*.Z?03JL7(%'<'E+L'
M9]`'LYZ^R\5#VZ'LYJ'H'PT/9S4/1]:A[7@HW1XZQS\-4U_.WU8\]X<@>93W
MT^:O@ER/YG/*XP/U+<N><]N5>OO#'?A$:#I\=%[5!T>(*#M>&@Z*#['PUVO'
M0?8^#Z`]BY)HW?QTDT<L'[%VD1=J\9/$3-W31R@H`E.FHF8Q#D,&@@(@/)5P
M3_#-EDMK1=P-9-BZM"X)6XH%9"$DT]U_;`7/`%=&D&*Y1,CY,_;%`4]TBZJV
MIE*N[#=GPJ#^[Y26BFTM8"\&O>+>=D6[(SN&>P#>(.F[.9RT<@<AF2A3+)BF
M!RB9,@$);5AXN?XF9C_)I.996>_LY+40`ZYG%V9(45ZDR8!O`G&F(X`!```X
MF*`L<SYUO<V2,F,9,9^/9M7$B_AV=Q"/7$N&7GIL"O91ZDJ/6HG421*14H*&
MZTP%$EJ\%6(!/[HW.>%5OE1-51L,B[E2>ZL7`/G`%$4HYFR*26D5"`8#D,0!
MT!%0BB-O6\@E(75+(,U[XO%5(`D+CE4"&$$TS&#5%@V,HH5DU+R$*(G/OK'5
M4.*4@U:NVY3`J*;Q!%PB4Q`'102+@)0$`$>73DY:?M;HD[-NJ>(@H!+&M*-A
M;HFWBX:B5F^3;%,U9:B&HC(+HAIRE`PB4!50Q)PY8UL&RV;_`%4NF*M"`AU4
MC(`=0K>>RD\:I+N5`W@ZQE&$)KJ45$#![,<W1IUSF8M+FLY\W;"(=6B[D(IZ
M@]7(&W>4(V0*;EV$+Z./<V6^DN24QM/FAYIZSWRN&D+<2R2T1**J![4C22;I
M(IF#00.\#:'*6RLC1KI!9[)1;=G=#5$4P/$W?'H$0N&-613_`(/=7U51`0#>
M0424``*<OH75#%>I$N_*4=(6+;$<54"NU&<H@#2ZI<"%'?*DT8+*!UP!H5=5
MN01`5`&K:-,(`WFLBR#K)+YN(#UK9G/L6S6WD%3&Y0$8UJT7.F(!U9U3E$-X
M#"/I^U79ZE#TFH:'MT/9^UH>@U#T>*H'^WT9YO2M8G_67R=YB0]8\]_L@>>K
MW]GYD_MIQ`_H,=5EWAKO_=;PN3;77C6$V5L1TZM2ZV"Q)>SKP8(G$N\M%R:#
M5X">^4%2D,B8=Q0VN1_FL,W1D@SNW`''-%9+M9LJ91PUM@(2Q+WQ[EJV6[I4
M"@9@O+2$3+Q!D2[BWE3YR`B54@CPZ9UO,W_T+8BX(+2R)-(E6!!9\SM/&Q9D
M8MFH)3_RAV9(K5L4"&,950A2E,80*/$_QAYFSKD?$;N7S/(LFER6$R9NY"];
MZNH%<@90\M=RJQ%$V[,9.&Z@J8F`XKG*80%$`KY>7$Y_Y%!_?5,>&2?NZ2G,
M3Y?;Q&&TKSG6Y6*EW6QFF*87!B^XEV30XMTW+:\$&,0[<F#=2`C_`'1*F<3#
M^QK$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0?0(M^
MK*GL[(5NMU&<+=S=B$DBYC#G,X&"GHWK417;]:8RB*A%2J(',<Q=XIU$SVYF
M*[KT:7O'8_DK9C;;NZ+N:;G7]GD82II"UDO(KF025:M$7QM$4T>L1(LJ`!_"
M<K92#PJSR&69%PT@;SC<67R]3<.FZIFCW</;;DD<X.@H&@E(D0$S`/6@8H[H
M1TOQ+Y'4L>TDW0/6UN/S,7+YL0X>Q5C+#M<4(Y!7<$4@6?KD<D#VY#\H&F75
MK13A>!L.-%2/9/W@*2EUW=./$V+1:6?%*4!5>/%4S.3HI`5)$#=4D5-,J83G
M%OQ&I$NEE/3;UY:4#)I"I'W++M'1F3B7?1ZH"G[DQHI`QC6("*9C)"4Q01;E
M(N!2@`%`````-```Y```"G$WD&5L&UFIBJNUGUS+P4:=R(GU443%_NG6.8XZ
M:$`QC&'0`$PZ47'7#U@2R<OS<PX+'-KFO+'#2:9R3Y5/R=!&V;*7:E>O3[IC
M%(J\ZH"B`AY.JF.M8/N3(D.PLJYKTO:WKTA(>,+%-7,,#6\6QTSKPT*0&3#1
M4P"BR3_@BAN'23TW/1F[;ETA7BKAB)*#DT`$`%:/EF1V#U(!,`A[)-0P<H#T
M#66N%'(3@K!U+SJX6VNY,+=HYNNVRJ);C0JN@;LU%F1=-3F'V8((D+J94H#2
MBRRA$444SJJJJG*FFDFF43J***'T`I2@`B(B.@!3S)S$BSS&6'%FTA#OP()6
MXQEG'4:V29)8P!H:1FCJ3"21PWQ1!8N@;@B7TX]G/7V7BH>W0]G-0]`^&A[.
M:AZ/K4/:\%&Z/'6.?AJFOYV^K'GO#D#S*>^GS5\$N1_,YY7&!^I;ESSGMRKU
M]X8[\(C0=/CHO:H.CQ!0=KPT'10?8^&NUXZ#['P?0DN(^R%W$;?V*H]HK.`Q
M,=!>5M2-D!>HRS9PWT,F]AU%#NBK;P"+<%`$V\BB6K2O29536NR.,ZM*\U$@
M(4JUQP&XFI(&(D!2E.]:*-'ZB92%*0RXD(&X4OH)<5O#:W+<DT]:Q_NA&(FA
ME92"?L+1)9#H"PTV8B3YD[CTR%$J(J+$5.H.X4`(H"%EL\</+5?R1MXUS,+.
M@H4Z38XB0Z*]QSKA:-:@``(ZE!-<.02&U$-4G6;N)90QGI2+/F:LK>62'#8=
M!`C8Q)IS'MA,0HB31)04R<I2"8N@BWE[R=W%E9^W*F*;"X56\3:P."#O>4&@
MX<"JJ\O_`'ET]62$.0R9MM,82!BX^%AHQN1I'142S;Q\<P:I^T;LV30I$TR!
MS%(4`KB-M5^"B;IBXQZJ9L)`W$'3%Q/1LH!C#H;>$W4E`!#]J.P=OH3UH71'
M(RUNW+%/H69CE]X$W<?(-S-G*6^F(&(;=-J10A@.0P`<@@8`$)^7MB(?9#P#
M=3D#[[L')89^U*J8L6VG)-BB<L3.M`/U(.11ZIT01,5)0OVM!5>)Q9D-Q=8L
MSF1BY%S;;.W@D-PO5I*S[9TNY%'>$V\H$:!M`#0FIAW67$)Q+,'45BQ@9NYM
MZVET'$8QN*/;+>51ML6O$.S&62A=X>L?/U!WG8&,5)511119!-%%,B***9$D
MDDB%33233+N)IIIDT`I2@````&@!]`[5=GJ4/2:AH>W0]G[6AZ#4/1XJ@?[?
M1GF]*UB?]9?)WF)#UCSW^R!YZO?V?>_SFA>()[,&N][?$HAA0V,4&!8N1OBR
MOR,=&5R,$^L+E%`AUETT@@D3"82%%30AA4IOQ!,\JW+@7)<G!QL'D!S;UHQ-
MX05^^X3<6,'/OXIZ\CE6\HDT!%BJZ([.FJW;MRB@50AU5+3^;?Q[GF:Q7:MM
MVEB2Q'F3):QVM_S5Q6KBMVSDP82=O,)6WDB'D7<>T76.B\*4@%%+JU"'$*QS
MPR6A<"MY)V::?D[BOIU"(6Z^O>ZKHG7$[,7`\AF[AV#<`ZY-FU0%VL9)J@@D
M9902"<:PIF6`X@'O#IDW$$$^ME2YF6,B9(4N*%0N`MU6>FB0EPVZJP7AY!62
M<(K`NN!Q=C[!,4]X\<UE'Y962;,&B$C*%:)QY9)\BW*F[?E8(F.1`%E`,H")
M3"!-=T!$`U_8UB?`/;'Z0;HJV/@'X>/T,PU!VO%7;\5!TEHO30=(4'30=KQT
M'1X@H/H-RX_O!C[HVW=<6XB91L4P)K`DKH=%TT6$#=6X;JE37;JZ")%2$.`:
MEJY>$^[Y`TA9-\2QR0#U8Y$FX2JT8:1LVZ&B!3*%2/*M2)Q[QN0VH+BD4QA\
MGY:NW&D?(-HJ=?#'2UMOWPK!'HSD(^(_:(R`H%.<$7!2J-E%"D,*8*=8!#B0
M"C&XW@<3FF[7LT';:*1/;$)=2?D*SM1QY.VD[;=D6<)`HH=1+V8J@`@4P[H`
M0%9;)&3WV)X%T;?2@I"X'5I@LV5'=!%.S<?I"(@F4--V6,FJ.T1,)A-1)/*F
M<+GN5XN<JL@C;<&VBW!Q`WLTPGKA<29U1$/^^&:$$-=-T=-1.UQE9,="/'"!
M6\A<#@592YI0A3"H)7T[(&47$@F$3=0F8B(#[5,H``!PV7B`'2%`EU:.4A*H
MKK;4Y#R@`FW..F\3RK>`1#0PCH(CIR>C!YUPEUC7+]E)M#/8^/<A'2=RL89<
M'L-)0KT#$`LM''`>I`Q@,NENIE."B**:@VAQ(8ONQ.]+?UCY67MEFQCY1XZ1
M+II-V9<)X\&3G3=%;JW.X8PB)44@T)2F"N&/'UQPD#<:9&ET2[DZ?Y1/(=P(
MI.D9N18'.QA8DX")'9S.5#+AHEUH%4.@JWM-)=O*W=-KISE]W`@0P)2,X9N"
M*;&/,J4J@,628=2U*<`$PBHL)2'6.4/3CV<]?9>*A[=#V<U#T#X:'LYJ'H^M
M0]KP4;H\=8Y^&J:_G;ZL>>\.0/,I[Z?-7P2Y'\SGE<8'ZEN7/.>W*O7WACOP
MB-!T^.B]J@Z/$%!VO#0=%!]CX:[7CH/L?!]"N"U)I,ZT/<T)+6]+))'ZI16-
MFF"D:^334T'=,9)0X`;3D'EK(O#'EN1.PM2XKA;-8.770="Q3NA55)K:UP()
MH%4!)I.QZS<%U3\B1B-^M,F5-40]-Q88^5(+<'CW(;AJ4"G;H'_);*`-FI$6
MQM.0[=^=5$=.1,!T'0W+Z*S9RBDX;.$E$'#==,BR"Z"Q!351624`2F(8HB4Q
M3`("`Z#03\1B3&,5.@8J@34;85JL98#D)U9#A(M6A5M0+[$!W^0.3Z%VJ[/4
MH>DU#0]NA[/VM#T&H>CQ5`_V^C/-Z5K$_P"LOD[S$AZQY[_9`\]7OT\L3X![
M8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#I"@Z:#M>.@Z/$%!]"Q7Q56,1PVG
M;,EXB!N!\V3.=-BO&20SUBSCDJ.FZ4CKRAFLJ<=#"HU2U`=T#1U_6<X,!@,C
M&7/"K)N2.K9NDD<@_DX)91PFF"Y4@<$%)TD`IJD$#%'>WBE]+ABZ`2*9"'NZ
MYX!1<2:F35N2&0D44@5UY`.$4H(ETY=T!_:U9<Z!^L":M.W)8%.L,MOA)0Z+
MP#]:?03:[^N\(:CM'TB:E\X]L>\U$2=4D>[+3@;B.DD!P4!-,TPW6$I=X`-H
M')J`#1(FUX"%MN+3,90D;`13&'CR'/[<Y&<<FFF`CSB!>7Z"/9SU]EXJ'MT/
M9S4/0/AH>SFH>CZU#VO!1NCQUCGX:IK^=OJQY[PY`\RGOI\U?!+D?S.>5Q@?
MJ6Y<\Y[<J]?>&._"(T'3XZ+VJ#H\04':\-!T4'V/AKM>.@^Q\'ISWADNX486
M..H9M&LTR&=S,Z_*GU@1\)%H_;%U=-!,(:)I@.\J<A-34Z-9F!'\I;K$PJ+/
M9N\!8R9V@*CN+NFD5&O$&8F3#E`7"Q0-K[(P%Y4K53![8%_N!,#&U+F<-5$Y
MS<2ZU0MN3;?=2=*%`!$6ZA$5Q`#&(D8A3&"H+-=M6^JYNVQ)%M&71)QJ2YWG
MY`N$G"Y7CTK?7>3CGPI'!42ZI)KK',8"%'2+<M)$2Y"MB(B&&0K?>;B<@WER
MM@;*SC8I="K,GRJ:BR"J?M1$4E`(H42^FS&DT`R"*_\`B$=RFD8Y2*^4,VCY
M;K@`>4#+B"@@;DW]!V@'T?M5V>I0])J&A[=#V?M:'H-0]'BJ!_M]&>;TK6)_
MUE\G>8D/6//?[('GJ]^GEB?`/;'Z0;HJV/@'X>/T,PU!VO%7;\5!TEHO30=(
M4'30=KQT'1X@H/3"8P@```B(B.@``<HB(C3RU\=P#_+DU'KN&;Z2CY-&"L]%
MXEJEU+&;.BZ5?"50-#';->H,'*DX/KR(1>5L.SMFMEG"95)6"F?=P[%JL!2E
M<NX22:,5C$(.\8YD53F$OM$S&#0T5>-D3\=<ULS2`N(V7BUNN;+E*84U4S@8
M`.FJF<#)K(*E*HF<#$4*4Y1`)RS;MBVTU;=R1SB+F(QT`BDZ:."Z&`#$$#$.
M0=%$E2&`Z9RE.0Q3%`0RI@'+;QW#VC/7"E$L;BD&Y6T>PE8QVJC;-SR`J``I
M1\JP7(8[DHB1/5`Y]U(JBA"*I'(HFH0JB:B9@.10APWB'(<O(("'*`AM]+"&
M7W.M1RU:RC+?/NF\I&W9E$_5%U#>-U)U>3E]CJ.G)J&!WSH#^4*8DQ^DJ90Y
MCG6.TMALT%P<Y@`1%7J^L'_X6T=OT8>SGK[+Q4/;H>SFH>@?#0]G-0]'UJ'M
M>"C='CK'/PU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC`_4MRYYSVY5Z^\,=^$1H
M.GQT7M4'1X@H.UX:#HH/L?#7:\=!]CX/33%QSKU&-A("+?S,O(.!W4&,9&-3
MO7SM80_:II$,<=.8*O'*635I1##%C.4D&5N%=.4`&.744_)FQXYPB8`0%5-(
MSZ9<MQZP3"(%ZLSA)5)I;EG6]#6Q`L2`1I$04<UC&".A`3$X-VA2E$Y@*&^H
M8!,80U,(CRU.YVP[#?DID^S"GNN;9VSOQZ%U1L:8'DC)-V;4Q"H2K(A#/47#
M4I5%]PY#E56,B<C1_/KD4R!9#E&U;U$-PIY-=)J5:)N?JB<A0D$-15T`I?*4
MG`$*5,"!2S9RBDX;.$E$'#==,BR"Z"Q!351624`2F(8HB4Q3`("`Z#5G<2^`
M3'BK-E9\[*5M@#N1BHB5=[[YY:[I-$2B:%E6Z:H(H";5NHD($,40;;MOY`LJ
M4:R4/.L&SHZ:#E%=U$/E$"J/(2631$11=M3F%)=(X`(&#4/8B`CZ+NZK[F$$
MWAT%RV[:[50BMP7/)%2,9NQC&`#O`03%`JSI0"HH@.JAP$2@;+G%S?>\56\G
M,[;\*/5+HH2<I-S2$[=#^.35'V+-CU#>/:@4QR>R62#=,W^C]JNSU*'I-0T/
M;H>S]K0]!J'H\50/]OHSS>E:Q/\`K+Y.\Q(>L>>_V0//5[]/+$^`>V/T@W15
ML?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0>FMCALQB+X]Y90;MUKC
M/#*+>[!K?DY`T-#VK'$:^S%68<D6(N`&`W4)]4)3$<B)89U(PL+<66G+=-Y<
MMZNV2#UU'OUR@=6&M9PY*8S5FVY$@41W#N#%%5734B:3FT<DVRQGHY4BHL7I
MDR(S4"\4)NDD[?EBAUS5P3D'>(.Z</M:I%$C&(9]P]WU*NWN)LFOF)("6=:)
M,5%9=<S&SKV;-Q.9-N<ZY!B9@I3%*`E%0PJ$:HB-.A.U;163X*-<#9-WID*F
MN"Z13N$+=G%`Y5HYPJ82F`VIFYCBLER]8166X8<O2BT=?=B/7$;8R-PK)H/U
MXN*,,?(V("JY@,HZBE4C"U0U,86XF3)]K:@`>BX>/'"+1FT05<NG3E5-!LV;
M()BJNX<+JB!2$(4!,<YA```!$1TK'?#+@0Z5UQ47<BCI]<C4ZQX64N<6BC-U
M(METP$IHN%8F=J+ORE,53?5%'>3(0ZW'+P8QTLK(6Q@'`?"O;.,T#N.N(WC<
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M[6-OQZ2ANJ3)%O4KVM$#[^N\9O#*.TAY]XPCKH`@-3U@WS$I35LW$S%G(,E#
M&34+H8%6[MFX3T.BX04*15!8@@8AR@8-E.YO`W$/,6H*Q=QJC*(R\%,MT0+O
M]0YNJSW!!7**@`(:1Z>@#L,)=3'+"<0*]T)EZT"*?XLW+*"<IP!3E+?+-,0-
MJ`%#E'='4`'='43),Y$\FFH0%CK`\X=GX$,&I12+[NE*J`@``(@F7='4.41U
M`"6N%O/XAP^,`J3;6#Q5&"FW4)U1TSSIS"U;@'*?>2$BX#[4W*!:;9"XKLF/
M+WE3.$G;VUHR6EYQS+`B8%46MQWQ,B1QU6NI%FS-#VH_:W1:80D%&,(:&BFJ
M+&,BHMHW81T>R;D!-!HR9-2D323(4``I"%``#8'T?M5V>I0])J&A[=#V?M:'
MH-0]'BJ!_M]&>;TK6)_UE\G>8D/6//?[('GJ]^GEB?`/;'Z0;HJV/@'X>/T,
MPU!VO%7;\5!TEHO30=(4'30=KQT'1X@H/399R3*JG?P^+G-TO+>`^JK-3\G7
M26.+2!-,X:$+U)E9),"[H]<0#CJ83"/H6)E!HD1*<L>\4X19Z03(N?<*YV:B
M@@"I.4PI/FC44@'VO6*&*(:F`V*[[=*'5D+GL2VI*6.<``331XQ-*;TW0`!#
MRLJVZ8`#4-!T#70*?Y"@;C?XWR#)E1/+OFD>E-6[/.FK<K=![(0IE6RB3D2)
MID.X;.2@;05%$5%1$QB)8YXJ7#J.:")6\<KD7)MM$%,2@W)N0Q4GK+V)!UT.
MJ&Z`>Q$3`6MR+OI6?*BFFL0WY6XXE3*J(")2-]^\4B&,80*`FZP=PVOLS".]
MIY1*0*DZGJBMU!8;!4L&XFIH=+J[/,57134`.&N^`!J42\HT@AG._5,?V.Y6
M*HYB9:2BF;8S,3[Q#HX]L'<1<K(Z[J99=1!30!$5>74SY2W2`_N)TR$]U9%N
M,&:4JY9MDP<.6Z*V@)Q\:0Q.N%LF?3V)3+J+&3*<'&87SQ9*&XM<E\0<!)GW
ME4!*RRJXD;VLF-!LOH/5!+LH1L1$X@*90*(`)DRD'Z*/9SU]EXJ'MT/9S4/0
M/AH>SFH>CZU#VO!1NCQUCGX:IK^=OJQY[PY`\RGOI\U?!+D?S.>5Q@?J6Y<\
MY[<J]?>&._"(T'3XZ+VJ#H\04':\-!T4'V/AKM>.@^Q\'IL;]6)_<S_%1#RL
M`!;<%]^24G[G"82CU>O5^5;N\&]MW>3?UQ4DT6%RU2QO8Z;9P)1**[<EL-2H
MK"4=--XH`;33G]'V&[IO&UW=--[_`'6QW]G/KKK]7]C]JNSU*'I-0T/;H>S]
MK0]!J'H\50/]OHSS>E:Q/^LOD[S$AZQY[_9`\]7OT\L3X![8_2#=%6Q\`_#Q
M^AF&H.UXJ[?BH.DM%Z:#I"@Z:#M>.@Z/$%!Z;B>9OEB.9A!2/2%R;K%%ER-[
MKDTI-8JZ@;P@=7J3&WAU,.@CL'3T+Y`XE`QIZQ@3`P@`B?\`*QJ80)KS[H&'
MDYM>;6L**+G%0Y;>DVY3"`!HBTNA^U;D]B`>U3(4H='+R^EE'EN0[:X)ULR6
M6BH1Y+!`M91Z0NJ+):9%!T#8IQY.M%N<"\Y:E"89^:U@&<$AY4FRNMC?1^*J
M3D6R!]`DF%GXB<P<@V5.3E3;.X]4=X=BH!H,S9&<<VY>P\WE6SQF\QY;UF-\
M!JI13PHMGL8L6"CHN:<-S@)TU`?O5S&*8R9C"0=VH&\[)N.<M"[[6EF,];-T
MVS*OH*X;>FXMP5W&R\+,QATG#5RW5*51%=%0IR&`#%$!"F,)B(V0.+UBV5(4
MMMW%@1WEP1Z@`37&4NRP6+*?%/=`!74<30%3`!/O$$3F-$H\3/S;MJXG@'A6
MQWN16^?8"T56Y3[H.`1PQ,$GIT#``BINNY!#3D3`3FWA)]#'LYZ^R\5#VZ'L
MYJ'H'PT/9S4/1]:A[7@HW1XZQS\-4U_.WU8\]X<@>93WT^:O@ER/YG/*XP/U
M+<N><]N5>OO#'?A$:#I\=%[5!T>(*#M>&@Z*#['PUVO'0?8^#TUQ/&#<73BQ
M+DMV^#I%*45`9,C+04FX3WMG4MI!98X@(#N$-MV#C4Z2JAW]E1YL>2Z2JA53
MMW-J`5G'$*8NGL#1QF2A`$`W0-N<N[O#1CG,4A"%$QSF$"E*4H:F,8P\@``<
MHB-9YSHW#RBW8%"Y5(%\0@@4Q)N13M2T#*::`!EH9J[.(#K[(!TUY1#]C=JN
MSU*'I-0T/;H>S]K0]!J'H\50/]OHSS>E:Q/^LOD[S$AZQY[_`&0//5[]/+$^
M`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0>FRGCZ5(6-
MALH.+K80`*D*1J4+J>(9$M(&ZI0#D$J9HY(`'3K#[A@WPU+Z&/,1QQ5'4_?=
MWA/JM&Q177]QK8;&:(MQ;IZGWW3Y\W\GT*.\*"I0#4*QE8"Q2%>6G9%N0TGN
M&WB'F&T6F$RL0VH\BCL5CAH.G+R<GIYFQLBVI`7E:L_'O(V3A+CB(Z:CUVSY
ML9JL/DDFDJF!P(<=P^YJ4=!#E"L8\/E_0K2=88,S%D][D)C*L&KR.,O@%"6<
MI$E(QV"J2B2TY&L&ITC%,&JH`/)J--X^,9M(Z/9I%1:,6+=%HS:HE]JDW;-P
M*0A0YBE*`?11[.>OLO%0]NA[.:AZ!\-#V<U#T?6H>UX*-T>.L<_#5-?SM]6/
M/>'('F4]]/FKX)<C^9SRN,#]2W+GG/;E7K[PQWX1&@Z?'1>U0='B"@[7AH.B
M@^Q\-=KQT'V/@]-,VW.,TY"$N"*D(288+;P(OHN5:'82#-7<$!W54E#D-H(#
MH/(-7!8E\MI.6P?D%P19O+I(&<&=P3=THE!WC%II:$%_'E5%M+LB>R,41$"G
MT:&,G<=E7;;UT0:C=)R,E"2S*0;()*I"L4'AD#B*!P*!M]-8"G((&`Q0$H@#
M_A^P!)FO&^[Q4&UKEG[5ZV20AV\B<&+BU[<<L@,#V4?;_DIS-!.5N4QR`;RH
M=$&<9-MTB9"O)5"Y;\5(*:AFCPZ.Y%6V5=(3%,2-0,*9A*8Q1<'<'(82'+I^
MQNU79ZE#TFH:'MT/9^UH>@U#T>*H'^WT9YO2M8G_`%E\G>8D/6//?[('GJ]^
MGEB?`/;'Z0;HJV/@'X>/T,PU!VO%7;\5!TEHO30=(4'30=KQT'1X@H/36QQ$
M8L:OQR%BWR<9P(3?"76MB+=FFHRX8XJ'LS.89WO+?:R[XHJG.(Z-REJ'B+HN
M"%MC,#%L@RN"VY!PWB4K@>IAU835H@Z.!7*3D`ZQ1HD856YQ,0Q!3!-51Q<F
M2+G910`W54BX)%1-U<MPN"%-U3*"A2&ZU8QSAN"J(%13$=Y95,@"8'7$K?T.
MK&8PQ[*L7$#&K]:XC`=P!@<VA9<:X6*4C@S=4P2DLH4FX90P@9-,'292_0/G
M-,V^YG5V\;'6+I2U'JR9R%<2?$N#:][P=-`$H)F52E;4ET%#$,8Q4U2;P@*X
ME^C#V<]?9>*A[=#V<U#T#X:'LYJ'H^M0]KP4;H\=8Y^&J:_G;ZL>>\.0/,I[
MZ?-7P2Y'\SGE<8'ZEN7/.>W*O7WACOPB-!T^.B]J@Z/$%!VO#0=%!]CX:[7C
MH/L?!Z<]GY-MMO<$25<'C%055F<G#R!2"F20AY1H8BS=4`$2FW#;IRZD4*<@
MB45'%MYMN&'@C.%3DBYBS(ZX)--L;044`F6DA')B8O+JH++V7)[$-!$2W%!L
MI"[KX*0Y$;QO`S)Z_B2JI"BNG;K%HBDW9;Y1,4RQ2&<"4QTQ7%,PD_9':KL]
M2AZ34-#VZ'L_:T/0:AZ/%4#_`&^C/-Z5K$_ZR^3O,2'K'GO]D#SU>_3RQ/@'
MMC](-T5;'P#\/'Z&8:@[7BKM^*@Z2T7IH.D*#IH.UXZ#H\04'IWET6H_E<3W
M#).57<F2WFC:3M9\Z74ZQP[&V79TO)U#<OL63I!'41,*(F$1%N]R'DRZ+]:M
MUB+#$0\,TL:/?%(<3"VD%2NI-V*1PT*;R9R@IM$JA=>2+M2SX.,MNW(5N#6+
MAHAHDR8LT=X5#]6BD``)SG,9150VIU#F,<YC',8P_0).XVT8R0G9J/B(J6ED
MD"$?2,=`+.W$*S>+E#4Y&QW[PR(&]KUQ]-OT8>SGK[+Q4/;H>SFH>@?#0]G-
M0]'UJ'M>"C='CK'/PU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC`_4MRYYSVY5Z^
M\,=^$1H.GQT7M4'1X@H.UX:#HH/L?#7:\=!]CX/I#VJ[/4H>DU#0]NA[/VM#
MT&H>CQ5`_P!OHSS>E:Q/^LOD[S$AZQY[_9`\]7OT\L3X![8_2#=%6Q\`_#Q^
MAF&H.UXJ[?BH.DM%Z:#I"@Z:#M>.@Z/$%!](![.>OLO%0]NA[.:AZ!\-#V<U
M#T?6H>UX*-T>.L<_#5-?SM]6//>'('F4]]/FKX)<C^9SRN,#]2W+GG/;E7K[
MPQWX1&@Z?'1>U0='B"@[7AH.B@^Q\-=KQT'V/@^D/:KL]2AZ34-#VZ'L_:T/
M0:AZ/%4#_;Z,\WI6L3_K+Y.\Q(>L>>_V0//5[]/+$^`>V/T@W15L?`/P\?H9
MAJ#M>*NWXJ#I+1>F@Z0H.F@[7CH.CQ!0?2`>SGK[+Q4/;H>SFH>@?#0]G-0]
M'UJ'M>"C='CK'/PU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC`_4MRYYSVY5Z^\,
M=^$1H.GQT7M4'1X@H.UX:#HH/L?#7:\=!]CX/I#VJ[/4H>DU#4C.S\FPA86)
M:+OI.6E'2#&/CV3<HJ+NGCMR8I$R%`-1,8P!2\<UONX;DZA0Z2CZWK)N):.$
MZ90`W4N9-%KUI=1$`42*8AMT1*82B43#NS-^<^VR'H;?_OM#NS%\]NRGH<W_
M`(2HJ"M22NQ60:76REUBOK6=,T@9H1+YFH8JISB`FWW">A?4U'FJPL1-Y"Y1
MO*WLT7M?$BB>W7)8\L#.VO'Q+!1%^)]TZHK-E0,F`:E#0>>K1QGD&<R&VNF&
ME;L=O4HJP7\FR*C,7(YE&0IO$E2@8125()@TY!U"O]H\J?%C)_QU?[1Y4^+&
M3_CJC;4:YA?63+S#P&$8;(UG7':D*NY.)`0*YN=1%6,9E4$Y@(H^=HDU(8!,
M`F3`Z+ELLDY;.4DUV[A!0BR"Z"Q`426153$2F(8H@8IBB("`ZAR?3BQ/@'MC
M](-T5;'P#\/'Z&8:@[7BKM^*@Z2T7IH.D*#IH.UXZ#H\04'T@'LYZ^R\5#VZ
M'LYJ'H'PT2ZLMWK&6?$.7'D;#RHCQ])2CP$C*BUB86*27>.3@4!$_4H&`@<I
MQ*'+2J2-P7PY(0YB$<(V-*%16`!T!1,')DU`*/-OD*/J@%#NS%]<VVR7H;/_
M`+Y0[LO?'*'/9;T/_P!I5GY=N*0N9.SH7),E<[Y9I;CEU(%BG3ARHD=-B4X&
M,?14FI`'U?4JT<F9!D;I;VM#15V-'JL5;+F3>E6F+;<QC($V:1RB8!55(!A`
M>0-1YJ_VCRI\6,G_`!U?[1Y4^+&3_CJ_VCRI\6,G_'4ZMO">7(Z8O%FV.]6L
MFX(N:LZ[%6:12F7=QD3<S=L+])+>#KU(\RY4M0ZP2ZAKZ&:O@ER/YG/*XP/U
M+<N><]N5>OO#'?A$:#I\=%[5!T>(*#M>&@Z*#['PUVO'0?8^#Z0]JNSU*'I-
M0UA_$42[<,H&^9"Y[JNP$%3H^ZI+1,Q:V_%.!3$!4;E6?+NE43ANBJDV/H)D
MP$K*9DI1ZB=^515)LS21("*1%C)$ZQ1<#B83;N]R%``UTY=H_P!+S/=8_P`5
M7]+S/=8_Q5?TO,]UC_%5_2\SW6/\57]+S/=8_P`57]+S/=8_Q5?TO,]UC_%4
MG,1TBY=(E<I-G*#PB/6%Z\#=6LDJB!0$`$`*)1+KRZZ\FE+VM>$B^EW.$\D3
M..+=D9!;RE?\C#P<?=$!%&<J"*IRL#/W#-N4^H)-DVZ*8@FF4I?IO8GP#VQ^
MD&Z*MCX!^'C]#,-0=KQ5V_%0=):+TT'2%!TT':\=!T>(*#Z0#V<]?9>*A[=#
MV<U#T#X:R1#R3Q;W/LRZ"XNM"+554,RB6$(N6,<J()`)@`7CX7#U8P!O"*F[
M[4A"E("TU+**@4.L.D1FBF8W.)$CD.)0^H)QZ:_I>9[K'^*K^EYGNL?XJOZ7
MF>ZQ_BJ_I>9[K'^*K^EYGNL?XJOZ7F>ZQ_BJ_I>9[K'^*JUKOL.Y7T1=5HR4
M1>5HW$Q,+60CI"/?"JS5$$Q$!$JJ)B*$'V"A-2F+NG$M?[Q?N3]N_P!WS_&O
MW"ZTO\+_`(<?EU[D]=LV_:=[9S^AFKX)<C^9SRN,#]2W+GG/;E7K[PQWX1&@
MZ?'1>U0='B"@[7AH.B@^Q\-=KQT'V/@^D/:KL]2AZ34-<.W]G\D?A.'JW/>X
MG_2&^@+^^,?_`-(-9S^'Y;]'<)].+$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#
MI+1>F@Z0H.F@[7CH.CQ!0?2`>SGK[+Q4/;H>SFH>@?#69?U@9WSM^@Q_]G6G
MX2=U_P"H)_[N_H9J^"7(_F<\KC`_4MRYYSVY5Z^\,=^$1H.GQT7M4'1X@H.U
MX:#HH/L?#7:\=!]CX/I#VJ[/4H>DU#7#M_9_)'X3AZMSWN)_TAOH"_OC'_\`
M2#6<_A^6_1W"?3BQ/@'MC](-T5;'P#\/'Z&8:@[7BKM^*@Z2T7IH.D*#IH.U
MXZ#H\04'T3(^7[7=BUO=.[<46[91"K@V,\EI+),8]F6A5M=0$81K*J!H4VNY
MH8NX)A""NF"=$?0ER0T7/PSU,0%-Y%3#(DC'NDQ*(@)5$5"'`0$>0?V&/9SU
M]EXJ'MT/9S4/0/AK,OZP,[YV_08_^SK3\).Z_P#4$_\`=W]#-7P2Y'\SGE<8
M'ZEN7/.>W*O7WACOPB-!T^.B]J@Z/$%!VO#0=%!]CX:[7CH/L?!^R89#(\Q(
MIRMP-WCR)@X.+6EI5RS8F!-5VHF42)(IF4$$DSKK$`YMX"Z@1020Y[4Q%$M[
M/15+[OM[AFGCRY9!#RH=X8=Y&]0U9GZC30%D'(;X[=T.6&R#8<F,E;TVFL*(
MK)"V?,G+5P9H\CY-D81,BNBH0Q3D$1`>0Y!,0Q3&]+VJ[/4H>DU#7#FJ*9P2
M/!9+3(J)3`F=1*1A3*IE/L$Q0.03``Z@!@UVA5O&2.4X$9"B?=$!W545SIJ$
M-IL$!#9]`,F<Y2G7DV)$2B/LE#%WU3`4/J%*(C5U8]Q7CRT[IO&]\OR%XR$]
MD$DZZM>+@FUI0\,A&L8JW7D<X</%E$5S**&?$(@4$A%-;K="15DYE\@X?<LN
MNK:I$GY4A\970^,8$DPM^\GH)`Q66'V16,L">AC%11=.U.40,40,4P`8IBB`
ME,40U`0$-H#]-K$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#I+1>F@Z0H.F@[7C
MH.CQ!0?1.%3`+5UJ>\\BWGEJ::IFT,DWQU;B5I0!G(::B1=2Y7XIAO:"9N81
M#4I1#A#N]=YY9(PN*V6,)50YSG=>7X=DG.+!.^,J(G,LLE$).#J'$14ZP%-1
MW]1^C\2%_6_*&BKLE8*`QY:BJ9BE75E,B76RM1^1`#"&HIQCE^Y.`#KU:1].
M6L:Y6@=WW#R;C^S<A0VZ<5"^Y-Z6XVN2.W5!`N\'4N2:&W0UVZ!Z`]G/7V7B
MJ&R#;MI1MYW7=M\,;(@(V;=O6D(Q.O"OIU[,RGD&ZJL1)-D")6Z:R1CG6*;K
M`*0P"SMGB-MHV&;E<*`@C>$*+^X,;O5%#;J8OR;JDE$B(F*0.L(Z0``,HJZ1
M+R!'W-:,_"W1;DNW!W%3UO2;*9AI)L<="N&,E''415((@(;Q#B&O)6:EG>K9
M-'/4ZZ5.L`I@1L-S^4@N;?T]@*8@<#;!*("')Z1V6/?-7HL'1V+WR5=-?R9X
MF0JBC984Q'=.4#%$2CRAKZM(Q)WK4DFX;*/$&!EDP=JM43@FHX30$=X2@8=!
M$`]7U!T]%J1-0ISMX)FBN4HZBDJ9XY<`F<.81(H0VGJ"`UY-U*OE/^X3U'D_
M5GZ_K_\`=ZZOJ>JTWM_>]CNZ:Z\FWT,U?!+D?S.>5Q@?J6Y<\Y[<J]?>&._"
M(T'3XZ+VJ#H\04':\-!T4'V/AKM>.@^Q\'[)OV\)68F).,/<\\RL]I+B9(\%
M9K:76+;T,WCRB*;;JF^X*R:8>R6%10XF4.<YJOO+#BX$OR8NHZ5JQUKM':BH
MGDX!UY2\FIAMN@1)5(JI46@`83F355,8"E%/>]+VJ;O\@WI;EH-GHN"L!G)1
MLR7D#-4@5<DCFBANM<&(42[Q42&$-XH::F*`Q$1#6_=DS;KQ1).6NLZ+>*+$
MBNZZD5$89WJLX(FG]M4$3I#IR%*<VNC"X+=E&,W"2S<CN-E8QRD\8O6RG(55
MNX1$2F#4!*(:Z@("`Z"`A5CX[RJZN")86Y<I[H93=I+Q[.X2-V[%0LS`HO9)
MNZ(FVD4BD(N()"8ITT52^R2`!$C6(R\V(8V\8B&5IE$IC::;PE32`!'0--:^
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M=,6QP\EEG`J@=!@!EBJ`4Y2+F4W2'^F%B?`/;'Z0;HJV/@'X>/T,PU!VO%7;
M\5!TEHO30=(4'30=KQT'1X@H/H3AUB'@4SGQ2E;1_EBDKC^[L2PD`+@Z>\2,
M1C7,P^NU58HZ@L*%HJ)AR=4HL(B`.8!/@S@.$<'9Q0:$S38>49Z^&RP;Q@!B
M_NTEN1JIA`AA^V0*@"`"(:`&M1&0N)C(ZN0[CMV(6MZVS$MRU+5C+?@5I!23
M&*C(BSV+!L!>M4,)EE4SKGT+UJIQ*`TCC?!V1H`<6I3DA<G^&]ZV+:]SV^,S
M+&2-)NDI0R"$T@5?JB[Z+6622U$QP(!S":HLDS\UK>6;(AZ0A5K\P(QR-8MM
M-P/NF2=E=7VQGHD^^40T26N!L`ZBH53=+N"SN6^\(9!P'/+[@+V/D>:QA.S)
M"G2!4';=]BV?GVG4CKH!7:K9R`@(*MDA#3Z-PS8*;.C)NLE9<N7(\@@BH8#J
MQ&*+5""30>%)_P!Z4=74BJF4X@!E&^\4#"D(EX;G"[DJ\UC:.N?#LXF4X'!F
M;'MTNHRV6VNHCJ,`:(5$#`703Z`&Z!3#0]G/7V7BK#/PX)^8<QZ'NQAW(<S;
M*"[@B\K;:BA92SYX2@!3!-6O(`HS6.)`ZL'`)E73*(]4JF/+4I>GS@4+D'#%
M_79$0$*K/XYF%4<'3$[&I>0'NFX@:-7=P1+Q=`K1H4IE'+$A$CKN7!#'WB1%
MVV'+9#O"T9MHF[@KCM3.3N>MZ48F]BFXBY6)ZUNLGR:`9(XAR:<U?<&9?C;G
M/XNK'R/PQX\OYY8GNV[:Y=R1*9*N&ZI"R17ZEE:L>YM@R2236/D5USD-,"HJ
M!7!$6I@;&61%U%3,_`+WA;*+G?G[13N.5M4+@:"B=($/=V'U7;*)F."J2Q2'
MT,4`,0Y!,0QY<SI=)Z*QE45$G+LQFA=X130;+N%%%0(F`[I-Y0PZ;1$=1''-
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MTJ\+(N+>F&;%`4D=]5P<(\Q#CUY"&Y"G(8M1DA?3=EBNU')6KIPO.+)/KI58
MK&*8Z;*VF)C&27W!$>KD%6XD'D,`B`EI#'EGN9&1;GE7L_,3$L=(7TS.R""+
M5R^52;E*DD4$6[=!)),NA4TR[PG/O'-Z7M5=,^^D&3Z`M^2E[3L4(U(4F);.
MBYUT>(=EWM#*JNBJ"X674#>,)@*`%3(F0E<3:"C6=EL=2<%;2&/XD!7E%%IY
MKD1JK<7Y+1*'6+)H`.^9WN)E(=;V10,<JP@"+;&.0W"Q@$2I(67<BJI@*&\8
M033;"(Z!RCR5_E!E'XO[L^]*_P`H,H_%_=GWI7^4&4?B_NS[TK_*#*/Q?W9]
MZ5_E!E'XO[L^]*_R@RC\7]V?>E?Y091^+^[/O2O\H,H_%_=GWI7^4&4?B_NS
M[TK_`"@RC\7]V?>E.Y::QED*'BF"0KOI.4LNY(^/9H`(%%9V]=MB)ID`1`-X
MY@#T+9A,00]XSF2'$F@M:3&P&LNZNX)5F/E2+R%+!`+I-1ON"MUZ0EZH"BH)
MB@43`W9<;MXVI<MT]5'A:C!J@G)9%@HLB`E699)O2)6",DG9?M92"V;K*Z@=
M1S(.U%-$LB9,@WD8SNQBT81%F^ZJ!G;=:Y9V22CF@$9@`@L=!(Z[LJ9PW!!$
M>L]@!JE9Z8<F>RTW)/I>4>'(DF=W(R3HSQ\Y,F@4I"BHJ<QQ*0H%#70``.2H
MQ>#6?-YI"09K0[B,570DD)1-R4\>M'KMA!0BY50(9(Z8@8#``E$!TK%C'/CM
MR]RRWMY0EUKOET'<GRRC@\$A,NVYC%6?)1HLTGRPG,91P50YSF.8QA]):MMO
M[4E+^O*Z6+F8+!Q<LQAV\-!H+>1HR,L^<$7.!G"P'(V1(W'?!)4QCI[I`/"3
M5O25EX_BX9=152UK>M5M)1-P)BZ.=-.XW5U&?O#_`&@P-S^1.6I1$!5(1-7<
M,1O<ELKM86\8]N7\M<=KR2+V;M1R9VJT06.<I$A<,G/5"JU=E2*!BF`IRIJ@
M=,OTHL3X![8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#I"@Z:#M>.@Z/$%!]#
M>1$W&Q\Q$R")FS^+E6;>0CGS<_MT'C)V4Z2I!YRG*(#ZE<,6;L.8LL7&L??K
M?(UB9$2Q_:4#9L5*7'`*1MPVE+2L?;R#=%P_<MGDJDH[4(*IDVJ9#'$I"`7`
M&6+EP]C1WF?)Z-UY&D<A2-BVQ(7T6#F[P?I6(R1O%VU-(`V)"),'"3<JX)I'
M75W"ZF,<_P!%!QPI\-N*\]O5F9]XEZ9^6Q;+1LB&\(%);3^VUF#YN(;FAQN=
MH<1$P"0@`!C224QPP2/#O"-BKE<W#A/`@9<BF3,@`8YG]_R3F^8E,PDU#RA)
M1#]L9+<,4!*UGN)#+>1,IW-;A'T5&A?TW(/PMA-=T"DG&P\*X$K>-*=8A1<(
MMFZ0&,0N^`B0NA+0X4<VY=M%&8F5II/'-GJN+JMF6N!=JFT=2Q<:2B$A&.'B
MJ#=!)=?W.,HHFBD4YC%23`L6WN'@;B,NP#@S-1S<N:;")PPS[AD8`WG[*8EI
M2VHP4E$]Y83(6ZY$_L10(("4ATI7B`Q38F'[T4.4OY*V)EI_EYF5$I=%'#Z<
M=VU;B:"IC!J5LW*[*4HZ"X,(<OV7BK#/PX)^8<QZ2VH/@_N.^Y"Y[KGV"(XB
MA&SNZ;4R"Z,J1,[.=L54%&BN^D`IJ2!4TG#9(3J)NF^Z*A2"J4A%1(45")G,
MJF102^S*10Q2"8`'4`,)"B(<N@;*O^_.(9E$W/9LS$R-GL,92:#5\IEN>FXM
M<&F.V<<[3634!\F17RM55$Z3=L55PJ'5ICK.2<-"H6U$24Q)OXJW6KQY(-H"
M->/3N&,*W?R!CN%R-4C%0(LN85#@4#'$3"(UB'+F;\:-\JXYM"Y$7LS;JYA4
M4BUCD%".O)A&GU0?NH5<Q))NP=!U2YT@()DSB15.U\C8[N2+N^Q[SAF5P6Q<
MD,OY1'2\3()`JV<H&$"F*.TJB2A2J)'`R:A"*%,4/2YJ^"7(_F<\KC`_4MRY
MYSVY5Z^\,=^$1H.GQT7M4'1X@H.UX:#HH/L?#7:\=!]CX/I#VJNED]@VT19]
MTW%<L[CE6/<D<QR]J+RIG+)@AJ8RJ:C!)=%JNDN`&`Q=XHG3,10[,UMV)+,(
M)T9$REV7*W5M^W$6BBH)'>H/9$"&>%)KJ9./374TU$":`(A&V!(SI;ADDI*5
MEY!ZW*NG'(N9-8#BSBD7/LRH)D*343``G4%13=+O[H-\TY4]U7<"TDB0#*!M
MU!J[N:XY69:K$3C;?:OUFS<ZY$2+NC^4.4DP21/O*%'=U_RMXJ/S(Q)_?BO\
MK>*C\R,2?WXK_*WBH_,C$G]^*_RMXJ/S(Q)_?BO\K>*C\R,2?WXK_*WBH_,C
M$G]^*_RMXJ/S(Q)_?BO\K>*C\R,2?WXI56U<,\1TS,@JV!!A<$/C*V8Q1`[@
MI7BBLO'7-+*D.FD)SI$!D8%#@!#&3`PJ%Q?EZQ$)C*UP9QM5_<V,[&:=5"*M
M$8Q^>#F#9%E%.O)%@PDDG,:X2;D=*J.4%2(%.B4SDBBV5[S59V4W>G=P6*[3
M,YA<?0@@?>;*FB"J'/(.D@U`CZ35<+EU,"9TR&$E0][Y12>X$PV\W'9)>Y(M
M0<@W2PY%"#:=E/!2411<%'[5)28HI;ABK()/">Q$UNX1L-I#/GK9-O<-[2QB
MS-_78*8E.)K@N=<A53)B<H*E9-BHM$SZF1;IZCZ&1\;6_&1LI=SMBRF++0DW
M7D*);F@I!.19@@^,=,B*RZ1%VB:BQRI`*NBP@D)QJ5QR[M2=&^X27DH*3M1I
M'.)&:;RT0J=&19E91X*F4%(4SB)DMXHE#?*(ET&HJXK[:GP9:B;V/=@\N@%4
M;\<MDWPE=J0UI-A\J9N403$R?NL+3413.0#D'7TV;;HN..E8>4D,D72D:%FS
MJ*2<(SCI12,BX9T*H!H+5LBB@!2@!0`H`0-W3T+^XC?R@</+@D7DOAU&W4FX
MHLH:.9C#W?)/'CDQQ\H<.C&8=44$R`@F0WLE!7$$OI18GP#VQ^D&Z*MCX!^'
MC]#,-0=KQ5V_%0=):+TT'2%!TT':\=!T>(*#Z).2\-%#*W+B#+^*;]A6[8FL
MBX&?G38B=LF@AH)BG+<Q5E4S"!-$@4-RI%$,.X<C`1\@Q3BZP<<M#-R`FBJC
M9=K-;=*N0H?_`!GDV^(CRB(B(ZB/[`X4^(J-B6S=U&W??&'[MF4&I2.),;G@
MFUWV.T?NB%U/Y,2#G10`YM=%3@&H!R8INI6':,;HS9<F0<HSCSR1L22<LGET
M*VE:X+O2%!0Z2D1#1[E(ACB!05V`.H>@-?9>*L,_#@GYAS'H1UK67;DY=MRR
MZP-HN`MN*?34S(+B&O5LXV.(HLH(!J([I!T`!$=`"K=B./6>RE:35[#-KDD,
M6</L/8EZY1:Q[M4/<QG=L_=DQ'PL"=XEOKHE0&5=%(4`<-&O6I*"-K\/_"OQ
M"6(FY;I-YJXD;!Q/*7M<_5""G67/>DM?2TD]#K`%4B"KCJ$C"(())%T*'^5O
M%1^9&)/[\5"E8VKQ7V1FK&C69/BRY']JXV5LM4TTHW6EK>O.$:WLM_)7@M4B
MA(-$!=-C@50"N$BG:JMI[C-@<M7/B.$CWRWY$XC80BLU=]P*$!O',9>8EYV!
M.QCD=\SM59DNHLJ=,B`%(FHHH6;8XXE<@#A=Q=!S6U.7E;=O$R-'V0X>`8HS
MENPTJ>,<RC-`QD]Q"511=G(53>9E5$B-I8#QICKC'EH2W3OI*2G+DMG%;V3N
M"YII4'4]-&;#?0MV*:ZWLDV+(A$4B\QU3*K*_P"5O%1^9&)/[\5_E;Q4?F1B
M3^_%6/C!&S,OV'`7LX1@TLAY$C[-C(N%NV1?ILH./F(RVYB5,G'.=\2*RHN`
M!NJ*8*MP;BJZ1]#-7P2Y'\SGE<8'ZEN7/.>W*O7WACOPB-!T^.B]J@Z/$%!V
MO#0=%!]CX:[7CH/L?!](>U31.Y+>@[@3CW(/&!)R)82Q&3L"[H.FA7Z:@)J`
M')ODT-]6M````-0``#0``.0```H:X=(3RE0(L(_)4J+,HZ)*/S.H9H5RJ`>V
M,1,!*F(^U`Q]--\VL.[7AXQT\?('<N73EF@Z64%1<XIEZQP4P@!2;I0*70.3
M7341$?Z!AOZK8_O*_H&&_JMC^\K^@8;^JV/[ROZ!AOZK8_O*_H&&_JMC^\K^
M@8;^JV/[ROZ!AOZK8_O*+)LXMBR>MG[5,J[-LBU,HBOO$.BJ"`%`P:Z&#>`1
M`0Y--1UE;DMS*["PKDQ3F.X[108W%`NIB"DK9G;4A;C`$'$:LFNV7;O5'*F@
MI*E6!<=12ZHN_%WA<S5'..:&@INBWU>40U+`VT^*8#D-8=EJF<-V1TA*44W[
MI5R\`X&.DL@0_4E](\O-K:=M-KPD6Y6DA=;>"BT;E?-2)IHD;/)U-('2J8$2
M2(!#JB``0H::%#3TS[,_#]#RM^J9(N)_(WW9PO8AL^MR<D"I')+PZL@HW!9B
M[6Z\[DISB=L<2B&\@811BYKB$R)&QD?U;-XZLC'?72,LH)Q376BI2ZY-))NW
M.0-]!<639R43:BBX$H`<R./\46VG;%L)R#J75:`^D9-R^EGR::3R3D)&5567
M664(BD3>.IH4A"$(!2%*4/I18GP#VQ^D&Z*MCX!^'C]#,-0=KQ5V_%0=):+T
MT'2%!TT':\=!T>(*#H^B/;7NZ'9S]OR1V2CZ)D"&4:.CQL@E*L16(40$>K<(
M)*EY?;%#7DY/H=^9BR$^-&V9CJVY"Y[@=D!,5BLF">H(-BK&(4RJR@D11*8Y
M0$YB@(AKKZ;/#:'C',M<N-WEBY8MUDS0,Y<&5M2[FK2XU$D4P,<PD@7LL8H$
M#>$=`V"-8-PHT(D5+$^),>8\,9(0$B[FT;3:0;QV)P$V\999!18Y]X=XQA,(
MB(Z^@/9SU]EXJM:*PU`#=MV6'DR/O!U:R+Q@QD):`/;<E!R)XE225125<MU'
M3=4&PJ`91,%.KWE"D34C[HXH+E#%=NG%-?\`P_M1S&SN0WZ`^RZJ2F2>4142
M!RB!BB3RY4.4BB*!^4!M[#..X*T$UT"(RDTDD>0NJ?ZL0/OS]TR(JOG0;X"H
M1%1?J4Q$0133+[$,W)3+A1X+G,\A;YE%#&$P1<9)IV]'-0$H@.ZBT121)H(:
M%*'+1$DK?A2)D*!2E",9#H`>J(DU$1VB(CJ(\H\M?T##?U6Q_>5_0,-_5;']
MY7]`PW]5L?WE?T##?U6Q_>5_0,-_5;']Y7]`PW]5L?WE?T##?U6Q_>4DE%M$
M62#R);/E&[<@)(%7.Z7;'%)(OL2`()%'=*`!KKR5_B/[KJ_EK_N7?EM[O=0T
MZ_\`*G_`[W=]U_)NKZC?\K^W;G5=7KR;F[R>AFKX)<C^9SRN,#]2W+GG/;E7
MK[PQWX1&@Z?'1>U0='B"@[7AH.B@^Q\-=KQT':^D/1J%=GJ4/2:AKAV_L_DC
M\)P]6Y[W$_Z0WT!?WQC_`/I!K.?P_+?H[A/V&)C"!2E`1,81````#41$1IP\
MMBXH*XVC1VNP=.H&683#9L^;&W'+)PO'J*%(JF8!`Z9A`Q1Y!`/I)8GP#VQ^
MD&Z*MCX!^'C]#,-0=KQ5V_%0=):+TT'2%!TT':\=!V<P5T:?L>\[42>';26=
M,FXSQ8R!`PE<G;-)=3*,S[0=XJ)VEMJMES^U$%@2-_"@`\+&7U'8O9.\,(V$
MI<CDQC'%2\H6#3MR]PWSB8Q@++LWI`,8=1`-1Y=?2R4'-L&DK#S#%U&2D8_0
M(Y92$>]1,W=LW3=4!*=-0AC$.40T$!]$>SZM=OQ4/;H>SFH>@?#69?U@9WSM
M^@Q_]G6GX2=U_P"H)_[N_H9J^"7(_F<\KC`_4MRYYSVY5Z^\,=^$1H.GQT7M
M4'1X@H.UX:#HH/L?#7:H*#]GZT/;H>SFTH>DU#7#M_9_)'X3AZMSWN)_TAOH
M"_OC'_\`2#6<_A^6_1W"?L*X\J7VX<I0L$1LW0:L6PO)"5F))<&<3%,&H&)O
M'65,&\)CE*0@'4.8I"&$#HW[E6X#0WEDFZ;VS;AT;4MYL252*V69'8P!4#.D
M4T2]2B$@HX.0AE-#[RRQE"77:HGF+6EU6:5^V(JZ18L+RC6*3A-DB>04;N3M
M'#8SE55JZ13$2F$2G*HD8Z9K(R1`HO6T+?=JP-VQ;:11\G?MF4_&IR;=N\2`
M1*"B95`(<2&,01#4AC$$##](K$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#I+1>
MF@Z0H.F@[7CH.SFTKZG[&%_FG-F)\3-`2ZTJN1\A6G9?7%Y-T&J=PNVYE3&$
M2E3(D4QCF$"E`3"`#PWXIX:<J1>4K9QR[R+>&19:WFLZG`%N::3C(.SF31]*
M-6R#M1LU0EU#K-#K$`KD@;Y1W@-&<-/$9GJS<1WUC[*%\I6/'7ZM+0D&^Q[>
M+M"]&LF2[WS<(9O_`.>Y&<25;JOR*)@0%CD`BQ3&"X<59)L')D`;3=G,?7C;
MMYPYM[VNDG;CERB.O-[/Z!T?6UH>W0]G-0]`^&LR_K`SOG;]!C_[.M/PD[K_
M`-03_P!W?T,U?!+D?S.>5Q@?J6Y<\Y[<J]?>&._"(T'3XZ+VJ#H\04':\-!T
M4'V/AH.CE[=!VN]0?13J*'*FFF4QU%#F`A"$(&\<YSFY```Y1$=E0V.S9:M!
MQ=UP+-6T5'Q[Y249N';Y0$F+)6=C2*QZ"ZQC%*B@NZ(H<3%`I1$Q=?V"/;&A
MH>DU#6`+\19J+6W'J7W:<B_(413834K[G2T0U<#L`72#1Z9+3_XA373DUBXV
M6D#Q[V/2,U43,Q?N"*%*H)DUDE&::H:"40`0,(#J`\FF@C_3W_5<U][5_3W_
M`%7-?>U?T]_U7-?>U?T]_P!5S7WM7]/?]5S7WM7]/?\`5<U][5_3W_5<U][4
M6)A'AWZZ[U!94P-'C9-!%OO&$3"\33$3&$0``*`\FNHAR:WQ=TRR.SB,D9NN
M.8M%10#`:4AK?MR,M)]*(B(:"E[I,WS,!`1'K&Z@#IH&O[!CY*)DS-(:WLFV
MP_NF.*5R'NJP>,WD/&E.HW*8NZ@]<MU.K7W4Q'=,!NM(F4]8AMQ"Q5LA1+K(
MMH$N>WA9NW,8O;0S*:L\::6;<B+4C(CE5910P$`A#";4H"%,XV-9M8^.CVK=
MBP8,6Z31DQ9-$@0:LV;5`"D222(4I$TR%`I2@````'TCL3X![8_2#=%6Q\`_
M#Q^AF&H.UXJ[?BH.DM%Z:#I"@Z:#M4'9]4*[.W7U?"'[$"(N[*?$KC4HL%HQ
M97!G$!D3&+%\U5UW0EK1CG2UOO3D$QA!1Y$*G-J!5!.4I"ED9C!_&!=[!VN=
M=PG$9KL2.O%U(.%`WBFD;YM!W$&(83:[ZH0:HCKKN@(>RL*W<VR^/+GCLHL;
MFD;&NG&\Q.R<1)(6F[9MYIF_0N.-BW+9XW+(,3JH]2HF`+%ZM90`$:DLPV!>
MF*\<8LA[XE+"=S=_/KI/<$C,0T0PF)%:V[;@(QRFZ;IDD4$A6</VQ14*J0HB
M9,0J*NC)G&%FN:GX]4')%,'PL-A5PV/N@(LT;BDG%RO13$P;JBJ(-U#DU`O5
M&T,"=F6S>>9;Z;%!L4\UFK,F1,PW"*;0#D;(-']]OWA&21"G$@(1R+=(2@0#
M$$$T]WTGU?0'LVUVAH>SFH>@?#68U[@8*H"YR8I?D:&[["1@;@=IW)%N6B@Z
M%.!DE.J,(#H54ITQ$#$,`%,,X9,3%`1(>+EQ,01#42&$C<Q=0V#H(AZ@C7]/
M?]5S7WM7]/?]5S7WM7]/?]5S7WM7]/?]5S7WM7]/?]5S7WM7]/?]5S7WM7]/
M?]5S7WM4<WM9L\EEG",;;\4W:M'!WDM(.7IQ;H,66[UICJ*N"HII[F\8W(`<
MH5_@=Y.U_+W_`'3?\*/).O/Y#^5_^#_Y(>3^5;F]U7EOL>LZO7=Y=W7D]#-7
MP2Y'\SGE<8'ZEN7/.>W*O7WACOPB-!T^.B]J@Z/$%!VO#0=%!]CX:#LY]*#L
MY>:MM:=G:KD^AS,3;\E<EL8^M,LK9S.W49QPDTGE&[]RRE[@EF+#JTS&?)B"
M/4*F6`B)0+O#OJ`)3D,8AR&`Q#E$2F*8HZE,4P<H"`\H"%7/;%]MUY1MC(]N
MP\!>RX+&<S#1^V<B:&EW3@YA<.V*:")NO(`F%)5/KM#[IUOHW)Z`]WM<P4/9
M]6A[.:AJ>QODB"0N&T[A1*F]9*G4070705!=E(QSU`2JMW+=4I5$5DS`8HAH
M.I1,47:UN9TO.*ASJ"9E'S-IPD](MDAY03<2K-U')K"'_**S3Z*Y.(&>';_]
M3V/#9_\`E:N3/DZ/_9_'A_\`.U1]QMLO2TZ=]<+6#%HO9S-@5,CB.=OA<`LG
M(*B(@+8"[NZ'MM=>3EM#.!<H2:KJY\H75CQ2W1M9J1NS1MR`931)0DB#X3',
MJ+L4Q2%$`*!0'>'70+<RV^XD+BM-Q/2%Q,CP;3&L;+H-@@YQ>((H5\M,MS&Z
MP$04$!2#01TY=-:^5I=7Q11'X_KY6EU?%%$?C^H^6R7GO(F1K99*IKN+3AK9
MA[`]UC)'WP:2,\F[E'!6RFFZL5H5!82B/5N$C:&"W+#L6`C;6LZT8=C`VW;L
M.W*UC8B(CD`;LV35$O,4H!J8PB8QM3',8PB(_L&2MF[(.(N6W)EL9G+04]'-
M):(DFIC`<6[Z/?$.DJ7>*4P`<@Z"`"'*`#4O/7A=UWW[9BK@ZMOV$MO6T6.1
M,[*N5K-W1"N0=OBE3`R`&;E9FT,)A$3@`@2V<6V+;=C0P$;E7;P$8@T7D3M2
M"F@YF9'07+Y<"F,`N'BRJHZCJ<=1^DEB?`/;'Z0;HJV/@'X>/T,PU!VO%7;\
M5!TEHO30=(4'30=G-R4'+6WUAH.6N4?V+B++[-$%7^',XLXY^<2#JVM3)MMN
MHJ27*J7701E(^#3W!``,!Q'>`2%*;A4MY=H5M,7C8R^7YQ44C(N'CG+TTYR!
M$J/"&T^V(13^.9!R![!`FO+J(^E[.2MM=FWU*'LY>>AZ*[/4H>@?#44O>Z<K
M;]XV\BHU@KYM=5JA-(1RIQ64AI-!ZDJ@]9=:/6D25("B1Q.*"J76K`H/_P#4
M%/#I_P#R\CP_^=Z'_P"G].FTT_\`J?1X;?\`\K4/_P!/F<'0-?\`8%@'_P`Z
MU;6$%\I2<0UG[X?6@>XDK5:O'#9-FLND#XL<=\F4QC=2`]6*P`&OMN2K<Q(^
MRQ*6FWGH^XGIYQI:3277;#!P:\N1,K%9^W*;K!1!,1%4-`'7ETTKY6EU?%%$
M?C^OE:75\441^/Z^5I=7Q11'X_J%RW/W-<^<,DVL]&1M%[=3",@K/MB23WRL
MIR/L^/,X%:00`^\@X?/UR)*E(N@BBNFFH7T,U?!+D?S.>5Q@?J6Y<\Y[<J]?
M>&._"(T'3XZ+VJ#H\04':\-!T4'9R4'9R^A]7PA0=FGH<O>K;6VMM;:VUMK;
M6VEVXJJH@NBHB*S=04ETNM().L05+RE.774I@V#H-7=9,PUD&CZVKAEHD2RC
M8S5XX;LGQT&C\R8\ABN$BE634()B'*8#$,8H@(L[<L^WY>Y9Q^JFBUBX5BX?
MNU#*'!,#F3;E-N$`1#?4/H0H<IC``"-6+9=_L&D3<;-2?D%XEN5N+F-;3<^Y
MEVC25<M#'35=`18#*F`?8`)41U%,1';6VMM;:VUMK;6VMM;:VUMKD[];?K5M
MKP5M]7NUV;`H>V/CH>SFH>W0]G[6AZ#4/1XJ@?[?1GF]*UB?]9?)WF)#UCSW
M^R!YZO?V4\EYJ181$5'H'=/Y.4>-V$>Q;)AJHX>/79B)I$+^V.<P`'.-/8O\
MLGV2KFCWC)JZMW&<:,Z*:3Q`7/EQ;F?G9PBJ290`%"MY-14#&*7J_;"6&R1C
M693E(.61*+ADLJR"<MZ0`-7$'<L<S67\D>H_MT3*"`E$JB9CI'(<W[/L3X![
M8_2#=%6Q\`_#Q^AF&H.UXJ[?BH.DM%Z:#I#P4'9MH.C_`$4%<G^D*V]OU.GT
M-O:K9W*YZYZYZYZYZYZYZYZYZYZYZYZYZYZYZYZYZYZX@.'N%%(MQWS:C!U:
MBBY2"4MUV=<K&^+;(!CF(!>M>1J*)AWRZE.8!,`"-6O9-NMA9V_9]NPEK033
MV'\EAK?C4HF,;_:RE+[!!$A?8E`.3D``Y*YZYZYZV=VMO<KL[]#R]NO!]>MM
M#V<HT/9S5VA\-#V<U#T?6H>UX*-T>.L<_#5-?SM]6//>'('F4]]/FKX)<C^9
MSRN,#]2W+GG/;E7K[PQWX1&@Z?'1>U0='B"@[7AHOU`"@[7>Y!KLVUV<E=G)
M6WMA7C"MO9VZVU_HK_17^BO]%?Z*_P!%?Z*_T5;TYD>$D'4O;B/D+60B)=U$
M.'D0+DSP861.WUZQOUIU#EW=U0@G/U:A-\VON78-FVW:#$Q2$51M^'8QAG($
M,8Y#/%VQ"J+F`3&'?6,8VHCR\M?Z*_T5_HK_`$5_HK_17^BO]%?Z*_T5_HK_
M`$5MK;6W7O5MU\`5MV\]#V<E#V=JA[?KT(T/;H>S]K0]!J'H\50/]OHSS>E:
MQ/\`K+Y.\Q(>L>>_V0//5[^RK=X88,T6%MJ0=OY$O9XW774EU9I23?MH.VG9
M4502201012DE$E4C&4,LV4*)`3#?J&A\5H2TAC^6<-5,U,`)I:Z5K-V;Q!A+
MS3M4AB(.VJBRJD8!#D566`40WDSJA](+$^`>V/T@W15L?`/P\?H9AJ#M>*NW
MXJ#I+1>F@Z0H.SE#EKL[5>IXAK;6WZPUM[0_7KU._6WL[=;>_6WOUM[];>_6
MWOUM[];>_6WOUM[];>_6WOUPW<')I))%CD_ABS=?[V*!<@*O[J1NB+>V&^.D
M80$`:Q=J7H0@%`=_KSCL2&MO?K;WZV]^MO?K;WZV]^MO?K;WZV]^MO?K;WZV
M]G:K;W*V]H/KUXOKUMKLV^I0]NAKM4/9S4/1]:A[7@HW1XZQS\-4U_.WU8\]
MX<@>93WT^:O@ER/YG/*XP/U+<N><]N5>OO#'?A$:#I\=%[5!T>(*#M>&@[.?
M2@[0_7]#LY:[.2MM>I]4*V@-<W=KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>
MO7KUZ]>O7KUZBSY.O%K;BTV#D8AB#&6EY%^#0"]>HFPA&[E4B8"8I.O6*1+>
M$`$X#4$VM3&-S2-H&53+<LK<+^-AI]!-1P*2IX*&C3OT%023T6+Y0\3%41ZH
M2HZ=:,->]E2R,Y;,^V.ZBY)%-PW!8B2YVKA-5L[(FJDHDJFHDJDJ0IB'*)3`
M`A7KUS5M$>\%;:VUX/J_5'T![?KC0T/;H>S]K0]!J'H\50/]OHSS>E:Q/^LO
MD[S$AZQY[_9`\]7O[*B.(&%MI=:P[AM.WK=N^XV[@7)6-\1CUU',R234QQ,W
M27C0CD6RA"`F=1-0!$%!#>1M_'MFW->DRLLW0"/MJ&?S"R1G1Q(B=UY$0Y4$
MQW3"*JPE(4I3&,8"E,(7QD#+3J,@G%\6S$0C"P8V5"6>,Q0D/=162N=9F`LB
M.$``$&R;9POH"J^^8G(!OV?8GP#VQ^D&Z*MCX!^'C]#,-0=KQ5V_%0=):+TT
M':^OZ3;T#XAK;6WNUSAWPK:`UM#OUM#OUM#OUM#OUM#OUM#OUM#OUM#OUM#O
MUM#OUM#OU9^5"2HEM+"&:,,81<O"N")^YUI$AVMFY93WRCNZ(NINX]4S'`#!
M[`XDWC;NT._6T._6T._6T._6T._6T._6T._6T._6T._6T._6T._6T*VB/@K;
MW/0'EZ1^M79W:'H[U#V<U"/U*'LYJ'H^M0]KP4;H\=8Y^&J:_G;ZL>>\.0/,
MI[Z?-7P2Y'\SGE<8'ZEN7/.>W*O7WACOPB-!T^.B]J@Z/$%!VJV^IZ]!79R#
M79R5MT^K7J>"MO<&MM<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U<U7I
M<LC,K2T&PGYN$L<AVPLDH^RV$PN2!;I,Q`#)F.B)5EQ.&^94YS&Y1T"KXOM]
M+F3Q[/F1AH2WQ?&7(ZN"*=;\E.>0@(E;=4F8&P&Y#+;X[P;J1!'FK;6WNC6W
M7P=VMH#X`K;0]_ZU#V<E#V;:'MT/9^UH>@U#T>*H'^WT9YO2M8G_`%E\G>8D
M/6//?[('GJ]_94K:5Y0$1=%L3C;R27@9U@VDXJ0;@H58A'+-T4Q#;BA"*)FT
MU(<I3E$#%`0:6ACNTX&S+99*++-X6W8YM&,2N')M]RZ42;E#K%E!`!464$QS
MB`;QAT^D-B?`/;'Z0;HJV/@'X>/T,PU!VO%7;\5!TEH*#M=Z@[.BMOK#6VNS
M2MO:&MNG36WN#Z&VMM;:VUMK;6VMM*'*0ZQB$,8J28I@HJ8I=033%42DWC;`
MWC`&NT0#EJ209_-\\;5[>Y9W8+7;,8\;V7B==-MK]N:Y#B3W!J7DWC"I'$`"
M"!@$W*!5VN(,-X3Q&P6WNK>31+ER==#7:!.HDG;B)C1Y!#>ZV%/J(<F@:A5Z
M94O265E+ZR#>-PW]=,V4B;15_=-TS2UP3,DFDT`A$14=+J*%(D4I2:@!````
M`8Q^5\=84S1'-2)$<R9HF>Q[>;_JTP3,966MUVM$D$PAOB)($/9"/-H4(Q%?
MYNOC1A$9)9!N-VXYLU+*V,(LZX`)%9B_91*V$T4A#>$HE:'.(!O`3=`PD8OS
M-'D>9ZS;.S,)%--&08F<HE6%F^22,H0JR6]N*E*<P`8!`#"'+6VMM;:VUMK;
M6VMOH;>Z-;>Y6W3Z@;:\7UZ'LUH>7I\04-#V_K!0]G-K0]'UJ'M>"C='CK'/
MPU37\[?5CSWAR!YE/?3YJ^"7(_F<\KC`_4MRYYSVY5Z^\,=^$1H.GQT7M4%!
MVOK#0=G305V<M!ZG@KLTK;IX*YAZ*VB';K:/=K:/=K:/=K:/=K:/=K:/=K:/
M=K:/=K:/=K:/=K:/=K:/=K:/=K:/=K:/=K:/=K:/=K:/=K:/=K:/=J<N<63,
M]B9%N>?F+3=1*(IM8TSMR$DM;;ULBBFFV50ZXQ&R91,"J)-\IC&*J!&3IU;I
M;`MIT1!P:?O43QZAFBVZIO,(!,#OUE#)COI`HBDD8=`,L376DK!BIM]<2JTN
M^N"9FGC<K`'\N_009JJ,XPBBP-D2HMD"$1Z]0=2F,)Q$PUM'NUM'NU]>MOH;
M>WZE>#ZOH#V=(T/;[]#0]!J'H\50/]OHSS>E:Q/^LOD[S$AZQY[_`&0//5[]
M/+$^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#[&@[/JT':[U=FST`Y>@?KU]7T-M
M<W=K96RME;*V5LK96RME;*V4X_QEX><-Y+<N=\32MWXZM68GT3J"`J+,KB<M
M1?MU#::&5;N2'$-0$V@B`Y$X.[,B5H&&N'B9@+(Q[",O*7"L)9V8K@82N/HY
MDH_ZU50&T3-L2)*+"<3E*!S&/J)A;&Q!PTX6L1\U`A4IV'Q];AKJ,"8`!/*;
MN>H*RBPAN@("L[,.NH[1$1V5LK96RME;*V5LK96RME<W=K;79K7BK;R]X*\%
M=FSGH>SZE#V?4"C=%#VO!1NCQUCGX:IK^=OJQY[PY`\RGOI\U?!+D?S.>5Q@
M?J6Y<\Y[<J]?>&._"(T'3XZ+VJ#LYZ#M=^@H.SM>AM#Q5MT\%?6Y0K:%;0[H
M5M_YU;?^=6W_`)U;?^=6W_G5M_YU;?\`G5M_YU;?^=6W_G5M_P"=6W_G5M_Y
MU;?^=6W_`)U;?^=6W_G5M_YU;?\`G5M_YU%!0I%`*<BA0.!3@51,V^FH4#!R
M&*(`(#M`>4*V_P#.K;_SJV_\ZMH?N@K:'=KU>\%;>T%>+Z]#V=JO#]0/0'M]
MT:&A'Z@]^AZ/%4#_`&^C/-Z5K$_ZR^3O,2'K'GO]D#SU>_3RQ/@'MC](-T5;
M'P#\/'Z&8:@[7BKM^*@[7@U]`.SHH*[.3T-NOU.>MO:&N?PA6T*VA6T*VA6T
M*VA6T*VA6T*VA6T*VA6T*X4<IA%E6M.:PD^S+<CL"E$37AA&-E+/CUA`^H:-
MW+BRQ`X<OLQ``*)0..T*VA6T*VA6T*VA6T*VA6T*VA6T*VA6T*VCX*VAVMM;
M=/#Z&WUZ'L[5#0]GU*'ZH>.A[5&Z/'6.?AJFOYV^K'GO#D#S*>^GS5\$N1_,
MYY7&!^I;ESSGMRKU]X8[\(C0=/CH.U0=FV@Y?4[G/79RA04'+V_KUV:5MKQA
M6WNA6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y
M6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6T.Y6WO!7./36WT!
M[`"MOKUX.FA[??VT-#VZ'H\50/\`;Z,\WI6L3_K+Y.\Q(>L>>_V0//5[]/+$
M^`>V/T@W15L?`/P\?H9AJ#M>*NWXJ#E]2@H.UW*V_P"B@Y>@:\7UO0V]VOK#
M6T:VC6T:VC6T:VC6T:VC6T:VC6T:VC6T:M_)CF,24O6V+1O"Q86:Y0<-+7ON
M9@[@N>+T#D,1P[MR(5]E[44?8Z;QM=HUM&MHUM&MHUM&MHUM&MHUM&MHUM&M
MHUZO2-?6K;7BH?5T[E;>SU:'HT#HYQH:'M_6"AZ0HW1XZQS\-4U_.WU8\]X<
M@>93WT^:O@ER/YG/*XP/U+<N><]N5>OO#'?A$:#M^&@[5=G/04'+T?6KL[U;
M?K#6WM#LK;IX*VAW:YZY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/W
MJY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/WJYZVAVQK;KT
M5M[05XOK^AV<@>AV;:'MAXJ'MU`_V^C/-Z5K$_ZR^3O,2'K'GO\`9`\]7OT\
ML3X![8_2#=%6Q\`_#Q^AF&H.UXJ"@KL[7H=G(/H>KX:V@/2.@UM[OUZVAW0K
M:'=K:'[JMH?NJVA^ZK:'[JMH?NJVA^ZK:'[JMH?NJVA^ZK:'[JMH?NJVA^ZK
M:'[JMH?NJVA^ZK:'[JMH?NJVA^ZK:'[JMH?NJVA^ZK:'[JMH?NJVA^ZK:'[J
MMH=VMH=T*V]RMH!V^6A[!&NSNC0]FM#]7LY*'LY:&A[/J4;H\=8Y^&J:_G;Z
ML>>\.0/,I[Z?-7P2Y'\SGE<8'ZEN7/.>W*O;WACOPB-!V<]!VN_05W.YZ`<O
M0/UZV_6]#;]:N;P5S=VO7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]
M>O7KUZ]>O7KUZ]>O7KUZYN[7-6VOK5XJV_6#T.SEH>SEYQH>7U?6H0Z*@?[?
MQ?F[*UB?]9?)WF)#UCSW^R!YZO?IY8GP#VQ^D&Z*MCX!^'C]#,-0=`5V=%!V
MN]7J_6KN4'J^&O"%;?KUM[M;1K;WJYN_7-WZYN_7-WZYN_7-WZYN_7-WZYN_
M7-WZYN_7-WZYN_7-WZYN_7-WZYN_7-WZYN_7-WZYN_7-WZYN_7-WZYN_7-WZ
MYN_6WO5M'T-NGAKQ>K7U?!79W:\'C&AZ/]%#V<U#T?7K'/PU37\[?5CSWAR!
MYE/?3YJ^"7(_F<\KC!(BFHJ<."G,*HE3(8Y@20N*W5UU!*4!'=(0ICG'8!0$
M1Y`&KT2$P`H>WF2A2<YB)20%4,'0)R@/30=FWEH.S;LH.SEH.]]:NSD]#;VA
M\5;=/J#7UJV][ZU;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;
M>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;>\-;
M>\-;>\-;>]]>N<:V]H*]3PUXJ'U.SD"NSD#T![.BA[/J5;K<1'K%+Z8K%#3D
MW$("13/J/2H72L-=?N)C(\1F5'S(@JIBHNT0M"*8++E3*(F`"K$,0VH!H.@[
M#%$<="8IB@I.9`.01`0`Y0O=\03$$=H;Q1#4.<!#F^GEB?`/;'Z0;HK'KDPJ
M"$QPZ</LB3?3$A0*EC)C$""1A]N7>:B(F#]MJ7]K3!\42"#QFU=`)-=P2N$0
M6U)O<NFAN36@[/J4'<[FR@[.U0<O)X!KL[WH>KX:V]VOK#7/WJY^]7/WJY^]
M7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^]7/WJ
MY^]7/WJY^]7/WJY^]7/WJY^]7/WJY^V-;0#HVUZGU1VUM[?H#R](^K0]G:H>
M7_3S4-#V^]R5BERV(9=5UE*9EC![!,?)T6[^4=K"4P@`;B1#G$H<O)H`".@5
MCSWAR!YE/?3WM"%("AIFT;DB@3%'RD#C(PRS0""W#^$`=_3<_;;.>LBV&)2*
M'R1PZYLL9%(3*`JJI,VOUO5MBI"4QCB5$W(40'=WA`0$-:*Q$XE+/6W,1Q2"
M80*=5N9*8*.[L$P%:GT'F`1]4:#L^J%!VO7K;T_7KN5M[==G+Z&VOK5M'NUM
M'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM
M'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NUM'NU]>MM=
MFM>+Z]?5[P>AV<HT/;H>[X@JP8$A]>M7G9=RGO!['J$V[)F<2;>7K'``.H;!
MVZ\G`[`B=(LA<(Y\R!+-@*83@E,7?',K;=`H8I>11FD("7E]D4>70"B.#&HE
M7)UL/=$GHXT!00FK]E9D#%T`OL#=?O)<GM!+J(CRC].\<2QM?)WN%XN.2]@<
M`ZZ+OB=<KZ*#[$?8O$]2ARAM':%<'N0$"`1O>/"-BQBX`G7"E[L6RV4"33(=
M8?\`O97J"0@4`#V`&Y1,(C8TJF83>56O"@MJ)1$'3=B1J\+J4``=U8ARZZ!K
MIL#90=G+7<_TUV<H4'9K]2OJ<X5ZOA"MM;:YJ]>O7KUZ]>O7KUZ]>O7KUZ]>
MO7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KDTK;W*VUMT\->H'
M?&NSDKP5VNP:'N_6J3E5_P"!C(]Y(+<H!]J9-C.5.4=G(4:2O30@H8UQGE2_
M)1^X*=8D:T0M)>WS2*H%U$0!:223-MU`XAM$*MUUNKF]Q;)OF3U2TZLG6Q(0
MV\YU`?8?RO0-!#V8DY=.0?3V]%.0".90.;KJQ:]353(D@C'W#*/<?I'4*4"E
M*DGY2DN!RZ%`"@</8A5WP"J!V,99.473ABD4@D,-C33L).(.0G('VV&>)"`!
MR:FT`1"BG(8#$.4#%,40$IBFY2F*(<@@/JT'9RUV=ROJ>"NSEKQ5M[0USAWP
MK:'9TUS=VN;NUS=VN;NUS=VN;NUS=VN;NUS=VN;NUS=VN;NUS=VN;NUS=VN;
MNUS=VN;NUS=VN;NUS=VN;NUS=VN;NUS=VN;NUS=VN;NUS=VN;NUM#NZUM$:V
MZ>&O4\/H#R]OZU=G)0]G)7?^L%#;D&BK(NHTD+9<6T;Z"9[+N7`KG;($$0#K
M!=.Q;"(Z:B0`V``UAW",:NFLUP7P_8[L=\"0""9[A.BM(2+T-FHN6QV*QC"4
M#&,(B;74-,+6@LB*#NW\6V+'2"8EW#!*HVVV&6.8F\;=$SD53"4##H(Z`(_3
MS!N1T$0!..F+LLB3<`3E.>:9-IZ"1,H`?M082)BE$?VPB`;:X;\EL=UW+8(O
MB\<7W5U)2!Y#$W+*G<QIW)BZCHFFE!D`#"'LG(B`:&UI>W%E-YW9\JNU*41U
M-[ES!SR;%0QMO\,+I,H#L*0`#DY`[G=YJ"MOK5]7U/0\85ZOAK:(=^MO>&MH
M5M"MH5M"MH5M"MH5M"MH5M"MH5M"MH5M"MH5M"MH5M"MH5M"MH5M"MH5M"MH
M5M"MH5M"MH5M#N#6T1[U<P5XQK;7BH>7I^M0T/=[8[*GTTU-Q[<PI6LS`!#4
MQ),IC2>\&W06:;@NOJB77;7'-G!X`M@=8^888MI]RD$TI>H'CY=%$X!KUB:D
MA#JEW1Y-=XP:``UEZ_A0,+6W<?QMIE<&3$4RN[NN%*6`B:@CIO@G#'UT*(@4
MVTH&T-Z=_?,4"K*.R7'PE_P;UO[$&EPQB:<//))*"(CUQ7;0C\VH:!Y20`Y.
M0.'?C/M-LC[FY,LZ-M&^O)!`4HZZ6;960CFRX$WMY9)4DO&.%!/H462)`$=0
MJ,0<J@>8M4"6[)@(B*BB31(/<IX.]RCUC;<*8PC[)0B@UW`'Z]=G+0=KL&O%
M]:O%Z'UJVUM[U;>]6WO5M[U;>]6WO5M[U;>]6WO5M[U;>]6WO5M[U;>]6WO5
MM[U;>]6WO5M[U;>]6WO5M[U;>]6WO5M[U;>]6WO5M[U;>]6WO5M[U;1K;W/0
M\`<XUV<GH#V^V/J5/W6]$I@C&9S,VYC:"]DUQ\GC61>?[8L8A3"`#NEWC::%
M&FV1+L*#NV,4(2N5[OEW_L699U,RA[;4=./:E5"1/[I%`>0Q&BH["C2#M5JL
MM"Y+RH,L];+E,91IC*UP!P+1T;30%$X"/(V`Q@`HJ[H:!O`'T]R:T:-_*)BR
M6S3),,`%$YDU;.4%Y-&3(7E$YXD\BD0`Y=XX<@[!XE^#N>?(()96LA2\;$*\
M5(FV:WM;@)HG7(!@,*BG6EB'IB$*)NJ8J&#301![:5V(*PIY%V^LBXF+_1%2
M'N..?B@W3>%UT*HD[3.T/J.A>L,([-:V]G-7<[8>A]3P=%;=0]7GK;K6WNUZ
M];1K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K
M:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K:/>K
M:/>KUZV^AZGU1KZG?'T/`'C&MO9ZM,+-C5>N96<DJ1Z9(V\5:?D@(=RB`$U`
MPMTB));=2J&5)H`@.O#;PKH'\EO&['#G,.5FZ0]2Y]TCHF*BQE4C:&,F5V[,
MS;B)`W@BBB8`,7E2NJ0:@A)95NZ9NU(QT]QT%OQY$[9A$5=0`=PQF;IXAJ(@
M)'`&`=#?0'-X0K(SNZ\,.W-YM"))[[EQ::Z!6U\,DO4*1NFA)*:#J(,MT-1$
M`K,/`KD!^5JXGF$C>^)Y1V!%@BI-$R3MXBP(82FWV$@DWEBMDC;RZ*C\#&*0
M#:S]H7VP<Q8Q\JXM&^XHV\;R15DZ%-"7;[H:+%0,/7HJ$`05;J&%/7K"C2#I
MJLDX;.44W#=PB<JJ*Z"Q`52624((@8IRB!BF`=!`=0KZG?"NS0?0]7P]VMO=
MKZPUSUS]P*Y^X%<_<"N?N!7/W`KG[@5S]P*Y^X%<_<"N?N!7/W`KG[@5S]P*
MY^X%<_<"N?N!7/W`KG[@5S]P*Y^X%<_<"N?N!7/W`KG[@5S]P*Y^X%<_<"N?
MN!7/W`KG[@5SU]>MO<KU/J\_H>+Z]#R](_6]!G8=N+&?0]MO#%<F:;ZP2MSJ
MZM3I($)KU@-0$R"8E#V2AU=-XNX-(XV.NU8Y\XG72@7FDF<@RD';+B,W)V-*
M=,1U)',5$HDX@82@Z?.541,`;P9%X@9EB8J9TR8YL==8F@*AUB<M><@@50.4
M"B6/:I+$'37RI,1U`P?3URR>H(NF;Q!9J[:N$RJH.6SA,45T%TC@)3$.41*8
MHAH("(#1%XYN]%MCJ]D+DM<53"0;JQG,J'ZIH#M0!*?RN*6<1CI4NNXN"Q=0
M.F.EF<8&*Q*_QCG>,AGTNZ9IE(2+O%Q%`Z9/7*:0B")I-HGO+)B&\1ZW==:;
MK%2EI)O(.`_*VW4F[&=24.`K/DRDW&LX0.<K@"B"NGM50.&@%,03!WJ^KS_5
MZ*V^AZO16WN_7KF'MUL[]<_=KG[M<_=KG[M<_=KG[M<_=KG[M<_=KG[M<_=K
MG[M<_=KG[M<_=KG[M<_=KG[M<_=KG[M<_=KG[M<_=KG[M<_=KG[M<_=KG[M<
M_=K9WZY@Z1K;W*\8^AMKP!XQH>^/BIU+B9)6<?\`6,+;CSB`BZDCIZ^4*);1
M0;`(*K#R`/L4]0,H6G.6K^,D7%V''87W>DS,&(5C+W(W$\O#Q;E=<0(8A54S
M24B8X&(""(IJ[OE!!$4;9!<J-^74TM"R$UD3F+;V/H03D1EGC;D,4$6*;F8?
MIZB(*'6`HZ;H5;5EVZV\C@+2@8FVX5KJ410BX1@G',4CF*!0,8$DR[QM`U'4
M>?Z`NU=((N6KE%1NY;.$R+(.$%B"FL@NBH`E.0Y1$IBF`0$!$!#2F%Q8\5<1
MD&C,IY"Q%+FZY=O[D&<B#ZUGQU=>N\B,=6-=HG.8RS4Z9U=`<:5$<9.`XLYL
MC6]%EB<NV`S(#N:=$A&I/*T>K1*4[A_%)"4[<X)[SR/,EN`!T4T3,\<7H]`D
M4HIU5KS3I0=V.65.`$A'JIN0&YS"(MU3#]J,/5B/5B3JMOK]->$*V]H:V]VM
MOCK;6WOUM[_KUM[_`*];>_Z];>_Z];>_Z];>_P"O6WO^O6WO^O6WO^O6WO\`
MKUM[_KUM[_KUM[_KUM[_`*];>_Z];>_Z];>_Z];>_P"O6WO^O6WO^O6WO^O6
MWO\`KUM[_KUM[_KUM[_KUM[_`*];>_Z];>_Z];>_Z];>_P"O6WO^O7-6VMM;
M=/#6WZXUV<E/K%M)WUUVOD!;RD@V4#<MIHN7[80%"?\`RU0@Z$*`@*11ZP1`
MVX`RW&7G?J(/%6+4GDQ903*8$:3D[#;WE-TBDL&JR$:L4J,<FD4QG,B)2ICO
MMA35:M81%RU)=4JE;]HQ[D#NF&/L<1*IEE)&1!(=`*@@*\D_$IOMKE0Y$N4Z
M*=6CC2SFGD=N6;"M(:.(8$P7<=2`J/))\9$I2G<NUS*NG2@%#?64.?34WT^:
M9/L^,\LR!B%%^_<-FJ.^_G[!7)Y1/QJ14PWEEF)R%D&J8B.A`=$3**BX`-V<
M">='!5+.R,A(%Q?*.E4DQAI]^H+Y:W62[C4B;D7H$E841#3RTJJ0]89=%.EK
M?G4R.',<'E,7*(D<M[?O^S7YQ(1VU%0!'<4W!(JF(G%LZ3$NIS)`8S6X;<>%
M705*0KMF<Q`?1;O=U58R"`"(D4*.N@^U.&AR"8H@([?KAT5M[=;=?#6WQ#6T
M:VUMK;6VMM;:VUMK;6VMM;:VUMK;6VMM;:VUMK;6VMM;:VUMK;6VMM;:VUMK
M;6T?!6WQC6W3I&MO;'Q5M[?.-/KCN-\1C&L2<H\AEW*Y@'J&3)#4!464$-"$
M#ZHB(%`1""M*T(I1>3GG?N7;L2941C[;@41%>0EY9T4-TB2"0'=/5]W4=-Q,
MIAZI,8#@;PK($7N.=C4Y',=R-Q23D%6,FD1623E/)Q$4WT\<A-]`QQ%",33;
MB!DETC!*<2=W,#)S5YM7-NXX;.D1(HQM))UNS5Q@17E`\DX2*@V/NE$&Z)SE
M,=)V'T*0L2;42B[@8G4E[&NKJ>N6MNY$T13154*7V2C-P7[0^0`?9ICO%T53
M2.6=MN[H:0)&HR#>&RICT7*(MYZ-2*92,G8-V?>1,X137\KC79#`19,XI&.5
M)8X@7BYX.DFMWV)=C=Q.7M8]MH*!)14F!S*R\Y"0G\*4P*"8)2'*D59LJ!E$
MDSI'.5!K:.1573Z!1W6T=<`@JYDH4A?8%:2*?*=PV('(0Q0%5(`W=%";I4VL
MI$/VDG'/$P5:OF+A)RU73$=-])=$1*.@Z@/+R#R#H(5ZOAK;W:YPZ*VCW*V]
MX:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]
MX:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]X:V]
MX:V]X:]MWJYQK:`5XQHZBARIIIE,=110P$(0A`WC',8W(```:B([*<VMC%ZD
M]DS"="1NI$"K,6!=!(HA"F-J59;73^4@`ID#VF^8=XCG.&?7#JT<#0H.IEQ(
M3;Y2$=Y"4;B9P]<)R[TQ#-XA(P&,^E1.`J&`R+<^_P!<LWA,#X'CEXC`UGNH
MV$MBW[?BU6"M_3#$X1T0NC"LR@<&"0[B</&]4!C&T75)UQDDFZEWWFT34S)?
M\<U-<('!%7\CH(3`[:6<Q6)K]MW]Q:34(;=46*FF7>(W(<_T^$I@`Q3`("`@
M`@("&@@(#2V;<7L%VN*+IF47RQ8@1;*8VO-TX%P#),K82F08.5@ZZ-73T*BH
M(M1W!*W%9E@+-\@A;7$C9$:Z<V+?.XD#JX%6S4"JS\6F82`X44223"X(<3!U
MQ2>6-A()-62T%=46M"29!$Z0ZK.[/OR!35$J;Z->$`A'38VH[I@W5VYQ$BA4
M5@,0$C13PC">(B!I&VGRI"2350I?MQVP#H#E`!Y2K)!LTZPJ9A$@;>SHK7OA
M6T!KG#H&N>N?O5S]ZN?O5S]ZN?O5S]ZN?O5S]ZN?O5S]ZN?O5S]ZN?O5S]ZN
M?O5S]ZN?O5S]ZN?O5S]ZN?O5S]ZN?O5S]ZN?O5S]ZN?O5S]ZN?O5S]ZN?O5S
MUSCTC6T`KZ];?K4+RX'P*2"Z9AC8%F8BLM)'#704T!$.K2`0T.NKND+L`1.)
M2C$V?:,*YE9%VJ8(N#9"N6WK2AQ7*FZFYQ]NB1%!$#D\J?K%`3B)$TRB8R*(
MO[/L>2@[YXN+^BFY)69.W3=*PB3HO6$DG313>%G#LA]G'L5A!1^N!%EB&2*8
M$)/(^3WDZ\QO'SJDOD.\9)PY&1OB?54!X>U(J14]D==?>*9\LF.C9N/()%5&
MY3,(B)9-HV*BF36-C(YDBFV9L(]B@5JS9-&Z0`5-)),I2)D*``4H``!H'T-J
MY:.&=L97M9NL2T+O50,+9VT4/URUL70#<HJK,%#ZG14*!E&BIC*I`8JBZ*\S
M;TE"N8[^4H)WKCFX14&V;RC$3F3:R\3((;Q`.)!.9A+LA,`#[%0%DNM;FE<C
M\.=Q1F*>(=1D>6N?&\V9*-:S<F`:O7$Q"M@,/VP^F].0Y5$C"<#O$!<*FW3Q
M-V6Y.68+M<VC66;!*65=!4-JT;)M#'9NM"Z;RK)R"Q`'=,8FHEI)G?+%>TY#
M0A1D&Q5Y2"74'D$P]24SEOJ.PIDU"E#E,J&E`O;MQ0TVF)0,(QDDT>F(`AKH
MJF@<QB"'.4X`(<X!6WN#6T>[6T:VC6T:VC6T:VC6T:VC6T:VC6T:VC6T:VC6
MT:VC6T:VC6T:VC6T:VC6T:VC6T:VC6T:VC6T:VC6T:VC6T>[6WNB-"[G9F+A
MFO+_`"B5D&D>A['E'15V<@#VAI9""7=7G*%*8J:,20S>+*J&P',P\*!1(/\`
MRVR:WAT:6+:T1+RRLLL*;&Q['CWK@SM/K0`5I0R.^JJDGJ4RRK@Y6Z8!U@E3
M#4:8YOXZ[PME-5L7RFWL1-G)99LZEDDP<I,9)-F)CSCL@AH:/8D.S*(;Z[A9
M#>W8S$^,K<F+:Q>J_9QMKXSM]N+FX+Q=-U2A$J7&WB-XJIDQ(0[:,;:MVX@!
MM5CIE6".RMEMNRF\S.&PJ1<0!F[^&QJFX*)3D8KIB=-S+&3'<7>D$2(@)DFP
MF#?76_X`2]KW1$,)ZW9Y@XBYF&E&Z;MA(L':8I.&SENJ`@8I@'I`=!`0$`&A
MRKB)6X);%"4J67C)N(5??E1BI^@X*Z8HS,@R$%BH)*:>03!#`("4I%S$6ZLZ
MZ?#[QWL(\RVX"=JYFZHD>*3T$^J;O)A^S)K$R:8[H%DT2>1N2:D>I)E`YG*>
M0\-NWF9L3K$).P-Y6.)7MS0D>8"NV3N4CH0QS+$(0=\DI%BH@8I!64!KO%3I
MO&WU&)W0R1W432C421]P)D(&[JX((>3N3%T`-!*D<1U$ZAAI+W-NZ.8O%`#6
M+GE2PD@501_@2$?B5-8W/_)U%`^KR#H4Y#@<ARE.0Y1`Q3E,&I3%,&H"`AR@
M(5MK;WZVC^ZK:/[JMH_NJVC^ZK:/[JMH_NJVC^ZK:/[JMH_NJVC^ZK:/[JMH
M_NJVC^ZK:/[JMH_NJVC^ZK:/[JMH_NJVC^ZK:/[JMH_NJVC^ZK:/[JMH_NJV
MC^ZK:/[JMH_NJVC^ZK:/[JMH_NJVC^ZK;WZV]^A,8P`4`$1$1````Y1$1'FI
M49F\X;RA+4#1\:Y"8DM_8"9F47UJA!$>=0"E#:(@'+2K#'$;[BM#$$@SLV@W
M<RYC#R"=G'E,HV1TYA5%81_Y)!I"^+J5D+'Q[(B1\]R3?"3E=]-,=`,*MJPK
MM1-P_*)/X-P8Z+,"@(%7$2]6,CA;@YC8F]LF.B%;79E%T9O-1C>40*9(\A+3
M:8`28>HB8_DS%GNQ[8QAU$3`HW4D,G7_`#,S&8Z>SKUY>&2)947-PWA+];UD
MA&VJ1X!_*'`J"":SQ0ODS8`,'VQ5,&QH*P;!@F=N6K;C,K*+BV11`I"@(G6<
MN5CB*B[A=03*N'"IC**J&,<YC&,(_13VKE"V&TJ5$BPPMP-=QE=%LNE2_=D#
M-IE%1(=X"F40/OH+;I0624*`!1K[QH>X+XM*$=FDH/(&._+VEXVR5/44UIR$
MBCB^9JI%WM]XR,JW`@;YU41-U11QQQ28\M[/]@NB$9R+J1CXMK=96Q/8`H^9
MNT31LD=(`^U]8BV7$_LSNA/RTM*X<X@GO#C<+S>5-9668]8+6:K'U5*FG*S;
MA))N4PF%,QB3SHJ>[J5+=T`P36-@L+,D!O=8QN3&&0(%=%5(2@<BJ9)Y6/.)
M^702-Q5T$!W1,70PBDOCWB'8MD1)J=K;]Y3L.D(Z$('E#%-TT`1U`NF]R[.7
M3D40<,LP(+HG,FJBM:,XDJDH4=#$43.R`2B`\@@(:U]SY;_-6:^\Z^Y\M_FK
M-?>=?<^6_P`U9K[SK[GRW^:LU]YU]SY;_-6:^\Z^Y\M_FK-?>=?<^6_S5FOO
M.ON?+?YJS7WG7W/EO\U9K[SK[GRW^:LU]YU]SY;_`#5FOO.ON?+?YJS7WG7W
M/EO\U9K[SK[GRW^:LU]YU]SY;_-6:^\Z^Y\M_FK-?>=?<^6_S5FOO.ON?+?Y
MJS7WG7W/EO\`-6:^\Z^Y\M_FK-?>=?<^6_S5FOO.ON?+?YJS7WG7W/EO\U9K
M[SK[GRW^:LU]YU]SY;_-6:^\Z^Y\M_FK-?>=?<^6_P`U9K[SK[GRW^:LU]YU
M]SY;_-6:^\Z^Y\M_FK-?>=?<^6_S5FOO.ON?+?YJS7WG7W/EO\U9K[SH6\;9
M/$:\ZP"$.JQM&^8UJF&Z*Q.N?(-D44MX"CH)U"[WM=1UTH\A/V0C:34Y3*N[
MDR1>4*R303('6**O6[9P]D@*0NIC&%F(`&O+KR4F^XE^+6%NJ7;:G<X[PH0)
MAUY4CIK'/I5@21=E*H(Z?;V;`=.4%"^V!W8/!/@FWL80RI.H<7U>35*5NV5,
MFF*:4@YCT5EQ6<ICJ*2\K)/@W1W10*'L0/?L](3CR$>K@C*Y<R.Z>^XJ+5-<
MPJ1]KMCAOO`1$5"HLHQ(K9$VB:AVQ3`-"\MQHI=60GC;R:7R/<+9M[LJ)*%T
M<,(!HGO)QC,XZB9%`YE%`W0777W""7_@$NU=((N6KE%1NY;.$R+(.$%B"FL@
MNBH`E.0Y1$IBF`0$!$!#2I2_>&P\=9]S+&6>R&,GZH-+.F5C:K+&M9\(#[DN
M%#:@1HIJR$1*4AF291$5;(>MINWF"2ZCESC'),6[D+1?@9005D((`43%,BAM
M1%Y#/2)K"`"<ZH``4+CB#QI</#[DYX)@=9)QZ7W1C'S@X`4'<JXB&BBCE0Y^
M4PR,&N9,@`4'@!J(`ZX8>*/#&8RK[BB5J2\XTM&^$RJFW$FY8I-5YOJ"/.Z(
MSUY="ZAH*Q6N+,G-4VYCB"F/YE&XB*```KUC=.QWKHYM[4!`-S>UY!*!@$`Z
MF7MS.\3U2WDYO=FQ[L;*E7,`J@@HI(L0/OZ`80*8==`Y`T"ON?+?YJS7WG7W
M/EO\U9K[SK[GRW^:LU]YU]SY;_-6:^\Z^Y\M_FK-?>=?<^6_S5FOO.ON?+?Y
MJS7WG7W/EO\`-6:^\Z^Y\M_FK-?>=?<^6_S5FOO.ON?+?YJS7WG7W/EO\U9K
M[SK[GRW^:LU]YU]SY;_-6:^\Z^Y\M_FK-?>=?<^6_P`U9K[SK[GRW^:LU]YU
M]SY;_-6:^\Z^Y\M_FK-?>=?<^6_S5FOO.ON?+?YJS7WG7W/EO\U9K[SK[GRW
M^:LU]YU]SY;_`#5FOO.ON?+?YJS7WG7W/EO\U9K[SK[GRW^:LU]YU]SY;_-6
M:^\Z^Y\M_FK-?>=?<^6_S5FOO.ON?+?YJS7WG7W/EO\`-6:^\Z^Y\M_FK-?>
M=*(1D+F^2,`IIJ%B[,N==4AEQ$$2B9DR$Y1.)1`N@@(Z#I14W>+,POR'TW$;
M[<+VFV)J<$M`1OQRQ33#4=1Y`Y-3;-1I.9XD<YX<P!!;H*G1E[D83=QJD*`F
M42;L55V#(YS:`1($9!4QC#H"8B``8[G'%F7-Q69.8&3%I=%[-4HZS6CY(0.H
MK'IS+5-!$$E2E,@NC".U0T]@[W1WC)XY@@EB1,YO-6F)\4L)!K'OVG(FK[OJ
MHG4=O4`*)3.!?N?)$]-\$D@UJ-O7B?>(OER=0\:8GMZ0$[)(^F]U-ZW&Q$.N
M$HB&\SC%>KU`-YVJ03)5'04!%Q\)"1#-O'141$LV\?&1K!HF"+5DP8M"D222
M3(`%(FF4"E`-`#]@.IB\+#2A[L>")E[TLEQ^3%Q.%3#J=Q("V(=F^5'D#K7[
M-<X```!@`*5=8=S%%/VYC#U,+DF*=1;AN0"\@'N6V$W9%S&'_P#%2(!ZHTJZ
MMZQY)^!`$`F\<WS"G,N`$$@@FV2>M)'VIS![-H&H"(!M&@C8Y+C#CFC4QDDV
ML9<F4462>Y[`>H*R=@D)>3D,3D$--!$-*^Z.-+\ZLM_?E?='&E^=66_ORONC
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MU+U1"D552NR2!SO%*)"[B:)E`T$-WV!MU%?)^5+*M!D80.=G:3&6O.6W`#4R
M"QI`L2V2.(\F^FJN4`T-H8?8TWECVLXR9<[<4U$I[)9V4\BT7*4=X\=;:""$
M8GH8=Y,ZK559,0+NK:@(BF@@FFBBBF1)%%(A4TDDDR@1---,@`!2E`````-`
M#D#_`(#*VQD>S;=O6"5WS!'W#%M9$C98Z8I"[CU5BBHV<%`1W'#<Y%2;2G`>
M6G<ABV\KLQ:\7%0Z,0\*2^+6;CJ)R)-V\DJWDR!J(%$RDHKH`!H41UU75M)U
MC[([4HJBU1AKC/`3"Q"#]K!PSNU%DT3.?F*5^H4.<_/2:<';'$9`KH@=%)6Q
M[HN)RFF0Q-\Y$WEG/U4P*(*#KH?01$P;0,`?='&E^=66_ORONCC2_.K+?WY7
MW1QI?G5EO[\K[HXTOSJRW]^5]T<:7YU9;^_*^Z.-+\ZLM_?E?='&E^=66_OR
MONCC2_.K+?WY7W1QI?G5EO[\K[HXTOSJRW]^5]T<:7YU9;^_*^Z.-+\ZLM_?
ME?='&E^=66_ORONCC2_.K+?WY7W1QI?G5EO[\K[HXTOSJRW]^5]T<:7YU9;^
M_*^Z.-+\ZLM_?E?='&E^=66_ORONCC2_.K+?WY7W1QI?G5EO[\K[HXTOSJRW
M]^5]T<:7YU9;^_*^Z.-+\ZLM_?E?='&E^=66_ORONCC2_.K+?WY7W1QI?G5E
MO[\K[HXTOSJRW]^5]T<:7YU9;^_*^Z.-+\ZLM_?E?='&E^=66_ORONCC2_.K
M+?WY7W1QI?G5EO[\K[HXTOSJRW]^5]T<:7YU9;^_*"*F(WBHFDC`"8(79==\
M)1^ZLJ4@E,M<S]-N`";=$VIM``-XV@`(@5Y=#.R\>E=*]>Z5O"[T9634*L<3
MJK^3V<G*[RIM=[<663$1'0XE'71H^RWD>Z+\=)BDLM"6PU;69;ZAP-O*M';I
M0SY^ND(>QZQ!=H<=H;NRB6WC"Q[=LJ(`J8+(PD>D@Y?G2U!->7DS[SIZL`&$
M.N=K**:<F]I_^I]2&+K`L]+)%[P8HI73(/)@T3:]M/U2%<##@=JBLL^>$3$`
M<IIF130.8"&5.J19$G^2MA_G!<'[VE`0PQ8":XIG!%16<N)9)-42B"9U$2"F
M)R@.@F*!RB(<@&#;2*EUX:L&6B-X`<-;>F;BM^2$H@("9%_)&DT@$!T'0S8=
M=!#4-=0B<F8^=N%(M^HJQDHQ^0B,Q;LXT(0TA!3#=(QRE72WR&`Q#F(HF<BJ
M9C$.41_XI[L@KD2/,,IS/]^)2:+Q9907R9;N?+"FY5WM\Q3"0`.`FY0U`>0:
M`?\`#&SN4/\`\`LOWE?Y86=_4++]Y5W7-"69"6_+P!(Q^RD(=@BP6WE)ANR6
M07%``WTSI*G`2FY`'0P<I:XC(8ZHC'L)#%DFV1U-HF\EVUP-'RH`(Z>S(Q;@
M.@`/L>41Y-/V?<O#]C_%>-+DQYBIO9`WD%U_E$6Z+U=WG8L;?:Q8:>BWI&\4
MFV;RB#=`QXUT;KDU%%`43,5(L5;7Y5_X)Y<?]2W_`,,LJ/6,5[J2*NA/)K,O
M/>)&2V^<=QNAUC=\IM\B*'_$.\*.PW$3?@#T#=,C1`%(##NAJ/(&O)7\"%9(
M<`00!1M`-="E`1ZQW=D>T2]3DWCAK]36N)G_`+&?_2OZ0<4/_8I_[.UH^A%6
MU^5?^-F(V'4M_P##+*CU]*^Y<<EH3R:S+SWCR<3N$#<;H=8X8I[?(C#45;7Y
M5_X)Y<?]2W_PRRH]8Q7NI(JZ$\FLR\]XD9+;YQW&Z'6-WRFWR(H>ECLE<0U_
MM\<V3+W5&V3&S3B"NBX0=W1+L'<JPBDXZT6,@[U.V8/%S*B@"9")&,<Y0TUM
MR^;*G8VY[0NZ$C;CMFXH=R1Y%S<',-"/XR38.4^0Z2R)RG(/J#R@`\E92O#'
ME]-[@MO"U]WOC3)TL,-<D0A:UZXY8(2EZ0ZQ)UFU4<@Q;N4%#.F1%FZ@&^TJ
MJ"4P`8H\4(")1$HB7"O$.<NH#H.Z<EI"`AZ@@.@U_O?!DEK_`+NOY/FNC_$8
MUO7>5+W%+-#;@K_DP:/":ZWR\/)`:^YW7BI[$$Q$:9V];_%5:K:2?NVS%L:[
MK/RACV+%P\$P(`M/7_!QC!(FI!`ZJKDI"")0.8HG+JDX;JIKH+ID6161.55)
M9)4H'3524((@8I@$!*8!T$.4*OS/EY1KV?96BA&-HBU(MRBUF+PN>X)5&#MV
MV8E1<I]%7+E<F^<J2@IHE56ZLX)B4;9S=Q/S1,)0,P2THV99O&5PWJO;]Z73
M&>6C9X%LJ/=NGBC91-RD=RBR!,2HG5-U9-ELY#Q]<47=MDWE#,;@MBY(9P#F
M-F(B11!=J[;*<@AJ`Z'3.4ITS@8BA2G*8H91C<6W<G=3W"^3;BPYDQ!.'N&)
M_)G(]IF(2X+;,I/-&I'8MC*%*+M@9=L<=036.)3`'IK<M#B.S"CCNY+L@U;D
M@(DMCY*O!=[!HOSQ9I%0]APTHFW(+A-1,@.3IF.)#[@&`IA`F)\!YP3OO("L
M)*7$E;Y\=Y9M,RT1#=7[I.49*]X&-9G,D"I#"B5P*IB[QBD$I#B6(X;;`P9F
MOB8SH[L;_%"=L7"\'%R`V=CPLB,::>N.4E7*!$U5%``K9J0AA.91N0YTC.FP
M+8-EYK&&7[RRCQ(.&$9B+`%K6RV_Q6EIQQ$-):6BIZ+D7"2,<>)\O:-I7>64
M.BLJ4I4U"E4.3A4-DG`F;<67;Q49E=X1B+#O>)@HNXK$N9G(FCPF+G(H]`BT
M4X`"N6;MB*IED#D."91$2AZ0V5N("^4<?6$$Y&6V6<4@KHN0ZLY,%54CHYO#
MV>RD'RAU"H+'$4VQBE*0QCB4H"-0UA8NXE[0E;PN)\6+M^!N*%O?'CV;E%3%
M3;1<3_B-%1)'#I<YRIMFZ1C*+G'<1*<_L?H-R8VNGB68Q-X6A<DQ:-QQZF,<
MU.6,9<$`_4BY=B>X65MJ1J@(N$E$Q72=F2,(:E4,`@(QN2<,W];.2+&E5%V[
M.X[6DDI%D#QJ(`[CGA2Z*MG2.\7KVCE--9/4-\A=0KB0L.V+=N:#D>&?+;W#
M]UO)X(L&4]-L4U%%).WACW"R@M1!,=/*2)*<H:D])PS8@N*W;FF)OBAO:XK&
MM&3A0BQBK?D+;C6TFZ=W&+YPBL"*A'1"I^2IJFU`=2@&@CZ3B(L)6TI''^1N
M&O,4QBJ^;0E)-"76<1Q=]S9.0(QZW10`8VX&B:SAD4Z8'+U2A1WB@10__!!U
M^L5??G5(T7H#P>AD/_PUF^?T57$S_P!C/_I7](.*'_L4_P#9VM'TEWV=?4CD
M.]>$6W\>2!;=N:^T'\E"6SD%A/Q[.%MBP[SF"F75(+(T@#J';.%&[8I"*"1N
M82`MZ/!1:ERQS>8MVY_G(.&^WI^(>%,9I*0LU;-V1LK'.BD$!%-=!51(X`(#
MNF'E"LW?-59:EG3PN,'4EESA)NB:4*BO?>`[MDE))U!L3J%3*NXBG*BCA0B(
MJ""YI5$NZWCBZ?.N_KP<=/Z-X*L%XDS[E&W;<RU:7^)OY60S["F5+N=,_=[,
M5PW-!=;<-MVQ(LG'61CUFJ7J7BG5@8$C[BA#$+Q"W+92C5>S[DQECJXK7<,F
M*L8T=0$[?]ORL2[0CW"2*B!54%B*`DHB0Y=[0Q"FU`(7AZB;AL/(F>I_A]Q?
MCNWK50L:0B'%L979VK&0Y;FF+]N:.8Q,66%?E.Z<2"TH0#%3.!3'(8XUPTV#
M=LW'7'<MGX-Q?;\U-0\NE<$.^?1EG-&RIX>>0.=-\T)N@FU>)G$BR12*D]B8
M`KYJWA?77ZRW+WXE)C-MY1AR&!M(M,"Q;.:AHYZ8VZ51%VF]E$CI`<1#0#"4
M!ZO7!L-+,V\C%2W&EP^QDG'O$BKM'\>_/+M7K-TB?4ITU4SF(<HAH)1$!K-'
MS6.1I%TI9[9>;SMP5W!,KF`]PXEN9ZM+W#8#!=R!1=.8I8'CE3<U,=PVFE>1
M$B0!\[*_A8@;@F67SDG%$[B8$K]M%FFY-L]!9A$%DWOVEL+E4I$075]@GO;Y
MO8@-7QQ-7!8O`S#6/C:T9C(ET\/R,GE:Y,BL;&MEBI-7.DZR(U<-X9Q,,V*;
MAP8S(WDABH@"1%U1ZI68X[<3V[#$FUL&1>5K=M2]TI"7A8^9>^3I2%OSI81S
M&N'2;1P=PW%5NY0%04P4*)2FTI7C5QK@/ANLO!%L6(GDA;$F4G.1'>=\E8^B
MX+W6NN_8U"!<)QL0W7;IJR4#&JNE'/DP]8J=]_)R.L#\3]E8XEKWR+Q2'L*T
ML&85*^\F>S65+];B4+:E)DJ7(TC5TG*2KI-$`<G*@DGU7E1%4R<2?$/C?A!R
MSA2%=Q#K+F.\&.,G0N3,;6Y+ODH\LG"SMVKK,'X-%7":3\W5.@*?0Y1*T!9V
MC962+.?>Z=HY!M*W+WM:2ZLR/NA;EUPZ,]!ONJ/[(O6M7"2FZ/*&N@UP?95X
MAIYE;6+(3A9O]G-R[^U[@O%J@\FI"ZHF%(>`MAA)/%14=JI$`R;0P$$=\PE*
M`F"ZXSA7O>`O*X;*B6,E=!([%U]6$ZCHB8=F:,U/++S@H@JY%%41*9-NHH)1
M`!.4`$HCQ1EMDW`@IQ*(\/6/D\@DN)3B$#!9,=B:W58%.QACP-/EEQWF)GGE
MH>3;PN13`=4ZX&$K4/PI#*$ELX*<)*=QFS",02)5LUJ6\S\0Y(W[8#LR9!"/
M&V0W!$I.OY`KYFW_`!Q#'H9;_P!\BV?R]#%!KD-CGW?!!#R@;0&[P"3\C$NX
M)`>_;`'4!$0T&N"3A<@X6SGE@<2D%Q`R5[S$JPFEKPB'.*,=KWA;Q;5?M)!!
MDBFLX2!-Z5W'N1.F.B1D3>RK@BL2S(6SI6'XE>(J-Q#?+BYV$T[DHFW'S=)0
M[^TUXJ09I(/2F4'11XBZ2T#3J=>6LD\+/%NRQM86.+DL23RYPL9B@V\]`Q5T
M63:S%W+WS:^1'D[)2+;W;BVC9RHHLW!DD)6:BGDP`^9$K*6<[FLRU[(X>YV_
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MKN%P*#DYP(BM>G`?D3AZPUE'B\?Q,'=F&+_QS+W);/#\KCV7!=6;R%EH9Y<\
MLVCH;JQ3%-@DBX>.">0))%6.@Y=.>!CCBMC"JEZW=BMSE_#.4\"A=C"T;KAX
MY\NA,6Y)Q=ZK'<B[1(U?&WDDT3(@T$#I+I.$G57_`,$G#?@W'&2[A_PJL"][
M)NV\%KG@+3QV,TJ<UY7KFNX(Q\J=Q"M2BU;,(Z)CF[Q=PL!"N%%.K15MK@HX
M\+7PJ>>S'9LY>G#_`)AP(2[V%GW0M;#=W*7%9]PQEYJJK)O4FK5<Q#%*AU1T
MTDMUV#Q%<*^<$MOBER!9]JW),\<6<[BAX>?L2YKRD9*V!?ECC*LTX"(DMXAW
M"#A(&^\!C&`?8:"`CQOYVQNG!6[@C.G%'<-PX:QQ$S,*N_LVWHU=Z=1S.6A`
MN%TK=5?(O62:$2N5%9-!JF)4O(O(U5?G9E53D222XW;B4444,4B::9&;HQSG
M.;0````1$1'0`J^LD<"UJ<,F-N&FT;NG+,L>^^))/),O>&:Y:VE02?34+#62
M*:<9"JB<I-5TC+D.&X5910KA%OQ9FXM+"8X6S?P,^Z*^?;4M5ZO-6[,0*<6Z
ME("Z,>FD%#*J$E!9N&S1D9VXWC"U5*Z.5XF5.$XJ<787X0X[$=VL$[QQ_P`.
MMX3N26^;KUQP[.+N)>!?Y3HP#64DV@IKQBJZ:+44E"*JH!J!%/F<YB<CQMMX
MXS=D>2EXIZ]:.#0#E6Q89U(1[N1;&%!06IA.FHLF;JS;HF*.Z(#68\HXLMNS
M6OS='"W:5ZOLQ\1%VPMR/;HRY>MH1+I^\MCAQ2CY1DS<((J$;I'?/&;DBXCH
MENF<LP53XO<;8MX0[4Q%,VH[R98'#W?#K*4SF2[\9>0^[<*Z=7O"JMHE.6EH
M_5U%`5!!`0.WZ](G6'`)3YQ+`EM6R>XO<2Q'+&R\B(RT]`0MQR>:HK$E]6]-
MDMYY#NW(,%G$B5FX2<-^M$B#@2"D<4C1>7\CXPPIBK@\R'!3$MCRR7SR[%^)
MR*AUD4WN/;GO4@'&$1&8;G!=RQ3$5FQ3$2,D0Y#*JRL3'B*$%Q@<%\9<4ZV(
MHFFB_P`CXIN!S$1L@JW(;>.JU@8(Z15#DY2N3@41W3Z?\$'7ZQ5]^=4C10^H
M'@K6LA_^'LWS_BJXF?\`L9_]*_3<2W!5A>Y+TDLZ\)TI>\/ER,G;%F("WFKW
M'61/\*[N+;]QO/M+TK6:$K<IB@7K2""J6^GJ8/H++YN20X@H-MQG2#-L\;87
M/:F0Q6_EMA&R@R8.;[)#C;"#Y>``LFA'+S1'2B1TMQ$QUDBG^C\4/_8I_P"S
MM:/H(I80QA(N;2*[%I*93NL5;7Q?"&34ZIR#BZWB9@>+(#IUS&)1>/"@(&\G
MW>6HJ\.(Q]_O+Y';=2Z]PY1DI#X;A'A=%.J0L_?.O-;@B9,RDTN=JN70PQJ)
MMD?"0,7'0D+$M$&$7$1#)M&Q<:P:I@DV91[!F4B2**9``J::9`*4`````])P
M%_\`VSGA<_`]TUCCC@P$U$G$?P13I\EQ!6*9R.[YQ,F8%<FV%)&:`"KAMY""
M[H6YC&WFPR#9(@J/1`WSCN2HIHZ81>0N*GB_OB-8OA3%ZS879AFVY]FT>"B(
MDZU--P4BFZ(AO`.@Z5P[XZRGQ*8;L"_+=_Q;]W;1NN^X*&GXGW7SG<T[&>7Q
MKQ4JB?7LW3=REO%#>34(8.0P5Q)9`QM=<%?%D7)9=LN8"ZK9D6\M!3#=KEJ'
MCW"T?(M#&35*1=%5(PE$=#$,&T*LNTLQ9(P'?9VW#)8MLW=C&$"WKHR!+7(W
MQHTCW-NLH>,;NG3>6!\04DWJA"`S<@5=59$$A4+A&#S&SFXJ954N^8M2#N1-
MPC.0N/)NZ',E:#1ZW>`"J2:J*AGC-%0=4VJZ!``A2@F3YH7)TA_LZXR7F+%B
MZY@.FDTN2^X.)@K5;J.``X"=XL]4*DGNAJ*)@$P`;4O#[^O!PY?SJ5JSN*;`
MJ9VG$]P7W"&9,<NV*!C/KHM*).1]D+'[HK;15T@Z9("[38^S\I,@=D4NCY41
M^=AXJ<16<M*7A/\`$CQ+9[QU8T@FI)+JS,U8:=_VU`/6L>)5'9TU%4DE&[8P
M*.!**20@<Y1"[,]9V^<4SAEOBNRKB#(:#/"T/Q$RL8T:9AN.!?QT#B>/X8[%
M,F9*&3>G:(2*;B.\C7;&.Z,9)DNF4/\`U3/_`$GK_P#UY_\`NW5\R[Q;>XDM
M<>-^%#*-AWME^/AVAY%U%V1,7,B9Q=ON>4Q0,+,\=Y*@H)O8.':.NA#',7)^
M/,*9DL3/&4N(RS38MQ;BW%,TUOC($K.9`%&)1-*V=!BK(Q1VJ#A1P*,HV;JF
M53!L1,SDQ4AX=L/W,9,US8XPSCNT;E!%1-5NE<4/:[9K.MVRR0B4Z2;L%DTC
M@/LBE`W/7!CD#+-\6SCNR(KA3R6VDKJNZ6:0D$Q<2B]VQ\<BYD7IBID,NNH1
M),!'V1C``<HTC8F(.(C$>2;S<,7LFA;%FWM"SLTK'QQ`4?O",&*IU!31*("H
M;30H#RUQN_JF8E_Z&SZ^:2_]9'S)2KYIS]>"W_YJVKYK?B-R@LI;V&K:><2.
M/[IOM=,XP5LSF1<<%M:!&=>$`2MDA.^%T8ZFG\G;NE`U*@H)?FU,?X*NUIEM
MEC7C!L26OG)-A*)W)BJ%E[HZM.VK-;W_`!8JQKV5=-VKUZ+=DX4!-)`V^;?`
MY$S<$&%E;>CX'A'M*Z<CY@S:_C0DV\#F2[K97B\;X482B)=Y)-TX306GRH*'
M]BDL(I^50_4J16-[CMUACO.7"T++`&;,5-6C2*&TIZPFPVW#23&&9Z)H,)%L
MR$R142`@FY2>-41,FV`YL>QSU('#)_Q4X=9.T#"8I5FKJ,G$'"1C$$#`!B&$
M!$!`?4&FEZ8?X;<;6I>,<=12*NM:.>7-<D*LLGU2J\#-W<N_<L5#$$R8J,U4
MS;ACDUW3F`?FM^(W*"REO8:MIYQ(X_NF^UTSC!6S.9%QP6UH$9UX0!*V2$[X
M71CJ:?R=NZ4#4J"@E^;4Q_@J[6F6V6->,&Q):^<DV$HG<F*H67NCJT[:LUO?
M\6*L:]E73=J]>BW9.%`320-OFWP.1/B?_4?QEYZQ56&(%`!/\V0\,<0``$Q@
MXA9H@&,(;1T``U'F`*X(OU3,M?\`0WA68I_-4PXL^QKZX4<76&.0'+!ZXM&T
M9][/LI2$->THT34+&LGIFJC1-\XW44UC)@L9-,3J$X+FG#C=4-E2S>$?'^6L
M@Y@R;8\NC/V)&&O6%/"P=O1URQ)A:/5Q=DC4U#-'*J1@=F)J<S5TF2OG`H3B
M(RMA:PKFDN/'-\Q"QN2IBW(^8>P/EJ;0'L<WF/MIV_E"2R8"F&@G*8`Y=:XX
M<[<)L*O%<%\[C6T;1D9J%@G=JXYOO/[!W#.E9NSH1=LT((MVZ=P&<F32UWW@
MNS:$D41/\\I:C5\>,=7-Q;9!MYM))F.0\>O-6\_C47Q#)^R`4C*@H`EY0TY.
M6AX2>)?)U@<.V<N&"^<J6M?5GY;N6%L%Y*$E<@25Z-I>WWEP+HH2P#[HJ-"D
M8J*+""!#@D**K=5;YZWBGPI!W"YQYF^Q+!QG@)<D+),GN8G>!(.,=7&\M2/<
MI%<+IR0VVT;LR]6!E57XMSE37163)A.:OW.]@6+<V+\.6-8EZXH?2B1,H1]V
M6#:[>U)6'@\:):S#XBSED86*K1F=(R1TQ,<GLMWYJ:R;K83!["S-D'+\+-QY
ME7=OSY+;O?&D2BY0,JW,"S-X1!QH.@B*:@:#KH(#Q2_,KY45=25[+8GNN[>`
MS(D:BA"EX@;"830WVEB=(I0ZL;A,LT=M"-!4,*^\Y9"<`2:*O,63.1^/;,>&
M\A05@0-N9.Q;=_'1=V)I"T[VM>&3A[KA8''UQ2C1<D<5TW6]S$&*"B8-Q22)
M[,HD#+<!PCR3J;P(J..I:RIUY(3LFO-'DN+2WE9Z1%W<2:+DQ32`.2ICU)$Q
M(4HI`*8E,:RO[)6Y^!T:P:TAA!=/!W`W==TW8LCJJ+-6[;IG+8;1[PO("0@6
M9C%R&U$3`L`:`'+_`,$77ZQ5]^=4C1/L?!0=JLA_^'LWS_BJXF?^QG_TK]-\
M\DYX9>$J]N,[B(SCQ%<:F+L78DM%ZYC6+-XTXOG]\3EYW@_8-GCDL9&LHM4Z
MI$TDBG$P%5>-"?;:RA\WYQM<,9>$OC,QU&W'+L;?CG-P)V[=1[.,B:[K0<VS
M=A5)&)EV;58)9H(OWC5^P*LNDJCU*0.\M\,WS<GS1MT9WBL,*0S&=XC<Y7:E
MC7$=XS$G9T?>KQCCTUP.[:C9%-JWD$D-]"Z5'"JVI?(T_8`KQ*\,7$!PY.N%
MCB]X57RQ,A8Z)<#RX866C6-UN;+N4[,DDU;NXU_`2J;>.E6+DZY#BX07;.%"
MG61;9OX;?F??FZUN-.VN&N2=1N3\PW#=3^-@9E:)F%X62<6TRC3L63)D\<L9
M!"W7+R:6=2Q4CN6T<":)TS0]X-/F^LO\/T#GUQ-VWQ777<UXS$#/\'5VX'XM
M+.M^SXY9@ZBHJ2D6M\2392-;*NFK`4B+F3W7`)G,?!6!\V<$MU8WX9L<\+II
M?%7&C.Y$/<+;.,]&WTPAX>!3MAZT371.\8OY1X1<'BQ4BQHIFY5D],^8"^9>
M^;Q@^,:S>%B<3@,O9QR9E"!L*TIJ32FGD*X0LE"7E[?8E;O%HV0+!+J3CEY(
MI(JNTXLB"0[_`,X/GZ3X?I#$O%/\V[B?+=\YRX9;CNI=:/>S..L>7%=T$G$7
M>>/1=MV<H_MB4B7R2\89S%N$3D4*X(9NLXX<;-X;/FOKBR"Q#(5DVYQMY#LY
M/*.0+)P_;^0LH+VC"O[8<VO%Z1H-H(B=P.WTZNL0VX\1*V(@S5>U87#.[X`,
M.O\`B$E\<JG2XWEKVN\F4F,G'\'<KDUE(!814O<!8Z<$P_)`CA5,7Q6QB+$>
ME30(SKC9^:\E<)6K:EF\*N-;PO>"RO'W=+R=S78]LZ^K,L]9E+6\Y:)-6Z3H
MMVF7***XF1%J!1%4%A,D/S0`X2M7\A/\+2WJ7,X7=+A=P2X80',IT1MCR3R,
M6P^QC03\H`X:"XZP=>H#)?`)&\&4QQ`*Q&-\>EP^VQM=$NME+*N=<I6Y%7#9
MUFDMY&,=)-XU4TF+-86J3IV'4BLB1=14C0,L<-?SA'S8V0L=\0T?$L!PCA_#
M+JX'5]7G?]TKM?\`#S&MPV]=B+E4Z$V@^260N6%,Z'[6)&\.[4733)87S>/S
MD?`1_N>7GG51L3$DDA)W4PEX%W.Q#F1L5C>$%>29RR[.<<,W$4WFHA=`J+_<
M;*,C:.5&OT*^LQ89M2T)_&.86^-U#7E+7W;=N,<?N;7QS$X]DV]WP\FN$PL`
M*1)GI%(6,?:HK$*`=<4Z98J\.(Q]_O+Y';=2Z]PY1DI#X;A'A=%.J0L_?.O-
M;@B9,RDTN=JN70PQJ)MD?"0,7'0D+$M$&$7$1#)M&Q<:P:I@DV91[!F4B2**
M9``J::9`*4`````]-$-[SM.V;M0M^=873`HW/`Q<\E"7-%%4)%W%$)RJ2H-G
M[8%50;NT0*JF!S@0X;PZF(<H&*8!*8I@`Q3%,&@E,`[0'G"G=LV'8EFV3;C]
MV[?OK?M&V(2VX1Z_?H$:OGKN*AD$4%%EDDTTU5#IB8Y2E*81`H`'R8N'GXEL
M;_BVAQFCC^R4<;F9+1PX^2M2"3L@8]PY,]78#:A$`8=2=8QE3I>3[HG$3"`F
M$1IE.VUP^8/MV<CEBN(^9@L3V'$RK!<OM5V4BP8)K)'#F,0X#]7T#0V)E63/
M/&);_LO.."9!\Z0CT$LCX_D17:L%9%P9--$'K)=ZU2455(D1<Z"JI@(F(A9H
M9AQQ:KN7!I;-URMF7&Q@KVC+1OIO'E<KECG3M-PV4<1KE5=!O(-^4=!.D?0V
MHT]C,?6/:%B1LG(K2\C'V;;4+;#*0EG!"I.)1ZTA$$$U7!RD(4ZZA1.8"@`F
M$`"IB^[=X?\`"4#?%PHR#>?O*%Q38D7=<XA+(F;RJ$Q<3%@F\<D<IF,1P598
MP*%$0.`@(A7^&WY"6;_AU[G>Y'Y`_DO"?D5[D]9UON7^2O4>0^3[_LNHZC<U
MY=W6OR2]PH;\E/<;\G/R9]RV/Y/?D]Y#[F>X7N+N>3>1>3?R?R7JNJZK[7N[
MO)2%EP=L6[#6<UCE8AK:<5"QL=;3:)7(9->+0@F:1&I&YRG.4Z!4@((&$!+R
MC2MY8SX>,&X[N]?RCKKKL7$M@VE<BWE>]Y5UL[`1[=T;K=\_6:J^RWC:ZZCZ
M#!_DS$V-,BOHMNHSC'M]6):UW.XYHLKURS5@YN!JX.BF<_LS$3,!1-RB&M)W
M+C[">([%N-)NX9I3]G8WLVV)I-H[*!'35.5A&2"X)J@``H0%-TP<@@-2E]LK
M1MAG>\Y'-8B:O)K`13>ZI>)9"0647*7"BD#MPW1ZLG5(*K&(3=+NE#0*MR[I
MNT;8F+KL_P!T?R1N>4@(J0N&UO=AN#26_)R:=I'<L?*D@!-SY,J3K"`!3[P<
ME6])7/:=LW)(VC*DG;4D)Z!BYA[;$VF``G,V\ZD$E%&3HH```X;&(H&@:&I]
M9^1K,M2_[2E`*63M:];=B+JMV1*0=2%?0DZBNV6`.8%$ATJV+9M;#F*[:MNR
M9\+KLRW[?Q[:4-"6C=``8`N2V(F.9IH,'^AC?RQHFFMRC[/E&KA>V?9EJ6F\
MNV8<7#=;NVK=B()S<\^[4,JZG+A7BT4C/7BACG,HY<B=0PF,(F$1&KBO"W[)
MM&"NV[Q;FNRZ8>VX:,N*Z#-`$&IKBFV2)'+T4M1ZL7*I]WFTIM$7W:%KWK$L
MY)I,LXN[;?B;CCFLPP`P,95LRF$5DB.4=\_4KE*!R;QMTP:CZ#ZS\C69:E_V
ME*`4LG:UZV[$75;LB4@ZD*^A)U%=LL`<P*)#I5L6S:V',5VU;=DSX779EOV_
MCVTH:$M&Z``P!<EL1,<S308/]#&_EC1--;E'V?*-/[[:VG;+:^)6*0@I2\F\
M#%HW7)0C54J[:&?W$FD#Q9JF<A#IMU%A3*8H"!0$`I'("EIVRI?C>"&UF]['
M@8L]W(6R9Z:2-;J-R&2\L*P%P<ZXM"K`EUAC'W-X1&HN^WMHVP\O>#CG41"W
MDZ@(IQ=41$O1.+V+B[A62%VW;K=8?K4$EBD/O&WBCJ-<1>:\AXU@+CX<,H<)
MECXH;/+D7LVXX.Z;EC+I82,O;,K8SU==X9$B+8ZAE'L<#8_L0*H8W(#N`P_B
MW'.*8)^[\O?0N-K(MFQ8EX_W.K\M=QMKM6J*BV[['K#D$VG)KIZ$E.SW#K@J
M;FYA\ZDY>8E\1V!)2LK)/EC.7LA)2#R/.LNNLH8RBJJIS'.81,81$1&F4';T
M1%P,+&H^3QT/"L&D7%L$-X3]2RCV)$TDB;PB.Z0@!J(CIRU<,E;%IVS;<C=T
MJ>=NN0@8&+AWMSS:@""DS<+J/234>NC`(@+AR8Z@ZCJ:FEQY9P%A7*%PL$4V
M[&=R)BRQKUF62")MY%%I*7*P<KID(/*4I#@`#L"H^$@8N.A(6):(,(N(B&3:
M-BXU@U3!)LRCV#,I$D44R`!4TTR`4H````!0Y55X?,'J90,^"3-DA3$]AGOT
M9(#;P2`W@9A[H]?KR];Y1O:\]6Y.W':=LS\W9SUQ)6C,S4#%RLK:L@[3*BZ?
MVY(/DE%F*RI"$*HJU.0Q@*`"(@`5;-PW39-HW+<%EO5)&SIRX+;AIF8M.054
M255?VS)R**B[!8QD$3&5:G(813((CJ4NBM]WMPU8`O&^%UR.EKRNK#>.KANM
M9RDJ*Z;A6XI:-6>&4*<QCE.*VH&$1`=1I:Q+GLRU+CL=P@P:KV;/6[$2]J+M
MHMTD^C&ZUNR"*C,R;9=!%9`AD1!,Z9#D`#$*()-VZ2:"""9$4442%22122*!
M$TDDR``%*4``"E`-`#D"N-7BSSS$,(?(6?LCQMIXTA&LW'SYK8X>\91Q(6Q!
M7<Q)U&[=Y,$(@YDF9%#[AVR1Q$JBBH?\$77ZQ5]^=4C11^H7P5I60_\`P]F^
M?\57$S_V,_\`I7Z;YX"<XJ,CQN(;1S%G[C<Q=:V1+F041L>(N\O&.YO-O&W?
M<1-XL4@\:Q3HJ#QR4&W7$*155(3$$;OXLN$M8UVX`Q'8-XRUU9(BHQRQA[RB
MK;X2`X8W%TJ&63;F,V>75+-&T4LOUAG;5LBZ3`$S`"/'#P;90^==1^:"X6N$
M>XLD6Y9+2&<V/C.Z,H(XKOYM9#B22RI>3R&,#F8134N8QW,TH1-@HFDSBUD!
M>N4OG7BX]XA;LXA(J;PAEME:'$]=X/37AE9%SGV!91.7)D7/5+G=2`[DB)S;
MAC"8#<FM?."<*G'3DRS>%C,$?E:UGIG.6G/Y+,YEYC9&9L2^K%/,NT2IIR,#
M()@<D>Y6*JN#U06B1Q2<[O&MQ`<+LW,9!Q3,W!B^"@;D-;4W"J3B.*N.6S;=
MNFXF,/+(I/21H#&NGJ+ARW2-Y(`+*II`!BEX4.%'%7$)8KWB8QOPPSI[YQ?%
M2:+O).-FUN7JK9C^ZYNU#&363;-I"4BSH**&(58KEL<AMQ4IJXP>&SB#^>(S
M)\SGEW&.2(Z-F[#9Y/M/"MEY*E+75D;2NWW5NF^W\9'J34`^:@U%DHY*L=!R
M11L18A'`H_\`_0?FSA0^<=FOG#<FY%X"N)J.XAKQ"3MBXX".NRZ\-7[?YKE=
MWQ:'E$?/2<V\\N<*O&LBN"8E6$X[S@!"[7"#9NBX?<8>85GJZ2*::SQ5&PK.
M;)*NE2`!E#%3(1,ICB(@4H%#D``K$WP?R7_YLRYJ^<INOB]O*)P=8^8,>Y`L
M"#O>^UG$5;4>]OQ[CC,]D2<G)I(K)(M)2,@SE;N%SI)`==,#J%/]K,PXB>'N
M3F+BP]<&+\AVG9EX2T(\@$;U1QMPJO;`F+JM]A(@5R,6ZD8YV#!5PDDJHD4#
M*(HG$R1<3%.4IP"P7YP`Q0,`'3^;/N51,P`/.4P`8!YA`!"OFYB+MFZQ#8(M
M)V)%44U"BZ9V7E1=FY$IP$.L2.DD=,^TIB%$H@)0T^8]?$;-R/G+?A^:.'A4
M4RNEVK+BBN19FV6<`&^9-$[A<Z1#"(%%102@`G-K_P`23K]8J^_.J1HO0'@]
M#(?_`(:S?/Z*KB9_[&?_`$K]-GDM[<&6$[B6XG+T3R/G)^_M]R,O?604I>5G
MD[W5FD7!'<?+`[G)A;W0BEVR^KQP&_NJ&"KBM#A$X?[#P=#7?(-92[3VLVD'
MD[=#Q@"I8P;CNNXG#V5?)LP77!D@Z>G2;@JH"!$P4/J3-G$KP@8MR?E86L>R
M?WR["Y+<FY]O$HI-8LEVJV;(1Q)D6Z"*39`\J1P8B!"H%$$0`E77F+A[X:\2
MX9R1>]HPMA7/<N.;59VJI)69;S=@UAK:+&Q75LD&B!(QAHDV;)@8R!#'WC:B
M+C,W$9P;XER+E-^5F69OH4+@M.X;F-'-TV;!:[WEC/XSW951011;)K2@.#E0
M331`W5$*0$^&"U<)XO@>'4EIR=C'PG'65`(XS=6E.$5+/0;^T`0%DY1D!<.%
M)#RA(YG2JJJJYE%5#G-=^2.$KACL7"M\WW`J6M=%S6\]NN3DGULK2Z$\O;[8
M]SR+\K-DH\:M7"C5D5%,QT4=XH@DF!5,J\2G!WB?(^2G3=NVD[[(A<%EW5/I
MM$^H:&NB;Q^^BEY51%+=126DCKG(F4B93`0A"ER5PZ81X8,3XYPUF:VY:T,O
M6;`V_P`F4;;G+><VI)Q.0K@>J+2DRFI&O7C,!D'RIB)KK`0Q>M.)E,1\,.([
M1PMC9:XI.[5K0LMHNSB5;EF6[=I*3*I'*BIS+K)-6R9S"<?8ID`-``*CN-UU
M@+'Z_%E$QYXN.SL>.<#?;-@I9:^.3H(O@5ZH-8)RO%"84=[R<YB:Z5;F0N*_
MA6QKF&^[5C2PL1>4L2>@;F&%2<"Z;0DO-V>]CG$DR04,H=LTD5%T4145ZHA.
MN5W\;YRQOPQXCL/*N'L;AB'%UWVC:[>WG=B8UZE\W/:%M,(L4F;9J<LG(]9N
M-]\XN5C'.8RAA&.XW76`L?K\643'GBX[.QXYP-]LV"EEKXY.@B^!7J@U@G*\
M4)A1WO)SF)KI5D<8UV8*L.=XGL;P9+;L;-#^/74O*VX1)I),4F$>Z*J"6Z1&
M8DDR&.B8Q07-H8-"[N*N)K*V"[%OK/6#RQ9<2Y0GF3IQ<UB!"S:]R1(P2Q%B
MI$%N_<+.TA.D82J&$P#R!I_Q)/E#;"<1%^&'H"Z9$:+O"&N@?MOJ5M#]U614
MDQ#D4LTP!KR_[?16M<3/_8S_`.E?TA8K3DJPB4I.6BX&.._=(M0?S4T[*PB8
MIGUHAUCAPL<I$DB:F,.P-`$0_P"(;($W=42_34M7-]X3+V/1!,KU>,D;A<R#
M-XQ!P)"'!=HY2=-MXY2J$,3V10-O``>2WKR?_B5C]^U]RWK_`%*Q^_:GK#MQ
MA<IW\^XA2G<2C)FR9LVT7-MYM143)N%CG.86Q4RD`@![(3"8-T`-G*^7;-RA
M#W9<%D0$.Y62,F@^6LYG*NI11H<P!UA2&EDDSF*(E`P"7VQ3`'T@^;Z58/SL
MWSSCEQGFF<;IB8QI?'7#HNE<-W0ZB!=!,DN[F(<%=#E'0-P/;ZE1<MEDG#9P
MDFNW<(*$60706("B2R*J8B4Q#%$#%,41`0'4/^(9E,Y#@Y2/NJ/:A'H7C:$B
MC"W$I'$WC(L'RCA!RV=)IF,)D?*6JAD^4"&*4QBF_P!N\\?G/C[^Z]?[=YX_
M.?'W]UZ;O'MP9EN!LBH0ZD3+W9:Z,>[*50#F2<*0$$Q=`4P`)#"DY(;01T$#
M:"$-9EEP<?;=K6\S*PAH2+1!!DQ;%.*IBIDY1,8YS'454.(G4.8RAS&.8QA^
MD&(,1VG<$9<,!@K!B)I9:*D&T@V89!R3=;R4N*-%5FHHGOIQ4=;YE`U`X',8
MARAN`(\(^2$)MG,7&?!..[<OPJ4BW?/VU\V9!$LNZU91%(YE$#NI"-=.DDU_
M9]6<HZF]L/I6.0N(/*=G8BLJ3N2.M".N.]95.*C7]SRS1S(1\&T4.`BHX4;L
MW;G<(4=U%!94VB:9S%A+IMB8C+BMJY8B-G[>N"$?-I2&G(.89DD8F8B)-D8Z
M+AJZ;J)KMUTCF(H0Q3E$2B`U>C[$E_6[?[/'60KCQ/>[FW'GEJ-M9'M%-NM<
MMH2:FZ`%>,R.VQEB!J``H701UK&6(LLYFL.P<EYE?H1F,+,N2:28S=XOG<LC
M`L6\8W,`@`N'RZ3-L*QB`LL(I)"<Y3`%9!R]D&3+#V-C&S;CON[9,0(<[2W[
M6B59F4402.8O6+"DB8J*(&`5%!*0OLC!5I<9EZ-)C`V);GQZ3*;H<PK0$/)V
MO8SM0ZL+.W"I!/9!FFG(,_)G[,B3HZAD7*!3$(N8R)87*>$\@VKD_'EP^5%B
M+NLZ6;3$.Z68.3,Y!F9=L(BDX;K$,DX;+%(JD<!(H0I@$*O3!<%?UNRF7L=0
M%OW1?./F;SK;BM>`NH@*V]*2S0`T33=D$ITO9".Z8AA``.41]-?/#?969K#N
M7.N-&"\G?6+XF:2<W5;;%HLT;/G#UD`:"#95^S1=`D<XH**D35`AQW?2(Y3X
MBLC16+[`<7%%VFC<DPQFY!HI<,R@NYC8P&\`U=K[RJ;9P?>%+<*4AA,8H5P]
MPF3&]V+O.)C/MB\.&.AMB(92J*&0<ANC-(!:Y#NW;46T<!RCY0Y2*L<@>U1/
MZ&..%VY<C143GS+ENS=V8YQNLQFU)6Z+>MQA(RDU)M'S9J=BD5!O$R*HE<.D
MSF!`^X4PZ`/HQ_"@YR-%)<0LI89\FL,9BQFQE7-C)N5VAY\LD5J,>!04;+!U
M)G@+:%$W5[H@(UD+)!;7N*]AL"RKHO/\C[13CEKJN@ML0J\T:`MQ"6<-6QWS
ML$10:D7<ID,H8H"<-:Q;Q&8H=.W-AY8M=O<D,E)$;)2T4N5PI&3EN3:+-5=$
MC^*D&[N-?D1743*X04*110H`<?\`B%?'X.N._'/#2U.V%NWMF7X9("])%X!R
M;BIW.3[DE)<S0P@)OMC.V=\!$IDCI&)J:9_Q'S1=/&=:BOE2CJ'LCB=DU;<\
MA5$QU?)L5Y.6M9N4QP*4%&<9&*B(B4I`4*74)+%F=\:7EB?(<2V9/7UI7Q!O
M(*8(PDDNOCI)!!X4`6;+DU%%RB8Z1]!W3B)1TM?,O"1A#*\3;\VD\5M;,K*]
M8;#$.[8-)(\7(O8"\[EEH91TBFY;J)']SCJB8Z9@*4QBZ!$GR5\Z=:5DVU_)
MO*;:O-E*\9EP(,^7K6+\,J1T>5,R>NA"QMT``@`%!<A``*B(?*M^062[U9)`
ME*7G;UB'QNQFC`0H`X/:8RTR1NH)M\3=2\W-!*`$*)1,;T>!&P+M8^Z=JWS\
MZ)PP6=<T;URS;W0M^YK.O6%F6/E#8Q5$^M;+J)[Z9@,774H@(`-9_P#F@,]3
M*TC>_"Q)OKXX9[MDS=4KE'A<N^2"4A%69U`*"SB(5?(G732,<J!79V"8`2)4
M-7SCG_VVOB^_`=H5\[AQN6DZFA><")+0P;P8S$2[<&(C<G"U+?XL<0DG"F)N
M)N'#E0KL\0=`ICC[II;AS@4H+\/_`!'1AVXGRIC:"FY]NT*!6T;>S),T%D&$
M0`!'V+"=:2+(!UY>JUY-E6#P]6Q(K1TSQD<4N"N&U59H=NB[3@K@G%KNDU2N
M'(E*FD=:&9M%QUT,1QU9P%(ZE<7%IVZP1B[?MCA]"WH*,;%W&\=#0KB/C8Q@
MW)S$102(F0.8`"L&\-MS.UD.$SYSS`^(\Z8"EWSA8T;9'%*XQ;##D:P%';K=
M(0\VX,"2"1-X=%[?;)ZG%P(?.4_JR<+7FY&5>5X84X"^'^VL:6A)7.C`V?F[
M.DDYSAEJ%MUXLDRF+9B[)22B8-:630$6+"8<'.45$Q.H)!WC!QIV5:*MMO&]
MCY)E9O'<O*%DO<"]\9MWI)>W5IIHDCY0T65:$7:NBH)G.U72.=))43)EA,[\
M'/`1CZ4MJW+?,[R!.YAR#+VRRRA>D8H<;JL/ALMQF9)W()1Y=UN$]*.BMUGA
M7+--`5F^BKKYR>]H&=L:S[=C)9A=^-D5T)RYVN3(FY@LI#'ENO#D:)/59.35
M:%CG2I$$P;N4UW@-2IN.I6XP;B^;UP87AU8VTGDF8PZQS7<8\44'BP6?NZZN
M:2,JR&(!=M%ZO'4<6.%ZD&I5&9%$U4R+\?\`;SUPZPXAA.YLSF;.U$&LP@G:
M,6[6G[)>=1UZ999M)LG,&JDB*H"\(*:?6ZEWOFS/GEL@NY)O>?%'Q(9(D^-R
M4<G<G9*XQXR7J\M8$XJR7/O)L8Z#07FR@.ZEY:NT*&Z8"G61XA&-H1][(-<J
M8ULJ;B)!=\B*%NWA-BPG)6/)'Z'5=MFY3J-D!$"J'T*80`=:B>,K*7S?=L6C
MP+.YJW49N#D\G+#Q9V59%W33:%M?(%\VND7W(C%7QWK4OY/F356;.5"M'CM#
M>!P/S>LGCK'.,YS!3SBWX<;_`,!WRZOF3C[GOS,TBP=2,!:EUVZ9`@1D,JFJ
M4WND0QU"@;70!$2@XRIQW\%W"U>5\%XF,:V3"X7DIU',V*G%LW$]8M8+(SE2
MXXU0J,TS=K2:;=`J1A3!))8JQ15,F7YL?*<A`7/=;#&OSEN!K_>VO9,66;O.
MY&EFI/;B<P%HPIU$0>2;PC8S=@U%8@*KG33$Y=[>"P^(+C.X&<<X[X,[ZN^W
M;9N-UCW++N^,[8":7>XZJ"E<I1X)$C7RA2Z@NVC6J*0+;K4[M%RH@DMP2X3)
M@O$%Z7!ES!F:KVMKB/E(2*D<J8]A;<M]Z_\`R?Q]<IFIW#>.ET@4*]*B\(15
M-8P"40$=ZR^!C@PP=%<0_%M=EAN<JW.C>%TGLW$N%,9(N_<]M=V1YYJ0ZZIG
M"^X1./;G14T6:Z',J\:(KXIX-?G'.'G'&(+KXA64TI@#.6#[ZEKJPU?UQPB0
M+O+#=L+H2"082`;Z+8IEG.^=RNT3\E*B[17'C#N"UN&KATE>)-_PSXR8Y#QC
M)9LFFN-K<L-J6V!MZ=MZ\@;%6>/5@!D*S8Z!`(*ZVFF[H.->'*X^'3#;3*,W
M\WR3-\SQ!-XV/E,M6]UF6']GR>&H2]%&*3Q6W$W+51X!17(554XG%`@B.MZ\
M$?S>F!<?9HROANU8"[.(#*>9KW?VAA?$QKK;IO;9M%8MNE-(RDJZ0534.DT4
M`R0B<@)*^3/3-;XB.+7AN2X><KX[NQ*W55+:NYI?.+,H0KZ*2EXR^,:7$EHN
M#804,V=L7>^JV5(!5%.M,J@W^<NX*$U`"W>%?C>OA]C>/,J0#0&*LPN7LC9D
M$V9$TZEL485X])H0"F6<N-TQBE`"_P#$/PI\039F<C/)>'+IQ9(NTB`+<TOB
M.[_RD;G=B0/8KK-;N*FF90=5$V^A-01/N\+F#7#(L?)XNP+BVT+A;@D*!C77
M%V<T3N]VJD(%$JCB4%VNJ`E`=\YM0U]-\W'_`/;:^$'\!W?6&/G0N'*-,MQ#
M<!$P-SW7&L0%!QD[AG>+G#*=CR[E/V1FK%FYD'A]O5,7,N9(!742KYV7C4M=
MRLS"6X]N*.[,/IRB*"4@M>67[,L5AB9)Y&G..^9*0EF#A^@F8PD027-RE3$0
MQ'8>/>+GA]Q;!W;;!,FW+C^]^$YS?=XQ-TY60+=]RPM]W6\N5F:4D&9G81;A
M91J0`(W(B`&(F41XX/FJLLS4?)W;PW9'99BQ?(,F#B'97/BK*D>T5DI"VX9P
MLX,UC6ZZD/(@@9PL9):941,LH*?)P#98>!K:V)_G'>'NXKP5*(%4809FLLN>
M3.930@)$.V*@83&#V:R?)IO"7C7^!>4_"[.N'&Q[/6]QL\XVX=.'C,7#==[9
MP6.E+>S%8V*(R0@6369WTA:)2Z?6Q*RXJ;C<RZ3P2G4:)`'&9GBZ[:DXS)B_
M")P[VGD^UUF1(I^.5\7M6]B7VBU8NNK(W*^DXU=RW;J&#J"K%14,!TSZ90XU
M^,OYV#,/!_%P.0;ZC3\/W#;E#&&!HO`MM6T[%"'MF[`N."F)Z?DWR6B[+KTA
M=.>M221*LN((DR@0Y3$.0W%D4Y#`)3%,6`7`Q3%'E`0'D$!K@V_L7>OZ6[AJ
M_P"<M"%<7,UQ#QX7MEZ^K:;MA>%FL?VODA:.N(CYJ7>$S-H+]&1?'%)0J3=L
MJLH0$TSG)?'$DVS]BVXK$N'$=P/[>M5.\+;5O>Z)V;ME=*,QF6R.O5?$G%W)
MO<]U&K-MYJ<%C.@30064)\V%\U=&+N;8SA\XQF&4GY>/>L'3I6P.'LN47.87
MEP3T6BH1VFDB@_MV>=);B0F;HR3<0$R1S#D?AQNGB]X:+RQT>PV"$!C"U^$=
M2R'CYUC8S>Y+`MBV;D1NE?W)-Y;&,6B#DJ"A4B"(&3.F)B&X<;VG'AG.0K`S
M_P`/>#\II+B;W2;WSB:\R6T=U-%.`"5Y)Q98N;<$W0W3/=-TNF@<9/\`8NRO
MTMV]7S,]\3KIO$6?9O&#P8REUW+(K)M(:W8Q'':L@O(S#]803;H$0:N%3K*"
M!"E(83"')0RF-[]LO(,9#<6/#S`3$C9%TP=UL(F>)<+::/"23N!7<)H.P9O6
M3L6RIBJ`BX15W=Q4AC?-C99NPLF:TL5?.58+R==QH6,<S,LC:>/FC^[[F=1\
M2S`57"J3%FX5*BF&IMW0*N3$N$,QV!FC(O%K=&#K4PC9N,+IB+QNBZW[+,\!
M?#A0MO0JJKQN4B<2JP4!TBD9-\JBS.!7!^JKYH*R)M4B\S9O`[FVU9==,Z2B
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MBJF8JB:B9A*8H@8HB`@-?.VX4XA[TMK&E[9]R%BO.^'[CR#-QEK1N2,?.&,W
M(DA+?GY]5)!TI#DG6S9LS1=*',*<@5-%+R%R4N2(K!F4[5RJ;$EP1UJ7]*62
M]/.VU#W+)Q@2Z,*UNMF4T:_630$/*@CG2Y6ZFJ"YDURG3+\^'E>/+OVQ/\65
MA8OCG28E5;N)W#!;OB;GZER`AOZ&DFIQ`$]TH'+NG4`=0_X0W%@'AHM*QY!S
MC5XG$Y"OK($=+3:+RZ?)@7?VY;$-%OF!4T6`J$0=/'*AS*."JIII)II`JO\`
MT/@'XO;D_']?T/@'XO;D_']?T/@'XO;D_']?T/@'XO;D_']-EG-O</SUNBX1
M579J6#=2)':*:@'5;'60N$JA`4*`D$Q#`8-=0$!J)S+`0ZMKSC&8>69D*T55
MQ=DMN^(ABVD)!K'OQ*47+)=N\:O&:XD*84U034`%DU"A^S^"6-9PQ90,;<>N
M`)R]U!1!R+?#%S2JUKY0(+<WL3$$JL<N<##IHCH/((^GM-CE;']IY"9V)?,#
MDRS&UVPK*:1MC(-KIKHV[>4(F]*8&\BR(Z<E;.D]#I@H?=$-X:=,'[5N]8O6
MZS1XS=HIN6CMHY3%%PU=-U@,11-0AA(<AP$#`(@("`TKA"/X8,',</.+Z1R<
MZQDTQQ;#>R'F0F[-*.0O)];:3<&J\@1NW;MRN54S'!))),!W$R%+3GB`0QI9
M:.;GEI%L)YE5*`CT[Z=665RF]+;#FXB$!RHR!5))0$#'$NI"#I[$-,]\.20-
M"7->5H&DL>/'IRH(,,F6@]2NRP55WIM!;H+2;-NS>K%Y0:K+@(&*82FQ597&
MAB!NVO>Z<36_:>>\4Y`"`NMC*W'!H%A;@7F"1SE^R<MI5PS"50)Y0H()KIE5
MW52G*6"M2V(EA`VU;,/&6];T'%MTV<9#0<*R)&Q,3'-$0`B2#=NDFBBF4``I
M"@4`T"LA97QWA['%D9,RRZ\MR9?EKVA"0MU7R[%X>15<W+-L$2+NCJN5#N5S
M*G$55AZU3>4]E2V?)GA-P3)Y=<S!KC=WH]QY`+O7US'<"[/=#]@=(6;B4,N8
M7!I)9L9R*VBPJBH`&"?QW8N.+/M*Q+JD+HEKDM*!@V,;`3DG>RAU;O?2<:V(
M5-562,HH9X<Y1%43#O:ZU`8UQ59MNX^Q_:K=PTMNSK3BVL+;T&V=OE9-TA&1
MC(I4D2J.%UEC`0H:G.8VT1IUCW%.-[-Q_8KZ2FI=[:-JP$?$6\[D[D5%:??.
M8IJ0$3J/#")G)C%'K-1WM:2RC!\&7#U&WJVDPFF4BWQQ`A'QTN14JZ,E%6T=
M,8MHLDH4JJ*C9D04SAOIB4_+5I9QG,;V;+YAL*#E+;LG)<C`1[R\[3@9Q)="
M8BK>GER&7:(NDW3E-<J!R[Y%5"&U*<P#5TX]_P!W/$`6+>^129=NZT2V/!EM
MZXLGIJD63OV6BBI`BM*%,DF8'AB]8&Z7EY`J?QKE6S;=R#C^ZF[=I<EG79%M
M9JWIQLT?)2;5"3C'I3)+%3<((K%`Y1T.0IMH!2V%,FXPLJ^L3+1L9$CC^YH!
MA*VPDPA$R)PB;2-<D$B!F0)IBS51W%$1*4R1BF`!K_=_M_AMQ''X7->3?(BV
M.`M"-<VR\OQIU`-;QD&;PJ@N9-(K5LFF]7,=4J:**93`1(A2V/(Y$L2U[T?8
MTN]C?^/W=R0[.67LZ]HQ!1M'W3;QW93"V?(IJJD3<)Z'`IC``Z"-*YMQIPJX
M1LO*AGKV2;7G`V)#,Y*'D9+>\N?VVB"8MXM94#J$,K&HH&W3G)KNG,`VCF>;
MQ_:<KEBP8>:M^R<B/H5FXNZUH.XT3H3T5!S:A17;H.R*'*X33,`'`P@(#K3:
MR^(/#^/LP6TQ=*/HR-ORVHV>]QGZJ8(JR$"]=$%PP<'(`)G79JI*"7V(F$O)
M4O&\.>"L:8>1N`Z1[@=V5;$?&3,^#<YE&B,Y/[IGSQ)`QSBW1<N3D1WC=44F
M\.MMW'Q$</6+LNW#:+48^WIZ\K99R$S'Q8NS/_<890FXNLQ!<ZBP,5U#MP44
M4.">\H<30V8V6,;(993MW':&(X&_6=NQC6YX7%[:2/,-L?Q<H@F51"(3=*'7
M38I""13F$0*%0B7$;@;&N7U;:ZXMO2-Y6VS?3<(BX-UCIG%3Z0)OD&ZQ@`ZS
M9-P"2A@*8Y#&*40O>$X4<`6A%FLRS;NN2P\,XSA+9LEC>M[LH)5Y$1!C%.P:
MB\E7:2#==^]<E.<3;ZJPCRU:EI9<0(EG[*=U7=GKB#4!>->./\5\G/BOY*.?
M/X@ZS9=Q&QZ,=%N5FZZJ)UFZAT5#)&(/_"+B434*4Z9^)V\"'(<H&(<AKU,4
MQ3%-R"`AR"`U_1<=_P"1-OWM?T7'?^1-OWM?T7'?^1-OWM?T7'?^1-OWM+*M
MV+-!4L@P`JB+9!)0`,<0$`.0H#RAR#6<_A^6_1W"?\4W%=<>-L!9JR=$6WQ*
MW0ZF7N-\7WG?#9AY9-%N1@V=.K<9N$4EG#%9%RBDLH03)J$/[4P#7R*>,K_[
M'#)/WG7R*>,K_P"QPR3]YU\BGC*_^QPR3]YU\BGC*_\`L<,D_>=3+V5X1^*J
MUX>%2&=FKANG`F0X2WX:(B4S.Y&2EI9RRZIN@BD4RBBRHE(0H"8Q@`-:S))N
M&BZ+"4X@I)*.=*D$B3TT?CV!(\%OO<IBIF4*03@&[O:E`1,4P!Z9EP=Y)XK(
M-CGU>\(G'\G:EO6'E.]XFUKWGI%*'B+5NV];+@W\*P?'>*D:NFZS\#L3ZC(`
MT(`GJW\5<67$K$X^R5<4;'SJ-C0=DY)R7<D1;<D[%JVN*Z(_&4/+FBVQ]TZJ
M)'PI+N$R&.T17`!K''!1:7$*QFN)K+F/8/*F.L;-\>9;23N6P[EQ,IG.#G$+
MV=0"=NH"XM-(\R5HZEDG()`"9D2KB"0_\3EXX]R'G/&>/<CI.XB;O>#?"Y:R
MJLE)6ZT:Q+V;<,FQTUG0Q35@D&^J94C8C8I@*GU05\J[%?\`6$G]ZU\J[%?]
M82?WK7RKL5_UA)_>M?*NQ7_6$G]ZU>S*6XE[$N"*=VC<C63@;<=R2UPS<>XA
MEDGD1!(BBEOO'*8F1:EZTFJIBAO%VABYYPDI0[/!+>%.PM"(B4G3=>#6;NU#
MS<5<+:1.H[++$>G7/)G>J'76<'.X.JMUP+*>DR;P,_-L<`V4_G&<WX+]T$<Z
M35IW@%@X]QU*P,JA%7+"H2"$+-*R"C!VH:'>N'0QR"4A]I;G?"0Q!XQ;MLK@
MHS\RXVN"1JD.5/F]VJKJXLP3\BI<8VHX98]DV4*D_DA8/T'K27;GME&09+-^
MK58?RAH*_%Q>61OFH,A<?=T<0V>;46NE^YQ2VR=+<&<I?&=)BXKDO7(2]R6M
M+(Q*H/ETU7;QXK$#UL0H8RY!2'JLY\6N9OFC,Y<3=\W);+EF\^;FOC&DSD++
M5A$B\)P-B1$O/6)/67(N`)&,&I)%,R]K)]6B[35`Q1$JQ^'6'MRTV-A6]$X5
M81D%8T9%LH.-LN&8?-;7`UB[3CX6,32;,T(Y`A&:35ND1-(B8)IE*4H`'$5\
MTJCP^/K?=X`QR\OM3/*F3F\FWNMPPB+8F'$,3&98!`S(G5W,B4CH9Y<1,@?5
M`H'*(8J^9V4X?'SYYD_&LG?J7$(3)[=NVAGL?AZXLPE@U,6C`',ND=M;RK,7
MH7"0Q55B&\G,0HZJ_-)\1'##(8/5N_R<N`^(QSE]G=-N9B/<$`,]C\Q[(&W(
MT(I.=.@^AFIDIU^9.71+'')UAS'2XP.'#!G#G(*<-O".H\@I'C*7RBW?0&0[
M[3N4+9A[9MK&K:WR`5O*BTG9&.D2W&L!V+`KA5%$SQ!*L2YOF,$R6?$,H9JC
M<3*6Y&Y#:XX6@62]J2=VR5S$E'4--E=JHHQHI(1XH(%6.H&\Z0*74UO93@/F
MN^)NX/F_+HO1[95G<8=UOK@QO'Y358OUV[N6Q?%3MJ*6Z]6*BP?KMH1Q=R3M
M8I!!R:-4172+BGYQS&&-#<46-LV3V)F&.8)E?P8K+*066[1?WE#3\A/NH2>5
M:';MF`I.6!XL5B+F%%7JCIG`'?SH9<,O+_8I8@X=,KM,*C?B-J.W'^\-=-J6
MO'0+G(`1$D1+W,/=*:J[HL,IUQ6Y@*B05`$EE_.]$X<Y"XFMZVOC&?9</YLI
MMH==FZR1D-O8)(]UE$+?=E%-F98SH7!+>$50*"?4IB83EL7-N'?FP^(+)?#`
M!;`M_,W$%/75.V1CJS,P73:#>?NW"UH7@E9DG#2<G`N7)VJ:\C(QQY,S54S=
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MDJ=)8I2.&ZBK=9%4_P#Q'<3C2345=)/.(^[8I83J'ZP6!+H&-2;D4`=2@1`I
M4R:#[$```V5_1CG^LG_\97]&.?ZR?_QE?T8Y_K)__&5_1CG^LG_\92DG$LUV
M[LCUHD!SO'*Y136,)3E$BQC!Z@ZARUFMBHNH=FTXA7[ELW,.J:*[W'%OD=*)
MAS"<$4M[_P""'U?2_.>X(COG;8?YJ?B";Y<D3WBC>V$,2Y&=\14G9F2[Q0NU
M..?Y1N"WD(YQ`+O2R)646HN:0;22CK<!".ZRN+;BU-\[;C;YQ+B&R?B%W;6=
MK,QWCW'-AOK=E,E9%A[Q8Y)R`QQS?%SMD7KE6U7+5DW/&LA,"[M8#&$P@;YZ
MGX0+6_31D&N,/X/[U_\`9TLVL3?!_)?_`)LRYJXU)SB,ONU<-6KD[&RMA6]>
M62)Z/LZT"3EV82Q[>UJ$D+GFSI,&Q))"*5;,U'3A(BKE1)N4XN%$TC\-V3^&
M_($3E/&L!8.3L9DOZVS"ZM.XKCLG@DR*VN-Q:,P'VN2CDG"PMT))OJW<BF95
MJHLV,DNIP-<`7!A8"-]<>V/[9N^?NZ^;<EC0<M9UN7`Q0R'9MASTZVW.I&(9
MQ<A=XKN%=8Y)ZD=KHI(N"FS)PGQ%GL\><3.#,T7'=^;H]XF\;7-DB'OQ8&-H
M7_)-Y(I%$UHDL<I:+R.1+NLPCVBZP$6DA`W"C^M^W_0Q=%8TQ+B'-^';ZR1D
M>RN$RRL7XHM6=AR9$QW=&(;CMV7R*K<.,F@A)0*45%P\O$+*OV;=N(O&X(**
MD=-A6^;QA;QBI8)F&OG!%_RI'@.%G$+9.1#WO<-AKR'7B)T4O()^$:IIFTZL
M54D0*70"AB#A_LOB)QO=N?<T\.G!#CN'PQ:5R1URY"M*\<)7=8=W97C<D6W&
M',[@$8@EM2C/RR5002=.`0*S,N1=-0<!_!_PO_\`M%LJ8M&\5&H-5>%'%<RJ
MV18M4FZLPOQ/0TRO*J(D*!3.3O!%V9<0WQ6^VB;?]E5VM2042BW>\#W%-=+U
M%LP;-2/;D99+NN8;3KP&Y2]:[*Z;-U^O4U.)TR"81T"O_6`_]]^KMPO)YOPZ
M.5F/!]EWAQ=X$6G8>&RLIQ$7RC+,;4=LL;'$DH^($K(L[D&::M%6ATD5W*CD
M#-W756=+78W?-HO(^?<VWUC\CTZX@>RRR#&R1<,D%A^U(*S$++J$*0`*<1,J
M&O6;QOH!U53D222(91550Q2)IID+O'.<YM````!$1$=`"HRY,NWNQM>/G'1F
M<&@1I(S4K-+)I@LN:,AX-%RY522*8AEG`)=4GOD`YRBH0#0-_6#/,KGM"YV7
MNA!SD?UP-WK<%C-E0%)R5-5)1)5-1%=!9,BB2A#IJ$*<IBA_Q!\2[APJF@@A
MQ-WDLLLL<J2***5Z&.HJJH<0`I2@`B8PCH`<HU_M1;O]=QO\;7^U%N_UW&_Q
MM?[46[_7<;_&U_M1;O\`7<;_`!M+-H^;B'[DS]B<&[*29NEQ(0XB<X)(',;0
M.<=*SG\/RWZ.X3THYEXD^&:+F<NN&[-G,Y(L:\;[Q=<]UM(]D6.8IWJ?'\E'
MMIE9%!-NW0?2;9=XD@@BW2<$;D!(;R9<'.$&N+GF148-"_KB=WA?=\W-=J5M
MJNUH-&3FK\DY)5-)L=\Z,FW9]2CJ<1%,1`!#.&3>%?"2.+;XXCI9E-YEG0R!
ME2]3W=)1TS)W`T6289$G)=K%D*\F)%8R,.@U2/UA2G(8B*!4[V^<+M;"2,7Q
M@Y$B74)>&7QR!E1\,K&O;?C[5=(I6#)3BUL-#J,(MDW,LSA4E="&-O[ZJQE(
MGYR!YA)-;C0@XM2&BLS_`.(65DS-8Y;'#G$:B/\`A\E.EM4YAMUXYC>M4@S*
M;I^M`W7E*J6VLH<6&`$;TR3:T*A;+*^K:O:^\<W+(VPU<JO&=NW$^L.1CPDF
MS=5=4[47I%%4-\Y4%$R'.4W#_P`1&&^%FU<<9?X7,:RV),'W1:UVY,C6EHV1
M/M[E;3[:0M-.;&&G)%^%WW&9].W!'OI1PH\,JL\.HDW.EF#C<Q9A,L)Q39Y+
M<Z>4<NS.1<LWS+3B%XS[:Y;A:14)?L])Q,*@LZ9-"IH0<>S30;HILT"I-"%0
M#(_'%AG`J..^)S+IKQ/DC(%NY(R\WB+M/D"31G+R-)8Q5N`]I`,@_;HR"XI0
M1/Y67RHNZX$R@\,\+@S#>5,SS4!Q7L9:<A<3X^NS(DQ#Q+G$MRQB$M*1=H-'
MBZ#4SE5%L#A5,J?6J)I[V^H0IL&9^R/P4P[3+Z-@8IN6];+>7/DJW\>.,C1U
MI,5YE>Z,+-91""ZP7Y#FDHE6.*R75`Y7313K%BJ7E@#->/+;R)AK(%OEM>[<
M?3C0WN#*0J*R3EDV338F15:J-%T&[EBY:*)+-5TD5VRB2R29RY-@[8X0H^62
MRU:<C8EU2=Y9/S!=-QL[/ER@G*PMEW-(SPO[=,Z)O(N7\$X:/ED3G;JNCH&%
M*H+YO*[\))RW![;47:D-"8A#(65H_P`@CK(N-*[;81+?\7.H70<S:013<&54
MFS**Z"FL91(QB&3^;UD<0IN>#]&RXG'J>(/RYR4D4MHP<\C<\7%?EXA,EN<3
M)/VZ+GRH9KR@QBZ'5,43%%Q\W_;V*"QW",[Q[=.*W&)"WOD=P"EAWJ\>/[G@
MQOMW,*7,`NEG[M0783(.2"H/5K$`I0+F#@Y^;^X>+X5M"V,@8KN6TL.XW3RE
MFF["$E.(2-O:]I5M[N.I^XGJ9%EW3YR91PJ5LB!A#JFZ0`3@<RGQC\%LU;W$
M>A@VU294B'EQ9@PC-W!+-'ZZS,V3[#MJ2AM9$S7J2N'*S5%XLF)0<*J:$$MK
M8[QW:T#9%B61`Q=KV?9]KQ;.$MVVK=A&9&$3"PL2P(1%NV;HD(FDDF0"E*``
M`?0,COK;R!CV$S,UM7R^QK6N.X[:2N%ZL[D4H\\K$VG*N"+/C-D3KN$4P04(
M=1("F(H7>(:?PUD&^$+EM^XY..>R$RI$,HBYC,8]471K>,^MX&:"S%=;JE5D
MW+90XBF4I5"IZD&*824M)R#&!:*L(-D^?NG;2&8N'BDBNRBFRYS$;I'<+*KG
M31*4HJ'.<0WC"(V`VG+RO67P7;JDPSG<9QAV<DQ-$3BCJ2>*0,/*KMFZ;PLB
MY%\58'*)A/O%,H*9SD,MD/&2DVE&L9MU;LO#W*P;QEP0LNT;(OA:OVK)=T@8
M%$'"*R2S=RJF8#"7?ZPBA">BSRQQ?9PM/"=DR<I[B0;N=1G)N=N67*EY0M&V
MG95GM)&;EED4OMSA.-CEQ13^V*[A/95E3-EH<85MM;&P@SM-_E<]V6#EFS[A
ML]I?%U-+)MAT-JW#`H2$FBYE'S1F+B%;O$4CJ:K*)E*<Q;BQA\X=EC!&*>(J
M_,X6!C#AGL#'V/<DV\7(?Y>I(PT?%G=JKS[(KA:;708M3NW[7V2@`;>`0,"-
MB\5O%!:=AY'<1:,PEC*!@KTR7D-)@\1\HC'$Q:N-(V6<Q2;PGLV:TP5HDL7V
M2:@D]E5SSG!OQ!6SF$;),P+>=OI1%VV7>UJEE!4)'.YNQ<A1\3+I-%SHK)-W
MX,C-5CIJ%17.)!TXEHR]^,>P[6E.$/(!<59[BINV,FL96VLCC*2T*:R[5C%H
M,%[MD".8*824;V>G*&)Y(L8^Z0F]5U3?!SGB%RJO8AHPM\VNO`W;9%[VC[L$
M.:-<3%FWXPC9`6BYDE4D9%L@JS453433<'.F<H6S9O%YQ(0>-KZN^/;34'8<
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M>\6+B\HR]XWW9M9K;6/SQOY3O9)VT`[@L,WA32!4TUC*-B`BJ).'9YP<<0T#
MD^3LGC!CG=W6:K%778>0+<0/AVZ$&,X^L6_&49*&8&44!)*5;-E&G6F%$%^M
MWB!C910QCG/8-G'.<YA,<YS6ZV,8QC&Y1$1Y1$:1L7BMXH+3L/([B+1F$L90
M,%>F2\AI,'B/E$8XF+5QI&RSF*3>$]FS6F"M$EB^R34$GLJN><X-^(*V<PC9
M)F!;SM]*(NVR[VM4LH*A(YW-V+D*/B9=)HN=%9)N_!D9JL=-0J*YQ(.G$M&7
MOQCV':TIPAY`+BK/<5-VQDUC*VUD<926A367:L8M!@O=L@1S!3"2C>STY0Q/
M)%C'W2$WJNJ;X.<\0N55[$-&%OFUUX&[;(O>T?=@AS1KB8LV_&$;("T7,DJD
MC(MD%6:BJ:B:;@YTSE!?"BN>.'TWS5C>R55%,_-\<94>7B:^$<3#,G:(330Y
MUE4ANL/<PIDK<,B9#02J"`@YK@=S2I\[/.<`N%L@7P:],7Y+L['.=,@P>>(N
M^[(;/X)RYMS$:\=,,UHED)G;9>5331;E=N4G/DZAM2_,=-2WM*72A#RF?%%+
MZE7IDI"Z%89?"R:-[2SG>`/*G("H\47$=2F5.("&HTSX8+8XV,>R>3).>;VG
M#R(0-_M,5S=V.G9F;:W8;-3V)3M-RJJ?JR-G*4P+1PHHF@W<JN#"D'"VIE[Y
MT"ZOFT(2-S-<",9/0&/LT9(896EY6V4D"LI&%PB[:2""\&BFJX:O7IO)$R.G
M!5#HB<J@066N)+B`MNT<6V?:=HQ4EF7)TTDP4O&0-"IH,'X%]FXD9B9ZH[I-
M@Q16<KJ&/U21Q`:@\)XDXQK?5R+=DXVMVRHJ_,=9@Q1&WG+OCIH1D?;]RY.M
M^)C#.GBZA6K)@X=HNW"X@DBW.8Y`-PJ<+>#,HX(F\%Q67+:L+YPN<NJPLAW!
M=.%61,MQMOY%0BIB+<LD0=15MJ2+T/(&,EN.4Q*<BIR^3#E7,^)OG(7'#%PZ
MNK\LEDZXM;#LC,%Q)M)FTLE,8YU8$G8=GI1=V.DY%^=NT%)DB!@4%!P)%VY3
M$/PZY`O3C/8YVP5C7!K2X)+C+RF:9L.-O"TS2KAPSGY-OD)PK),$&W7I0T<Q
MD5CN]Q%NVW3+F*F,5P]X(XO[;N;+%R2GN+9]NW!C_+V.6U[RPI;Y8RT+@R1;
M\3'/G2AP,BW:).NO<'*/DZ:I#$.;_A#-YYP;DN$QO>=[*(N\@VI>L=+/[6FY
MY)`K8]T1$Q$"LY8++III@Z:"R6254U6(=$1.0_\`GG@'_6Y$_$M?YYX!_P!;
MD3\2U_GG@'_6Y$_$M?YYX!_UN1/Q+31*;S_A&/B3J@#Y[%,;[F)%LAH.JC2,
M=Q[%-8^NGL#NT@_[KF&#PACUX]FDF\E(7-=MVRC=!I*7G>DRDBWE;B>LFHF3
M0#J&S5FU;E.?JFS=!,RBQRF5/^SLJ9*@&4Y'Q$W--&3%K<#U!Y(%1MR';VT5
M71L4"()*^2=:DU`RG5%,!!4.(:^CC?%!)%6'+?=U1L"XED&B3Y:+8N%-^0D4
MV:RJ!5110*HH!!5+KIH&H\@FQ[C@LNX:O956?GIN?>)O9F>G5V:+!5^Z,W32
M12*"3=)-)!NB1,A2ZZ&.8YS^CP4\4W!G:./,V7[P479=MS2W#EDH8):(R4PE
M;BMJ\F)FT->"[6%F&H+6V+.<@'[Q`TBT7*B@94Y11/G_`((^,CYI7`7##QNV
MEBY!OFK'MQX"L65L?+N/\>7_``\\O;USVQ>T"C(,3PL\Y@YJ-M^="22`2DDV
M;X3I[I.*#+64<`83R3E7$W$9C&0Q7DR_L56+>.0<9R$?9WNZP?8_O.XF#F2A
MED'R:;Q%6.<HF(N0JI1!0H&#*W#OP7?,U6G\YQ\Y:PM>UAS9DZ^9?']M6Q8$
M9:]G1;>,3B;NR7'7`S9)Q+&0B(N9=)!`M@=+)-%7CET7JZXT;>OCAGM7@ANF
M8X<LF.[ZX4\:WC:EXV#C5_)R6.[K"%B)W'YAA'39RLJG-)I1X`@V4<B@F1/J
MMPOSPS?B>Q%:.;K<PYG;C>R)9]BY#BF=SX^6N][QD.+-+*739<J16/F"-V,B
M\!NTDD%FQ53E7%$RR*)T_G"\#X'MYOCG$,3@C)"D18%OF,SMN)8W,;&F1G$'
M&QB6B2,>UDWRQHYF0H)M4BIHI`4B90KYU8_&SC^S\VI8;4X@QQKBO,$1#9`L
MZ4;XOR[;F!+%EY&UKB(YCG[6+M4R8LHYTV4(B9RBONE6:E,'#[BCAAM"!QWC
MEW9N3+[>X[M9RD:V;(O"\^!:_P"4N*&M^(2$WN4T5-U4@C%`()M@<[K9-%H+
M=%/*W#OP7?,U6G\YQ\Y:PM>UAS9DZ^9?']M6Q8$9:]G1;>,3B;NR7'7`S9)Q
M+&0B(N9=)!`M@=+)-%7CET7JZXT;>OCAGM7@ANF8X<LF.[ZX4\:WC:EXV#C5
M_)R6.[K"%B)W'YAA'39RLJG-)I1X`@V4<B@F1/JMPOSO\9Q38TB<P6=AG/7'
M#DFV,?72!G5DREXO.,5Q9C5_=L$&B<F@T9R+PZ#)SO("N9-91,YD2`'S&7S>
M:L.CC+@G;RV.;,"TH!^K$6A;MIY%X@8'%%XH,622I3HC#VXP;D;.%#ZHIN#@
MB<F\MKPE9?X;.'[$/#SDZ9RU)XGDHK#UMV[CF)O;'C6Q'UR.).X+*MM)NWD'
M\:_08IFG3("ZW7G4O%U@.U!+&GP?V;YN-JRMP[\%WS-5I_.<?.6L+7M8<V9.
MOF7Q_;5L6!&6O9T6WC$XF[LEQUP,V2<2QD(B+F7200+8'2R315XY=%ZNN-&W
MKXX9[5X(;IF.'+)CN^N%/&MXVI>-@XU?R<ECNZPA8B=Q^881TV<K*IS2:4>`
M(-E'(H)D3ZK<+\\,WXGL16CFZW,.9VXWLB6?8N0XIG<^/EKO>\9#BS2RETV7
M*D5CY@C=C(O`;M))!9L54Y5Q1,LBB=/YPO`^![>;XYQ#$X(R0I$6!;YC,[;B
M6-S&QID9Q!QL8EHDC'M9-\L:.9D*";5(J:*0%(F4*7X<W?"[PZNN'MUA56?<
MX(<83QJOAIQ.K\'XW6M-+XO5C!A#NSR@C)&<F8BH+H1<";KO9U\WW86/[5MN
MQ;&LW,EWVQ9]EV=!QELVG:EMPF+D8Z&MZV[=A4D&;%BT;IIH-6C5$B2292D3
M(4H``?,APLNL9O$R\+Q$Q<HX(LFV.A'/V.%6CU8KA4!(F)4CF,!S`(%TU$-`
MKAOO7AKX?<3X-R!8O$'8N([>NBQK=BHF\\FV7<6,+CDIYADFZ6Q`D;J>%/!L
M9(LO..';I(Z:P$6*#Q8%/F.K_P`CN7CS(=\8\Q1>%^/)`7)I!W>=S<*$#-70
MY?&>'46%91\NN9455#'WA'>,)M1'YB3@TRO+R43PNW\C@IW?)$W[B.AW2V6\
MS0F*\@R[LZ`IE%S%6ZU(#=P903MB/%NK%+KU!4PIES"G#MA'`V4+-XD<>XPM
M*=Q+8MG8RDINR9S'ES/I6RY5&V&K499!$8EI(-^O!1=L=L=1)1--5V5;_P#Y
M<+TR)AG%KN]^,G'WS>]\<80R&+[2:N.(2^<DY*L%ODA_G9@NR`;E<R1'KUG(
MA/@Y.JBHHW6WDS&*/$#C;!&)L9X4QW'9,P/(Q]@XDL.UL;V6QD);/$*\E7S.
MUK.:LF*2SE8PJN%2(`90XB8XB8=:^8WQ1!NI!GC[)S>:N"_A9JJ(M9.2QM$.
M#65"RHIAHJB8\R_?$04/N"LT25W#'1(9/A=EL=<)>!V<CPX/,>7]@_+]JVHQ
MM;(Q[EMQFBXMV]IO)-K&9R\^I(*BF_>HSCYXW?.#%6=)+J%(8/\`B&R-<=K8
M;DK9Q?(L[=G(ZY+9MB6"T)5T\MQ![=4N\?M@48MG7NEY>5PBF*``5,JQDM5#
M*JTK;>-;-N*^)]"/<2JT1;48YE7Z4:U4(DX>J-VI3&!,IU$R"8?VQBAM$`K%
M62;TNR"QBS+,L+EG[:=$F/\`$BW$8>:!U'HM&K5$6A7;E)$BI15>IG:B<N^F
M=0AD_2X=S3P:?.09<X#\GXGM^XK3DH>`MQ;(6)LG0-Q2K:3WKOL%>7C6)WS,
MZ)C(NGS20(8H$2!!$P`N7-?'=Q*\6%Z<:7&MG2WWUHW#E&;M5.PK<A+9E'T<
M\E4&5NDD9-1X^<%AXML1XHN@BU:(`S:,T4Q.=1OF;A1^<YS%B3A)?9UL',-\
M<+MNVQ<,,]R-:N.KK4N>$PKD.ZH&Z6L9-Q1TE7,.N_=P0&/'NG"1VAS&,=2^
M/G)/F\OG!KHX%<T9AM]6$R]&!BMGD^'F',A$LH:XI"%.ZEF"/D<H6-CW[N(D
MV#LA)-'W0;.4#E;I-KPX^Y_CDR1Q/WODC#=SV+D5EE/&K=I>%VY*ON7AK@O/
M)[S)"-R/!!JL[BU08P9X=11L@LDD>3<BW%1?CN^<(+Q*J91-QKW!F.=#$AL/
M%LHN,_\`%W.I<V+M1OP+HEO=KR`Q0C2']QF'6A]O$J8_::XD/G;`XBU+C_W@
M<=O[$)P_CB4L1^2"K^"M&%4ES96_*9U[H%+^2YU2M@MMJ/\`*@**W\G$R[[Y
MQ+@9XYK\X#>(:\6:!,DOK5MZ>E$Y:=3MHEGOKHM6?M*?@7L8:4C$$&TU&J`X
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M);T##P9'9TP1.Z)$QZ;`KDR)3&`@G!/>$H&'3734=M7Q\Y)\WE\X-='`KFC,
M-OJPF7HP,5L\GP\PYD(EE#7%(0IW4LP1\CE"QL>_=Q$FP=D))H^Z#9R@<K=)
MM>''W/\`')DCB?O?)&&[GL7(K+*>-6[2\+MR5?<O#7!>>3WF2$;D>"#59W%J
M@Q@SPZBC9!9)(\FY%N*B_'=\X07B54RB;C7N#,<Z&)#8>+91<9_XNYU+FQ=J
M-^!=$M[M>0&*$:0_N,PZT/MXE3'[37$A\[8'$6I<?^\#CM_8A.'\<2EB/R05
M?P5HPJDN;*WY3.O=`I?R7.J5L%MM1_E0%%;^3B9>T?G$^$CCAO3@FXFHFUXF
MUKAN""M25GE'AX2VG5E,KJM.YK:G8.1B'BL&X]PY)H(N&[QISH#UY'7!-PH7
MSQRWA%7OPE1\*%U\0]^XF=9BO#/-Q-,<-K'G[JN:-D;RB'31Y(ND#R:BSJ;D
ME]3BFNNZ5WG9^`^/O7B$DL665P;NKU:75;D=C+\K9+-%HW\>R4+A@6=QIW'#
MC;#DS2SSH(R!6LGN'>];U`^3`1?#L+Q7_.HY[XE^#/A]D.HQ5@.]8*YE[JAL
M?)N&QT<8Q5V3%V/XR#;J-F[>->R</#$.HS:HHM6K`H-RL>'["T+GUKPN1.`+
MRDKEAG$=AI'*4;(1+RTR6HSMEE`(7-:Q(])HDFF9%0CA4H$+U8)%#0P8>QI>
M>0[DQ#E_AY;G3POGJV(!C<#R"+(1+&*N2'NFRW3MD$I$R`QS!X=HWE63E%TV
M040>II^4HN<0R7SI7SL><^-["6$G#9W:^$%H2Z80DXJF)!=MI:];JNB9.T3>
M$00:RSQM&GE7S412))LSI)+!PUWWBW/DMPE9UX4S.(_&%ZV[:2ER6_\`DN=^
MPF(F(+$Q,G"O(M["/HYN\@Y2-?`+<3+IG;K"=!5I<7S:O$;\X3D3,>7KTR!%
MY!N3BZR-8<QD6724BLKM<CL+2CK&N&[4GBD:U:M"134%;F*"8F,X3221`C$F
M#OFL<P92G)U7AZ@[=6QIQ%6Y9[2VK@@LCVP21;,KV;V$\DI)$6;EI*OH^0A5
MI90%FRQMQTBY(@Y0X9KBXF/G>\^\27#SP>7]:>1,*<,Z,'><!8ZEP8_<"O8`
M2S>[KRN"/9,(GJT4F[!M%N#I-C*-&3Q@F&\I_P`0UW8]NA%9Q;E[6W,VM-I-
ME?)W0QDXP4CG9FCC0W5K%(H)D5-T=PX%,`<E7&^N:/<9I<3/D[>-3R1'1#N/
MMV/;.BO0(PCF21$CNE3D(5=V<-3)EZHA$TU%RJE:VE:EN6PV(S8QY4+?A(V&
@2!A&-P:QS/<CDDPZI!(I4T4_:D*`%*``&G_Z$_\`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 11pt/1pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NanoAntibiotics, Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>9511 Collins Avenue., Suite 807</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Surfside, Florida 33154</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">October 31, 2013</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>VIA EDGAR AND FACSIMILE</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Attention: Jay Ingram, Legal Branch Chief</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Division of Corporate Finance</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">100 F Street, N.E.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Mail Stop 3561</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Washington, D.C. 20549</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Tel: (202) 551-3397</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Fax: (703) 813-6963</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt">RE:</TD><TD><B>NanoAntibiotics, Inc.</B><BR>
<B>Amendment No. 2 to Registration Statement on Form S-1</B><BR>
<B>Filed October 15, 2013</B><BR>
<B>File No. 333-190635</B></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0">Dear Mr. Ingram:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are providing the Company&rsquo;s responses
to the U.S. Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) comment letter dated October 24, 2013 regarding
the Company&rsquo;s Amendment No. 2 to its Registration Statement on Form S-1 as filed with the Commission on September 26, 2013
(the &ldquo;<U>Registration Statement</U>&rdquo;). The Company&rsquo;s responses to the Commission&rsquo;s letter, provided below,
are in identical numerical sequence. For the convenience of the Commission, each comment is repeated verbatim with the Company&rsquo;s
response immediately following.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>Description of Business, page 26</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in">COMMENT 1:</TD><TD STYLE="text-align: justify">We note your revisions in response to comment four of our letter dated October 2, 2013. We note
in particular your disclosure regarding the total U.S. sales amount for each of the three major branded antibiotics in 2011. It
is unclear how this disclosure is relevant to your business at this stage of your development. Please delete this disclosure or
tell us why you believe such disclosure is appropriate.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in"><B>RESPONSE:</B></TD><TD STYLE="text-align: justify"><B>In response to the Commission&rsquo;s comment, we have deleted the referenced disclosure in
Amendment No. 3 to the Registration Statement (&ldquo;<U>Amendment No. 3</U>&rdquo;).</B></TD></TR></TABLE>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">SEC</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Page 2</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">October 31, 2013</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in">COMMENT 2:</TD><TD STYLE="text-align: justify">We note that certain of the sources that you cite in this section are from 2005 and 2009. Given
the date of these sources, please advise us why you believe that these sources continue to remain reliable.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in"><B>RESPONSE:</B></TD><TD STYLE="text-align: justify"><B>We believe that these sources continue to remain reliable after verifying such disclosure with
Ashok Kumar, PhD, Beverly MA, a microbiologist and published author on the subject. Dr. Kumar has confirmed with us immediately
prior to the date of this response letter that the discussion on the antibiotic topics and subtopics covered in Amendment No. 3
are well-establish facts and remain current, and that the review article cited (Nikaido 2009) summarizes these established facts.
Although this information has <FONT STYLE="color: windowtext">been known for a long time, the scientific community has not been
able to develop effective drugs for the many drug resistant bacteria that are increasing in scope. A selection of relevant publications
of Dr. Kumar is set forth below:</FONT></B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Kumar, A. Grimes, B., Logan, M., Wedgwood,
S., Williamson, H. and Hayward, R.S.&nbsp;&nbsp;(1995)&nbsp;&nbsp;A hybrid sigma subunit directs RNA polymerase to a hybrid promoter
in&nbsp;<I>Escherichia coli.</I>&nbsp;J. Mol. Biol.<U>&nbsp;246</U>, 563-571.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Kumar, A., Williamson, H., Fujita,
N., Ishihama, A. and Hayward, R.S.&nbsp;&nbsp;(1995) A partially functional 245 amino acid internal&nbsp;deletion derivative of&nbsp;<I>Escherichia
coli</I>&nbsp;sigma-70.&nbsp;&nbsp;J. Bacteriology<U>.</U>&nbsp;177, 5193-5196.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Kumar, A., Grimes, B., Fujita, N.,
Makino, K., Hayward, R. S. and Ishihama, A., (1994) The role of the sigma 70 subunit of&nbsp;<I>Escherichia coli</I>&nbsp;RNA polymerase
in transcription activation.&nbsp;&nbsp;J. Mol. Biol.<U>&nbsp;</U>235, 405-413.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Kumar, A., Malloch, R.A., Fujita, N.,
Smillie, D.A., Ishihama, A. and Hayward, R.S. (1993). The minus 35 recognition region of&nbsp;<I>Escherichia coli</I>&nbsp;sigma
70 is inessential for initiation of transcription at an &quot;extended minus 10&quot; promoter.&nbsp;J. Mol. Biol.<U>&nbsp;</U>232,
406-418.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Oliver, J., Kumar, A. and Hayward,
R.S. (1992) Hypersymmetry in a transcriptional terminator of&nbsp;<I>Escherichia coli&nbsp;</I>confers increased efficiency as
well as bidirectionality.&nbsp;The EMBO Journal&nbsp;11, 1957-1964.</B></FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 2pt; border-bottom: rgb(98,145,178) 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">SEC</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Page 3</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">October 31, 2013</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in">COMMENT 3:</TD><TD STYLE="text-align: justify">You state herein and elsewhere that on October 3, 2013, Kard and Mr. Menon assigned all of their
rights, formulations, and all studies and data related to efflux pump antibiotics to the Company. Please tell us how you have accounted
for this transaction. The guidance in SAB Topic 5:G may apply.</TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: -1.5in"><B>RESPONSE<FONT STYLE="color: windowtext">:&#9;<FONT STYLE="background-color: white">According
to ASC 845-10-S99, transfers of non-monetary assets to a company by its promoters or shareholders in exchange for stock prior to
or at the time of the entity&rsquo;s initial public offering should be recorded at the transferors' historical cost basis determined
under GAAP. &nbsp;</FONT>As such, the<FONT STYLE="background-color: white"> cost basis carried on Kard&rsquo;s books and records
was zero. &nbsp;Therefore, the accounting principles in ASC 845-10-S99 were followed and the Company recorded the rights at its
historical cost basis, which was </FONT>at the historical cost basis of zero. Although the transfer was at $1, this amount was
determined by the Company to be de-minimus and immaterial. The Company has revised its disclosure in the MD&amp;A section of Amendment
No. 3 and under the heading &ldquo;Non-Monetary Transaction&rdquo; in Note 1 to the financial statements in Amendment No. 3 to
disclose this in response to the Commission&rsquo;s comment.</FONT></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in">COMMENT 4:</TD><TD STYLE="text-align: justify">You disclose on page 29 that S&amp;T is paid on an hourly basis for their work and that thus far
you have incurred $9,600 in costs by S&amp;T for the months of July through September 30, 2013. Please disclose whether you have
actually paid the $9,600 and the nature of the consideration, i.e., cash, stock, etc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in"><B>RESPONSE:</B></TD><TD STYLE="text-align: justify"><B>The Company has revised its disclosure in Amendment No. 3 to state that it actually paid the
$9,600 in cash to S&amp;T.</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in">COMMENT 5:</TD><TD STYLE="text-align: justify">Please clarify whether the payments for either or both of the Kard assignment and the S&amp;T costs
would be included in the $250,000 cash you have allocated for &ldquo;lab studies&rdquo; through December 31, 2013 as stated on
page 24.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in"><B>RESPONSE:</B></TD><TD STYLE="text-align: justify"><B>The Company has revised its disclosure in Amendment No. 3 to clarify that both the de-minimus
assignment payment and the S&amp;T costs are included in the $250,000 cash we have allocated for &ldquo;lab studies&rdquo; through
December 31, 2013.</B></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-align: justify; text-indent: -1.5in"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We trust this response satisfactorily responds
to your request. Should you require further information, please contact Matthew Ogurick, Esq. of K&amp;L Gates LLP at (305) 539-3352.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="color: black">Sincerely,</FONT><FONT STYLE="color: gray">
</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt"><I>/s/ Elliot Ehrlich</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Elliot Ehrlich</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">cc:&nbsp;&nbsp;&nbsp;Matthew Ogurick, Esq., K&amp;L Gates
LLP</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
